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Preface 
Despite the increasing attention on the topic of pharmacokinetics our understanding of 
advanced concepts and its applications in drug development remains limited. The
intention of this book is to bridge the theory-practice gap by providing advanced 
pharmacokinetics concepts, methods, and applications. Graduate students as well as 
scientists in the area of clinical pharmacology and pharmacokinetics will find the
contents of this book very enlightening and helpfull. The comprehensive coverage of 
topics on pharmacokinetics in this book offers readers “à la carte” choice to build their
knowledge based on their scientific needs.
I would like to personally thank all the authors for their excellent contributions to the 
book. These researchers are at the forefront of innovation in pharmacokinetics and its 
application to the clinical science and to drug development.
Ayman Noreddin MS, PhD, RPh
Associate Professor and Chair, Department of Pharmacy Practice,
School of Pharmacy, Hampton University 
USA
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 Bioequivalence Studies 
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Pakistan 
1. Introduction 
During last four decades there is an increased use of generic drug products in order to lower 
the healthcare cost. With increased availability and use of generic drug products, healthcare 
professionals are encountered with a large number of multisource products from which they 
have to select therapeutically equivalent products. Generic substitution is of concern not 
only for healthcare professionals but also for pharmaceutical industries, consumers and 
government officials. Many research papers have pointed out the concern regarding 
standards for approval of generic products which may not always ensure therapeutic 
equivalence (Boix-Montanes, 2011; Skelly, 2010; Tothfalusi et al., 2009; Midha et al., 2005; 
Chen & Lesko, 2001; Chen et al., 2000; Strom, 1987; Lamy, 1986). To alleviate this fear many 
guidelines/guidance and regulations covering the licensing of generic products have been 
introduced to ensure that the medicinal products reaching the market have well-established 
efficacy and safety profile (FDA, 1992, 1996, 2001a, 2001b, 2003, 2011; CDSCO, 2005; SFDA, 
2005; Health Canada, 2004; CPMP, 2000; WHO, 1986).  
Generally, demonstration of bioequivalence (BE) is the most appropriate method of 
ensuring therapeutic equivalence between two medicinal products. Bioequivalence studies 
should be conducted for comparison of medicinal products containing same active 
substance. Such studies need to be carefully designed to take into account 
biopharmaceutical, ethical, medical, pharmacokinetic, analytical and statistical 
considerations. The studies should be aimed to critically assess the possibility of alternate 
use of these products. In the 2003 United States Food and Drug Administration (FDA) 
guidance, bioequivalence is defined as: 
 “the absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical 
alternatives becomes available at the site of drug action when administered at the 
same molar dose under similar conditions in an appropriately designed study” (FDA, 
2003). 
Bioequivalence is actually the comparison of the bioavailability of two drug products. In the 
2003 United States Food and Drug Administration (FDA) guidance, bioavailability is 
defined as: 
“the rate and extent to which the active ingredient or active moiety is absorbed from a 
drug product and becomes available at the site of action. For drug products that are not 
 1 
 Bioequivalence Studies 
Aisha Qayyum 
National University of Sciences and Technology 
Pakistan 
1. Introduction 
During last four decades there is an increased use of generic drug products in order to lower 
the healthcare cost. With increased availability and use of generic drug products, healthcare 
professionals are encountered with a large number of multisource products from which they 
have to select therapeutically equivalent products. Generic substitution is of concern not 
only for healthcare professionals but also for pharmaceutical industries, consumers and 
government officials. Many research papers have pointed out the concern regarding 
standards for approval of generic products which may not always ensure therapeutic 
equivalence (Boix-Montanes, 2011; Skelly, 2010; Tothfalusi et al., 2009; Midha et al., 2005; 
Chen & Lesko, 2001; Chen et al., 2000; Strom, 1987; Lamy, 1986). To alleviate this fear many 
guidelines/guidance and regulations covering the licensing of generic products have been 
introduced to ensure that the medicinal products reaching the market have well-established 
efficacy and safety profile (FDA, 1992, 1996, 2001a, 2001b, 2003, 2011; CDSCO, 2005; SFDA, 
2005; Health Canada, 2004; CPMP, 2000; WHO, 1986).  
Generally, demonstration of bioequivalence (BE) is the most appropriate method of 
ensuring therapeutic equivalence between two medicinal products. Bioequivalence studies 
should be conducted for comparison of medicinal products containing same active 
substance. Such studies need to be carefully designed to take into account 
biopharmaceutical, ethical, medical, pharmacokinetic, analytical and statistical 
considerations. The studies should be aimed to critically assess the possibility of alternate 
use of these products. In the 2003 United States Food and Drug Administration (FDA) 
guidance, bioequivalence is defined as: 
 “the absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical 
alternatives becomes available at the site of drug action when administered at the 
same molar dose under similar conditions in an appropriately designed study” (FDA, 
2003). 
Bioequivalence is actually the comparison of the bioavailability of two drug products. In the 
2003 United States Food and Drug Administration (FDA) guidance, bioavailability is 
defined as: 
“the rate and extent to which the active ingredient or active moiety is absorbed from a 
drug product and becomes available at the site of action. For drug products that are not 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
4 
intended to be absorbed into the blood stream, bioavailability may be assessed by 
measurements intended to reflect the rate and extent to which the active ingredient or 
active moiety becomes available at the site of action” (FDA, 2003). 
According to World Health Organization (WHO) guidelines, bioavailability is defined as: 
 “the rate and extent to which the active drug ingredient or therapeutic moiety is 
absorbed from a drug product and becomes available at the site of drug action” (WHO, 
1986). 
According to the United States Food and Drug Administration (FDA) “pharmaceutical 
equivalents” are drug products that contain identical active ingredients and are identical in 
strength or concentration, dosage form, and route of administration (FDA, 2011).  
The CPMP (Committee for Proprietary Medicinal Products) guidance on bioavailability and 
bioequivalence confers the concept of therapeutic equivalence as:   
“A medicinal product is therapeutically equivalent with another product if it contains 
the same active substance or therapeutic moiety and, clinically, shows the same efficacy 
and safety as that product, whose efficacy and safety has been established. In practice, 
demonstration of bioequivalence is generally the most appropriate method of 
substantiating therapeutic equivalence between medicinal products, which are 
pharmaceutically equivalent or pharmaceutical alternatives, provided they contain 
excipients generally recognized as not having an influence on safety and efficacy and 
comply with labeling requirements with respect to excipients. However in some cases 
where similar extent of absorption but different rates of absorption are observed, the 
products can still be judged therapeutically equivalent if those differences are not of 
therapeutic relevance. A clinical study to prove that differences in absorption rate are 
not therapeutically relevant, will probably be necessary”(CPMP, 2000).   
In early 1960’s extensive work in pharmacokinetics offered substantial evidence that 
composition and dosage form of a drug product can affect in vivo properties as well as 
therapeutic effects. These differences have been attributed to the effect of different drug 
excipients used, variations in manufacturing procedures and the properties of final dosage 
form on the rate and extent of the drug absorption from its site of administration. The 
importance of bioavailability came into lime-light after an incidence in Australia where a 
change in an inactive excipient of phenytoin formulation by the manufacturer resulted in 
low plasma levels of active drug leading to therapeutic failure and seizures in epileptic 
patients who were previously well-controlled with the same dose of same drug. Similarly in 
Europe marked variations in the plasma levels of digoxin were observed with different 
preparations of the drug resulting in either toxicity or therapeutic failure (Crawford et al., 
2006; Welage et al., 2001; Soryal & Richens, 1992; Lindenbaum et al., 1971; Tyrer et al., 1970). 
Bioequivalence and bioavailability studies are important during drug development of both 
new drug products and their generic equivalents. Provision of bioavailability and/or 
bioequivalence study data is an important element in support of Investigational New Drug 
Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications 
(ANDAs) and their supplements. The term generic drug product has been defined as 
“interchangeable multi-source pharmaceutical product”. Generic products are the copies of 





and toxicity profile as the original innovator drug. Concern about lowering healthcare costs 
has resulted in an increase in the use of cheaper generic drug products instead of branded 
products. The innovator drugs are protected from copying by patents that last for 20 years 
from the first filing of the new chemical entity. Many people are concerned why generic 
drugs are often cheaper than the brand-name versions. It is because all the development 
work and clinical trials on new chemical entity are carried out by innovator to get initial 
drug approval which is later on reflected in its high price whereas the generic 
manufacturers only need to submit the bioequivalence data of the generic product to get a 
product license. The new products need to undergo bioequivalence testing before they are 
marketed. The difference may exist in absorption reflected in differing bioavailability profile 
of various brands, production batches or dosage forms of a drug. This can lead to either 
over- or under-medication if one entity is substituted for the other. The under-medication 
can lead to therapeutic failure and on the other hand over-medication can lead to toxicity. 
To avoid such risk it is best to study the bioavailability of all products but practically it is not 
possible. So each drug and any change in formulation must be considered individually 
while keeping in mind the real medical need for such studies in order to ensure efficacy and 
safety of these drugs. Many clinicians while switching or interchanging the different 
products are concerned with the safety and effectiveness of the new product. This concern is 
because of the fact that small changes in bioavailability can lead to significant changes in the 
efficacy or safety of the drug. Bioequivalence studies are designed with this concern in mind 
and to devise the strategies that minimize the risk to the patient. So when the generic 
product is pharmaceutically equivalent as well as bioequivalent to the innovator drug, then 
it is expected to be therapeutically equivalent (Kowalski et al., 2006; Crawford et al., 2006; 
FDA, 2003; Welage et al., 2001; Vasquez & Min, 1999; Banahan & Kolassa, 1997; Benet & 
Goyan, 1995; Marzo and Balant, 1995; WHO, 1986).  
2. Design and conduct of bioequivalence studies  
The basis of a bioequivalence study is the comparison of the drug product to be tested with 
an appropriate reference product (branded innovator drug). In bioequivalence studies an 
applicant compares the systemic exposure profile of a test drug to that of a reference drug 
product. Bioequivalence of two products can be assessed using in vitro standards, 
pharmacokinetic profile, clinical or pharmacodynamic end points. Different approaches for 
determination of bioequivalence of a drug product are: 
 An in vivo test in humans in which the concentration of the active ingredient and when 
appropriate, its active metabolites, in blood, plasma, serum or other suitable biological 
fluid is measured as a function of time. 
 An in vivo test in humans in which the urinary excretion of the active ingredient and 
when appropriate, its active metabolites are measured as a function of time. 
 An in vitro test that has been correlated with and is predictive of human bioavailability 
profile or the one acceptable to FDA (e.g. dissolution rate test) that ensures human in 
vivo bioavailability. 
 An in vivo test in humans in which an appropriate pharmacological effect of the active 
ingredient and when appropriate, its active metabolites are measured as a function of 
time if this effect can be measured with adequate accuracy, sensitivity and 
reproducibility. 
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 Well-controlled clinical trials that establish the efficacy and safety of the drug product, 
for purpose of determining bioavailability, or comparative clinical trials, for purpose of 
demonstrating bioequivalence. 
 Any other approach considered adequate by the FDA to measure bioavailability or 
ascertain bioequivalence.        
Bioequivalence for most of oral tablets or capsules is demonstrated in vivo by comparing the 
rate and extent of absorption that is bioavailability of the generic product with that of the 
innovator product. This is done by measuring the active ingredient concentration in blood, 
plasma, serum or other biological fluids over a certain period of time for both the generic 
and innovator products, also called test and reference drugs respectively. By doing so the 
bioequivalence studies frequently rely on pharmacokinetic measures such as area under the 
concentration-time curve (AUC) and peak drug concentration (Cmax) (Niazi, 2007; FDA, 
2001a, 2003; Pidgen, 1996; Nation & Sanson, 1994). 
2.1 Study design 
Many authors have debated whether multi-dose or single-dose studies should be used to 
assess bioequivalence. Generally single-dose pharmacokinetic studies are recommended 
for both immediate- and modified-release drug products as they are more sensitive in 
assessing the active ingredient released from drug into circulation. For assessing 
bioequivalence of two formulations of a drug, two-sequence, two-period, crossover study 
is conducted after administration of single dose under fasted conditions. In crossover 
design the subjects serve as their own controls and they crossover from one treatment to 
the other. A large variability in drug clearance often exists among the individuals. 
However the intrasubject variation is usually smaller relative to inter-subjects variability. 
Parallel studies are appropriate if the drug has extremely long half life, repeated 
pharmacokinetic profile is difficult to obtain, or residual pharmacodynamic effects are 
relevant. Furthermore, if carry over effects from one treatment period to another are of 
concern or if intrasubject variability is high, then replicated design is used. Nonreplicate 
study designs are usually recommended for bioequivalence studies of most of the orally 
administered, modified-release and immediate-release dosage forms. Replicate study 
designs are often recommended for bioequivalence studies of highly variable drug 
products (intra-subject coefficient of variation ≥ 30%), including those that are modified-
release, immediate release, and other orally administered drug products. Replicate study 
designs have several scientific advantages compared to nonreplicate designs. (SFDA, 
2005; FDA, 2001a, 2003; Welage et al., 2001; Nation & Sanson, 1994; Steinijans et al., 1992; 
Metzler, 1989).  
2.2 Study subjects 
The subjects should be selected with the objective of minimizing variability and 
permitting detection of difference between the drug products. Therefore, the study is 
normally carried out with healthy subjects. The study is performed in accordance with the 
Declaration of Helsinki for biomedical research involving human subjects (WMA 
Declaration of Helsinki, 2008) and the Guideline for Good Clinical Practice (FDA, 1996). 





capable of giving informed consent. Generally adults between 20-40 years should be 
selected. According to FDA guidance and Canadian and European guidelines a minimum 
of 12 subjects are recruited for bioequivalence studies. For logistic reasons the total 
number normally does not exceed 24 subjects. The subjects should be in good health. The 
subject’s health is assessed by medical examination including medical history and 
laboratory tests. They should be screened for the history of use of medications or drugs of 
abuse, alcohol intake and smoking. The subjects should not take any medication one week 
before start of study (CDSCO, 2005; FDA, 2001a, 2003; Marzo & Balant, 1995; Nation & 
Sanson, 1994; WHO, 1986). 
2.3 Drug administration and sampling 
A bioequivalence study should be a single dose comparison of test drug with appropriate 
reference drug product carried out in healthy adults. The drug is administered to the 
subjects in fasting state, unless some other approach is more suitable for valid scientific 
reasons. Co-administration of food with oral drugs may either enhance or interfere with 
drug absorption. Thus, feeding increases the inter- and intra-subject variations in rate and 
extent of absorption. The sponsor should provide the rationale for conducting 
bioequivalence study under fed or fasting conditions. The subjects are randomly selected 
for each group in the study and the sequence of drug administration is randomly assigned 
to the individuals. In a typical situation of comparing a test formulation (T) with a 
reference formulation (R), the two-period, two-sequence crossover design is the RT/TR 
design as shown in table 1. Subjects are randomly allocated to two treatment sequences; in 
sequence 1, subjects receive the reference drug and test drug in periods 1 and 2 
respectively, on the other hand in sequence 2, subjects receive the drug products in 
reverse order. The administration of each product is followed by a sufficiently long wash 
out period of time to ensure complete elimination of drug before next administration. A 
time period of more than 5 half-lives of the drug is considered adequate washout period. 
In selected cases, it may be necessary for the test and reference products to be compared 
after multiple-dose administration to determine steady-state levels of the active drug 
moiety. A multiple-dose study should be crossover in design, unless a parallel or other 
design is more suitable for valid scientific reasons (Hauschke et al., 2007; Niazi, 2007; 
FDA, 2003; Makoid et al., 1999). 
In fasted state studies an overnight fast of at least 10 hours is recommended. Generally in 
single dose studies the highest marketed strength is administered. The doses of the test 
and reference products should be same. The test or reference products are administered 
with 240 ml of water. Liquids are allowed after one hour and standard meal after 4 hours 
of drug administration. In all the studies the standardization of study environment, diet, 
fluid intake and exercise is important (CDSCO, 2005; FDA, 2003; WHO, 1986). 
 
 
Sequence Period 1  Washout Period 2 
1 R  T 
2 T  R 
Table 1. RT/TR Design 
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Under most of the conditions blood or plasma is collected rather than urine or tissue. Blood 
samples are drawn at appropriate times to assess the absorption, distribution and 
elimination phases of the drug. For most of the drugs 12-18 samples are recommended 
including pre-dose sample from each subject. Generally sampling for a period equal to at 
least 3 times the terminal half life of the drug is recommended. Other approach is that the 
duration of sampling should be sufficient to define at least 80% of the total area under the 
concentration–time curve (AUC). The exact timings for sampling depend on nature and 
pharmacokinetic profile of individual drug and its dosage form (FDA, 2001a, 2003; Nation & 
Sanson, 1994; WHO, 1986). 
2.4 Bioanalytical methodology  
The measurement of drug concentration in collected samples is done through bioanalytical 
methods. Prior to sample analysis, the selected analytical method is validated in accordance 
with the recommended guidelines (Niazi, 2007; ICH, 2005; FDA, 2001b). Assay validation 
involves different steps: 
 Quality control samples  
 Identification and specificity  
 Sensitivity and limit of detection 
 Range, linearity and limit of quantitation 
 Precision and accuracy 
 Analyte and system stability 
 Reproducibility  
A properly validated assay method is crucial for the acceptance of any pharmacokinetic 
study. During validation, quality control samples are run in replicates to assess the intra- 
and inter-day variability during sample analysis.    
2.5 Data analysis 
Data analysis is carried out: 
 By direct observation and measurement 
 By simple mathematical calculations 
 By use of different softwares   
2.5.1 Pharmacokinetic analysis 
Pharmacokinetic analysis is done using the blood or plasma concentration-time profile. The 
pharmacokinetic parameters to be measured depend on the type of study whether single-
dose or multiple-dose study (FDA, 1992). 
For single dose bioequivalence study the parameters are:  
 Area under the plasma / blood concentration-time curve from time zero to  






 Area under the plasma / blood concentration-time curve from time zero to time infinity 
(AUC0–∞) where 
 AUC0–∞ = AUCt + Ct / λz  
Ct is the last measurable drug concentration and λz is the terminal elimination rate 
constant calculated according to an appropriate method. The terminal or elimination 
half life of the drug should also be documented. 
 Peak drug concentration (Cmax) and the time to peak drug concentration (Tmax), 
obtained directly from the data without interpolation.  
For multiple-dose studies, the parameters measured are: 
 Area under the plasma / blood concentration-time curve from time zero to time  over 
a dosing interval at steady state (AUC0-), where  is the dosing interval. 
 Peak drug concentration (Cmax) and the time to peak drug concentration (Tmax), 
obtained directly from the data without interpolation, after the last dose is 
administered.  
 Drug concentrations at the end of each dosing interval during steady state (Cmin). 
 Average drug concentration at steady state (Cav), where Cav = AUC0- /. 
 Degree of fluctuation (DF) at steady state, where DF = 100% × (Cmax — Cmin) / Cav.      
2.5.2 Statistical analysis 
The pharmacokinetic parameters AUC and Cmax are analyzed statistically to determine if 
the test and reference products produce comparable values. The FDA’s statistical criteria 
for approval of test or generic drugs requires calculation of a confidence interval (CI) for 
the ratio between the means of test and reference product’s pharmacokinetic variables. 
The two products are said to be bioequivalent if the 90% CI for the ratio of test to 
reference formulation falls within the bioequivalence acceptance range of 80-120% for 
data in original scale and 80-125% for log-transformed data of AUC and Cmax. This 
method is equivalent to a testing procedure called two one-sided tests (TOST) procedure, 
where one test verifies that the bioavailability of the test product is not too low and the 
other to show that it is not too high as compared to standard reference product. The 
current practice is to carry out two one-sided tests (TOST) procedure with the null 
hypothesis (H0) of non-bioequivalence at 5% level of significance (α=0.05). Traditional 
statistical approach is often designed to test the null hypothesis of equality. If data is 
sufficiently strong, null hypothesis is rejected and alternate hypothesis (H1) is accepted. 
Before 1980s, most of the bioequivalence studies were conducted in this way; researchers 
tested for differences between drug formulations and if they found none, they concluded 
them to be bioequivalent (i.e. H0 = bioequivalence, H1 = non-bioequivalence). During 
further studies, many flaws were recognized in this approach. If sample size was large 
enough, minor differences even not important clinically, were found to be significant, 
whereas if sample size was small, the potential important differences were neglected.  
The purpose of bioequivalence (BE) study is generally not to demonstrate a difference but 
to assess the equivalence of test product to that of reference standard. So the method of 
difference statistics with null hypothesis of no difference is not applicable to BE studies. 
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Instead, the equivalence testing with the null hypothesis of a difference or non-
bioequivalence is used. According to the FDA this difference is set at –20 / +25 percent.  
In order to verify that –20 / +25 percent rule is satisfied, the two one-sided tests are 
carried out. The rejection of the two one-sided tests null hypotheses at 5% level of 
significance (α=0.05) is equivalent to the inclusion of the 90 percent CI in the acceptance 
range (Hauschke et al., 2007; Riffenburgh, 2006; Welage et al., 2001; FDA, 1992, 2001a; 
Pidgen, 1996; Hauck & Anderson, 1992; Schuirmann, 1987).  
The statistical analysis ANOVA (analysis of variance) is used to calculate estimates of the 
error variance. ANOVA should be performed on AUC and Cmax accounting for the sources 
of variation which are: 
 Sequence (group) 
 Subjects in a sequence 
 Period (phase)  
 Treatment (drug formulation).  
The results of ANOVA are calculated at 5% level of significance (α=0.05). The sponsor may 
use untransformed or log-transformed data. The choice should be made with concurrence 
by the FDA prior to conducting the study. The validity of statistical analysis is improved by 
log-transforming the raw data prior to analysis (FDA, 1992).    
2.6 Presentation and documentation of data 
The drug concentration in the biological fluid at each sampling time point for all the subjects 
should be presented in original form. Pharmacokinetic parameters like Cmax, Cmin, Tmax, are 
directly observed from original data. Pharmacokinetic parameters like AUC0-t, AUC0–∞, 
AUC0-, λz, t1/2 are derived from original data by mathematical calculations or by using 
different softwares like APO MWPHARM, PK Solutions, PK-fit and WinNonlin PK 
software. The pharmacokinetic data recommended for submission is: 
 Plasma concentrations and time points 
 Subject, period, sequence, treatment 
 AUC0-t, AUC0–∞,  λz, t1/2, Cmax and Tmax 
 AUC0-, Cmin, Cav and degree of fluctuation are also submitted for multiple-dose studies 
 Intersubject, intrasubject, and/or total variability 
The mean values and standard deviation (SD) can be calculated by computer programs like 
Microsoft Excel, SAS, SPSS. The statistical analysis for bioequivalence testing is carried out 
by using different computer softwares like EquivTest 2.0, Minitab Release 13.1, BioEquiv 
and DAS 2.0 software. The statistical information recommended to be provided for 
pharmacokinetic parameters are: 
 Geometric mean 
 Arithmetic mean 
 Ratio of means 
 Confidence interval 






Parameters Test mean ± SD 
Reference 







(hr.mg/l)     
AUC(0-∞)  
(hr.mg/l)     
Cmax (mg/l)     
Tmax (hrs)     
Table 2. Bioequivalence Parameters    
3. Waivers of in vivo bioequivalence studies   
Under certain circumstances, FDA may waive the requirement for in vivo bioequivalence 
studies if drug product meets one of the following criteria: 
 When the drug product is a parentral solution intended solely for administration by 
injection, and contains the active drug ingredient in the same solvent and concentration 
as a solution that is subject of an approved full New Drug Application (NDA). 
 The drug product is a topically applied preparation intended for local therapeutic effect 
e.g. ophthalmic/otic solutions or it is administered by inhalation and contains the active 
drug ingredient in the same dosage form as a drug product that is the subject of an 
approved full NDA and ANDA. 
 The drug product is a solution for application to the skin, an oral solution, elixir, syrup, 
tincture, a solution for nebulization, a nasal solution, or similar other solubilized form, 
and contains an active drug ingredient in the same concentration and dosage form as a 
drug product that is the subject of an approved full NDA or ANDA, and contains no 
inactive ingredient or other change in formulation from the drug product that is the 
subject of an approved full NDA and ANDA that may significantly affect absorption of 
the active drug ingredient or moiety for products that are systemically absorbed, or that 
may significantly affect systemic or local availability for products intended to act 
locally. 
 The drug product is a solid oral dosage form (other than controlled release or enteric-
coated) that has been determined to be effective for at least one indication in a Drug 
Efficacy Study Implementation (DESI) notice and is not included in the FDA list of 
drugs for which in vivo bioequivalence testing is required.  
 The in vivo bioavailability or bioequivalence may be self-evident for certain drug 
products. The FDA may waive the requirement for the submission of evidence obtained 
by in vivo measuring the bioavailability or demonstrating the bioequivalence of these 
drug products. A drug product’s in vivo bioavailability or bioequivalence may be 
considered self-evident based on other data in the application.  
 For certain drug products, bioavailability or bioequivalence may be demonstrated by 
evidence obtained in vitro in lieu of in vivo data. The FDA may waive the requirement of 
the submission of in vivo data if a drug product meets the following criteria: 
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 The drug product is in the same dosage form, but in the different strength, and is 
proportionally similar in its active and inactive ingredients to another drug product 
for which the same manufacturer has got the approval and certain conditions are 
met, that the bioavailability of this other drug product has been measured and both 
meet an appropriate in vitro test approved by the FDA; and the applicant submits 
evidence showing that both products are proportionally similar in their active and 
inactive ingredients. 
 The drug product is shown to meet an in vitro test that assures bioavailability, that 
in vitro test has been correlated with in vivo data. 
 The drug product, for which only an in vitro bioequivalence data has been required 
by FDA for approval. 
 The drug product is a reformulated product that is identical, except for a different 
color, flavor, or preservative, to another drug product for which the same 
manufacturer has obtained approval and the following conditions are met: the 
bioavailability of the other product has been measured; and both the drug products 
meet an appropriate in vitro test approved by the FDA.                   
In above circumstances bioequivalence studies may be waived by the drug regulatory 
authorities (FDA, 2011, 2000, 2003; Niazi, 2007; CDSCO, 2005; Makoid et al., 1999). 
4. Conclusion 
Keeping in view the health-care cost, the pharmaceutical companies are manufacturing and 
marketing cheaper generic drug products. It is vital for the regulatory authorities of every 
country to ensure the efficacy and safety of these generic formulations. Carefully planned 
and designed bioequivalence studies are the only way to ensure uniformity in standards of 
quality, efficacy and safety of pharmaceutical products. 
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1. Introduction  
The analyte to be measured in a Bioequivalence study when an oral drug undergoes a 
metabolic step in intestine or liver is still today a controversial issue with different 
recommendations in European Medicines Agency (EMEA/EMA) and Food and Drug 
Administration (FDA) guidance documents (EMA, 2010; EMEA, 2001; FDA, 2002). 
In the current EMA guidance it is stated that in principle, evaluation of bioequivalence 
should be based upon measured concentrations of the parent compound (also for inactive 
pro-drugs) as the Cmax of the parent compound is usually more sensitive to detect 
differences in absorption rate than the  Cmax of the metabolite. Only for some pro-drugs 
with very low plasma concentrations and quickly eliminated it is acceptable to demonstrate 
bioequivalence for the main active metabolite without measurement of parent compound. 
Nevertheless in these exceptional cases the applicant should adequately justify that it is not 
possible to reliably measure the parent compound after single dose administration (even 
with supra-therapeutic doses) and moreover the applicant should present any available data 
supporting the view that the metabolite exposure will reflect parent drug and that the 
metabolite formation is not saturated at therapeutic doses (EMA, 2010)  
FDA guidance recommends metabolite measurement if it is formed as a result of gut-wall or 
other pre-systemic metabolism and if the metabolite contributes meaningfully to safety 
and/or efficacy. In this case parent drug data is used to confidence interval approach 
whereas metabolite data is used as supportive evidence of comparable therapeutic outcome 
(FDA, 2002). 
The extent of pre-systemic metabolism and the non-linearity of the metabolic processes are 
the controversial aspects that require harmonization with regards to analyte selection. The 
lack of agreement in FDA and EMEA/EMA recommendations and the changes in the new 
                                                 
*  This article reflects the author’s personal opinion and not necessarily the policy or recommendations 
of the AEMPS. 
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EMA guideline makes evident that the simulations on which those recommendations were 
based, if any, were performed in different set of scenarios under a different set of 
assumptions leading to different answers to the same question.  
2. Simulation models of bioequivalence scenarios 
The critical issues that have been considered in the literature to create the simulated 
scenarios, apart from the true differences in extent and/or rate of absorption are  
a. the extent of pre-systemic metabolism, intestinal or hepatic 
b. the non-linearity of the metabolic processes 
c. the intrinsic clearance magnitude (high or low) and  
d. the intra-subject variability (high or low) 
For instance Chen and Jackson (Chen & Jackson, 1991,1995) and Jackson (Jackson, 2000) 
constructed models of two compartments with and without a linear metabolic step. They 
considered the difference in absorption rate with Cmax as target parameter and the final 
criterion to select the best analyte was intra-individual variability.  
The factor of parent drug or metabolite variability, nevertheless, is an arguable aspect to 
make a decision about the analyte. Once a study design is selected, the larger the intra-
subject (inter-occasion) variability of the analyte, the lower the percentage of successful 
bioequivalent studies for a given real difference. In another words, the lack of power can be 
solved by increasing the number of patients in the study but the lack of sensitivity cannot be 
improved once the insensitive analyte has been selected. The ability to reflect the 
formulations differences in the estimations (accuracy) should not be confounded with the 
variability of the estimations (precision). The analyte selection should be based on the 
accuracy of the estimations. Statistically, the consumer and producer risk offered by each 
analyte (with the adequate sample size) should be the main determinants for this decision 
(Fernandez-Teruel et al., 2009b). 
The issue of parent drug and metabolite variability has been addressed in other papers 
based on simulations with controversial conclusions (Blume & Midha, 1993; Jackson, 2000; 
Rosenbaum, 1998). Many of these simulation works have employed the percentage of failed 
studies as end-point to select the analyte to be measured. This depends not only on the 
difference between formulations but also, and in a higher extent, on the variability of the 
analytes. In spite of the interest of sponsors in decreasing the percentage of failed studies, to 
select the analyte based on its rate of failures should never be the regulatory criterion. On 
the contrary, the study design and analyte should be defined according to their ability to 
detect differences between formulations (i.e reducing the consumer risk of accepting 
bioinequivalent formulations)(Fernandez-Teruel et al., 2009a; 2009c)  
Brady and Jackson (Braddy & Jackson, 2010) used a model similar to Chen and Jackson 
models but with non linear metabolism. As in the previous papers the main conclusion was 
that the parent drug (either AUC or Cmax data) was more sensitive to formulation 
differences than the metabolite. Apart from their simplicity the main objection of these 
models was the over parameterization as the first-pass metabolic clearance was modelled as 
a different and independent parameter than the metabolic systemic clearance. 
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A second group of papers present simulations based on semi-physiological models 
(Rosenbaum, 1998; Rosenbaum & Lam, 1997; Tucker et al., 1993)  that solved the over-
parameterization issue but they do not included in the simulations the problem of non-
linear metabolism. In all the cases, their simulations showed that parent drug and 
metabolite have the same sensitivity to detect differences in extent of absorption (AUC) 
when the system is linear, but the Cmax of parent drug is more sensitive to differences in 
rate of absorption. 
The study design (single dose versus steady state studies) has also been addressed by 
simulation approaches (el-Tahtawy et al., 1994, 1995; 1998; Jackson, 1987, 1989, 2000; Zha & 
Endrenyi, 1997) with the conclusion that single dose studies are more sensitive to detect 
differences in absorption rate. 
3. BCS-based simulations 
The Biopharmaceutic classification system (BCS) has changed the focus of bioequivalence 
demonstration from plasma levels to the absorption site, as permeability of the intestinal 
membrane (P), solubility (S) in luminal fluids and in vivo dissolution rate are recognized as 
the main determinants of rate and extent of absorption. The combination of the two levels of 
the permeability and solubility factors (High (H) or Low (L) permeability and High or Low 
solubility) defines the 4 BCS classes (Class 1: HP, HS ; Class 2: HP, LS; Class 3: LP, HS;  
Class 4: LP, LS) (Amidon et al., 1995; FDA, 2000) 
It is generally accepted, and it has been shown through gastrointestinal simulation 
technology (computer simulations) that for class 1 and 3 formulation impact on extent of 
absorption is minimal, and regarding absorption rate, the formulation influence is also 
minimal for class 3 drugs while it could be reflected in Cmax differences for class 1 drugs 
(Kuentz, 2008). Class 2 drugs having good permeability but low solubility are the candidates 
showing a great dependence on formulation factors as for these drugs solubility and in vivo 
dissolution rate are the limiting factors. As BCS classification is relevant for the probabilities 
of bioequivalence problems related to the formulation, this classification system has been 
taken into account recently for the simulation approach to the analyte selection discussion 
(Fernandez-Teruel et al., 2009a; 2009b; 2009c; Navarro-Fontestad et al., 2010)  
The authors addressed all the issues mentioned in the previous section that have been 
discussed in the literature i.e. the intrinsic clearance magnitude, the variability of the 
analyte, the linearity of the metabolic step and single dose versus steady state designs. In 
top of that, the four drug BCS classes were simulated in formulations of decreasing 
quality compared to the reference one. Results were analyzed from the point of view of 
the analyte giving the right answer to the BE criteria. As BE scenarios were simulated for 
each drug, it was possible to calculate which analyte detects better the lack of 
pharmaceutical quality. 
The authors explored semi-physiological models of increasing complexity starting with a 
model considering  hepatic first pass effect under linear and non linear conditions, then, 
adding the intestinal metabolic step and finally considering the existence of two metabolic 
pathways of different magnitude.  The latest addition to those models is the involvement 
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of intestinal transporters that could eventually lead to a non linearity in the absorption 
process. 
In all the models the scheme for generating the scenarios is depicted in Figure 1 and briefly 
































































Scenarios: 4BCS x 2Clearance x 2variability x 6quality x 2 kinetic x 2design = 384  
Ka: absorption rate constant; Kd: in vivo dissolution rate constant; IO Var: inter-occasion variability 
expressed as %; SD: single dose; SS: steady state 
Fig. 1. Scenarios and drug types generation scheme for performing the BCS-based  
simulations. The semiphysiological models of increasing complexity were tested under 
these assumptions for a given set of pharmacokinetic parameters.  
(Fernandez-Teruel et al., 2009b, with permission from the authors). 
3.1 Description of drug types, study designs and explored scenarios 
The aim of these simulations was to define the most sensitive analyte, parent drug or 
metabolite, for in vivo bioequivalence studies. In this way, several drug types, study design 
and scenarios are used: 
 Drug types: simulations can be made for different class of drugs by varying the kinetic 
parameter values as clearance, permeability, solubility. Simulations have been 
performed for: 
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 Four drug classes corresponding to Biopharmaceutical Classification System by 
combining high and low permeability (Ka) and solubility (S). 
 High and low intrinsic hepatic clearance (Clint,0H). 
 High and low inter-individual variability in intrinsic hepatic clearance (this point 
will be explained in detail in the model). 
 High and low Michaelis-Menten constant (KmH): differences between this 
parameter and liver drug concentrations defines the metabolic pathway saturation 
so when KmH is small (it takes values around liver drug concentrations) the 
metabolism becomes non-linear (saturated), but when KmH is large (it takes values 
so much greater than liver drug concentrations) the metabolic system remains 
linear (non-saturated). 
 Study design: it refers to perform the bioequivalence study after dosing the drug in 
single dose or in multiple doses. In the case of multiple doses, drug is administered 
every 8 hours (or a dosing scheme considered) and the bioequivalence study should be 
performed when steady state is reached. 
 Scenarios: defining the most sensitive analyte to detect differences in pharmaceutical 
quality performance requires comparing a reference product with different test 
products of varying quality. This pharmaceutical quality has been defined in these 
simulations as similar dissolution rate constant, so good quality has been considered 
when reference and test products have similar dissolution rate constant value (in vivo 
in lumen), and six different scenarios were explored by decreasing the value of this 
parameter from 100% to 3% of reference value. 
The combination of all these different factors and levels correspond to a total of 384 
bioequivalence scenarios:  32 drug types explored at single dose and steady state, by using 6 
different formulations of decreasing quality compared to the reference one. The 
pharmacokinetic parameters used in Table 1. 
3.2 The model implementation 
A detailed explanation of the mathematical description of this semi-physiological 
approach is presented here as well as some examples of the outcomes that could be 
obtained in order to illustrate how this tool can be applied to particular drugs with known 
pharmacokinetics parameters in order to not only select the best analyte and study design 
but also to explore the impact of the quality of the formulation on the outcome of the 
Bioequivalence trial thus allowing to risk-analysis based decisions. A basic scheme of the 
model is shown in Figure 2. 
The model is a semi-physiological one which includes six compartments: intestinal lumen 
(C1), liver (C2), systemic compartment (C3), metabolite compartment (C4), solid dosage 
form (C5) and kidney (C6). Each compartment is represented by Cn, and the processes 
involved in drug pharmacokinetics are represented by En.  
The solid dosage form is administered by oral route, and it dissolves in lumen (E1). Then, 
the dissolved fraction can be degraded in lumen (E2) or absorbed (E3), but the absorption 
process duration depends on the intestinal transit time. Once absorbed, the drug is partially 
metabolized in the liver (E4) and it reaches the systemic plasma compartment, where the 
drug is rapidly distributed. Finally, the drug is eliminated by both routes: hepatic 
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the dissolved fraction can be degraded in lumen (E2) or absorbed (E3), but the absorption 
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metabolism (E4) and renal excretion (E5), while the metabolite formed is eliminated by renal 
excretion (E6).  
 
  
Fig. 2. The basic semi-physiological model used to perform simulations of BE trials for all 
BCS drugs. These model can be updated with more processes (as intestinal metabolism, or 
different metabolic routes).  
 
Parameter Value
Operative absorption time (OAT) (h) 7 
Degradation rate in lumen (h−1) 0 
Dissolution rate for reference form (h−1 mg−1) 4 
Maximum soluble amount (mg)  
10 
1000 
Intrinsic absorption rate constant of the drug(h−1)
0.2 
2 
Intrinsic clearance (L/h) 
10 
300 
Km intrinsic clearance (mg/L) 
1 
10000 
Renal clearance of parent drug (L/h) 0.05 
Clearance of metabolite (L/h) 20 
Hepatic flow (QH) (L/h) 90 
Central compartment volume (L) 40 
Hepatic volume (L) 1 
Metabolite compartment volume (L) 40 
Table 1. Pharmacokinetic parameters used in the simulations of Bioequivalence trials 
 
Computer Simulations as a Tool for Optimizing Bioequivalence Trials 
 
23 
1. Dissolution in lumen (E1) is considered limited by the solubility:  
 1 5 1E Kd·  A · (S - A )  (1) 
Where E1 is the dissolution rate, A1and A5 represent the amount of drug in lumen and in 
solid dosage form respectively and S is the maximum soluble amount. The term Kd should 
not be interpreted as the first order dissolution rate as it has units of h-1•mg-1 . This 
parameterization is equivalent to this second one:  
 11 5 1 AE Kdis·  A · 
S
   
 
 (2) 
where Kdis would represent the typical first order intrinsic dissolution rate constant and its 
units would be h-1. 
2. The drug dissolved can be degraded in lumen (E2) or absorbed (E3): 
 2 1degE K ·  A  (3) 
Where E2 is the degradation rate, Kdeg is the first order degradation rate constant and A1 
the amount of drug in lumen. The luminal degradation was fixed to zero in the simulations, 
but both the degradation kinetic model and the value of the corresponding parameters can 
be easily changed to accommodate a degradation step in lumen.  
Drug absorption can be implemented as a first order process: 
  3 1·E Ka·  A   (4) 
Where E3 is the absorption rate, Ka the first order absorption rate constant and A1 the 
amount of drug in lumen and α is the operator to account for the intestinal transit time. α 
takes value "1" when the time is less than the intestinal transit time (or operative absorption 
time OAT in the model) and is set to "0" when time is higher than OAT. 
After the OAT the compartment dose C5 was reset to zero, simulating the effect of the 
intestinal transit and therefore the drug in solid form was not accumulated in the gut for the 
scenarios of multiple dosage administrations. 
Other absorption kinetics can be easily implemented, as an active absorption transport or an 
efflux mechanism, by adding the corresponding term to the equation. 
For example in order to account for an efflux transport mechanism, a new compartment 










·13   (5) 
where VmE and KmE are the Michaelis-Menten parameters and Cgut is the concentration in 
gut wall. 
3. The drug is partially metabolized in the liver (E4) after its absorption: 
 4 2· ·E H EH C  (6) 
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The hepatic metabolic rate E4 depends on the hepatic blood flow (ΦH), the drug 
concentration in the liver (C2) and the hepatic extraction ratio (EH). 
EH is a parameter dependent on the hepatic blood flow (ΦH), and the intrinsic clearance at 

























Thus  Clint, CH is a non-linear function of three parameters: clearance at infinite blood flow 
and zero hepatic concentration (Clint, 0H), the Michaelis-Menten value (KmH) and liver drug 
concentration (C2). 
Thanks to this modeling of the hepatic metabolism a wide range of drug types and scenarios 
can be explored by changing the value of the intrinsic clearance or by changing the value of 
KmH. that would lead to linear or non linear conditions depending on the liver 
concentrations compared to KmH. In another words first-pass effect was managed as linear 
using a high value of KmH and as non linear using a KmH value around the drug 
concentration found in liver. 
4. Drug is eliminated by hepatic metabolism (E4) and renal excretion (E5): 
 5 3E Clrenal·  C  (9) 
Where E5 represents the renal excretion rate. Clrenal is the renal clearance of drug and C3 is 
the drug concentration in systemic compartment (so it is assumed that systemic 
concentration equals the concentration in kidney). 
As in the other kinetic processes, different excretion mechanism or kinetics (linear-non 
linear)  can be considered and easily implemented. 
a. Gut metabolism:(Navarro-Fontestad et al., 2010) In order to describe a first pass 
metabolic step in small intestinal tissue, similar equations as the ones used for 
describing hepatic metabolism can be implemented: 





















where ‘G’ corresponds to ‘GUT’ parameters, and Cgut is the drug concentration in gut 
compartment. The other parameters having the same meaning than previously explained i.e 
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E metabolism rate, EG extraction ratio in gut and Clint intrinsic clearance (in the examples 
presented in this chapter gut metabolim was not included.) 
b. Several metabolic pathways:(Navarro-Fontestad et al., 2010) it can be considered 
that drug is metabolized by two different routes, leading to different metabolites. 
The way to implement this model is equivalent to the present one, but it is 
important to estimate in a good way the extraction ratio, because EH (or ‘EG’) is 




































































 where M1 and M2 correspond to parameters (intrinsic clearance, Michaelis-Menten 
constant or extraction ratio) for metabolite 1 and 2 respectively and the other terms have 
been already defined. 
5. Metabolite formed is eliminated by renal excretion (E6): 
 6 4E Clmet·  C  (17) 
where E6 represents the excretion rate of the metabolite, Clmet is the renal clearance of 
metabolite and C4 is the plasma concentration of metabolite. 
Metabolite elimination could be also described a sequential phase where the first generation 
of metabolites is also eliminated by metabolism so a second generation of metabolite(s) is 
formed. 
Once the individual kinetic processes have been described, the next step is to build the 
equations describing the time-concentration profile in each compartment: 
 Intestinal lumen: drug is dissolved in lumen (E1) and then it can be degraded in lumen 
(E2) or absorbed (E3). 
  1 5 1 1 1deg· · ·dA Kd·  A · (S - A ) K A Ka A
dt
    (18) 
where dA1/dt represents the drug amount change over time in lumen. 
 Liver compartment: after absorption (E3), drug is partially metabolized in the liver (E4), 
and it is distributed to systemic compartment. 
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The hepatic metabolic rate E4 depends on the hepatic blood flow (ΦH), the drug 
concentration in the liver (C2) and the hepatic extraction ratio (EH). 
EH is a parameter dependent on the hepatic blood flow (ΦH), and the intrinsic clearance at 

























Thus  Clint, CH is a non-linear function of three parameters: clearance at infinite blood flow 
and zero hepatic concentration (Clint, 0H), the Michaelis-Menten value (KmH) and liver drug 
concentration (C2). 
Thanks to this modeling of the hepatic metabolism a wide range of drug types and scenarios 
can be explored by changing the value of the intrinsic clearance or by changing the value of 
KmH. that would lead to linear or non linear conditions depending on the liver 
concentrations compared to KmH. In another words first-pass effect was managed as linear 
using a high value of KmH and as non linear using a KmH value around the drug 
concentration found in liver. 
4. Drug is eliminated by hepatic metabolism (E4) and renal excretion (E5): 
 5 3E Clrenal·  C  (9) 
Where E5 represents the renal excretion rate. Clrenal is the renal clearance of drug and C3 is 
the drug concentration in systemic compartment (so it is assumed that systemic 
concentration equals the concentration in kidney). 
As in the other kinetic processes, different excretion mechanism or kinetics (linear-non 
linear)  can be considered and easily implemented. 
a. Gut metabolism:(Navarro-Fontestad et al., 2010) In order to describe a first pass 
metabolic step in small intestinal tissue, similar equations as the ones used for 
describing hepatic metabolism can be implemented: 





















where ‘G’ corresponds to ‘GUT’ parameters, and Cgut is the drug concentration in gut 
compartment. The other parameters having the same meaning than previously explained i.e 
 
Computer Simulations as a Tool for Optimizing Bioequivalence Trials 
 
25 
E metabolism rate, EG extraction ratio in gut and Clint intrinsic clearance (in the examples 
presented in this chapter gut metabolim was not included.) 
b. Several metabolic pathways:(Navarro-Fontestad et al., 2010) it can be considered 
that drug is metabolized by two different routes, leading to different metabolites. 
The way to implement this model is equivalent to the present one, but it is 
important to estimate in a good way the extraction ratio, because EH (or ‘EG’) is 




































































 where M1 and M2 correspond to parameters (intrinsic clearance, Michaelis-Menten 
constant or extraction ratio) for metabolite 1 and 2 respectively and the other terms have 
been already defined. 
5. Metabolite formed is eliminated by renal excretion (E6): 
 6 4E Clmet·  C  (17) 
where E6 represents the excretion rate of the metabolite, Clmet is the renal clearance of 
metabolite and C4 is the plasma concentration of metabolite. 
Metabolite elimination could be also described a sequential phase where the first generation 
of metabolites is also eliminated by metabolism so a second generation of metabolite(s) is 
formed. 
Once the individual kinetic processes have been described, the next step is to build the 
equations describing the time-concentration profile in each compartment: 
 Intestinal lumen: drug is dissolved in lumen (E1) and then it can be degraded in lumen 
(E2) or absorbed (E3). 
  1 5 1 1 1deg· · ·dA Kd·  A · (S - A ) K A Ka A
dt
    (18) 
where dA1/dt represents the drug amount change over time in lumen. 
 Liver compartment: after absorption (E3), drug is partially metabolized in the liver (E4), 
and it is distributed to systemic compartment. 
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  2 1 2 3· · · · ·dA Ka A H EH C H C
dt
      (19) 
where dA2/dt represents the drug amount change over time in liver and ΦH•C3 represents 
distribution from systemic compartment to the liver. 
 Systemic compartment: Drug is rapidly distributed in systemic compartment, and the 
elimination of parent drug is renal (E5) and hepatic (E4). 
 3 2 3 3· · · ·dA H FH C H C Clrenal C
dt
     (20) 
where dA3/dt represents the drug amount change over time in plasma and ΦH•FH•C2 
corresponds to the fraction of drug escaping metabolism in liver (FH=1-EH) 
 Metabolite compartment: finally, the metabolite formed (E4) is eliminated by renal 
excretion (E6) 
 42··4 Clmet · CCEHH
dt
dA
  (21) 
 Solid dosage form compartment: Dosage solid form has to be dissolved in lumen (E1) in 
order to release the drug for absorption. This compartment was added at the end of 
model, although dissolution form solid form is the first kinetic process, because of 
model development reasons as in first place the behaviour of the model was checked 
for a drug solution and then the dissolution from different dosage forms (or 
formulations) was implemented. 
 5 5 1dA Kd·  A · (S - A )
dt
   (22) 
dA5/dt represents the dissolution from the dosage form and the other terms have been 
previously defined. 
3.3 Description of bioequivalence studies 
All bioequivalence studies were evaluated with 2400 simulations per study. The number of 
healthy volunteers per study was 24, and they were distributed into two groups of 12 
volunteers receiving the formulations in a cross-over design. Each volunteer received an 
oral dose of 100mg of drug products, reference and test in solid dosage form, with a period 
of a washout between the doses. 
A total of 17 samples of both analytes, parent drug and metabolite, were collected for each 
individual at 0.1, 0.2, 0.4, 0.8,1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48h after the administration 
of the drug at single dose. In the case of multiple doses, drug was administered every 8 h 
until steady state was attained (160 hours) and a total of 10 samples of parent drug and 
metabolite were collected at 0.1, 0.2, 0.4, 0.8, 1, 2, 4, 6, 8h after the administration of reference 
or test product. 
For the bioequivalence analysis, AUC0-t (calculated by trapezoidal rule) and Cmax were 
considered: differences between dissolution rates from test and reference products are 
transformed into AUC and Cmax ratios of both analytes for each drug type and scenario: 
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 AUC ratio=(AUC test)/(AUC reference) (23) 
 Cmax ratio=(Cmax test)/(Cmax reference) (24) 
These results are then presented as bar graphs where each color and group bars represents a 
different analyte and scenario, respectively. 
For the bioequivalence analysis, 90% confidence intervals (90%CI) were calculated for the 
ratio of AUC0-t and Cmax values for the test and reference dosage forms, using logarithmic 
transformed data. ANOVA was used to assess the formulation, subject and period effects. 
Finally, reference and test dosage forms were considered bioequivalent if the 90%CI 
ofAUC0-t and Cmax ratios lay inside 80–125% limits. 
On the other hand, the percentage of studies which would conclude bioequivalence using 
each  analyte separately (with this particular study design of 24 subjects) can be estimated 
and compared to the nominal percentage of failure of 5%. (Type  I error: failure is 
considered when a bioequivalence study states bioequivalence when the products were 
actually non-equivalent.) 
3.4 Individual parameters and data simulation 
Parameter values presented in Table 1 correspond to the population parameters values. The 
individual parameters were generated from these population parameters using an 
exponential model. Moreover, an inter-occasion variability was added to the individual 
parameters due to reference and test products are administered in different times: 
 1 1 2 2· ·· · ·IID IO O IO OPi Pp e e e    (25) 
where Pp is the population parameter; Pi is the individual  parameter; ηIID is the inter-
individual variability; ηIO1 is the inter-occasion variability corresponding to first 
administration (O1) and ηIO2 is the inter-occasion variability corresponding to second 
administration (O2). O1 and O2 are the identifier variables for occasion 1 and 2 
In these simulations, inter-individual variability of 20% was added to all parameters, while 
an inter-occasion of 10% was fixed in all parameters with the exception of intrinsic hepatic 
clearance for which a high (30%) or low (10%) level of inter-occasion (or intra-individual) 
variability was considered.  
Finally, the individual plasma concentrations were simulated with the structural model, the 
individual parameters and a proportional residual error: 
    1,  ,  ·iCp f Pi Dose Time    (26) 
where Cpi is the individual concentration and ε is the residual error. 
Other different approach can be used in order to generate population and individual 
parameters: if it is necessary to add different effects to the parameters, as sequence, period 
or formulation effects, the population parameters could be generated by using a 
multiplicative model as: 
 · · ·seq per formPp Pt Eseq Eper Eform  (27) 
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considered when a bioequivalence study states bioequivalence when the products were 
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parameters due to reference and test products are administered in different times: 
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Other different approach can be used in order to generate population and individual 
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where Pt is the typical parameter; "Eseq", "Eper" and "Eform" are the effects corresponding 
to the sequence, period and formulation respectively; and "seq", "per" and "form" are the 
identifiers of sequence, period and formulation respectively. 
All these effects can be coded in the model and fixed to zero, in order to be easily modified. 
All simulations were performed in NONMEM VI. The control files were edited under 
Microsoft Excel worksheet and the lines containing the parameters which defined the 
scenarios were identified. These lines were modified to produce all the scenarios using a 
Visual Basic (VB) code for Excel. The code included specific commands under 6 layers which 
were treated as loops for: solubility, absorption, clearance of parent drug, Km, inter-occasion 
variability in intrinsic hepatic clearance and dissolution rate for test. The VB code created 
192 scenarios which were executed under batch processing. The same control file was used 
for single and multiple dosage simulations as the databases defined this additional layer to 
simulate the 384 scenarios above declared.  
The control file managed the differential equations to simulate the plasma concentrations for 
test and reference drugs following the conditions defined in Table 1. Additionally the 
control file calculated the individual AUC and Cmax which were updated for each time. 
Therefore, the last time contained the final value of AUC and Cmax of each volunteer. All 
this information was reported in tables after run execution. 
The tables generated in each simulation had hundreds of thousands of records and were 
filtered with SPSS syntax to select the last record of each volunteer which contained the 
individual Cmax and AUC. 
The final step was to capture the 192 filtered tables under MS Excel and calculate using VB 
programming the AUC and Cmax ratios and ANOVA test for each simulated trial in each 
scenario. The results were reported into a worksheet of the Excel file with the mean AUC 
and Cmax ratios for each scenario and the percentage of bioequivalence achieved between 
test and reference.  
4. Results and discussion 
Modelling and simulation approaches are useful tools to assess the potential outcome of 
different scenarios in bioequivalence studies. The aim of these studies  was to propose a new 
semi-physiological model for bioequivalence trial simulations and apply it for different drug 
classes by considering a basic structural model that can be easily modified to accommodate 
other kinetic processes or non-linearities in any of them. 
In order to present the results in a way easy to understand and useful for regulatory 
decisions or for optimization of the trial design, the AUC or Cmax ratios were plotted 
versus the pharmaceutical quality (decreased dissolution rate in vivo in lumen) and 
relative absorbed fraction. An example of this kind of plots is shown in Figures 2 and 3. 
These type of figures allow assessing how the decrease of biopharmaceutical quality of 
test product in each scenario is reflected in the average AUC or Cmax ratios of parent 
drug or metabolite so it is easily observed which one is more sensitive to the changes in 
quality. 
 




PD: Parent drug; PM: Principal metabolite; SM: Secondary metabolite 
Fig. 3. True AUC and Cmax ratios (y axis) versus the relative absorbed fraction (Fabs rel) 
and the relative dissolution rate constant (Kd rel expressed as %) (x axis) obtained for each 
scenario. This model corresponds to a class III drug, administered at low dose scheme in 
single dose, when both metabolic pathways become saturated 
In all the simulations performed with these models  parent drug is the most sensitive 
analyte to detect the differences of in vivo dissolution. Some exceptions to this rule have 
been detected but it would be desirable to check these results with real examples of 
pharmacokinetic parameters. i.e. with known parameters from particular drugs. 
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Fig. 3. True AUC and Cmax ratios (y axis) versus the relative absorbed fraction (Fabs rel) 
and the relative dissolution rate constant (Kd rel expressed as %) (x axis) obtained for each 
scenario. This model corresponds to a class III drug, administered at low dose scheme in 
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been detected but it would be desirable to check these results with real examples of 
pharmacokinetic parameters. i.e. with known parameters from particular drugs. 
 




PD: Parent drug; PM: Principal metabolite; SM: Secondary metabolite 
Fig. 4. True AUC and Cmax ratios (y axis) versus the relative absorbed fraction (Fabs rel) 
and the relative dissolution rate constant (Kd rel expressed as %) (x axis) obtained for each 
scenario. This model corresponds to a class III drug, administered at low dose scheme in 
single dose, when the principal metabolic pathway becomes saturated. 
For instance when a model with pre-systemic metabolism (intestinal and hepatic) was 
checked (Navarro-Fontestad et al., 2010) it was concluded that, the metabolites (either 
principal or secondary metabolite) do not show higher sensitivity than the parent drug to 
detect changes in the pharmaceutical performance, even when pharmacokinetics of the 
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parent drug is non-linear. In case of non-linear metabolism, higher parent drug sensitivity 
can be found, as compared with non-linear metabolites. Same conclusion was achieved in 
the case of linear hepatic metabolism despite of FDA requirements (Fernandez-Teruel et al., 
2009c).  
In the case of BCS classes with hepatic metabolism under linear conditions the differences in 
Cmax are detected more sensitively with the parent drug in the single dose study, except in 
the case of class III drugs with low intrinsic clearance (Fernandez-Teruel et al., 2009c)  
In the particular examples represented in Figures 3 and 4 where the participation of an 
efflux transporter at intestinal level has been included, the parent drug is the most sensitive 
analyte to detect the lack of pharmaceutical quality in the problem formulation versus the 
reference one. The presence of an efflux carrier in the structural part o of the model even if it 
is non-saturated does not change the outcome in relation to previous scenarios. 
Regarding the study design (single dose versus steady state) this aspect has been 
investigated in a model with hepatic metabolism under linear or non linear conditions and 
considering that a low percent of the dose is eliminated by renal clearance. With these 
assumptions interestingly, for class III drugs with non-linear pharmacokinetics the steady 
state design is necessary in addition to the single dose study, as required by EMEA and in 
contrast to FDA requirements, to compare with the highest sensitivity the Cmax of the 
parent drug not only in case of low intrinsic clearance but also in case of high intrinsic 
clearance and a small worsening of the in vivo dissolution (relative kd= 0.5). In the case of 
AUC (class III drugs) the steady state design is more sensitive in case of drugs with low 
intrinsic clearance but as sensitive as the single dose study when the intrinsic clearance is 
high (Fernandez-Teruel et al., 2009a)  
A particular concern about this result is that following the Biopharmaceutic and Drug 
Disposition Classification System, BDDCS (Benet et al., 2008; Chen et al., 2010; Wu & Benet, 
2005) it would be arguably that such a drug with high solubility, low permeability and 
highly metabolized (even if at slow rate) is an exception or does not exists. Further 
simulations with a higher renal clearance of parent drug to allow for a lower percent of the 
dose being metabolized should be done to clarify if the behavior is the same. 
5. Conclusions 
A simulation model of Bioequivalence trials have been developed taking into account the 
biopharmaceutical properties that determine rate and extent of absorption i.e. permeability, 
solubility and dissolution rate in relation with the human intestinal transit time. This BCS 
approximation have not been included in the previous simulation exercises found in the 
literature. 
This work illustrates a methodology that could be implemented by the applicant of a 
marketing authorization of a generic product in order to justify the selected study design 
and analyte. Once the pharmacokinetic behaviour of the drug under investigation in known 
it is possible to identify the sensitivity of the different active species in the different study 
designs. Some structural models have been explored but as it has been explained the model 
could be adapted to incorporate other kinetic processes and non linear components on them 
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as well as it could be possible to perform the simulations in saturating or non saturating 
conditions for each particular non linear step. 
The final objective would be to develop customized models for each particular drug in order 
to justify the selection of the bioequivalence study design and analyte or, when the most 
sensitive scenario cannot be performed due to analytical or tolerability/safety limitations, to 
estimate the loss of sensitivity of an alternative design that has to be used pragmatically. In 
summary, virtual bioequivalence studies may serve as a tool to guide regulatory decisions 
both for sponsors and Regulatory Agencies. 
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as well as it could be possible to perform the simulations in saturating or non saturating 
conditions for each particular non linear step. 
The final objective would be to develop customized models for each particular drug in order 
to justify the selection of the bioequivalence study design and analyte or, when the most 
sensitive scenario cannot be performed due to analytical or tolerability/safety limitations, to 
estimate the loss of sensitivity of an alternative design that has to be used pragmatically. In 
summary, virtual bioequivalence studies may serve as a tool to guide regulatory decisions 
both for sponsors and Regulatory Agencies. 
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1. Introduction 
Local enhanced tissue delivery (LETD) of non-steroidal anti-inflammatory drugs (NSAIDs) 
provides a means to avoid adverse effects, such as gastrointestinal disorders (Hawkey & 
Truelove, 1983; Taha et al., 1994). Regarding the skin dispositions of drugs, it is considered 
to be more important to evaluate the drug LETD from the formulation than the drug uptake 
into the body from the cutaneous microvascular network (Morgan et al., 2003). Assessment 
of drug concentrations in the skin is crucial for the development of topical products, such as 
patches, and other transdermal formulations. Several studies have demonstrated the skin 
permeabilities and local tissue concentrations of NSAIDs after topical administration (Singh 
& Rogerts, 1994; Grupta et al., 1995). However, the drug concentrations in those in vitro 
studies were calculated as accumulated volumes across the skin, and the drug contents 
within the skin consequently remain unclear. It has also been suggested that the diffusion 
length of the viable epidermis and dermis is longer in vitro than in vivo (Scheuplein, 1976), 
thereby leading to possible discrepancies in the permeation data between in vitro and in vivo 
studies. Almost all previous in vivo studies have evaluated drug concentrations within the 
whole skin layer after topical application. In addition, only one or two points of the skin 
were sampled and measured for their drug concentrations, and it therefore remains unclear 
how drugs permeate the skin layer from the surface to the deep regions over time. 
To solve such problems, we developed a new evaluation method involving transdermal 
pharmacokinetics (Goi et al., 2010). In this chapter, we first explain the details of the dermal 
lateral sectioning approach and clearly summarize the results. Next, we apply this 
evaluation method to a more realistic model. Finally, we analyze the correlation between the 
time course changes of the drug concentration at the deepest layer of skin and the 
expression rate of drug efficacy, and suggest that our lateral sectioning approach is an ideal 
method for predicting therapeutic expression. 
2. Evaluation method of transdermal drug permeability 
The aim of this study was to establish a new method for clearly analyzing the flow of drugs 
in the skin layers and evaluating the drug levels in the target area of the skin tissue. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
34
Tucker, G.T., et al. (1993).Bioequivalence—a measure of therapeutic equivalence?, In:Bio-
International: Bioavailability, Bioequivalence and Pharmacokinetics, Midha, K.K., Blume, 
H.H. (Eds.), pp. (35-43), Medpharm Scientific Publishers, Stuttgart 
Wu, C. Y. & Benet, L. Z. (2005). Predicting drug disposition via application of BCS: 
transport/absorption/ elimination interplay and development of a 
biopharmaceutics drug disposition classification system. Pharm Res, Vol.22, No.1, 
(Jan-2005), pp. (11-23), ISSN 0724-8741 
Zha, J. & Endrenyi, L. (1997). Variation of the peak concentration following single and 
repeated drug administrations in investigations of bioavailability and 
bioequivalence. J Biopharm Stat, Vol.7, No.1, (Mar-1997), pp. (191-204), ISSN 1054-
3406  
3 
Evaluation of Percutaneous  
Drug Permeation Using a Lateral  
Sectioning Approach  
Nobuhiro Goi, Katsunori Morishita,  
Akihito Taniguchi and Takayuki Ishii 
Mikasa Seiyaku Company Limited 
Japan 
1. Introduction 
Local enhanced tissue delivery (LETD) of non-steroidal anti-inflammatory drugs (NSAIDs) 
provides a means to avoid adverse effects, such as gastrointestinal disorders (Hawkey & 
Truelove, 1983; Taha et al., 1994). Regarding the skin dispositions of drugs, it is considered 
to be more important to evaluate the drug LETD from the formulation than the drug uptake 
into the body from the cutaneous microvascular network (Morgan et al., 2003). Assessment 
of drug concentrations in the skin is crucial for the development of topical products, such as 
patches, and other transdermal formulations. Several studies have demonstrated the skin 
permeabilities and local tissue concentrations of NSAIDs after topical administration (Singh 
& Rogerts, 1994; Grupta et al., 1995). However, the drug concentrations in those in vitro 
studies were calculated as accumulated volumes across the skin, and the drug contents 
within the skin consequently remain unclear. It has also been suggested that the diffusion 
length of the viable epidermis and dermis is longer in vitro than in vivo (Scheuplein, 1976), 
thereby leading to possible discrepancies in the permeation data between in vitro and in vivo 
studies. Almost all previous in vivo studies have evaluated drug concentrations within the 
whole skin layer after topical application. In addition, only one or two points of the skin 
were sampled and measured for their drug concentrations, and it therefore remains unclear 
how drugs permeate the skin layer from the surface to the deep regions over time. 
To solve such problems, we developed a new evaluation method involving transdermal 
pharmacokinetics (Goi et al., 2010). In this chapter, we first explain the details of the dermal 
lateral sectioning approach and clearly summarize the results. Next, we apply this 
evaluation method to a more realistic model. Finally, we analyze the correlation between the 
time course changes of the drug concentration at the deepest layer of skin and the 
expression rate of drug efficacy, and suggest that our lateral sectioning approach is an ideal 
method for predicting therapeutic expression. 
2. Evaluation method of transdermal drug permeability 
The aim of this study was to establish a new method for clearly analyzing the flow of drugs 
in the skin layers and evaluating the drug levels in the target area of the skin tissue. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
36
2.1 Animals  
All experiments were carried out in accordance with the Institutional Animal Care and Use 
Committee of Mikasa Seiyaku Co. Ltd. (Tokyo, Japan). Male hairless rats (8 weeks of age, 
weighing 190–250 g; Japan SLC Inc., Shizuoka, Japan) were used in all experiments. The rats 
were housed in an animal room with a room temperature of 23±2°C, relative humidity of 
55±15% and 12-h/12-h light/dark cycle (lights on at 07:00). The animals had free access to a 
mouse/rat diet (#5002, pellet form; PMI Nutrition International Inc., Richmond, IN) and tap 
water throughout the experiments. 
2.2 Drugs 
Flurbiprofen and ketoprofen are racemic propionic acid-derived NSAIDs with proven 
efficacy and safety in the treatment of osteoarthritis, rheumatoid arthritis and acute 
musculoskeletal disorders (Brogden et., 1979; Buchanan & Kassam, 1986; Waikakul et al., 
1997). As a matter of course, tape-type patches of flurbiprofen (FP-T) and ketoprofen (KP-T) 
have been used and investigated for their anti-inflammatory and analgesic effects on local 
tissues (Martens, 1997; Mazieres, 2005). 
The FP-T tape-type patches (ZEPOLAS® TAPE; Mikasa Seiyaku Co. Ltd., Tokyo, Japan) 
contained 2.2% flurbiprofen (1.1 mg/4 cm2) in a hydrophobic adhesive-like 
styrene/isoprene/styrene copolymer without water. The KP-T tape-type patches (MOHRUS® 
TAPE; Hisamitsu Pharmaceutical Co. Ltd., Tosu, Japan) contained 2% ketoprofen (1.1 mg/4 
cm2). Both patches are widely used clinically. Other chemical agents used were flurbiprofen 
and ketoprofen (purity, >99.7%; Daito Pharmaceutical Co. Ltd., Toyama, Japan). 
2.3 In vivo evaluation of the transdermal permeability of drugs  
Rats were anesthetized with ether and 2.0×2.0 cm flurbiprofen or ketoprofen patches were 
individually applied to the center of their abdomen. The region with the applied patch was 
covered with a bonded-fiber fabric bandage and the body was wrapped with an adhesive 
elasticized bandage (Elastopore® No. 50; Nichiban Co. Ltd., Tokyo, Japan) to prevent the patch 
from becoming dislodged. The rats were then housed individually in blanket cages (240 mm 
width × 380 mm length × 200 mm height) and supplied with food and water ad libitum. Both 
types of patches were removed at 2, 4, 8, 12, 14, 16 and 24 h after application, including an 
extra time point of 1 h after application for FP-T, and the rats were euthanized by collection of 
whole blood from the abdominal aorta under ether anesthesia. The area of skin tissue where 
each patch was applied was removed and the harvested skin tissues were embedded in OCT 
compound (Sakura Finetechnical Co. Ltd., Tokyo, Japan) and frozen at –80°C.  
The most important part of the technique was the procedure for freezing skin tissues in a 
flat manner. As shown in Fig. 1, the embedding agent was poured into a case to about half-
full and frozen in advance. The case was then left for about 15 min at room temperature and 
1) the surface of the embedding agent was lightly rubbed with the flat part of a finger to 
make the surface parallel. 2) Subsequently, the harvested skin tissues were placed on the flat 
surface and 3) pins were placed at the corners of the skin tissues to clarify the outline 
(because the place where the skin existed became unknown after the OCT compound was 
frozen). 4) Finally, the embedding agent was gently poured into the rest of the case and 
frozen at –80°C. 
 




Fig. 1. Procedure for freezing skin tissues in a flat manner. 
One-half of each frozen skin tissue sample (1.0×2.0 cm) was cut with a microtome (Cryotome 
CR-502; Nakagawa Co. Ltd., Tokyo, Japan) into 20 μm-thick slices parallel to the surface. The 
drug concentrations in the individual slices were measured after the slices were weighed. At 
this point in the slicing, the most crucial part of the handling was how the initial slice of frozen 
skin was cut parallel to the plane surface of the skin. When continued slicing became able to 
catch the embedded skin surface along the way, the angle of the cutting plane was adjusted 
and the slicing was operated several more times. This procedure was repeated until the cut 
plane became parallel to the surface of the skin tissue. Once the slicing of the skin was 
initiated, the operation was carried through without any further adjustments. The drug 
concentrations were obtained by dividing the measured amount of the drug in each skin slice 
by the weight of the slice. The microtome was not able to slice frozen samples thicker than 20 
μm. The other half of each frozen skin tissue sample was sliced perpendicular to the skin 
surface and stained with hematoxylin and eosin (HE) for measurements of the skin thickness. 
Images were obtained using a fluorescence microscope (IX81-ZDC; Olympus, Tokyo, Japan). 
For measurement of the thickness of each layer, 10 points of the layer in a microscopic field 
were randomly picked up and the thickness was calculated using the software Lumina Vision 
LV-WIN TM-SOFT (Mitani Co. Ltd., Fukui, Japan). The average value from each image was 
taken as the individual thickness of each layer. 
The thicknesses of the stratum corneum, epidermis and other tissues (dermal and 
subcutaneous tissues) were measured (Table 1) when the rats were 8 weeks of age (n=4). 
The whole skin thickness was approximately 700 μm and 35 pieces of skin tissue were 
theoretically obtained when the frozen tissues were sliced laterally every 20 μm. However, it 
was necessary to take account of individual differences and surface irregularities. Therefore, 
the skin tissue was sliced an extra five times (=100 μm thickness) and weighed, and the drug 
concentrations in the skin layers from 0 to 800 μm were measured. Images of the slicing and 
measuring protocol are shown in Fig. 2.  
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stratum corneum epidermis dermal and subcutaneous tissues 
15.9 ± 0.9 38.4 ± 2.0 659.8 ± 32.6 
        (μm) 
Table 1. Skin layer thicknesses of hairless rats 
2.4 Analytical methods 
The frozen skin tissue samples were dissolved in a solution at room temperature. Briefly, a 
piece of skin sample (about 3 mg) was added to 250 μL of 1 mol/L KOH and incubated at 
60°C for 15 min. Next, 750 µL of 5% (v/v) H3PO4 was added, and 500 μL of the resulting 
solution was subjected to solid-phase extraction (Oasis® MAX 96-Well Plate 30 μm; Waters, 
Milford, MA) after the cartridge had been successively prewashed with 1 mL of methanol 
and 1 mL of water. The cartridge was consecutively rinsed with 1 mL of 50 mM sodium 
acetate (pH 7.0) and 1 mL of methanol, and eluted with a mixed solution 
(isopropanol/acetonitrile/formic acid = 58:40:2). A 5-µL aliquot of each eluate was analyzed 
by HPLC and LC/MS. 
 
Fig. 2. Images of skin slicing and analysis of the drug contents of individual slices.  
The concentrations of flurbiprofen in the dissolution media were determined by HPLC. The 
HPLC conditions were as follows: pump, LC-20AD; detector, RF-10AXL; system controller, 
CBM-20A; auto-injector, SIL-20ACHT; column oven, CTO-20AC (Shimadzu Co. Ltd., Kyoto, 
Japan); column, ZORBAX SB-C18 (150×4.6 mm, 1.8-μm particles; Agilent Technologies Inc., 
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Wilmington, DE); column temperature, 60°C. The mobile phase consisted of acetonitrile and 
0.1% (v/v) formic acid at a ratio of 60:40, delivered at a flow rate of 1 mL/min. The 
fluorescence was determined at 310 nm (emission) and 260 nm (excitation). The retention 
time of flurbiprofen was approximately 5.5 min.  
The concentrations of ketoprofen were measured by LC/MS. Mass spectrometry was used 
to confirm the chromatographic profile obtained by a diode-array detector. The Shimadzu 
LCMS-2010A system used was equipped with a column (ZORBAX SB-C18, 150×2.1 mm, 3.5-
μm particles; Agilent Technologies Inc.), a photodiode array detector (SPD-M20A) and a 
single quadrupole analyzer (LCMSF-2010EV). The other pieces of equipment were the same 
as those used for the HPLC analyses. Identification was achieved using the full-scan mode 
at a mass range of m/z 100-500. The mobile phase consisted of acetonitrile and 0.1% (v/v) 
formic acid at a ratio of 60:40, delivered at a flow rate of 0.2 mL/min.  
The accuracy values of blank skin samples with added flurbiprofen and ketoprofen  
(2.5, 10 and 80 ng/mL) were in the ranges of 102.7–111.5% and 98.1–107.1%, respectively, 
within 24 h for the sample preparation and measurements by HPLC and LC/MS described 
above. The recovery rates of the individual drugs from the skin tissue samples were both 
>93.0%.  
The flurbiprofen and ketoprofen contents of the FP-T and KP-T patches were also measured 
by HPLC. The residual ratios were calculated as follows: 
  
Drug contents in patches after applicationResidual ratio %  100
Drug contents in patches before application
   (1) 
The HPLC conditions were as follows: column, Mightysil RP-18 GP (150×4.6 mm, 5.0-μm 
particles; Kanto Chemical Co. Inc., Tokyo, Japan); column temperature, 40°C. The mobile 
phase consisted of acetonitrile and 0.1% (v/v) formic acid at a ratio of 60:40. The retention 
times of flurbiprofen and ketoprofen were both approximately 4.0 min. The other conditions 
were the same as those used for the skin tissues. 
2.5 Statistical analysis 
The results were expressed as means ± SD. The significance of differences between 
measurements for the FP-T-applied and KP-T-applied groups was evaluated using the 
Mann–Whitney U test. The criterion for statistical significance was a value of P<0.05 for all 
statistical evaluations. 
3. Estimation of the percutaneous permeation of flurbiprofen and ketoprofen 
from the surface to the deep layer 
To examine the drug permeation in the skin tissue, the skin areas where the tapes were 
applied were cut into 20 μm-thick horizontal slices from the surface, and the drug 
concentrations in the slices were measured individually. Later, we calculated each drug 
concentration in the skin tissue per 100 μm thickness, corresponding to five pieces of skin 
tissue, to clearly indicate the drug distributions, because we considered that it was not easy 
to evaluate the drug disposition in the finely-divided state (every 20 μm). 
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tissue, to clearly indicate the drug distributions, because we considered that it was not easy 
to evaluate the drug disposition in the finely-divided state (every 20 μm). 
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3.1 Single application of FP-T and KP-T 
The drug levels in the skin tissues after application of FP-T and KP-T are shown in Fig. 3. 
Initially, the flurbiprofen concentrations in the skin layers from 0 to 400 μm were highest at 
2 h after FP-T application and then decreased gradually, although the concentrations in the 
skin layers from 0 to 300 μm increased transiently after 12 h (Fig. 3A). The flurbiprofen 
concentrations at 2 h after application of FP-T were 2270±770, 1410±260, 1110±200 and 
650±160 ng/mg of skin layer from 0 to 100 μm, 100 to 200 μm, 200 to 300 μm and 300 to 400 
μm, respectively. Subsequently, the flurbiprofen concentrations in the skin layers from 400 
to 800 μm, except for 500 to 600 μm, were highest at 4 h after FP-T application and then 
decreased until 24 h after FP-T application (Fig. 3C). On the other hand, the ketoprofen 
concentrations in the skin layers from 0 to 500 μm reached their peaks after 4 h of tape 
application (Fig. 3B and D). 
 
Fig. 3. Time-course profiles of the skin tissue concentrations of flurbiprofen and ketoprofen 
after FP-T and KP-T application. (A) Flurbiprofen concentrations in the layers from 0 to  
400 μm. (B) Ketoprofen concentrations in the layers from 0 to 400 μm. (C) Flurbiprofen 
concentrations in the layers from 400 to 800 μm. (D) Ketoprofen concentrations in the layers 
from 400 to 800 μm. Each point represents the mean ± SD (n=5). 
 
Evaluation of Percutaneous Drug Permeation Using a Lateral Sectioning Approach 
 
41 
The ketoprofen concentrations at 4 h after application of KP-T were 900±130, 680±170, 
460±160 and 300±160 ng/mg of skin layer from 0 to 100 μm, 100 to 200 μm, 200 to 300 μm 
and 300 to 400 μm, respectively. Similar to the case for flurbiprofen, the ketoprofen 
concentrations in the skin layers from 0 to 300 μm increased transiently after 12 h. The 
ketoprofen concentrations in the skin layers from 500 to 800 μm were highest at 8 h after KP-
T application and decreased until 24 h (Fig. 3D).  
Traditionally, information on percutaneous absorption has been obtained using in vitro skin 
diffusion chambers, mathematical models (Potts & Guy, 1992; Singh & Roberts, 1996) and 
indirect methods such as radiolabeled drug absorption techniques in vivo (Schaefer et al., 
1978). However, percutaneous absorption depends on various multiple components, and 
consequently the series of equations is complicated. Autoradiography has the advantage 
that the drug levels are represented visually, but is not considered to be a quantitative 
method. Our technique of lateral sectioning of frozen skin tissues and measurement of the 
drug concentration in each slice may be primitive, but allowed us to clearly understand the 
diffusion of drugs in the skin layers. 
Table 2 shows the time courses of the changes in the residual ratios of flurbiprofen and 
ketoprofen after topical application of FP-T and KP-T. No significant differences between 
flurbiprofen and ketoprofen were observed with respect to the residual ratios until 12 h after 
patch application, suggesting that the drug release rates of FP-T and KP-T were nearly equal 
and that the higher skin concentrations of flurbiprofen shown in Fig. 3 followed another 
mechanism that was separate from the drug release rate. From 12 to 16 h, a high volume of 
flurbiprofen was released compared with ketoprofen. Therefore, flurbiprofen seemed to be 
released from FP-T to the greatest possible extent until 16 h and no more flurbiprofen was 
subsequently released until 24 h, whereas ketoprofen was continuously released from KP-T 
until 24 h after application. 
 
 Time after tape application (h) 
  2 4 8 12 16 24 
Flurbiprofen 73.7 ± 2.6 65.1 ± 2.6 45.3 ± 6.2 37.3 ± 2.0 22.7 ± 1.2* 22.0 ± 2.6 
Ketoprofen 76.8 ± 4.0 60.0 ± 2.9 48.7 ± 3.8 40.8 ± 6.2 34.7 ± 5.7 22.3 ± 2.8 
       (%) 
Table 2. Residual ratios of flurbiprofen and ketoprofen after tape application. Each value 
represents the mean ± SD (n=4). *P<0.05 vs. ketoprofen. 
3.2 Second application of FP-T 
Since the FP-T patch is removed and replaced with a new patch every 12 h, we also 
investigated the flurbiprofen concentrations in the skin tissues after a second application of 
FP-T. The second FP-T was applied to the same skin site as the first patch under the 
assumption that patches are applied to the same affected area more than once. The time 
courses of the changes in the concentrations of flurbiprofen in the whole skin layer (0 to  
800 μm) after tape application are shown in Fig. 4. It was clearly demonstrated that 
flurbiprofen rapidly reached the deepest layer of the whole skin within a short time, but 
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there was a low content of flurbiprofen in the area deeper than 600 μm from 16 to 24 h after 
administration with only a single application. This was because a very low amount of 
flurbiprofen was released from FP-T from 16 to 24 h, as shown in Table 2. On the other 
hand, the flurbiprofen concentration in all regions of the whole skin increased promptly 
after 14 h and a high concentration of flurbiprofen was maintained until 24 h after 
application, even in the deepest layer in cases where a second application was carried out. 
The time courses of the changes in the concentrations of flurbiprofen and ketoprofen in the 
deepest skin layer (700 to 800 μm) after FP-T application are shown in Fig. 5. This layer is 
adjacent to the intramuscular tissue and plays a major role in the evaluation of drug 
permeability and pharmacodynamics. The concentration of flurbiprofen (109.4±44.8 ng/mg) 
was significantly higher than that of ketoprofen (44.4±9.8 ng/mg) at 4 h after tape 
application, but there were no significant differences in the concentrations of the two drugs 
at 12 h and thereafter, except for 16 h. However, the flurbiprofen concentration in the 
deepest skin tissue layer increased again at 2 h (total exposure, 14 h) after the second 
application of FP-T (115.3±44.6 ng/mg) and was maintained at a significantly higher level 
than ketoprofen for the next 10 h (total exposure, 24 h).  
 
Fig. 4. Time-course profiles of the skin tissue concentrations of flurbiprofen after FP-T 
application. (A) Single application. (B) First and second applications. The color density is 
dependent on the drug concentration in the skin tissues. 
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A second application of FP-T reduced the time required to reach the maximal concentration 
in the deepest skin layer (700 to 800 μm) from 4 h to 2 h after administration (Fig. 5). The 
skin permeation of a drug is generally enhanced by occlusive application (Schaefer & 
Redelmeier, 1996). Hydration of corneocytes and weakening of the stratum corneum barrier 
function induced by 12 h of continuous FP-T application appeared to comprise the main 
mechanisms for how the permeability rate of flurbiprofen released from the new FP-T patch 
was increased. In addition, the flurbiprofen contents in the superficial layer (0 to 300 μm) 
increased slightly at 12 h after administration compared with the contents at 8 h (Fig. 3A). 
This observation means that enormous proportions of the flurbiprofen were stored in the 
superficial layer, and that this layer acted as a drug reservoir. Fundamentally, stored 
flurbiprofen is slowly released to the deeper tissues (Sugawara et al., 1987). However, it 
should be considered that the powerful driving force produced by the application of a 
second FP-T extruded the deposited flurbiprofen and a greater amount of flurbiprofen was 
able to permeate quickly into the deepest layer of the skin as a result. These findings are 
consistent with a previous study in which Tmax was decreased by successive patch 
applications (Taburet et al., 1995). 
 
 
Fig. 5. Time-course profiles of the skin tissue concentrations of flurbiprofen and ketoprofen 
in the layer from 700 to 800 μm after FP-T and KP-T application. The unbroken lines for 
flurbiprofen and ketoprofen show data for continuous FP-T and KP-T administration for  
24 h. The broken line for flurbiprofen shows data after a second administration of FP-T from 
12 to 24 h (the previous FP-T was removed and the new patch was applied at 12 h).  
Each point represents the mean ± SD (n=5). *P<0.05 and **P<0.01 vs. ketoprofen. 
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3.3 Effect of stratum corneum stripping on the transcutaneous permeability of 
flurbiprofen 
What factors would affect the LETD of NSAIDs in practical usage? The FP-T patch is 
removed and replaced with a new patch every 12 h as mentioned above. We observed that 
the stratum corneum was hardly stripped when FP-T was removed after 4 h of adhesion, 
but was slightly stripped to about 1.5-μm thickness after removal of the first FP-T patch at 
12 h (Table 3). To investigate the effect of this decrease in the thickness of the stratum 
corneum on the transcutaneous penetration of flurbiprofen, we measured the concentrations 
of flurbiprofen in skin layers of 100-μm thickness with and without tape-stripping.  
 
Normal Time after FP-T administration (h) 
2 4 8 12 
15.9 ± 0.9 15.1 ± 1.0 15.2 ± 1.6 14.5 ± 0.6 14.5 ± 0.9 
(μm) 
Table 3. Stratum corneum thicknesses after removal of adherent FP-T at a fixed time.  
Each value represents the mean ± SD (n=4). 
 
Fig. 6. Effect of stratum corneum stripping on the transcutaneous permeability of 
flurbiprofen. The skin tissue concentrations of flurbiprofen per 100-μm thickness are 
expressed after FP-T application for 2 h (A) and 4 h (B). The data represent means ± SD 
(n=4). *P<0.05 vs. the non-stripped group (=normal). 
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Tape-stripping is used to measure drug uptake into the skin (Touitou et al., 1998; Bashir et 
al., 2001). The tapes have different propensities to cause barrier disruption. Some 
individuals do not exhibit increased TEWL despite an equivalent mass of stratum corneum 
being removed compared with those who do show a response (Bashier et al., 2001). In our 
situation, the abdominal skin of some rats was tape-stripped using two strokes of adhesive 
tape (Transpore® Surgical Tape; Sumitomo 3M Co. Ltd., Tokyo, Japan) before placing FP-T 
patches. The score of TEWL was 9.3±0.4 g/m2h before stripping and increased slightly to 
11.6±0.5 g/m2h after two strokes of tape-stripping. Therefore, it seemed that two strokes of 
tape-stripping replicated the decrease in thickness of the stratum corneum when FP-T was 
removed after 12 h of adhesion without disrupting the horny layer formation. We compared 
the drug concentrations in the skin tissues between the stripping and non-stripping models 
to evaluate the effect of stratum corneum stripping on the transcutaneous permeability of 
flurbiprofen. 
At the time when the skin tissue was previously stripped and FP-T had been administered 
for 2 h, the skin tissue concentrations of flurbiprofen were higher than those without 
stripping in the layers from 0 to 200 μm, and a significant difference was observed in the 
layer from 100 to 200 μm (Fig. 6A). In the deeper layers beyond 200 μm, there were no 
significant differences in the flurbiprofen concentrations between the two groups. 
Likewise, at the time when the skin tissue was previously stripped and FP-T had been 
administered for 4 h, the skin tissue concentrations of flurbiprofen were higher than those 
without stripping in the layers from 100 to 800 μm, and a significant increase was 
observed in the deepest layer (Fig. 6B). Therefore, the transcutaneous permeability of 
flurbiprofen into the deepest layer of the skin tissue was not affected by stratum corneum 
stripping when FP-T had been applied for 2 h, but was affected by stripping after FP-T 
had been administered for 4 h. Our evaluation method revealed that only a small 10% 
decrease in the thickness of the stratum corneum could change the drug LETD to the 
deepest layer. 
4. Pharmacokinetics 
4.1 Pharmacokinetic parameters 
Blood samples (0.2 mL) were collected from the jugular vein of the rats at 2, 4, 8, 12, 14, 16 
and 24 h after both types of patches were applied. The analytical methods were slightly 
modified compared with those for the skin tissues. Briefly, 50 μL of plasma sample was 
applied to measure the drug contents. The mobile phase of HPLC consisted of acetonitrile 
and 0.1% (v/v) formic acid at a ratio of 55:45, delivered at a flow rate of 1 mL/min, and the 
mobile phase of LC/MS consisted of acetonitrile and 0.1% (v/v) formic acid at a ratio of 
50:50, delivered at a flow rate of 0.2 mL/min. 
The pharmacokinetic parameters following topical administration of flurbiprofen and 
ketoprofen are summarized in Table 4. These pharmacokinetic values are based on the 
plasma concentration/time profiles of the drugs after administration of one patch.  
FP-T exhibited higher and more rapid flurbiprofen permeation compared with ketoprofen 
permeation from KP-T. As shown in Table 4, FP-T exhibited a higher Cmax value  
(4.6±0.7 μg/mL) and shorter Tmax value (6.3±2.1 h) than KP-T. Moreover, FP-T 
administration produced a high AUC0-12h value of 44.5±7.3 μg•h/mL, which was five 
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3.3 Effect of stratum corneum stripping on the transcutaneous permeability of 
flurbiprofen 
What factors would affect the LETD of NSAIDs in practical usage? The FP-T patch is 
removed and replaced with a new patch every 12 h as mentioned above. We observed that 
the stratum corneum was hardly stripped when FP-T was removed after 4 h of adhesion, 
but was slightly stripped to about 1.5-μm thickness after removal of the first FP-T patch at 
12 h (Table 3). To investigate the effect of this decrease in the thickness of the stratum 
corneum on the transcutaneous penetration of flurbiprofen, we measured the concentrations 
of flurbiprofen in skin layers of 100-μm thickness with and without tape-stripping.  
 
Normal Time after FP-T administration (h) 
2 4 8 12 
15.9 ± 0.9 15.1 ± 1.0 15.2 ± 1.6 14.5 ± 0.6 14.5 ± 0.9 
(μm) 
Table 3. Stratum corneum thicknesses after removal of adherent FP-T at a fixed time.  
Each value represents the mean ± SD (n=4). 
 
Fig. 6. Effect of stratum corneum stripping on the transcutaneous permeability of 
flurbiprofen. The skin tissue concentrations of flurbiprofen per 100-μm thickness are 
expressed after FP-T application for 2 h (A) and 4 h (B). The data represent means ± SD 
(n=4). *P<0.05 vs. the non-stripped group (=normal). 
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Tape-stripping is used to measure drug uptake into the skin (Touitou et al., 1998; Bashir et 
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mobile phase of LC/MS consisted of acetonitrile and 0.1% (v/v) formic acid at a ratio of 
50:50, delivered at a flow rate of 0.2 mL/min. 
The pharmacokinetic parameters following topical administration of flurbiprofen and 
ketoprofen are summarized in Table 4. These pharmacokinetic values are based on the 
plasma concentration/time profiles of the drugs after administration of one patch.  
FP-T exhibited higher and more rapid flurbiprofen permeation compared with ketoprofen 
permeation from KP-T. As shown in Table 4, FP-T exhibited a higher Cmax value  
(4.6±0.7 μg/mL) and shorter Tmax value (6.3±2.1 h) than KP-T. Moreover, FP-T 
administration produced a high AUC0-12h value of 44.5±7.3 μg•h/mL, which was five 
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times higher than that of KP-T (8.6±1.8 μg•h/mL). The plasma concentration of 
flurbiprofen peaked at 6.3±2.1 h after the first FP-T application, although this peak was 
shortened to 3.2±1.1 h after the second FP-T application. The Cmax and AUC0-12h values for 
the second FP-T application were slightly increased, and the T1/2 value after the 
successive applications was longer than that after the first FP-T application. The drug 
delivery during the second patch application indicated relatively good permeability as 
mentioned previously, and this is probably the reason why the shorter Tmax value and 





 first second 
Dose (mg/kg) 4.5 4.5 4.5 
Cmax (μg/ml) 4.6 ± 0.7 5.9 ± 0.4 1.5 ± 0.2 
Tmax (h) 6.3 ± 2.1 3.2 ± 1.1 19.2 ± 3.4 
T1/2 (h) 7.3 ± 1.1 10.3 ± 1.3 ― 
AUC0-12h (μg・h/ml) 44.5 ± 7.3 55.2 ± 2.6 8.6 ± 1.8 
A.B. (%) 43.0 53.4 14.8 
Table 4. Pharmacokinetic parameters following topical administration of flurbiprofen and 
ketoprofen. Each value represents the mean ± SD (n=3–5). Cmax: maximum plasma 
concentration; Tmax: time to reach Cmax; T1/2: terminal half-life; AUC0-12h: area under the 
plasma concentration-time curve from time 0 to 12 h; A.B.: absolute bioavailability in an 
intravenous group. 
4.2 Differences in the time-course changes in the skin and plasma concentrations 
between flurbiprofen and ketoprofen 
The time-course changes in the flurbiprofen concentrations in the skin layer from 700 to 
800 μm were very similar to the plasma concentrations of flurbiprofen after both single 
and repeated applications (Fig. 7A). In contrast, the transcutaneous absorption of 
ketoprofen into the systemic circulation was relatively slow, and the plasma concentration 
of ketoprofen peaked about 8 h later than the peak in the skin layer from 700 to 800 μm 
(Fig. 7B).  
The two formulations of NSAIDs examined have their own characteristic features. FP-T 
with a twice-daily application frequency induced a quick increase in the skin 
concentration of flurbiprofen and maintained a high level in the deepest layer via LETD 
(Fig. 7A). This shows the potential for prompt onset and prolonged duration of NSAID 
activity in intramuscular tissues. However, the systemic concentrations of the drug 
increased at the same rate as the concentrations in the deepest layer of the skin, which 
may increase the risk of adverse effects. On the other hand, the diffusion of ketoprofen 
from KP-T to the maximal depth of the skin by LETD was relatively slow (Fig. 7B), 
suggesting the possibility that several hours are required to realize its efficacy as an anti-
inflammatory drug. However, the plasma concentrations of ketoprofen absorbed by the 
systemic circulation route were relatively low, which may lower the risk of adverse 
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effects. These observations are consistent with previous reports indicating that ketoprofen 
is an effective and safe therapeutic option for the treatment of local painful inflammation 
(Mazieres, 2005; Flouvat et al., 1989). In many studies, including the present study, 
pharmacokinetics parameters have been evaluated using the time courses of the total 
plasma or serum concentrations. However, the theory of practical pharmacokinetics 
emphasizes the importance of the unbound fraction of a drug in understanding concepts 
such as clearance, apparent volume of distribution and pharmacodynamic action (Wright 
et al., 1996). Borgå & Borgå (1997) reported that the lowest dissociation constant (highest 
affinity) was found with flurbiprofen, which exhibited an 80-fold difference compared 
with the highest affinity for ketoprofen. This high affinity of flurbiprofen for albumin may 
contribute to a reduction in the incidence of gastrointestinal disorders, although its 





Fig. 7. Time-course profiles of the skin tissue and plasma concentrations of flurbiprofen and 
ketoprofen after FP-T and KP-T application. (A) The skin tissue concentrations of 
flurbiprofen in the layer from 700 to 800 μm are expressed on the left axis and the plasma 
concentrations of flurbiprofen are expressed on the right axis. (B) The skin tissue and plasma 
concentrations of ketoprofen are expressed in the same way as described for (A). Each point 
represents the mean ± SD (n=3–5). 
Skin concentrations result from the balance of permeation into the tissue and clearance 
from the tissue, combined with partitioning into the various skin components (Kretsos et 
al., 2008). Percutaneous absorption depends on the physicochemical properties of the 
compound, and small moderately lipophilic molecules are generally the most readily 
absorbed. The log Ko/w values for flurbiprofen and ketoprofen are 3.75 and 2.76, 
respectively (Valko et al., 2003). The binding affinity of flurbiprofen for albumin is 
superior to that of ketoprofen, as mentioned above, and the binding ratios of the two 
drugs are 99.9% and 98.7%, respectively (Valko et al., 2003). It is notable that both the 
viable epidermis and dermis contain, on average, about 2% extravascular albumin, to 
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times higher than that of KP-T (8.6±1.8 μg•h/mL). The plasma concentration of 
flurbiprofen peaked at 6.3±2.1 h after the first FP-T application, although this peak was 
shortened to 3.2±1.1 h after the second FP-T application. The Cmax and AUC0-12h values for 
the second FP-T application were slightly increased, and the T1/2 value after the 
successive applications was longer than that after the first FP-T application. The drug 
delivery during the second patch application indicated relatively good permeability as 
mentioned previously, and this is probably the reason why the shorter Tmax value and 
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(Fig. 7B).  
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(Fig. 7A). This shows the potential for prompt onset and prolonged duration of NSAID 
activity in intramuscular tissues. However, the systemic concentrations of the drug 
increased at the same rate as the concentrations in the deepest layer of the skin, which 
may increase the risk of adverse effects. On the other hand, the diffusion of ketoprofen 
from KP-T to the maximal depth of the skin by LETD was relatively slow (Fig. 7B), 
suggesting the possibility that several hours are required to realize its efficacy as an anti-
inflammatory drug. However, the plasma concentrations of ketoprofen absorbed by the 
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pharmacokinetics parameters have been evaluated using the time courses of the total 
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compound, and small moderately lipophilic molecules are generally the most readily 
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which both flurbiprofen and ketoprofen can bind (Bert et al., 1986). The high lipophilicity 
and an effect of the superior protein-binding activity on the clearance mechanism are 
likely to be the major reasons why the skin concentration of flurbiprofen was higher than 
that of ketoprofen. Besides, other important factors may affect the transdermal 
absorptions of the two drugs. In general, LETD-mediated drug permeation has been 
explained in terms of passive diffusion of non-ionized compounds (Potts, 1992). However, 
several studies have focused on the possible involvement of transporters expressed in the 
skin, similar to the case for other tissues (Schiffer et al., 2003; Bonen et al., 2006; Li, 2006). 
Organic anion transporter 2 (OAT2) is thought to be a candidate for an exchanger 
involved in the uptake and/or efflux of flurbiprofen in the skin, and the flurbiprofen 
permeability in the absorptive direction was higher than that in the secretory direction 
(Ito et al., 2007). The superior permeability of flurbiprofen in the skin may be attributable 
to a more predominant exchange capacity with several transporters compared with other 
NSAIDs. 
5. Pharmacodynamics 
From our lateral sectioning approach, it was predicted that FP-T had the potential for 
prompt onset and prolonged duration of NSAID activity, while KP-T needed several hours 
to demonstrate its efficacy as an anti-inflammatory drug in intramuscular tissues. Therefore, 
we investigated whether the results for the percutaneous drug permeation using lateral 
slicing were in accordance with the drug efficacies. 
5.1 Topical anti-inflammatory efficacy in carrageenin-induced rat paw edema 
The topical anti-inflammatory efficacy was evaluated for carrageenin-induced 
inflammation edema in Wistar rats weighing 124±11 g. The activities of the drugs were 
evaluated by measuring the changes in paw volume with a plethysmometer (TK-101CMP; 
Muromachi Co. Ltd., Tokyo, Japan). FP-T or KP-T (0.5×3.5 cm) was applied to the right 
paw for 3 h with the help of adhesive tape, at 0.5 h prior to the carrageenin injection. 
Acute inflammation was produced by injecting 0.1 mL of 1% (w/v) carrageenin solution 
into the subplantar region of the right hind paw. The paw volume was measured at 0, 3, 4 
and 5 h after the injection. 
The percentage of swelling in the paw was calculated by the following formula. 
  
b-aSwelling %  100
a
   (2) 
where a is the paw volume before producing the edema and b is the paw volume measured 
after producing the edema. 
In this acute model, the percentage swelling was promptly suppressed by flurbiprofen 
released from FP-T, whereas it required some time to be suppressed by ketoprofen from  
KP-T (Fig. 8). In addition, the FP-T efficacy was much stronger than that of KP-T. These 
findings support the accuracy of the evaluation method of percutaneous drug permeation 
using a lateral sectioning approach. 
 





Fig. 8. Effects of FP-T and KP-T on edema produced by carrageenin in the hindpaw of rats. Each 
point represents the mean ± SE (n=7). *P<0.05 and ***P<0.001 vs. Control by Dunnett’s test. 
5.2 Antinociceptive efficacy in the inflamed paw pressure test 
This experiment was performed according to the method of Randall & Selitto (1957) using 
Wistar rats weighing 114±19 g. FP-T or KP-T (0.5×3.5 or 1.0×3.5 cm) was applied to the right 
paw for 3 h with the help of adhesive tape, at 0.5 h prior to an injection of baker’s yeast. 
Briefly, 0.1 mL of a 10% (w/v) solution of baker’s yeast in saline was given by subplantar 
injection into the hind paw. Nociception was measured by applying an increased weight to 
the paw with a pressure meter (Ugo Basile, Varese, Italy) until the rats vocalized or drew 
their feet back. The algesic threshold was measured at 2, 3 and 4 h after the injection and the 
level of the algesic threshold was expressed as the sum of the algesic thresholds between 2 
and 4 h. 
As shown in Fig. 9, FP-T significantly increased the paw pressure threshold required for the 
nociceptive response, indicating a probable analgesic action. Besides, the drug efficacy 
depended on the applied area of FP-T. However, KP-T had no effect on the nociceptive 
response, even when its applied area was expanded. 
From these pharmacodynamics studies, our predictions derived from the lateral sectioning 
approach were consistent with the facts that FP-T had the potential for prompt onset and 
prolonged duration of NSAID activity and that KP-T required a reasonable time to 
demonstrate its efficacy. 
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released from FP-T, whereas it required some time to be suppressed by ketoprofen from  
KP-T (Fig. 8). In addition, the FP-T efficacy was much stronger than that of KP-T. These 
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using a lateral sectioning approach. 
 





Fig. 8. Effects of FP-T and KP-T on edema produced by carrageenin in the hindpaw of rats. Each 
point represents the mean ± SE (n=7). *P<0.05 and ***P<0.001 vs. Control by Dunnett’s test. 
5.2 Antinociceptive efficacy in the inflamed paw pressure test 
This experiment was performed according to the method of Randall & Selitto (1957) using 
Wistar rats weighing 114±19 g. FP-T or KP-T (0.5×3.5 or 1.0×3.5 cm) was applied to the right 
paw for 3 h with the help of adhesive tape, at 0.5 h prior to an injection of baker’s yeast. 
Briefly, 0.1 mL of a 10% (w/v) solution of baker’s yeast in saline was given by subplantar 
injection into the hind paw. Nociception was measured by applying an increased weight to 
the paw with a pressure meter (Ugo Basile, Varese, Italy) until the rats vocalized or drew 
their feet back. The algesic threshold was measured at 2, 3 and 4 h after the injection and the 
level of the algesic threshold was expressed as the sum of the algesic thresholds between 2 
and 4 h. 
As shown in Fig. 9, FP-T significantly increased the paw pressure threshold required for the 
nociceptive response, indicating a probable analgesic action. Besides, the drug efficacy 
depended on the applied area of FP-T. However, KP-T had no effect on the nociceptive 
response, even when its applied area was expanded. 
From these pharmacodynamics studies, our predictions derived from the lateral sectioning 
approach were consistent with the facts that FP-T had the potential for prompt onset and 
prolonged duration of NSAID activity and that KP-T required a reasonable time to 
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Fig. 9. Effects of FP-T and KP-T on nociception produced by baker’s yeast in the hindpaw of 
rats. Each column represents the mean ± SE (n=10). *P<0.05 and ***P<0.001 vs. Control by 
Dunnett’s test. 
6. Evaluation of the technique 
There are several limitations to our technique for evaluating transdermal permeability. First, 
information on the percutaneous absorption is obtained from invasive skin biopsies and this 
method cannot be applied to humans. Next, this technique is limited by the location. As 
previously mentioned, this technique depends on the procedure for freezing and slicing 
samples in a flat manner. Therefore, the abdominal skin is a suitable area for removal and 
preparation as samples. However, there are many sites in the body other than the 
abdominal area that are not flat, such as the circumferences of joints, and we ought to 
measure the drug concentrations at these sites. Our pharmacodynamic studies focused on 
the hindpaw and not on the abdominal area, although our predictions were derived using 
the abdominal region. Nevertheless, the therapeutic expressions were accordance with the 
efficacy predictions. This means that the lateral sectioning approach at the abdominal area 
could be applied to understand drug flow in other places of the body. Furthermore, it is well 
known that rodent skin is generally more permeable than human skin (Poet et al., 2000). 
Therefore, another method is required to precisely calculate the drug permeability in human 
skin. However, our lateral sectioning approach can simply and clearly indicate the time 
courses of the flow of drugs in skin tissues and the obtained data should facilitate the 
prediction and estimation of the pharmacodynamics of patches with other transdermal 
formulations. Recently, a hydrogel patch has been applied as a transcutaneous vaccination 
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system against viral and bacterial infections (Ishii et al., 2008; Matsuo et al., 2011). In this 
case, the drug levels in the epidermal layer where Langerhans cells reside are crucial, and 
there is no point in measuring the total amounts of drugs that permeate the whole skin. 
Furthermore, we can check the conformational changes of the protein in the process of 
passing through the stratum corneum to judge whether the activity of the protein is 
maintained at that site. 
As a matter of course, the sites in the skin where different drugs have efficacy tend to differ. 
However, our slicing method makes it possible to evaluate the drug levels at the skin sites 
where individual drugs exert their beneficial effects. These studies focused on the skin 
region for the present data, and clarification of the musculocutaneous pharmacokinetics is 
an issue for future studies. In addition, we would like to concentrate on the surrounding 
environments of the drugs in the skin tissues.  
7. Conclusions 
The present experimental data suggest that our approach involving lateral sectioning of 
frozen skin tissues and measurement of the drug concentration in each slice makes it 
possible to easily and clearly determine the tissue concentrations of drugs in skin layers 
adjacent to the target area, albeit in a rodent model. This technique has the advantage of 
simplicity and therefore has the potential to be applied to evaluations of the 
pharmacokinetics of other transdermal formulations. 
8. References 
Bashir, S. J.; Chew, A. L.; Aniqboqu, A.; Dreher, F. & Maibach, H. I. (2001). Physical and 
physiological effects of stratum corneum tape stripping. Skin Research and 
Technology, Vol.7, No.1, (February 2001), pp. 40-48, ISSN 0909-752X 
Bert, J. L. (1986). Pearce RH, Mathieson JM. Concentration of plasma albumin in its 
accessible space in postmortem human dermis. Microvascular Research, Vol.32, No.2, 
(September 1986), pp. 211-223, ISSN 0026-2862 
Bert, J. L.; Mathieson, J. M. & Pearce, R. H. (1982). The exclusion of human serum albumin 
by human dermal collagenous fibres and within human dermis. Biochemical 
Journal, Vol.201, No.2, (February 1982), pp. 395-403, ISSN 0264-6021 
Bonen, A.; Heynen, M. & Hatta, H. (2006). Distribution of monocarboxylate transporters 
MCT1-MCT8 in rat tissues and human skeletal muscle. Applied Physiology and 
metabolism, Vol.31, No.1, (February 2006), pp. 31-39, ISSN 1715-5312 
Borgå, O. & Borgå, B. (1997). Serum protein binding of nonsteroidal antiinflammatory 
drugs: A comparative study. Journal of  Pharmacokinetics and  Biopharmaceutics, 
Vol.25, No.1, (February 1997), pp. 63-77, ISSN 0090-466X 
Brogden, R.N.; Heel, R. C.; Speight, T. M. & Avery, G. S. (1979). Flurbiprofen: a review of its 
pharmacological properties and therapeutic use in rheumatic diseases. Drugs, 
Vol.18, (December 1979), pp. 417-438, ISSN 0012-6667 
Buchanan, W. W. & Kassam, Y. B. (1986). European experience with flurbiprofen. A new 
analgesic/anti-inflammatory agent. American Journal of Medicine, Vol.80, No.3A, 
(March 1986), pp. 145-152, ISSN 0002-9343 
 





Fig. 9. Effects of FP-T and KP-T on nociception produced by baker’s yeast in the hindpaw of 
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Dunnett’s test. 
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There are several limitations to our technique for evaluating transdermal permeability. First, 
information on the percutaneous absorption is obtained from invasive skin biopsies and this 
method cannot be applied to humans. Next, this technique is limited by the location. As 
previously mentioned, this technique depends on the procedure for freezing and slicing 
samples in a flat manner. Therefore, the abdominal skin is a suitable area for removal and 
preparation as samples. However, there are many sites in the body other than the 
abdominal area that are not flat, such as the circumferences of joints, and we ought to 
measure the drug concentrations at these sites. Our pharmacodynamic studies focused on 
the hindpaw and not on the abdominal area, although our predictions were derived using 
the abdominal region. Nevertheless, the therapeutic expressions were accordance with the 
efficacy predictions. This means that the lateral sectioning approach at the abdominal area 
could be applied to understand drug flow in other places of the body. Furthermore, it is well 
known that rodent skin is generally more permeable than human skin (Poet et al., 2000). 
Therefore, another method is required to precisely calculate the drug permeability in human 
skin. However, our lateral sectioning approach can simply and clearly indicate the time 
courses of the flow of drugs in skin tissues and the obtained data should facilitate the 
prediction and estimation of the pharmacodynamics of patches with other transdermal 
formulations. Recently, a hydrogel patch has been applied as a transcutaneous vaccination 
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system against viral and bacterial infections (Ishii et al., 2008; Matsuo et al., 2011). In this 
case, the drug levels in the epidermal layer where Langerhans cells reside are crucial, and 
there is no point in measuring the total amounts of drugs that permeate the whole skin. 
Furthermore, we can check the conformational changes of the protein in the process of 
passing through the stratum corneum to judge whether the activity of the protein is 
maintained at that site. 
As a matter of course, the sites in the skin where different drugs have efficacy tend to differ. 
However, our slicing method makes it possible to evaluate the drug levels at the skin sites 
where individual drugs exert their beneficial effects. These studies focused on the skin 
region for the present data, and clarification of the musculocutaneous pharmacokinetics is 
an issue for future studies. In addition, we would like to concentrate on the surrounding 
environments of the drugs in the skin tissues.  
7. Conclusions 
The present experimental data suggest that our approach involving lateral sectioning of 
frozen skin tissues and measurement of the drug concentration in each slice makes it 
possible to easily and clearly determine the tissue concentrations of drugs in skin layers 
adjacent to the target area, albeit in a rodent model. This technique has the advantage of 
simplicity and therefore has the potential to be applied to evaluations of the 
pharmacokinetics of other transdermal formulations. 
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1. Introduction 
1.1 Drug discovery and clinical evaluation 
The discovery of a drug is focused on the goal of producing a useful therapeutic agent 
through a process utilizing the multiple skills and expertise of basic scientists, 
pharmaceutical chemists, toxicologists, clinical investigators, governmental regulators and 
clinicians (Mager DE, 2009; Michel MC, 2009; Nagase H, 2011). Drug development and its 
clinical evaluation is thus a very lengthy and expensive endeavor. One has to first come up 
with a novel mechanism, identifying relevant target(s) and pathway(s) towards formulation 
of a new chemical entity (NCE) to treat a disease. Both in vitro and in vivo models that are 
relevant to the disease form the basis of preclinical testing and identification of lead 
compounds, and the development of an Investigational New Drug (IND), and ultimately the 
entry of only a select few into human clinical trials. Therefore, initial studies in drug 
developments involve the synthesis and extraction of new compounds, their biological 
screening and pharmacological testing, followed by small animal model testing of 
toxicology and safety profiles. These early pharmacokinetic (PK) measurements guide 
researchers to formulate effective pharmaceutical dosage, in vivo stability, elimination and 
eventually the therapeutic index of lead compound(s). In pre-clinical studies, a favorable PK 
outcome can lead to the FDA approval for the phase-I, -II and -III clinical evaluation process 
(Fasolo A, 2009). However, even after clinical approval, drugs have to be continuously 
monitored towards improvements in their bioavailability, therapeutic, and toxicologic 
differences especially in a large patient population with patient-specific variability. For 
example, the azathioprine and mercaptopurine intolerance in patients were found to be 
linked to the deficiency of a metabolic enzyme, thiopurine S-methyltransferase, and formed 
the genetic basis for a molecular diagnostic test to designate specific population (Yates CR, 
et al. 1997). Thus, before testing in humans can start, a significant body of pre-clinical data 
on PK must be compiled and an appropriate dose should be established to ensure human 
safety. Toxicology, pharmacology and pharmaceutical sciences all represent the core of pre-
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clinical drug development which is repeatedly addressed in the clinical trials and post-
clinical approval phases. Each phase of drug development has to be designed to accrue the 
necessary information to assess the probability of success of an NCE which remains the 
fundamental pathway to successful clinical approval (DiazGranados N, 2008). The 
continually expanding knowledge base on the development of new agents and novel 
delivery and formulation strategies are enabling a favorable in vivo PK and a more 
efficacious drug discovery process. Advances in the understanding of multiple factors that 
regulate drug disposition and response in individuals are elucidating the molecular basis of 
ethnic and inter-individual variability in drug action (Xie HG, et al. 2001; Soldin OP, et al. 
2009). Furthermore, due to their in vivo safety and efficacy profiles, a number of natural 
products have recently entered clinical trials as potent anti-inflammatory agents (Basnet P, 
2011; Abdel-Tawab M, 2011), however, their role in drug-drug interaction issues is not being 
addressed in specific patient populations. 
1.2 Importance of preclinical in vivo models 
The use of in vivo models to obtain vast quantities of PK/PD data is a well-established pre-
clinical approach. Before any clinical testing can be initiated in humans, it is important to 
compare the PK and PD properties of candidate molecules; model potential relationships 
among dose, concentration, efficacy, and/or toxicity in appropriate animal model systems 
(Sausville EA, 2006; Kennedy AJ, 2010; Miyagawa F, 2010). For a more thorough and 
comprehensive understanding of the experimental approaches in mouse models, please refer 
to ‘The handbook of experimental animals’ by Elsevier Academic Press (Hans H, 2004). 
Numerous inbred mouse models are available to delineate the efficacy of drugs in specific 
disease models, such as the WKY and SHR strains which are optimal for studying 
antihypertensive and antidiabetic agents (Kennedy AJ, 2010) and the leptin knockout mice 
(ob/ob) as models for obesity and insulin resistance (Lijnen HR. 2011). Several disease specific 
knockout and transgenic mouse models are also used, for instance, to study cardiovascular 
drugs (Avila MD, 2011; Xiangdong L, 2011; Zaragoza C, 2011) and autoimmune disease 
targeting agents (Gulinello M, 2011; Schroeder MA, 2011). Immunodeficient animals, such as 
nude, SCID and SCID/NOD tumor xenograft mouse models, are also important for testing 
and development of new chemotherapeutic drugs (Sausville EA, 2006; Khan N, 2009; Umar A, 
2010; Baiocchi M, 2010). The utility of these animal models to study cancer-initiating cells 
which are responsible for tumor recurrence and resistance, is showing great promise towards 
development of more potent anti-cancer agents (Wee B, 2011).  
Studies completed in laboratory animals give useful indications for drug development, and 
many lead compounds that show compromised potency in vitro can turn out to be more 
effective in vivo because of their favorable pharmacokinetics, e.g. greater absorption, better 
distribution and stability, etc. Studies are first initiated in small animal models, e.g. mouse, 
rats, rabbits, to test for acute, sub-chronic and then chronic toxicity. In acute toxicity tests, 
one administration of the drug or chemical is given to each animal in order to generate a 
safe and effective dose–response curve. Appropriate pharmacological testing in disease 
models are carried out to determine 50% effective dose (ED50). For some anti-tumor and 
anti-viral agents, even IC90 (90% inhibitory concentration) is incorporated in these initial 
studies in order to demonstrate the potency (Cummins CL, et al, 2003). Following acute 
administration, analytical methods are developed for determination of absorption, 
distribution, metabolism and excretion (ADME) of the drug. The subchronic toxicity tests 
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usually involve animals exposed to the drug for 60–90 days duration. Both multiple 
administrations and/or continuous exposure via food or water to one dose level of a 
chemical per animal, is carried out to measure drug accumulation and possible toxicities. 
Depending on the animal species being used, the chronic toxicity tests usually takes 2 to 5 
years to complete and may include both multiple administrations per day or continuous 
exposure measures via subcutaneous or intramuscular depot. Indeed, alterations in drug 
elimination rates and toxic outcomes are particularly important when drugs are given 
repeatedly. Certain therapeutic agents tend to accumulate toxic concentrations in tissues 
and organs when eliminated slowly or their metabolism is compromised, drug 
accumulation may occur with toxic concentrations reached in important tissues and organs. 
Alternately, faster elimination than expected due to increased breakdown of the agent may 
cause sub therapeutic concentrations to be reached, thus enabling the rapid selection of drug 
resistance, often observed with antibiotics and antimicrobials. Therefore, a commonly 
employed formula for ascertaining therapeutic dose levels in both pre-clinical and clinical 
models is, “Maintenance dose = Dosing amount X Dosing interval”. Both in vitro and in vivo 
uptake experiments in rats have been able to predict the hepatic and renal clearance of a 
number of drugs, and were able to delineate drugs which are substrates for drug-
metabolizing enzymes and drug-transporters (Watanabe T, et al. 2009). Several transgenic 
and knockout mouse models have also been used to understand the role of drug-
metabolizing enzymes and drug-transporters, and in the discovery of novel inhibitors of 
these factors in order to increase drug efficacy in vivo (Salphati L. et al., 1998; Shitara Y. et al., 
2002; van Waterschoot RA, 2011). Because the drug levels in plasma or tissues are often 
more predictive of a safe dose which can be extrapolated to humans, preclinical toxicology 
in animals underscores the importance of PK studies. The choice of endpoints and correct 
surrogate markers are very important and careful consideration must be given to the 
definition of therapeutic efficacy. Safety is the most important concern in clinical trials and 
then the emphasis is directed towards drug efficacy. In addition to examining safety and 
effectiveness, studies in animal models also emphasize critical aspects of drug kinetics, 
including proper dose determination, biotransformation, drug binding to plasma proteins, 
induction or inhibition of enzymes and potential interaction with other drugs (Evans W, et 
al. 1989; Evans W, et al. 1992). The choice of representative controls is also an essential 
component in PK studies in both preclinical and clinical settings. Indeed, most concurrently 
controlled trials are double-blind and randomized studies where both objective evidence 
and subjective complaints are taken into account towards a clearer representation of 
therapeutic value of the drugs being tested for a specific disease indication.  
2. Pharmacokinetics 
Cell membranes are biologic barriers that selectively inhibit passage of drug molecules. Drugs 
may cross cell membranes by passive diffusion, facilitated passive diffusion, active transport, or 
pinocytosis. Thus, drug PK is critically affected by body mass, obesity as well as age and health 
status of the subject. Since numerous currently used drugs may manifest toxic effects and may 
have long-term teratogenic effects, therapeutic drug monitoring in children has become an 
essential component of clinical testing as emphasized by pediatric pharmacokinetics (McLeod 
HL, et al. 1992). In general, drug elimination may occur through biotransformation and by the 
passage of molecules from the blood to the outside of the body through urines, bile or other 
routes. Therefore, the PK study relies on measurements of levels of the test drug in blood and 
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necessary information to assess the probability of success of an NCE which remains the 
fundamental pathway to successful clinical approval (DiazGranados N, 2008). The 
continually expanding knowledge base on the development of new agents and novel 
delivery and formulation strategies are enabling a favorable in vivo PK and a more 
efficacious drug discovery process. Advances in the understanding of multiple factors that 
regulate drug disposition and response in individuals are elucidating the molecular basis of 
ethnic and inter-individual variability in drug action (Xie HG, et al. 2001; Soldin OP, et al. 
2009). Furthermore, due to their in vivo safety and efficacy profiles, a number of natural 
products have recently entered clinical trials as potent anti-inflammatory agents (Basnet P, 
2011; Abdel-Tawab M, 2011), however, their role in drug-drug interaction issues is not being 
addressed in specific patient populations. 
1.2 Importance of preclinical in vivo models 
The use of in vivo models to obtain vast quantities of PK/PD data is a well-established pre-
clinical approach. Before any clinical testing can be initiated in humans, it is important to 
compare the PK and PD properties of candidate molecules; model potential relationships 
among dose, concentration, efficacy, and/or toxicity in appropriate animal model systems 
(Sausville EA, 2006; Kennedy AJ, 2010; Miyagawa F, 2010). For a more thorough and 
comprehensive understanding of the experimental approaches in mouse models, please refer 
to ‘The handbook of experimental animals’ by Elsevier Academic Press (Hans H, 2004). 
Numerous inbred mouse models are available to delineate the efficacy of drugs in specific 
disease models, such as the WKY and SHR strains which are optimal for studying 
antihypertensive and antidiabetic agents (Kennedy AJ, 2010) and the leptin knockout mice 
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rats, rabbits, to test for acute, sub-chronic and then chronic toxicity. In acute toxicity tests, 
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usually involve animals exposed to the drug for 60–90 days duration. Both multiple 
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elimination rates and toxic outcomes are particularly important when drugs are given 
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Alternately, faster elimination than expected due to increased breakdown of the agent may 
cause sub therapeutic concentrations to be reached, thus enabling the rapid selection of drug 
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employed formula for ascertaining therapeutic dose levels in both pre-clinical and clinical 
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urine at various times after administration. If a drug is ineffective at the given dose, the above 
measurements resolve issues of efficacy vs. poor absorption or rapid elimination. All the organs 
except the lungs are in parallel because they are perfused by a fraction of the whole blood in 
each passage. Drug levels in blood achieve equilibrium with drug entry into subvascular tissues 
and drug levels which are excreted or metabolized. PK studies investigate the parameters 
which regulate therapeutic concentrations of drugs and/or its metabolites, and their movement 
in different parts of the body (Ritschel WA & Kearns GL. 1999). Initial studies of in vivo PK 
measurements required complex mathematical modeling of absorption (A) and distribution 
(D). Absorption indicates the passage of drug molecules from the administration site to the 
blood, and distribution indicates the passage of drug molecules from blood to the tissues. As the 
roles of liver and kidney in drug disposition become clearer, essential components, such as the 
rate of drug metabolism (M) and drug excretion (E) from the body are increasingly examined. 
The choice of best route of drug administration establishes the best dose regimen and 
determines whether dose individualization would be necessary based on patient and disease 
characteristics, e.g. drug elimination rates (Ritschel WA & Kearns GL. 1999). Recent findings 
clearly indicate that these two later parameters in ADME are also critically regulated by 
intracellular drug metabolizing enzymes and membrane bound drug-transporters (Wikinski, S. 
2005). Flexibility in the design of studies is very desirable at this stage. Furthermore, extremely 
slow metabolism of certain drugs may result in their accumulation and toxicity, thus mandating 
changes in subsequent doses. All drugs are eventually excreted from the body, and many 
require bio-activation to form the active compound [Figure-1]. 
 
Fig. 1. Drug absorption and disposition. A graphic representation of drug disposition is shown 
where drug entry first occurs in the blood circulation and then drugs pass through tissues 
and organs. Blocks designate the equilibrium seen between drug absorption, distribution, 
metabolism and elimination (ADME) parameters.  
2.1 Routes of administration 
To gain a proper understanding of drug PK, first of all, it is essential to understand, compare 
and contrast different routes of drug administration, and acknowledge their advantages and 
disadvantages. Drug absorption is determined by the drug's physicochemical properties, 
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formulation and route of administration. Depending on the preclinical findings on ADME in 
animal models, administration could be either Enteral (oral, buccal/sublingual) or Parenteral 
[subcutaneous (SC), intramuscular (IM) or intravenous (IV)] (Evans W, et al. 1992; Ritschel 
WA. 1999; Hans H. 2004). Dosage forms (e.g., tablets, capsules, solutions) are formulated to be 
given by various routes. Regardless of the route of administration, drugs must be in solution to 
be absorbed. Unless given IV, a drug must cross several semipermeable cell membranes before 
it reaches the systemic circulation. Oral drug delivery is highly advantageous since it is 
convenient and cheap and patient compliance is good. Different formulations such as fast 
release tablets, capsules, enteric coated pills, suspensions and mixtures can be used to enhance 
drug uptake by intestinal epithelial lining and to facilitate drug stability in the stomach and 
small intestine. However, there are several disadvantages related to oral delivery, especially its 
inefficiency in reaching therapeutic plasma levels. Low oral bioavailability can be due to 
decreased stability and solubility of the drug in the gastrointestinal (GI) tract. In addition, the 
GI lining expresses a number of Cytochrome P450 (CYP450) enzymes and drug-efflux 
transporters which can suppress drug uptake and enhance metabolism.  
Presystemic metabolism is a significant challenge even after intestinal uptake due to the 
transport of drugs to the liver via the hepatic portal vein. Examples of drugs that experience 
a significant ‘first-pass effect’ are imipramine, morphine, propranolol, buprenorphine, 
diazepam, midazolam, demerol, cimetidine, and lidocaine. The first pass effect and liver 
metabolism can be bypassed via buccal or sublingual administration which significantly 
increases bioavailability (Brockmeier D. 1988; Haber PS, 1996; Brown AS, 1998). In recent 
years, the first pass effect has also been exploited in converting an inactive form of a drug 
(e.g. 3-methylmorphine or Codeine) to the pharmacologically active form (morphine) by 
first pass metabolism (KuKanich B. 2010; Nieminen TH, 2010). However, under most 
circumstances, the oral drug delivery approach is inconvenient and only small doses can be 
accommodated. Hence, several strategies to directly infuse drugs, so that rapid plasma 
levels can be achieved, are SC, IM and IV delivery methods. One advantage of SC delivery is 
that drugs can be self-administered. Although absorption is slow via this route, it can be 
improved by local massage or heat. Unfortunately, this method can be painful and irritant 
drugs can cause local tissue damage. In contrast, IM injections can accomodate a larger 
volume of drug delivery, and now a number of drugs are using IM strategies to facilitate 
depot formation for sustained release effects. The trained personnel are required for IM 
injections, however, the site of injection can significantly influence systemic absorption of 
the drug. A quicker response is possible with IV drug delivery and large doses may be given 
into a peripheral vein over 1 to 2 minutes or longer by infusion. In most of the pre-clinical 
PK studies, this is the route of choice for drug infusion and monitoring of toxicity, especially 
of chemotherapeutic agents (Wong J, 2008; Serwer LP, 2011). The IV method however 
requires trained personnel to maintain sterility, and pyrogen testing, while the cost of 
preparation, transport and storage of such preparations can be expensive. 
2.2 Fick's law of diffusion 
Drugs diffuse across a cell membrane from a region of high concentration to one of low 
concentration. Diffusion rate is directly proportional to the gradient but also depends on the 
molecule's lipid solubility, size, degree of ionization, and the area of absorptive surface. Lipid-
soluble drugs diffuse most rapidly and small molecules tend to penetrate membranes more 
rapidly than larger ones. Drug effectiveness using any of the above delivery approaches 
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formulation and route of administration. Depending on the preclinical findings on ADME in 
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convenient and cheap and patient compliance is good. Different formulations such as fast 
release tablets, capsules, enteric coated pills, suspensions and mixtures can be used to enhance 
drug uptake by intestinal epithelial lining and to facilitate drug stability in the stomach and 
small intestine. However, there are several disadvantages related to oral delivery, especially its 
inefficiency in reaching therapeutic plasma levels. Low oral bioavailability can be due to 
decreased stability and solubility of the drug in the gastrointestinal (GI) tract. In addition, the 
GI lining expresses a number of Cytochrome P450 (CYP450) enzymes and drug-efflux 
transporters which can suppress drug uptake and enhance metabolism.  
Presystemic metabolism is a significant challenge even after intestinal uptake due to the 
transport of drugs to the liver via the hepatic portal vein. Examples of drugs that experience 
a significant ‘first-pass effect’ are imipramine, morphine, propranolol, buprenorphine, 
diazepam, midazolam, demerol, cimetidine, and lidocaine. The first pass effect and liver 
metabolism can be bypassed via buccal or sublingual administration which significantly 
increases bioavailability (Brockmeier D. 1988; Haber PS, 1996; Brown AS, 1998). In recent 
years, the first pass effect has also been exploited in converting an inactive form of a drug 
(e.g. 3-methylmorphine or Codeine) to the pharmacologically active form (morphine) by 
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circumstances, the oral drug delivery approach is inconvenient and only small doses can be 
accommodated. Hence, several strategies to directly infuse drugs, so that rapid plasma 
levels can be achieved, are SC, IM and IV delivery methods. One advantage of SC delivery is 
that drugs can be self-administered. Although absorption is slow via this route, it can be 
improved by local massage or heat. Unfortunately, this method can be painful and irritant 
drugs can cause local tissue damage. In contrast, IM injections can accomodate a larger 
volume of drug delivery, and now a number of drugs are using IM strategies to facilitate 
depot formation for sustained release effects. The trained personnel are required for IM 
injections, however, the site of injection can significantly influence systemic absorption of 
the drug. A quicker response is possible with IV drug delivery and large doses may be given 
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PK studies, this is the route of choice for drug infusion and monitoring of toxicity, especially 
of chemotherapeutic agents (Wong J, 2008; Serwer LP, 2011). The IV method however 
requires trained personnel to maintain sterility, and pyrogen testing, while the cost of 
preparation, transport and storage of such preparations can be expensive. 
2.2 Fick's law of diffusion 
Drugs diffuse across a cell membrane from a region of high concentration to one of low 
concentration. Diffusion rate is directly proportional to the gradient but also depends on the 
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soluble drugs diffuse most rapidly and small molecules tend to penetrate membranes more 
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ultimately requires transport across membrane barriers. In addition, membrane transporters 
play active roles in both drug influx and efflux and therapeutic levels in sequestered tissues. 
Oral drugs need efficient transport across intestinal epithelial lining and subsequently through 
the endothelial lining of blood capillaries. Drugs diffuse across a membrane in an attempt to 
equalize the drug concentration on both sides of the membrane. Fick's law was the driving 
force that represented a tendency for molecules to move from levels of higher concentration to 
lower concentration in accordance with random molecular motion. This has been attributed to 
the fact that the rate of diffusion across a membrane is directly proportional to the 
concentration gradient of a substance on either side of the membrane and is inversely related 
to the thickness of the membrane. Therefore, the rate of drug transport across the membrane 
has been described by the Fick's law of diffusion [Figure-2]. 
 
Fig. 2. Fick's law of diffusion. Molecules tend to move from a higher concentration to a lower 
concentration where the rate of diffusion across a membrane is directly proportional to the 
concentration gradient and inversely related to the thickness of the membrane. Rate of 
movement of Molecules per unit time = (Area)x(Permeability coefficient)x(Ch - Cl)/ Thickness.  
Previously, most drugs were thought to cross biologic membranes by passive diffusion 
which occurs when the drug concentration on one side of the membrane is higher than on 
the other side. Therefore, in the past, the absorption principles for a drug molecule were 
primarily dependent on its aqueous diffusion, especially within large aqueous components 
(e.g. interstitial space, intracellular cytosol). This view of drug movement is dictated by their 
ability to transport drugs across epithelial and endothelial membrane tight junctions 
(Matsuhisa K, 2009; Furuse M. 2010). Both physiological conditions and disease status, 
especially inflammatory cytokines, are known to regulate drug transport from the blood to 
the tissues via these tight junctions (Tarbell JM. 2010; Srinivas SP. 2011). This drug 
absorption into tissues is also facilitated via transport through aqueous pores which allows 
diffusion of molecules with molecular weights up to 30 kDa. Lipid diffusibility of drugs is 
also an essential component in a drug’s ability to be transported from one compartment to 
another since many lipid barriers separate tissue compartments and drug partition 
coefficients between aqueous and lipid environments. In addition, the ionization states of 
drugs have been studied to determine their PK efficacy and bioavailability. However, rapid 
dissolution and absorption is not always the objective. Sometimes a slower release is 
required, e.g. for Tolbutamide (used to lower blood sugar): a more sustained release is 
better, causing a more gradual reduction in blood sugar (Tassaneeyakul W, 1992; Lee CR, 
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2003). In addition, as mentioned earlier, the rate at which a drug dissolves is also dependent 
on its solubility and acid-base dissociation constants, according to the ‘Henderson 
Hasselbalch equation, e.g. free acid or base forms of Penicillin achieve different serum 
levels. Also, absorption of antimicrobials can be extended by using IM injection of their less 
insoluble salt forms (e.g. Penicillin G). For other drugs, suspensions or solutions in 
nonaqueous vehicles (e.g., crystalline suspensions for insulin) are designed to delay 
absorption. Most drugs are weak organic acids or bases, existing in un-ionized and ionized 
forms in an aqueous environment. The un-ionized form is usually lipid soluble (lipophilic) 
and diffuses readily across cell membranes. The ionized form has low lipid solubility 
(hydrophilic) and high electrical resistance and thus cannot penetrate cell membranes easily. 
The proportion of the un-ionized form present (and thus the drug's ability to cross a 
membrane) is determined by the pH and the drug's pKa (acid dissociation constant). 
However, whether a drug is acidic or basic, most absorption occurs in the small intestine 
because the surface area is larger and membranes are more permeable.  
Although the surface area of the epithelial lining allows for high rate of absorption, the 
endothelial lining of blood vessels is relatively non-porous. For numerous diseases of the 
central nervous system (CNS), e.g. gliomas, AIDS dementia, epilepsy, etc., drug absorption 
into the brain has been a significant problem (Aragon-Ching JB, 2007; Reichel A. 2009). This 
is especially due to the presence of blood-brain barrier (BBB) and blood-cerebrospinal fluid 
(CSF) barrier (Mehdipour AR, 2009; Johanson CE, 2011). The membranes between the blood 
and brain have effectively no pores and prevent many polar materials (often toxic materials) 
from entering the brain. However, smaller lipid materials or lipid soluble materials, such as 
diethyl ether, halothane, can easily enter the brain. Several in vitro models have been 
developed to overcome drug inefficacies in the brain (Wilhelm I, 2011; Tóth A, 2011; 
Potschka H. 2010). The absorption of a drug and/or its metabolites into the kidney is also 
very crucial in dictating drug elimination and in suppressing accumulation of toxic levels of 
the drug. This is especially important since the membranes of the renal tubules and renal 
glomerulus are quite porous allowing non-polar and polar molecules (~ M.W. 70 kDa) to 
pass through and allows for rapid excretion of polar substances (drug and waste 
compounds) (Verbeeck RK, 2009; Hartmann B, 2010).  However, lipophilic compounds or 
non-ionized species are reabsorbed dependent on the pH and pKa of the drug which 
dictates the elimination rate and is measured in patients via creatinine clearance rates (CCR) 
(Kooman JP. 2009; Bogard KN, 2011; Fesler P, 2011), a parameter which will be emphasized 
later in this chapter in relation to drug-transporter expression in the liver and the kidney.  
In contrast to passive diffusion, active transport is selective, requires energy expenditure and 
may involve transport against a concentration gradient. Active transport seems to be limited to 
drugs structurally similar to endogenous substances (e.g. ions, vitamins, sugars, amino acids). 
These drugs are usually absorbed from specific sites in the small intestine. As will be discussed 
in more detail in this chapter, we have discovered that complex mathematical modeling is 
necessary to determine the volume of distribution and therapeutic window for drug action. 
Furthermore, we now appreciate the role of special carriers present on lipid membranes that 
regulate drug transport into various compartments. 
2.3 Compartmental models and important PK parameters 
Compartmental analysis uses kinetic models to describe and predict the concentration-time 
curve. PK compartmental models are often similar to kinetic models used in other scientific 
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ultimately requires transport across membrane barriers. In addition, membrane transporters 
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the fact that the rate of diffusion across a membrane is directly proportional to the 
concentration gradient of a substance on either side of the membrane and is inversely related 
to the thickness of the membrane. Therefore, the rate of drug transport across the membrane 
has been described by the Fick's law of diffusion [Figure-2]. 
 
Fig. 2. Fick's law of diffusion. Molecules tend to move from a higher concentration to a lower 
concentration where the rate of diffusion across a membrane is directly proportional to the 
concentration gradient and inversely related to the thickness of the membrane. Rate of 
movement of Molecules per unit time = (Area)x(Permeability coefficient)x(Ch - Cl)/ Thickness.  
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2003). In addition, as mentioned earlier, the rate at which a drug dissolves is also dependent 
on its solubility and acid-base dissociation constants, according to the ‘Henderson 
Hasselbalch equation, e.g. free acid or base forms of Penicillin achieve different serum 
levels. Also, absorption of antimicrobials can be extended by using IM injection of their less 
insoluble salt forms (e.g. Penicillin G). For other drugs, suspensions or solutions in 
nonaqueous vehicles (e.g., crystalline suspensions for insulin) are designed to delay 
absorption. Most drugs are weak organic acids or bases, existing in un-ionized and ionized 
forms in an aqueous environment. The un-ionized form is usually lipid soluble (lipophilic) 
and diffuses readily across cell membranes. The ionized form has low lipid solubility 
(hydrophilic) and high electrical resistance and thus cannot penetrate cell membranes easily. 
The proportion of the un-ionized form present (and thus the drug's ability to cross a 
membrane) is determined by the pH and the drug's pKa (acid dissociation constant). 
However, whether a drug is acidic or basic, most absorption occurs in the small intestine 
because the surface area is larger and membranes are more permeable.  
Although the surface area of the epithelial lining allows for high rate of absorption, the 
endothelial lining of blood vessels is relatively non-porous. For numerous diseases of the 
central nervous system (CNS), e.g. gliomas, AIDS dementia, epilepsy, etc., drug absorption 
into the brain has been a significant problem (Aragon-Ching JB, 2007; Reichel A. 2009). This 
is especially due to the presence of blood-brain barrier (BBB) and blood-cerebrospinal fluid 
(CSF) barrier (Mehdipour AR, 2009; Johanson CE, 2011). The membranes between the blood 
and brain have effectively no pores and prevent many polar materials (often toxic materials) 
from entering the brain. However, smaller lipid materials or lipid soluble materials, such as 
diethyl ether, halothane, can easily enter the brain. Several in vitro models have been 
developed to overcome drug inefficacies in the brain (Wilhelm I, 2011; Tóth A, 2011; 
Potschka H. 2010). The absorption of a drug and/or its metabolites into the kidney is also 
very crucial in dictating drug elimination and in suppressing accumulation of toxic levels of 
the drug. This is especially important since the membranes of the renal tubules and renal 
glomerulus are quite porous allowing non-polar and polar molecules (~ M.W. 70 kDa) to 
pass through and allows for rapid excretion of polar substances (drug and waste 
compounds) (Verbeeck RK, 2009; Hartmann B, 2010).  However, lipophilic compounds or 
non-ionized species are reabsorbed dependent on the pH and pKa of the drug which 
dictates the elimination rate and is measured in patients via creatinine clearance rates (CCR) 
(Kooman JP. 2009; Bogard KN, 2011; Fesler P, 2011), a parameter which will be emphasized 
later in this chapter in relation to drug-transporter expression in the liver and the kidney.  
In contrast to passive diffusion, active transport is selective, requires energy expenditure and 
may involve transport against a concentration gradient. Active transport seems to be limited to 
drugs structurally similar to endogenous substances (e.g. ions, vitamins, sugars, amino acids). 
These drugs are usually absorbed from specific sites in the small intestine. As will be discussed 
in more detail in this chapter, we have discovered that complex mathematical modeling is 
necessary to determine the volume of distribution and therapeutic window for drug action. 
Furthermore, we now appreciate the role of special carriers present on lipid membranes that 
regulate drug transport into various compartments. 
2.3 Compartmental models and important PK parameters 
Compartmental analysis uses kinetic models to describe and predict the concentration-time 
curve. PK compartmental models are often similar to kinetic models used in other scientific 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
62
disciplines such as chemical kinetics and thermodynamics. At different times after drug 
administration, much information can be obtained on the passage of drug molecules 
between blood and tissues and on the rate of drug elimination in the urine or feces by 
measuring the concentrations of drugs in different body fluids or within tissues [Figure-3]. 
The advantage of compartmental over some non-compartmental analyses is the ability to 
predict the concentration at any time post drug infusion; however, the disadvantage of this 
complex system is the difficulty in developing the proper model and validating the proper 
rate constants for the ADME principles.  
 
Fig. 3. Compartment models used in drug disposition measurements. The simplest PK compartmental 
model (Model-I) is the one-compartmental PK model with IV bolus administration and first-
order elimination. In multicompartmental modeling, the rate constants for drug transport to-and-
from the central reservoir (blood) to tissues such as fat, bone or skin (k12 and k21) and the rate of 
elimination by the kidney and liver (kel), are needed to be determined.  
The planning, execution and analysis of the results of a PK study depends closely on the 
purpose of the experiment. For example some studies may be planned to get accurate 
estimates of drug absorption or to obtain information on the drug elimination kinetics 
(Evans W, et al. 1989; Evans W, et al. 1992; Ritschel WA & Kearns GL. 1999). Consequently 
the experimental protocols may vary considerably. Hence, to effectively plan a 
pharmacokinetic experiment, the following conditions should be well defined: the route of 
drug administration, dose regimen, which tissues to sample, sample times, analytical 
method, and the animal species. In clinical settings, the inclusion and exclusion criteria of 
subjects for observation and the population kinetics of the drug are taken into account.  
Mathematical models are essential tools in PK measurements because these models aid in 
defining a set of parameters that describe drug disposition and the relationship of underlying 
biological processes. In model building, the linear compartmental models, the clearance 
models, and the multiexponential functions, constitute various passages of drugs through 
different compartments. Starting from a simple description of the drug profile in the plasma, 
the experimenter may gain better insight and reasonable approximations of the biological and 
physiological aspect of the system. The analysis of the assumptions, approximations of the 
model, and a comparison of the performance of different models may thus be very useful in 
identifying new aspects of the system and to design experiments able to deliver continuous 
and increasingly relevant knowledge. This chapter will only touch briefly on each of these 
important PK parameters to familiarize the reader with the concepts, but for detailed 
descriptions of these mathematical models the reader is requested to consult the following 
more comprehensive reviews on PK (Evans W, et al. 1992; Ritschel WA & Kearns GL. 1999).  
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During mathematical calculations estimate drug disposition rates, to compartmental models 
have been beneficial tools to understand the effects of the overall system under study. Both 
single and multicompartmental modeling is needed to obtain accurate measures of drug 
levels in tissues and possible efficacies at site of action. This is carried out following oral or 
IV infusion of the drug and sampling of plasma concentrations at different time points. The 
following parameters are determined simultaneously which include peak plasma 
concentrations (Cmax), peak time to attain Cmax (Tmax), half-life (t1/2), and area under the 
plasma concentration curve (AUC). It should be noted that each parameter of this model 
which deals with the rate constants, do not represent a single physical variable, but a set of 
variables which may not be distinguished at a given time point. The kinetic profile of a 
single drug in the plasma may be well summarized by the above parameters, and is 
depicted in the plasma concentration vs. time curves [Figure-4]. 
 
Fig. 4. The plasma concentration vs. time curve. The curve on the left illustrates plasma 
concentration of the drug at different times following IV introduction. The onset of drug 
effect, magnitude and duration of drug effect, as well as the therapeutic window for the 
drug can be determined from these in vivo measurements. The line graph on the right 
illustrates the rate of change in plasma concentration (∆C/∆t) of the drug which is 
dependent on the initial drug concentrations. This type of rate change analysis is helpful in 
determining the rates of elimination and metabolism, as well as the half-life of the drug. 
The Cmax and Tmax may be directly obtained from experimental observations of each subject 
and these two parameters are closely dependent on the experimental protocol because the 
concentrations are always decreasing after the initial dose. The peak time corresponds to the 
time of infusion if the drug is infused by IV at a constant rate. However, after oral 
administration Cmax and Tmax are dependent on the extent and the rate of drug absorption, 
and on the disposition profile of the drug. Consequently these two parameters can 
characterize the properties of different formulations of the drug in the same subject. All of 
the initial information on Cmax and Tmax should be generated when presenting the design of 
a pharmacokinetic study.  
The half life of a drug has a significant relevance in the determination of dosage of a drug. 
Half-life (t1/2) is derived from a mathematical property of the monoexponential function curve 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
62
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which results in elimination of half of the drug after a fixed time interval [Figure-5]. This 
means that the kinetic profile of many drugs is well approximated by a monoexponential 
function in the terminal phase and consequently it makes sense to define the half-life, or 
terminal half-life, in order to characterize the slope of the curve in this phase. Therefore, the 
drug elimination rate (Kel) is the sum of the rate constants due to the rate of metabolism (Km) 
and the rate of excretion (Kex), and it can be defined as Kel = Km + Kex. Since drug elimination 
is an exponential process, the time required for a twofold decrease is proportional to ln(2) or 
0.693 which equals the natural logarithm of two, and t1/2 = (0.693)/Kel. Therefore, if Co is the 
drug concentration at time 0 and λ is dependent on the half-life of the curve, then the following 
relationship can be extrapolated as: t1/2 = 0.693 /λ. With a single compartmental model, a 
monoexponential function can thus be used to calculate plasma concentration at a specific time 
after administration. This can be written as:- c(t) = C0 x e–λ.t where c(t) is the drug concentration 
at time t. Indeed, the terminal half-life is often used to describe decay of the drug concentration 
during the terminal phase.  
 
Fig. 5. The half life of drugs in vivo. Half life of a drug is dependent on Rate of Elimination of 
the drug. The semi-log plot shows plasma levels of drugs (Cp) and different time post 
infusion (e.g. t1, t2, etc.). It is a constant rate of decline which is independent of the starting 
time of drug administration. 
 
Fig. 6. The AUC analysis. The AUC is calculated by adding the different AUC-segments 
together. Each very narrow segment has an area of Cp.dt. The AUC depends on the volume 
of distribution (V) and the rate of elimination (Kel). It is calculated from time 0 
(administration time, Cp0) to infinity as shown in equations 1 and 2. 
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The extent and rate of drug absorption and distribution thus play important roles in 
pharmacokinetics. These parameters are usually referred to as the drug bioavailability (BA). 
The area under the plasma concentration curve (AUC) value is very useful for calculating the 
relative efficiency and BA of different drugs and possibly their metabolic products, e.g. the 
metabolic products of the anti-cancer agent irinotecan (Mathijssen RH, et al. 2001).  The AUC is 
calculated by adding the AUC-segments together under the plasma concentration vs. time 
curve. Each very narrow segment of the cure has an area equal to plasma concentration at 
different time intervals (i.e. Cp x dt) [Figure-6]. The AUC is calculated from time 0 
(administration time) to infinity after single drug administration, and within the dose interval 
after multiple dose treatment. By integrating this equation that t1/2 = 0.693 / λ between 0 and 
infinity, we can obtain the values for AUC = Co/λ.  This suggests that the area under the curve 
can also be computed easily from the Co, e and λ values. The Co and λ can be estimated by a 
non-linear regression technique or by linearizing the data using the log-transformation.  
The AUC can also be used to measure both the volume of distribution (Vd) and the drug 
elimination process. Under very general assumptions, the AUC is closely dependent on the 
drug amount that enters into the systemic circulation and on the ability that the system has 
to eliminate the drug (clearance). Therefore, AUC can be used to measure the drug amount 
absorbed or the efficiency of physiological processes that characterize drug elimination. 
Clearance (CL), on the other hand, depends on the functionality of the eliminating organs, 
i.e. the kidney or the liver, therefore possible inefficiencies of these organs can have 
consequences on clearance, AUC and drug levels. For example, a fraction of a dose may be 
metabolized during the early passage through the gastrointestinal (GI) tract or through the 
liver after an oral dose and part of the dose may not even reach the blood due to drug 
malabsorption. The consequences are incomplete absorption of the drug into the systemic 
circulation and incomplete drug availability which may result in an ineffective treatment. 
Evidence that drug PK may drastically be changed due to either IV or oral administration of 
the anti-diabetic agent metformin, were also clearly shown in these early studies 
(Pentikainen PJ, 1979). From the plasma AUC and the CL, it is possible to compute the drug 
amount which enters into the systemic circulation in a particular subject. The following very 
general definitions can be given: CL = D/AUC x Vd where CL = drug amount eliminated 
per unit of time/drug concentration in plasma, and the volume of distribution (Vd) = drug 
amount in the body/drug concentration in plasma [Figure-7].  
For drugs with narrow therapeutic index and significant side-effect profiles, it is common 
that multiple exponential terms are needed to fit the plasma concentrations after an IV 
bolus, and more complex mathematical modeling is carried out to more accurately 
determine the PK parameters. In order to get a good interpolation of the data after oral or 
extravascular administration, multiple exponential terms should be added to the above 
simple equations of PK. Although plasma drug concentrations are increasing just after oral 
administration and decreasing after the peak time, the predicted data may be biased when 
fitted by a monoexponential function, and interpolation of oral or IV profile may be 
obtained by adding new exponential terms with the following equation: C(t) = A1 x e–λ1.t + A2 
x e–λ2.t, which is called a biexponential function. In order to get the best fit of the 
experimental data and the best accuracy in the estimated parameters, a number of these 
exponential terms should be chosen. By taking into account the numerous compartments 
that the drug can be distributed to, as well as the number of rate constants necessary to 
ultimately determine the drug concentration remaining at a certain time, the above equation 
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is frequently changed to represent an integration function: C(t) = ΣAi x e–λi.t. Following these 
calculations, the initial drug level and the AUC can be computed by the integrated 
parameters of the curve as represented by the equation: Co = Σ Ai x e x AUC = Σi Ai /λi 
where Co is equal to 0 after oral or extravascular administration. This literally means that 
the terminal half-life is always represented by 0.693/λn, where the λn is the lowest exponent.  
 
Fig. 7. Multicompartmental Models. Frequently, a multicompartmental model and equation 
are implemented where the rate constants for drug absorption and distribution are 
calculated. In this model, the k0 represents initial absorption process and the processes of 
tissue absorption, distribution and excretion are denoted by using multiple rate constants 
such as k12, k21, and k10. In this multicompartmental system, a drug appears to be dissolved 
in total body volume which is also referred to as the 'apparent' volume of distribution (VD). 
The VD can be used to determine how readily a drug will displace into the body tissue 
compartments relative to the blood, where: VP = plasma volume; VT = apparent tissue 
volume; fu = fraction unbound in plasma and fuT = fraction unbound in tissue.  
Although these multiexponential functions require complex calculations, they are needed to 
determine drug disposition in both preclinical and clinical settings. The importance of such 
rigorous calculations was recently underscored by findings that Clopidogrel, an anti-platelet 
drug used to treat heart attack and stroke, which had a very narrow therapeutic index and 
caused significant side effects in the elderly (Roden, DM. & Stein, CM. 2009), needed careful 
dose adjustments depending on the patient’s renal clearance rates (Goteti K, 2008).  
The majority of drugs currently used have approximately a biexponential profile in plasma after 
an intravenous bolus, but there are exceptions especially after oral administration. Indeed, very 
often the drug profile is not monoexponential, and the concentrations of many drugs in plasma 
and tissues may not decay in a linear fashion (Evan W., 1989). Highly comprehensive data on 
drug profiles, not only in the plasma, but also in all other tissues or fluids, and especially 
addressing the differences due to the routes of administration are needed. Therefore, for a given 
drug, a single kinetic profile may be well summarized by Cmax, Tmax, t1/2 and AUC, however, 
with drugs having more than one profile, the mean and standard deviation of these individual 
parameters, may be needed to summarize the drug kinetics especially in multiple animals or in 
the whole population (Dreisbach AW, 2008 & 2009).  
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3. Drug metabolizing enzymes and drug-transporters 
Until recently, when a drug exhibited poor oral bioavailability, it was generally assumed 
that this was due to either physicochemical problems associated with poor solubility in the 
GI fluids or inability to diffuse through the intestinal membrane, or alternatively, due to 
significant first-pass hepatic metabolism. Based on a series of cellular, animal and human 
studies, we now realize that both intestinal metabolic enzymes and efflux transporters, 
working together as a protective mechanism, may be responsible for the poor bioavailability 
of a number of drugs (Furuta T, 1998; Schellens JH, 2000; Luo FR, 2002). Drug metabolizing 
enzymes and drug-transporters critically regulate the extent of drug distribution throughout 
the body and the rate of drug clearance from the body (Volm M, 1991; Wacher VJ, 1995). The 
CYP450 enzymes are the major enzymes involved in drug metabolism and bio-activation, 
accounting for ∼75% of the total metabolism. The CYP enzymes catalyze the oxidation of 
organic substances such as lipids, steroidal hormones, and xenobiotics, and they are the 
primary enzymes involved in drug metabolism and bioactivation (Guengerich, 2008). The 
first evidence of the Cyp450 system in regulating drug-interactions was observed when the 
effects of ketoconazole, a potent inhibitor of multiple drug-metabolizing enzymes, were 
shown to increase digoxin absorption and disposition in a rat model (Salphati, L. 1998). The 
ATP-binding cassette (ABC) transporters are a family of transmembrane proteins that 
harness the energy of adenosine triphosphate (ATP) hydrolysis to translocate a variety of 
substrates including lipids, sterols, metabolic products and drugs across extra- and 
intracellular membranes (Davidson et al., 2008).  
 
 
Table 1. Both drug metabolizing enzymes and drug-transporters regulate ADME. 
Over the past several decades, considerable efforts to delineate the characteristics 
influencing activation and regulation of these enzymes and proteins have provided a 
valuable foundation of data illustrating their different effects on the distribution, 
metabolism and clearance of drugs. Increasing evidence suggests that CYP450 enzymes and 
ABC transporters significantly impact drug bioavailability, and a variety of factors including 
age, sex, health and genetics influence their activity (Sai K, 2003; Allabi AC, 2004). The 
following section summarizes how the aforementioned factors may impact PK and PD to 
ultimately guide health care providers in making informed decisions about the type of drug, 
dosage and dosage scheduling for safe administration. Since all drugs are eventually 
excreted from the body, and many require bio-activation to form the active compound, the 
field of PK has begun to focus not only on drug metabolism by the CYPs, but also on the full 
spectrum of drug disposition, including a growing list of transporters that influence 
absorption, distribution and excretion [Table-1]. 
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is frequently changed to represent an integration function: C(t) = ΣAi x e–λi.t. Following these 
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Fig. 7. Multicompartmental Models. Frequently, a multicompartmental model and equation 
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drug, a single kinetic profile may be well summarized by Cmax, Tmax, t1/2 and AUC, however, 
with drugs having more than one profile, the mean and standard deviation of these individual 
parameters, may be needed to summarize the drug kinetics especially in multiple animals or in 
the whole population (Dreisbach AW, 2008 & 2009).  
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3.1 The CYP450 system 
CYP450 enzymes are present in most tissues of the body and play important roles in 
hormone synthesis and breakdown (including estrogen and testosterone synthesis and 
metabolism), cholesterol synthesis and vitamin D metabolism (Salphati, L. 1998; 
Guengerich, 2008; Bjorkman S. 2005). CYP450 enzymes also function to metabolize 
potentially toxic compounds, including drugs and products of endogenous metabolism such 
as bilirubin, principally in the liver. A subset of CYP450 enzymes play important roles in the 
synthesis of steroid hormones (steroidogenesis) by the adrenals, gonads, and peripheral 
tissue: CYP11A1 (steroid 20α-hydroxylase), CYP11B1, CYP17A1, CYP21A1 (in the adrenal 
cortex conducts 21-hydroxylase activity) and CYP19A all catalyze aromatization of 
androgens to estrogens. These enzymes belong to the superfamily of proteins containing a 
heme cofactor and, therefore, are hemoproteins which have been named on the basis of their 
cellular (cyto) location and spectrophotometric characteristics (chrome). When the reduced 
heme iron forms an adduct with carbon monoxide (CO), the P450 enzymes absorb light at 
wavelengths near 450 nm, identifiable as a characteristic Soret peak, thus the name CYP450.  
These drug metabolizing enzymes are primarily membrane-associated proteins, located 
either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. 
Often, they form part of multi-component electron transfer chains, called P450-containing 
systems. Each enzyme is termed an isoform since each derives from a different gene. It 
should be noted, however, that structural similarity of enzymes cannot be used to predict 
which isoforms will be responsible for a drug's metabolism. Because of the vast variety of 
reactions catalyzed by CYPs, the activities and properties of the many isoenzymes differ in 
many respects. Each CYP450 enzyme and their isozymes can metabolize multiple drugs and 
recognize molecules with disparate structures as their substrates. Drug interactions 
involving the CYP450 isoforms generally result from one of two processes, enzyme 
inhibition or enzyme induction. Enzyme inhibition usually involves competition with 
another drug for the enzyme binding site. This process usually begins with the first dose of 
the inhibitor and onset and offset of inhibition correlate with the half-lives of the drugs 
involved (Dossing M, 1983; Murray M, 1990). Enzyme induction occurs when a drug 
stimulates the synthesis of more enzyme protein, enhancing the enzyme's metabolizing 
capacity. It is somewhat difficult to predict the time course of enzyme induction because 
several factors, including drug half-lives and enzyme turnover, determine the time course of 
induction. Broadly, the CYPs are divided into two categories, i.e. Phase-I enzymes that 
introduce or remove functional groups in a substrate through oxidation, reduction or 
hydrolysis; and Phase-II enzymes that transfer moieties from a cofactor to a substrate via 
conjugation. According to a standardized nomenclature system adapted in 1996, the CYPs 
are divided into 18 families and 43 subfamilies on the basis of amino acid sequence 
homology (Ingelman-Sundberg M. 2004 & 2009; Nelson, DR. 2009). A schematic of recent 
guidelines for the nomenclature of CYP450 isoenzyme families, is provided [Figure-8].  
The Phase-I CYP450 is a gene superfamily consisting of more than 57 genes coding for 
functional proteins, and 58 pseudogenes. The most common reaction catalyzed by the Phase-I 
enzymes is a monooxygenase reaction, e.g. insertion of one atom of oxygen into an organic 
substrate (RH) while the other oxygen atom is reduced to water: RH + O2 + 2H+ + 2e– → ROH 
+ H2O. The majority of these genes are polymorphic. Current information on genetic variants 
can be found at the human CYP allele home page (http://www.imm.ki.se/CYPalleles/ and 
http://www.cypalleles.ki.se/). More than 434 different alleles of the genes encoding 
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xenobiotic metabolizing P450 enzymes are presented on this site. Among these, three 
subfamilies of CYPs, including CYP1, CYP2, and CYP3, contribute to the oxidative metabolism 
of more than 90% of clinically used drugs. Overall, approximately 10 of the CYP450 enzymes 
are responsible for the metabolism of a large number of pharmacologic agents in human 
beings, and six of them are considered most important: CYP3A4, CYP2D6, CYP2C19, CYP2C9, 
CYP1A2 and CYP2E1. CYP3A4 is the most abundantly expressed cytochrome and composes 
30 to 40% of the CYP in the liver and in the small intestine. CYP2D6 is implied (at 20%) in the 
metabolism of active compounds and CYP2C9 coupled with CYP2C19 can metabolize at least 
15% of commonly prescribed drugs (Desta Z, 2006).  
 
Fig. 8. CYP450 gene nomenclature. Enzymes that share at least 40% sequence homology are 
assigned to a family designated by an Arabic numeral, whereas those sharing at least 55% 
homology makeup a particular subfamily designated by a letter (A, B, C, etc.). Single 
members of a subfamily represent a particular enzyme and are designated by the number 
following the subfamily description (e.g. CYP2D6, CYP3A4). For each enzyme, the most 
common or “wild-type” allele is denoted as -1, and allelic variants are sequentially 
numbered as they are identified (i.e. -2, -3, etc.). 
The most clinically important Phase-II enzymes are uridine diphosphate 
glucuronosyltransferase (UGT), sulfotransferase (SULT), glutathione S-transferases (GST), 
N-acetyltransferase (NAT) and thiopurine methyltransferase (TPMT). The human UGT 
superfamily is a group of conjugating enzymes that catalyze the transfer of the glucuronic 
acid group of uridine diphosphoglucuronic acid to the functional group (e.g. hydroxyl, 
carboxyl, amino, and sulfur) of a specific substrate. Glucuronidation increases the polarity of 
the substrates and facilitates their excretion in bile or urine. Seventeen human UGT genes 
have been identified thus far and are classified into two subfamilies (i.e. UGT1 and UGT2) 
(Nagar S, 2006). The super family of human GST catalyzes the conjugation of glutathione 
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(GSH) to a wide range of endogenous metabolites and xenobiotics including alkylating and 
free radical generating anticancer drugs (Townsend DM, 2005; Board PG. 2007). NAT2 plays 
an important role in the activation and/or deactivation of a large and diverse number of 
aromatic amine and hydrazine drugs used in the clinic, and therefore the NAT2 genotype is 
particularly relevant to the response to these drugs (Hein DW. 2002). TPMT is best known 
for its key role in the metabolism of the thiopurine drugs (e.g., 6-mercaptopurine, 
azathiopurine and 6-thioguanine) which are clinically used to treat cancers or as immuno-
suppressants (Booth RA, 2011). 
3.2 The ABC and SLC transporters 
Our knowledge of membrane expressed drug transporters has increased considerably in 
the past decade. Several transporters have been cloned and advances have been made in 
understanding their structure- function and characteristics (Davidson AL, 2008; Borst P, 
2000; Shitara Y, 2002 ). Many tissues express these drug transporters such as the brain, 
liver, kidney and intestine; and they play an important role in defining characteristics of 
drug absorption, distribution and excretion of drugs. Thus, they are pivotal in affecting 
absorption and tissue distribution, hepatic uptake and export, as well as renal and biliary 
elimination of a variety of drugs. Conversely, the active transporters dictate the entry of 
drugs into different compartments and actively efflux drugs from intracellular 
compartments. Thus, drug transport via these membrane pumps could be classified as 
passive or active [Figure-9].  
 
Fig. 9. Simple diffusion vs. active and passive transporters. Simple diffusion of drug across 
cellular membranes occur via the ‘Fick’s law’. However, transporters on cell membranes can 
both facilitate and inhibit drug transport. 
URL: http://year12biologyatsmc.wikispaces.com/Active+Transport) 
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A drug that moves across a membrane along its concentration gradient without expending 
metabolic energy is said to be transported passively. The intestinal uptake of glucose in the 
human body serves as a good example of passive transport (Awad WA, 2007; Durán JM, 
2004). Passive transport can be divided into two sub-types. The first two involves 
spontaneous movement of membrane permeable substances across the membrane utilizing 
the laws of simple diffusion. The second type of non-energy dependent transport is 
facilitated diffusion where the movement of membrane impermeable substances across the 
membrane is aided via transporters and via co-transport of other charged ions (Dobson PD, 
2008; Visentin M, 2011).  Both passive and carrier-mediated drug transport processes are 
known to coexist in tissues and regulate drug concentrations within subvascular sites 
(Sugano K, 2010; Lau YY, 2007; Varghese Gupta S, 2011). 
Conversely, active transport requires energy and may involve transporting the drug against 
their concentration gradient, involving multiple saturable carriers (Choo EF, 2000; Hinoshita E, 
2000; Conrad S, 2002; Krishnamurthy P, 2006). The primary active transporters utilize 
adenosine triphosphate (ATP) to produce energy for transport. The transport protein itself 
consists of an ATPase, which hydrolyzes ATP for the required energy. However, a secondary 
active transport mechanism also exists where the transporter protein does not have a direct 
ATP coupling and utilizes the potential gradient created when ions are transported across the 
membrane by primary active transport, but these are mostly found in bacteria or protozoans 
(Boiangiu CD, 2005; Simon J, 2008). Although, a few of these active ion-pumps have been of 
potential importance in cancer therapeutics, e.g. proton pump inhibitors (Harguindey S, 2009). 
In general, drug transporters that are of clinical significance have been divided into two main 
classes; the solute carrier family (SLC) of passive transporters and the ATP binding cassette 
(ABC) family of active transporters [Table-2 & Table-3].  
3.2.1 The ABC transporters 
The drug-efflux function of ABC transporters enables extrusion of a wide range of 
substrates from the inside to the outside of a cell membrane or organelle (Jones PM, 2009; 
Locher KP. 2009; Degorter MK, 2011). They are known to transport lipids and sterols, ions 
and small molecules, drugs and large polypeptides. P-gp (ABCB1) is ubiquitously expressed 
in a number of important organs such as liver, intestine, lymphocytes, placenta and the 
brain endothelial cells. P-gp can transport mainly cationic or electrically neutral substrates 
as well as a broad spectrum of amphiphilic substrates. The ABCC family members confer 
MDR to organic anion compounds, and MRP1 is more ubiquitous than MRP-2. 
Interestingly, their expression can either be at the apical (AP) or on the basolateral (BL) 
membranes of epithelial or endothelial barriers. The ABCG2 transporter, also known as 
BCRP (breast cancer resistance protein) are also expressed on apical surfaces and confer 
resistance to Topoisomerase inhibitors and doxorubicin [Table-2]. 
The best characterized ABC-transporter is P-glycoprotein (also known as P-gp, MDR-1 or 
ABCB1) (Brinkmann U, 2001; Fromm MF. 2003; Kroetz DL, 2003). MDR-1 displays a broad 
substrate spectrum comprising of both neutral and cationic organic compounds. Another 
ABC-transporter, recently cloned from a drug resistant breast cancer line, is BCRP (a.k.a. 
ABCG2) and substrate specificities and tissue localization of BCRP have been found to be 
similar to that of MDR-1 (Jonker JW, 2000; Krishnamurthy P, 2006). BCRP is also referred to 
as a half transporter since it has one transmembrane domain and functions as a dimer to 
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transport a variety of drugs. The immunosuppressant cyclosporine-A and verapamil, a 
calcium channel antagonist, are competitive inhibitors of MDR-1 mediated efflux (also 
referred to as MDR-modulators) and have often been used in the laboratory to determine 
MDR-1 specific drug-efflux (Eilers M, 2008; Roy U, 2009). A newly discovered group of ABC 
transporters is the MDR associated proteins (MRPs) also referred to as the ABCC family of 
transporters (Gradhand U, 2008). MRPs are found to cotransport drugs along with 
glutathione (GSH) or transport GSH-drug conjugates and glucuronide-drug conjugates. 
Amongst the nine members of the MRP transporters family, the first five (MRP-1, MRP-2, 
MRP-3, MRP-4 and MRP-5) are frequently associated with the efflux of therapeutic agents. 
MRP-1, MRP-2 and MRP-3 transport hydrophilic anionic compounds, large molecules and 
peptidomimetics; however, both MRP-4 and MRP-5 transport small polar compounds such 
as nucleosides, cyclic nucleotides and nucleoside analogs (Schuetz JD, 1999). The 
overexpression of ABC transporters had been shown to result in chemotherapeutics being 
pumped out of cells faster than they can enter, and is an well accepted mechanism leading 
to the development of multidrug resistance (MDR) in cancer cells (Gottesman MM, 2002; 
Luqmani YA. 2005; Tiwari AK, 2011). Recent studies by us, and others, have also shown that 
several anti-HIV-1 drugs, especially HIV protease inhibitors (HPIs) and nucleoside analog 
reverse transcriptase inhibitors (NRTIs) are substrates of ABC-transporters (Choo EF, 2000; 
Roy U, 2009) and their expression on both lymphocytes and BBB endothelial cells (ECs) can 
suppress drug entry into the cellular and anatomical reservoirs of HIV-1 (Eilers M, 2008; 
Tarbell JM. 2010; Shen S, 2010). The polarized expression of MRPs regulates the directional 
transport of drugs in and out of various tissue compartments. Both P-gp and MRP1 are 
predominantly expressed in the human lung; thus, these transporters may be pivotal in the 
protection against toxic compounds.  
 
Table 2. ABC family of drug transporters. The gene name and common protein names for the 
most common transporters are shown. Their tissue distribution, expression polarity (apical 
or basal) and representative drugs that are transported by each of the drug-efflux pumps, 
are shown. (Adapted from Bluth MH, 2011).URL: http://dx.doi.org/10.2147/PGPM.S18861 
3.2.2 The SLC transporters 
The solute carrier family functions by facilitative diffusion and secondary active transport 
(Shitara Y, 2002; Hagenbuch B, 2003; Niemi M, 2004; Lau YY, 2007; Visentin M, 2011). SLC 
transporters, also known as the organic anion transporter polypeptide (OATP) belong to a 
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large superfamily that comprises of approximately 300 SLC genes classified into 43 families. 
The SLC transporters transport both endogenous molecules like amino acids, sugars etc. and 
many exogenous drugs [Table-3]. They are located on the cell membrane as well as on the 
intracellular membrane of organelles. Except for SLC22A11 (OAT4) all others are expressed 
on basolateral membranes. They can transport a variety of small molecules and inhibitors of 
the SLC transporters have proved useful in the treatment of a variety of disorders, 
including depression, epilepsy and Parkinson's disease (Kuroda M, 2005; Gether U, 2006; 
Thwaites DT, 2011). Variance in the expression and function of these transporter proteins 
can significantly impact the PK profile of a number of drugs.  
Uptake transporters belong to the SLC family while efflux transporters belong to the ABC 
family. Many of these drug transporter proteins contain polymorphisms which can 
significantly alter their function. Within the last decade more information has become 
available reinforcing the fact that polymorphisms which effect expression or activity of the 
drug transporters contribute to the variability seen in the drug disposition between 
individuals. A number of studies have demonstrated the importance of P-gp for drug 
disposition in humans (Fromm MF, et al, 2003). Chemotherapeutic drugs (e.g. paclitaxel), 
uricosuric agents (e.g. probenecid), and the leukotrienes (LT) receptor antagonist (e.g. MK-
571), are known inhibitors of MRPs (Eilers M, 2008). A number of preclinical and clinical 
trials are also being carried out to discover new and more effective efflux pump inhibitors 
(EPIs). Initial studies showed that PSC 833, a P-gp specific EPI was able to increase the 
efficacy of vincristine and digoxin in rat models (Song, S. 1999). In recent years, both 
verapamil and cyclosporine-A analogs are showing significant promise as safe and effective 
EPIs (Bauer F, 2010; Kolitz JE, 2010; O'Brien MM, 2010; Patel NR, 2011).  
 
Table 3. SLC family of drug transporters. The gene name and common protein names, tissue 
distribution, polarity (apical or basal) and representative drugs transported by each, are 
shown. (Addapted from Bluth MH, 2011). 
URL: http://dx.doi.org/10.2147/PGPM.S18861 
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Even using the same medications, different patients respond in different ways. Defining the 
changes seen in drug efficacy and toxicity are of crucial significance since PK measurements 
alone cannot explain such variability (Kuehl P, 2001; Evans WE, 1999; Kroetz DL, 2003; Lai 
Y, 2011).  The intrapatient variability and large population differences suggest that genetic 
inheritance may be a critical determinant of the therapeutic responses to drugs which are 
substrates for ABC-transporters and CYP450 enzymes (Ameyaw MM, 2001; Dorne JL, 2002; 
Evans WE, 2001). Although we know many nongenetic (or epigenetic) factors influence the 
effects of medications, including age, organ function, concomitant therapy, drug interactions 
and the nature of the disease, there are now numerous examples of cases in which inter-
individual differences in drug response are attributed to sequence variants in genes 
encoding drug-metabolizing enzymes and drug transporters. Moreover, recent findings 
demonstrate that genetic differences in both drug metabolizing enzymes and drug 
transporters ultimately regulate the individualistic differences in drug PK (Evans WE, 2003; 
Staatz CE, 2010). Because most drug effects are determined by the interplay of several gene 
products that influence the PK and PD of medications, including inherited differences in 
drug targets (receptors) and drug disposition (metabolizing enzymes and transporters), the 
genetic characteristics in different patient populations, as well as within individuals, have 
become increasingly important in regulating PK. This new field of Medicine is now known 
as pharmacogenomics (PG).  
A gene is considered to be polymorphic when the frequency of a variant allele in a  
specific population is at least 1% (Sachidanandam R, 2001). More than 1.4 million single-
nucleotide polymorphisms (SNPs) were identified in the initial sequencing of the  
human genome, with over 60,000 of them in the coding region of genes 
(www.ncbi.nlm.nih.gov/SNP/GeneGt.cgi?geneID=5243). Some of these SNPs have already 
been associated with substantial changes in the metabolism or effects of medications and 
some are now being used to predict clinical response. The burgeoning field of PG uses these 
genome-wide approaches to elucidate the inherited differences between persons and their 
drug responses (Lamba JK, 2002; MacPhee IA, 2005; Tamura A, 2007a ; Song IS, 2008; Staatz 
CE, 2010a). It has been suggested that 20 to 95 % of the variability in drug disposition and 
effect can be attributed to genetics; therefore, considerable efforts to investigate the genetic 
factors influencing drug response via PG studies hold the promise of personalized medical 
care in the future. Such an approach focuses on drugs and drug combinations that are 
optimized to each individual’s unique genetic makeup (Tamura A, 2007b; Staatz CE, 2010b). 
Mutations play a clear role in the functioning of the majority of the body’s organs (lung, 
liver, brain, etc.) in which CYP and ABC transporter expression may regulate drug 
distribution and clearance. For example, mutations in the ABC transporter, cystic fibrosis 
transmembrane conductance regulator (CFTR) is responsible for the development of the 
lung disorder cystic fibrosis, while the cause of Tangier disease, a high cholesterol-related 
condition, is attributed to mutations in ABCA1 (van der Deen et al., 2005). Other studies 
provide evidence that genetic polymorphisms exert an effect on interethnic variation and 
frequency of CYP and multi-drug resistance gene (MDR1) alleles among Orientals, 
Caucasians and Africans (Iida A, 2002; Lai et al., 2011). Furthermore, interpatient variability 
in drug response and toxicity to standard doses of the most commonly prescribed 
chemotherapeutic agents is often explained, in part, by genetic polymorphisms in genes 
encoding CYP enzymes and ABC transporters. Single nucleotide polymorphisms (SNPs) 
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account for 80% of all sequence variations residing in genes and these sequence variations 
can result in a multitude of adverse drug reactions (Lee et al, 2010). We may be able to 
facilitate personalized clinical treatment of pain and opioid addiction by understanding the 
PK and PD of methadone. Methadone, a P-gp substrate primarily metabolized by CYP3A4 
and CYP2B6, has a narrow therapeutic index and large interpatient variability. Genetic 
polymorphisms in genes coding for the methadone-metabolizing enzymes and P-gp 
contribute to the interindividual variability of methadone kinetics and methadone blood 
concentrations (Li et al., 2008). Ensuing discussion illustrates the relevance of cancer 
pharmacogenomic studies in optimizing chemotherapeutic response by enhancing the 
efficacy and safety of some select chemotherapy drugs. 
4.1 Polymorphisms in the CYP-450 genes 
Polymorphisms within the CYP genes include gene deletions, missense mutations, 
deleterious mutations creating splicing defects or premature stop codon and gene 
duplications, which can result in abolished, reduced, normal or enhanced enzyme activity 
(Ball SE, 1999; Lamba JK, 2002; Daly AK. 2006; Bluth MH, 2011) [Table 4]. A number of 
studies have shown interindividual variability and tissue specificity in the expression of 
cytochrome P450 gene expression (Koch I, et al, 2002). As a result, patients can be classified 
into four phenotypes based on the level of a CYP enzyme activity: poor metabolizer 
(abolished activity), intermediate metabolizer (reduced activity), extensive metabolizer 
(normal activity), and ultrarapid metabolizer (enhanced activity). Substantial evidence 
suggests that genetic polymorphisms within the CYP genes have significant impact on drug 
disposition and/or response. The lack of functional CYP3A5 may not be readily evident, 
because many medications metabolized by CYP3A5 are also metabolized by the universally 
expressed CYP3A4. For medications that are equally metabolized by both enzymes, the net 
rate of metabolism is the sum of that due to CYP3A4 and that due to CYP3A5; the existence 
of this dual pathway partially obscures the clinical effects of genetic polymorphism of 
CYP3A5 but contributes to the large range of total CYP3A activity in humans. Notably, the 
most pharmacologically and clinically relevant CYP polymorphisms are found in CYP2D6, 
CYP2C9, and CYP2C19 genes (Ingelman-Sundburg M. 2004; Bluth MH, 2011). Of the Food 
and Drug Administration (FDA)-approved drug labels referring to human genomic 
biomarkers, 62% pertain to polymorphisms in the CYP enzymes, with CYP2D6 (35%), 
CYP2C19 (17%), and CYP2C9 (7%) being the most common [Table-2]. The genetic basis of 
CYP3A5 deficiency is predominantly a SNP in intron 3 that creates a cryptic splice site 
causing 131 nucleotides of the intronic sequence to be inserted into the RNA, introducing a 
termination codon that prematurely truncates the CYP3A5 protein. Although it is now 
possible to determine which patients express both functional enzymes (i.e., CYP3A4 and 
CYP3A5), the clinical importance of these variants for the many drugs metabolized by 
CYP3A remains unclear. Differences in the CYP450 genotypes may contribute to the inter-
ethnic variations in the disposition and response of substrate drugs (Burk O, 2002; Rettie AE, 
2005; Lim HS, 2007). However, pharmacogenetic testing for drug metabolizing enzymes is 
not yet frequently implemented in the clinic practice (Gardiner SJ, 2005). 
The most common functional polymorphisms occurring in few of the major human CYP 
genes, along with allele frequencies and functional effects, are provided in Table-4. CYP1 
genes are mainly expressed in extrahepatic tissues and have been linked to bioactivation of a 
variety of carcinogens. Multiple SNPs in CYP1 increase their functional activity by inducing 
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gene expression or protein stability and have been linked to ethnic differences in  
PK (Mcilwain CC, 2006). The CYP1A1 polymrphism, CYP1A1*2C is associated with 
increased lung cancer risk in African Americans. Their role in estrogen activation has also 
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Table 4. Most common functional polymorphisms in major human CYP genes (adapted 
from Bluth MH, 2011).  
DOI: http://dx.doi.org/10.2147/PGPM.S18861 
Since both CYP1A2 and CYP2A6 can convert nicotine to cotinine, polymorphisms in these 
enzymes are associated with nicotine addiction and tobacco-related cancers. The CYP2B6 
polymorphisms may affect the PK and therapeutic outcome of anti-HIV agents such as 
efavirenz and nevirapine. Indeed, the CYP2B6 variant, Q172H is linked to increased 
breakdown of these anti-HIV drugs in different minority population (Musana AK, 2005). 
The CYP2C9 accounts for ~20% of total hepatic CYP contents, and the CYP2C9*2 (R144C) 
and CYP2C9*3 (I359L) variants may affect PK of numerous important pharmaceutical 
agents such as warfarin, celecoxib, ibuprofen, phenytoin, etc. (Rettie AE, 2005). 
Interestingly, the CYP2C8*3 (R139K; K39R) is associated with lower activity and 
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decreased clearance of both R- and S-ibuprofen, and polymorphisms in CYP2C19 effect 
the response of several classes of drugs, including proton pump inhibitors and 
barbiturates. Although CYP2D6 is involved in the metabolism of ~25% of all drugs, SNPs 
in this gene is mostly due to changes in activity rather than induction in gene expression. 
The CYP2D6 genotypes exhibit large interethnic differences and are of significant 
importance for the dosing of many drugs, including tricyclic antidepressants, 
antiarrhythmics, neuroleptics, analgesics, antiemetics, and anticancer drugs. CYP3A4 has 
the highest abundance in the human liver (~40%) and metabolizes over 50% of all 
currently used drugs. Genetic polymorphisms in CYP3A4 appear to be more prevalent in 
Caucasians, but a direct clinical association has not been established. The clinical 
relevance of CYP3A5 polymorphisms are demonstrated by changes in PK of 
immunosuppressive drugs such as tacrolimus.   
4.2 Polymorphisms in drug-transporters 
Within the SLC superfamily, genetic variance in organic anion-transporting polypeptides 
(OATPs) have been most well characterized (Kameyama Y, 2005; Xu G, 2005; Song IS, 2008; 
Franke RM, 2009). The OATPs are expressed in many tissues like liver, gut and BBB. 
OATP1B1 is one of the major uptake transporters expressed in hepatocytes and transports 
drugs like rifampin and statins etc. This protein is encoded by SLCO1B1, several allelic 
variants of which have been characterized and resulted in decreased transporter activity. 
Another example is OATP-C, which is a liver-specific transporter involved in the 
hepatocellular uptake of a variety of clinically important drugs. A number of functionally 
relevant SNPs have been reported in OATP (Xu G, 2005). In in vitro experiments several 
variants showed reduced uptake of the OATP-C substrates estradiol, estrone sulfate and E2-
17-βG (Kameyama Y, 2005). Also, OATP-C variants were found to have reduced cell 
membrane expression compared with the wild-type transporter, especially under 
inflammatory conditions (Le Vee M, 2008). These studies have implicated SLC and OATP 
transporters in drug disposition as well as in normal physiological functions such as 
hormonal signaling.   
Polymorphisms within the ABC transporter super family have been well classified and 
SNPs within ABCB1 or MDR-1 gene (coding for P-gp) serves as an excellent example 
(Hoffmeyer S, 2000; Tanabe M, 2001; Brinkmann U, 2001; Ieiri I, 2004). P-gp genes have a 
wide range of substrates including anti cancer agents, antiarrhythmics and 
immunosuppressive drugs (Drescher S, 2002; Hulot JS, 2005; Elens L, 2007; Thervet E, 2008). 
P-gp expression is widely distributed, liver, the intestines both small and large, and the 
blood brain barrier (BBB) endothelial cells. In addition, polymophisms in both MRP 
(ABCCs) and BCRP (ABCG) are expected to affect the pharmocokintics of several drugs, 
however, a clear pattern of increase or decrease has not yet been decipherable (Tamura A, 
2006a & 2006b). Large inter-individual variability in P-gp expression, almost two to eight 
folds, has been observed in healthy volunteers, leading to significant differences in the 
bioavailability of P-gp substrate drugs within a population. Individual variations in the 
expression of ABC transporters may give rise to a change in the bioavailbility of a particular 
drug and may thus lead to a need for change in dosing. Increasing evidences demonstrate 
that both genotypic and phenotypic polymorphisms may affect membrane transporters and 
that this may well be the cause for variability of a drugs PK profile and toxicity in different 
ethnic groups [Table-5].  
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expression of ABC transporters may give rise to a change in the bioavailbility of a particular 
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inhibition by some of the efflux-pump modulators. Several genetic polymorphisms in the 
ABCC1 gene are associated with doxorubicin-induced cardiotoxicity (Wojnowski L, 2005). 
These SNPs were found to be associated with reduced intestinal expression of P-gp, along 
with increased oral bioavailability of digoxin. Several of the ABCC genes, which code for the 
MRP transporters, are known to affect both drug-efflux and apical to basal drug transport 
(Fellay J, 2002). Several ABCC1 SNPs have been associated with anthracycline-induced 
cardiotoxicity. The ABCC2 associated SNPs can alter their expression and localization 
within the cells. Also, several of them, e.g. 3563T>A (V1188E) and 4544G>A (C1515Y), have 
also been associated with anthracycline-induced cardiotoxicity. Several ABCG2 genetic 
variants, which code for the BCRP transporter, are also found to change transporter 
activities and have been associated with MDR tumors. Interestingly, unlike ABCB1 (P-gp), a 
clear clinical correlation with race has not been established with any of these other ABC-
transporters.  
Less emphasis has been placed on changes in passive diffusion due to polymorphisms  
in the SLC genes. Although numerous polymorphisms have been identified and code  
for altered protein such as SLCO1A2, SLCO1B1, CLCO1B3, etc, most of them have  
been shown to suppress facilitated diffusion of their substrates and some of these may 
also affect substrate specificities. However, due to the lack of correlative studies with 
these SNPs occurring in different OATP transporters, we know very little about their 
ultimate effects on drug disposition. Also, less is known about the role of polymorphisms 
in the phase-II enzymes, such as the UGT family members (Guillemette C. 2003; Han JY, 
2006; Lo HW, 2007). Genetic variations in UGT genes alter the function or expression of 
the protein, and potentially modify the glucuronidation capacity of the enzyme. 
Furthermore, SNPs have been identified in most of the human SULT genes (Glatt H, 2004) 
which are associated with altered enzymatic activity and have the potential to influence 
therapeutic response. Two human NAT genes, NAT1 and NAT2, carry functional 
polymorphisms that influence the enzyme activity (Hein DW. 2002; Walker K, 2009) and 
bioactivation (via O-acetylation) of aromatic and hetercyclic amine carcinogens. Patients 
who inherit defective TPMT alleles are at significantly increased risk for thiopurine-
induced toxicity (e.g. myelosuppression) (Peregud-Pogorzelski J, 2010; Ben Salem C, 
2010). Indeed, clinical diagnostic tests are now available for the detection of the SNPs in 
human TPMT gene that lead to decreased or abolished enzyme activity (Nguyen CM, 
2011). 
The above findings reiterate the fact that both genotypic and phenotypic polymorphisms 
may affect variability in drug disposition. Further studies of the polymorphisms in human 
drug-metabolizing enzymes and drug-transporters would shed more light on the subject 
of pharmacogenomics, and could be used in selecting drugs and dosages according to 
genetic and specific individual markers in order to individualize drug therapy. Just as for 
CYP450’s, the possibility of defining patient populations and even individual patients on 
the basis of drug transporter polymorphisms may improve drug safety and efficacy in the 
future. Positron emission tomography (PET) may serve as a very useful tool in 
determining the in vivo effects of transporters and their polymorphisms (Martínez-
Villaseñor D, 2006; Cantore M, 2011). Also in the future it would be valuable to establish a 
correlation between genotype and phenotype and then assess the effects of 
polymorphisms on drug transporter expression and function and in turn, effects on drug 
disposition.  
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5. Pharmacogenomics: A potent tool for maximizing chemotherapeutic response 
5.1 Genetic variations in TMPT may be used to predict toxicity to 6-Mercaptopurine 
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of 6-MP to form inactive 
metabolites. Genetic variations in the TPMT gene have profound effects on the 
bioavailability and toxicity of 6-MP. It has been demonstrated that about 1 in 300 
individuals inherit TPMT deficiency as an autosomal recessive trait. Patients who carry 
TPMT polymorphisms are at risk for severe hematologic toxicities when treated with 6-MP 
because these polymorphisms lead to a decrease in the rate of 6-MP metabolism (Evans WE, 
1991; Lennard L, 1993). Currently, TPMT testing is being used for dose optimization in 
children with ALL before 6-MP therapy is initiated. 
5.2 Genetic variations in UGT1A1: The basis of inter-patient variability with Irinotecan 
therapy 
Irinotecan (Camptosar®; Pfizer Pharmaceuticals; New York, NY, http://www.pfizer.com) 
has potent antitumor activity against a wide range of tumors, and it is one of the most 
commonly prescribed chemotherapy agents. However, dose-limiting toxicities of irinotecan 
interfere with optimal utilization of this important drug. Once consumed the drug requires 
metabolic activation by carboxylesterase to form the active metabolite 7-ethyl-10-
hydroxycamptothecin (SN-38), which in turn inhibits topoisomerase-I. SN-38 is further 
detoxified via formation of SN-38 glucuronide (SN38G) (Gupta E, 1994). Toxicity of 
irinotecan has been associated with increased levels of SN-38. Clinical pharmacogenetics of 
irinotecan is mainly focused on polymorphisms in UDP-glucuronosyltransferase 1A1 
(UGT1A1), the enzyme responsible for glucuronidation of SN-38 to the less toxic, inactive 
metabolite SN38G (Iyer L, 1998 & 1999). Variations in UGT1A1 activity most commonly 
arise from polymorphisms in the UGT1A1 promoter region that contains several repeating 
TA elements. The presence of seven TA repeats (referred to as UGT1A1*28), instead of the 
wild-type number of six, results in reduced UGT1A1 expression and activity (Beutler E, 
1998). Clinical trials are ongoing to address the impact of dose on irinotecan safety in 
patients with different UGT1A1*28 genotypes (McLeod HL, 2004). 
5.3 CYP2D6 allele activity affects clinical outcome of patients treated with tamoxifen 
One in eight women above seventy develops breast cancer each year in the United States. 
Approximately 70 percent of them have estrogen receptor–positive cancer. Many of these 
women are prescribed tamoxifen following surgical treatment. Tamoxifen is an anti–
estrogen drug that prevents relapse of cancer in 50% of patients and reduces the mortality 
rate by one–third in women with early breast cancer. However, there is a large group of 
women who do not respond to tamoxifen. CYP2D6 encodes for an enzyme involved in the 
metabolism of up to 25 percent of all drugs. The enzyme is present in different forms in 
different people and some lack it entirely. Tamoxifen is a "pro–drug," meaning that it is 
relatively inactive until the liver recruits the CYP2D6 enzyme and converts it into active 
molecules. The key role of CYP2D6 in catalyzing the conversion of tamoxifen to its 
abundant active metabolite endoxifen has been shown to directly affect the clinical outcome 
of patients treated with tamoxifen. This is because the functional alleles of CYP2D6 in some 
individuals result in abolished, decreased, normal, or ultrarapid CYP2D6 enzyme activity. 
Women with nonfunctional and reduced-function CYP2D6 alleles appear to have 
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significantly lower circulating endoxifen concentrations than those with wild-type CYP2D6. 
It has also been shown that use of CYP2D6 inhibitors such as SSRIs and SNRIs has a 
negative impact on the efficacy of tamoxifen. Together, these studies support the notion that 
low CYP2D6 activity, caused by genetic polymorphisms or drug interactions, leads to low 
levels of the active tamoxifen metabolite ( Jin Y, 2005; Lim HS, 2007; Hoskins JM, 2009). The 
effect of CYP2D6 activity on tamoxifen pharmacokinetics also translates into an effect on 
clinical outcome. Despite conflicting data in some instance, the majority of retrospective 
studies suggest that the presence of nonfunctional or reduced-function alleles of CYP2D6 is 
associated with worse outcome of patients receiving tamoxifen. A recent large retrospective 
analysis of 1325 patients with early-stage breast cancer treated with adjuvant tamoxifen 
suggests that compared with extensive metabolizer, those with decreased CYP2D6 activity 
(heterozygous extensive/intermedidate and poor metabolizers) have significantly increased 
risk of recurrence as well as worse event-free survival and disease-free survival (Schroth W, 
2009). In addition, CYP2D6 genotype has also been shown to influence the efficacy of 
tamoxifen as a chemopreventive agent, whereby tamoxifen-treated women with poor 
metabolizer phenotype was associated with a significantly higher incidence of breast cancer 
compared with controls (Higgins MJ, 2010). Findings from these studies support a role for 
the CYP2D6 genotype in the activation of tamoxifen and likelihood of therapeutic benefit 
from testing for CYP2D6 genoptype. 
6. Consequences of epigenetic factors on PG and PK 
Genetic polymorphisms exhibited by many of the Phase-I and Phase-II drug-metabolizing 
enzymes as well as both passive and active drug-transporters, can alter drug distribution, 
drug metabolism and drug-drug interactions and are of great clinical relevance. However, a 
number of other factors may also contribute to the variation in polymorphism activity, 
including; (1) environmental factors, (2) age, sex and ethnicity of the patient, (3) 
physiological status, and (4) disease state. Therefore, in addition to genetic variations, 
changes in CYP450 enzyme functions and ABC and SLC transporter activities are 
responsible for the occurrence of adverse effects or lack of therapeutic efficacy of drugs in 
many cases. 
6.1 Drug-drug interactions regulate drug disposition 
Many coadministered drugs can increase or decrease the activity of various CYP isozymes, 
by either inducing the biosynthesis of an isozyme (enzyme induction) or by directly 
inhibiting the activity of the CYP (enzyme inhibition). If one drug inhibits the CYP-mediated 
metabolism of another drug, the second drug may accumulate within the body to toxic 
levels. Hence, these drug interactions may necessitate either dosage adjustments or choosing 
drugs that do not interact with the CYP system (Anglicheau D, 2003). Such drug interactions 
are especially important to take into account when using drugs of vital importance to the 
patient. Drugs with important side-effects and drugs with small therapeutic windows may 
be subject to an altered plasma concentration due to altered drug metabolism. A classical 
example includes anti-epileptic drugs (Li XQ, 2004; Li Y, 2008). CYP450 enzyme induction 
can occur following repeated administration of antibiotics such as Rifampin (Zhang HX, 
2009). Numerous immunosuppressive drugs such as cyclosporine-A and FK-506, used in 
organ transplantation, show potent drug interactions and are important in 
pharmacogenetics (Thervet E, et al, 2008). Certain drugs can cause CYP enzyme inhibition 
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by either binding to the cytochrome component or act to competitively inhibit drug 
metabolism. The histamine (H2) receptor antagonist, Cimetidine (Tagamet) and the 
antifungal agent, Ketoconazole (Nizoral) are known to be potent inhibitors of multiple 
CYPs. Several antibiotics can cause catalytic inactivation of CYPs as well. The Macrolide 
antibiotics (e.g. erythromycin), which are themselves metabolized by CYPs are known to 
complex with the cytochrome heme-iron, producing a complex that is catalytically inactive. 
In addition, Chloramphenicols which are also substrates of CYPs have been shown to 
inactivate these enzymes by their direct inactivation. It is expected that poor metabolizers 
would have higher concentrations of a drug that is inactivated by that enzyme pathway and 
therefore require a lower dose to avoid adverse reactions, whereas ultrarapid metabolizers 
would require a higher dose to achieve therapeutically effective drug concentrations. The 
opposite pattern of reactions is expected for a drug that undergoes metabolic activation. 
Both tobacco use and drugs of abuse, as well as dietary factors can impact CYP450 enzymes 
and ABC transporters, expression and function. One of the most documented relationships 
between disease and transporter expression is the association between the overexpression of 
ABC transporters and the concomitant increased efflux of chemotherapeutic drugs such as 
vinca-alkaloids, epipodophyllotoxins, and anthracyclines.  
6.2 Social and dietary factors regulate drug disposition 
Increasing evidence supports the assertion that one mechanism behind clinically significant 
herb-drug and food-drug interactions is interference at the level of ABC transporters and CYP 
enzymes (Zhang W, 2005; Marchetti et al., 2011). Naturally occurring compounds may also 
induce or inhibit CYP activity. For instance, grapefruit, orange, and pimelo juices inhibit 
CYP3A4 and P-gp function, which impacts metabolism and increases drug bioavailability, and, 
thus, the strong possibility of overdosing. Approximately 10% of all admissions in general 
hospitals are the result of inappropriate administration of drugs or combinations of drugs that 
can cause severe to lethal drug-drug or herb-drug interactions. Grapefruit Juice, regularly used 
as a digestive and dieuretic agent, is also known to be a potent inhibitor of CYPs (Bailey DG, 
1998). The drugs most susceptible to pharmacokinetic interactions with citrus juices are those 
with a narrow therapeutic index and a reported affect by P-gp or CYP enzymes; thus, 
physicians and patients should be cognizant of these clinically significant food-drug interactions 
when prescribing or following drug treatment (Marchetti et al., 2011). The principle compounds 
in these Citrus fruits, furanocoumarins and flavonoids, cause interactions with over 50% of the 
most commonly prescribed drugs in major drug classes such as antiallergics, antibiotics, 
anxiolytics, calcium channel blockers and HIV protease inhibitors (Cuciureanu M, 2010; Kakar 
SM, 2004; Pillai et al., 2009). In contrast, although regular consumption of these citrus juices may 
decrease the therapeutically efficacious dose required, co-administration with drugs such as 
astemizole, terfenadine, or verapamil may severely increase drug plasma levels and result in 
toxicity or fatality (Bailey et al., 1998; Pillai et al., 2009).  
Several other dietary components and supplements influence drug bioavailability. For 
example, Watercress is also a known inhibitor of CYP2E1, which may result in altered drug 
metabolism for individuals on certain medications (e.g., chlorzoxazone) (van Erp NP, 2005). St. 
John's Wort (SJW), a common herbal remedy and antidepressant, can induce CYP3A4, and 
also inhibit multiple CYP enzymes such as CYP1A1, CYP1B1 and CYP2D6 (Schwarz UI, 2007; 
Lei HP, 2010; Lau WC, 2011). Clinical studies demonstrated that coadministration of SJW 
significantly reduced plasma concentrations of drugs including oral contraceptives, warfarin, 
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pharmacogenetics (Thervet E, et al, 2008). Certain drugs can cause CYP enzyme inhibition 
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by either binding to the cytochrome component or act to competitively inhibit drug 
metabolism. The histamine (H2) receptor antagonist, Cimetidine (Tagamet) and the 
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opposite pattern of reactions is expected for a drug that undergoes metabolic activation. 
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between disease and transporter expression is the association between the overexpression of 
ABC transporters and the concomitant increased efflux of chemotherapeutic drugs such as 
vinca-alkaloids, epipodophyllotoxins, and anthracyclines.  
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with a narrow therapeutic index and a reported affect by P-gp or CYP enzymes; thus, 
physicians and patients should be cognizant of these clinically significant food-drug interactions 
when prescribing or following drug treatment (Marchetti et al., 2011). The principle compounds 
in these Citrus fruits, furanocoumarins and flavonoids, cause interactions with over 50% of the 
most commonly prescribed drugs in major drug classes such as antiallergics, antibiotics, 
anxiolytics, calcium channel blockers and HIV protease inhibitors (Cuciureanu M, 2010; Kakar 
SM, 2004; Pillai et al., 2009). In contrast, although regular consumption of these citrus juices may 
decrease the therapeutically efficacious dose required, co-administration with drugs such as 
astemizole, terfenadine, or verapamil may severely increase drug plasma levels and result in 
toxicity or fatality (Bailey et al., 1998; Pillai et al., 2009).  
Several other dietary components and supplements influence drug bioavailability. For 
example, Watercress is also a known inhibitor of CYP2E1, which may result in altered drug 
metabolism for individuals on certain medications (e.g., chlorzoxazone) (van Erp NP, 2005). St. 
John's Wort (SJW), a common herbal remedy and antidepressant, can induce CYP3A4, and 
also inhibit multiple CYP enzymes such as CYP1A1, CYP1B1 and CYP2D6 (Schwarz UI, 2007; 
Lei HP, 2010; Lau WC, 2011). Clinical studies demonstrated that coadministration of SJW 
significantly reduced plasma concentrations of drugs including oral contraceptives, warfarin, 
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verapamil and fexofenadine which was associated with both failures of therapies and under 
treatment (Marchetti et al., 2011). Coadministration of SJW and the HIV protease inhibitor, 
indinavir, or the cardiac glycoside, digoxin increased intestinal P-gp expression and produced 
significantly lower plasma area under the concentration-time curves. Chronic administration 
of SJW and cyclosporine-A significantly reduced plasma levels of cyclosporine-A, and 
increased acute organ rejection in transplanted patients. Curcumin, curcuminoids and 
catechins from green tea reduce P-gp expression in vitro and reports indicate that piperine, 
ginsenosides, capsaicin, resveratrol and silymarin inhibit in vitro P-gp activity.  
Socially used factors such as tobacco and alcohol activate receptors that modulate P-gp and 
CYP expression. A genetic polymorphism in the regulatory sequences of human CYP2E1 has 
been associated with increased liver toxicity following ethanol consumption, especially in 
obese individuals (McCarver DG, 1998). Tobacco smoking also induces CYP1A2 and changes 
the bioavailability of numerous CYP1A2 substrates such as clozapine and olanzapine (Bartsch 
H, 2000). Significantly greater non-small cell lung cancer tumors were P-gp positive in smokers 
compared to non-smokers (Volm et al., 1991). Although it remains unclear if P-gp expression 
levels definitively play a defensive role towards tobacco-derived agents, there is a correlation 
between current smoking and resistance to the anthracycline drug doxorubicin. Therefore, 
significant amount of current literature verifies that drug bioavailability can be modulated by 
components in foods and herbs that regulate drug-metabolizing enzymes and drug-
transporters. Hence, dietary components and herbal supplements has important clinical 
implications, especially in those individuals containing specific augmenting or suppressing 
polymorphisms in their CYP450 enzymes and/or ABC-transporters. 
6.3 Drug disposition: Effects age, sex and ethnicity 
Aging is characterized, in part, by alterations in all stages of pharmacokinetic processes 
(absorption, distribution, metabolism, and excretion), several of which can affect the 
safety/efficacy profile of a variety of drugs (McLeod HL, 1992; Aronoff GR, 1999; Bjorkman 
S. 2006; Corsonello A, 2010). The elderly population is more sensitive to bleeding 
complications arising from warfarin administration which may be attributed to variations in 
CYP2C9 function. In addition, elderly patients are especially susceptible to adverse drug 
reactions due to comorbidity, use of multiple pharmaceutics, and age-related changes in PK 
(Burk O, 2002; Anglicheau D, 2003). Specific CYPs are inhibited by numerous drugs 
commonly prescribed to elderly patients, a fact that may help explain significant 
pharmacological interactions. For instance, the distribution of drugs acting on the CNS can 
be significantly affected by the changes of BBB permeability which occurs with aging. 
Several drugs are effluxed via the activity of cerebrovascular P-gp at the BBB; therefore, age-
related regression in P-gp function could increase drug levels in the CNS (Corsonello et al., 
2010). The CYP450-mediated hepatic drug clearance in neonates, infants and children were 
found to differ significantly from adults and was a predictor of drug response (Bjorkman S. 
2006). The hepatic clearance of drugs in older patients can be reduced more than 40%, some 
of which may be attributed to alteration in CYP enzyme activity. Although some studies 
suggest that CYP-mediated activity and enzyme affinity for their substrates are not altered 
during the aging process, clinically relevant changes in drug-metabolizing enzyme 
expression have been observed. For instance, a clear age-related decline (20%) in the 
metabolism of CYP2D6 substrates has been demonstrated (Corsonello et al. 2010; Dorne et 
al., 2002; O’Connell et al., 2006). Selective serotonin reuptake inhibitors (SSRIs) can inhibit 
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CYP2D6 activity and therefore reduce the efficiency of drugs that need to be activated by 
CYP2D6 when coadministered, such as tamoxifen and codeine. The antiplatelet drug 
clopidogrel is prescribed to prevent stroke and heart attack and it requires CYP2C19 for 
activation. Omeprazole, a drug used to treat gastroesophageal reflux disease, is both a 
substrate and an inhibitor of CYP2C19. As a result, individuals with reduced CYP2C19-
mediated activity will suffer from impaired clopidogrel bioactivation and enhanced 
accumulation of omeprazole (Furuta et al., 1998; Li et al., 2004; Roden et al., 2009).  
The predominant enzymes involved in phase I hepatic drug metabolism are CYPs, several of 
which show clear sex-related differences and impact drug clearance (Soldin OP, 2009). 
Individuals exhibit great variation in biotransformation and although most ‘sex-dependent’ 
differences are eliminated with correction for height, as well as weight, composition, and 
surface area of the body, sex-dependent differences in biotransformation of a few drugs such 
as nicotine, aspirin, heparin, flurazepam, and chlordiazepoxide have been demonstrated. For 
instance, the activity of enzymes CYP1A and CYP2E1 is higher in men, while a higher activity 
of CYP2D6 and CYP3A4 enzymes have been observed in women (O’Connell MB, 2006). A 
series of physiological changes that are known to affect drug plasma concentrations occur 
during gestation and pregnancy, one of which causes significant changes in CYP enzyme 
activity. To date, the PK data amassed pertaining to menopause-related intestinal and hepatic 
CYP3A4 activity found no significant differences in biotransformation and drug clearance in 
pre- and postmenopausal women. Sex-related and pregnancy-related changes in drug 
metabolism and elimination may guide changes in dosage regimen or therapeutic monitoring 
to reduce possible toxicity and increase drug efficacy (Soldin and Mattison, 2009).  
Race related changes in the CYP enzyme and ABC transporter activation and regulation 
may alter drug accumulation and contribute to the increasing occurrence of adverse drug 
reactions in elderly patients. Pharmacodynamic differences between races can be associated 
with changes in drug transporters, and both differences in baseline performance and 
sensitivity to treatment is attributed to drug efflux from tissues. For instance, some drugs 
may penetrate the CNS more readily with advancing age thereby increasing their 
bioavailability. The variation in frequency of SNPs for MDR1 in different racial/ethnic 
populations has been previously documented. Allelic frequency can differ among these 
groups (Kim RB, 2001; McLeod H. 2002; Hesselink DA, 2004). The incidence of C/T and 
C/C genotypes at position 3435 has been found to be much higher in African than in 
Caucasian or Asian populations (Wang D, 2005; Wang J, 2006). One crucial factor regulating 
drug levels is African Americans is P-gp function since decreases in P-gp expression has 
been linked to increased drug serum concentrations and extended drug residence time 
within the brain (Tirona RG, 2001). While only 26% of Caucasians and 34% of Japanese were 
homozygous for the C allele, 83% of Ghanaians and 61% of African Americans were 
homozygous for the C allele (Xie XG, 2001. Certain common allelic variants of CYP3A4 were 
found to be highly prevalent in different minority populations (Lamba JK, 2002a & 2002b 
Koch I, 2002). Population distribution and effects on drug metabolism of a genetic variant in 
the promoter region of CYP3A4 were also previously documented (Ball SE, 1999; Schaeffeler 
E, 2001). In fact, the functional decline in P-gp may play a role in the increased sensitivity to 
selected benzodiazepines such as flurazepam reported in patients with specific P-gp SNPs. 
Therefore, individualized prescriptions for patients should incorporate knowledge from 
basic pharmacology, race or ethnicity, clinical practice and pharmacosurveillance (Sim SC, 
2005; Corsonello et al., 2010). Therefore, age, sex and race related changes in the CYP 
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enzyme and ABC transporter activation and regulation may alter drug accumulation and 
contribute to the increasing occurrence of adverse drug reactions.  
6.4 Patient health status dictate drug disposition 
The most noteworthy condition which alter drug bioavailability in patients is chronic renal 
failure (CRF) which has been shown to significantly reduce renal clearance of drugs which are 
predominantly metabolized by the liver and intestine (Bjorkman S, 2006). Patients with CRF 
exhibit decreased volume of distribution for a variety of drugs due to reduced renal and skeletal 
muscle mass and decreased tissue binding. In both preclinical and clinical studies, drug 
transporters such as P-gp and CYPs are affected. In fact, CRF causes a 40 to 85 % 
downregulation of hepatic and intestinal CYPs with high levels of hormones, cytokines, and 
uremic toxins also reducing CYP activity. The alteration in these enzymes and proteins affects 
drug bioavailability and increases the risk for adverse drug reactions (Dreisbach and Lertora 
2008; Dreisbach 2009). In transplant patients on cyclosporine-A or tacrolimus, studies have 
shown changes in both CYP3A4 and P-glycoprotein activity in healthy controls and patients 
(Lemahieu WP, 2004).  In addition to the condition or disease alone regulating enzyme activity 
and transporter expression, consideration should be applied during treatment for patients on 
multiple medications (van der Deen M, 2005). P-gp can regulate drug uptake in the CNS and is 
expressed constitutively in endothelial cells that form the BBB. The expression, however, can be 
activated or inhibited by other compounds or modified under pathological conditions. For 
instance, antipsychotics, antiepileptics, or antidepressants that are P-gp substrates can interact at 
the P-gp level and may be responsible for some documented cases of drug resistance. An 
induction of P-gp expression decreases psychotropic drug uptake in the central nervous system, 
which ultimately reduces drug efficacy (Wikinski, 2005). While the health of a patients during 
treatment may be primarily shaped by their disease and drug disposition, social factors will also 
influence treatment outcome and should be taken into account during therapeutic decisions. 
7. Drug efflux-drug metabolism alliance 
There is considerable overlap in the substrate selectivity and tissue localization of specific 
groups of CYP450 enzymes and ABC transporters (Benet LZ, 2001 & 2004).  Common 
substrates, inhibitors and inducers for CYP3A and P-gp clearly implicate that both common 
regulatory mechanisms and cross-talk between this CYP iso-enzyme and drug-efflux pump 
can ultimately regulate drug disposition. Interestingly, in CYP3A4-transfected Caco-2 cells the 
expression of several efflux transporters, e.g. P-gp, MRP1, and MRP2 were upregulated, 
especially after stimulation of cells with either the protein kinase-A (PKA) inducer sodium 
butyrate or the protein kinase-C (PKC) inducer phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (PMA) (Cummins, CL, 2001 & 2002). In an in vivo intestinal perfusion model, these 
investigators had also shown modulation of intestinal CYP3A metabolism by P-gp (Cummins, 
CL, 2003). This has led to the hypothesis that both drug-transporter and drug-metabolizing 
enzymes act as a coordinated barrier against xenobiotic agents. Several animal studies using 
mdr1a (−/−) knockout mice have demonstrated P-gp’s importance in limiting drug absorption 
and decreasing bioavailability. Human clinical studies investigating the importance of 
intestinal CYP3A and P-gp through inhibition or induction of these proteins have provided 
further evidence of this interaction. Recent in vitro studies using CYP3A4-expressing Caco-2 
cells reveal that the role of P-gp in the intestine not only limits parent drug absorption, but also 
increases the access of drug to metabolism by CYP3A through repeated cycles of absorption 
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and efflux. These early findings suggested a biochemical link or coregulation of the drug-efflux 
and drug-metabolism functions in cells (Benet LZ, 2001; Cummins CL, 2002). A number of 
recent studies further corroborate this dynamic interplay between different ABC-transporters 
and different Cyp450 enzymes (Lam JL, 2006; Lee NH, 2010). These studies, carried out in 
cellular systems, isolated organ, whole animal and human studies, have elucidated the 
importance of these interacting processes. The importance of this phenomenon with respect to 
the intestine and the liver, characterizing inhibition and induction of apical and basolateral 
transporters and how drug metabolism can change independent of any change in the 
metabolic enzymes, has been effectively shown.  
8. Conclusions 
As alluded to in the previous section, drug-drug interactions, environmental and 
physiological factors significantly contribute to inter-individual variability in drug PK. 
However, these differences are not sufficient to explain the significant heterogeneity 
associated with patient responses to therapeutic agents and their narrow therapeutic 
indices. Continued investigation and adaptation of PG with respect to understanding PK 
should provide improved benefit to therapeutic efficacy versus side-effect profiles of many 
drugs currently available. Studies are being translated to clinical practice via molecular 
diagnostics (genotyping) and identifying relevant inherited variations that may better 
predict patient response to chemotherapy. Among these, nucleotide repeats, insertions, 
deletions, and SNPs, which can alter the amino acid sequence of the encoded proteins, RNA 
splicing and gene transcription particularly in drug-metabolizing enzymes and drug 
transporters have been actively explored with regard to functional changes in phenotype 
(altered expression levels and/or activity of the encoded proteins) and their contribution to 
variable drug response. Recent studies also indicate that information on combination of 
polymorphisms that are inherited together (haplotype analysis) can often result in better 
correlation with phenotypes than with individual polymorphisms. The potential is 
enormous for PG to yield a powerful set of molecular diagnostic methods that will become 
routine tools with which clinicians will select medications and drug doses for individual 
patients. Gene-expression profiling and proteomic studies are evolving strategies for 
identifying genes that may influence drug response. Thus, patient oriented PG will provide 
a very unique approach towards increasing the therapeutic efficacies of numerous anti-
cancer, anti-viral as well as anti-diabetic drugs. Furthermore, an effective re-evaluation of 
new drug design toward the generation of specific therapies focused on drugs that are not 
critically affected by the Cyp450 enzymes and the drug-transporter biology may eventually 
lead to personalized and individualized medicine. However, there are a number of issues 
which must be considered before developing strategies that target these inherited 
determinants of drug effects. One formidable challenge would be the fact that these 
inherited components are often polygenic and a complex interplay between genetic and 
epigenetic factors may ultimately dictate drug disposition. Therefore, the limitations of the 
current PG approaches will be the lack of complete knowledge and understanding of the 
complex mechanisms of drug distribution and drug-drug interactions. Another very 
important hurdle in correctly delineating the pharmacogenetic traits that regulate 
individualistic differences is the need for well characterized in vivo models. Studies in 
transgenic and knockout animals are proving highly efficacious in this respect, but only 
accounts for monogenic traits. Patient populations, with race, gender and ethnicity 
specified, who have been uniformly treated and systematically evaluated for drug action 
and toxicities, will be highly instrumental in making it possible to quantify the role of 
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predict patient response to chemotherapy. Among these, nucleotide repeats, insertions, 
deletions, and SNPs, which can alter the amino acid sequence of the encoded proteins, RNA 
splicing and gene transcription particularly in drug-metabolizing enzymes and drug 
transporters have been actively explored with regard to functional changes in phenotype 
(altered expression levels and/or activity of the encoded proteins) and their contribution to 
variable drug response. Recent studies also indicate that information on combination of 
polymorphisms that are inherited together (haplotype analysis) can often result in better 
correlation with phenotypes than with individual polymorphisms. The potential is 
enormous for PG to yield a powerful set of molecular diagnostic methods that will become 
routine tools with which clinicians will select medications and drug doses for individual 
patients. Gene-expression profiling and proteomic studies are evolving strategies for 
identifying genes that may influence drug response. Thus, patient oriented PG will provide 
a very unique approach towards increasing the therapeutic efficacies of numerous anti-
cancer, anti-viral as well as anti-diabetic drugs. Furthermore, an effective re-evaluation of 
new drug design toward the generation of specific therapies focused on drugs that are not 
critically affected by the Cyp450 enzymes and the drug-transporter biology may eventually 
lead to personalized and individualized medicine. However, there are a number of issues 
which must be considered before developing strategies that target these inherited 
determinants of drug effects. One formidable challenge would be the fact that these 
inherited components are often polygenic and a complex interplay between genetic and 
epigenetic factors may ultimately dictate drug disposition. Therefore, the limitations of the 
current PG approaches will be the lack of complete knowledge and understanding of the 
complex mechanisms of drug distribution and drug-drug interactions. Another very 
important hurdle in correctly delineating the pharmacogenetic traits that regulate 
individualistic differences is the need for well characterized in vivo models. Studies in 
transgenic and knockout animals are proving highly efficacious in this respect, but only 
accounts for monogenic traits. Patient populations, with race, gender and ethnicity 
specified, who have been uniformly treated and systematically evaluated for drug action 
and toxicities, will be highly instrumental in making it possible to quantify the role of 
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different CYP450 enzymes and ABC-transporters, objectively. The marked population 
heterogeneity has deterred a clear understanding of the effects of specific genotypes and 
their importance in determining efficacy. The effects of a medication for one population or 
disease may not as effective for another population; therefore, PG relations must be 
validated for each therapeutic indication and in different racial and ethnic groups, which 
will indeed be a daunting task. However, since genotyping methods are improving rapidly, 
it will be possible to test for thousands of polymorphisms which determine patient 
responses. In a clinical setting, it should be easy to collect patient samples and carry out a 
panel of genotypes and test for those which are important determinants of drug disposition. 
With the advent of new computer programming and new softwares to delineate pathways 
and interactions, it will be possible to simplify the complexities of the alliances between 
drug metabolizers and drug transporters. We believe that in the near future, genotyping 
results will be of great clinical value only if they are interpreted according to the patient’s 
diagnosis. An effective and safe treatment option can then be recommended by the 
physician. 
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Genetic variation is an important source of pharmacokinetic variability and leads to 
modification of drug response. It is one of the several factors contributing to variability in 
drug disposition. Any alteration in drug disposition, influences circulating drug 
concentrations, as well as the concentrations at the sites of action. Drug disposition is mainly 
affected by drug metabolizing enzymes, drug transport proteins, plasma protein binding 
and transcription factors. The knowledge about the factors influencing drug disposition is 
useful in predicting potential drug interactions and pharmacokinetic variations. Among the 
above factors the most important mechanism by which genetic variation modifies drug 
response is by altering drug metabolizing enzymes that in turn alter drug metabolism. 
These enzymes are proteins that catalyse the chemical alteration of drugs and other 
molecules inside  the body. Metabolism converts most of the drug to inactive product but 
few others to more toxic product. The main organ for drug metabolism is liver; kidney, GI 
mucosa and lungs play smaller role. The drug metabolizing enzymes can either be 
functionalizing (oxidation, reduction, and hydrolysis) or conjugating (glutathione, 
glucuronide). Genetic variation in drug metabolizing enzymes can either increase or 
decrease drug metabolism. For example some individuals have genetically determined 
insufficiency to metabolise succinylcholine, a short-acting neuromuscular-blocking drug, 
widely used as muscle relaxant and in anaesthesia. It is normally rapidly hydrolysed by 
plasma cholinesterase. If succinylcholine is administered to such individual, he/she fails to 
inactivate succinylcholine rapidly and experiences prolonged neuromuscular block. This is 
because a recessive gene gives rise to an abnormal type of plasma cholinesterase and this 
abnormal enzyme has a modified pattern of substrate and inhibitor specificity. 
Plasma binding proteins often bind a large fraction of a drug in circulation Binding varies 
from drug to drug. Sometimes drug bind more than 99%. Albumin is main plasma protein 
to which drug bind and mostly acidic drug bind with plasma albumin. Other drug binding 
plasma proteins are globulin, alpha acid glycoprotein etc. Protein binding affects 
pharmacology of drug. It alters unbound drug concentration in circulation and only 
unbound (free) drug can enter tissues. So any genetic variation in plasma protein brings 
about variation in drug response. Similarly, transcription factors are proteins that regulate 
gene expression. When bound to exogenous chemicals, certain transcription factors induce 
the expression of drug metabolizing enzymes and modify drug response. Some genetically 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
100 
Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of 
cytochrome P450 3A and P-glycoprotein: implications for drug delivery and 
activity in cancer chemotherapy. Mol Carcinog. 1995;13:129–134. 
Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism 
in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. 
J Toxicol Environ Health B Crit Rev. 2009;12(5-6):440-72. Review. 
Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 
3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15 (10): 693-704 
Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in 
Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet 
Genomics. 2006;16:191-198. 
Watanabe, T.; Maeda, K.; Kondo, T.; Nakayama, H.; Horita, S.; Kusuhara, H.; Sugiyama, Y. 
Prediction of the hepatic and renal clearance of transporter substrates in rats using 
in vitro uptake experiments Drug Metab. Dispos. 2009, 37, 1471– 1479  
Wee B, Charles N, Holland EC. Animal models to study cancer-initiating cells from 
glioblastoma. Front Biosci. 2011 Jun 1;17:2243-58. Review.  
Wikinski, S. Pharmacokinetic mechanisms underlying resistance in psychopharmacological 
treatment. The role of P-glycoprotein. Vertex. 2005. 16, 64, pp. 438 – 441.  
Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol 
Exp (Wars). 2011;71(1):113-28. Review. 
Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance 
protein genetic polymorphisms are associated with doxorubicin-induced 
cardiotoxicity. Circulation. 2005;112:3754–3762. 
Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. Suspensions 
for intravenous (IV) injection: a review of development, preclinical and clinical aspects. 
Adv Drug Deliv Rev. 2008 May 22;60(8):939-54.Epub 2008 Feb 7. Review.  
Xiangdong L, Yuanwu L, Hua Z, Liming R, Qiuyan L, Ning L. Animal models for the 
atherosclerosis research: a review. Protein Cell. 2011 Mar;2(3):189-201. Epub 2011 
Apr 6. Review.  
Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition 
and response. Annu Rev Pharmacol Toxicol.2001;41:815–850. 
Xu G, Bhatnagar V, Wen G, et al. Analyses of coding region polymorphisms in apical and 
basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, 
OAT3, OAT4, URAT (RST)]. Kidney Int. 2005;68:1491–1499. 
Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-
methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine 
intolerance. Ann Intern Med 1997;126:608-14. 
Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, 
Tarin C, Mas S, Ortiz A, Egido J. Animal models of cardiovascular diseases. J 
Biomed Biotechnol. 2011;2011:497841. Epub 2011 Feb 16. Review.  
Zhang HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting 
effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: 
unmasking the differential effects of enzyme induction and transporter inhibition 
for a drug and its primary metabolite Clin. Pharmacol. Ther. 2009, 85, 78– 85. 
Zhang W, Han Y, Lim SL, & Lim LY. Dietary regulation of P-gp function and expression. 
Expert Opinion in Drug Metabolism and Toxicology.2009. 5, 7, pp. 789 – 801. 
5 
Genetic Variation in Drug Disposition 
Balmukunda Regmi and Laxman Bharati 




Genetic variation is an important source of pharmacokinetic variability and leads to 
modification of drug response. It is one of the several factors contributing to variability in 
drug disposition. Any alteration in drug disposition, influences circulating drug 
concentrations, as well as the concentrations at the sites of action. Drug disposition is mainly 
affected by drug metabolizing enzymes, drug transport proteins, plasma protein binding 
and transcription factors. The knowledge about the factors influencing drug disposition is 
useful in predicting potential drug interactions and pharmacokinetic variations. Among the 
above factors the most important mechanism by which genetic variation modifies drug 
response is by altering drug metabolizing enzymes that in turn alter drug metabolism. 
These enzymes are proteins that catalyse the chemical alteration of drugs and other 
molecules inside  the body. Metabolism converts most of the drug to inactive product but 
few others to more toxic product. The main organ for drug metabolism is liver; kidney, GI 
mucosa and lungs play smaller role. The drug metabolizing enzymes can either be 
functionalizing (oxidation, reduction, and hydrolysis) or conjugating (glutathione, 
glucuronide). Genetic variation in drug metabolizing enzymes can either increase or 
decrease drug metabolism. For example some individuals have genetically determined 
insufficiency to metabolise succinylcholine, a short-acting neuromuscular-blocking drug, 
widely used as muscle relaxant and in anaesthesia. It is normally rapidly hydrolysed by 
plasma cholinesterase. If succinylcholine is administered to such individual, he/she fails to 
inactivate succinylcholine rapidly and experiences prolonged neuromuscular block. This is 
because a recessive gene gives rise to an abnormal type of plasma cholinesterase and this 
abnormal enzyme has a modified pattern of substrate and inhibitor specificity. 
Plasma binding proteins often bind a large fraction of a drug in circulation Binding varies 
from drug to drug. Sometimes drug bind more than 99%. Albumin is main plasma protein 
to which drug bind and mostly acidic drug bind with plasma albumin. Other drug binding 
plasma proteins are globulin, alpha acid glycoprotein etc. Protein binding affects 
pharmacology of drug. It alters unbound drug concentration in circulation and only 
unbound (free) drug can enter tissues. So any genetic variation in plasma protein brings 
about variation in drug response. Similarly, transcription factors are proteins that regulate 
gene expression. When bound to exogenous chemicals, certain transcription factors induce 
the expression of drug metabolizing enzymes and modify drug response. Some genetically 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
102 
determined drug response based on factor other than pharmacokinetic variation. Consider 
an example of the individuals having red blood cells deficient in an enzyme called glucose-
6- phosphate dehydrogenase. Deficiency of this enzyme increases the risk of hemolysis, if 
certain drugs such as aspirin and sulfonamides are administered.  
Differences in metabolism, transportation, plasma protein binding of drugs are significant 
factors affecting drug disposition and results modification of drug action. This chapter 
summarizes the reviews of the findings on genetic variation related with drug disposition. 
Genetic variation is an important source of pharmacokinetic as well as pharmacodynamic  
variability and leads to modification of drug response. It is one of several factors 
contributing to variability in drug disposition. The branch of science that deals with 
individual variation in drug response is termed pharmacogenetics. It deals with the genetic 
basis of variability of drug response in an individual and is a useful parameter for 
individualization of drug therapy. It is a rapidly emerging branch in which thousands of 
studies are carried out annually. Besides, it has important role in clinical practice and on 
drug development. 
Recently, pharmacogenetic deals with   the study of drug response in unrelated individuals. 
The difference in drug response is due to the variation of genotype, that encodes for drug-
metabolizing enzymes, receptors for the drug, drug transport proteins, transcription factors 
and various ion channels. A change in genotype or a mutation in gene sequence may 
increase  quantity  and/ or activity of a protein or an essential enzyme. In some cases, such a 
change results in an exaggerated or reduced therapeutic response to a drug. In general, 
variation in genotype account for15%–30% of inter-individual differences in drug 
metabolism and response, but for some drugs, genetic factors are of most common and 
account for up to 95% of inter-individual variability in drug disposition and effects. 
The important drugs under different therapeutic categories are shown in Table 1. 
The knowledge about the factor influencing drug disposition is useful in predicting 
potential drug interaction and pharmacokinetic variation.  
The genetic mechanisms for variation of drug response are variation in gene sequence. It 
includes changes in the primary nucleotide sequence of coding, regulatory, and splice 
regions of a gene. Less common forms are variability in the structure and function of the 
genome. Among these are sequence variation in microRNA (miRNA) binding sites, which 
affects the ability of miRNA to regulate translation; pharmacoepigenetics, which examines 
heritable chromatin modifications; and copy number variation.   
2. Pharmacokinetic variability 
The effectiveness of the medication is determined by how much of the drug is present at its 
site of action and how long sufficient concentrations of the drug remain at the site. 
Pharmacokinetics is the quantitative study of the time course of drug concentration in the 
body. It is the term used to describe the disposition of a drug throughout the body – that is, 
the drug’s absorption, distribution, metabolism, and excretion (ADME).  Pharmacokinetic 
variability is the variation in drug movement throughout the body. Drugs produce an effect  
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Table 1. Common drug substrates of CYP2D6, CYP2C9, and CYP2C19 according to 
therapeutic Categories  
only if they can reach its physiological target(s) in sufficient concentration. These processes 
determine the fate of a drug in the body. A combination of metabolism and excretion 
constitutes drug elimination. Following factors are the sources of individual variation in 
drug disposition. 
1. Drug-metabolizing enzymes, 
2. Drug transport proteins,  
3. Receptors for the drug, 
4. Various ion channels 
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drug disposition. 
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2.1 Drug-metabolizing enzymes 
Metabolism is biochemical reaction that takes place inside body. Almost all tissues are 
capable to metabolize drugs but the liver is the major site of metabolism. Besides liver, GI 
tract, kidney and lungs also metabolize certain fraction of drug. The main objective of 
metabolism is to convert lipophilic to hydrophilic so that drug is easily excreted from the 
body. In general, metabolites lack pharmacological activity and are more water soluble than 
the parent substance. But in few conditions, active metabolites are formed from inactive 
parent drugs; such parent drugs are termed as prodrug. The chemical reactions that involve 
in drug metabolism are categories into two types – Phase 1 reactions and – Phase 2 or 
conjugation reactions. 
Phase 1 reactions occur in the cytosol, mitochondria, microsomes of cells of the liver and 
other organs. It includes oxidation, reduction, hydrolysis, cyclization and decyclization 
reactions. Much phase I drug metabolism is performed by polymorphic enzymes, 
particularly various forms of cytochrome P450 (CYP). The influence of genetic 
polymorphisms of drugs metabolized by CYP2C9, CYP2C19, and CYP2D6 indicates 
polymorphisms and affects the metabolism of 20%–30% drugs.   
In Phase 2 reaction drugs or metabolites combine with other substances and results in 
increased water solubility of the substance, which decreases the amount that is reabsorbed 
through renal tubules and thereby increases the fraction that is excreted in the urine. It is 
also known as conjugation. The most common conjugation reaction is glucuronide, glycine, 
glutathione, glutamate and sulfate conjugation. 
The cytochrome P450s are a multigene family of enzymes found predominantly in the liver, 
that are responsible for metabolism. Genetically determined variability in the level of 
expression or function of these enzymes has a profound effect on drug efficacy. Genetic 
polymorphisms for many drug-metabolizing enzymes and drug targets have been 
identified. Polymorphisms refer to sequence variations with an allele frequency of greater 
than or equal to 1%. Polymorphism in any one of many genes—including those encoding 
drug receptors, drug transporter are important determinants of clinical response. 
Polymorphisms have now been identified in more than 20 human drug metabolizing 
enzymes. Important examples are polymorphisms in the cytochrome P450 enzymes and in 
thiopurine methyltransferase. Polymorphism not only affects drug disposition but can also 
be important in the conversion of prodrugs into their active form. For example, codeine is 
metabolized into the analgesic morphine by CYP2D6, and the desired analgesic effect is not 
achieved in CYP2D6 poor metabolizers.  
Cytochrome P450 system refers to a family of enzymes (usually hepatic) which are located 
on the endoplasmic reticulum, which performs oxidative metabolism of broad array of 
substances. Cytochrome P450 comprises the most important group of phase I enzymes. The 
most important CYP 450 enzymes are: 
CYP3A4 (50% of P450 metabolism) followed by 
CYP2D6 (20%),  
CYP2C9 and CYP2C19 (together 15%) 
Others: CYP2E1, CYP2A6, and CYP1A2. 
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2.1.1 Some common drug metabolizing enzymes and genetic polymorphisms 
CYP2D6— The notable substrates for this enzyme include the tricyclic antidepressants 
amitriptyline, clomipramine, desipramine, amphetamines, ß-blockers, imipramine, and 
nortriptyline. Metabolism of these drugs is influenced by the polymorphism in gene that 
code CYP2D6. Polymorphism in gene that code CYP2D6 may either  reduce the rate of the 
metabolism and increased plasma concentrations of above mentioned drugs when given in 
recommended doses, or it may enhance the rate of metabolism and results  into therapeutic 
failure because the drug concentrations at normal doses are far too low.  
CYP 3A4- The notable substrates for this enzyme include alprazolam, triazolam, 
carbamazepine, methadone, pimozide, quetiapine, risperidone, zolpidem. 
 
Daly AK. Pharmacogenetics and human genetic polymorphisms (2010). Biochem. J. 429: 435–449 
Table 2. CYP genes and polymorphic drug metabolism 
CYP2C9— The notable substrates for this enzyme include warfarin. tolbutamide, glipizide, 
and phenytoin. 
The CYP genes (See Table 2) have well characterized roles in pharmacogenetic studies on 
drug metabolism. Other CYP genes also contribute to drug and xenobiotic metabolism or 
have physiological roles, but pharmacogenetic data is more limited.  
2.2 Drug transport protein  
In addition to metabolizing enzymes, drug transport proteins also contribute to alteration in 
drug disposition. Many drugs are transferred by active transporter systems, membrane 
proteins that maintain both inward and outward transport of drugs and their metabolites in 
cells. Variation in a drug transporter producing a clinical impact is less common than is 
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observed for other pharmacokinetic mechanisms. However, there are examples of variation 
in drug transport that can be attributed to adverse drug effects. One such example is 
the SLCO1B1 gene that encodes a polypeptide, OATP1B1, which mediates hepatic uptake of 
anionic drugs, including most HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) 
inhibitors (statins). Although statins are the safest drugs, they sometimes develop myopathy 
in relatively small percentage of treated individuals. Variability in drug transporters also 
contributes to resistance to a variety of medicines, most commonly observed in the 
treatment of a variety of cancers. 
Transport proteins are embedded in a the cell membrane and responsible for transport of 
endogenous compounds or drugs into the cell or outside of the cell i.e. across the biological 
membranes. They are classified into either efflux or uptake proteins, depending on the 
direction of transport. The extent of expression of genes coding for transport proteins can 
have a profound effect on the bioavailability and pharmacokinetics of various drugs. 
Additionally, genetic variation such as single-nucleotide polymorphisms (SNPs) of the 
transport proteins can cause differences in the uptake or efflux of drugs. Genetic variants of 
transport proteins can cause or contribute to a number of diseases, such as anemia.  
There are two superfamilies of transport proteins that have important effects on the 
absorption, distribution, and excretion of drugs. These are the ATP-binding cassette (ABC) 
and the solute-carrier (SLC) superfamilies. 
ATP-binding cassette (ABC) transporters are present in cellular and intracellular membranes 
and can be responsible for either importing (influx) or removing (efflux) of substances from 
cells and tissues. They often transport substances against a concentration gradient by using 
the hydrolysis of ATP to drive the transport. 
2.2.1 ABC transporters 
There are at least 49 ABC transporter genes. These genes  are particularly important for drug 
transport. Genetic polymorphisms affecting ABC transporter genes expression or changing 
their affinity for substrates and alter the absorption and elimination of drugs. It also alters 
drug concentrations at the site of action despite similar blood concentrate. The majority of 
ABC transporters move compounds from the cytoplasm to the outside of a cell, although 
some of them move compounds into an intercellular compartment such as the endoplasmic 
reticulum, mitochondria, or peroxisome. ATP-binding transporters are responsible for the 
efflux of drugs and substrates, including bilirubin, several anticancer drugs, cardiac 
glycosides, immunosuppressive agents and glucocorticoids. 
2.2.2 Solute Carrier Proteins 
Solute carrier proteins (SLCs) are important in the transport of ions and organic substances 
across biological membranes in the maintenance of homeostasis. Members of the SLC 
superfamily consist of membrane channels, facilitative transporters, and secondary active 
transporters. Examples of some of the endogenous solutes that are transported include 
steroid hormones, thyroid hormones, and prostaglandins. Additionally, SLCs are important 
in the transport of a large number of drugs. In all, more than 40 families of transporters 
make up the SLC superfamily. Genetic variants of solute carrier proteins, such as SLC6A3 
gene encodes for the dopamine transporter DAT1, the SLC6A4 gene codes for the serotonin 
transporter (SERT) that has been associated with variation in drug response. 
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2.3 Receptors for the drug 
Receptors are the macromolecules that are located in cell membrane or inside cell  or in 
organism to which drugs bind to initiate the series of biochemical reaction that leads to 
biological response. Most receptors are regulatory proteins (hormones, neurotransmitter), 
enzymes (dihydrofolate reductase), transport proteins (Na+/K+ ATPase) and structural 
proteins (tubulin). Sequential variations in the receptor protein can affect target molecules or 
the structural integrity of the receptor and change ligand binding. 
Genetic variation not only varies towards drug response by altering metabolism but also 
have important role in drug receptors. A growing number of drug targets (e.g., receptors) 
are known to exhibit genetic polymorphisms and alter drug response in humans. Many 
researches have been conducted to show polymorphisms in the gene encoding 
receptor/effectors contribute variation in drug response e.g. β2-adrenergic receptor, is 
encoded by the gene ADRB2. This receptor interacts with endogenous catecholamines and 
various medications altering the effects of medications. Polymorphisms in the gene 
encoding this receptor have been associated with altered expression, down-regulation, and 
altered cell signaling and finally on clinical responses to endogenous and exogenous 
agonists. 
2.4 Various ion channels 
Ion channels are multimeric protein complexes and exert functionally overlapping control 
over excitability and signaling in both the plasma membrane and intracellular organelles. 
These channels control the electrical activity of muscles and nerves. There are various genes 
encoding the ion channels that have been identified.  
Ion channel genes constitute about 1.2% of known protein coding genes. Mutations of these 
genes alter the functioning of ion channel resulting into a diverse array of clinical disorders 
in the body, especially in brain, nerve, muscle and heart. Predisposition of some common 
disorders like migraine and epilepsy might be mediated by genetic variation in ion-channel 
genes. Genetic variation in cellular ion transporter can also have a role in the alteration of 
drug response. 
The most important ionic pores for generation and control of the action potential  are 
voltage-dependent sodium and potassium channels. Specific genes coding for these 
channels are expressed in the central nervous system. So, it could be expected that a 
mutation in these genes may be at the origin of unbalance between excitation and inhibition 
and thus could cause epilepsy. Three types of epilepsies have been linked to mutations in 
human genes encoding subunits of:  
 The neuronal nicotinic acetyl choline receptor (nAChR) (α4, CHRNA4, and β2, 
CHRNB2, subunits),  
 The voltage-gated potassium (KCNQ2, KCNQ3) channels and  
 The voltage-gated sodium (SCN1A, SCN1B) channels.  
Mutations in CHRNA4 and CHRNB2 are associated with some cases of familial epilepsies 
classified as autosomal dominant nocturnal frontal lobe epilepsies with an important intra 
and interfamilial clinical heterogeneity. Mutations in voltage-gated potassium channels 
KCNQ2 and KCNQ3 have been identified in benign familial neonatal convulsions.  
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The sodium channel is composed of four homologous domains that contain well-characterized 
voltage-sensing and pore regions. The four domains form a sodium-permeable pore within the 
membrane that is remarkably selective for the individual ion that it conducts. Each domain 
comprises six membrane-spanning segments, each of which has an α-helical structure. And 
each sodium channel α subunit associates with one or more different β subunits. This 
association of α and β auxiliary subunits has an important influence on the voltage 
dependence, kinetics and cell-surface expression of most voltage-gated ion channels. Most 
neurological channelopathies associated with dysfunction of voltage-gated ion channels are 
caused by mutations in the gene encoding the pore-forming subunit. 
Myotonia is a clinical disorder in which patients experience muscle stiffness because of a 
failure of normal electrical inactivation of activated muscle. Myotonia can result from 
mutations in either the CLCN1 gene, that encodes the muscle voltage-gated chloride 
channel, or SCN4A encoding the voltage-gated sodium channel.  
3. Pharmacogenetics and adverse drug reactions 
Drug is any substance or product that is used or intended to be used to modify or explore 
the physiological system or pathological state for the benefit of the recipients. Interacting 
with receptors drugs not only produce desire effect but also produce undesired effect. Most 
undesirable effect associated with drugs is overdose/ poisoning, development of resistance, 
and adverse drug reaction (ADR). Amongst these effects ADR are important and leads to 
morbidity and mortality. Fortunately, when drugs are used properly, many ADR can be 
avoided or at least kept to a minimum. According to WHO 'ADR is any noxious, 
unintended and undesirable effect that occur at doses normally used in men for 
prophylaxis, diagnosis or therapy of the disease or modification of physiological function'. 
Adverse effect to drug may develop promptly or only after prolonged medication or even 
after stoppage of medications. Type B ADRs, which are not directly predictable from drug 
pharmacology and are unrelated to pharmacological actions of the drugs and often caused 
by immunological and pharmacogenetic mechanism, these effects are rare, but they are 
potentially very serious consequences for the patient. Type A (Predictable), can be 
predictable from drug pharmacology and is dose dependent. It is common and found to 
occur in 80%. It includes side effects, toxic effect, withdrawal symptoms.  
Polymorphisms in the genes that code for drug-metabolizing enzymes, drug transporters, drug 
receptors, and ion channels can alter drugs pharmacokinetics as well as pharmacodynamics. 
Polymorphism results in  individual’s risk of having adverse drug reactions 
Some pharmacogenetically determined adverse drug reactions include prolonged muscle 
relaxation after succinylcholine injection due to inherited deficiency of a plasma 
cholinesterase, resulting alteration of metabolism. Haemolysis is caused by antimalarials 
and sulfonamides due to glucose-6-phosphate dehydrogenase deficiency. 
It was found that the genetic polymorphism of the drug-metabolising enzyme CYP2D6 due 
to the antiarrhythmic drug, sparteine, is responsible for adverse drug reactions such as 
nausea, diplopia, and blurred vision. Similarly, orthostatic hypotension after the 
antihypertensive agent debrisoquine is also due to genetic polymorphism. It was found that 
ticlopidine induced hepatotoxicity. The incidence of hepatotoxicity is more common among 
Japanese patients than Europeans because hepatotoxicity is associated with HLA (human 
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leucocyte antigen) genes. HLA gene is predominantly presented in Japanese. 
Carbamazepine, a widely used anticonvulsant, can cause hypersensitivity  reactions but 
rarely  showed Stevens–Johnson syndrome. Various study showed that Taiwanese have 
high incidence of CBZ-induced Stevens–Johnson syndrome because they have very strong 
association between the HLA gene and CBZ-induced SJS. 
4. Clinical applications 
The importance of genetic variation has been best illustrated by the approval of BiDil, a 
cardiovascular combination product of isosorbide dinitrate and hydralazine, by FDA for the 
Afro-American population in 2005. Similar race- or gene-specific drugs are likely to be 
marketed in near future as a response to need for safer and more effective drugs. 
4.1 Cancer treatment 
Genetic variation at CYP2D6 has important therapeutic implications in cancer treatment. 
Tamoxifen are used to treat breast cancer. It is a pro-drug, requiring metabolic activation to 
active metabolites endoxifen and 4-hydroxytamoxifen. These reactions are catalyzed by 
CYP2D6. Variation in gene coding CYP2D6 enzyme activity has been shown to affect 
tamoxifen treatment outcomes. Besides, CYP2D6  polymorphism can also affect the efficacy 
of antiemetic drugs, which are often used for nausea and vomiting induced by cancer 
chemotherapy. Serotonin type receptor antagonist ondansetron, is metabolized by enzyme 
CYP2D6. CYP2D6-related rapid metabolism decrease therapeutic effect (severe emesis) and 
dose adjustment is necessary.  
4.2 Oral anticoagulation therapy 
Warfarin, as the most commonly used anticoagulation therapy, is indicated for the 
prophylaxis and/or treatment of thromboembolism. It is also indicated for treatment and 
prophylaxis of deep vein thrombosis, acute myocardial infarction, and stroke. Warfarine act 
as vitamin K antagonists by inhibiting the liver microsomal enzyme, vitamin K epoxide 
reductase, which is essential in the vitamin K cycle and formation of clotting factors. 
Warfarin is administered as a racemic mixture of R- and S-enantiomers, the latter of which is 
predominantly responsible for the anticoagulant effect and metabolized by CYP2C9. Similar 
doses of warfarin given to different individuals can result in varied drug responses. Patients 
with a two genetic variants have a significantly increased occurrence of a serious or life-
threatening bleeding incident. This is due genetic polymorphism of drug metabolizing 
enzyme CYP2C9. 
4.3 Proton Pump Inhibitor (PPI) therapy 
PPIs, such as omeprazole, lanzoprazole, are widely used for the treatment of acid-related 
diseases, including gastroesophageal reflux disease and peptic ulcer, as well as for the 
eradication of Helicobacter pylori in combination with antibiotics. PPIs are mainly 
metabolized by CYP2C19 in the liver, and the clinical outcome of drug therapy depends on 
genetic variation at the encoding gene CYP2C19. Ultra-rapid CYP2C19-related metabolism 
is an important factor contributing to therapeutic failures in drug treatment with PPIs, 
especially in European populations. 
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leucocyte antigen) genes. HLA gene is predominantly presented in Japanese. 
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4.4 Psychiatric drug therapy 
Genetic variation is an important factor for the variation in psychiatric drug response. The 
meta-analysis conducted by Kirchheiner et al. showed that of 36 commonly used 
antidepressants, for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and 
that in 14 drugs such genetic variation would require at least doubling of the dose in 
extensive metabolizers in comparison to poor metabolizers. They also showed that out of 38 
antipsychotics, CYP2D6 and CYP2C19 genotype was of relevant in 13 drugs. Amitriptyline  
has  relatively narrow therapeutic range  and high toxicity at increased concentrations, 
leading to severe adverse effects. The main CYPs involved in amitriptyline metabolism are 
CYP2C19. Genetic variation of these enzymes has been shown to correlate with the serum 
concentrations of amitriptyline, as well as with the occurrence of side-effects related to 
amitriptyline therapy. 
5. References 
Classsen T et al. Exome Sequencing of Ion Channel Genes Reveals Complex Profiles 
Confounding Personal Risk Assessment in Epilepsy (2011). Cell 145: 1036–1048, 
Daly AK.  Pharmacogenetics and human genetic polymorphisms (2010). Biochem. J. 429: 
435–449 
Evans WE and McLeod HL. Pharmacogenomics — Drug Disposition,Drug Targets, and Side 
Effects (2003) N Engl J Med 348: 553-549. 
Kirchheiner J et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution 
of allelic variations to the phenotype of drug response (2004). Mol Psychiatry.  9 
(5):442-73. 
Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP 
transporters. Naunyn Schmiedebergs Arch Pharmacol  (2006). 372(6):432-443. 
Meyer UA. Pharmacogenetics and adverse drug reactions (2000). The Lancet 356: 1671-1675 
Sistonen J.  Pharmacogenetic variation at CYP2D6, CYP2C9, AND CYP2C19: Population 
Genetic and Forensic Aspects Department of Forensic Medicine University of 
Helsinki Finland 2008 
Wikinson GR. Drug Metabolism and Variability among Patients in Drug Response (2005). N 




in Designing Effective Antibiotic  
Treatment Regimens 
Ghada F. Ahmed1 and Ayman M. Noreddin2,* 




Designing antibiotic dosing regimens is often not optimal and the dose-response 
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time profile at the site of action to the drug effect (PK/PD), the effect of varying dosage 
regimens against pathogens could be simulated enabling the identification of effective 
dosage strategies. It is known that inadequate antibiotic dosing could not only lead to a 
therapeutic failure, but also to the development of bacterial resistance. Importantly, the 
evolution of resistance in pathogenic bacteria combined with the decreasing interest from 
the pharmaceutical industry in developing new antibiotics has created a major public health 
problem3. Therefore, the activities to maintain the effects of existing antibiotics and prolong 
their useful life span have a high priority.  
PK/PD analysis proved to be a useful tool for investigating effective therapies that minimize 
the emergence of antibiotic tolerance. Although the European Medicine Agency and FDA 
clearly recommends PK/PD assessment for new compounds, there are no standardized 
procedures for such analyses for antibiotics3. For characterizing the PD of an antibiotic, 
bacterial growth and death under antibiotic exposure have to be investigated. Since these are 
difficult to measure in human tissues, animal and in vitro models have been developed.  
Although animal models provide similar growth conditions for bacteria and imitate the 
characteristics of human infection, they exhibit different PK and drug disposition profiles 
compared to humans4. In contrast, in vitro models have the advantage of simulating human 
PK and bacterial resistance analysis. Therefore, they are considered adequate for the 
investigation of antimicrobial activity4. 
Frequently, the pharmacodynmic relationship is reduced to a single parameter, the 
Minimum inhibitory concentration (MIC), even though antibiotics with the same MIC can 
                                                                          
* Corresponding Author 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
110 
4.4 Psychiatric drug therapy 
Genetic variation is an important factor for the variation in psychiatric drug response. The 
meta-analysis conducted by Kirchheiner et al. showed that of 36 commonly used 
antidepressants, for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and 
that in 14 drugs such genetic variation would require at least doubling of the dose in 
extensive metabolizers in comparison to poor metabolizers. They also showed that out of 38 
antipsychotics, CYP2D6 and CYP2C19 genotype was of relevant in 13 drugs. Amitriptyline  
has  relatively narrow therapeutic range  and high toxicity at increased concentrations, 
leading to severe adverse effects. The main CYPs involved in amitriptyline metabolism are 
CYP2C19. Genetic variation of these enzymes has been shown to correlate with the serum 
concentrations of amitriptyline, as well as with the occurrence of side-effects related to 
amitriptyline therapy. 
5. References 
Classsen T et al. Exome Sequencing of Ion Channel Genes Reveals Complex Profiles 
Confounding Personal Risk Assessment in Epilepsy (2011). Cell 145: 1036–1048, 
Daly AK.  Pharmacogenetics and human genetic polymorphisms (2010). Biochem. J. 429: 
435–449 
Evans WE and McLeod HL. Pharmacogenomics — Drug Disposition,Drug Targets, and Side 
Effects (2003) N Engl J Med 348: 553-549. 
Kirchheiner J et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution 
of allelic variations to the phenotype of drug response (2004). Mol Psychiatry.  9 
(5):442-73. 
Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP 
transporters. Naunyn Schmiedebergs Arch Pharmacol  (2006). 372(6):432-443. 
Meyer UA. Pharmacogenetics and adverse drug reactions (2000). The Lancet 356: 1671-1675 
Sistonen J.  Pharmacogenetic variation at CYP2D6, CYP2C9, AND CYP2C19: Population 
Genetic and Forensic Aspects Department of Forensic Medicine University of 
Helsinki Finland 2008 
Wikinson GR. Drug Metabolism and Variability among Patients in Drug Response (2005). N 




in Designing Effective Antibiotic  
Treatment Regimens 
Ghada F. Ahmed1 and Ayman M. Noreddin2,* 




Designing antibiotic dosing regimens is often not optimal and the dose-response 
relationship for most antibiotics is not well-known1. Both Pharmacokinetics (PK) and 
Pharmacodynamics (PD) are characteristics of antimicrobial agents that should be 
considered in the development of effective antibiotic therapy. By linking the concentration 
time profile at the site of action to the drug effect (PK/PD), the effect of varying dosage 
regimens against pathogens could be simulated enabling the identification of effective 
dosage strategies. It is known that inadequate antibiotic dosing could not only lead to a 
therapeutic failure, but also to the development of bacterial resistance. Importantly, the 
evolution of resistance in pathogenic bacteria combined with the decreasing interest from 
the pharmaceutical industry in developing new antibiotics has created a major public health 
problem3. Therefore, the activities to maintain the effects of existing antibiotics and prolong 
their useful life span have a high priority.  
PK/PD analysis proved to be a useful tool for investigating effective therapies that minimize 
the emergence of antibiotic tolerance. Although the European Medicine Agency and FDA 
clearly recommends PK/PD assessment for new compounds, there are no standardized 
procedures for such analyses for antibiotics3. For characterizing the PD of an antibiotic, 
bacterial growth and death under antibiotic exposure have to be investigated. Since these are 
difficult to measure in human tissues, animal and in vitro models have been developed.  
Although animal models provide similar growth conditions for bacteria and imitate the 
characteristics of human infection, they exhibit different PK and drug disposition profiles 
compared to humans4. In contrast, in vitro models have the advantage of simulating human 
PK and bacterial resistance analysis. Therefore, they are considered adequate for the 
investigation of antimicrobial activity4. 
Frequently, the pharmacodynmic relationship is reduced to a single parameter, the 
Minimum inhibitory concentration (MIC), even though antibiotics with the same MIC can 
                                                                          
* Corresponding Author 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
112 
have different PD functions1. Differences in the kill profiles exhibited by antibiotics is 
hypothesized to be influenced by disparities of their PD characteristics that- if not taken into 
account during the design of treatment regimens- may lead to therapeutic failure and 
development of resistance.  
In this study, five antibiotics of five different classes were considered for PK/PD analysis. 
The antibiotics were Ciprofloxacin (a fluorquinolone that acts by inhibiting bacterial DNA 
gyrase enzyme), Ampicillin (a beta-lactam antibiotic acts by inhibiting bacterial cell wall 
synthesis), and finally Rifampin, Streptomycin, and Tetracycline (protein synthesis 
inhibitors). The antibiotics were further classified according to their pharmacodyamic 
properties into concentration dependent antibiotics (Ciprofloxacin, Rifampin and 
Streptomycin), and time dependent antibiotics (Ampicillin and Tetracycline).   
PK/PD simulations using STELLA® (Version 9.1, isee system inc, NH, USA) were used to 
investigate the effect of various PD parameters on the achievement of the therapeutic 
outcome and in designing effective dosing regimen that help overcome the development of 
resistance to the antibiotic. 
2. Pharmacokinetic analysis 
The PK of the antibiotics was assumed to follow one compartment disposition 
characteristics with a first order elimination rate constant. The drug was given in a dose that 
gave an initial plasma concentration equivalent to 5 times the MIC and the plasma 
concentration was allowed to decrease mono-exponentially to a minimum of 0.5 times the 
MIC over 8 hours according to the following equation 
 Ct=C0 exp{-kt}  (1) 
Where Ct is the plasma concentration at time t, C0 is the initial plasma concentration and k is 
the first-order elimination rate constant. 
Doses were administered as multiple IV boluses with a time interval of 8 hours. The system 
was assumed to be at a steady state. The volume of distribution was assumed to be fixed 
(equals 1); since the data were obtained from an in vitro experiment. Clearance (k*v) was 
then assumed to be equivalent to the value of the elimination rate constant k. For this 
analysis, Ciprofloxacin, Ampicillin, Rifampin, Streptomycin and Tetracycline were the 
considered antibiotics. 
3. Pharmacodynamic analysis 
3.1 Effect of exposure to antibiotics on the bacterial net growth rate 
The net growth rate under certain antibiotic pressure could be described by the following 
equation:- 
 ( ) max ( )a a     (2) 
Where is the net growth rate at antibiotic concentration a, is the growth rate of the bacteria 
in absence of antibiotic, and is the death rate of the bacterial population exposed to an 
antibiotic concentration a. Therefore, the net growth rate of the bacterial population under 
antibiotic treatment could be described by the following model:- 
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Whereis the minimum net growth rate of the bacteria at high antibiotic concentration, a is 
the antibiotic concentration, zMIC is the pharmacodynamic MIC (concentration of the 
antibiotic at which the net bacterial growth rate was calculated to be zero), and K is the Hill 
coefficient which is a measure of the steepness of the sigmoidal relationship between 
antibiotic concentration and the net growth rate. 
The model was constructed to evaluate the effect of the antibiotics against a single micro-
organism (E. coli); and therefore, the maximum growth rate is assumed to be constant. 
The minimum growth rate, zMIC as well as the Hill coefficient will, however, change due to 
different antibiotic treatments. Bacterial net growth rate against the antibiotic concentration 
was analyzed for the aforementioned antibiotics. 
4. PK/PD analyses 
The bacterial population was modeled during the mono-exponential growth phase. The 
change in bacterial density was modeled according to the following equation:- 
dx/dt = growth rate – kill rate due to antibiotic 
Where x is the bacterial density measures in colony forming units per mL (CFU/mL) 
Time plots of the logarithm to the base 10 of the bacterial density were generated and the 
effect of the PD parameters (MIC, K, minimum growth rate, and maximum growth rate) on 
the achievement of the target treatment outcome was investigated through a sensitivity 
analysis in STELLA®. The target treatment outcome was defined as three log10 decrease in 
the bacterial density over a 24 hour course of the treatment. 
4.1 Design of antibiotics treatment strategies 
Antibiotics are generally classified to concentration dependent and time dependent agents. 
In the current analysis, treatment strategies were constructed and tested under different 
scenarios. Results from the simulation were used to conclude on the most appropriate 
treatment option for different classes of antibiotics.  
Increasing the MIC by two fold and four folds supported the simulation of bacterial 
resistance against the antibiotic treatments. The outcome target of the treatment is to 
achieve three log10 decrease in the bacterial density over a 24 hours course of treatment 
through the given dosage regimen. Towards that target, two treatment strategies were 
used. The first was to increase the area under the antibiotic concentration time curve 
above the minimum inhibitory concentration (AUC>MIC) through increasing the 
administered dose, while the second was to increase the percentage of time during which 
the drug concentration is above the MIC relative to the dosing interval (% t>MIC) through 
decreasing the dosing interval with smaller maintenance doses. Both scenarios were 
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applied to each of the investigated antibiotics and the outcomes of the treatment regimens 
were compared. 
5. Results 
5.1 The pharmacokinetic model  
The disposition of the antibiotics was shown to follow a one compartment model with a first 
order elimination rate. The achievement of the steady state was assumed form the beginning 
of therapy. (Figure 1a and 1b) 
The antibiotics were given as multiple intravenous boluses every 8 hours over a course of 24 
hours. 
amt Ampicillin






Fig. 1a. STELLA model simulating the one compartment PK model with first order 
elimination rate constant for Ampicillin  
 
Fig. 1b. Simulation of the Ampicillin steady state concentration time profile form the PK 
model.  
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5.2 Pharmacodynamic analysis 
5.2.1 Effect of antibiotic concentration on the bacterial net growth rate 
Changing antibiotic concentration is assumed to be affecting the net growth rate of the 
bacteria cultured in the in vitro system. The infection was therefore assumed to occur in the 
central compartment. The pharmacodynamic parameter estimates for the five considered 
antibiotics are displayed in Table 1. STELLA model (Figure 2) was created to determine the 
effect of changing drug concentration on the net bacterial growth rate according the 







rate (h-1) K zMIC (µg/mL) 
Ciprofloxacin 0.75 -6.5 1.1 0.017 
Ampicillin 0.75 -4.0 0.75 3.4 
Rifampin 0.75 -4.3 2.5 12.0 
Streptomycin 0.75 -8.8 1.9 18.5 
Tetracycline 0.75 -8.1 0.61 0.67 
Table 1. Pharmacodynamic parameter estimates1  
 
Fig. 2. Sketch of the STELLA model used to assess the pharmacodynamic effect of the 
antibiotic Ampicillin. 
Bacterial net growth rate against the antibiotic concentration displayed a nonlinear 
inhibitory PD function with increasing antibiotic concentration. It is assumed that the four 
PD parameters (MIC, K, minimum growth rate, and maximum growth rate) contribute to 
the shape of the PD curve. 
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It is noticed that concentration dependent antibiotics (Ciprofloxacin, Rifampin, and 
Streptomycin) showed a sharper decrease in the net growth rate in relation to antibiotic 
concentration (greater K value), while time dependent antibiotics (Ampicillin and 
Tetracycline) showed slower decline with respect to increase in concentration (lower K 
values) (Figure 3). Additionally, Figure 4 shows that three antibiotics with the same MIC 
values and minimum growth rate against a specific microorganism can have different 
microbiological activity depending on the value of the Hill coefficient K. 
 
Fig. 3. Effect of antibiotic concentration on bacterial net growth rate  
 
Fig. 4. Pharmacodynamic sensitivity analysis shows the effect of three antibiotics with the 
same MIC and minimum growth rate on the bacterial net growth rate due to different 
values of Hill coefficient (K).  
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5.3 PK/PD analysis 
Change in the bacterial density over time was modeled using STELLA as in figures 5a and 
b. the model assumes that bacterial growth over time follows an exponential pattern. 
 
Fig. 5a. STELLA model constructed to investigate the change in bacterial density over time. 
 
Fig. 5b. Bacterial growth curve from the PD model.  
The drug effect was added to the previous model through the inclusion of a first order kill rate. 
This resulted in a decline in the log10 bacterial density over time. The decline was found to be 
governed by the magnitude of the PD model parameters. The effect of the Hill coefficient, the 
minimum growth rate, and the maximum growth rate was investigated for both concentration 
dependent and time dependent agents. The values of the PD parameters that were used in the 
sensitivity analysis are reported in Table 2. The results from the sensitivity analysis are shown 
in Figures 6, 7 and 8. It is noticed that as K increases, there is a sharper decline in the bacterial 
density due to a faster rate of killing. In addition, on the single dose level, ciprofloxacin 
showed greater rate of killing compared to ampicillin (Figure 6). 
Similarly, minimum growth rate achieved under high antibiotic concentration was related to 
the treatment outcome. Increased minimum growth rate under certain high antibiotic 
pressure, led to a decreased antibiotic efficacy. This could be attributed to development of 
resistance. It is also noticed that the effect was greater for concentration dependent 
antibiotics than the for time dependent agents (Figure 7).  
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PD parameter Hill coefficient (K) Minimum growth rate (h-1) 
Maximum growth 
rate (h-1) 
Scenario 1 0.5 -3 0.75 
Scenario 2 1 -6 1.2 
Scenario 3 3 -9 2 
Table 2. Pharmacodynamic parameters incorporated in the sensitivity analysis 
 




Fig. 7. Effect of variation of minimum growth rate achieved under high antibiotic 
concentration on the treatment outcomes for the investigated antibiotics.  
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In addition to the previously mentioned PD parameters, maximum growth rate of the 
bacteria achieved in the absence of antibiotic was an influential parameter. Change in that 
parameter could be considered when the effect of the antibiotic on different bacterial strains 
is a point of interest. Moreover, it could be important for a single microbial strain. For 
instance, it is known that the growth rate of the bacterial biofilm is reduced compared to the 
planktonic cultures due to the development of a matrix of extracellular polymeric substance 
that is referred to as a slime2. This will result in reduced penetration of the antibiotics as well 
as nutrients. Figure 8 augments that by showing that the increase in the maximum growth 
rate led to a more susceptible micro-organism and a faster kill by the antibiotic.  
 
Fig. 8. Effect of variation of maximum growth rate of the microorganism on the treatment 
outcome with Ciprofloxacin, Tetracycline and Ampicillin.  
6. Development of microbial resistance 
Development of microbial resistance is a major challenge that faces antibiotic treatments and 
causes reduction in the treatment efficacy. In order to simulate cases of bacterial resistance, 
MIC values were allowed to vary two and four fold from the original MIC through 
conducting a zMIC sensitivity analysis (Table 3). The pharmacokinetic profiles of the five 
antibiotics were simulated using the previously mentioned one compartment disposition 
model. It is noticed that as the MIC increases, the level of resistance of the microorganism 
increases, thus an expected reduction in the rate of kill will occur. Under such 
circumstances, the antibiotic may no longer be effective in eradicating the microorganism as 
shown in Figure 9 
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/antibiotic Scenario 1 Scenario 2 Scenario 3 
Ciprofloxacin 0.017 0.034 0.068 
Ampicillin 3.4 6.8 13.6 
Rifampin 12 24 48 
Streptomycin 18.5 37 74 
Tetracycline 0.67 1.34 2.68 
Table 3. MIC values incorporated in the sensitivity analysis for simulating the development 
of resistance. 
 
Fig. 9. Effect of the development of resistance (simulated through increasing zMIC) on the 
antimicrobial outcome for the different antibiotics.  
7. Design of treatment strategies  
Each of the five antibiotics was allowed to follow two treatment scenarios to overcome the 
emergence of the resistant microbe (Figure 10) and the treatment outcome was then 
evaluated. Treatment modalities included two protocols: the first implemented a method to 
increase the AUC/MIC by increasing the doses of the antibiotic. The second allowed the 
percentage of time that the drug concentration stays above the MIC to increase by 
decreasing the dosing interval while giving small maintenance doses of the antibiotic. 
Shown in Figure 10 is a representation of the concentration profiles expected from the 
treatment scenarios and in Figures 11a, b, and c are the simulated treatment outcomes 
expected from each protocol for three of the antibiotics. 
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Fig. 10. Simulation of the concentration time profile for the treatment scenarios proposed to 
overcome resistance. 1. Represents original treatment protocol. 2. Represents increasing 
AUC>MIC scenario and 3. Represents the case of increased % t>MIC. 
 
Fig. 11a. Simulation of the target outcome for the two treatment scenarios used against the 
Rifampin resistance. Upper left: increasing the dose of Rifampin 1.5 folds over 8 hours 
interval. Upper right: decreasing the dosing interval to 4 hours while maintaining the 
original dose. Down: decreasing the dosing interval to 2 hours while maintaining the 
original dose. 
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Fig. 11b. Simulation of the treatment outcomes obtained after implementation of the two 
treatment scenarios with Ciprofloxacin. Left side curve represents increasing the dose by 
four times over 8 hours dosing interval. Right side curve represents decreasing the dosing 
interval by 4 hours while maintaining the original dose. 
Rifampin is known to be a concentration-dependent antibiotic. Increasing the exposure to the 
drug above the MIC (by 1.5 fold increase in the dose) improved the treatment outcome, yet 
increasing the percentage of time relative to the dosing interval (tau) that the drug 
concentration was above the MIC- by decreasing tau from 8 hours to 4 and 2 hours 
simultaneously- did not achieve the target outcome even when the dosing interval decreased 
to 2 hours. Ciprofloxacin- a fluoroquinolone known to be a concentration dependent 
antibiotic- displayed similar results to Rifampin upon increasing exposure above MIC (four 
fold increase in the dose) compared to t>MIC (reducing the dosing interval to 2 hours).  
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Fig. 11c. Simulation of the treatment outcomes achieved after increasing Tetracycline dose 
(four folds over 8 hours dosing interval, left side curve), or decreasing the dosing interval (2 
hours, while maintaining original dose, right side curve). 
On the other hand, the efficacy of Tetracycline is known to be time dependent. Therefore, 
increasing the percent of time the drug stays above MIC relative to the dosing interval 
seems to be more relevant than increasing the exposure above the MIC. Surprisingly, the 
two scenarios have achieved nearly the same treatment outcome for microbial resistance 
against Tetracycline. Both treatment scenarios succeeded to achieve the target outcome of 
three log10 reduction in bacterial density by the end of the antibiotic treatment.  
8. Discussion 
This study addressed the complex relationship between the exposure to antibiotics and the 
growth and death rates of bacteria. PK/PD simulations using STELLA showed that 
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although MIC is an important PD parameter, it is not the only parameter that governs the 
interaction of the antibiotic and the bacteria. Other PD parameters should additionally be 
taken into consideration when designing antibiotic dosage regimens. For instance, Figure 4 
showed that three antibiotics with the same MIC (the concentration corresponding to a net 
growth of zero) could show different microbiological activity depending on the magnitude 
of the Hill coefficient (K). Other PD parameters to be considered are the minimum growth 
rate and the maximum growth rate, which can capture effects that cannot be accounted for 
by solely considering the MIC and can importantly affect the therapeutic outcomes.  
Pharmacodynamic simulations of the antibiotics concentration against net bacterial growth 
showed that the shape of the sigmoidal functions differs among antibiotics from different 
classes with some of them showing greater sensitivity to changing concentrations 
(Ciprofloxacin and Streptomycin) than others (Tetracycline and Ampicillin). The shape of 
the pharmacodynamic function is determined by the values of PD parameters displayed in 
Table 2. 
Additionally, using a STELLA model for the change in bacterial density over time, it was 
found that the parameters that govern the PD function have a profound effect on the 
microbiological activity. The Hill coefficient influences the sensitivity of the bacteria to the 
change in the antibiotic concentration as was shown in Figure 4. Assuming a PK model in 
which the drug reaches steady state form the beginning of the treatment, a concentration 
that is above the MIC most of the time, and all other parameters are equal, the simulation 
predicts that antibiotics with a high Hill coefficient are more effective than those with a low 
value of the coefficient.  
Considering the minimum bacterial net growth rate at high antibiotic concentrations, the 
simulation predicts that antibiotics that induced lower values of minimum bacterial net 
growth rate are more effective than those with higher values. Increase in the minimum 
bacterial net growth rate could be atrributed to the development of resistance or to the 
utilization of ineffective therapy against a specific bacterial strain. 
Maximum growth rate in the absence of antibiotic is another important parameter to 
consider in the design of antibiotic treatment. That PD parameter is subject to change when 
treating different micro-organisms or if the nature of infection by the same microbe has been 
changed. Regarding the later condition, biofilm infection could be considered as a change in 
the nature of the infection by the same micro-organism5. It is well-known that biofilm is a 
type of persistent infections that is developed in chronic disease statuses and is 
characterized by a slower rate of growth compared to acute infections2. This phenomenon is 
also observed in the in vitro systems- where the planktonic cultured bacteria exhibit a faster 
rate of growth compared to the biofilm cultured ones6. Therefore, increasing the maximum 
growth rate in the sensitivity analysis has led to a faster kill by different antibiotics due to 
the greater exposure of the bacteria to the antibiotic compared to the slowly growing biofilm 
infection. 
Interestingly enough, estimates of the parameter K was higher for antibiotics that are 
concentration dependent (Ciprofloxacin, Rifampin, and Streptomycin) compared to those 
that are time dependent (Ampicillin and Tetracycline) which means that the formers are 
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characterized by a steeper pharmacodynamic function. The steeper the function, the more 
dramatically the bacterial killing is sensitive to the change in antibiotic concentration 
above the MIC. Therefore, it could be a reasonable assumption that for antibiotics that 
have grater K, increasing the concentration above MIC (AUC/MIC) is the most effective 
strategy to improve the treatment outcomes. This hypothesis was fully augmented by the 
PK/PD simulation shown in both Figures 11a and b. Increasing the % t>MIC for Rifampin 
by reducing the dosing interval to 4 hours and even 2 hours did not achieve the target 
outcome for the resistant strain as did the increase in the AUC/MIC. Furthermore, 
Ciprofloxacin achieved the target therapeutic outcome only when the dose increased 
allowing AUC>MIC to increase. It is worth mentioning that the magnitude of the dose 
increase for concentration dependent antibiotics appears to be related to the PD parameter 
K (the Hill coefficient); since Rifampin- has a K value of 2.5 compared to 1.1 for 
Ciprofloxacin- has achieved the target therapeutic outcome upon 1.5 fold increase in the 
dose compared to a four folds increase for Ciprofloxacin. In another way, one can 
conclude that as K increases, as the antibiotic efficacy is more sensitive to small changes in 
concentration. 
On the other hand, it was assumed that lower values of K could be associated with time 
dependence of the antibiotics. This assumption is not fully supported by the current 
simulation, since for Tetracycline (k=0.61) both scenarios of increasing the AUC/MIC and 
% t>MIC worked well and achieved comparable therapeutic outcomes. It is worth 
mentioning, however, that the maintenance dose used in the former scenario (12.08 µg 
every 8 hours) was four times higher than that used in the later scenario (2.95 µg every 2 
hours). Although it is known that longer dosing intervals are more convenient and can 
improve patient adherence to therapy, drug toxicity is an important consideration as well. 
In case where toxicity is expected from higher doses of a time-dependent antibiotic, the 
strategy of dividing the doses into smaller fractions for shorter dosing intervals may be 
considered.  
Finally, it should be noted that this model may suffer some limitations due to many causes. 
The model assumes that the kill rate increases with increasing antibiotic concentration, 
however in reality, the development of an adaptive resistance- a mechanism by which the 
bacteria becomes increasingly refractory to the antibiotic treatment- may lead to the 
decrease in kill rate with time and therefore limit such assumptions. Moreover, the 
constitutive and inducible immune defense of the human body contributes to the efficacy of 
the antibiotic treatment protocols in a way that could not be fully represented by the current 
PK/PD analysis under in vitro conditions.  
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1. Introduction 
Discovering and developing safe and effective new medicines is a long, difficult and 
expensive process involving multi-billion dollar investments in Research and Development 
by research-based pharmaceutical industries yearly. On average, it will cost a 
pharmaceutical company up to $800m and upwards of 15 years to get one new medicine 
from the laboratory to the pharmacist's shelf. Only five in 5,000 compounds that enter 
preclinical testing will actually progress into human clinical trials, and of these five, only 
one is likely to be approved by the regulatory authorities using new drug approvals systems 
that are extremely rigorous, costly and time-consuming (1). 
One of the regulatory requirements for an investigational new drug (IND) approval is pre-
clinical pharmacokinetics of the new drug entity. However, for the majority of herbal 
remedies used in ethnomedical or conventional medical practice, data on their disposition 
and biological fate in humans are lacking or in paucity. It is vital in the drug development 
chain, to understand the disposition of these herbal products and how they interact with 
conventional drugs before their launch in the market, in order to ensure the rational use of 
herbal medicines. For natural products, the additional challenge currently is in their 
pharmacokinetics, arising from the multiplicity of components, inability to identify 
biological markers and lack of knowledge of the fate of the agents and/or their metabolites 
in vivo. Are these processes currently largely ignored in drug development, due to the rigor, 
cost and time consumption of the conventional drug development process? The clinical 
consequences of diminished drug efficacy can be as devastating as those of enhanced drug 
toxicity. Also sometimes, the clinical effect may not be obvious in a short term study and 
therefore may go unrecognized, possibly leading to the inappropriate discontinuation of an 
effective medication or the unnecessary addition of other drugs. Does the extent and volume 
of botanical – drug interactions observed in today’s medical care and understanding the 
processes involved therein, make it a critical area for in-depth attention in pharmaceutical 
research & development? 
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Herbal medicines are classified as dietary supplements and the Food and Drug 
Administration (FDA) regulatory requirements for their approval are not as stringent as 
those for new chemical entities yet these are products with pharmacological properties with 
the potential to cause harm. 
The term ‘Herbal products’ has become a colloquial term which commonly refers to all 
types of preparations obtained from herbs, spices, roots, stems, leaves and other non-
botanical materials of natural origin. They can be used therapeutically as prescription or 
over-the-counter medicines or even as cosmetics orally or topically. Plants are important 
sources of medicines and plant derived drugs came into use in modern medicine through 
the uses of plant materials as indigenous cure in folklore or traditional systems of medicine. 
The use of plant extracts and herbs as medicines preparations has been since the beginning 
of recorded time, probably originating from ancient China and Egypt. Over 80,000 species of 
plants are in use throughout the world. In the last century, roughly 121 pharmaceutical 
products were formulated based on the knowledge of plant use in traditional medicine from 
various sources and presently about 25% of pharmaceutical prescriptions in the United 
States contain at least one plant-derived ingredient.  
Herbal medicine, phytotherapy, phytomedicine, nutraceuticals, natural product medicine, 
complimentary & alternative medicine, ethnomedicine, botanicals, herbal medicinal 
product, dietary supplements and phytopharmaceuticals are all terms used interchangeably 
to denote the use of botanicals in healthcare and are therefore used as such in this text. 
Increasing number of patients and consumers are using plant-based therapeutic products as 
complementary therapy in the treatment and management of chronic ailments such as 
tuberculosis, diabetes, hypertension, HIV/AIDS, cancer and diseases of endemicity and 
high recrudescence especially malaria, as well as other social conditions like obesity, 
cigarette smoking and drug abuse. This upsurge in the use of phytomedicines is a global 
phenomenon, with more than 80% of people in Africa and Asia using herbal medicines and 
an increasing number in the Western world. It is estimated that 60% to 70% of the American 
population is taking botanical products (2). 
The World Health Organisation promotes the use of herbal medicine, thus herbal medicine 
has become big business. Many Americans use complementary and alternative medicine 
(CAM) to prevent or alleviate common illnesses, with the effect that in the United States, 
botanical products are now a $1.5 billion per year industry. In 2005, trade in herbal medicine 
was worth 14 billion USD in China, 5 billion USD in Western Europe in 2003-2004 and 160 
million USD in Brazil in 2007. In Africa where all types of plant derived medicines and 
dietary supplements (both domestic and foreign) are seen, the volume of trade in botanicals 
is unquantified.  
In recent times many factors have contributed to the current surge in phytomedicine use. 
The therapeutic superiority of many plant extracts over single isolated constituents, as well 
as the bioequivalence of many phytopharmaceuticals with synthetic chemotherapeutics is 
well documented (3). The gradual transition from the long-standing use of monodrug 
therapy in classical medicine to the new concept of a multidrug and multitarget therapy is 
greatly promoting phytotherapeutics. There is a gradual shift from the orthodox use of 
mono-substance therapy and an increasing transition to multidrug therapy of patients with 
Pharmacokinetics and Drug Interactions of Herbal Medicines:  
A Missing Critical Step in the Phytomedicine/Drug Development Process 
 
129 
drug combinations, such as is done presently for the treatment of diabetes, cancer, acquired 
immune deficiency syndrome (AIDS), malaria, tuberculosis or hypertension (4, 5). 
The rationalization for this strategy is based on therapeutic experiences that the use of drug 
combinations can target the multiple aetiologies, disease dynamics and/or complications 
that are seen in many ailments better than each of the components separately, while 
promoting patient compliance. Also there is the consideration that a complex 
pathophysiological process can be influenced more effectively and with fewer or no severe 
side-effects by a combination of several low-dosage compounds or the corresponding 
extracts than by a single large dosage isolated compound. Phytotherapy has long followed 
and developed these strategies by using mono-extracts or extract combinations containing 
mixtures of bioactive compounds that complement one another to elicit an efficacy of 
superior power. It is also believed that these components do primarily activate self-healing 
and protective processes of the human body (especially the immune system, which can then 
properly fight foreign invaders), promote the balancing of regulatory process in the body 
and help to destroy offending pathogens without toxic side effects, rather than attacking 
and directly destroying the damaging agents. 
Most consumers often consider herbal therapies as accessible and affordable therapeutic 
alternatives to orthodox therapy without any safety concerns and sometimes even as the 
only effective therapeutic way left to treat certain disorders that have defied conventional 
drugs or promote and maintain health. The above factors have led to a situation where the 
concomitant administration of phytomedicines and orthodox drugs has become inevitable. 
One of the consequences of concurrent use of herbal medicines and orthodox drugs is the 
possibility of interactions. The interaction of drugs with herbal medicines is a significant 
safety concern, especially for drugs with narrow therapeutic indices (e.g. warfarin and 
digoxin), drugs with long-term regimens and drugs used in the management of life-
threatening conditions due to the fact that an alteration in the pharmacokinetics and/or 
pharmacodynamics of the drug by herbal remedies could bring about potentially severe and 
perhaps even life-threatening adverse reactions. Because of the clinical significance of drug 
interactions with herbs, it is important to identify drugs and compounds in development 
that may interact with herbal medicines. This can be achieved by incorporating timely herb-
drug interaction studies using appropriate in vitro and in vivo approaches in order to 
identify such drugs has important implications for drug development. 
With the availability of over 30000 over-the-counter products, more than 1000 different 
chemical substances that are constituents of prescription drugs and hundreds of herbs, 
vitamins, and minerals, the possibilities of drug interaction are endless. A drug interaction is 
defined as any modification caused by another exogenous chemical (drug, herb, or food) in 
the diagnostic, therapeutic, or other action of a drug in or on the body. The risk for drug 
interactions increases with the number of products consumed: for 2 products, the risk is 6%; 
for 5 products, 50%; and for 8 or more products, 100% (6). The use of complimentary 
alternative medicine alongside conventional therapy continues to grow rapidly especially in 
the developed countries. It is estimated that less than a third of Americans taking botanical 
products inform their physicians of such use (7). In oncology therapy alone, about 72% of 
cancer patients taking herbal medicines with their conventional treatments do not inform 
their physicians (8) and 27% of them were at risk for developing herb – drug interaction (9). 
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Because the issue of botanical-drug interaction has not been well appreciated and is 
definitely under-studied, today, our understanding of the interactions between drugs and 
herbs and between drugs and food has not advanced much, therefore much research is still 
required in herbal therapy to examine individual plant constituents and to determine how 
plants interact with drugs and foods. Therefore in our effort to understand the potential 
therapeutic role of botanicals and promote their safe use, one must not only focus on 
evaluating toxicity, efficacy, mechanism of action but also on their safe and appropriate use 
particularly with respect to the research and knowledge on botanical-drug interactions. 
A general lack of knowledge of the interaction potentials of concurrent use of botanicals 
with prescription and/or over-the-counter medicines, poses a great challenge for health care 
professionals and a safety concern for consumers. Although most people especially in 
developing countries believe that herbs are harmless plants, about a third of our drugs 
(including digitalis, morphine, atropine, and several chemotherapeutic agents) were 
developed from plants. So, indeed, herbs can be potent products. Herbs can affect body 
functions; therefore, when they are taken concurrently with orthodox drugs, interactions are 
possible, impacting on the clinical effects of the latter. That natural products are largely 
unregulated contributes to the misconception that they are safe, with the effect that patients 
don’t feel the need to tell their physicians that they are using them, and physicians don’t 
routinely ask patients if they are taking them.  
2. Selected clinically relevant botanical–drug interactions 
Although our knowledge of interactions of phytomedicines with conventional drugs in 
patients is still relatively young and not well understood, many case reports, controlled 
clinical and in vitro studies constitute strong evidence that support the assumption that 
significantly more of the large inter-individual variations in the response to treatment seen 
in medical practice can be attributed to botanical–drug interactions. This assumption is 
supported by several studies which show that some herbal medicinal products have the 
capacity to influence plasma levels of drugs (10, 11), giving rise to clinical problems of 
unexpected toxicities and under-treatment seen in different groups of patients. Factors 
relating to co-administered drugs (dose, dosing regimen, administration route, 
pharmacokinetic and therapeutic range), herbs (species, dose, dosing regimen, and 
administration route) and patients (genetic polymorphism, age, gender and pathological 
conditions) largely determine the extent and thus the clinical relevance of drug interactions 
with herbs (12). In general terms, the appearance of enhanced drug effects and/or adverse 
effects is usually associated with a doubling or more in drug plasma concentration (13). 
However, less marked changes may still be clinically important for drugs with a steep 
concentration–response relationship or a narrow therapeutic index. In most cases, the extent 
of drug interactions with herbs varies markedly among individuals, depending on inter-
individual differences in drug metabolizing enzymes and transporters, co-medication with 
other drugs, age and many of other factors (14). 
Several clinically important botanical-drug interactions have been reported leading to altered 
efficacy and/or toxicity, adverse reactions that are sometimes life threatening or lethal (15). 
Often times, the evidence of interactions with dietary supplements is often based on presumed 
pharmacologic activity, data derived from in vitro or animal studies, or anecdotal single case 
Pharmacokinetics and Drug Interactions of Herbal Medicines:  
A Missing Critical Step in the Phytomedicine/Drug Development Process 
 
131 
reports and to a lesser extent, well-designed clinical studies. Tamarind, an Asian fruit used not 
only in ayuverdic medicine but also as a food flavouring agent, has been shown to 
significantly increase the extent of absorption of a single 600mg dose of aspirin in six healthy 
volunteers, posing potential danger if a large amount of aspirin is ingested concomitantly with 
tamarind. Ginseng induced mania when used concomitantly with phenelzine (16). An 
enhanced hypoglycemic effect has also been reported when a meal containing garlic and 
Mormodica charantia L. (balsampear) family: curcubitaceae, a herb traditionally used in the 
treatment of type 2 diabetes was consumed with chlorpropamide (17). 
The over-the-counter antidepressant herb St John’s Wort (SJW) is probably the most studied 
of all herbal preparations when considering interactions with orthodox drugs. Several 
clinically relevant drug–drug interactions have been reported between SJW and a wide 
range of drugs. Chronic administration of SJW together with cyclosporin A has been 
associated with a significant reduction in cyclosporin plasma levels and a higher risk for 
acute organ rejection in transplanted patients (18, 19). In healthy volunteers, administration 
of SJW together with the protease inhibitor indinavir produced an approximately 57% lower 
plasma AUC of indinavir (20). Co-administration of SJW with digoxin produced an18% 
lower plasma AUC of digoxin and a 40% higher expression level of intestinal P-gp (21). 
Other drugs with reported clinically relevant interactions with St. John’s Wort include 
tacrolimus, warfarin, verapamil, fexofenadine, imatinib, (ethinylestradiol/desogestrel), 
loperamide, or selective serotonin-reuptake inhibitors (e.g. sertraline, paroxetine, and 
nefazodone) with attendant clinical implications such as under-treatment and failure of 
therapies (22, 23)  
Ginkgo is a popular herbal product used to improve cognitive function in alzeihmer and 
dementia as well as to improve blood flow and improve impaired memory in vascular 
disease. Several reports of bleeding associated with its concurrent use with drugs like 
aspirin, warfarin, acetaminophen, or an ergotamine caffeine preparation have been 
documented (24, 25). Matthew MK, reported the association of a recent use of Gingko biloba 
with the occurrence of cerebral haemorrage in a patient who had been stabilized for five 
years on warfarin (26). Also, a combined use of ginkgo with a thiazide diuretic may 
precipitate high blood pressure and coma when combined with trazodone (27, 28). 
Grapefruit juice is another botanical product that has widely been reported to affect the 
plasma concentrations and bioavailabilities of conventional drug products ingested with it, 
such that the FDA includes documented information on drug-grape fruit juice interactions 
in the product insert of certain medications including statins, drugs for blood pressure 
reduction, some antiretroviral agents (29) and the Health Canada in 2002 advised the public 
not to consume grape fruit juice with medications for anxiety, depression among others (30).  
As part of the drug development process,’ before ‘studies studies from our laboratories have 
investigated possible interactions of the concomitant administration of various natural 
products being developed as phytomedicines and various drugs routinely used in the 
treatment of co-morbidities in the respective disorders. The alteration in bioavailability and 
pharmacokinetic parameters of paracetamol by an investigational antimalarial 
phytomedicine (AM-1), when concomitantly administered in humans was reported by us 
(31). AM-1 an extract from the plant Nauclea latifolia Smith (family:Rubiaceae) used in the 
treatment of uncomplicated malaria was orally administered to healthy volunteers with and 
without 500mg of acetaminophen. Almost a 50% reduction in the area under the curve of 
paracetamol was observed in the presence of 500mg capsules of AM-1 
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Niprisan® an anti-sickling phytomedicine has been shown to also significantly affect the 
systemic concentrations of paracetamol when both products were concomitantly 
administered (32), as well as the pharmacokinetic disposition of chloroquine and 
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Table 1. Effect of Niprisan, AM-1, and Nifadin on the pharmacokinetic parameters of 
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Table 2. Effect of Niprisan, AM-1, and Nifadin on the pharmacokinetics parameters of 
chloroquine (CQ) in rats 
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Not all botanical-drug interactions result in undesirable effect, while some studies have 
shown a lack of interaction in the concurrent use of some botanical-drug combinations, 
other interactions may have beneficial effect on drug therapy. In the presence of the extract 
of Chinese medicinal plant Tripterygium wilfordi, the dose of cyclosporine needed for 100% 
kidney allograft survival in animals was reduced by 50% - 75% (34). The adverse effect of 
‘statins’ therapy arises from a decreased biosynthesis of endogenous coenzyme Q10 leading 
to depleted tissue levels, the co-administration of coenzyme Q10 with statin in this therapy 
reduces the adverse effect (35). In women receiving long-term phenothiazine or 
buyrophenone therapy, researchers found that intake of 800 mg daily of mistletoe extract 
silymarin was associated with a significant improvement in liver function tests due to a 
decrease in malondialdehyde (a polyunsaturated fatty acid oxidation product). Thus the 
coadministration of this herbal product in the psychoactive therapy has the potential to 
prevent drug-induced hepatotoxicity (36). 
Recently, we have also shown that the concomitant administration of three first line 
antiretroviral drugs (lamivudine, stavudine and nevirapine) and a plant – based immune 
booster from Andrographis paniculata Nees (Acanthaceae) known in north-eastern India as 
‘king of bitters’, used in the management of HIV/AIDS as an immune stimulant, 
precipitated interactions observed as beneficial changes in food and water intake as well as 
the haematological and biochemical indices including CD4, in the presence of the herb (37). 
There was observed steady increase in red blood cells, white blood cells, food and water 
intake without an associated increase in cholesterol and high density lipoprotein levels and 
a decrease in platelet counts. Concomittant administration of this herb with the first line 
antiretrovirals can ameliorate the anemia and lipodystrophy associated with the use of these 
drugs. A good review of reported cases and clinical studies of drugs that interact with 
herbal medicinal products can be found in (38, 13). 
3. Challenges to botanical-drug interactions research 
In spite of growing concern and examples of herb-drug interactions, little systematic research 
has been published or funded in this area. An important limiting factor that has majorly led to 
this situation is the reliability of the existing evidence. A survey of 44 of the leading dietary 
supplement manufacturers in 2003 revealed that only 10 of 15 respondents considered 
interactions to be an important issue, and only 2 allocated funds to study herbal-drug 
interactions (39). Poor reliability of the It was reported in a study that of one hundred and eight 
cases of suspected interactions studied, 68.5% were classified as ‘unable to be evaluated’, 13% as 
‘well-documented’ and 18.5% as ‘possible’ interactions (40). One of the major reasons for this 
unreliability of reports of the clinical evidence on interactions between herbal and conventional 
drugs is the inherent scientific and clinical challenges in the use of herbal medicines.  
3.1 Predictability of herb-drug interactions 
Predicting the potential for a botanical medicine to interact with other drugs can be possible, 
applying the same principles and study designs as for new chemical entities (NCEs) to 
evaluate the potential inductive/inhibitory effects of herbal extracts on metabolic enzymes 
and transporters. However, while it may be easier to define the overall pharmacokinetic 
and/ or pharmacodynamic mechanisms of interactions for NCEs, especially with those 
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Table 2. Effect of Niprisan, AM-1, and Nifadin on the pharmacokinetics parameters of 
chloroquine (CQ) in rats 
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Not all botanical-drug interactions result in undesirable effect, while some studies have 
shown a lack of interaction in the concurrent use of some botanical-drug combinations, 
other interactions may have beneficial effect on drug therapy. In the presence of the extract 
of Chinese medicinal plant Tripterygium wilfordi, the dose of cyclosporine needed for 100% 
kidney allograft survival in animals was reduced by 50% - 75% (34). The adverse effect of 
‘statins’ therapy arises from a decreased biosynthesis of endogenous coenzyme Q10 leading 
to depleted tissue levels, the co-administration of coenzyme Q10 with statin in this therapy 
reduces the adverse effect (35). In women receiving long-term phenothiazine or 
buyrophenone therapy, researchers found that intake of 800 mg daily of mistletoe extract 
silymarin was associated with a significant improvement in liver function tests due to a 
decrease in malondialdehyde (a polyunsaturated fatty acid oxidation product). Thus the 
coadministration of this herbal product in the psychoactive therapy has the potential to 
prevent drug-induced hepatotoxicity (36). 
Recently, we have also shown that the concomitant administration of three first line 
antiretroviral drugs (lamivudine, stavudine and nevirapine) and a plant – based immune 
booster from Andrographis paniculata Nees (Acanthaceae) known in north-eastern India as 
‘king of bitters’, used in the management of HIV/AIDS as an immune stimulant, 
precipitated interactions observed as beneficial changes in food and water intake as well as 
the haematological and biochemical indices including CD4, in the presence of the herb (37). 
There was observed steady increase in red blood cells, white blood cells, food and water 
intake without an associated increase in cholesterol and high density lipoprotein levels and 
a decrease in platelet counts. Concomittant administration of this herb with the first line 
antiretrovirals can ameliorate the anemia and lipodystrophy associated with the use of these 
drugs. A good review of reported cases and clinical studies of drugs that interact with 
herbal medicinal products can be found in (38, 13). 
3. Challenges to botanical-drug interactions research 
In spite of growing concern and examples of herb-drug interactions, little systematic research 
has been published or funded in this area. An important limiting factor that has majorly led to 
this situation is the reliability of the existing evidence. A survey of 44 of the leading dietary 
supplement manufacturers in 2003 revealed that only 10 of 15 respondents considered 
interactions to be an important issue, and only 2 allocated funds to study herbal-drug 
interactions (39). Poor reliability of the It was reported in a study that of one hundred and eight 
cases of suspected interactions studied, 68.5% were classified as ‘unable to be evaluated’, 13% as 
‘well-documented’ and 18.5% as ‘possible’ interactions (40). One of the major reasons for this 
unreliability of reports of the clinical evidence on interactions between herbal and conventional 
drugs is the inherent scientific and clinical challenges in the use of herbal medicines.  
3.1 Predictability of herb-drug interactions 
Predicting the potential for a botanical medicine to interact with other drugs can be possible, 
applying the same principles and study designs as for new chemical entities (NCEs) to 
evaluate the potential inductive/inhibitory effects of herbal extracts on metabolic enzymes 
and transporters. However, while it may be easier to define the overall pharmacokinetic 
and/ or pharmacodynamic mechanisms of interactions for NCEs, especially with those 
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drugs mainly metabolized by CYPs, the prediction of drug interactions with herbs appears 
to be more difficult and complex (41). Predictability is complexed by factors mainly 
associated with the drug, and herb (active ingredients complex and not well characterised as 
well as poorly understood mechanisms of action). Every herbal product is a complex 
mixture of multiple secondary metabolites / constituents contained in a preparation 
regarded as one single active substance, even when the preparation is made from a single 
herb. Masimirembwa et al, using LC MS/MS analysis of six herbal extracts, observed peaks 
predictive of over 300 chemical species for each herb (42). Each constituent may have a 
different modulatory potential for the same enzyme and/or modulate a different enzyme. 
Potentially therefore, a herb may increase, reduce or not affect the effect of a co-
administered drug through a combination of simultaneous activities on the same drug 
target. The inhibition/induction of metabolic enzymes by herbal medicines may vary 
depending on the herb’s method of preparation (different extraction methods may yield 
different types and quantities of constituents from the same herb). In the work of Gwaza et 
al, 2mg/ml methanolic extract of the African potato Hypoxis obtuse had greater inhibitory 
effects than same concentration of the water extract. Similar effect was also obtained with 
the extracts of Dicoma anomala (43). Dosing, route of administration, oral bioavailability of 
the product and other factors are equally confounding factors. 
Most often, herbal medicinal products are ingested in a chronic manner by its users, thus a 
predicted interaction outcome from a single exposure with a target conventional drug may 
be different in clinical situation. Other drug and patient related factors such as presence of 
extra-hepatic metabolism; and active transport in liver, age, disease, renal and hepatic 
functions and genetic polymorphisms are as for conventional drugs and all contribute to the 
final outcome of drug interaction with herbal medicines. A pharmacological basis of 
qualitative prediction may be on the ‘rule of thumb’ simply by comparing the biological 
effects of the drugs that is, if both products are expected to give similar response, then a 
potentiation of effect may be expected and vice versa. Also if a drug is a substrate for 
CYP3A4 and P-gp, its potential for interaction with herbal medicines would be high. 
3.2 Lack of consistency in the quality of herbal medicinal products 
In a study of 81 published studies on randomized controlled trials of herbal drug 
interactions, only 15% reported performing tests to quantify actual contents of the herbal 
supplements used in the studies (43). There are reports of disparity in content of 
constituents among different brands of echinacea, ginseng, St John’s Wort and of particular 
concern is the fact that inconsistency is also observed even within the same product and 
same batch (45). Conflicting results of studies of the effect of St John's wort on CYP3A4 are 
evident. While three enzyme marker studies indicated a potent inducing effect of St John's 
wort (300 mg three times daily × 14 days) on CYP3A4 activity (46, 47) two others found no 
effect (both 300 mg three times daily, one for 3 days (48), the other for 8 days (49) on 
CYP2D6 or 3A4 activities. Lack of batch-to-batch uniformity in the composition and quality 
of the herbal medicinal products used might explain the discrepancy. Most of these 
inconsistencies can be attributed to the fact that when compared with conventional drugs, 
herbal medicines present additional challenges related to quality; 
- No established methods to establish the quality of herbal medicines 
- Lack of stringent methods for Batch - to - Batch controls 
- Susceptibility to environmental contamination  
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- Herbal medicines are prone to counterfeit practises 
- Quality of product prone to seasonal variation & regional source 
Thus, there is often great disparity in reported patient response to the use of same herbal 
medicinal product. The results from many of the published interaction studies therefore 
may be of little value, since the identity, purity, quality, strength, and composition of the 
supplements is not always confirmed. 
3.3 Lapses in the phytomedicine drug development process 
The current phytodrug development process has introduced gaps and lapses that are 
unfavourable to botanical – drug interaction studies as an integrated step. The argument 
often is concerning the usefulness of such studies especially where these products have been 
used therapeutically for centuries without such information. The World Health 
Organization promotes drug development from traditional medicines partly due to the 
saving in time and cost that makes the products affordable and accessible, leading to 
cheaper and cost-effective primary healthcare it offers its teeming population of users. The 
fast tracking is based on the assumption that the substantial experience from the long 
history of human use increases the chances that a remedy will be effective and safe, and that 
precautions will be known. Conventional drug development is slow and expensive and 
often the finished products are unavailable and unaffordable to resource-limited countries, 
unless when made available by donors from high-income countries, under heavily 
subsidized schemes (50). For most phytomedicines, drug development from complimentary 
and alternative medicines usually follows a “reverse pharmacology” approach (51, 52). 
The first step is to select a remedy for development, through a retrospective treatment-
outcome study or an ethnobotanical survey to identify medicinal plants used in the 
treatment of target disease conditions. This step usually will yield insufficient clinical 
information but is often a good guide to identification of plants and remedies for a given 
ailment (53, 54). This is because the traditional medicine practitioners often do not have 
enough records as regards observed patient status as well as progress and treatment 
outcome and their perception of the efficacy and limitations of their remedies is subjective. 
Generally also their ability to accurately diagnose a disease condition may be inadequate 
because a lot of similar symptoms which may present in entirely different disease conditions 
may be treated with the same remedy. Thus often times, same remedies are employed in the 
treatment of ‘fevers’, ‘stomach pains’, et cetera. Therefore a lot of the information collected 
at this stage is largely vague, needing evidence-driven scientific evaluation.  
The second step usually spins off the first. Following the analyses of the collated remedies, 
treatment claims and subsequent plants identification, two essential elements are added to 
the ethnobotanical survey by performing an organized treatment of a fairly large sample 
size, aimed at generating clinical information and evidence of efficacy in the presentation 
and progress of an episode of the target disease and statistically correlating treatment with 
reported clinical recovery as the marker of effectiveness. 
Step three involves further research on a selected candidate remedy, to determine the possible 
pharmacological basis for the therapeutic claim through bioassays. Also at this pre-clinical 
stage, standardization and characterization of raw materials, intermediates and extracts are 
commenced, to generate quality control specifications data and chemical finger printing and 
identification of markers that can be used for monitoring of batch - to – batch uniformity.  
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drugs mainly metabolized by CYPs, the prediction of drug interactions with herbs appears 
to be more difficult and complex (41). Predictability is complexed by factors mainly 
associated with the drug, and herb (active ingredients complex and not well characterised as 
well as poorly understood mechanisms of action). Every herbal product is a complex 
mixture of multiple secondary metabolites / constituents contained in a preparation 
regarded as one single active substance, even when the preparation is made from a single 
herb. Masimirembwa et al, using LC MS/MS analysis of six herbal extracts, observed peaks 
predictive of over 300 chemical species for each herb (42). Each constituent may have a 
different modulatory potential for the same enzyme and/or modulate a different enzyme. 
Potentially therefore, a herb may increase, reduce or not affect the effect of a co-
administered drug through a combination of simultaneous activities on the same drug 
target. The inhibition/induction of metabolic enzymes by herbal medicines may vary 
depending on the herb’s method of preparation (different extraction methods may yield 
different types and quantities of constituents from the same herb). In the work of Gwaza et 
al, 2mg/ml methanolic extract of the African potato Hypoxis obtuse had greater inhibitory 
effects than same concentration of the water extract. Similar effect was also obtained with 
the extracts of Dicoma anomala (43). Dosing, route of administration, oral bioavailability of 
the product and other factors are equally confounding factors. 
Most often, herbal medicinal products are ingested in a chronic manner by its users, thus a 
predicted interaction outcome from a single exposure with a target conventional drug may 
be different in clinical situation. Other drug and patient related factors such as presence of 
extra-hepatic metabolism; and active transport in liver, age, disease, renal and hepatic 
functions and genetic polymorphisms are as for conventional drugs and all contribute to the 
final outcome of drug interaction with herbal medicines. A pharmacological basis of 
qualitative prediction may be on the ‘rule of thumb’ simply by comparing the biological 
effects of the drugs that is, if both products are expected to give similar response, then a 
potentiation of effect may be expected and vice versa. Also if a drug is a substrate for 
CYP3A4 and P-gp, its potential for interaction with herbal medicines would be high. 
3.2 Lack of consistency in the quality of herbal medicinal products 
In a study of 81 published studies on randomized controlled trials of herbal drug 
interactions, only 15% reported performing tests to quantify actual contents of the herbal 
supplements used in the studies (43). There are reports of disparity in content of 
constituents among different brands of echinacea, ginseng, St John’s Wort and of particular 
concern is the fact that inconsistency is also observed even within the same product and 
same batch (45). Conflicting results of studies of the effect of St John's wort on CYP3A4 are 
evident. While three enzyme marker studies indicated a potent inducing effect of St John's 
wort (300 mg three times daily × 14 days) on CYP3A4 activity (46, 47) two others found no 
effect (both 300 mg three times daily, one for 3 days (48), the other for 8 days (49) on 
CYP2D6 or 3A4 activities. Lack of batch-to-batch uniformity in the composition and quality 
of the herbal medicinal products used might explain the discrepancy. Most of these 
inconsistencies can be attributed to the fact that when compared with conventional drugs, 
herbal medicines present additional challenges related to quality; 
- No established methods to establish the quality of herbal medicines 
- Lack of stringent methods for Batch - to - Batch controls 
- Susceptibility to environmental contamination  
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- Herbal medicines are prone to counterfeit practises 
- Quality of product prone to seasonal variation & regional source 
Thus, there is often great disparity in reported patient response to the use of same herbal 
medicinal product. The results from many of the published interaction studies therefore 
may be of little value, since the identity, purity, quality, strength, and composition of the 
supplements is not always confirmed. 
3.3 Lapses in the phytomedicine drug development process 
The current phytodrug development process has introduced gaps and lapses that are 
unfavourable to botanical – drug interaction studies as an integrated step. The argument 
often is concerning the usefulness of such studies especially where these products have been 
used therapeutically for centuries without such information. The World Health 
Organization promotes drug development from traditional medicines partly due to the 
saving in time and cost that makes the products affordable and accessible, leading to 
cheaper and cost-effective primary healthcare it offers its teeming population of users. The 
fast tracking is based on the assumption that the substantial experience from the long 
history of human use increases the chances that a remedy will be effective and safe, and that 
precautions will be known. Conventional drug development is slow and expensive and 
often the finished products are unavailable and unaffordable to resource-limited countries, 
unless when made available by donors from high-income countries, under heavily 
subsidized schemes (50). For most phytomedicines, drug development from complimentary 
and alternative medicines usually follows a “reverse pharmacology” approach (51, 52). 
The first step is to select a remedy for development, through a retrospective treatment-
outcome study or an ethnobotanical survey to identify medicinal plants used in the 
treatment of target disease conditions. This step usually will yield insufficient clinical 
information but is often a good guide to identification of plants and remedies for a given 
ailment (53, 54). This is because the traditional medicine practitioners often do not have 
enough records as regards observed patient status as well as progress and treatment 
outcome and their perception of the efficacy and limitations of their remedies is subjective. 
Generally also their ability to accurately diagnose a disease condition may be inadequate 
because a lot of similar symptoms which may present in entirely different disease conditions 
may be treated with the same remedy. Thus often times, same remedies are employed in the 
treatment of ‘fevers’, ‘stomach pains’, et cetera. Therefore a lot of the information collected 
at this stage is largely vague, needing evidence-driven scientific evaluation.  
The second step usually spins off the first. Following the analyses of the collated remedies, 
treatment claims and subsequent plants identification, two essential elements are added to 
the ethnobotanical survey by performing an organized treatment of a fairly large sample 
size, aimed at generating clinical information and evidence of efficacy in the presentation 
and progress of an episode of the target disease and statistically correlating treatment with 
reported clinical recovery as the marker of effectiveness. 
Step three involves further research on a selected candidate remedy, to determine the possible 
pharmacological basis for the therapeutic claim through bioassays. Also at this pre-clinical 
stage, standardization and characterization of raw materials, intermediates and extracts are 
commenced, to generate quality control specifications data and chemical finger printing and 
identification of markers that can be used for monitoring of batch - to – batch uniformity.  
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The last step is clinical studies, usually involving a dose optimization observational study 
that will help select the safest and most efficacious dose through a dose-response 
phenomenon and finally a randomized controlled trial to compare the phytomedicine to the 
gold standard treatment for the target disease is conducted. 
This ‘short – cut’ approach facilitates the production of standardized phytomedicines faster 
and more cheaply than conventional drugs. In recent times, advances in this drug 
development strategy employs great efforts in standardization of mono- and multi- 
component phyto-preparations using all available high-tech methods, screening of extracts 
and their constituents by integration of modern molecular biological bioassays and controlled 
clinical studies, aimed at evidence based phytotherapy. However, it is still deficient in 
pertinent steps that involve systematic studies in the systemic effect of the phytomedicines 
inclusive of pharmacokinetic, bioavailability and drug interaction investigations.  
For any medicine, efficacy and safety are the major issues thus before proceeding to clinical 
studies, it is important to establish that the remedy is safe. Safety of medicines in 
comprehensive sense would consist of not just the absence of toxicity but also the ability to 
use it effectively in a manner that avoids adverse reactions, therapeutic failure, minimizing 
risk-benefit ratio associated with its use while promoting rational drug use. WHO 
guidelines state that: “If the product has been traditionally used without demonstrated 
harm, no specific restrictive regulatory action should be undertaken unless new evidence 
demands a revised risk-benefit assessment.” The guideline relies heavily on evidence of 
traditional use or recent clinical experience as sufficient proof for safety (55, 56) and also 
arguing that often times, the same plants are traditionally used both as a food and as a 
medicine and no toxicological tests are required for foods, which are usually consumed in 
greater quantities than medicines (57). This may not be sufficient reason to de-emphasis 
detailed safety studies for herbal medicinal products because, one may argue that most 
often herbs are used as spices and condiments in foods at smaller quantities than when used 
as medicines, meaning that they will be consumed in smaller quantities as foods than as 
medicines. The differences in dosing can introduce variation in an observed response. For 
example, Zingiber officinale has been used and tested as an antinauseant and antispasmodic 
agent with very good results (58). Ginger has been shown to be a potent inhibitor of 
thromboxane synthetase and thus prolongs bleeding time and persons taking warfarin or 
other drugs that affect platelet activity have been advised to refrain from taking ginger in 
tablet form (59). Using ginger as a spice does not give same effect. Therefore, even when 
preliminary field studies show that a herbal medicinal preparation is of common and 
ancient use, with no known important side effects, to avoid or minimize toxic drug–herb 
interactions, it is important to identify the interaction potential of such herb(s) using proper 
in vitro and in vivo models in the early stages of drug development. The essence is to obtain 
enough information that may be useful for providing warning and proper advice to patients 
in clinical practice and improve the safe utilization of the herb. 
In the past, the focus to address the above issues has been on scientific standardization and 
appropriate regulatory controls in the manufacture of phytomedicines in the following areas: 
- application of all available modern, high-tech methods to standardize phytopreparations 
before conducting systematic pharmacological investigations and clinical studies 
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- using new molecular biological assays for screening of extracts and plant constituents to 
evaluate their exact pharmacological profiles, to elucidate the pharmacological basis of the 
claimed actions of the constituents of an extract and bioassay guided fractions thereby gain a 
better understanding of the various mechanisms underlying these pharmacological effects 
- controlled clinical studies paralleled by pharmacokinetic and bioavailability studies (60). 
However in addition, we propose one more research focus in the area of; 
- incorporation of conventional principles in studies addressing additional safety 
concerns such as herb-drug interaction for the clinical use of herbal medicines, early in 
the drug development process 
3.4 Poor knowledge of pharmacokinetics of botanicals 
There is limited information on the pharmacokinetics of herbal medicines even though their 
use either alone or in addition to conventional drugs is increasing. One of the major reasons 
is that for most of these multicomponent mixtures, their active ingredient(s) are not known. 
In addition, there is the difficulty of measuring the quantities of the actives in systemic 
circulation due to very low concentrations, arising from the very small amount per dose in 
the final product. These challenges have lead to the situation that most herb – drug 
interaction studies and case reports in literature only evaluate the outcome of adding a 
herbal medicinal product to an existing conventional drug therapy and monitoring changes 
in pharmacokinetics and/or clinical response of the orthodox drug. The reverse is rarely the 
case. Therefore, a better understanding of the pharmacokinetics of herbal medicines is 
needed to support the predictability of botanical – drug interactions. Giant strides in the 
availability of specific high-tech analytical methods and equipment has resulted to the fact 
that complex extracts and phytopreparations can be analyzed today, to quantify the major 
active compounds, which are supposed to be responsible for the efficacy of an extract. The 
effectiveness of these modern tools and processes has been illustrated in several reports (61). 
Also, they meet the quality standards of drug authorities with high reproducibility of 
pharmacological studies subjected to good clinical practice (GCP) and conform to clinical 
trials requirements (62).  
4. Mechanisms of herbal-drug interactions 
Basically, the same principles and mechanisms responsible for drug-drug interactions are 
still involved in interactions between phytomedicines and drugs, resulting in 
pharmacokinetic and pharmacodynamic interactions. Herbal medicinal products or 
botanicals share the same metabolic and transport proteins, including cytochrome P450 
enzymes (CYP), glucuronosyltransferases (UGTs), and P-glycoprotein (Pgp), with over-the-
counter and prescription medicines increasing the likelihood of drug—botanical 
interactions. In other words, herbal products can interact with drugs by affecting the 
biological processes that regulate their metabolism and elimination.  
The family of enzymes known as the cytochrome P450s (CYPs) are involved in 75% of drug 
metabolism. These monooxygenase enzymes are located mainly in intestinal and liver cells 
and catalyzes several phase I metabolic processes of many prescription drugs. Of its many 
subtypes, CYP3A4 is one of the most important, being responsible for about 50% of CYP450 
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The last step is clinical studies, usually involving a dose optimization observational study 
that will help select the safest and most efficacious dose through a dose-response 
phenomenon and finally a randomized controlled trial to compare the phytomedicine to the 
gold standard treatment for the target disease is conducted. 
This ‘short – cut’ approach facilitates the production of standardized phytomedicines faster 
and more cheaply than conventional drugs. In recent times, advances in this drug 
development strategy employs great efforts in standardization of mono- and multi- 
component phyto-preparations using all available high-tech methods, screening of extracts 
and their constituents by integration of modern molecular biological bioassays and controlled 
clinical studies, aimed at evidence based phytotherapy. However, it is still deficient in 
pertinent steps that involve systematic studies in the systemic effect of the phytomedicines 
inclusive of pharmacokinetic, bioavailability and drug interaction investigations.  
For any medicine, efficacy and safety are the major issues thus before proceeding to clinical 
studies, it is important to establish that the remedy is safe. Safety of medicines in 
comprehensive sense would consist of not just the absence of toxicity but also the ability to 
use it effectively in a manner that avoids adverse reactions, therapeutic failure, minimizing 
risk-benefit ratio associated with its use while promoting rational drug use. WHO 
guidelines state that: “If the product has been traditionally used without demonstrated 
harm, no specific restrictive regulatory action should be undertaken unless new evidence 
demands a revised risk-benefit assessment.” The guideline relies heavily on evidence of 
traditional use or recent clinical experience as sufficient proof for safety (55, 56) and also 
arguing that often times, the same plants are traditionally used both as a food and as a 
medicine and no toxicological tests are required for foods, which are usually consumed in 
greater quantities than medicines (57). This may not be sufficient reason to de-emphasis 
detailed safety studies for herbal medicinal products because, one may argue that most 
often herbs are used as spices and condiments in foods at smaller quantities than when used 
as medicines, meaning that they will be consumed in smaller quantities as foods than as 
medicines. The differences in dosing can introduce variation in an observed response. For 
example, Zingiber officinale has been used and tested as an antinauseant and antispasmodic 
agent with very good results (58). Ginger has been shown to be a potent inhibitor of 
thromboxane synthetase and thus prolongs bleeding time and persons taking warfarin or 
other drugs that affect platelet activity have been advised to refrain from taking ginger in 
tablet form (59). Using ginger as a spice does not give same effect. Therefore, even when 
preliminary field studies show that a herbal medicinal preparation is of common and 
ancient use, with no known important side effects, to avoid or minimize toxic drug–herb 
interactions, it is important to identify the interaction potential of such herb(s) using proper 
in vitro and in vivo models in the early stages of drug development. The essence is to obtain 
enough information that may be useful for providing warning and proper advice to patients 
in clinical practice and improve the safe utilization of the herb. 
In the past, the focus to address the above issues has been on scientific standardization and 
appropriate regulatory controls in the manufacture of phytomedicines in the following areas: 
- application of all available modern, high-tech methods to standardize phytopreparations 
before conducting systematic pharmacological investigations and clinical studies 
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- using new molecular biological assays for screening of extracts and plant constituents to 
evaluate their exact pharmacological profiles, to elucidate the pharmacological basis of the 
claimed actions of the constituents of an extract and bioassay guided fractions thereby gain a 
better understanding of the various mechanisms underlying these pharmacological effects 
- controlled clinical studies paralleled by pharmacokinetic and bioavailability studies (60). 
However in addition, we propose one more research focus in the area of; 
- incorporation of conventional principles in studies addressing additional safety 
concerns such as herb-drug interaction for the clinical use of herbal medicines, early in 
the drug development process 
3.4 Poor knowledge of pharmacokinetics of botanicals 
There is limited information on the pharmacokinetics of herbal medicines even though their 
use either alone or in addition to conventional drugs is increasing. One of the major reasons 
is that for most of these multicomponent mixtures, their active ingredient(s) are not known. 
In addition, there is the difficulty of measuring the quantities of the actives in systemic 
circulation due to very low concentrations, arising from the very small amount per dose in 
the final product. These challenges have lead to the situation that most herb – drug 
interaction studies and case reports in literature only evaluate the outcome of adding a 
herbal medicinal product to an existing conventional drug therapy and monitoring changes 
in pharmacokinetics and/or clinical response of the orthodox drug. The reverse is rarely the 
case. Therefore, a better understanding of the pharmacokinetics of herbal medicines is 
needed to support the predictability of botanical – drug interactions. Giant strides in the 
availability of specific high-tech analytical methods and equipment has resulted to the fact 
that complex extracts and phytopreparations can be analyzed today, to quantify the major 
active compounds, which are supposed to be responsible for the efficacy of an extract. The 
effectiveness of these modern tools and processes has been illustrated in several reports (61). 
Also, they meet the quality standards of drug authorities with high reproducibility of 
pharmacological studies subjected to good clinical practice (GCP) and conform to clinical 
trials requirements (62).  
4. Mechanisms of herbal-drug interactions 
Basically, the same principles and mechanisms responsible for drug-drug interactions are 
still involved in interactions between phytomedicines and drugs, resulting in 
pharmacokinetic and pharmacodynamic interactions. Herbal medicinal products or 
botanicals share the same metabolic and transport proteins, including cytochrome P450 
enzymes (CYP), glucuronosyltransferases (UGTs), and P-glycoprotein (Pgp), with over-the-
counter and prescription medicines increasing the likelihood of drug—botanical 
interactions. In other words, herbal products can interact with drugs by affecting the 
biological processes that regulate their metabolism and elimination.  
The family of enzymes known as the cytochrome P450s (CYPs) are involved in 75% of drug 
metabolism. These monooxygenase enzymes are located mainly in intestinal and liver cells 
and catalyzes several phase I metabolic processes of many prescription drugs. Of its many 
subtypes, CYP3A4 is one of the most important, being responsible for about 50% of CYP450 
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– mediated metabolism. Thus natural products interfering with actions and/or quantities of 
CYP3A4 have the potential to affect a high percentage of drugs to variable extents. One way 
that a natural product can alter the action of an enzyme is to modulate by up or down 
regulating it. Also precipitators may affect bioavailability by modulating absorption or first 
pass metabolism, altered protein binding, or pharmacological effect. Interactions between 




Fig. 1. Possible mechanisms for drug interactions with combined herbal medicines. (ref 63) 
Pharmacodynamic interactions can occur when a herbal product produces additive, 
synergistic, or antagonist activity in relation to the conventional drug with no change in the 
plasma concentration of either herbal product or drug. Such interactions are related to the 
pharmacological activity of the interacting agents and can affect organ systems, receptor 
sites, or enzymes. A pharmacodynamic interaction may occur when herbals that possess 
antiplatelet activity are administered with antiplatelet/ anticoagulant drugs, thus increasing 
the risk for bleeding. When Kava, a herbal that depresses the central nervous system (CNS) 
was administered concomitantly with CNS depressant drug alprazolam, a semicomatose 
state was induced (64). When a sedative botanical like valerian is co-administered with 
diazepam or other such sleep inducing agents, a potentiation of sleeping effect could occur. 
In addition, herbals with the potential to cause organ toxicity may cause further risk of 
toxicity when drugs with similar toxicity are administered concurrently, such as when the 
hepatotoxic herbal comfrey is given with large and prolonged doses of acetaminophen (65). 
An example of an antagonistic interaction is when an herbal with high caffeine content, such 
as guarana, is administered with a sedative-hypnotic.  
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In pharmacokinetic interactions on the other hand, the herbal changes the absorption, 
distribution, metabolism, protein binding, or excretion of a drug which results in altered levels 
of the drug or its metabolites. The resultant alterations caused by the combination of drugs 
may or may not alter the dose-response relationship despite the change in the plasma levels 
and /or drug disposition profile of the drugs because an observable pharmacodynamic change 
will depend on the degree of change in systemic concentration. 
Absorption. Absorption of drugs can be impaired when herbs that contain hydrocolloidal 
fibers, gums, and mucilage are taken together. Examples of such herbs include psyllium, 
rhubarb, flaxseed, marshmallow and aloe gel. These herbals can bind to drugs preventing 
their absorption and, subsequently, reduce systemic availability of the compounds. Psyllium 
a herb with high content of mucilage, used in the treatment of constipation, inhibits the 
absorption of lithium (66). Herbal laxatives such as aloe latex, buckthorn, cascara sagrada, 
rhubarb, and senna can cause loss of fluids and potassium and can potentially increase the 
risk of toxicity with digoxin (67) as well as reduction in the action of drugs that have a 
narrow therapeutic index (eg, digoxin, warfarin) due to the diarrhea (68). 
Distribution. Salicylates can displace highly protein-bound drugs such as warfarin and 
carbamazepine from plasma proteins thereby increasing the adverse/toxic effects of the 
drugs. Meadowsweet and black willow herbs contain salicylates and can potentially interact 
with such drugs (69). Potential pharmacokinetic interactions can occur with displacement of 
a drug from protein binding sites. Drug displacement of highly protein-bound drugs by 
another compound may result in increased activity of the displaced drug. Although 
displacement of protein-bound drugs has been described as a mechanism for potential drug 
interactions, there are no documented reports of herbal-drug interactions attributable to 
displacement of drugs from protein-binding sites.  
Metabolism. Licorice when used as an herb, not a sweetener decreases the metabolism of 
corticosteroids and the anticoagulant action of warfarin is enhanced by ginkgo and possibly 
by many other herbs (70). Change in renal clearance of a drug is another potential 
mechanism for producing herbal-drug interactions. Herbals that can inhibit tubular uptake 
or in other ways that can interfere with the renal clearance of a drug should be considered as 
having potential to produce pharmacokinetic herbal drug interactions (71). 
Two important processes involved in drug disposition in man have been implicated in most 
of the current evidence of herbal-drug interactions. Several of the documented herb-drug 
interactions are pharmacokinetic in nature, involving metabolizing enzymes related to 
oxidative metabolism by the cytochrome P-450 system (CYP) and / or the efflux drug 
transporter Pglycoprotein, with fewer evidence of the involvement of other enzymes such as 
glutathione S-transferases and uridine diphosphoglucuronyl transfereases (UGTs) and more 
than half of all medications undergo metabolism by CYP3A4 substrates (72). Besides 
CYP3A4 which has been shown to be involved in most herbal – drug interactions, other CYP 
isoenzymes, which have been found to be involved in significant pharmacokinetic reactions 
in humans, include CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E. Because some herbals 
and various drugs may be substrates of the same CYP isoenzyme, either of them may inhibit 
or induce the activity of the enzyme when ingested concomitantly, the choice of which is 
dependent on the enzyme –substrate affinity and concentration among other factors.  
The other important system that significantly contributes to drug disposition in human is 
the P-glycoprotein drug transporter. It is a glycoprotein encoded by the MDR1 gene and 
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– mediated metabolism. Thus natural products interfering with actions and/or quantities of 
CYP3A4 have the potential to affect a high percentage of drugs to variable extents. One way 
that a natural product can alter the action of an enzyme is to modulate by up or down 
regulating it. Also precipitators may affect bioavailability by modulating absorption or first 
pass metabolism, altered protein binding, or pharmacological effect. Interactions between 




Fig. 1. Possible mechanisms for drug interactions with combined herbal medicines. (ref 63) 
Pharmacodynamic interactions can occur when a herbal product produces additive, 
synergistic, or antagonist activity in relation to the conventional drug with no change in the 
plasma concentration of either herbal product or drug. Such interactions are related to the 
pharmacological activity of the interacting agents and can affect organ systems, receptor 
sites, or enzymes. A pharmacodynamic interaction may occur when herbals that possess 
antiplatelet activity are administered with antiplatelet/ anticoagulant drugs, thus increasing 
the risk for bleeding. When Kava, a herbal that depresses the central nervous system (CNS) 
was administered concomitantly with CNS depressant drug alprazolam, a semicomatose 
state was induced (64). When a sedative botanical like valerian is co-administered with 
diazepam or other such sleep inducing agents, a potentiation of sleeping effect could occur. 
In addition, herbals with the potential to cause organ toxicity may cause further risk of 
toxicity when drugs with similar toxicity are administered concurrently, such as when the 
hepatotoxic herbal comfrey is given with large and prolonged doses of acetaminophen (65). 
An example of an antagonistic interaction is when an herbal with high caffeine content, such 
as guarana, is administered with a sedative-hypnotic.  
Pharmacokinetics and Drug Interactions of Herbal Medicines:  
A Missing Critical Step in the Phytomedicine/Drug Development Process 
 
139 
In pharmacokinetic interactions on the other hand, the herbal changes the absorption, 
distribution, metabolism, protein binding, or excretion of a drug which results in altered levels 
of the drug or its metabolites. The resultant alterations caused by the combination of drugs 
may or may not alter the dose-response relationship despite the change in the plasma levels 
and /or drug disposition profile of the drugs because an observable pharmacodynamic change 
will depend on the degree of change in systemic concentration. 
Absorption. Absorption of drugs can be impaired when herbs that contain hydrocolloidal 
fibers, gums, and mucilage are taken together. Examples of such herbs include psyllium, 
rhubarb, flaxseed, marshmallow and aloe gel. These herbals can bind to drugs preventing 
their absorption and, subsequently, reduce systemic availability of the compounds. Psyllium 
a herb with high content of mucilage, used in the treatment of constipation, inhibits the 
absorption of lithium (66). Herbal laxatives such as aloe latex, buckthorn, cascara sagrada, 
rhubarb, and senna can cause loss of fluids and potassium and can potentially increase the 
risk of toxicity with digoxin (67) as well as reduction in the action of drugs that have a 
narrow therapeutic index (eg, digoxin, warfarin) due to the diarrhea (68). 
Distribution. Salicylates can displace highly protein-bound drugs such as warfarin and 
carbamazepine from plasma proteins thereby increasing the adverse/toxic effects of the 
drugs. Meadowsweet and black willow herbs contain salicylates and can potentially interact 
with such drugs (69). Potential pharmacokinetic interactions can occur with displacement of 
a drug from protein binding sites. Drug displacement of highly protein-bound drugs by 
another compound may result in increased activity of the displaced drug. Although 
displacement of protein-bound drugs has been described as a mechanism for potential drug 
interactions, there are no documented reports of herbal-drug interactions attributable to 
displacement of drugs from protein-binding sites.  
Metabolism. Licorice when used as an herb, not a sweetener decreases the metabolism of 
corticosteroids and the anticoagulant action of warfarin is enhanced by ginkgo and possibly 
by many other herbs (70). Change in renal clearance of a drug is another potential 
mechanism for producing herbal-drug interactions. Herbals that can inhibit tubular uptake 
or in other ways that can interfere with the renal clearance of a drug should be considered as 
having potential to produce pharmacokinetic herbal drug interactions (71). 
Two important processes involved in drug disposition in man have been implicated in most 
of the current evidence of herbal-drug interactions. Several of the documented herb-drug 
interactions are pharmacokinetic in nature, involving metabolizing enzymes related to 
oxidative metabolism by the cytochrome P-450 system (CYP) and / or the efflux drug 
transporter Pglycoprotein, with fewer evidence of the involvement of other enzymes such as 
glutathione S-transferases and uridine diphosphoglucuronyl transfereases (UGTs) and more 
than half of all medications undergo metabolism by CYP3A4 substrates (72). Besides 
CYP3A4 which has been shown to be involved in most herbal – drug interactions, other CYP 
isoenzymes, which have been found to be involved in significant pharmacokinetic reactions 
in humans, include CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E. Because some herbals 
and various drugs may be substrates of the same CYP isoenzyme, either of them may inhibit 
or induce the activity of the enzyme when ingested concomitantly, the choice of which is 
dependent on the enzyme –substrate affinity and concentration among other factors.  
The other important system that significantly contributes to drug disposition in human is 
the P-glycoprotein drug transporter. It is a glycoprotein encoded by the MDR1 gene and 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
140 
functions as a transmembrane efflux transporter that pumps drugs out of cells as they try to 
get into the intestinal wall from the gut lumen where they again become available for 
oxidative elimination from the body. They are found mainly in organs responsible for drug 
absorption or elimination, such as the intestine, liver, and kidneys and also present in many 
tissues. This drug efflux therefore limits the rate and extent of drug absorption from the 
intestinal tract. Altered expression or activity of several drug transporters and drug-
metabolizing enzymes can lead to lower therapeutic efficacy or greater toxicity. The P-
glycoprotein has high transport capacity and broad substrate specificity thus it can transport 
a wide number of clinically relevant drugs with structurally different features and 
belonging to different classes such as several anticancer drugs, some HIV protease 
inhibitors, H2 receptor antagonists, antiarrhythmics—(cardiac glycosides and calcium 
channel blockers), immunosuppressive immunosuppressive agents, corticosteroids, 
antiemetic and antidiarrheal agents, analgesics, antibiotics, anthelmintics, antiepileptics, 
sedatives, antidepressants. 
Drugs that are substrates of CYP3A4 often affect P-glycoproteins as well (73), thus the 
interplay of both intestinal P-gp and CYP3A4 has a strong effect on the bioavailability of 
most orally administered drugs including proton pump inhibitors (PPIs), cyclosporine, 
midazolam, talinolol, statins, HIV protease inhibitors and verapamil (74, 75, 76). Therefore 
concomitant intake of herbal medicinal products that are P-gp and/or CYP3A4 substrates 
with othodox drugs has a higher potential for interaction. Studies have shown that in cancer 
therapy several anticancer drugs (such as vincristine, vinblastine, vinorelbine, irinotecan, 
etoposide, docetaxel, and paclitaxel), as well as certain supportive care agents concomitantly 
and commonly used by cancer patients, such as ondansetron, fentanyl, morphine, 
loperamide, and domperidone can modulate P-glycoprotein and/or CYP isoenzymes (77). 
Thus, the modulation of intestinal and hepatic Pgp and CYP enzymes by herbal medicines 
represents a potentially important mechanism by which the bioavailability of co-
administered drugs can be modulated.  
Inhibition or induction of metabolizing enzymes or drug transporters involved in the 
systemic disposition of drugs is the mechanism of most pharmacokinetic interactions 
elicited by herbs or their active constituents. Inhibition occurs when herb is able to decrease 
the normal activity level of a metabolic enzyme or drug transporter via a competitive or 
noncompetitive mechanism. Induction on the other hand is a much slower process 
involving gene regulation and expression. The herbal product activates increase in the 
mRNA leading to increased expression of the corresponding gene or drug transporter. 
Discontinuation of the precipitator usually brings enzyme levels back to normal, making the 
process reversible. Induction of the enzymes involved in the metabolism and transport of 
chemotherapeutic drugs irinotecan or imatinib is responsible for the lower plasma levels 
observed when each is concurrently administered with St John’s Wort (78, 79). On the other 
hand, inhibition of CYP3A4 by grapefruit juice was responsible for the increase in plasma 
levels of felodipine when a 5mg tablet was taken with the juice (80). Some botanicals that 
actively inhibit CYP enzymes include evening primrose oil, kava, garlic, Ginkgo biloba, 
Echinacea purpurea, milk thistle, while Pgp activity was shown to be inhibited by curcumin, , 
piperine, green tea, quercetin, and silymarin (81 - 83). Ginseng and ginsenosides inhibit both 
CYP enzyme and Pgp. 
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In a broad sense, the mechanisms behind induction of metabolizing enzymes will include 
processes that involve enhanced translational efficiency, increased gene transcription rates, 
improved enzyme stability and ligand binding / other enzyme-related actions. However, the 
most commonly encountered is that involving the activation of certain nuclear receptors in man. 
This mechanism has been further elucidated, giving rise to new possibilities for the identification 
of herbal preparations capable of causing induction because the mechanistic knowledge about 
induction processes can be an aid in the prediction of clinically relevant interactions.  
Pregnane X receptor (PXR), the constitutive androstane receptor (CAR), and the vitamin D-
binding receptor (VDR) are nuclear receptors that have been identified to be involved in the 
induction of metabolizing enzymes and some drug transporters. After activation by 
endogenous or exogenous ligands, these receptors form heterodimers with the 9-cis retinoic 
acid receptor (RXR) and bind to xenobiotic response elements in the target genes (84). 
Because of this, the transcription of the target genes is increased, leading to detoxification 
and elimination of xenobiotics. 
PXR, is one of the main transcriptional regulators of CYP3A4 and Pgp, while possessing 
some transcriptional control over CYP2B6, CYP2C9, sulfotransferase (SULT), UGT1A1, 
glutathione S-transferases (GST), and MRP-2. Studies have shown that the activation of PXR 
is one of the main mechanisms behind induction of metabolizing enzymes and drug 
transporters by herbal medicines (85). The inductive capacity of SJW is mediated via this 
mechanism. Hyperforin, a bioactive constituent in St John’s wort, forms a complex with the 
ligand-binding domain of human PXR thereby activating the PXR and consequently 
inducing CYP3A4 and CYP2C9 expression (86, 87). Studies using gene reporter assays or 
measuring mRNA levels of CYP3A4 in human hepatocytes have also shown that gugulipid, 
or its chemical constituents guggulsterones, derived from the Mukul myrrh tree, hops, two 
traditional Chinese medicines (TCMs), Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao 
(Glycyrrhiza uralensis Fisch), and their selective constituents, carotenoids, especially β-
carotene, and retinol have the potential to induce CYP3A4 by activation of PXR (88-90). 
Both P-gp and CYP3A4 are abundantly expressed in the villus tip of enterocytes and 
hepatocytes, correspondingly, both intestine and liver express significant concentrations of 
PXR. This is important because the transcriptional regulation of drug metabolizing enzymes 
is cell-mediated and tissue-selective, thus significant inductions will not be found in tissues 
that have low concentrations of the receptors and enzymes when in contact with the 
relevant ligands. Known ligands of human PXR include rifampicin, dexamethasone, 
clortrimazole, and paclitaxel and all are established inducers of CYP3A4 (91). 
Metabolizing enzymes are also induced to a lesser extent by other nuclear receptors such as 
CAR and VDR. CYP2B gene is the main target of CAR but the expression of other hepatic 
genes, such as UGT1A1 and CYP2C9 and MDR-1 is also modulated by this receptor (92, 93). 
VDR is the receptor responsible for modulating cytogenesis and cell death in response to 1α, 
25-dihydroxy vitamin D3 as the ligand. In addition, it also regulates CYP3A4, CYP2B6 and 
CYP2C9 (94). Though PXR has been shown to mainly regulate CYP3A4 expression while 
CAR regulates CYP2B expression, it is clear that one type of nuclear receptor has the ability to 
modulate the expression of several enzymes, meaning that the specificity is not absolute but 
rather there is some overlap in both the nuclear transcription function as well as the ligand-
binding capacity and the extent of induction will vary depending on the ligand, tissue 
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involved. Consequently, more than one enzyme modulated by different receptors may be 
responsible for an observed effect in a herb induced interaction. For example, PXR, CAR and 
the aryl hydrocarbon receptor (AhR) are all known to modulate the overall UGT1A1 response 
to flavonoids, though the AhR is mainly responsible for the UGT1A1 expression (95). 
In vitro screening for potential inhibition or induction of CYP enzymes by various herbals is 
gaining momentum (96), but data about the inductive capacity of herbal medicinal products 
and their interaction with nuclear receptors is scarce and mainly focused on PXR. However, 
with the discovery of the mechanistic processes involving nuclear receptors in the induction 
of metabolizing enzymes and drug transporters drug transporters, recent efforts to address 
these challenges are more optimistic. 
5. Investigating herb–drug interaction 
FDA requires that the extent of metabolism for all new drugs be defined, the CYP enzymes 
involved in the formation of its major metabolite be identified and their potency for enzyme 
inhibition evaluated. This is with a view to complying with the regulatory requirement that 
a warning towards such interactions be added in the product insert and label (97). Thus, in 
the discovery of conventional drugs, new chemical entities (NCEs) are tested for inhibitory 
effects on CYP3A4, potent inhibition is associated with a potential for drug-drug 
interactions. Similarly, there is a need to identify the potentials for herbal medicinal 
products to interact with drugs in the early stages of drug development using proper in 
vitro and in vivo models, so as to improve their safe use in clinical practice. 
 
 
(2) Is Investigational New Drug an interacting entity?
No in vivo study required.
No further in vivo studies required
(1) Conduct in vivo studies with most sensitive/specific 
substrate(s) 
(2( Is there a significant interaction?
Consider: (1) Can potential for in vivo interaction be predicted from 
available  in vitro data? (2)Conduct in vivo studies with other 
substrates selected based on likely co-administration and/or narrow 
therapeutic range or if appropriate, apply mechanistic modeling (3)  
Dose adjustment  (4)  Other drug interaction evaluations needed for 
safe administration of the drug.
(1) Conduct in vitro metabolism and drug-drug interaction 






Fig. 2. Simplified schematic representation of the FDA recommended approach to 
evaluating Investigational New Drugs for possible drug-drug interactions (DDIs). 
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Although there are challenges of content of numerous constituents of unknown 
pharmacokinetics and pharmacology inherent in herbal agents that limit the application of 
methods used in screening conventional drugs, several of these methods can be adapted for 
determining whether a phytomedicine will affect metabolic enzymes and drug transporter 
systems thereby deduce its interaction potential. For example, an inhibition study can be 
adapted from the FDA guidance document on drug /drug interaction as shown in figure 3.  
 
 
Fig. 3. Schematic representation on how to employ CYP inhibition at different stages of drug 
development process 
 
Likelihood Ki (µM) I/Ki 
Probable <1 >1 
Possible 1<Ki<50 0.1<1/Ki<1 
Unlikely >50 <0.1 
Table 3. Inhibition studies Interpretation: Potential for in vivo inhibition.  
Compounds with Ki< 1µM are generally predicted to cause drug / drug interaction hence in 
vivo studies recommended. Hyperforin one of the constituents of St John’s wort, purpoted 
to be the active constituent and the most potent agonist of PXR, has a Ki of 27nM (98).  
In vitro models generally use subcellular fractions of human liver tissues, whole-cell models 
of isolated human hepatocytes, liver slices, or human cell lines (99). Changes in the activity 
or concentration of enzymes or transporters can be demonstrated through use of selective 
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chemical inhibitors of specific CYP enzymes or transporter systems. For metabolic studies, 
the major models usually are subcellular fractions (liver microsomes, cytosols and 
homogenates), precision-cut liver slices, isolated and cultured hepatocytes or liver cell lines, 
and cDNA-expressed enzymes while human gastrointestinal absorption and cancer cell 
lines, as well as membrane vesicles and cDNA expressed drug transporters are widely used 
for transport studies (100, 101). 
High throughput screening has been successfully adapted to the study of drug–herb, 
herb–CYP and herb/P–gp interactions (102). This has an advantage that a large number  
of herbs, their bioactive fractions and constituents can be screened at the same time in a 
multiple well plate (see figure 4), thereby providing in vitro inhibition data as a criterion 
for further investigation. This method has been used in our laboratories to study in  
vitro, inhibition studies involving the inhibition of CYP-specific marker reactions by test 
herbal medicinal products. These phytomedicines are being developed for use in the 
treatment and management of malaria, HIV infection, diabetes and sickle cell disease 
respectively. 
The products were investigated at two concentrations for CYP-specific marker reactions 
using recombinant CYP3A4 and fluorescent based marker reactions. Inhibition of the CYP 
activity by more than 20% was considered significant and in such cases, the IC50 (the 
concentration of product bringing about 50% inhibition of enzyme activity) value was 
determined. All the products had inhibition greater than 50%, some comparable to the 
troleandomycin, a known inhibitor of CYP3A4. Their IC50 ranged from 0.004 – 0.060mg/ml 
and was compared with that of ketoconazole, a potent inhibitor of CYP3A4 with an IC50 of 
0.016mg/ml (Obodozie et al, unpublished data). 
 

















Fig. 4. Design of HTS for CYP Inhibition (ref. 102) 
The IC50 curves for four of the five products and control inhibitor is shown in figures 5a – 5e  
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Fig. 5. (a – e): IC50 Curves for some natural products and control inhibitor. [a] M1=AM-1 
extract from Nauclea latifolia, [b] SAN=NIPRISAN [c] D1F= Fraction component of the 
extract of Vernonia amygdalina and [d] HI=extract Andrographis paniculata 
If absorbed, these products are predicted to result in significant clinical drug-herb 
interactions. Therefore further in vivo studies are necessary as recommended by FDA 
approach (see figure 2). 
Other in vitro methods involve the use of in silico methods to determine the interactions 
potential of CYPs, Phase II enzymes, P-gp with botanicals, often by the use of rule-based 
modelling, and structure–activity relationships (103, 104).  
Often times, to obtain enough information that is useful for a test herbal product in 
evaluating how the herb may affect CYPs and P-gp, various methods may be used in 
combination. For example, in an in vitro study performed to investigate the inductive 
properties of several flavonoids, including quercetin, resveratrol, and curcumin to activate 
nuclear receptors and to induce metabolizing enzymes using primary cultures of human 
hepatocytes of 17 individuals, it was found that only quercetin led to an increase in the 
quantity of CYP3A4 mRNA. To further elucidate the involvement of PXR, a reporter gene 
assay with hPXR was used. Quercetin did not show a significant increase in luciferase 
activity, suggesting that CYP3A4 was induced by mechanisms not involving PXR (105). 
Kava-kava also increases CYP3A4 mRNA levels in hepatocytes with enhanced luciferase 
activity, others like grapeseed extract, ginseng and garlic stimulates only CYP3A4 mRNA 
without increasing luciferase activity indicating that that the induction CYP3A4 by some 
herbs may not always be mediated via PXR.  
Each of these models has very different cost, reliability, advantages and limitations. For 
example, some models will maintain the structure and integrity of isolates and cellular 
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hepatocytes of 17 individuals, it was found that only quercetin led to an increase in the 
quantity of CYP3A4 mRNA. To further elucidate the involvement of PXR, a reporter gene 
assay with hPXR was used. Quercetin did not show a significant increase in luciferase 
activity, suggesting that CYP3A4 was induced by mechanisms not involving PXR (105). 
Kava-kava also increases CYP3A4 mRNA levels in hepatocytes with enhanced luciferase 
activity, others like grapeseed extract, ginseng and garlic stimulates only CYP3A4 mRNA 
without increasing luciferase activity indicating that that the induction CYP3A4 by some 
herbs may not always be mediated via PXR.  
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cultures with a loss in quality and quantity of the target enzymes. Thus they may be useful 
for the study of Phase I and II reactions (106, 107) but not suitable for inhibition and 
transport studies (108) due to the rapid down regulation of certain enzymes and 
transporters which occurs after isolation of hepatocytes. Primary liver cell cultures have 
been used for a long time to study inductive potentials of products but its major set back is 
the availability, quality and inter-individual variation of human liver tissue and the fact that 
it can only give information about the inductive capacity and not about the nuclear receptor 
involved. The development of reporter gene assays has reduced some of the challenges 
associated with the use of human liver tissue. 
Making decisions on whether an herbal-drug interaction occurs based on data from in vitro 
or animal test models is inadequate. When drug interactions with a herbal medicinal 
product is suspected to be likely based on in vitro results or significant in animal studies, 
they should be confirmed with further well conducted in vivo studies and in human to 
validate the clinical significance. Such studies are needed because most often in vitro assays 
do not necessarily correlate with in vivo and human metabolism. This is most important for 
herbal medicines which usually contain multiple constituents because the entity that is 
precipitating enzyme modulation in vitro may not be systemically available due to 
instability in the GIT, unabsorbed or is inactive prodrug. 
As reported earlier, the in vitro studies using rCYP3A4 and paracetamol as the substrate 
showed AM-1as a potent inhibitor of the enzyme indicating that an increase in paracetamol 
(acetaminophen) blood levels will be likely if both drugs are co-administered. However, 
further in vivo studies in human volunteers showed reduction in AUC of paracetamol when 
both products were concurrently administered (31). Grapefruit juice, a potent inhibitor of 
intestinal CYP3A4 precipitated lower AUC of etoposide when both were taken 
concomittantly orally in humans, contrary to the expected increase in oral bioavailability of 
the CYP3A4 substrate. The involvement of another mechanism, possibly an inductive effect 
of grapefruit juice on Pgp-mediated transport of etoposide may have been responsible for 
this lower AUC (109). Another example is the use of in vitro preparations of liver 
microsomes to predict drug interaction potentials. These results may not agree with in vivo 
studies because human liver microsomes are not able to predict enzyme induction due to 
inability of microsomal preparations to synthesize new proteins thus may not give an 
indication of potential induction in vivo.  An example of this is the case of St John’s Wort 
which has been shown to induce both CYP3A4 through an action on PXR in vivo, as well as 
Pgp and CYP2C19 but in vitro, it inhibits CYP2D6, CYP 2C9 and CYP3A4 (110, 111). 
Animal models are widely used for the evaluation of drug–herb interactions. Such models 
include the use of wistar rats, rabbits, mice, transgenic mice et cetera. Caution should be 
exercised in the interpretation and extrapolation of in vivo results obtained from animal 
models to humans because the species differences in nuclear receptors and inductive 
processes make extrapolation difficult. Also there are observed species differences in the 
ligand-binding domains (LBDs), especially in the LBD of PXR of wild-type laboratory 
animals that may produce discrepancies between in vivo animal and human study data. The 
report by Bakare-Odunola et al (112), showed that metronidazole pharmacokinetic 
parameters were significantly altered by concomitant administration of the antimalaria 
phytomedicine AM-1, such that AUC and maximum serum concentration were increased by 
over 100% and Vd and Cl were similarly reduced in rats, another study showed no 
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significant alteration in the oral bioavailability of the same drugs when concurrently 
administered to healthy human volunteers (113). 
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Fig. 6. (a – b): (a) Serum concentration-time curve of metronidazole in human volunteers 
following oral administration of two tablets of 200mg metronidazole (flagyl®) alone and 
after concurrent administration with 400mg AM1 (b) Serum concentration-time curve of 
metronidazole in rats following oral administration of 7.5mg/kg metronidazole alone and 
after co-administration with 16mg/kg NIPRD AM-1 
Not with standing, results from animal studies can also be source of useful information 
especially when human transgenic animals are used (114). 
Clinical studies on drug-herb interaction usually employ the use of human participants and 
most are designed to monitor pharmacokinetic interactions. The studies follow principally 
three basic designs, while the first and third give an idea of the involvement of specific 
enzyme in an interaction, the second provides general information on the effect of the herb 
on a target drug. Several well conducted clinical studies some popularly used botanicals 
demonstrate these methods. 
(I) The use of probe drugs that are known to be metabolized by specific enzymes and 
monitoring the change in AUC of the probe drug with and without the test herbal product. 
The effect of different herbal drugs on various metabolizing enzymes and transporters in 
humans have bee shown. Artemisinin was shown to be a potent inhibitor of CYP1A2 activity 
by decreasing the paraxanthine levels when co-administered with caffeine in humans (115). 
Citrusaurantium, Panaxginseng, Echinaceapurpurea, milk thistle, and saw palmetto extracts taken 
by healthy volunteers all had no effect on the activity of CYP3A4, CYP1A2, CYP2E1, and 
CYP3A4 measured using model substrates (116). Meanwhile the disposition profile of some 
substrates for other enzymes CYP3A4, CYP1A2, CYP2E1, and CYP2D6 were not affected by 
gingko when administered to healthy volunteers or elderly patients (117, 118). FDA 
recommended substrates for specific enzymes include Theophylline/caffeine for CYP 1A2, S-
warfarin/Lorstan for CYP 2C9, Desipramine for CYP2D6, mizodolam, buspirone, felodipine, 
simvastatin, lovarstatin for CYP3A4 while fexofenadine and digoxin are P-gp substrates. 
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significant alteration in the oral bioavailability of the same drugs when concurrently 
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(II) Administering the test herbal product with and without a target conventional drug and 
monitoring the change in pharmacokinetic profile of the latter. 
Mills et al have given a good review the effects of St John’s Wort on the pharmacokinetics of 
some conventional drugs (119). One of the renowned cases of herb – drug interaction is the 
effect of garlic preparations on the plasma concentrations of antiretroviral drugs saquinavir 
and ritonavir. The effect of garlic supplements on the pharmacokinetics of saquinavir was 
reported by Piscitelli et al. Garlic preparations decreased the mean AUC and the mean Cmax 
of saquinavir by 51% and 54% respectively (120), while not having effect on neither ritonavir 
concentrations nor the metabolism of acetaminophen in healthy volunteers (121, 122). 
Ritonavir is now known to be a CYP3A4 inhibitor, an effect that has prompted its use in 
antiretroviral therapy with positive therapeutic benefit in boosting (by inhibition of 
CYP3A4) other protease inhibitors and enhancing their bioavailability (saquinavir, 
lopinavir) as well as reducing hepatic clearance (indinavir, amprenavir, and atazanavir). 
Administering the test herbal without a target conventional drug or enzyme probe and 
monitoring the change in an enzyme activity marker before and after treatment. 
Omeprazole hydroxylation, a CYP2C19 mediated action was shown to be induced in 
healthy male subjects by Ginkgo biloba, one of the most widely used herbal products, 
indicating that the effect of omeprazole could be reduced with the concurrent adminstration 
of Gingko (123). The effect of P. Ginseng on the 6-B-hydroxycortisol to cortisol ratio, a 
marker of CYP3A4 activity was evaluated in twenty healthy human participants before and 
after a 14 day intake of 100mg of P. Ginseng standardized to contain 4% ginsennosides. The 
results suggested that there was no induction of CYP3A4 activity (124) 
6. Risk factors for herbal-drug interactions 
The risk of having an herbal-drug interaction is based on a variety of factors related to 
patient, dosing regimen, co-administered drug and herb, and not solely based on the 
pharmacologic and pharmacokinetic characteristics of the herbal. One important factor that 
increases the likelihood of having a herbal-drug interaction is concomitant use of a herbal 
product with drugs that have a narrow therapeutic index because while a doubling or more 
in drug plasma concentration has the potential for enhanced drug effects and/or 
appearance of adverse effects (125), less marked changes may still be clinically important for 
such drugs with steep concentration–response relationship. Drugs in this category include 
digoxin, antiepileptic drugs, antineoplastic agents, immunosuppressants and warfarin. 
Patient populations who are at increased risk for having herbal-drug interactions include 
the elderly, critical care patients, patients undergoing surgical procedures, patients with 
liver or renal disease, and patients receiving multiple medications. In most cases, the extent 
of drug interactions with herbs varies markedly among individuals, with gender and 
genetic polymorphism as additional factors for the inter-individual differences. 
In persons using herbal products chronically, hepatic and intestinal metabolism or drug 
transport may be affected by the same herb differently for the same substrate. In vitro data 
obtained in human hepatocyte cultures, showed that St John’s Wort a known CYP3A4 
inhibitor, can induce greater docetaxel metabolism in patients using the herb chronically 
(126). The oral bioavailability of midazolam after echinacea intake was significantly greater, 
while in contrast, multiple dosing of the same herb in volunteers for 8 days resulted in a 
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significantly lower AUC and 34% increase in systemic clearance of the drug (127). CYP3A4 
was inhibited by single dose administration of ritonavir, chronic administration resulted in 
an induction of same enzyme (128). Herb related factors that are risk factors in drug 
interactions with herbal medicinal product include species, dose, dosing regimen, and 
administration route (13) 
7. Conclusion 
The metabolism of a drug can be altered by another drug or foreign chemical, and such 
interactions can often be clinically significant. Cytochrome P450 (CYP) enzymes, a 
superfamily of enzymes found mainly in the liver, are involved in the metabolism of a 
plethora of xenobiotics and have been shown to be involved in numerous interactions 
between drugs and food, herbs and other drugs. The observed induction and inhibition of 
CYP enzymes by natural products in the presence of a prescribed drug has (among other 
reasons) led to the general acceptance that natural therapies can have adverse effects, 
contrary to the popular beliefs in countries where there is an active practice of 
ethnomedicine. Majority of the classes of conventional drugs have been shown to be affected 
by different types of botanical preparations leading to various consequencies, including 
treatment failure, adverse / toxic effects and even death. In order to improve the safety of 
ethnomedicines use alongside conventional therapies in public healthcare, it is necessary to 
understand how the former will interact with the latter, early in drug development. It is also 
necessary to predict early so as to eliminate regulatory obstacles and avoid market pressure 
for recalls that may have been induced by adverse effects linked to interactions. 
It is possible and highly recommended that the conventional industrial preclinical platform 
be used to evaluate herbal extracts for metabolism based drug-herb interactions, thereby 
incorporating such studies into drug development for phytomedicines. Although the 
presence of numerous active ingredients in herbal medicines, foods and dietary 
supplements complicate experimentation, the observable interactions with CYP enzymes 
warrant systematic studies, so that metabolism-based interactions can be predicted and 
avoided more readily. Over the years, there has been great advances in the availability of 
“high tech” tools, in vitro and in vivo study designs and analytical equipment that can be 
adapted for use in such studies. Pharmaceutical research must go beyond focusing on 
pharmacological efficacy of botanicals but also in studies that improve their effectiveness in 
order for humanity to fully benefit from their inherent therapeutic potentials. 
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It is possible and highly recommended that the conventional industrial preclinical platform 
be used to evaluate herbal extracts for metabolism based drug-herb interactions, thereby 
incorporating such studies into drug development for phytomedicines. Although the 
presence of numerous active ingredients in herbal medicines, foods and dietary 
supplements complicate experimentation, the observable interactions with CYP enzymes 
warrant systematic studies, so that metabolism-based interactions can be predicted and 
avoided more readily. Over the years, there has been great advances in the availability of 
“high tech” tools, in vitro and in vivo study designs and analytical equipment that can be 
adapted for use in such studies. Pharmaceutical research must go beyond focusing on 
pharmacological efficacy of botanicals but also in studies that improve their effectiveness in 
order for humanity to fully benefit from their inherent therapeutic potentials. 
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1. Introduction 
Pharmacokintics deals with study of absorption, distribution, metabolism and excretion 
(ADME) of drugs. Pharmacokinetics, the study of time course of drug concentrations in the 
body, provides means of quantifying ADME parameters. In a clinical situation 
pharmacokinetics provides the practitioners a useful tool to design optimally beneficial drug 
dosage regimen for patient. Understanding pharmacokinetic principles allows clinician to 
make more rational therapeutic decisions. It also provides conceptual understanding to 
utilize withdrawal time to prevent drug residues that remain in the milk and edible tissues 
of food producing animals. 
Various steps involved in governing fate of drugs must be defined and quantified 
concentration of free, non-protein bound drug dissolved in serum or plasma is taken as 
reference point for pharmacokinetic analysis. Serum or plasma drug concentrations 
generally retract extra cellular fluid drug concentrations. A drug generally be present at its 
site of action in a tissue at sufficient concentration for a specific period to produce 
pharmacologic effect. This understanding is important in veterinary medicine where specific 
difference in any of ADME process significantly affect the extent and/or time course of drug 
absorption and disposition in the body. 
The concentration of antimicrobial achieved at site of infection depends on systemic 
availability of the drug, which varies with the dosage form and route of administration. The 
chemical nature and physicochemical properties of the drug influence the extent of 
absorption, pattern of distribution and rate of elimination. Effective antimicrobial therapy 
depends on triad of bacterial susceptibility, pharmacokinetic characteristics of the drug and 
the dosage regimen. 
Antimicrobials are administered either as flock medication in poultry and individually or 
group in swine and cattle. Systemic antimicrobial treatment is given orally through 
medicated feed or water, or by injections. Antimicrobials used in animals are generally the 
same to antimicrobials used in humans. Tetracyclines constitute the antimicrobials class 
quantitatively most used in animals followed by macrolides, lincosamides, penicillins, 
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sulfonamides, aminoglycosides, fluoroquinolones, cephalosporins and phenicols. The most 
common antimicrobial drug used as growth promoters include macrolides (tylosin and 
spiramycin), polypeptides (bacitracin), glycolipids (bambermycin), streptogramins 
(virginiamycin), glycopeptides (avoparcin), quinoxalines (carbadox and olaquindox) and 
ionophores (monensin and salinomycin). 
In human and veterinary practice the primarily concern in antimicrobial drug selection and 
use is the therapeutic outcome. Larger than therapeutic doses may lead to potential toxicity. 
Clinicians involved in the treatment of diseases in food animals have additional concern of 
the persistence of drug residue in the edible tissues after the disease has been treated. 
Adulteration of food supply with antimicrobial agents and other chemicals is growing 
concern to general public. 
2. Beta-lactam antibiotics: Penicillins, cephalosporins and related drugs 
Beta-lactam constitutes one of the most important and frequently used antimicrobial agents. 
The penicillins, cephalosporins, carbapenems, monobactams and -lactamase inhibitors are 
referred to as beta-lactams antibiotics. 
2.1 Penicillins 
The Penicillins are a large group of naturally occurring and semi-synthetic antibiotics. The 
penicillins are organic acids available as sodium or potassium salts. The Penicillins (Pka 2.7) 
are predominantly ionized in plasma. Penicillins in general have relatively small apparent 
volumes of distribution (0.2-0.3 L/kg) and short half-lives (0.5-1.2 hours) in all species of 
domestic animals. 
Penicillins are hydrolyzed & inactivated in the acidic pH of the stomach and therefore not 
absorbed orally except penicillin-V, aminopenicillins (ampicillin & amoxicillin) and 
isoxazolylpenicillins (cloxacillin, dicloxacilin & oxacillin). Aminopenicillins are absorbed 
poorly in horses and ruminants. Following oral administration, absorption of ampicillin in 
adult horses is only 2-3.5% (Sarasola & Mc Kellar, 1994; Ensink, et al, 1996). Systemic 
availability of oral amoxicillin is higher (2-10%) than ampicillin in adult horses. (Ensinic, 
et al, 1996; Wilson, et al, 1998). Serum concentrations of penicillins generally peak within 2 
hrs of PO administration. Penicillins in aqueous solution are rapidly absorbed from 
parenteral administration. Penicillins suspended in vegetable oil vehicles or sparingly 
soluble penicillins (procaine penicillin G and benzathine penicillin G) administered 
parenterely absorbs slowly resulting in longer persistence of plasma and tissue drug 
concentrations.  
Penicillins are widely distributed in body fluids & tissues. Protein binding of penicillins is 
low to moderate ranging from 30-60%. The penicillins have moderate volume of distribution 
and gets diffuse into extracellular fluid easily. Sufficient concentrations are achieved for 
susceptible bacteria in kidneys, synovial fluid, liver, lung, skin and soft tissues (Strover et 
al., 1981; Brown et al., 1982). Penicillins cross biologic membranes poorly. Entry of penicillin 
across blood-brain, placental, mammary or prostatic barriers is enhanced by inflammation 
or massive dose. 
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Penicillins are generally excreted unchanged except penicillin G, penicillin V, nafcillin, 
ticarcillin and aminopenicillins, which are metabolized to some extent by hydrolysis of β–
lactam ring. The metabolites are inactive. Penicillins are eliminated entirely by Kidney 
(Glomerular   filtration and tubular secretion), which results in very high level in the urine 
except nafcillin, which is excreted mainly in bile. Active tubular secretion of penicillins can 
be comparatively inhibited by organic acids such as probenicid. Penicillins are also 
eliminated in milk in trace amounts and may persist for 90 hours. Penicillin residue in milk 
has been detected after intrauterine infusion also.  
2.2 Cephalosporins 
The pharmacokinetic characteristics of cephalosporins are typical of penicillins. Very few 
cephalosporins (cephalexin, cepharidine, cefadroxil & cefachlor) are acid stable and given 
orally. Pro-drug formations of such drugs enhance oral bioavailability. Cefadroxil is 
absorbed better in the foal than adult horses (Dufee et al., 1989). Most of the other 
cephalosporins are either administered IV or IM. Peak plasma concentration usually 
observes at ~ 30 min after parenteral administration.  
Cephalosporins are widely distributed through most body fluids & tissues including 
kidneys, lung, joints, bone & soft tissues except prostate & CNS. The volume of distribution 
is <0.3 L/kg. Protein biding for most cephalosporins is low in animals compare to human. 
For example ceftriaxone & cefazolin has high (85-95%) protein binding in human as 
compared to dogs (19-25%) (Popick et al., 1987). 
Cephalosporins are minimally metabolized in the liver. Several Cephalosporins like 
cephalothin, cephapirin, cephacetrile & cefotaxime are deacitylated to less active derivatives 
except ceftiofur, which is transformed to desfuroyl ceftiotur, which is largly responsible for 
its antibacterial efficacy. Most of the cephalosporins are excreted by renal tubular secretion 
except cefoperazone, which is largly excreted in the bile. In general cephalosporins have 
half-lives of 1 to 2 hours except some third generation cephalosporins like ceftiofur having 
half-life of 3-6 hr in cattle, 4 hours in dogs and 2.5 hr in horses. The pharmacokinetic 
parameters of some cephalosporins given to food animals like cattle, sheep and goat are 
given in Table 1. 
2.3 Other Beta-lactam antibiotics 
2.3.1 Carbepenems 
Carbepenems differ from penicillins by the substitution of a CH2 group for the sulphur in 
the five- membered ring attached to β-lactam ring. They have very broad spectrum of 
activity and are resistant to most β - lactamases. It includes imipenem, doripenem, 
ertapenem, meropenem and biopenem. The carbepenems are not absorbed orally, hence 
must be given parenterally. Following IV Injection, they are widely distributed to extra 
cellular fluid throughout body & achieve therapeutic concentrations in most tissues. 
Carbepenems  have low volume of distribution like penicillins & cephalosporins.Following 
IM administration imipenem has excellent bioavailability (>95%) and distributed widely 
throughout body except CSF. Imipenem gets largely eliminated through kidneys and gets 
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sulfonamides, aminoglycosides, fluoroquinolones, cephalosporins and phenicols. The most 
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isoxazolylpenicillins (cloxacillin, dicloxacilin & oxacillin). Aminopenicillins are absorbed 
poorly in horses and ruminants. Following oral administration, absorption of ampicillin in 
adult horses is only 2-3.5% (Sarasola & Mc Kellar, 1994; Ensink, et al, 1996). Systemic 
availability of oral amoxicillin is higher (2-10%) than ampicillin in adult horses. (Ensinic, 
et al, 1996; Wilson, et al, 1998). Serum concentrations of penicillins generally peak within 2 
hrs of PO administration. Penicillins in aqueous solution are rapidly absorbed from 
parenteral administration. Penicillins suspended in vegetable oil vehicles or sparingly 
soluble penicillins (procaine penicillin G and benzathine penicillin G) administered 
parenterely absorbs slowly resulting in longer persistence of plasma and tissue drug 
concentrations.  
Penicillins are widely distributed in body fluids & tissues. Protein binding of penicillins is 
low to moderate ranging from 30-60%. The penicillins have moderate volume of distribution 
and gets diffuse into extracellular fluid easily. Sufficient concentrations are achieved for 
susceptible bacteria in kidneys, synovial fluid, liver, lung, skin and soft tissues (Strover et 
al., 1981; Brown et al., 1982). Penicillins cross biologic membranes poorly. Entry of penicillin 
across blood-brain, placental, mammary or prostatic barriers is enhanced by inflammation 
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(Glomerular   filtration and tubular secretion), which results in very high level in the urine 
except nafcillin, which is excreted mainly in bile. Active tubular secretion of penicillins can 
be comparatively inhibited by organic acids such as probenicid. Penicillins are also 
eliminated in milk in trace amounts and may persist for 90 hours. Penicillin residue in milk 
has been detected after intrauterine infusion also.  
2.2 Cephalosporins 
The pharmacokinetic characteristics of cephalosporins are typical of penicillins. Very few 
cephalosporins (cephalexin, cepharidine, cefadroxil & cefachlor) are acid stable and given 
orally. Pro-drug formations of such drugs enhance oral bioavailability. Cefadroxil is 
absorbed better in the foal than adult horses (Dufee et al., 1989). Most of the other 
cephalosporins are either administered IV or IM. Peak plasma concentration usually 
observes at ~ 30 min after parenteral administration.  
Cephalosporins are widely distributed through most body fluids & tissues including 
kidneys, lung, joints, bone & soft tissues except prostate & CNS. The volume of distribution 
is <0.3 L/kg. Protein biding for most cephalosporins is low in animals compare to human. 
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half-lives of 1 to 2 hours except some third generation cephalosporins like ceftiofur having 
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metabolized in renal tubules by a dihydropeptidase enzyme. Cilastatin, an inhibitor of renal 
dipeptidase decrease renal metabolism of impenem, leading to increase in elimination half-
life and decrease excretion of the drug largely in urine in active form. Half-life of 















(g x  h/ml)
Cl  
(ml/min/kg F (%) Reference 
Cephapirin Cows (lactating)       12.7  
Prades et 
al., 1988 
Cephalexin Calves    0.32 2.0  1.9  Garg et al., 1992 
Cefazolin Calves    0.17 0.62  5.8  Soback et al., 1987 
Ceftriaxone 
Goat IV 20 - 0.58 1.50 77.51 4.50 - Tiwari et al., 2009 IM 20 21.51 0.53 2.03 66.78 3.04 59 
Sheep 
IV 10 - 0.41 1.21 42.65 3.91 - Swati et 
al.,2010  IM 10 15.53 0.43 2.24 47.68 2.22 64 
   0.30   3.7  Guerrini et al., 1985 
Calves 
(Buffalo) 
IV 10 - 0.48 1.27 40.0 4.40 - Gohil et 
al, 2009 IM 10 15.8 1.53 4.38 29.67 4.01 70.2 
Calves 
(Cow) 
IV 10 - 0.44 1.58 57.35 3.15 - Maradiya 
et al., 2010 IM 10 15.34 1.16 5.02 28.15 2.71 47 
Cefepime 
Goat IV 10 - 0.52 2.71 78.38 2.19 - Patni et al., 2008 IM 10 15.75 - 4.89 93.12 1.27 69 
Sheep IV 20 - 0.42 2.54 135.5 2.48 - Patel et al., 2010 IM 20 26.34 1.11 5.17 140.90 0.15 103 
Calves 
(Cow) 
IV 5 - 0.57 3.70 47.73 1.81 - Patel et al., 2006a 
IM 5 8.61 0.99 6.71 47.45 1.72 98 Patel et al., 2006b 
Cefoxitin Calves     1.12    Soback, 1988 
Ceftazidime Sheep    0.36 1.60    Rule at al., 1991 
Cefoperazone 
Calves     0.89    Carli et al., 1986 
Sheep IV 47  0.16   2.7  Guerrini et al., 1985 
Moxalactam      2.40    Soback, 1989 
Table 1. Pharmacokinetic parameters of selected cephalosporins administrated to food 
producing animals. 
2.3.2 Monobactams 
Monobactums are simple monocyclic β-lactam compounds active only against bacteria or 
anaerobes. Aztreonam is a synthetic monobactam. It is not absorbed orally. It is 
administrators IV or IM having extensive distribution throughout body including CSF. It is 
having elimination half-life of 1.6 hour in man. 
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2.3.3 β-lactamase inhibitors 
Beta lactamase enzyme production is a major factor in constitutive or acquired resistance of 
bacteria to β-lactam antibiotics. These drugs are combined with penicillins & cephalospirins 
to prevent degradation. It includes clavulanic acid, sulbactam and tazobactam. 
Clavulanic acid is a synthetic compound. It is combined with amoxillin (4:1) or ticarcillin 
(15:1). Clavulanic acid is well absorbed following oral administration having bioavailability 
more than 60%. It has widespread tissue distribution in extra cellular fluid but penetration 
in milk and CSF is poor. It gets largely eliminated unchanged in urine. Sulbactam 
(penicillinic acid sulfonate) is synthetic derivative of 6-aminopenicillinic acid. It is combined 
with either ampicillin or cefoperazone. The combination of sulbactam ampicillin gets 
absorbed after IM injections, distributes well into tissues and penetrates CSF through 
inflamed meninges. It is poorly absorbed orally but a pro-drug “sultamicillin” having 
double esters linkage of sulbactam with ampicillin gets absorbed from small intestine. 
Tazobactam is combined with piperacillin (piperacillin: tazobactam,  8:1) having 
pharmacokinetic properties similar to β-lactam drugs.     
3. Tetracyclines 
Tetracyclines are a group of broad- spectrum antibiotics having a nucleus of four cyclic 
rings. The tetracyclines are crystalline amphoteric substances that can exist as acid or base 
salts. The tetracyclines are strong chelating agents. Its chelation with calcium causes tooth 
discoloration. Tetracyclines include chlortetracycline, oxytetracycline, tetracycline, 
doxycycline and minocycline. 
Tetracyclines have low absorption following oral administration except doxycycline. The 
tetracyclines are relatively lipophilic drugs that remains ionized in the gastrointestinal tract. 
Oral absorption of tetracyclines gets drastically reduced in the presence of food (Neilsen and 
Gurd-Hansen 1996). Its oral absorption decrease with co-administration of food, dairy 
products, polyvalent cations (Ca++, Mg++, Fe++, Al+++), Kaolin/pectin preparations, ion 
containing supplements and antacids. Tetracyclines (oxytetracycline) can be administrated 
IV or IM. All tetracycline produce varying degree of tissue irritation on parenteral 
administration. The bioavailability of   orally administrated oxytetracycline is 5% compared 
to 37% for chlortetracycline in non fasting calves. The long acting formulation of 
oxytetracycline used for IM administration to food animals have long acting effect due high 
dosage and prolonged persistence at the site of IM injection as a result of tissue irritation 
(Nouws et al.,1990). The bioavailability of most tetracyclines is very poor following oral 
administration in pigs. Intravenous administration of oxytetracycline is preferred over IM 
injection in horses as it results in higher and more persistent serum concentration.   
Tetracyclines bind to plasma proteins at varying degrees in different species of animals. 
Tetracyclines are widely distributed in most tissues including kidney, liver, lungs, bile and 
bones. Tetracyclines have volume of distribution in excess of 1.0 L/kg indicating higher 
drug concentration  intracellular or binding to tissues. Tetracyclines are more lipophilic than 
other classes of antibiotics hence it can cross lipid membrane easily. Minocycline and 
doxycycline attain high concentration in brain, ocular tissues, spinal fluid and prostate than 
other tetracyclines. Doxycycline has high affinity for intracellular accumulation than other 
tetracyclines (Davis et al., 2006). Tetracyclines cross the placenta and enter foetal circulation 
and are secreted in milk of lactating animals.  
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to prevent degradation. It includes clavulanic acid, sulbactam and tazobactam. 
Clavulanic acid is a synthetic compound. It is combined with amoxillin (4:1) or ticarcillin 
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more than 60%. It has widespread tissue distribution in extra cellular fluid but penetration 
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(penicillinic acid sulfonate) is synthetic derivative of 6-aminopenicillinic acid. It is combined 
with either ampicillin or cefoperazone. The combination of sulbactam ampicillin gets 
absorbed after IM injections, distributes well into tissues and penetrates CSF through 
inflamed meninges. It is poorly absorbed orally but a pro-drug “sultamicillin” having 
double esters linkage of sulbactam with ampicillin gets absorbed from small intestine. 
Tazobactam is combined with piperacillin (piperacillin: tazobactam,  8:1) having 
pharmacokinetic properties similar to β-lactam drugs.     
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rings. The tetracyclines are crystalline amphoteric substances that can exist as acid or base 
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Oral absorption of tetracyclines gets drastically reduced in the presence of food (Neilsen and 
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to 37% for chlortetracycline in non fasting calves. The long acting formulation of 
oxytetracycline used for IM administration to food animals have long acting effect due high 
dosage and prolonged persistence at the site of IM injection as a result of tissue irritation 
(Nouws et al.,1990). The bioavailability of most tetracyclines is very poor following oral 
administration in pigs. Intravenous administration of oxytetracycline is preferred over IM 
injection in horses as it results in higher and more persistent serum concentration.   
Tetracyclines bind to plasma proteins at varying degrees in different species of animals. 
Tetracyclines are widely distributed in most tissues including kidney, liver, lungs, bile and 
bones. Tetracyclines have volume of distribution in excess of 1.0 L/kg indicating higher 
drug concentration  intracellular or binding to tissues. Tetracyclines are more lipophilic than 
other classes of antibiotics hence it can cross lipid membrane easily. Minocycline and 
doxycycline attain high concentration in brain, ocular tissues, spinal fluid and prostate than 
other tetracyclines. Doxycycline has high affinity for intracellular accumulation than other 
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and are secreted in milk of lactating animals.  
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With exception of lipid soluble tetracyclines (doxycycline, minocycline), the tetracycline 
antibiotics are not metabolized to a significant extent in the body. About 60% of the dose 
gets eliminated in urine via glomerular filtration and 40% in faeces. Doxycycline gets 
excreted largely in the large intestine. Doxycycline & minocycline undergo entero-hepatic 
circulation, which contributes to their longer half-life (6-10 hr) than tetracycline that are 
eliminated mainly by renal excretion.       
4. Aminoglycosides 
The aminoglycosides are bactericidal natural and semi-synthetic antibacterials primarily 
used for treatment of gram negative infections and staphylococci. The group consists of 
hexose nucleus to which amino sugars are attached by glycosidic linkages. The 
aminoglycosides are basic polycations with pKa value ranging from 7.2 to 8.8. The chemical 
structure determines the antimicrobial activity, resistance patterns and inherent propensity 
to cause toxicosis. The group includes drugs like gentamicin, amikacin, kanamycin, 
apramycin, tobramycin, neomycin, streptomycin, dihydrostreptomycin, paromomycin and 
spectinomycin. 
The pharmacokinetics of the aminoglycosides is similar across most veterinary                          
species. However, variability within each animal population is large that necessitates close 
monitoring of serum concentrations to optimize efficacy and minimize toxicosis. Equines 
receiving multiple doses of parenteral amino-glycosides require therapeutic drug 
monitoring (Martin & Riviere, 1998)  
Aminoglycosides are poorly absorbed (<10%) from gastrointestinal tract because of their 
highly polar and cationic nature. Aminoglycosides given orally to young animals (neonate) 
with enteritis, significant absorption occur leading to violative tissue residues. The 
aminoglycosides are well absorbed following IM or SC injection. The peak serum 
concentration is achieved within 30 to 45 minutes following extravascular administration. 
Intravenous and intraperitoneal routes produce rapid effects but should be avoided because 
of serious side effects. Following intrauterine or intramammary infusion to cows, 
gentamicin is well absorbed and results in prolonged tissue residues. Absorption is 
extremely rapid and complete, if aminoglycosides are instilled into body cavities that 
contain serosal surfaces. 
Aminoglycosides are extensively distributed in extracellular fluid, as these are large 
molecules and highly ionized at physiological pH. They are poorly lipid soluble and have 
limited capacity to enter cells and penetrate cellular barriers. These drugs attain very low 
concentration in cerebrospinal, respiratory and ocular fluid. In the renal tubular cells and 
the endolymph and perilymph of inner ear, aminoglycoside attain high concentration 
causing nephro and oto-toxicity, respectively. Their apparent volume of distribution is 
relatively small (<0.35L/Kg). The amino glycosides binds poorly (<20%) to plasma proteins. 
Gentamicin is distributed into synovial fluid in normal horses; local inflammation may 
increase drug concentration in the joint. 
The aminoglycosides are not metabolized and are excreted largely as such (~90%) in urine 
by glomerular filtration. Plasma elimination half lives are short (1-2 hr) in domestic animals 
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having normal renal function. It increases to 24-48 hr in patients having renal insufficiency. 
The disposition of aminoglycosides varies among animals because of differences in 
glomerular filtration rates. The prolonged terminal elimination phase of aminoglycosides 
has major implications for veterinary therapeutics in food producing animals. 
Aminoglycosides accumulate in renal cortex for prolonged periods of time, resulting in 
tissue residues even after short periods of administration. 
5. Fluoroquinolones 
Fluoroquinolones are synthetic antibacterial agents introduced in veterinary medicine in the 
1980s. Currently available quinolones contain basic structure of 4-quinolone (Short for 4- 
oxo-1,4- hydroquinoline) with carboxylic acid moiety. Fluoroquinolones are amphoteric 
molecules having pKa ranging from 6.0-6.5 (Carboxy group) and 7.5-8 (nitrogen of 
piperazine group). Fluoroquinolones at physiological pH occurs as zwitterions. 
Fluoroquinolones  commonly used in veterinary medicine inciude enrofloxacin, difloxacin, 
orbifloxacin, marbofloxacin, ibafloxacin and danofloxacin. Other compounds having 
potential interest in veterinary practice include ciprofloxin, levofloxacin, moxifloxacin, 
gatifloxacin and pradofloxacin. 
The fluoroquinolones have good rate and extent of absorption after oral administration in 
monogastric animals and pre-ruminant calves. Presence of food has little effect on oral 
absorption. In dogs, cats and pigs, oral absorption of fluoroquinolones approaches to 100%, 
but in large animals it is less. Enrofloxacin is more lipid soluble than ciprofloxacin and has a 
higher oral bioavailability than ciprofloxacin in horses and small animals.  
The oral bioavailability of enrofloxacin is 63% (Giguere et al., 1996) in adult horses and 42% 
in foals (Bermingham et al., 2000). Absorption is complete following IM and SC Injection of 
fluoroquinolones. The pharmacokinetic parameters of some fluoroquinolones given to food 
animals like cattle, sheep, goat, pig and chicken are given in Table 2. 
Following absorption, fluoroquinolones show rapid and extensive tissue distribution due to 
hydrophilic nature and low (<50%) protein binding. In general, fluoroquinolones 
concentration in interstitial fluid, skin and bones are 35-100% of those obtained in serum, 
where as bronchial secretions and prostatic concentrations are two to three times of 
corresponding serum concentrations. Penetration into CSF is approximately 25% of serum 
concentration (Davis  et al., 2002). Fluoroquinones attain high intracellular concentrations in 
macrophages and neutrophils. Intracellular concentrations are 4 - 10 times greater than 
plasma concentrations.  
The fluoroquinolones are largely eliminated uncharged in the urine by glomerular filtration 
and active tabular secretion, except difloxacin, which is excreted largely (80%) in faeces. 
Parent compound as well as metabolites of some fluoroquinolones is excreted in bile and 
urine. Enrofloxacin undergoes de-ethylation to active metabolite ciprofloxacin. In cattle the 
proportion of ciprofloxacin in plasma was 25 - 41% following administration of enrofloxacin 
(Davis et al., 2002). The ciprofloxacin concentration residues were present in tissue of 
chicken 12 days after dosing of enrofloxacin (Anadon et al., 1995). Pefloxacin gets completed 
metabolized to active metabolite norfloxacin. The elimination half-life (3-6 hr) of 
fluoroquinolones is dependent on the drug and animal species.       
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
162 
With exception of lipid soluble tetracyclines (doxycycline, minocycline), the tetracycline 
antibiotics are not metabolized to a significant extent in the body. About 60% of the dose 
gets eliminated in urine via glomerular filtration and 40% in faeces. Doxycycline gets 
excreted largely in the large intestine. Doxycycline & minocycline undergo entero-hepatic 
circulation, which contributes to their longer half-life (6-10 hr) than tetracycline that are 
eliminated mainly by renal excretion.       
4. Aminoglycosides 
The aminoglycosides are bactericidal natural and semi-synthetic antibacterials primarily 
used for treatment of gram negative infections and staphylococci. The group consists of 
hexose nucleus to which amino sugars are attached by glycosidic linkages. The 
aminoglycosides are basic polycations with pKa value ranging from 7.2 to 8.8. The chemical 
structure determines the antimicrobial activity, resistance patterns and inherent propensity 
to cause toxicosis. The group includes drugs like gentamicin, amikacin, kanamycin, 
apramycin, tobramycin, neomycin, streptomycin, dihydrostreptomycin, paromomycin and 
spectinomycin. 
The pharmacokinetics of the aminoglycosides is similar across most veterinary                          
species. However, variability within each animal population is large that necessitates close 
monitoring of serum concentrations to optimize efficacy and minimize toxicosis. Equines 
receiving multiple doses of parenteral amino-glycosides require therapeutic drug 
monitoring (Martin & Riviere, 1998)  
Aminoglycosides are poorly absorbed (<10%) from gastrointestinal tract because of their 
highly polar and cationic nature. Aminoglycosides given orally to young animals (neonate) 
with enteritis, significant absorption occur leading to violative tissue residues. The 
aminoglycosides are well absorbed following IM or SC injection. The peak serum 
concentration is achieved within 30 to 45 minutes following extravascular administration. 
Intravenous and intraperitoneal routes produce rapid effects but should be avoided because 
of serious side effects. Following intrauterine or intramammary infusion to cows, 
gentamicin is well absorbed and results in prolonged tissue residues. Absorption is 
extremely rapid and complete, if aminoglycosides are instilled into body cavities that 
contain serosal surfaces. 
Aminoglycosides are extensively distributed in extracellular fluid, as these are large 
molecules and highly ionized at physiological pH. They are poorly lipid soluble and have 
limited capacity to enter cells and penetrate cellular barriers. These drugs attain very low 
concentration in cerebrospinal, respiratory and ocular fluid. In the renal tubular cells and 
the endolymph and perilymph of inner ear, aminoglycoside attain high concentration 
causing nephro and oto-toxicity, respectively. Their apparent volume of distribution is 
relatively small (<0.35L/Kg). The amino glycosides binds poorly (<20%) to plasma proteins. 
Gentamicin is distributed into synovial fluid in normal horses; local inflammation may 
increase drug concentration in the joint. 
The aminoglycosides are not metabolized and are excreted largely as such (~90%) in urine 
by glomerular filtration. Plasma elimination half lives are short (1-2 hr) in domestic animals 
 
Pharmacokinetics of Antimicrobials in Food Producing Animals 
 
163 
having normal renal function. It increases to 24-48 hr in patients having renal insufficiency. 
The disposition of aminoglycosides varies among animals because of differences in 
glomerular filtration rates. The prolonged terminal elimination phase of aminoglycosides 
has major implications for veterinary therapeutics in food producing animals. 
Aminoglycosides accumulate in renal cortex for prolonged periods of time, resulting in 
tissue residues even after short periods of administration. 
5. Fluoroquinolones 
Fluoroquinolones are synthetic antibacterial agents introduced in veterinary medicine in the 
1980s. Currently available quinolones contain basic structure of 4-quinolone (Short for 4- 
oxo-1,4- hydroquinoline) with carboxylic acid moiety. Fluoroquinolones are amphoteric 
molecules having pKa ranging from 6.0-6.5 (Carboxy group) and 7.5-8 (nitrogen of 
piperazine group). Fluoroquinolones at physiological pH occurs as zwitterions. 
Fluoroquinolones  commonly used in veterinary medicine inciude enrofloxacin, difloxacin, 
orbifloxacin, marbofloxacin, ibafloxacin and danofloxacin. Other compounds having 
potential interest in veterinary practice include ciprofloxin, levofloxacin, moxifloxacin, 
gatifloxacin and pradofloxacin. 
The fluoroquinolones have good rate and extent of absorption after oral administration in 
monogastric animals and pre-ruminant calves. Presence of food has little effect on oral 
absorption. In dogs, cats and pigs, oral absorption of fluoroquinolones approaches to 100%, 
but in large animals it is less. Enrofloxacin is more lipid soluble than ciprofloxacin and has a 
higher oral bioavailability than ciprofloxacin in horses and small animals.  
The oral bioavailability of enrofloxacin is 63% (Giguere et al., 1996) in adult horses and 42% 
in foals (Bermingham et al., 2000). Absorption is complete following IM and SC Injection of 
fluoroquinolones. The pharmacokinetic parameters of some fluoroquinolones given to food 
animals like cattle, sheep, goat, pig and chicken are given in Table 2. 
Following absorption, fluoroquinolones show rapid and extensive tissue distribution due to 
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corresponding serum concentrations. Penetration into CSF is approximately 25% of serum 
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(g x h/ml 
F (%) Reference 
Ciprofloxacin 
Sheep IV 5 - 1.67 1.88 8.40 - Patel et al., 2004 IM 5 0.95 3.40 3.67 5.48 68 
Calves 
(cow) IV 5 - 1.67 1.80 7.90 - 
Bhavsar et al., 
2004 
Calves 
(Buffalo) IV 5 - 1.98 1.25 4.56 - 
Sarvaiya et al., 
2006 
Pigs IV 3.06 0.17 3.83 2.57 2.88 37 Nouws et al., 1988 
Chicken PO 5 4.67 2.0 9.0 78.04 70.0 Atta and Sharif, 1997 
Levofloxacin Poultry (Broiler) 
IV 10 - 3.25 (Vdss) 3.18 11.33 - Varia et al., 2009 PO 10 0.93 - 3.64 6.70 59.5 
Enrofloxacin 
Cattle 
SC 12.5 0.96 - 6.79 14.95 - Davis et al., 2006 
IV 8 0.81 - 7.28 7.51 - Ter Hune et al., 2005  
IV 5  1.63 1.68 7.42  
Kaartinen et 
al., 1997 IM 5 0.73  5.9  82 
SC 5 0.98  5.55  137 
 2.5  2.98 2.82 5.28  Bergante et al., 1999 
Goat IV 5 6.7 1.3 1.1 6.7  Rao et al., 2002 
Sheep 




IM 2.5  2.18 3.73 5.47 85.0 Mengozzi et al., 1996 
PO 2.5 0.78 1.3 3.8 10.4 60.6 Pozzin et al., 1997 
Pig IM 
2.5 0.61 3.5 7.73 9.94 95 Richez et al., 1997 
2.5 0.75 3.95 5.5 5.03 101 Pijpers et al., 1997 
Chicken 
IV 10.0 1.88 (PO) 
5.0 
(IV) 5.6 16.17 89.2 
Knoll et al., 
1999 
PO 10.0 1.5 - 14 35 - Da Silva et al., 2006 
Danofloxacin 
Cattle 
IV 6 1.7  4.21 9.72 - Ter Hune et al., 2005 
IM 1.25 0.28 2.04 2.25 132.85 289 Shem-Tov et al., 1998 
IM 5 0.82  2.9 4.7 78 Mann and Frame, 1992 
Goat SC 1.25 0.33 3.8 4.67 2.29 110 Aliabdi and lees, 2001 
pig IM 5 0.8 - 8.0 6.0 76 Mann and Frame, 1992 
Marbofloxacin Goat IM 2 1.9 1.3  (Vdss) 7.2 8.44 100.7 
Waxman et al., 
2001 
Table 2. Pharmacokinetic parameters of selected fluoroquinolones administrated to food 
producing animals. 
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6. Sulphonamides and potentiated sulphonamides 
The sulphonamides are oldest antimicrobial compounds, derivatives of sulphanilamide 
which was obtained from the azo dye “prontosil”. Sulphonamides are white crystalline 
powders that are quite insoluble. They are more soluble at an alkaline pH than an acidic pH. 
Solubility of sulphonamides increases in the presence of another sulphonamide in the 
solution because it follow law of independent solubility. The sodium salts of sulphonamides 
are readily soluble in water. These solutions are highly alkaline (used for parenteral 
preparation) in reaction except sodium sulphonamide which is near neutral and used for 
ophthalmic instillation. The pKa values of sulphonamies range are from 10.4 (sulfanilamide) 
to 5.0 (sulfisoxazole). They exist in lipid soluble non-ionised form in biologic fluids of pH 
lower than their pKa. Sulphonamides commonly used in veterinary medicine include 
sulphadimethoxine, sulphamethazine (sulphadimidine),  sulphaquinoxaline,  
sulphamerazine,  sulphathiazole, sulphasalazine, sulphadiazine, Sulphabromomethazine, 
sulphaethoxypyridazine, sulphisoxazole and sulphachlorpyridazine. The potentiated 
sulphonamides are combination of a sulphonamide with diaminopyrimidine compounds 
(trimethoprim or ormethoprim). Potentiated sulphonamide combinations used in veterinary 
practice includes Trimethoprim - sulphadiazine, Trimethoprim - sulphamethaxazole, 
Trimethoprim - sulphachlorpyridazine and ormetoprim - sulphadimethoxine. 
Most sulphonamides (except gut acting and topical sulphonamides) get well absorbed 
following oral administration. The absorption rate is affected by the solubility of 
sulphonamides and presence of ingesta in the gastrointestinal tract. In general dogs, cats 
and birds absorb sulphonamides rapidly, pigs takes some time and ruminants require much 
longer time. In ruminants, age and diet markedly affect oral trimethoprim and 
sulphadiazine disposition in calves. Orally administered sulphadiazine (30mg/kg) was 
absorbed slowly in calves fed milk diets, with absorption slightly higher in ruminating 
calves. Trimethoprim was absorbed in pre-ruminant calves but not absorbed in mature 
ruminants after oral administration (Shoaf et al., 1987). 
Sulphonamides are widely distributed throughout body including soft tissues, CNS 
(cerebrospinal fluid) and joints (synovial fluid). Plasma protein binding varies from 15 -90 % 
depending on sulphonamide to sulphonamide and species to species. Extensive (>80%) 
protein binding increases half-life. Sulfonamides are weak acids and timethoprim is a weak 
base. Trimethoprim has higher volume of distribution than sulfonamide due to ion trapping 
of trimethoprim in tissues. Calculation of dosages of sulphonamides to maintain steady state 
of 100 µg/ml requires consideration of the extent of protein binding, apparent volume of 
distribution and half-life as it varies between individual within a species. 
Sulphonamides and trimethoprim are metabolized faster and more extensively by 
herbivores than carnivore or omnivores. Acetylation of NH2 group on N-4 is a major 
mechanism of metabolism. Hydroxylation of methyl group on the pyrimidine ring and 
carboxylation also occurs. Ruminants metabolize sulphonamides by acetylation pathways 
and acetylated metabolites are the major urinary metabolites in cattle, sheep and swine. 
Acetylated metabolites are less soluble than the parent compound and increase risks of renal 
tubular injury due to precipitation and crystal formation. The canines’ lacks the ability to 
acetyl ate sulphonamides, relying on alternate metabolic pathway. Glucuronide conjugation 
and aromatic hydroxylation are two additional pathway for sulphonamide metabolism. 
Sulphonamide metabolites are therapeutically inactive (N 4- acetyl metabolites) or have 
reduced therapeutic activity (hydroxy metabolites).  
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and aromatic hydroxylation are two additional pathway for sulphonamide metabolism. 
Sulphonamide metabolites are therapeutically inactive (N 4- acetyl metabolites) or have 
reduced therapeutic activity (hydroxy metabolites).  
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Sulfonamides are excreted in urine. Renal excretion mechanisms include glomerular 
filtration of free drug in the plasma, active carrier-mediated proximal tubular excretion of 
ionized unchanged drug and metabolites and passive reabsorption of nonionized drug from 
distal tubular fluid. Urinary alkalization increases both the fraction of dose that is 
eliminated by renal excretion and the solubility of sulphonamides in the urine. 
7. Peptide antibiotics: Polymyxins, glycopeptides and bacitracin 
7.1 Polymyxins 
Polymyxins are group of N-mono-acetylated decapeptides. Polymyxin B and polymyxin E 
(colistin) are chemically related and therapeutically useful. The polymyxins are not 
absorbed into the body when given orally. Polymyxin B sulfate or colistin methane 
sulphonate sodium is given parenterally for systemic therapy. Following absorption 
polymyxins bind moderately (70-90%) to plasma proteins. Polymyxins bind extensively to 
muscle tissues. It binds to mammalian cell membrane and accumulates following long term 
dosing. They are slowly excreted unchanged by glomerular filtration in the urine. The 
polymyxins are highly nephrotoxic damaging the renal tubular epithelial cells.  
7.2 Glycopeptides 
Vancomycin, teicoplanin and avoparcin are glycopeptide antibiotics. The former two have 
been considered as the drugs of “last resort” to treat serious infections due to drug resistant 
gram-positive bacteria in human. Vancomycin and avoparcin are used in veterinary 
medicine in some countries. 
Vancomycin is poorly absorbed following oral administration. Its tissue distribution is poor 
following parenteral administration. Most of the intravenously administered drug is 
excreted through the kidneys, with small proportion excreted in bile. Vancomycin 
hydrochloride is given IV as infusion and it requires monitoring in patients with renal 
impairment. Teicoplanin is not absorbed after oral administration. Absorption and 
distribution into tissue and extracellular fluid is excellent following IM Injection. It gets 
eliminated entirely in urine.  
7.3 Bacitracin   
It is polypeptide product derived from Bacillus subtilis. It is bactericidal to Gram-positive 
bacteria but has little activity on Gram-negative organisms. It is highly nephrotoxic after 
parenteral administration. It is only used for topical treatment of superficial infections of the 
skin and mucosal surfaces. In veterinary medicine it is used at low dose as growth promoter 
in chicken.  
8. Lincosamides, pleuromutilins and streptogramins 
8.1 Lincosamides 
Lincosamides are a group of monoglycoside antibiotics containing amino-acid like side 
chain. It includes lincomycin, clindamycin and pirlimycin. Lincosamides are basic 
compounds with pKa of  7.6. They have high lipid solubility and large apparent volume of 
distribution. 
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Lincomysin is rapidly but incompletely absorbed following oral administration (20-50%) in 
pigs (Hornish et al, 1987). Peak levels are achieved within 60 minutes following oral 
administration and 2-4 hr after IM Injection. It is well distributed in tissues (liver, kidney, 
muscle & skin) with low levels in CSF (Vd: 1-1.3 L/kg). Following oral administration most 
of the drug gets excreted through faeces (85%) and remainder in urine. Following IM 
Injection 38% gets excreted in faeces and 49% in urine. 
Clindamycin is 7- chlorolincomycin having better antibacterial effect compared to 
lincomycin. Clindamycin absorb better from gastrointestinal tract than lincomycin. It is 
distributed well to tissues and attains high intracellular concentration (Vd: 1.6-3.1 L/kg). It 
also achieves effective concentration in bone. Following parenteral administration half life 
ranges from 3.2 hr (IV) to 5-7 hr (IM or SC). It has excellent bioavailability (80-100%) 
following IM Injection.   
8.2 Pleuromutilins 
Tiamulin and valnemulin are semisynthetic derivatives of naturally occurring diterpene 
antibiotic pleuromutilin. Tiamulin hydrogen fumarate is used for oral administration 
whereas tiamulin base is used for Injection. Valnemulin hydrochloride is used as medicated 
feed premix. Tiamulin gets rapidly absorbed after oral administration in monogastric 
species but gets inactivated in rumen if given orally to ruminants. It has half life of 25 
minutes following parental administration (Ziv et al., 1983). It gets concentrated into milk as 
it is more lipophilic having pKa- 7.6. Valnemulin bioavailability exceeds 90% in pigs when 
given with feed. 
8.3 Streptogramins 
Streptogramins are a group of natural (virginiamycin, pristinamycin) or semisynthetic 
(quinupristin/dalfopristin) cyclic peptides. Virginiamycin is used in veterinary medicine as 
growth promoter (5-20 ppm). It is not absorbed after oral administration. Its use as growth 
promoter has been banned in several countries because of resistance in enterococcal isolates. 
9. Macrolides, azalides and ketolides 
The macrolide antibiotics are a group of structurally similar compounds containing 12-20 
atoms of carbon in lactone ring. Various combinations of deoxy sugars are attached to 
lactone ring by glycosidic linkages. Macrolides used in veterinary medicine include 
erythromycin, tylosin, spiramycin, tilmicosin and tulathromycin. Other macrolides like 
oleandomycin and carbomycin have been used as feed additives for growth promotion in 
food animals. 
9.1 Erythromycin 
It is base having pKa of 8.8. It is poorly soluble in water and unstable in gastric acid. 
Erythromycin base is absorbed well following oral administration but it is highly susceptible 
to degradation from gastric acids. Erythromycin base in entric-coated formulation or 
erythromycin estolate or stearate or phosphate or ethyl-succinate ester can be given orally. 
The stearate form is hydrolyzed in the intestine to the base and ethylsuccinate and estolate 
ester forms are hydrolyzed in the body to the active base. The presence of food in the 
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atoms of carbon in lactone ring. Various combinations of deoxy sugars are attached to 
lactone ring by glycosidic linkages. Macrolides used in veterinary medicine include 
erythromycin, tylosin, spiramycin, tilmicosin and tulathromycin. Other macrolides like 
oleandomycin and carbomycin have been used as feed additives for growth promotion in 
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9.1 Erythromycin 
It is base having pKa of 8.8. It is poorly soluble in water and unstable in gastric acid. 
Erythromycin base is absorbed well following oral administration but it is highly susceptible 
to degradation from gastric acids. Erythromycin base in entric-coated formulation or 
erythromycin estolate or stearate or phosphate or ethyl-succinate ester can be given orally. 
The stearate form is hydrolyzed in the intestine to the base and ethylsuccinate and estolate 
ester forms are hydrolyzed in the body to the active base. The presence of food in the 
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stomach interferes quite markedly with oral absorption. Aqueous solution of erythromycin 
glucophate and lactobionate forms can be given IV. Pain and irritation at site of Injection 
prohibits use of erythromycin by SC or IM routes. The drug is well distributed in the body, 
being concentrated in the tissue like lungs, liver, spleen, heart, kidney and bile, prostatic, 
seminal, pleural and peritoneal fluids. Prostatic fluid concentrations are approximately half 
that of serum concentration. Penetration of erythromycin to CSF is low. The drug is largely 
metabolized by demethylation and metabolites are excreted largely in bile, which is lost in 
faeces. Urinary excretion is only 3-5% of administrated dose. The drug has half life of 3-4 hr 
in cattle. 
9.2 Tylosin 
Tylosin is more extensively used as a feed additive to promote growth in food-producing 
animals. Tylosin is a weak base (pKa 7.1) and is highly lipid soluble. The drug has good 
absorption from gastro-intestinal tract. It is widely distributed in tissues like lung, liver, 
spleen, heart and kidney. It is metabolized in liver and excreted via the bile and feaces. The 
elimination half-life in dogs and cattle is about 1 hr with apparent volume of distribution of 
1.7 and 1.1 L/kg, respectively. The half-life is longer (4 h) in sheep, goat and pigs.  
9.3 Tilmicosin 
It is semisynthetic derivative of tylosin. It has slow absorption and low bioavailability (22%) 
in cows. It has large volume of distribution (>2 L/ kg), with accumulation and persistence in 
tissues like lung. The drug administrated to cow (10 mg/kg, SC) resulted in milk 
concentration > 0.8 μg/ml for eight to nine days (Ziv et al.,1995) 
9.4 Spiramycin 
Spiramycin has quite exceptional ability to concentrate in tissues, resulting in tissue 
concentrations reaching 25-60 times those of serum. Persistence of drug residues for 
prolonged periods limits its use in food producing animals. 
9.5 Tulathromycin 
Tulathromycin is an azalide derivative of erythromycin. It is rapidly and extensively 
absorbed from SC & IM injection in cattle and pigs having bioavailability of 90%. The drug 
has half-life of 90 hr. The apparent volume of distribution following IV administration is  
12 L/Kg. Lung concentrations are 25-80 times higher than serum concentrations. 
9.6 Roxithromycin, dirithromycin, clarithromycin and azithromycin 
The newer macrolides are acid stable, produce few gastro-intestinal side effects, have higher 
oral bioavailability and longer elimination half- lives and produce higher therapeutic tissue 
concentration as compared to erythromycin. Oral bioavailability of azithromycin is 97% in 
dogs and about 50% in cats and foals. Elimination half-life of azithromycin is 20 hr and 30 hr 
in foals and cats, respectively. Clarithromycin half-life (4.8 hr) is shorter than azithromycin 
but longer than erythromycin (1 hr) in foals. The major route of excretion is bile and 
intestinal tract for azithromycin. The major route of excretion for clarithromycin is kidney. 
Tissue concentration of azithromycin is 10-100 times of those achieved in serum. The 
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extensive tissue distribution of azithromycin is due to its concentration within macrophages 
and neutrophils. 
9.7 Ketolides 
Ketolides are members of a new semisynthetic 14 membered ring macrolide, with a 3-keto 
group instead of a α-L cladinose on the erythronolide A ring. It includes telithromycin and 
cethromycin, which are given orally. Their pharmacokinetics display a long half-life as well 
as extensive tissue distribution and uptake into respiratory tissues and fluids, allowing once 
daily dosing 
10. Chloramphenicol and derivatives 
10.1 Chloramphenicol 
Chloramphenicol is a derivative of dichloroacetic acid and contains a nitrobenzene moiety. 
It is slightly soluble in water and freely soluble in propylene glycol and organic solvents. 
Chloramphenicol base or its palmitate salt is used for oral administration. Chloramphenicol 
palmitate is hydrolyzed in the small intestine by estrases, which release the free base form of 
chloramphenicol to systemic circulation. Chloramphenicol succinate is freely soluble in 
water and is used for IV or IM administration. It gets hydrolyzed in plasma to produce 
active drug. Pharmacokinetic parameters of chloramphenicol in food producing animal 








T1/2 ß  
(hr) Reference 
Cattle 
IV 40 Base 0.35 2.81 
Sanders et al., 1988 IM 90 Base - 1.35 
SC 90 Base - 1.15 




1.03 (1 day old) 
0.81 (7 day old) 
0.90 (14  day old) 
0.69 (28 day old) 
1.38 (9 months 
old) 
7.56 (1 day old) 
5.96 (7 day old) 
4.0 (14  day old) 
3.69 (28 day old) 
2.47 (9 months old) 
Burrows et al., 1983 
Sheep 
IV 30 Base 0.69 1.70 
Dagorn et al., 1990 IM 30 Base - 2.71 
SC 30 Base - 17.93 
Goats 
IV 25 Succinate 1.68 1.22 
Kume and Garg, 
1986 
IV 25 Succinate 1.96 1.29 
IM 25 Succinate 3.02 1.46 
IM 25 Succinate 2.77 1.45 
IV 10 Succinate 0.31 1.47 Abdullah and Baggot, 1986 
Pigs 
(Adult) IV 22 base 1.05 1.3 Davis et al., 1972 
Piglets IV 25 Base 0.94 12.7 Martin and Weise, 1988 
Chicken 
IV 20 Succinate 0.24 8.32 
Atef et al., 1991 IM 20 Succinate 0.44 7.84 
PO 20 Succinate 0.41 8.26 
Table 3. Pharmacokinetic parameter of chloramphenicol in food producing animal 
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Chloramphenicol is well absorbed from gastro-intestinal tract in monogastric and pre-
ruminant calves. The oral bioavailability in foals is 83%. Chloramphenicol palmitate is 
poorly absorbed in cats. Chloramphenicol administrated orally to ruminants gets 
inactivated in rumen. High lipid solubility and low plasma protein-binding (30-46%) enable 
it to attain effective concentration most tissues and body fluids including cerebrospinal fluid 
and central nervous system. It also get readily diffuse into milk and pleural and ascetic 
fluids. It also readily crosses the placenta and achieves high concentration in fetus. The drug 
has large volume of distribution (1-2.5 L/kg) due to its lipophilic nature. 
Chloramphenicol is metabolized in the liver. Phase-II glucuronidation is the principal 
pathway producing metabolite chloramphenicol glucuronide. Rapid metabolic clearance 
produces short half-lives in many species and requires frequent administration. The 
elimination half-life of chloramphenicol varies widely among species. It is short (1hr) in 
horses (Sisodia et al, 1975) and long (5-6 hr) in cats (Watson, 1991). Most of the absorbed 
chloramphenicol (80%) gets excreted into the urine as inactive metabolite via tubular 
secretion. 
10.2 Thiamphenicol 
Thiamphenicol is a semisynthetic structural analogue of chloramphenicol, in which the p-
nitro group has been replaced by a sulfomethoxyl group. Absorption and distribution are 
similar to those of chloramphenicol. Bioavailability in pre-ruminant lambs and calves is 60 
% following oral administration. It is well distributed in the body. Thiamphenicol is not 
eliminated by hepatic glucronide conjugation but excreted unchanged in the urine. The 
pharmacokinetics of thiamphenicol follow allometric scaling, in that values of elimination 
half-life and volume of distribution increase with body size (Castells , 2001). 
10.3 Florfenicol 
Florfenicol is a fluorinated derivative of thiamphenicol, in which the hydroxyl group has 
been replaced with fluorine. The oral bioavaibility of florfenicol is 89% in calves. 
Bioavailability following IM injection and intramammary infusion in lactating dairy cattle is 
38% and 54%, respectively. Florfenicol is well distributed into many tissues and fluids 
including lungs, muscle, bile, kidney and urine. Concentrations in brain and CSF are             
¼ to ½ , respectively of the corresponding concentrations in plasma. The drug has volume of 
distribution of 0.7-0.9 L/kg with low plasma protein binding (13-19%) in cattle. Most of the 
administrated dose gets excreted as the parent drug (64%) in urine of cattle. Florfenicol 
amine metabolites persist longer in tissues of cattle and are used as marker residue for 
withdrawal determination. The elimination half-life is 2-4 hr in cattle. The commercially 
available formulation of florfenicol is long-acting, so that “flip-flop” kinetics occur, where 
elimination is prolonged due to slow absorption from the injection site. 
11. Miscellaneous antimicrobials 
11.1 Ionophore antibiotics 
Carboxylic ionophore polyether antibiotics are streptomyces products used as growth 
promoters. Ionophore antibiotics used in veterinary medicine include monensin, lasalocid, 
maduramicin, narasin and salinomycin. 
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Following oral administration, monensin gets rapidly and completely absorbed in 
monogastric animals. In ruminants, oral bioavailability of monensin is 50%. Ionophore 
antibiotics do not attain higher concentration in tissues even at larger doses. Ionophores are 
rapidly and extensively metabolized in the liver and the metabolites are excreted in the bile 
and eliminated in the faeces. Horses are most sensitive to monensin toxicity because of very 
slow elimination as compared to cattle. 
11.2 Nitrofurans 
Nitrofurans are broad spectrum antimicrobials. They are used topically because of toxicity 
following systemic use. Nitrofurans are carcinogenic, hence their use in food animal has 
been banned in several countries (United States, Canada and European Union) of the world. 
In veterinary medicine, nitrofurazone is still used in non-food animals for skin infections. 
11.3 Nitroimidazoles 
The nitroimidazoles like metronidazole, dimetridazole, ronidazole, tinidazole and 
ipronidazole were once widely used in veterinary medicine but because of potential 
carcinogenicity, their use is banned in several countries (United States, Canada and 
European Union). Metronidazole is still used in companion animals against anaerobes & 
protozoa. 
Metronidazole is absorbed rapidly in monogastric animals following oral administration. 
The drug has oral bioavaibility of 75-85% in horses and 59-100% in dogs (Neff-Devis et al., 
1981; Steinman et al., 2000). It is lipophilic and widely distributed in tissues. It penetrates 
bone, abscesses and the central nervous system. It crosses the placenta and also distributed 
to milk attaining concentration similar to those in plasma. The drug has volume of 
distribution of 0.7 to 1.7 L/kg in mares, 0.95 L/kg in dogs and 0.8 L/kg in cow calves. 
Metronidazole is primarily metabolized in the liver by oxidation and conjugation. Parent 
drug & metabolites are excreted in urine & faeces. The drug has half-life of 3-4 hr in horses, 
8 hr in dogs and 1.9 hr in cow calves. Following oral administration in cow calves and 
sheep, half-lives were 4.38 & 1.72, respectively. Oral bioavailability in calves was 33.7 
percent (Patel et al., 1993; Bhavsar & Malik, 1994).  
11.4 Rifamycins 
Rifampicin is the most important synthetically modified derivative of natural antibiotics 
rifamycins. Rifampicin is soluble in organic solvents and water at an acidic pH. The drug 
gets rapidly absorbed after oral administration in calves, dogs and horses. In horses, 
bioavailability is low and administration with food prolongs the time to maximum serum 
concentration. Rifampin is very lipophilic and penetrates most tissues including milk, bone, 
abscesses and central nervous system. It is well distributed in milk. It crosses placenta and is 
teratogenic in rodents. The volume of distribution of rifampin in horses is 0.6 - 0.9 L/kg. It is 
highly bound to plasma proteins. The biotransformation and elimination of rifampin in 
animals is not well known. The elimination half-life of rifampin in horses is 6-8 hrs after IV 
injection and 12-13 hrs after oral administration. In dogs, elimination half-life is 8 hrs. 
Rifampin causes induction of hepatic enzymes in many species. 
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12. Animal origin foods and antimicrobial drug residues 
Food safety is one of the most significant issues for animal produce. During last several 
years great concern has been shown about the presence of chemical adulterants or residues 
especially antimicrobials and pesticides in the meat, poultry egg and milk. A chemical 
residue is either the parent compound or metabolite of that parent compound that may 
accumulate, deposit or otherwise be stored within the cells, tissues, organs or edible 
products of an animal following its use to prevent, control or treat animal disease or to 
enhance production. Residues can also result from unintentional administration of drugs or 
food additives. Contamination of the food supply with chemical residue is rarely an 
intentional act and usually results either from failure to observe the correct meat withdrawal 
or milk discard time for a drug after it has been used to treat a disease process in food 
animals or from accidental contamination of feed by chemicals or drugs.  
12.1 Regulation of drug residue 
Livestock and poultry production depends on drugs and other chemicals to protect animal 
health. Consumers are protected from adverse effects by regulation of chemicals and drugs 
and the detection of chemical and drug residues in foods of animals’ origin through national 
agencies (FDA in USA, Veterinary Drug Directorate in Canada, Medicines and healthcare 
products regulatory agency in UK and others). The codex alimentarius committee on 
residue of veterinary drugs in foods is subsidiary body of the world health organization 
(WHO) and the food and agriculture organization (FAO). One of the primary functions of 
the codex alimentarius is the establishment of the internationally acceptable concentrations 
of the veterinary drugs in food animal products. Extensive toxicological evaluations of the 
drugs and its metabolite are required before the drug is approved for use in food-producing 
animals. Based on the results of toxicity tests, regulatory agencies establish an acceptable 
daily intake (ADI). The ADI represents a level of daily intake of a chemical which, during an 
entire life time, appears to be without appreciable risk to the health of the consumer. The 
ADI is used to determine the maximum concentration of a marker residue in edible tissues, 
honey, milk or eggs that is legally permitted or recognized as acceptable. These acceptable 
concentrations are also termed as “tolerances” (USA) or “maximum residue limits” (MRL) 
(Canada and European union). 
12.2 Pharmacokinetics and drug residues 
Pharmacokinetics is the science of quantitating the change in drug concentration in the body 
over time as a function of the administered dose. How a drug or combination of drugs 
behaves in the body after administration not only is important from therapeutic point of 
view but is of paramount importance in order to prevent residues in the edible tissues after 
the disease process has been resolved and the animal is slaughtered. For determining 
withdrawal times of drug, half-life (t1/2) of drug is more relevant. The t1/2 of a drug by 
definition is the time taken for 50% of the drug in the animal to be eliminated from the body. 
It is calculated by the equation. 
 t1/2 = ln2/ slope or t1/2 = 0.693/ slope           (1) 
Half-life is influenced by biological factors like volume of distribution and elimination rate. 
The volume of distribution (Vd) is the quantitative estimate of the extent of the distribution 
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of the drug in the body and it influence t1/2 of the drug. It is proportionality constant 
relating the concentration of drug in the serum to the total amount of drug in the body. 
 Vd = amount of drug in the body / serum drug concentration    (2) 
In addition to Vd, the clearance (Cl) of the drug also play important role in determining the 
withdrawal time of the drug. Clearance quantitates the efficiency of the elimination process 
and is defined as the rate of drug elimination from the body relative to the concentration of 
drug in the serum. 
 Cl = rate of elimination / Serum drug concentration     (3) 
The t1/2 dependent on two functions: Volume of distribution and clearance. By combining 
term, an equation can be derived that reflects the influence of Vd and Cl on the t1/2 of a 
drug.  
 t1/2 = ln2 Vd/Cl or t1/2 = 0.693Vd/Cl          (4) 
For an orally or extrvascularaly administrated drug withdrawal can be derived as 
 Withdrawal time = 1.44 ln CCº (tolerance) (t1/2)     (5) 
Where Cº is the initial concentration of drug in the body derived by ratio bioavailability to 
Vd. 
The above equation is useful to gain a perspective on what the withdrawal time is relative to 
the terminal half-life. If the drug has a short half-life (eg. penicillin), the withdrawal time is 
short. However, If a drug (eg. An aminoglycoside) has a prolonged tissue half-life the 
withdrawal time could be very long. Similarly, a drug with a very low tissue tolerance has a 
longer withdrawal time. 
For lactating dairy cows and goats milk discard times are determined using pharmacokinetic 
principles. The milk discard or withdrawing time is the time after drug administration when 
the milk cannot be used for human consumption. This is determined by administering the 
drug and collecting and analyzing milk until drug concentrations are below the milk tolerance 
established for that drug. It is based on the half-life of the drug in the milk. Basic drugs like 
erythromycin have longer discard times than acidic drugs such as penicillin because the 
former tend to distribute more readily into milk due to pH partitioning phenomenon. 
Similarly, lipophilic drugs will tend to have longer milk discard times. 
13. Conclusion 
Food safety is one of the most significant issue faced by livestock owners and consumers of 
animal derived food. Residues of drugs and chemicals in food of animal origin raise special 
concern for human safety. Consumer concern about drug residue in animal food has led to 
reduction in demand in many countries. It has also disturbed international trade of food. 
Globally, food safety programs are advancing but formal training in drug residue 
prevention is limited. It is global need that Veterinarians should be acquainted with legal 
and regulatory issues concerning control of drug and other chemicals residues in food 
animals. The primary pharmacokinetic parameters used by veterinarians to prevent 
violative tissue residues are withdrawal time for meat and discard time for milk. 
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definition is the time taken for 50% of the drug in the animal to be eliminated from the body. 
It is calculated by the equation. 
 t1/2 = ln2/ slope or t1/2 = 0.693/ slope           (1) 
Half-life is influenced by biological factors like volume of distribution and elimination rate. 
The volume of distribution (Vd) is the quantitative estimate of the extent of the distribution 
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of the drug in the body and it influence t1/2 of the drug. It is proportionality constant 
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In addition to Vd, the clearance (Cl) of the drug also play important role in determining the 
withdrawal time of the drug. Clearance quantitates the efficiency of the elimination process 
and is defined as the rate of drug elimination from the body relative to the concentration of 
drug in the serum. 
 Cl = rate of elimination / Serum drug concentration     (3) 
The t1/2 dependent on two functions: Volume of distribution and clearance. By combining 
term, an equation can be derived that reflects the influence of Vd and Cl on the t1/2 of a 
drug.  
 t1/2 = ln2 Vd/Cl or t1/2 = 0.693Vd/Cl          (4) 
For an orally or extrvascularaly administrated drug withdrawal can be derived as 
 Withdrawal time = 1.44 ln CCº (tolerance) (t1/2)     (5) 
Where Cº is the initial concentration of drug in the body derived by ratio bioavailability to 
Vd. 
The above equation is useful to gain a perspective on what the withdrawal time is relative to 
the terminal half-life. If the drug has a short half-life (eg. penicillin), the withdrawal time is 
short. However, If a drug (eg. An aminoglycoside) has a prolonged tissue half-life the 
withdrawal time could be very long. Similarly, a drug with a very low tissue tolerance has a 
longer withdrawal time. 
For lactating dairy cows and goats milk discard times are determined using pharmacokinetic 
principles. The milk discard or withdrawing time is the time after drug administration when 
the milk cannot be used for human consumption. This is determined by administering the 
drug and collecting and analyzing milk until drug concentrations are below the milk tolerance 
established for that drug. It is based on the half-life of the drug in the milk. Basic drugs like 
erythromycin have longer discard times than acidic drugs such as penicillin because the 
former tend to distribute more readily into milk due to pH partitioning phenomenon. 
Similarly, lipophilic drugs will tend to have longer milk discard times. 
13. Conclusion 
Food safety is one of the most significant issue faced by livestock owners and consumers of 
animal derived food. Residues of drugs and chemicals in food of animal origin raise special 
concern for human safety. Consumer concern about drug residue in animal food has led to 
reduction in demand in many countries. It has also disturbed international trade of food. 
Globally, food safety programs are advancing but formal training in drug residue 
prevention is limited. It is global need that Veterinarians should be acquainted with legal 
and regulatory issues concerning control of drug and other chemicals residues in food 
animals. The primary pharmacokinetic parameters used by veterinarians to prevent 
violative tissue residues are withdrawal time for meat and discard time for milk. 
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1. Introduction 
In veterinary clinical practice the sensitivity of a given animal species to a certain drug can 
be attributed to pharmacodynamic and pharmacokinetic variations. In contrast to human 
medicine where individual differences are of primary importance, interspecies and also 
inter-breed distinctions are crucial in comparative veterinary medicine. Pharmacokinetics 
describes the behaviour of the drug in the body. Similarly to human nomenclature, the 
ADME process describes the absorption (other than IV adiministration), the distribution, the 
metabolism and the elimination of certain drugs. To produce a systemic effect, the drug 
must be absorbed and distributed to attain therapeutic concentration at the site of action. If 
the target site is the GI tract, then no absorption is needed after oral application. Significant 
variations can be seen in the extent of absorption and distribution, the rate and the manner 
of metabolism and elimination between animal species. Because of pronounced interspecies 
variations extrapolation of parameters from pharmacokinetic data of human or other animal 
origin is inappropriate and can be hazardous in case of several drugs. Lack of 
pharmacokinetic data however, necessitates the empiric application of extrapolated human 
dosages in many cases. This chapter concentrates on the variations in the ADME process 
between animals of different species, breed and age.  
2. Administration routes in veterinary practice 
Administration routes in the veterinary medicine are mainly similar to those in the human 
medicine with minor differences. Major application routes include intravenous (IV), 
intramuscular (IM), subcutaneous (SC), oral (PO), topical, intramammary and inhalational 
administration. Intravenous (IV) administration is frequent in all animal species. Drug action 
is the fastest when applied IV because no absorption is necessary. Drugs applied as an 
intravenous bolus achieve high plasma levels and produce a quick, immediate action and 
usually a pronounced effect. Drugs can also be applied IV as a continous infusion with 
which the surgeon can easily govern the effects of the substance as the concentration and the 
rate of infusion determines plasma steady state levels. It is a common way of applying 
intravenous anaesthetics like propofol. Although the IV route has many advantages, it is 
probably the most toxic way of administration. Drugs administered IV have to be applied 
slowly and observe the patient for potential side effects. Intramuscular (IM) and subcutaneous 
(SC) application is very frequent in the veterinary medicine. It is common in ruminants, 
swine, horse, dogs, cats and rabbits. Rate of absorption is determined principally by the 
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administration route, the vascularity and area of the region, the concentration and the 
ionization of the drug. There are also differences in the localization of the injection. For 
example, suprascapular IM injection is frequently applied in small animals, as it results in 
much faster absorption when compared to the gluteal muscles because of better vascularity 
and the proximity of the periosteum. Depending on the injection site, peak plasma 
concentrations are usually achieved 20-40 minutes after administration. There are several 
drugs that are formulated as sustained release preparations. Ampicillin and amoxicillin 
trihydrate, procaine and benzathine penicillin are antibiotics frequently formulated as depot 
injections resulting in prolonged absorption and effective plasma levels. These preparations 
are usually applied with 2-3 day intervals that is a great advantage in food producing 
animals where restraint is an important and avoidable stress factor. Bioavailability is 
generally higher or equal to oral administration and it is infrequently 100%. Inactivation or 
precipitation at the injection site and damage of the tissues are common contributing factors 
to low IM bioavailability values, like in case of diazepam. Oral administration is the most 
frequent mode of application in animals as food producing animals are primarily treated via 
this route. In poultry and swine drugs are commonly dissolved in the drinking water or 
mixed into the feedstuff to treat a large number of animals. Boluses, drenches, oral gels and 
oral pastes are common dosage forms for the oral treatment of ruminants and horses. 
Tablets, capsules, oral solutions and suspensions are the primary oral dosage forms in 
companion animals. Differences in oral bioavailability between animal species are 
conspicouos, detailed comparative aspects are discussed in the “Absorption of drugs” 
Chapter. Topical administration also raises several comparative pharmacokinetic issues that 
are discussed in the „Absorption of drugs” Chapter. Intramammary application is an 
important veterinary application route in the treatment and prevention of mastitis in cattle. 
3. Absorption of drugs 
Once the drug has been administered by any route other than IV it has to be absorbed into 
the bloodstream to exert its systemic effect. The extent of absorption is termed bioavailability, 
and defined as the ratio of AUC (area under the curve) after extravascular and intravenous 
administration.  
F (bioavailability) = AUCextravascular/AUCintravenous 
Depending on the administration route we can talk about oral, intramuscular, 
subcutaneous, topical etc. bioavailability. As the greatest interspecies differences occur after 
oral administration, this chapter concentrates on this application route. The extent and rate 
of absorption depends mainly on the lipophilicity, molecular weight and degree of 
ionization of the substance at the site of administration. Weak acids (like most of the 
NSAIDs) are mainly in nonionized form in the acidic environment of the stomach thus their 
absorption starts in the proximal regions of the GI tract resulting in lower Tmax values. Weak 
bases are mainly in ionized form in the stomach, thus their Tmax values are usually higher. 
Oral bioavailability can also be influenced via biotransformation by intestinal epithelial cells 
or by the liver. This is called the „first pass effect”. Many drugs are inactivated via this 
mechanism, examples include lidocaine, diazepam, xylazine, detomidine, medetomidine, 
morphine or cimetidine. In case of prodrugs, like codeine, cefuroxime-axetil or pivampicillin 
first pass metabolism is essential in activating the substance. To avoid first pass metabolism 
the drug can be applied parenterally or rectally as the rectum is not connected to the portal 
vein. Pharmaceutical formulations can also significantly alter the rate of absorption. 
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Modified release or coated tablets can delay dissolution of the substance in the 
gastrointestinal (GI) tract thereby protract absorption. Some examples for these preparations 
are retard tablets and capsules containing potassium, phenytoin, azythromycin, NSAIDs, 
sedatives and water soluble vitamins. Oily solutions, emulsions and suspensions can be 
used for the formulation of depot injections which - if injected subcutaneously or 
intramuscularly - can provide delayed absorption of the active substance. Chemical 
modifications are also used to prolong absorption. Ceftiofur is a veterinary third generation 
cephalosporin that has three different formulations for use in swine and ruminants. 
Ceftiofur sodium and ceftiofur hydrochloride are rapidly absorbed after intramuscular 
administration, while the free crystalline acid form have a protracted absorption resulting in 
approximately 150 hours effective plasma levels against certain respiratory pathogens, like 
Pasteurella multocida or P. haemolytica. Additional important factors that affect drug 
absorption include physical or chemical interaction with feed constituents, increased 
gastrointestinal motility or inflammation of the GI tract and disruption of GI epithelium. An 
example for the former phenomenon are the tetracyclines that are well known about their 
ability to form insoluble complexes with calcium and magnesium ions. Thus, feedstuff 
containing these ions in a high amount (e.g. milk products) should not be administered 
together with these antibiotics. Diseases with inherent increased GI motility will result in 
decreased absorption of the administered drugs. Inflammation of the GI mucosa and 
disruption of the GI epithelium (e.g. canine or feline parvovirosis) will result in increased 
absorption of the active substances. Aminoglycosides that are practically not absorbed from 
the intact GI tract can have much higher bioavailability and can exert systemic toxic effects 
(ototoxicity and nephrotoxicity) in animals with parvovirosis (Gemer et al., 1983, 
Riviere&Papich, 2009).  
3.1 Differences in oral and parenteral absorption in different animal species 
Discriminating monogastric and ruminant, herbivorous, omnivorous and carnivorous 
animal species is essential when defining comparative pharmacokinetics. Although there are 
notable differences in the whole ADME process, perhaps oral absorption and metabolism 
phases show the greatest distinctions. The length and volume of the GI tract in ruminants 
and horses is much more pronounced when compared to the other important domestic 
species (poultry, swine, dog and cat). This will result in longer passage time and usually 
delayed absorption after oral application of drugs. An example for this are the 
benzimidazole class of anthelminthics. A single oral dosage of these substances (e.g. 
albendazole, fenbendazole) can provide a protracted duration of action in horses, cattle, 
sheep and goats to eliminate the most important parasitic worms. In other animal species, 
multiple oral administration is usually necessary to eliminate the GI parasites. Dogs, cats 
and swine usually resemble in the rate and extent of oral absorption and these parameters 
are usually similar to humans. There are several exceptions however, that necessitate 
pharmacokinetic investigations in the certain species and need to arise precautions when 
extrapolating dosages or dosing intervals to humans or other species. Namely, oral 
bioavailability values show pronounced differences between animal species. The frequently 
applied broad spectrum aminopenicillin, amoxicillin shows an oral bioavailability of 5% in 
horses (Ensink et al., 1992), 28-33% in swine (Agerso&Friis, 1998), 59-68% in poultry (El 
Sooud et al., 2004, Jerzsele et al., 2009, Jerzsele et al., 2011) and 60-80% in dogs and cats 
(Küng et al., 1994). 
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administration route, the vascularity and area of the region, the concentration and the 
ionization of the drug. There are also differences in the localization of the injection. For 
example, suprascapular IM injection is frequently applied in small animals, as it results in 
much faster absorption when compared to the gluteal muscles because of better vascularity 
and the proximity of the periosteum. Depending on the injection site, peak plasma 
concentrations are usually achieved 20-40 minutes after administration. There are several 
drugs that are formulated as sustained release preparations. Ampicillin and amoxicillin 
trihydrate, procaine and benzathine penicillin are antibiotics frequently formulated as depot 
injections resulting in prolonged absorption and effective plasma levels. These preparations 
are usually applied with 2-3 day intervals that is a great advantage in food producing 
animals where restraint is an important and avoidable stress factor. Bioavailability is 
generally higher or equal to oral administration and it is infrequently 100%. Inactivation or 
precipitation at the injection site and damage of the tissues are common contributing factors 
to low IM bioavailability values, like in case of diazepam. Oral administration is the most 
frequent mode of application in animals as food producing animals are primarily treated via 
this route. In poultry and swine drugs are commonly dissolved in the drinking water or 
mixed into the feedstuff to treat a large number of animals. Boluses, drenches, oral gels and 
oral pastes are common dosage forms for the oral treatment of ruminants and horses. 
Tablets, capsules, oral solutions and suspensions are the primary oral dosage forms in 
companion animals. Differences in oral bioavailability between animal species are 
conspicouos, detailed comparative aspects are discussed in the “Absorption of drugs” 
Chapter. Topical administration also raises several comparative pharmacokinetic issues that 
are discussed in the „Absorption of drugs” Chapter. Intramammary application is an 
important veterinary application route in the treatment and prevention of mastitis in cattle. 
3. Absorption of drugs 
Once the drug has been administered by any route other than IV it has to be absorbed into 
the bloodstream to exert its systemic effect. The extent of absorption is termed bioavailability, 
and defined as the ratio of AUC (area under the curve) after extravascular and intravenous 
administration.  
F (bioavailability) = AUCextravascular/AUCintravenous 
Depending on the administration route we can talk about oral, intramuscular, 
subcutaneous, topical etc. bioavailability. As the greatest interspecies differences occur after 
oral administration, this chapter concentrates on this application route. The extent and rate 
of absorption depends mainly on the lipophilicity, molecular weight and degree of 
ionization of the substance at the site of administration. Weak acids (like most of the 
NSAIDs) are mainly in nonionized form in the acidic environment of the stomach thus their 
absorption starts in the proximal regions of the GI tract resulting in lower Tmax values. Weak 
bases are mainly in ionized form in the stomach, thus their Tmax values are usually higher. 
Oral bioavailability can also be influenced via biotransformation by intestinal epithelial cells 
or by the liver. This is called the „first pass effect”. Many drugs are inactivated via this 
mechanism, examples include lidocaine, diazepam, xylazine, detomidine, medetomidine, 
morphine or cimetidine. In case of prodrugs, like codeine, cefuroxime-axetil or pivampicillin 
first pass metabolism is essential in activating the substance. To avoid first pass metabolism 
the drug can be applied parenterally or rectally as the rectum is not connected to the portal 
vein. Pharmaceutical formulations can also significantly alter the rate of absorption. 
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Modified release or coated tablets can delay dissolution of the substance in the 
gastrointestinal (GI) tract thereby protract absorption. Some examples for these preparations 
are retard tablets and capsules containing potassium, phenytoin, azythromycin, NSAIDs, 
sedatives and water soluble vitamins. Oily solutions, emulsions and suspensions can be 
used for the formulation of depot injections which - if injected subcutaneously or 
intramuscularly - can provide delayed absorption of the active substance. Chemical 
modifications are also used to prolong absorption. Ceftiofur is a veterinary third generation 
cephalosporin that has three different formulations for use in swine and ruminants. 
Ceftiofur sodium and ceftiofur hydrochloride are rapidly absorbed after intramuscular 
administration, while the free crystalline acid form have a protracted absorption resulting in 
approximately 150 hours effective plasma levels against certain respiratory pathogens, like 
Pasteurella multocida or P. haemolytica. Additional important factors that affect drug 
absorption include physical or chemical interaction with feed constituents, increased 
gastrointestinal motility or inflammation of the GI tract and disruption of GI epithelium. An 
example for the former phenomenon are the tetracyclines that are well known about their 
ability to form insoluble complexes with calcium and magnesium ions. Thus, feedstuff 
containing these ions in a high amount (e.g. milk products) should not be administered 
together with these antibiotics. Diseases with inherent increased GI motility will result in 
decreased absorption of the administered drugs. Inflammation of the GI mucosa and 
disruption of the GI epithelium (e.g. canine or feline parvovirosis) will result in increased 
absorption of the active substances. Aminoglycosides that are practically not absorbed from 
the intact GI tract can have much higher bioavailability and can exert systemic toxic effects 
(ototoxicity and nephrotoxicity) in animals with parvovirosis (Gemer et al., 1983, 
Riviere&Papich, 2009).  
3.1 Differences in oral and parenteral absorption in different animal species 
Discriminating monogastric and ruminant, herbivorous, omnivorous and carnivorous 
animal species is essential when defining comparative pharmacokinetics. Although there are 
notable differences in the whole ADME process, perhaps oral absorption and metabolism 
phases show the greatest distinctions. The length and volume of the GI tract in ruminants 
and horses is much more pronounced when compared to the other important domestic 
species (poultry, swine, dog and cat). This will result in longer passage time and usually 
delayed absorption after oral application of drugs. An example for this are the 
benzimidazole class of anthelminthics. A single oral dosage of these substances (e.g. 
albendazole, fenbendazole) can provide a protracted duration of action in horses, cattle, 
sheep and goats to eliminate the most important parasitic worms. In other animal species, 
multiple oral administration is usually necessary to eliminate the GI parasites. Dogs, cats 
and swine usually resemble in the rate and extent of oral absorption and these parameters 
are usually similar to humans. There are several exceptions however, that necessitate 
pharmacokinetic investigations in the certain species and need to arise precautions when 
extrapolating dosages or dosing intervals to humans or other species. Namely, oral 
bioavailability values show pronounced differences between animal species. The frequently 
applied broad spectrum aminopenicillin, amoxicillin shows an oral bioavailability of 5% in 
horses (Ensink et al., 1992), 28-33% in swine (Agerso&Friis, 1998), 59-68% in poultry (El 
Sooud et al., 2004, Jerzsele et al., 2009, Jerzsele et al., 2011) and 60-80% in dogs and cats 
(Küng et al., 1994). 
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In horses, oral bioavailability of a large number of drugs show great individual variations. 
Absorption of most antimicrobial agents is significantly hindered by feeding, thus 2-4 hours 
fasting is essential before applying these drugs. Even in these cases systemic availability can 
show wide variations between individuals, as in case of metronidazole between 60 and 90% 
(Baggot et al., 1998). Bioavailability of several drugs can be very low compared to other 
domestic species. Examples include several antibiotics, like ampicillin and amoxicillin that 
have 0-1% and 5% oral bioavailability, respectively (Ensink et al. 1992, Ensink et al. 1996). 
This phenomenon can result in severe dysbacteriosis because of the low extent of absorption 
and accumulation of the substance in the intestinal lumen. Pivampicillin, an ester of 
ampicillin can be used to overcome this problem, as the oral bioavailability of this drug is 
31-36% (Ensink et al. 1992). In foals per os absorption is usually more pronounced, oral 
bioavailability and age being frequently in a negative correlation. Cefadroxil shows 
approximately 100% oral bioavailability in neonatal foals that decreases to 15% until 5 
months of age (Duffee et al. 1997). Metformin, an antidiabetic substance has also very low 
oral absorption compared to humans (Hustace et al., 2009). Absorption of drugs from the 
oral mucosa can be quite significant. Detomidine, a frequently applied veterinary α2-agonist 
has significant first pass metabolism resulting in low oral bioavailability if ingested. If 
applied sublingually however, absorption form the oral mucosa eventuates 22% 
bioavailability (Kaukinen et al., 2010) which is clinically useful. In horses, subcutaneous 
injection of drugs is infrequent, intramuscular application is more common. Bioavailability 
values are similar after these administration routes, although IM administration usually 
produce lower Tmax values indicating faster absorption. As IM injections can cause sterile 
abscesses, IV administration is prevalent, in this case no absorption of the drug is necessary. 
In ruminants the presence of the reticulorumen has some important clinical consequences.  
Large volume of the ruminal fluid (60-70L in cattle) dilutes the drugs and decreases their 
rate of absorption delaying the effect of orally applied medicines. Ruminal microbial flora 
restricts the oral usage of most antibacterial agents in adult individuals. As calves do not 
possess a mature ruminal microflora, antibiotics can also be applied orally. The bacterial 
flora plays an important role in the biotransformation of certain substances, like the already 
banned chloramphenicol. In several cases, however, ruminal microflora can transform a less 
active substance to a more active/toxic one. For instance, urea is almost nontoxic to 
monogastric animals, while highly toxic to ruminants as urea is rapidly transformed to 
ammonia by the bacterial urease enzyme. Netobimine, an inactive prodrug of the 
anthelminthic molecule albendazole is converted to its active form, albendazole and 
albendazole sulfoxide in the rumen (Capece et al., 2001). Anthelmintics as one of the most 
commonly used medications in ruminants can be administered orally to young and adult 
ruminants alike. In ruminants, sustained release boluses represent an important group of 
formulations. These preparations often contain anthelminthics which are released slowly 
and/or intermittently from the product resulting in excellent activity against 
gastrointestinal endoparasites. These formulations are retained in the reticulorumen and 
release the substance for months resulting in a very long withdrawal period. 
In swine oral administration of drugs via feedstuff or drinking water is a common practice. 
Pharmacokinetic investigations are frequently conducted, especially in case of antibiotics 
and anthelminthics. In infectious diseases where bacteria are localized mainly in the GI tract 
antibiotics with no or very low oral bioavailability have an important role. Colistin and the 
aminoglycosides are frequently applied in these cases as they have excellent activity against 
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Enterobacteriaceae, mainly E. coli and S. enterica and retained in the intestinal lumen. 
Apramycin is an important exception however, it has 25-30% availability, thus it can also be 
used for the treatment of systemic or urinary tract infections. Oral bioavailability of 
amoxicillin is approximately half when compared to those in poultry, dogs and cats. The 
exact explanation is not yet known, but it can be attributed to acid-catalysed hydrolysis, 
intestinal enzymes or a carrier mediated uptake mechanism, that can be saturated (Reyns et 
al., 2007). Thus, increasing dosage decreases oral bioavailability, as described in humans 
(Arancibia et al., 1988). When using an microencapsulated granule formulation, 
bioavailability is significantly increased to nearly 100%, that might be an explanation as 
microencapsulation protects amoxicillin from enzymatic degradation (Anfossi et al., 2002).  
Dogs and cats are carnivorous animals, they do not possess basal secretion of hydrochloric 
acid in the stomach, thus the gastric pH varies in fasted and fed animals. In animals with 
empty stomach gastric pH can reach values of 5-6, while in fed animals it is declined to 1-2. 
This phenomenon has clinical pharmacological consequences in some cases. As an example, 
proton pump inhibitors (like omeprazole) as they need a strongly acidic pH to be activated 
should be administered along with food. Certain NSAIDs, like the newly developed long 
acting veterinary coxib, mavacoxib should be administered together with food. The oral 
bioavailability of mavacoxib in fasted animals is approx. 46.1%, while being 87.4% in fed 
animals (Cox et al. 2010). Other examples that have greater systemic availability when 
applied with feeding include doxycycline or ketoconazole. Ketoconazole also needs acidic 
pH in the stomach to be absorbed thus it should to be given with food (Giguere et al, 2006). 
In contrast, several substances should be applied to fasted animals, as feeding significantly 
decreases absorption. Examples are ampicillin (Kung et al., 1995, Kluge et al., 1999), 
oxytetracycline, chlortetracycline (Giguere et al. 2006) or cimetidine (Le Traon, 2009). Drug 
formulations can also influence oral bioavailability. In case of amoxicillin oral availability 
was 77%, 68% and 64% after oral suspension, oral drops and tablet administration, 
respectively (Küng et al., 1994).  
In poultry the main administration route of drugs is oral application via drinking water or 
feedstuff. Oral bioavailability values are mainly similar than those in humans. Infectious 
diseases where bacteria are localized mainly in the GI tract are less frequent compared to 
swine as E. coli and salmonellae frequently penetrate into the bloodstream. Combinations 
including colistin (that has a very low bioavailability) and an other antibiotic with good 
absorption helps inhibiting and destroying bacteria systemically and luminally alike. 
Intramuscular administration of drugs is uncommon, but it comes into question when 
valuable breeding animals must be treated. IM bioavailability values are similar to oral. In 
case of marbofloxacin in ducks, oral and IM bioavailability was 87% and 81%, respectively. 
In case of amoxicillin in broiler chickens, oral and IM bioavailability was 61% and 77%, 
respectively. Although veterinary products licensed for poultry frequently have two or 
more target animal species, pharmacokinetic profile and thus dosage can show significant 
differences. Clavulanic acid has an IM bioavailability of 76% in turkeys and 87% in chickens. 
The oral bioavailability of the lactamase inhibitor is 61% in turkeys and 66% in chickens. 
3.2 Percutaneous absorption after topical administration 
Percutaneous absorption consists of three distinct phases. The drug must be dissolved, 
penetrate the stratum corneum and the epithelial layer and finally enter the bloodstream. 
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In horses, oral bioavailability of a large number of drugs show great individual variations. 
Absorption of most antimicrobial agents is significantly hindered by feeding, thus 2-4 hours 
fasting is essential before applying these drugs. Even in these cases systemic availability can 
show wide variations between individuals, as in case of metronidazole between 60 and 90% 
(Baggot et al., 1998). Bioavailability of several drugs can be very low compared to other 
domestic species. Examples include several antibiotics, like ampicillin and amoxicillin that 
have 0-1% and 5% oral bioavailability, respectively (Ensink et al. 1992, Ensink et al. 1996). 
This phenomenon can result in severe dysbacteriosis because of the low extent of absorption 
and accumulation of the substance in the intestinal lumen. Pivampicillin, an ester of 
ampicillin can be used to overcome this problem, as the oral bioavailability of this drug is 
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oral absorption compared to humans (Hustace et al., 2009). Absorption of drugs from the 
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injection of drugs is infrequent, intramuscular application is more common. Bioavailability 
values are similar after these administration routes, although IM administration usually 
produce lower Tmax values indicating faster absorption. As IM injections can cause sterile 
abscesses, IV administration is prevalent, in this case no absorption of the drug is necessary. 
In ruminants the presence of the reticulorumen has some important clinical consequences.  
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monogastric animals, while highly toxic to ruminants as urea is rapidly transformed to 
ammonia by the bacterial urease enzyme. Netobimine, an inactive prodrug of the 
anthelminthic molecule albendazole is converted to its active form, albendazole and 
albendazole sulfoxide in the rumen (Capece et al., 2001). Anthelmintics as one of the most 
commonly used medications in ruminants can be administered orally to young and adult 
ruminants alike. In ruminants, sustained release boluses represent an important group of 
formulations. These preparations often contain anthelminthics which are released slowly 
and/or intermittently from the product resulting in excellent activity against 
gastrointestinal endoparasites. These formulations are retained in the reticulorumen and 
release the substance for months resulting in a very long withdrawal period. 
In swine oral administration of drugs via feedstuff or drinking water is a common practice. 
Pharmacokinetic investigations are frequently conducted, especially in case of antibiotics 
and anthelminthics. In infectious diseases where bacteria are localized mainly in the GI tract 
antibiotics with no or very low oral bioavailability have an important role. Colistin and the 
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Enterobacteriaceae, mainly E. coli and S. enterica and retained in the intestinal lumen. 
Apramycin is an important exception however, it has 25-30% availability, thus it can also be 
used for the treatment of systemic or urinary tract infections. Oral bioavailability of 
amoxicillin is approximately half when compared to those in poultry, dogs and cats. The 
exact explanation is not yet known, but it can be attributed to acid-catalysed hydrolysis, 
intestinal enzymes or a carrier mediated uptake mechanism, that can be saturated (Reyns et 
al., 2007). Thus, increasing dosage decreases oral bioavailability, as described in humans 
(Arancibia et al., 1988). When using an microencapsulated granule formulation, 
bioavailability is significantly increased to nearly 100%, that might be an explanation as 
microencapsulation protects amoxicillin from enzymatic degradation (Anfossi et al., 2002).  
Dogs and cats are carnivorous animals, they do not possess basal secretion of hydrochloric 
acid in the stomach, thus the gastric pH varies in fasted and fed animals. In animals with 
empty stomach gastric pH can reach values of 5-6, while in fed animals it is declined to 1-2. 
This phenomenon has clinical pharmacological consequences in some cases. As an example, 
proton pump inhibitors (like omeprazole) as they need a strongly acidic pH to be activated 
should be administered along with food. Certain NSAIDs, like the newly developed long 
acting veterinary coxib, mavacoxib should be administered together with food. The oral 
bioavailability of mavacoxib in fasted animals is approx. 46.1%, while being 87.4% in fed 
animals (Cox et al. 2010). Other examples that have greater systemic availability when 
applied with feeding include doxycycline or ketoconazole. Ketoconazole also needs acidic 
pH in the stomach to be absorbed thus it should to be given with food (Giguere et al, 2006). 
In contrast, several substances should be applied to fasted animals, as feeding significantly 
decreases absorption. Examples are ampicillin (Kung et al., 1995, Kluge et al., 1999), 
oxytetracycline, chlortetracycline (Giguere et al. 2006) or cimetidine (Le Traon, 2009). Drug 
formulations can also influence oral bioavailability. In case of amoxicillin oral availability 
was 77%, 68% and 64% after oral suspension, oral drops and tablet administration, 
respectively (Küng et al., 1994).  
In poultry the main administration route of drugs is oral application via drinking water or 
feedstuff. Oral bioavailability values are mainly similar than those in humans. Infectious 
diseases where bacteria are localized mainly in the GI tract are less frequent compared to 
swine as E. coli and salmonellae frequently penetrate into the bloodstream. Combinations 
including colistin (that has a very low bioavailability) and an other antibiotic with good 
absorption helps inhibiting and destroying bacteria systemically and luminally alike. 
Intramuscular administration of drugs is uncommon, but it comes into question when 
valuable breeding animals must be treated. IM bioavailability values are similar to oral. In 
case of marbofloxacin in ducks, oral and IM bioavailability was 87% and 81%, respectively. 
In case of amoxicillin in broiler chickens, oral and IM bioavailability was 61% and 77%, 
respectively. Although veterinary products licensed for poultry frequently have two or 
more target animal species, pharmacokinetic profile and thus dosage can show significant 
differences. Clavulanic acid has an IM bioavailability of 76% in turkeys and 87% in chickens. 
The oral bioavailability of the lactamase inhibitor is 61% in turkeys and 66% in chickens. 
3.2 Percutaneous absorption after topical administration 
Percutaneous absorption consists of three distinct phases. The drug must be dissolved, 
penetrate the stratum corneum and the epithelial layer and finally enter the bloodstream. 
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Lipophilicity is a major determining factor. Several substances have excellent 
transcutaneous absorption, e.g. the ectoparasiticidal amitraz, avermectins and the 
organophosphates, lipophilic glucocorticoids, omega fatty acids etc. Absorption can be 
enhanced by formulation, namely surfactant or organic solvents, like dimethyl sulphoxide 
(DMSO). These auxiliary substances help penetration of the substances through the outer 
layer of the skin. Percutaneous absorption is also enhanced by inflammation or excoriation 
of the skin. It is important to note that there are pronounced differences between animals. 
Cats have relatively thin skin compared to other domestic species thus absorption from the 
skin can be more significant. This fact together with the metabolic deficiencies in this species 
contributes to several important toxicological occurences in cats. Therefore spot on 
preparations containing pirethroids are highly toxic to cats, because of pharmacokinetic and 
pharmacodynamic peculiarities.  
3.3 Intranasal absorption 
Intranasal application is uncommon in the veterinary practice, although there is an 
increasing number of medicines that are to be applied via this route. The notable advantage 
of this method is to avoid first pass metabolism and thereby increasing bioavailability. 
Oxytocin can be applied intranasally to induce labor, promote milk letdown and for the 
adjunctive treatment of mastitis mainly in swine. Absorption is variable however, IM or SC 
administration is more common. Another example is diazepam, a frequently applied 
anticonvulsive benzodiazepine. Nasal bioavailability of diazepam is 41-42% in dogs 
(Musulin et al., 2011), providing an alternative route next to rectal administration in status 
epilepticus. 
3.4 Intramammary absorption 
Intramammary application of antibiotics, antiinflammatories and other substances is a 
common practice in dairy cattle. The large inner surface of the mammary gland provides 
opportunity for the extensive absorption of lipophilic substances. In mastitis inflammation 
enhances intramammary absorption as described about cefoperazone (Cagnardi, 2010), 
probably because of disturbances in epithelial cell lining. Florfenicol, a small, lipophilic 
molecule has 54% intramammary bioavalability compared to 38% when applied IM (Soback 
et al., 1995). This phenomenon worth considering as drug residues will be present also in the 
milk and the edible tissues raising a public health issue if the animal must be slaughtered. 
Less lipophilic substances are absorbed usually in a negligible amount, especially in healthy 
animals as proved about cloxacillin in vitro by Kietzmann et al. (2010)  
4. Drug distribution 
After the drugs are absorbed or applied intravenously they are distributed in the body. 
Certain drugs reach and are retained only in extracellular fluids, some are also penetrating 
cell membranes and distributed intracellularly and extracellularly alike. Finally, the drug 
reaches the target cell or tissue and/or its receptor sites. Tissue concentration achieved 
primarily depend on penetration across capillary membranes. Drug distribution is mainly 
influenced by the lipophilicity, the molecular weight and the degree of ionization of the 
substance and tissue blood flow rates. Generally, the more lipophilic, the smaller and less 
ionized the molecule, it is more completely distributed in the body. Distribution shows 
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significant differences between domestic species, breeds and individuals of a certain breed. 
This can be attributed to distinctions in body composition. For instance highly lipophilic 
barbiturates are much more dangerous in greyhounds as they do not possess large volume 
of fat tissue where the drug could be redistributed. Some substances have such high plasma 
protein binding or large molecular weight that they are retained in the bloodstream after IV 
administration. Mannitol in a 5-25% concentration is applied intravenously to treat or 
prevent pulmonary edema, life threatening acute renal failure and reduce intracranial 
pressure. As it remains in the intravascular space it establishes an osmotic gradient between 
intravascular and extracellular compartments resulting in rapid decline in extracellular fluid 
amount.  
For quantitating the extent of drug distribution, the volume of distribution (Vd) term need to 
be introduced. Vd is the volume that would be necessary for the drug to be distributed in the 
body according to its plasma concentration. Thus, Vd can be described as 
Vd (volume of distribution) = A(t)/Cp 
where A(t) is the amount of drug in the body, Cp is the plasma concentration and t is time. 
According to this definition, the larger the Vd, the more extensive the drug distribution with 
higher tissue concentrations. The above mentioned mannitol has a very low Vd as it does not 
leave the intravascular space. Thus, Vd is practically equivalent with the blood volume, 
which is 0.08 L/kg. Drugs with Vd values of 0.3-0.8 L/kg (e.g. penicillins) are distributed in 
the body and achieving concentrations in tissues similar to the plasma. Drugs with 
moderate to high Vd are for instance marbofloxacin with a Vd of 1.2 L/kg in the horse 
(Carretero et al., 2002), or pentoxyfilline in chickens (De Boever et al., 2005). These drugs 
achieve much higher concentrations in the tissues than in the plasma. Chloroquine has 
extremely high Vd values in all species including humans. The substance has a Vd of  
53.3 L/kg in dogs (Aderounmu et al., 1983) representing an almost complete penetration 
from the plasma to the tissues. 
After distribution, redistribution occurs when administering certain drugs. Ultrashort acting, 
highly lipophilic barbiturates (e.g. thiopental) is applied IV, is rapidly distributed, crosses 
the blood brain barrier and causes general anesthesia. Meanwhile, the drug is quickly 
redistributed in high blood flow tissues, mainly the voluntary muscles causing a rapid 
decline in plasma drug levels. As plasma levels decrease, brain concentrations also decline 
resulting in awakening of the animal. The substance – as being highly lipophilic – is then 
accumulated in the fat tissue for a certain amount of time. Thus, readministration of 
thiopental after awakening is prohibited as the tissues featured in redistribution are already 
saturated. As mentioned above, animals with low amount of fat, like starving animals, or 
greyhounds are exposed to risk when applying the thiobarbiturates.  
Certain drugs are liable to accumulation in different regions of the body. Aminoglycosides 
for instance have very high affinity to the cortical regions of the kidney, probably because of  
high phospholipid content of this area as the cationic aminoglycosides have high affinity to 
these anionic molecules. Certain antifungal agents (e.g. griseofulvin, ketoconazole) can be 
accumulated in the stratum corneum of the skin achieving high concentrations and 
providing excellent activity against dermatophytosis and onychomycosis. The pK value of 
the molecule largely influences its ability to accumulate in certain regions of the body. In 
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Lipophilicity is a major determining factor. Several substances have excellent 
transcutaneous absorption, e.g. the ectoparasiticidal amitraz, avermectins and the 
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skin can be more significant. This fact together with the metabolic deficiencies in this species 
contributes to several important toxicological occurences in cats. Therefore spot on 
preparations containing pirethroids are highly toxic to cats, because of pharmacokinetic and 
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3.3 Intranasal absorption 
Intranasal application is uncommon in the veterinary practice, although there is an 
increasing number of medicines that are to be applied via this route. The notable advantage 
of this method is to avoid first pass metabolism and thereby increasing bioavailability. 
Oxytocin can be applied intranasally to induce labor, promote milk letdown and for the 
adjunctive treatment of mastitis mainly in swine. Absorption is variable however, IM or SC 
administration is more common. Another example is diazepam, a frequently applied 
anticonvulsive benzodiazepine. Nasal bioavailability of diazepam is 41-42% in dogs 
(Musulin et al., 2011), providing an alternative route next to rectal administration in status 
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Intramammary application of antibiotics, antiinflammatories and other substances is a 
common practice in dairy cattle. The large inner surface of the mammary gland provides 
opportunity for the extensive absorption of lipophilic substances. In mastitis inflammation 
enhances intramammary absorption as described about cefoperazone (Cagnardi, 2010), 
probably because of disturbances in epithelial cell lining. Florfenicol, a small, lipophilic 
molecule has 54% intramammary bioavalability compared to 38% when applied IM (Soback 
et al., 1995). This phenomenon worth considering as drug residues will be present also in the 
milk and the edible tissues raising a public health issue if the animal must be slaughtered. 
Less lipophilic substances are absorbed usually in a negligible amount, especially in healthy 
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significant differences between domestic species, breeds and individuals of a certain breed. 
This can be attributed to distinctions in body composition. For instance highly lipophilic 
barbiturates are much more dangerous in greyhounds as they do not possess large volume 
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intravascular and extracellular compartments resulting in rapid decline in extracellular fluid 
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accumulated in the stratum corneum of the skin achieving high concentrations and 
providing excellent activity against dermatophytosis and onychomycosis. The pK value of 
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case of weak acids pH values above the pKa result in accumulation in regions with higher 
pH, while in contrast  weak bases tend to accumulate at lower pH values than the pKa. The 
clinical relevance of this phenomenon is widely accepted. Alkaline drugs are accumulated in 
the reticulorumen in ruminants (pH 5.6-6.5), the milk (pH 6.5-6.8) or the intracellular 
environment (pH~7.0) - regions that have lower pH values compared to the plasma - if they 
are lipophilic enough to penetrate these membranes. This phenomenon is called „ion 
trapping”. Thus, lipophilic, alkaline drugs, like erythromycin, azythromycin, 
clarythromycin, clindamycin, minocycline or florfenicol have important clinical role (Davis 
et al., 2002, Yamazaki et al., 2008) in the treatment of infections caused by intracellular 
pathogens (Mycoplasma spp., Chlamydia spp., Rhodococcus equi etc.) or mastitis. 
Plasma protein binding decreases the extent of distribution as it limits capillary membrane 
transport of the molecule. Drugs are primarily bound to plasma albumin reversibly, 
maintaining an equilibrium between bound and free molecules. As the concentration of the 
free drug declines (because of metabolism, redistribution or excretion) the protein bound 
ratio acts as a reservoir thereby protracts elimination and increases half-life of the drug. A 
newly developed third generation cephalosporin, cefovecin has 96-98.7% plasma protein 
binding in dogs and 99.5-99.8% in cats resulting in long half-lives and prolonged action. 
Desfuroylceftiofur, the metabolite of ceftiofur, another third generation cephalosporin is 
highly protein bound and has a moderately long, 10 hour half-life in cattle (Brown et al., 
1991) and 8 hour in the horse (Meyer at al., 2009), uncommon to other beta lactams. If the 
drug is extensively bound to plasma proteins, it raises also toxicological issues. If such kind 
of drugs are applied together (like NSAIDs with anticoagulants) the competition for 
albumin results in higher free drug concentrations and more pronounced pharmacological 
effects, and finally, toxicosis. The same phenomenon can be observed in hypoalbuminaemia. 
It was reported that anesthesia achieved with propofol, a highly protein bound injectable 
anesthetic increases free fraction of propranolol by approx. 6% compared to untreated 
control (Perry et al., 1991). Competition for plasma albumin is one of the most frequent 
cause of pharmacokinetic interactions in the veterinary medicine. Some examples for drugs 
extensively protein bound can be found in Table 1. 
 
Drug Protein binding (%) 
Cefovecin 98-99.8 (dog, cat) 
Ceftiofur ~65% (cattle) 
Digitoxin ~88% (dog) 
Phenytoin ~78% (dog) 
Phenylbutazone ~99% (horse) 
Furosemide ~95% (dog) 
Propranolol ~92% (dog) 
Propofol 95-99% 
Warfarin 96.5% (cat) 
Table 1. Examples of drugs with extensive plasma protein binding 
In the course of distribution drugs are able to penetrate certain physiological special barriers in 
a lesser or higher degree. Clinically relevant barriers include the blood brain barrier (BBB), 
blood milk, blood prostate, blood testicle and blood placenta barriers. Diffusion through 
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these barriers is mainly affected by lipophilicity, molecular weight, ionization of the 
substance and the presence of inflammation. Inflamed meninges, mammary gland tissue or 
prostate markedly increases drug concentration in these areas. Acute or chronic nature of 
inflammation influences penetration of antibiotics across these barriers. Most of the beta 
lactams (like penicillin or ampicillin) achieve only low concentrations in the cerebrospinal 
fluid (CSF), the milk or the prostate. In acute meningitis, mastitis or prostatitis, however, 
penetration is significantly increased and can achieve inhibitory concentrations. In healthy 
tissues or those with chronic inflammation this diffusion is worse, and need emerges for the 
administration of more appropriate antibiotics, like third generation cephalosporin 
ceftriaxone or the phenicols. In modern veterinary practice usually the latter substances are 
used in the first line treatment of meningitis (Giguere et al., 2006). Another clinically 
relevant aspect is the sensitivity of some dog breeds to certain drugs including ivermectin. 
Ivermectin is a highly lipophilic endectocidal agent that readily crosses the BBB, but a P-
glycoprotein mediated efflux mechanism helps to pump out the molecule from the CSF 
(Schinkel, 1999). Some dog breeds (Collie, Sheltie, Australian Shepherd) however,  carry a 
mutated MDR-1 gene encoding a false P-glycoprotein (Roulet et al., 2003) thereby causing 
disturbances in this efflux mechanism in sensitive individuals. Selamectin, a derivative of 
ivermectin is tolerated better thus can also be used in MDR-1 mutant dog patients (Geyer et 
al. 2009). Other substances for P-glycoprotein are loperamide, domperidone or 
doxorubicine. Penetration of the blood milk barrier is important in the antibacterial therapy 
of acute mastitis in cattle. Although inflammation increases the level of antibiotics in the 
milk, only a limited number of substances is able to achieve therapeutic concentrations in 
this region. Penethamat, a narrow spectrum penicillin is a drug with excellent penetration is 
appropriate for intramuscular treatment of Gram-positive mastitis. In contrast, 
intramuscular injection of ceftiofur resulted in tissue and milk concentrations below 
detectable limits (Owens et al., 1990). In conclusion it can be pronounced that given 
parenterally, most of the beta lactams licensed for the treatment of mastitis are usually 
inappropriate in the sole treatment of the disease, but they do potentiate the efficacy of 
intramammary applied antibiotics (Ehinger et al., 2006, Owens et al., 1990). Certain 
lipophilic and alkaline substances however, can reach high concentrations in the mammary 
tissue and the milk because of excellent lipophilicity and the ion trapping mechanism (see 
above). For comparison, milk:plasma level ratios are 0.1-0.3 in case of penicillins and first 
generation cephalosporins, while 4.6 and 8.7 in case of spiramycin and erythromycin, 
respectively (Giguere et al., 2006). In conclusion it should be emphasized that among certain 
physiological barriers the BBB is the less permeable and is protected also by pump 
mechanisms, like P-glycoprotein. For comparison, fluoroquinolones can attain 2-3 times 
higher concentrations in the prostatic fluid than in the serum, while only 25% of serum 
levels can be achieved in the CSF (Giguere et al., 2006). 
5. Drug metabolism 
Metabolism or biotransformation involves a series of reactions that will render the 
xenobiotic (drug) available for excretion. These enzymatic processes decrease lipophilicity 
and increase polarity and hence water solubility of the parent molecule which can be 
eliminated via one of the excretion mechanisms present in the organism. Metabolism 
immediately begins after absorption and runs parallel with further absorption, distribution 
and exretion. Biotransformation generally takes place in two phases (Figure 1).  
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
186 
case of weak acids pH values above the pKa result in accumulation in regions with higher 
pH, while in contrast  weak bases tend to accumulate at lower pH values than the pKa. The 
clinical relevance of this phenomenon is widely accepted. Alkaline drugs are accumulated in 
the reticulorumen in ruminants (pH 5.6-6.5), the milk (pH 6.5-6.8) or the intracellular 
environment (pH~7.0) - regions that have lower pH values compared to the plasma - if they 
are lipophilic enough to penetrate these membranes. This phenomenon is called „ion 
trapping”. Thus, lipophilic, alkaline drugs, like erythromycin, azythromycin, 
clarythromycin, clindamycin, minocycline or florfenicol have important clinical role (Davis 
et al., 2002, Yamazaki et al., 2008) in the treatment of infections caused by intracellular 
pathogens (Mycoplasma spp., Chlamydia spp., Rhodococcus equi etc.) or mastitis. 
Plasma protein binding decreases the extent of distribution as it limits capillary membrane 
transport of the molecule. Drugs are primarily bound to plasma albumin reversibly, 
maintaining an equilibrium between bound and free molecules. As the concentration of the 
free drug declines (because of metabolism, redistribution or excretion) the protein bound 
ratio acts as a reservoir thereby protracts elimination and increases half-life of the drug. A 
newly developed third generation cephalosporin, cefovecin has 96-98.7% plasma protein 
binding in dogs and 99.5-99.8% in cats resulting in long half-lives and prolonged action. 
Desfuroylceftiofur, the metabolite of ceftiofur, another third generation cephalosporin is 
highly protein bound and has a moderately long, 10 hour half-life in cattle (Brown et al., 
1991) and 8 hour in the horse (Meyer at al., 2009), uncommon to other beta lactams. If the 
drug is extensively bound to plasma proteins, it raises also toxicological issues. If such kind 
of drugs are applied together (like NSAIDs with anticoagulants) the competition for 
albumin results in higher free drug concentrations and more pronounced pharmacological 
effects, and finally, toxicosis. The same phenomenon can be observed in hypoalbuminaemia. 
It was reported that anesthesia achieved with propofol, a highly protein bound injectable 
anesthetic increases free fraction of propranolol by approx. 6% compared to untreated 
control (Perry et al., 1991). Competition for plasma albumin is one of the most frequent 
cause of pharmacokinetic interactions in the veterinary medicine. Some examples for drugs 
extensively protein bound can be found in Table 1. 
 
Drug Protein binding (%) 
Cefovecin 98-99.8 (dog, cat) 
Ceftiofur ~65% (cattle) 
Digitoxin ~88% (dog) 
Phenytoin ~78% (dog) 
Phenylbutazone ~99% (horse) 
Furosemide ~95% (dog) 
Propranolol ~92% (dog) 
Propofol 95-99% 
Warfarin 96.5% (cat) 
Table 1. Examples of drugs with extensive plasma protein binding 
In the course of distribution drugs are able to penetrate certain physiological special barriers in 
a lesser or higher degree. Clinically relevant barriers include the blood brain barrier (BBB), 
blood milk, blood prostate, blood testicle and blood placenta barriers. Diffusion through 
 
Comparative Veterinary Pharmacokinetics 
 
187 
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administration of more appropriate antibiotics, like third generation cephalosporin 
ceftriaxone or the phenicols. In modern veterinary practice usually the latter substances are 
used in the first line treatment of meningitis (Giguere et al., 2006). Another clinically 
relevant aspect is the sensitivity of some dog breeds to certain drugs including ivermectin. 
Ivermectin is a highly lipophilic endectocidal agent that readily crosses the BBB, but a P-
glycoprotein mediated efflux mechanism helps to pump out the molecule from the CSF 
(Schinkel, 1999). Some dog breeds (Collie, Sheltie, Australian Shepherd) however,  carry a 
mutated MDR-1 gene encoding a false P-glycoprotein (Roulet et al., 2003) thereby causing 
disturbances in this efflux mechanism in sensitive individuals. Selamectin, a derivative of 
ivermectin is tolerated better thus can also be used in MDR-1 mutant dog patients (Geyer et 
al. 2009). Other substances for P-glycoprotein are loperamide, domperidone or 
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inappropriate in the sole treatment of the disease, but they do potentiate the efficacy of 
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above). For comparison, milk:plasma level ratios are 0.1-0.3 in case of penicillins and first 
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mechanisms, like P-glycoprotein. For comparison, fluoroquinolones can attain 2-3 times 
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levels can be achieved in the CSF (Giguere et al., 2006). 
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Metabolism or biotransformation involves a series of reactions that will render the 
xenobiotic (drug) available for excretion. These enzymatic processes decrease lipophilicity 
and increase polarity and hence water solubility of the parent molecule which can be 
eliminated via one of the excretion mechanisms present in the organism. Metabolism 
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and exretion. Biotransformation generally takes place in two phases (Figure 1).  
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Phase I – or non-synthetising phase - involves chemical reactions that „prepare” the 
xenobiotic for Phase II, namely oxidative processes (oxidation or reduction), dealkylation or 
hydroxilation that are prerequisites for conjugation in Phase II. Functional groups converted 
or attached to the molecule in this Phase are future targets of conjugation. During Phase I 
the molecule can be inactivated or on the contrary, attain activity. Diazinon, a frequently 
applied organophosphate in dogs is metabolised into diazoxon in the liver that is more 
active and more toxic than the parent molecule (Kappers et al., 2001., Costa, 2006). Certain 
antibiotics can be metabolised into an other active form, like the veterinary enrofloxacin to 
ciprofloxacin in dogs (Kung et al., 1993) or ceftiofur to desfuroylceftiofur. Those drugs that 
attain activity after biotransformation are called prodrugs. Ramipril and enalapril, two 
frequently applied angiotensin-convertase enzyme inhibitor is metabolised into active 
ramiprilat and enalaprilat to exert their pharmacological effects. Febantel, a frequently 
applied benzimidazole anthelminthic achieves activity when it is metabolised to 
fenbendazole. Fenbendazole is further converted into oxfendazole, a metabolite with higher 
activity (Montesissa et al., 1989). Netobimine, an other benzimidazole prodrug is 
transformed to active albendazole which is rapidly metabolised to albendazole sulfoxide 
(Gokbulut et al., 2006). In most of the cases however, drugs are converted to an inactive 
form, like phenobarbital to hydroxy-phenobarbital. 
 
Fig. 1. Summary of Phase I and Phase II metabolic reactions 
Phase I metabolic reactions are catalyzed by microsomal enzymes, mainly by the 
cytochrome P450 (CYP450) superfamily. The cytochrome P450 enzyme family is located in the 
smooth endoplasmic reticulum. When the cells are homogenized, these cell organs form 
vesicles known as microsomes, thus the nomenclature microsomal enzyme garniture. 
Microsomal CYP450 enzymes are monooxigenases that account for approx. 70-80% of Phase I 
metabolic reactions in animals and can be divided into CYP450 families and subfamilies. In 
humans, 18 families are distinguished. There are great differences in activity of the distinct 
CYP450 families in animals and humans. In humans, the largest and widely investigated 
enzymes belong to the CYP3A1 family. In laboratory animals CYP2E1, CYP1A2 have the 
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highest activity, but CYP4A, CYP2D and CYP3A subfamilies also play important role in 
metabolic processes (Guengerich, 1997, Fink-Gremmels, 2008). In dogs, CYP1A2 is 
expressed the most, while CYP2B11 is unique to dogs and account for approx. 20% of CYP450 
metabolic activity in this species. In chickens, CYP2H1 and CYP3A37 have the highest 
activity. Not only the presence of certain enzymes but also their activity show great 
differences between animals. For instance, the highest overall CYP450 activity was measured 
in rabbits (1.77 nmol/mg protein), the lowest in chickens (0.25 nmol/mg protein) (Nebbia et 
al., 2003, Fink-Gremmels, 2008). 
In addition to microsomal CYP450 monooxigenases, several enzymes play role in the 
biotransformation of drugs in animals. Alcohol and aldehyde dehydrogenases, monoamino 
oxidase (MAO) and enzymes responsible for conjugation in Phase II are also participate in 
drug metabolism. 
Phase II – or synthetising phase – results in conjugation of the molecule with a polar 
substance, primarily glucuronic acid (glucuronidation), acetic acid (acetylation), less 
frequently sulphate, glutathion or glycine. This process results in a water soluble, almost 
exclusively inactive metabolite that can be excreted. In comparative veterinary 
pharmacokinetic differences in metabolic processes mainly affect Phase II reactions and are 
discussed in details in the next Chapter.  
The primary organ of metabolism is the liver, but several organs have metabolic activity. It 
is reported in cats (and humans) that propofol is extensively metabolized in the lungs next 
to the liver making it relatively safe also in patients with hepatic failure (Matot et al., 1993, 
Dawidowicz et al., 2000). The intestinal tract also has metabolic activity, as several drugs are 
transformed into active or inactive forms in the intestinal wall. For instance, pivampicillin is 
hydrolysed to active ampicillin, or cefuroxime-axetil is converted to active cefuroxim. The 
kidney has also large metabolic capacities. Vitamin D for instance achieves activity in the 
proximal tubules where it is converted to active dihydroxy-cholecalciferol. Cyclosporin, an 
immunsuppressive agent is metabolized by renal cytochrome P450 enzymes and also causes 
enzyme induction (Nakamura et al., 1994). 
5.1 Comparative veterinary aspects of metabolism 
Several domestic animal species show defects in certain metabolic reactions. Phase I 
reactions show relative similarity among domestic animal species, the clinical relevance of 
these, usually only quantitative distinctions is not known. Defects in Phase II conjugation 
reactions, however, result in the clinically most relevant consequences. The most important 
metabolic pathway is glucuronidation which is present at low levels in cats rendering this 
species highly sensitive to several substances. 
In cats glucuronide conjugation is very slow as this species has a low activity of the enzyme 
glucuronyl transferase. This metabolic defect is known for long to be responsible for the 
high sensitivity of cats to several drugs (Weisburger et al., 1964). Feline species are one of 
the most endangered species from a toxicological aspect, drugs potentially toxic to cats 
include paracetamol (acetaminophen), most of the NSAIDs, especially salicylates, morphine 
or phenobarbital. Paracetamol toxicosis is a frequently fatal, common household and 
malicious poisoning in cats. Paracetamol is primarily metabolised by glucuronidation or 
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sulphate conjugation, and in less amount by microsomal enzymes into reactive 
intermediers, mainly N-acetyl-p-benzoquinine-imine (NAPQI) (Figure 2). In cats however, 
in the absence of glucuronic acid conjugation, NAPQI is accumulated (Figure 3) and causes 
methemoglobinaemia, liver necrosis leading to death.  
 
Fig. 2. Paracetamol metabolism in humans and animal species excluding the cat 
 
Fig. 3. Paracetamol metabolism in cats 
Non-steroidal antiinflammatory drugs like aspirin, ibuprofen, naproxen, diclofenac, 
phenylbutazone or piroxicam are also conjugated with glucuronic acid in most of the 
mammalian species. Slow glucuronidation in cats results in long elimination half-lives and 
consequent gastroduodenal ulcers and renal damage associated with NSAIDs. Diazepam 
and its several metabolites are also conjugated to glucuronic acid in the liver. Half-lives of 
diazepam are 2.5-3.2 h and 5.5 h in dogs and cats, and half-lives of nordiazepam (the 
primary metabolite of diazepam) is 3 h and 21.3 h in dogs and cats, respectively, indicating 
significant differences between the two species (Plumb, 2005). 
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In dogs, Phase II acetylation reactions are absent, but this has much less importance in 
veterinary medicine compared to the deficiencies in the cat. These reactions occur when 
conjugating aromatic amino groups (Williams, 1967), for instance in case of most 
sulfonamides (Figure 4.). This defect in dogs has an advantage however, as acetylated 
sulfonamides are less water soluble than the parent compounds and are precipitated in 
kidney tubules causing renal damage in humans and several animal species. In dogs, 
however, this side effect is less frequent according to the lack of acetylated metabolites. 
 
 
Fig. 4. Sulfametoxazole, an antibacterial agent with an aromatic amino group 
In pigs, sulphate conjugation is present only in a low extent, but as this pathway is primarily 
an alternative to glucuronidation, the latter mechanism overcomes this deficiency, resulting 
in no known clinical importance in the veterinary practice. 
5.2 Induction and inhibition of enzymes involved in metabolism  
Enzyme induction and enzyme inhibiton are the most important factors affecting drug 
metabolism. Additional factors include decrease in plasma protein binding or decrease in 
hepatic blood flow. 
Enzyme induction in humans has been experienced for instance in case phenobarbital, 
phenytoin or rifampin. In animals, inducive capabilities are different. In rats, for instance 
phenobarbital has much lower while rifampin has negligible effect on CYP3A enzymes (Lu 
et al, 2001). The most thoroughly studied inducer of CYP450 enzymes is phenobarbital, a 
frequently applied antiepileptic sedative in dogs and cats. In humans it is a potent inducer 
of CYP3A4, CYP2B6 and CYP2C19. As this medication is given long term (usually lifelong) 
to veterinary patients, the phenomenon has significant clinical consequences. Phenobarbital 
accelerates metabolism and thus decreases duration of action of drugs given in conjunction 
with the barbiturate and metabolised on inducible CYP450 enzymes. Examples include 
amitriptyline, benzodiazepines, phenothiazines, tramadol or fentanyl. As phenobarbital also 
induces CYP2C19, the enzyme responsible for its own metabolism, the half-life of 
phenobarbital is subsequently decreased. Therefore, in animals receiving phenobarbital, 
plasma phenobarbital levels should regularly be checked and dosage adjusted to attain 
therapeutic levels. Phenytoin is another antiepileptic, that has pronounced enzyme inducer 
activity. Clinically it is useless in dogs, as it is a strong inducer of microsomal enzymes and 
therapeutic concentrations can only be achieved in the first days of treatment, after that 
autoinduction decreases plasma levels rapidly (Frey et al., 1980).  
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sulphate conjugation, and in less amount by microsomal enzymes into reactive 
intermediers, mainly N-acetyl-p-benzoquinine-imine (NAPQI) (Figure 2). In cats however, 
in the absence of glucuronic acid conjugation, NAPQI is accumulated (Figure 3) and causes 
methemoglobinaemia, liver necrosis leading to death.  
 
Fig. 2. Paracetamol metabolism in humans and animal species excluding the cat 
 
Fig. 3. Paracetamol metabolism in cats 
Non-steroidal antiinflammatory drugs like aspirin, ibuprofen, naproxen, diclofenac, 
phenylbutazone or piroxicam are also conjugated with glucuronic acid in most of the 
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diazepam are 2.5-3.2 h and 5.5 h in dogs and cats, and half-lives of nordiazepam (the 
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significant differences between the two species (Plumb, 2005). 
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Enzyme inhibition is peculiar to several drugs, like cimetidine, omeprazole, macrolide 
antibiotics (erythromycin, clarithromycin), ketoconazole, certain fluoroquinolones or 
chloramphenicol. Omeprazole and lansoprazole are known inhibitors of the human CYP1A 
subfamily, while pantoprazole has the lowest inhibitory action among the proton pump 
inhibitors (Masubuchi et al., 1997). These drugs increase half-life of numerous drugs leading 
to potential side effects. Erythromycin and clarithromycin increases risk of toxicity in case of 
terfenadine or theophylline. Azithromycin seems to have little potential of CYP450 induction. 
Cimetidine and some fluoroquinolones also increase theophyllin plasma levels by inhibiting 
CYP1A2 in dogs (Fink-Gremmels, 2008). Ketoconazole increases midazolam plasma levels 
by interacting with CYP3A4 (Kuroha et al., 2002). One of the most significant metabolic 
interaction is observed in case of macrolides or pleuromutilins and the ionophore 
antibiotics. Namely, administration of erythromycin, tiamulin and valnemulin 
concomittantly with anticoccidial ionophores (monensin, salinomycin, narasin) causes 
significant increase in mortality, mainly because of decreased elimination of the latter 
substances. The most frequently investigated interaction is between monensin and tiamulin. 
According to these data it can be pronounced that tiamulin inhibits biotransformation of 
monensin on CYP3A subfamily, and very low margin of safety associated with monensin 
can increase mortality (Nebbia et al.,1999, Szucs et al., 2004). 
6. Drug excretion 
In the course of metabolism the primary purpose of biotransformation is to increase water 
solubility of drugs making them capable of elimination. Certain drugs are polar and 
hydrophilic enough to be excreted unchanged. Examples include the penicillins or the 
aminoglycosides, that are excreted with the urine in an active form. In point of fact 
elimination consists of metabolism and excretion, but polar drugs are eliminated mainly by 
excretion only. Excretion of xenobiotics follows usually first order kinetics, a certain ratio of 
a drug is eliminated in a certain amount of time. In some cases however, elimination follows 
zero order kinetics, and only a certain amount of drug is eliminated in a certain amount of 
time. This happens, when the excretion mechanisms become saturated, for instance in 
severe renal insufficiency. 
Renal excretion is the most important route of elimination. Polar, hydrophilic drugs can be 
eliminated via the urine and this includes several unchanged (not metabolised) substances. 
In case of antibiotics it is of great importance, whether the drug is excreted in an active or 
inactive form when treating urinary tract infections. Antibacterial agents, like penicillins, 
most of the cephalosporins and aminoglycosides are practically not metabolised, short 
acting tetracyclines and fluoroquinolones are metabolized in a low extent, but eliminated 
mainly with the urine. All of the before mentioned substances are effective in the treatment 
of urinary tract infections, but certainly pharmacodynamic considerations must also be 
considered. Renal excretion involves passive glomerular filtration and active tubular 
secretion, mainly in the proximal tubule. The latter requires energy and carrier molecules 
(„organic anion transporters”), and the process can be saturated. As active secretion plays 
an important role in the excretion of several substances, like most of the beta lactams, 
inhibiting the process significantly reduces elimination, thus increases half-life of these 
medicines. Probenecid, a substance inhibiting these carrier mediated transport mechanisms 
played an important role in prolonging the effect of penicillin (Kampmann et al., 1972). 
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Probenecid is still used concurrently with several medicines (carbapenems, antiviral agents) 
to increase their half-life.  
Glomerular filtration is a passive process and is significantly hindered by extensive (>80%) 
plasma protein binding. For instance, cefovecin, a third generation veterinary cephalosporin 
has over 95% protein binding in dogs and cats, therefore half-lives in these species are very 
long, 133 h and 166 h, respectively. 
Reabsorption in the distal tubule plays an important role in prolonging half-life of drugs. 
Nonionized, lipophilic substances can diffuse passively from the tubular fluid back to 
plasma. As several drugs are weak acids or bases, pH of the urine has top priority when 
predicting tubular reabsorption of these substances. Acidification of the urine increases 
ionization of weak alkaline substances, while alkalinization increases ionization of weak 
acids, and these polar molecules are ion trapped in the tubular fluid. This fact helps to 
govern the elimination of some potentially toxic substances via urine. Excretion of alkaloids, 
like atropine or caffeine can be enhanced by urine acidifiers. Elimination of acidic 
substances, like most of the NSAIDs or the barbiturates can be accelerated by alkalizing the 
urine. 
Biliary excretion of xenobiotics is less decisive, than renal excretion and mainly depends on 
molecular weight. Molecules larger than 500D are usually excreted with the bile in all 
animal species and humans. Dogs, rats and chickens are „better” biliary eliminators, in these 
animal species smaller (300-400D) molecules are also excreted via this route. The nature of 
the xenobiotic largely influences the route of excretion. Certain drugs, like erythromycin, 
lincomycin, clindamycin, chloramphenicol, ketoconazole, griseofulvin or the 
methylxanthines are primarily excreted with the bile. Conjugated forms of these substances 
can be deconjugated in the small intestine by bacterial β-glucuronidase enzymes and can be 
reabsorbed. This enterohepatic circulation (Figure 5.) can significantly increase half-life of 
certain drugs, like the xanthine derivatives. Thus, administration of activated charcoal in 
theophylline or theobromine (chocolate) toxicosis in dogs and cats is highly effective in 
reducing half-life by binding to intestinal portions of the substance and hindering its 
reabsorption. 
 
Fig. 5. Enterohepatic circulation of drugs 
Elimination via milk and eggs is also important in the veterinary medicine. Several lipophilic 
drugs are excreted partly with the milk. As an example, 3.8% and 6.8% of the dosage of 
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erythromycin and spiramycin, two lipophilic macrolide antibiotics is excreted via the milk, 
respectively (Giguere et al., 2006). Penethamat can also attain high concentrations in the 
milk after intramuscular administration. Relatively high drug concentrations in the milk 
necessitate caution when determining and observing withdrawal time for these substances. 
Elimination via the eggs is of high practical importance in laying hens. For instance, several 
anticoccidials, like robenidine must not be applied to egg producing animals, as drug 
reaches high concentrations and gives an unpleasant taste to the egg. 
6.1 Half-life of drugs 
Elimination half-life (t1/2) is the time when plasma levels of the drug decline to half and is an 
essential parameter when comparing elimination of drugs between species. The half-life is 
usually independent from the dosage, as elimination generally follows first order kinetics, 
and a certain ratio is eliminated from the body in a certain amount of time. As the dosage is 
increased and excretion capacity becomes saturated, the elimination will show zero order 
kinetics, and half-lives will be significantly longer. An example for this is acetyl-salycilic 
acid (aspirin) in cats. Because of this phenomenon, aspirin is usually administered with 48-
72 hour intervals to cats if less toxic drugs are not available or not appropriate for the 
disease condition. As half-life of drugs show pronounced differences, it is crucial in 
determining dosage and dosing interval and to predict toxic effects in animals. Theobromine 
for instance that has approx. 7 hours half-life in humans is very slowly eliminated in dogs 
and cats (dog t1/2 is 17.5 h), and frequently causes posioning when chocolate is given to 
these species. Sulfonamides and trimethoprim are good examples to demonstrate 
differences in half-lives among species. Trimethoprim for instance has 1.25 h half-life in 
cattle, 3.2 h in horses, 4.6 h in dogs and 10.6 h in humans. Its partner sulfamethoxasole has 
2.3 h half-life in cattle, 4.8 h in horses and 10.1 h in humans. Differences in these parameters 
necessitate the adaptation in drug dosing in the different species. Similar half-life of 
sulfonamides and trimethoprim in humans makes it an excellent combination 
pharmacodynamically and pharmacokinetically. In animals, however, half-life of the 
sulfonamides and trimethoprim is infrequently similar, thus efficacy of the combination is 
less pronounced and needs correction in the ratio of the  substances in veterinary products. 
An other important group with pregnant differences are the NSAIDs. Aspirin for instance 
has 7.5 h elimination half-life in dogs and 37.6 h in cats. This necessitates the prolongation of 
the dosage interval in cats, as described above. In conclusion it can be stated that half-life of 
drugs is essential when determining dosage and dosage intervals in each animal species, 
and prolonged half-lives of certain drugs play a crucial part in evoking toxicoses in animals, 
especially in those with defects in elimination, like cats. 
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1. Introduction  
Knowledge of the anesthesia drug concentration in a patient during a surgical procedure has 
potential to improve patient monitoring and control of drug administration. High-fidelity 
estimates of anesthesia drug concentration would allow anesthesiologists to make relevant 
low-level dose adjustment as well as high-level clinical decisions. The estimated drug 
concentrations may also be useful for computerized anesthesia delivery, including, but not 
limited to, targeting/limiting the drug concentration itself (Van Poucke et al., 2004; Gentilini et 
al., 2002) as well as monitoring and maintaining hemodynamic stability (Rao et al., 2000). 
Currently, anesthesia drug concentration is estimated based primarily on a model-based 
open-loop prediction (Fig. 1(a)), in which the drug concentration is predicted by solving a 
population-based patient pharmacokinetics (PK) and pharmacodynamics (PD) described in 
terms of a multi-compartmental model. In the absence of any feedback correction capability, 
the discrepancy between the real PK of an individual patient and its population-based 
model counterpart is a major source of errors in drug concentration estimation. The open-
loop prediction has been widely used despite this apparent drawback, mainly due to the 
lack of alternative solutions. 
Recently, efforts have been made to improve the fidelity of drug concentration estimation 
over open-loop prediction. Sartori et al. (2005) proposed a method based on an extended 
Kalman filter to adapt PD parameters in real-time. Hahn et al. (2011) proposed a robust 
estimation strategy based on H∞ control theory. The results strongly suggest that the efficacy 
of drug concentration estimation can be improved by exploiting the measurements of the 
clinical effect. Motivated by these pioneering investigations, this chapter aims to study 
alternative observer design strategies for estimating anesthesia drug concentration. In 
contrast to open-loop prediction, observer-based approaches can be regarded as closed-loop 
estimation that exploits the clinical effect measurement for feedback correction (Fig. 1(b)), in 
order to suppress the adverse influence of patient variability and effectively deal with 
unknown surgical stimulation (shown as d in Fig. 1) that acts as a disturbance to distort the 
clinical effect measurement. The specific focus of this chapter is to examine the design and 
analysis of a robust linear observer (RLO), a robust nonlinear observer (RNO), and an H∞ 
observer (H∞O) in the context of estimating propofol concentrations at the plasma and the 
effect sites. A depth of hypnosis index called WAVCNS (Zikov et al., 2006) was used to 
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describe the clinical effect of interest for feedback correction. The observers were evaluated 
against the traditional open-loop prediction using a Monte-Carlo simulation of surgical 
procedures using a wide range of patient models. H∞O boasted the best overall performance 
with its capacity to deliver statistically significant reduction in plasma and effect site 
propofol concentration errors over open-loop prediction, regardless of the presence of a 
surgical stimulation disturbance. RNO was more effective than open-loop prediction in 
suppressing the effect site propofol concentration error, but its efficacy for plasma propofol 
concentration was susceptible to surgical stimulation disturbance. RLO was good at 
reducing the effect site propofol concentration error in the absence of surgical stimulation 
disturbance, but perfomed poorly in the presence of a surgical stimulation disturbance. 
 
Fig. 1. Open-loop prediction versus closed-loop estimation of anesthesia drug concentration. 
This chapter is organized as follows. Section II describes the patient model. Section III 
details the design of observers for anesthesia drug concentration estimation. Section IV 
details the Monte-Carlo simulation and statistical analysis to compare the performance of 
observer-based estimation and open-loop prediction strategies. The results are presented 
and discussed in Section V, followed by conclusions in Section VI.  
2. Patient model 
An anesthetized patient can be described by a series connection of a PK model, a PD model, 
and a monitor model, as shown in Fig. 2. The input to this process is the drug infusion rate 
(IH), while the output is the clinical effect measurement (WAVCNS). The surgical stimulation 
is modeled as an output disturbance, because it counteracts the effect of anesthesia drug in 
an unpredictable manner and thereby distorts the WAVCNS measurement. 
 




Fig. 2. PK/PD and effect monitor models of anesthesia drug delivery process. 
2.1 PK and PD models 
A 3-compartment model of propofol developed by Schüttler and Ihmsen (2000) was used to 
describe the PK (Fig. 3). Denoting x1, x2, and x3 as drug concentrations in the plasma, fast 
peripheral, and slow peripheral compartments, the state-space representation of the PK is 
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where xPK=[x1 x2 x3]T, u=IH, kij are the rate constants, and V1 is the volume of the plasma 
compartment. To account for the PD lag associated with the distribution of drug into the effect 
site (i.e. the brain), the following delay-plus-first-order model was used (Zikov et al., 2006): 
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where Td and kd are respectively the transport delay and the rate of drug distribution from 
the plasma to the brain. Finally, the saturating Hill equation was used to describe the 




















  is the effect site drug concentration normalized by the 50% effect 
concentration (EC50), and  is the cooperativity coefficient. 
 
Fig. 3. A 3-compartmental PK model. 
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2.2 WAVCNS monitor model 
The WAVCNS index reflects the combined effect of the anesthesia drug and the unknown 
surgical stimulation. It takes values ranging from 100 to 0, where WAVCNS=100 corresponds 
to fully awake state, WAVCNS=50 corresponds to adequate anesthesia, and WAVCNS=0 
corresponds to an isoelectric electroencephalogram (EEG). The WAVCNS monitor model 
derived by Zikov et al. (Zikov et al., 2006) was used:  
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, (4) 
where d is the unknown surgical stimulation. Note that maximum (=1) and minimum (=0) 
clinical effects correspond to WAVCNS=0 and WAVCNS=100, respectively. 
2.3 Observer design model 
The observer design model is obtained by locally linearizing the PD model in the 
neighborhood of the operating regime of E=0.5 during the maintenance phase of anesthesia, 
which yields 
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Combining (1), (2), (4), and (5) results in the following observer design model, where the 
state variables x5 and x6 are associated with the WAVCNS monitor model (4): 
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3. Observer design  
A patient undergoing anesthesia is subject to a significant amount of uncertainty arising 
from the inherent inter-patient physiologic variability and unknown surgical stimulation. 
The population-based PK and PD models have thus limited predictive accuracy (Schüttler & 
Ihmsen, 2000). Besides, the PK and PD model parameters may fluctuate in response to the 
individual patient’s physiologic condition. Furthermore, the clinical effect measurement is 
persistently corrupted by unpredictable surgical stimulation. The observer must be 
designed to be robust against these multiple confounding factors.  
3.1 Design strategies 
The following alternatives were considered as observers for drug concentration estimation: 
1) RLO: a linear observer with a robust feedback gain, 2) RNO: a nonlinear observer with a 
robust feedback and a nonlinear disturbance rejection gain, and 3) H∞O: a robust dynamic 
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observer designed based on  H∞ control theory. The RLO was intended to explore the limit 
of performance of a simple linear observer. The RNO was motivated by the effort to 
separate the tasks of robustness and disturbance rejection: the linear feedback was designed 
to achieve robustness against PK/PD model uncertainty, whereas the nonlinear feedback 
was designed to compensate for the unknown surgical stimulation. The requirements of 
disturbance rejection and the observer matching condition necessitates the use of WAVCNS 
and its derivative as measurements in the design of RNO. The purpose of the H∞O was to 
examine if its added complexity is worth exploiting in order to improve the fidelity of drug 
concentration estimation. 
3.2 Robust linear observer (RLO) design 
A standard linear observer assumes the following form: 
  ˆ ˆ ˆu   x Ax B L y Cx , (7) 
where the upper bar on a matrix denotes its nominal value. L is designed to satisfy the 
inequality (8) for a positive definite matrix P in order to place the closed-loop poles in the 
left-half plane: 
    T   A LC P P A LC 0 . (8) 
Considering the patient model (6) and the observer (7), the propofol concentration estimates 
provided by the observer are susceptible to the model perturbations included in Ed that 
stem from the PK/PD uncertainty and unknown surgical stimulation. The observer gain 
matrix L must be designed so as to achieve robustness against these confounding factors. It 
is possible to determine L such that the state estimation error is bounded within a prescribed 
ellipsoid in the presence of model perturbations and/or disturbances by exploiting Theorem 
1 below: 
Theorem 1 (Set-Theoretic Robustness Condition) (Blanchini & Miani, 2008): Consider the 
system of the form 
 x Ax Fw  
which is subject to a persistent external disturbance w. Assume that the disturbance is 




   QA A Q Q FF 0  
for some >0.  
Rewrite (6) as follows where the matrices A and B are decomposed into their nominal and 
uncertain parts: 
    u d u d       x Ax B E A A x B B E  . (9) 
Subtracting (7) from (9) yields the following error dynamics: 
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observer designed based on  H∞ control theory. The RLO was intended to explore the limit 
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    u d       e A LC e Ax B E A LC e Fw  . (10) 
where F specifies the uncertainty bound and is chosen such that wTw≤1. Then according to 
Theorem 1 the state estimation error e is bounded within the ellipsoid {e: eTPe≤1} if Q=P-1 
satisfies the following inequality for some >0: 
    T T1      Q A LC A LC Q Q FF 0 . (11) 
Pre- and post-multiplying (11) by P results in (12): 
    T T1      A LC P P A LC P PFF P 0 . (12) 
Noting that P and PFFTP in (12) are positive definite and positive semi-definite, respectively, 
the inequality (12) is stronger than (8) and the pair of matrices L and P satisfying (12) 
automatically satisfies (8). Also, the “size” of P is directly related to the size of the error 
ellipsoid within which the state estimation error is bounded. Therefore, the optimal observer 
gain L for (7) can be determined by finding the pair of matrices L and P which maximizes 
the size of P while satisfying the set-theoretic robustness condition (12). 
The optimal RLO gain design problem can be cast into a linear matrix inequality (LMI) 
problem by manipulating (12) as follows. The inequality (12) implies that, for any e≠0, 
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Summarizing, the optimal RLO gain design is equivalent to solving the following LMI: 
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where the size of P is measured in terms of its trace norm, which is equal to the sum of its 
eigenvalues. 
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3.3 Robust nonlinear observer (RNO) design 
The RNO to be designed in this chapter assumes the following form: 
  ˆ ˆ ˆu    x Ax B L y Cx η , (17) 
where L is the linear feedback designed to suppress the adverse effect of the PK/PD 
uncertainty, and  is the nonlinear feedback to compensate for the unknown surgical 
stimulation. The error dynamics is derived by subtracting (17) from (9): 
    u d d         e A LC e Ax B E A LC e Gw E η  , (18) 
where G specifies the uncertainty bound and is chosen such that wTw≤1. Note that 
 d Fw Gw E , (19) 
which suggests that within the RNO framework the PK/PD uncertainty Gw is taken care of 
by L, whereas the surgical stimulation is accounted for by , in contrast to the RLO where 
both of these confounding factors Fw=Gw+Ed must be dealt with by L. 
To exploit  to cancel out the effect of d, it is required that the following observer matching 
condition be satisfied for some function h(x,u): 
  1 T ,d uE P C h x , (20) 
where P satisfies (8). Note that (20) cannot be satisfied by the output matrix C in (6); it 
violates the positive definite requirement on P by imposing p66=0. In order to resolve this 
problem, we assume that WAVCNS and its time derivative are available as sensor 
measurements: 
  4 4 2 2  y 0 I x Dx . (21) 
With this choice of the output, the following constraints are imposed on P: 
 16 26 36 46 0p p p p    ,  56 164 ,p d h u x ,  66 264 ,p d h u x . (22) 
Then the linear feedback gain L of the RNO can be designed by solving the LMI (16) with F 
substituted by G, subject to (22). Once a feasible L and P are obtained from the LMI, the 
function h(x,u) is directly obtained from (22). 
Assuming that the linear feedback gain L and the positive matrix P are designed to satisfy 
(16) with F substituted by G and the observer matching condition (20), the nonlinear 









which can be shown by considerng the Lyapunov function V(e)=eTPe. Using the error 
dynamics (18), the time derivative of V(e) becomes: 
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where the size of P is measured in terms of its trace norm, which is equal to the sum of its 
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Note that 1) the term (a) is strictly negative whenever e is outside of the ellipsoid defined by 
{e: eTPe≤1}, and 2) the term (b) is always strictly negative. Thus, the time derivative of V(e) is 
strictly negative if eTPe≤1 is violated. Therefore, the observer error is guaranteed to 
converge to and be bounded within the ellipsoid {e: eTPe≤1}. 
3.4 H∞ observer (H∞O) design 
The H∞O was designed as described in Hahn et al. (2011) and the detailed discussion on its 
design is therefore omitted here. Briefly, the H∞O assumes the same form as the RLO (6). 
However, in contrast to the RLO whose observer gain L is a constant matrix, the observer 
gain L of the H∞O is a transfer matrix: L=L(s), where s is the Laplace variable. Therefore, the 
state estimation is given by: 
 ˆ ˆ u  x Ax B υ , (25) 
where the feedback  is the output of a dynamic system with the clinical effect estimation 
error as its excitation signal: 
  ˆy  ξ ξξ A ξ B Cx ,  ˆy  ξ ξυ C ξ D Cx . (26) 





    ξ ξ ξ ξL C I A B D . (27) 
The objective is to design a feedback gain L(s) of the H∞O that is robust against Fw. In the 
frequency domain, (6) and (25) are expressed as follows: 
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. (28) 
where      ˆy s y s s Cx . Subtracting  ˆ sx  from x(s) yields the following error dynamics: 
           11 1s s s s s s s           ewe T w I I A L C I A Fw . (29) 
Based on (29), the H∞O can be designed by minimizing the H∞ norm of the frequency-
weighted closed-loop disturbance-to-error transfer function Tew(s): 
 











W T , (30) 
where We(s) is a weighting function specifying the desired error bound. The linear fractional 
transformation (LFT) (Skogestad & Postlethwaite, 1996) can be used to convert (30) to the 
standard H∞ optimization set-up (Skogestad & Postlethwaite, 1996) shown in Fig. 4, where 
P(s) is given by: 
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where z(s)= We(s)e(s). This chapter employed a simple first-order filter (32) as We(s), which 
aims at small errors in the low frequency region: 











W I 0 , (32) 
where k specifies the error bound at steady state, 1 specifies the observer bandwidth, and 
2>1. Then the state-space representation (33) of P(s) is obtained: 
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Fig. 4. Standard H∞ optimization set-up for H∞O design. 
Based on (33), the optimal H∞O can be designed using the D-K iteration (Skogestad & 
Postlethwaite, 1996). Note that although (33) does not satisfy all the regularity assumptions 
required for H∞ optimization (Skogestad & Postlethwaite, 1996), the problem can be 
resolved by any standard regularization procedure (e.g. Pertew et al., 2006). 
 





   
    
T T
TT T T T














         
     
    
e e Pe e Pe
e A LD P P A LD e e PGw e PE e Pη
e Pe e PGG Pe e PGw e PE e Pη




Note that 1) the term (a) is strictly negative whenever e is outside of the ellipsoid defined by 
{e: eTPe≤1}, and 2) the term (b) is always strictly negative. Thus, the time derivative of V(e) is 
strictly negative if eTPe≤1 is violated. Therefore, the observer error is guaranteed to 
converge to and be bounded within the ellipsoid {e: eTPe≤1}. 
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The objective is to design a feedback gain L(s) of the H∞O that is robust against Fw. In the 
frequency domain, (6) and (25) are expressed as follows: 
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where      ˆy s y s s Cx . Subtracting  ˆ sx  from x(s) yields the following error dynamics: 
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Based on (29), the H∞O can be designed by minimizing the H∞ norm of the frequency-
weighted closed-loop disturbance-to-error transfer function Tew(s): 
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where We(s) is a weighting function specifying the desired error bound. The linear fractional 
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where z(s)= We(s)e(s). This chapter employed a simple first-order filter (32) as We(s), which 
aims at small errors in the low frequency region: 











W I 0 , (32) 
where k specifies the error bound at steady state, 1 specifies the observer bandwidth, and 
2>1. Then the state-space representation (33) of P(s) is obtained: 
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Fig. 4. Standard H∞ optimization set-up for H∞O design. 
Based on (33), the optimal H∞O can be designed using the D-K iteration (Skogestad & 
Postlethwaite, 1996). Note that although (33) does not satisfy all the regularity assumptions 
required for H∞ optimization (Skogestad & Postlethwaite, 1996), the problem can be 
resolved by any standard regularization procedure (e.g. Pertew et al., 2006). 
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4. Methods  
4.1 Design of observers 
The demographic and PD data of 15 patients aged 18-30 (22+/-3.2) listed in Dumont et al. 
(2009) were used to obtain a nominal PK and PD model (1)-(4). Then 100 random Monte-
Carlo models were created for the nominal model by applying up to +/-15% perturbations 
to all the PK and PD parameters. The PK/PD variability was specified as follows: 
  iu d diag    Fw Ax B E w  , (34) 
where i, i=1,...,6 were chosen to encompass the resultant effect of up to +/-15% random 
PK/PD parametric perturbations as well as surgical stimulation of up to +/-20 WAVCNS 
units. 
Before designing the observers, the observability of the system was analyzed by evaluating 
the observability grammian matrix (35) with the nominal patient model: 
  T T
0
exp expo d  
    W A C C A , (35) 
using which the relationship between the dominant direction of each eigenvalue and the 
propofol concentration at each compartment was examined. The condition number of Wo 
was also calculated to assess the well-posedness of the observer design problem. 
Using the nominal patient model, the observer gain matrix L for RLO and RNO were 
designed by solving the LMI (8) and (16) with =1 and =10-5, respectively. In the RNO 
design, the constraint (22) was imposed on P. The H∞O was designed by applying the D-K 
iteration procedure to the standard set-up (33). The weighting function (32) was specified as 
k=5.0, 1-1=2.0×10-5Hz, and 2-1=1.0×109Hz, which requires the error to be bounded by 20% 
up to 2.0×10-5Hz, beyond which an increase in size of the error is permitted. 
4.2 Monte-Carlo simulation 
The 100 randomly created patient models were used for the Monte-Carlo simulation. TCI 
administration of propofol to target the effect site propofol concentration of 3mcg/ml was 
chosen as the simulation scenario (Fig. 5). The duration of the simulated procedure was 
2000s. The surgical stimulation shown in Dumont et al. (2009) was adopted and applied to 
the patient models from 1200s to 1700s (Fig. 5). The open-loop-predicted propofol 
concentrations were calculated by solving the PK and PD models (1) and (2). 
4.3 Statistical analysis 
From the simulation of each of the 100 random patient models, the following plasma and 
effect site percentage errors (PE) were calculated for both observer-based estimation (RLO, 
RNO, and H∞O) and open-loop prediction: 
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where PEjs denotes the PE for the sample j at the site s (s=p for plasma and s=e for effect 
site), and Cs(j) and  ˆ sC j  are the true versus open-loop predicted or closed-loop estimated 
drug concentrations for the sample j at the site s. The median absolute PE (MDAPE), mean 
absolute PE (MNAPE) and maximum absolute PE (MXAPE) were calculated as follows and 
were used to compare the performance of the observers and its potential over the open-loop 
prediction: MDAPEs=median{|PEjs|}, MNAPEs=mean{|PEjs|}, and MXAPEs=max{|PEjs|} 
(Varvel et al., 1992). The errors were calculated for the induction phase of anesthesia 
(t<600s) and the entire procedure (t<2000s) in order to examine the effectiveness of the 
observers against surgical stimulation. The reduction in errors by the observers over the 
open-loop prediction was assessed in terms of the median value of the 100 observer-
estimated MDAPE, MNAPE and MXAPE normalized by their open-loop-predicted 
counterparts. The statistical significance of the error reduction was determined by applying 
the two-sample t-test to the 100 pairs of observer-estimated and open-loop predicted 
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Fig. 5. Propofol effect site TCI scenario for Monte-Carlo simulation. 
5. Results and discussion  
5.1 Observability analysis and observer design 
The effect site propofol concentration x4 (which is the primary concentration of interest) was 
associated with the second smallest eigenvalue of Wo, whereas the peripheral 
compartmental concentrations x2 and x3 corresponded to its largest and second largest 
eigenvalues. This implies that the influence of x4 on the output (x5) is relatively weak 
compared to x2 and x3, because x2 and x3 can dominate x4 in terms of output energy through 
their slowly decaying dynamics (i.e. x2 and x3 decay much slower than x1 and x4). The 
condition number of Wo was very large (approximately 821), indicating that the degree of 
observability for propofol concentrations in different compartments can be significantly 
different. Essentially, the observability analysis clearly illustrates that estimating x4 is 
inherently a challenging task. 
RLO design resulted in L with optimal tr[P]=6.7×108. The real part of the closed-loop 
eigenvalues ranged from -4.5 to -0.4. RNO design resulted in L with optimal tr[P]=8.2×108. 
The real parts of the closed-loop eigenvalues range from -2.1×102 to -1.2×10-4. H∞O design 
resulted in L(s) that has robust stability margin of ∞ and robust performance margin of 1.1, 
indicating that the closed-loop system is always stable, and is robust against up to 1.1 times 
the uncertainty incorporated in the observer design (Balas et al., 2009). 
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where PEjs denotes the PE for the sample j at the site s (s=p for plasma and s=e for effect 
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5.2 Performance evaluation and statistical analysis 
The distributions of MDAPE, MNAPE, and MXAPE of the propofol concentration errors at 
the plasma and the effect site are shown in Fig. 6 and Fig. 7 for the induction phase of 
anesthesia and the entire procedure, respectively. Tables 1-3 summarize mean (SD) of these 
errors. 





























































Fig. 6. Distributions of MDAPE, MNAPE, MXAPE during the induction phase of anesthesia. 
OL: open-loop prediction, RL: RLO, RN: RNO, RH: H∞O. 





























































Fig. 7. Distributions of MDAPE, MNAPE, MXAPE during the entire procedure. OL: open-
loop prediction, RL: RLO, RN: RNO, RH: H∞O. 
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The RNO and the H∞O outperformed the RLO. Except for its benefit in reducing MXAPE of 
Ce during the induction phase of anesthesia (by 21%, p<10-5; Table 3), the RLO was no better 
than the open-loop prediction (Table 1 and Table 2). Compared with the open-loop 
prediction, the RNO was capable of reducing MXAPE of Ce (by 59%, p<10-5) and Cp (by 38%, 
p<10-5) during the induction phase of anesthesia (Table 3), and MXAPE of Ce (by 43%, p<10-
5) during the entire procedure (Table 3). Its MDAPE and MNAPE were as good as those of 
the open-loop prediction during the induction phase of anesthesia, but they deteriorated 
more than the open-loop prediction when evaluated for the entire procedure (Table 1 and 
Table 2). The degraded performance of the observers in the presence of surgical stimulation 
is expected because it distorts the clinical effect measurement, resulting in an inappropriate 
feedback correction, whereas the open-loop prediction is not affected by surgical stimulation 
(see Fig. 1). In contrast to RLO and RNO, the H∞O was able to deliver statistically significant 
reduction in all the PE metrics over the open-loop prediction, regardless of the presence of 
surgical stimulation (see Table 4). Moreover, the SD of all the metrics for the H∞O were 
significantly smaller than those of the open-loop prediction, indicating that the propofol 
concentrations provided by the H∞O are more reliable. This suggests that, in contrast to the 
open-loop prediction in which the PK/PD variability directly deteriorates the propofol 
concentration estimates, the observer’s feedback correction based on the clinical effect 
measurement is viable in suppressing the propagation of the adverse influences of the 
PK/PD variability into the propofol concentration errors. 
 
 Induction Phase Entire Procedure 
 OL RLO RNO H∞O OL RLO RNO H∞O 
Ce 8.08 (5.61) 14.6 (9.91) 9.70 (6.81) 7.07 (4.96) 8.67 (6.06) 15.1 (10.2) 11.6 (7.78) 6.82 (4.99) 
Cp 8.07 (5.65) 14.6 (9.95) 9.70 (6.83) 7.18 (5.06) 8.66 (6.07) 15.1 (10.1) 11.6 (7.77) 6.93 (5.07) 
Table 1. Distribution of MDAPE: mean (SD). 
 
 Induction Phase Entire Procedure 
 OL RLO RNO H∞O OL RLO RNO H∞O 
Ce 8.70 (5.06) 14.8 (9.47) 9.51 (6.44) 7.01 (4.80) 8.68 (5.71) 16.3 (8.94) 12.3 (7.60) 6.78 (4.84) 
Cp 8.24 (5.18) 14.9 (9.58) 9.48 (6.42) 7.11 (4.90) 8.55 (5.76) 16.6 (9.02) 12.3 (7.58) 6.89 (4.94) 
Table 2. Distribution of MNAPE: mean (SD). 
 
 Induction Phase Entire Procedure 
 OL RLO RNO H∞O OL RLO RNO H∞O 
Ce 29.7 (10.8) 22.1 (9.40) 13.9 (7.29) 9.44 (4.81) 29.8 (10.7) 38.1 (12.1) 20.1 (8.61) 10.1 (4.94) 
Cp 18.9 (7.11) 25.1 (9.09) 13.2 (7.28) 8.85 (4.83) 19.2 (6.98) 582. (53.7) 19.9 (8.70) 9.61 (4.93) 
Table 3. Distribution of MXAPE: mean (SD). 
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Fig. 6. Distributions of MDAPE, MNAPE, MXAPE during the induction phase of anesthesia. 
OL: open-loop prediction, RL: RLO, RN: RNO, RH: H∞O. 





























































Fig. 7. Distributions of MDAPE, MNAPE, MXAPE during the entire procedure. OL: open-
loop prediction, RL: RLO, RN: RNO, RH: H∞O. 
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 Induction Phase Entire Procedure 
 MDAPE MNAPE MXAPE MDAPE MNAPE MXAPE 
Ce 13% (p<10-10) 21% (p<10-10) 73% (p<10-10) 24% (p<10-10) 25% (p<10-10) 72% (p<10-10) 
Cp 11% (p<10-10) 15% (p<10-10) 59% (p<10-10) 22% (p<10-10) 21% (p<10-10) 56% (p<10-10) 
Table 4. Reduction of PE metrics over open-loop prediction by H∞O. 
Several important observations can be made from the overall results. First, the observers 
were effective in reducing MXAPE (except for the RLO in the presence of surgical 
stimulation, i.e. during the maintenance phase). This is attributed to the philosophy behind 
the design of robust observers – the observers considered in this chapter were designed to 
improve the worst-case performance (Skogestad & Postlethwaite, 1996). Due to the design 
objective of guaranteeing performance and robustness even in extreme situations, the 
behaviour of these observers on patients whose dynamics are rather close to the nominal 
design model may not be optimal (this may partly explain why MDAPE and MNAPE 
metrics of RLO and RNO are not as good as the open-loop prediction). 
Second, in spite of its robustified feedback gain, the standard linear observer was not an 
attractive strategy for anesthesia drug concentration estimation, due to its limited 
performance in the presence of surgical stimulation. In our attempt to overcome this 
limitation, we presented an RNO and an H∞O as alternatives to the RLO. The RNO could 
provide a marginal improvement that was not sufficient to justify the cost of additional 
measurement (i.e. the time derivative of the clinical effect). The H∞O exhibited significantly 
superior performance to RLO and RNO without any extra measurement requirements, by 
virtue of the additional flexibility in its structure: the feedback gain L(s) is a dynamic system 
rather than a constant matrix as in RLO and RNO. Despite their limited performance in the 
presence of surgical stimulation, RLO and RNO can still be considered as valid options for 
applications in the induction phase of anesthesia and the operations involving minor 
surgical procedures, by virtue of their structural simplicity in implementation in comparison 
with H∞O. 
From the design perspective, one advantage of the observer-based strategies investigated in 
this chapter is the explicit specification of the amount of PK/PD uncertainty and surgical 
stimulation it must tolerate (see the matrix F in (16) for RLO and RNO and in (33) for H∞O) 
and its systematic use for optimizing the observer performance so that the observer is tuned 
to appropriately exploit the clinical effect measurement distorted by surgical stimulation, in 
order to better estimate the drug concentrations over the open-loop prediction in spite of the 
PK/PD uncertainty. 
6. Conclusion 
This chapter investigated alternative observer-based strategies for estimation of anesthesia 
drug concentrations. The design objective was dedicated to robustness of observers against 
the PK/PD model uncertainty and the unknown surgical stimulation. In this chapter, we 
considered linear (RLO), nonlinear (RNO), and  dynamic (H∞O) observers. The performance 
of the observers in comparison with traditional open-loop prediction was evaluated using a 
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Monte-Carlo simulation of a surgical procedure. Based on the PE-based metrics, it was 
concluded that the use of H∞O is optimal. However, RLO and RNO can be viable 
alternatives for the induction phase of anesthesia and/or minimally stimulating procedures.  
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1. Introduction 
Calcineurin inhibitors (CNIs) are maintenance immunosuppressive drugs that have been 
used as the main therapy for organ transplantation for many years. Of the CNIs, 
cyclosporine (CYA) and tacrolimus (TAC) are used in clinical practice. The CYA binding 
protein is cyclophilin and that of TAC is FK-binding protein (FKBP), but both drugs have 
same mechanism of action: the inhibition of interleukin 2 (IL-2) production by binding the 
binding protein complex to calcineurin (CN). It is thought that the area under the 
concentration time curve (AUC) for both drugs may be the pharmacokinetic (PK) parameter 
that is the most associated with clinical effect. However, oral CYA administration gave a 
blood concentration–time curve with a high CYA peak concentration (Cp), and oral TAC 
showed a gradual blood concentration–time curve, keeping at the minimum of the 
therapeutic range; both drugs vary significantly in their pharmacokinetics1). The Cp of CYA 
has increased since the Neoral® preparation of CYA was used, compared with 
Sandimmune®, whereas the Cp of TAC decreased since using a sustained release 
preparation; thus the differences between CYA and TAC are considerable2). Although the 
optimal pharmacokinetics of both drugs may be similar to those of other drugs with the 
same mechanism of action, no conclusions have been reached on whether the peak blood 
concentration, or a specific maintained blood concentration, is required for CNI 
pharmacokinetics, even if both drugs show identical AUCs. In addition, although CYA and 
TAC are similar CNI drugs, there are differences in the recommended monitoring points of 
CYA and TAC; these points are the C2 level (the blood concentration 2 h after oral 
administration), which mainly reflects Cp, and the trough concentration (Ct)3-8), respectively9-
11). To solve these problems, it is necessary to consider comprehensively not only AUC, but 
also Cp, Ct, and time above the minimum effective concentration (%T > MEC). We discuss 
the optimal pharmacokinetics of CNIs by comparing various aspects of CYA and TAC. 
2. Which parameter is the most closely associated with clinical results? 
2.1 Cyclosporine 
It is a well-known fact that Ct is associated with clinical effect. As when the Ct become 
higher, the AUC and the Ct p are consequently higher. it is not surprising that Ct, Cp, and 
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AUC are all correlated with clinical effect. The question, therefore, is which of these PK 
parameters is the most associated with clinical effect. It is commonly thought that the AUC 
of CYA is most closely associated with clinical effect12,13). However, it is often difficult to 
measure AUC0–12 for 12 h after administration in clinical practice. Accordingly AUC0–4 (the 
area under the concentration time curve at 0–4 h following oral administration) is generally 
used as an alternative absorption phase to AUC0–12. This earlier blood sampling point that 
has been used since the introduction of cyclosporine microemulsion preconcentrate 
(Neoral), in which oral absorption is significantly stabilized3,14,). Even AUC0–4 requires 
several blood sampling points, and this causes problems such as increased burden on 
patients, cost, and medical staff duties. It has therefore been recommended that a single 
blood sampling point, C2, be used; this is the sampling point at which the majority of 
patients show peak level in the absorption phase, and is better correlated with AUC0–12 than 
C03-8). It has been reported that AUC0–4 and C2 are associated with the incidence rate of acute 
rejection and nephropathy or similar conditions3,15-19), and a relationship with clinical effects 
and side effects was demonstrated. Nevertheless, there are several problems relating to the 
use of C2 because its determination involves the measurement of absorption values. As it 
means the change in blood concentration over time is great; there is a possibility that C2 may 
vary significantly over a small interval in blood sampling times, in comparison with trough 
value 20,21), and complicated procedures for outpatients are increased. Given the above, the 
monitoring of C2 in routine clinical practice is questionable 22,23), and it has been reported 
that there is little evidence in which it is useful to monitor C224）.  
2.2 Tacrolimus 
On the other hand, the AUC of TAC, like that of CYA, is commonly considered to be a 
parameter which is highly associated with clinical effect, despite little evidence for TAC 
treatment showing clinical effects such as acute rejection25,26）or side effects such as 
nephrotoxicity27). Therefore, TAC was examined to show which blood sampling point is the 
best correlated with AUC as CYA. One study reported that Co is the best correlated with 
AUC27), whereas another study suggested that a formula with fewer blood sampling points, 
and not Co, is the most closely correlated with AUC (limited sampling strategy) 28-31). 
Thus, although the AUC of CNIs is regarded as the PK parameter, which is the most closely 
associated with clinical effect, its monitoring point is not clear. In addition, it has not been 
much discussed whether the peak blood concentration, or a specific maintained blood 
concentration, is required for pharmacokinetics even if both drugs show identical AUC. For 
the purpose of solving this problem, the authors analyzed the pharmacokinetics of CYA and 
TAC by comparing AUC, Cp, and Ct parameters, used not as independent parameters but in 
a new manner, which could indicate the interrelationship between these parameters. 
2.3 Comparison between pharmacokinetics of oral cyclosporine and tacrolimus1)  
There has been no study comparing the differences between the blood concentration time 
curves of CYA and TAC in detail. Therefore, the authors thought that the pharmacokinetics 
of both drugs could be compared by using the blood concentration (C/D/BW), adjusted for 
dose per body weight. Although the AUC/(D/BW) of both CYA and TAC, which should 
show the relative availabilities, was equal, the Cp/(D/BW) of CYA was comparatively 
higher than that of TAC and, on the other hand, the Ct/(D/BW) of CYA was lower than that 
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of TAC, which illustrated a blood concentration time curve with a sharp peak. On the other 
hand, the pharmacokinetics of TAC showed that the Cp/(D/BW) of TAC was lower and the 
Ct/(D/BW) was higher, which illustrated a gently hunched blood concentration time curve, 
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(n = 20) (n = 24)
AUC/Ｄ/ＢＷ(ng/mL・h)/(mg/kg) 2323±447 2507±1255 N.S.
Cｐ/Cｔ 6.00±1.78 1.93±0.43 <0.0001
Ｃｐ/Ｄ/ＢＷ(ng/mL)/(mg/kg) 433.1±90.3 292.6±135.7 <0.005
Cｔ /Ｄ/ＢＷ(ng/mL)/(mg/kg) 77.1±23.6 160.0±91.8 <0.005
AUTL/AUC（%) 41.9±6.9 73.4±8.1 <0.0001
（Takeuchi H. Biol Pharm Bull. 2008 ）  
Table 1. Comparison of pharmacokinetic parameters between CYA and TAC 
Thus, even if the AUC of both drugs were equal, the pharmacokinetics of the both drugs is 
totally different, from the viewpoint of the correlation with each peak value and each trough 
value. We developed AUTL/AUC% (percentage of the area under the trough level in the 
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area under the blood concentration) in order to assess the interrelationship between AUC, 
Cp, and Ct in comparing CYA and TAC (Figure 2). As a result, the AUTL/AUC% of CYA 
was as low as 41.9%, and the AUC had a higher percentage of dependence on Cp than on Ct. 
On the contrary, the AUTL/AUC% of TAC was as high as 73.4%, and the AUC had a higher 






















%T > MEC：time above minimum effective concentration 
AUTL：area under the trough level
AATL： area above the trough level
AUTL/AUC%：a ratio accounting for AUTL in AUC
MEC%T > MEC
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Fig. 3. Comparison of the pharmacokinetic parameters of AUTL/AUC% between CYA and 
TAC. 
To demonstrate these results further, we examined the correlation between the AUC and the 
area above trough level (AATL) or AUTL, and found that these results were consistent with 
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the theory that CYA had higher correlation with AATL, and TAC had higher correlation 
with AUTL (Table 2). If AUC is most closely associated with clinical effect, it may be 
appropriate to monitor Cp and Ct for CYA and TAC, respectively. However, considering 
that the blood concentration per unit time for Cp changes dramatically, and taking into 
account the measurement convenience and complexity of the methods, it is thought that 
TAC to measure Ct is preferable as a drug to perform TDM than CYA to recommend 
measuring C2. However, it is thought that Ct as monitoring paint is not a clinical problem, 
as the measurement of CYA Ct reflects the AUC adequately.  
 
Table 2. Comparison of correlation coefficients between AUC and AUTL or AATL in CYA- 
and TAC-treated recipients 
Furthermore, the influences on clinical effect, such as effectiveness or side effects, would be 
different between pharmacokinetics with a higher peak value, namely with low 
AUTL/AUC% and pharmacokinetics with a maintained minimum effective concentration, 
namely with high AUTL/AUC%, such as the blood concentration of continuous intravenous 
infusion, even if the AUC of both drugs were equal. By illustrating this, as shown in Figure 
4, it is possible to see a difference between the pharmacokinetics of A and B, even if both 
AUCs are equal. The Cmax of A is lower than that of B but the Cmin of A is higher than that of 
B. This relation can be applied to the correlation of CYA and TAC discussed above.  
In addition, considering PK parameters involved pharmacodynamics (PD) such as the 
minimum effective concentration (MEC), A may maintain MEC over a certain time  
(%T > MEC), which is longer than for B, even if the AUCs for both A and B are equal. CNIs 
may be a drug for which time above MIC (MEC) is associated with drug efficacy, as is the 
case with antimicrobial agents such as beta-lactam antibiotics, This suggests that the effects 
of A and B may be different, by the correlation of AUC, Cp, and Ct. 
Thus, the examination of clinical effect using only AUC is limited, and therefore, an analysis 
including the interrelationship between AUC, Cp, Ct, and time is required. 
3. Correlations among AUTL/AUC%, effects, side effects, and PK parameters 
for other drugs practicing TDM 
Table 3 shows the results of correlations among the PK parameters, effects, and side effects 
of current drugs investigated for TDM in the literature. As a result, the blood concentration 
time curves can be classified into the following categories: a drug group showing a sharp 
peak curve (AUTL/AUC < 50%, Cp/Ct > 6), such as aminoglycoside antibiotics (AGs), and a 
drug group showing a gentle peak curve (AUTL/AUC% > 60％, Cmax/Cmin < 2), such as 
antiarrhythmic drugs, bronchodilators, and anticonvulsant drugs (Figure 5). 
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area under the blood concentration) in order to assess the interrelationship between AUC, 
Cp, and Ct in comparing CYA and TAC (Figure 2). As a result, the AUTL/AUC% of CYA 
was as low as 41.9%, and the AUC had a higher percentage of dependence on Cp than on Ct. 
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Fig. 3. Comparison of the pharmacokinetic parameters of AUTL/AUC% between CYA and 
TAC. 
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Fig. 4. Pattern diagrams in the case that Cp, Ct, and MEC time are different, even though 







Cyclosporine MEPC* 41.9±6.9 6.0±1.8 AUC0-4、C2、Ct AUC0-4，C2，Ct
Tacrolimus 73.4±8.1 1.9±0.4 Ct Ct
Amikacin*(injection) 16.5 14.4 Cmax Ct（Cmax）
Vancomycin*(injection) 29.8 11.1 Ct Ct（Cmax）
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Table 3. AUTL/AUC%, Cp/Ct, and parameters of the efficacy and side effect of drugs that 
are used in therapeutic drug monitoring (TDM) 
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Fig. 5. Two patterns of blood concentration curve based on AUTL/AUC%
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Fig. 5. Two patterns of blood concentration curve based on AUTL/AUC% 
All drugs except AGs, glycopeptide antibiotics, and CYA, which required AUTL/AUC% 
≥60% and Cp/Ct ≤2 to maintain the therapeutic range, had a gentle blood concentration 
time curve and the monitoring point was Ct. It is preferred that AGs maintain a 
concentration to the peak value for as long as possible, but it must be reduced to below a 
specific blood concentration on a temporary basis to avoid nephrotoxic side effects. 
Therefore, AUTL/AUC% decreased to a low level and Cp/Ct increased to a high level to 
show a blood concentration time curve with a sharp peak. Furthermore, AGs have a post-
antibiotic effect (PAE), so that it can maintain its effect even if it falls below the 
therapeutic range. 
Furthermore, the pharmacokinetics of AGs and glycopeptide antibiotics relate to 
administration by injection, and these drugs are not required to control a clinical condition 
for a long period. Therefore, the results showed that CYA (Neoral) was the only oral drug 
used for prevention of a long-term pathologic condition that showed a sharp peak curve. 
Drugs with a sharp peak concentration were the only drugs for which the blood 
concentration needed to be reduced on a temporary basis to avoid side effects, and there 
was no drug that needed to be at peak concentration in order to have an effect. However, 
when the CYA used was switched from Sandimmune to Neoral to increase and stabilize 
absorption, the absorption rate constant (Ka) became large such that the peak value 
necessarily increased, and the AUTL/AUC% decreased.  
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for a long period. Therefore, the results showed that CYA (Neoral) was the only oral drug 
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necessarily increased, and the AUTL/AUC% decreased.  
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CYA may not require higher peak concentration, if the trough concentration can be higher to 
keep the AUC, although it is impossible that raising the trough value and decreasing the 
peak value (to increase the AUTL/AUC%) using the existing CYA formulation, keep the 
AUC. 
4. Optimal pharmacokinetics based on PK/PD analysis 
In connection with the preceding paragraph, regarding patients treated with CYA (Neoral), 
it has been reported that the inhibitory action of CN was in proportion to the blood 
concentration following administration32), and that IL-2 was stably suppressed at the peak 
value rather than the trough value33). On the other hand, another report showed that TAC 
above a certain level continuously had an inhibitory action of CN after administration34). It 
is possible that the differences between the both drugs may contribute to these results 
(Figure 6). In other words, CYA shows sufficient CN inhibitory action at the peak value, but 
the data suggests that the CN inhibitory action may be insufficient at the trough value. On 
the other hand, TAC is at a concentration that shows a certain level of CN inhibitory action 
throughout all time points, including the trough value, which suggests that it may always 
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Fig. 6. Relationship between blood concentration and calcineurin activity in CYA and TAC. 
The authors analyzed the relationship of the concentration—lymphocyte proliferation rate 
curves (PD) of CYA and TAC with the target blood concentration (PK) and found that 
lymphocyte proliferation was completely suppressed at the trough level of TAC. On the 
other hand, CYA had a low inhibition ratio at the trough value and was more than sufficient 
inhibited at the peak value, so that there was no need for the concentration to be as high as 
the peak value in terms of pharmacodynamics; consequently, it was necessary to make the 
trough value higher (Figure 7). 
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Fig. 7. Relationship between average concentration-lumphocyte proliferation rate curves 
and target blood concentration of calcineurin inhibitors. 
5. Optimal blood concentration for continuous intravenous infusion based on 
AUC 
Currently, intermittent intravenous administration and 24-h continuous intravenous 
administration can be compared for optimal pharmacokinetics in clinical practice. 
For patients undergoing hematopoietic stem cell transplantation, drugs are administered by 
intravenous injection for relatively long periods, from several weeks to several months, 
because ingestion is not possible. However, the theoretical optimum targeted blood 
concentration for continuous infusion has never been clearly determined. If AUC is the 
parameter most closely associated with clinical effect, it can be considered correct, in theory, 
to adjust the blood concentration of oral and intravenous administration to the level that 
achieves the same AUC. We used the AUTL (area under trough level) parameter developed 
by the authors to calculate the target blood concentration for continuous intravenous 
infusion from the trough level for oral administration35,36). As a result, the target blood 
concentration for continuous intravenous infusion of TAC (Css) was 1.4 times that of the Ct 
because AUTL/AUC% is large. These results were almost close to the blood concentration 
in the present practice of continuous intravenous infusion. Meanwhile, CYA has a small 
AUTL/AUC% so that a trough value 2.55 times higher and a considerably high Css were 
required in theory (Figure 8). 
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because ingestion is not possible. However, the theoretical optimum targeted blood 
concentration for continuous infusion has never been clearly determined. If AUC is the 
parameter most closely associated with clinical effect, it can be considered correct, in theory, 
to adjust the blood concentration of oral and intravenous administration to the level that 
achieves the same AUC. We used the AUTL (area under trough level) parameter developed 
by the authors to calculate the target blood concentration for continuous intravenous 
infusion from the trough level for oral administration35,36). As a result, the target blood 
concentration for continuous intravenous infusion of TAC (Css) was 1.4 times that of the Ct 
because AUTL/AUC% is large. These results were almost close to the blood concentration 
in the present practice of continuous intravenous infusion. Meanwhile, CYA has a small 
AUTL/AUC% so that a trough value 2.55 times higher and a considerably high Css were 
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AUCpo＝ AUCiv→CSS = Ct×（AUCpo/AUＴＬ）
Formula for calculating Css from Ct
Ex；Ct 
(ng/mL) Css (ng/mL)
TAC ：Css = Ct×1.40 10 14
CYA：Css = Ct × 2.55 200 510
 
Nakamuka Y, Transplant Proc, 2005  
 
 
Fig. 8. Formula for calculating Css from Ct, and the relationship between the AUC of oral 
administration and continuous intravenous infusion. 
In actual hematopoietic stem cell transplantation, it has been reported that continuous 
intravenous infusion of CYA at 250–400 ng/mL Css, which is lower than the theoretical 
value, showed lower nephrotoxicity than intermittent intravenous administration twice a 
day, and that the incidence rate of acute graft-versus-host disease (GVHD) was high37). 
However, in a study by the same group, comparing a 300 ng/mL Css group with a  
500 ng/mL Css group, it was reported that the incidence rates of acute and chronic GVHD 
were significantly lower in the 500 ng/mL group, and there was no difference in side effects, 
such as nephrotoxicity, between both groups of the trial38). In another study by Miller et al. 
using a Css of 450–500 ng/mL, similar results on acute GVHD and tolerability were 
reported39) and these reports were consistent with the authors’ hypothesis. Continuous 
intravenous infusion is the ultimate method for maintaining a minimum effective 
concentration (Figure 4-A), and it may be possible for the pharmacokinetics to have no peak 
if the AUC of CYA can be obtained; in other words, the pharmacokinetics as minimum 
effective concentration is maintained.  
Meanwhile, in many institutions, patients undergoing hematopoietic stem cell 
transplantation received different dosages, such as 3 mg/kg/day twice a day  
(3 h continuous infusion) by I.V. infusion, once a day (4 h continuous infusion) by  
I.V. infusion, once a day (10 h continuous infusion) by I.V. infusion, and 24 h continuous 
intravenous. However, there are slight differences in the clinical results40). Each AUC was 
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almost the same, at around 11,000 ng·h/mL, in all the dosages above, but the results 
calculated by the authors revealed that each AUTL/AUC% was approximately equal  
(35–44%) in intermittent administration and it was 100% in continuous intravenous 
infusion (Figure 9). Moreover, we set various therapeutic ranges to simulate and calculate  
%T > MEC and found that the values significantly varied depending on MEC (Figure 10). 
These results suggest that CYA has a wide tolerance of blood concentration in terms of 
action and side effects, and that all dosages might be clinically equal.  
 
 
Fig. 9. Comparison of pharmacokinetic parameters among various administration methods 
of CYA in hematopoietic stem cell transplants. 
For TAC, it has already been shown in a clinical trial that numerous side effects, such as 
nephropathy or neurologic symptoms, are caused by twice daily intermittent intravenous 
administration. Therefore, the package insert indicates that it should be administered by 24 
h continuous intravenous administration, and it is known that continuous intravenous 
administration is appropriate. It may be because the method for oral use has a large 
AUTL/AUC% and no high peak, whereas intravenous injection twice a day by high speed 
drip has a high peak. It is considered that the effect range and the side effect range of TAC 
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may be closer than those of CYA and that pharmacokinetics showing a gentle blood 
concentration time curve (large AUTL/AUC%) may be suitable. 
 
MEC 24-hCIV 4 h×1 p.o.×2* 3 h×2 10 h×1
300 ng/mL 100% 73% 69% 69% 69%
400 ng/mL 100% 61% 54% 51% 43%








Fig. 10. T%>MEC of various CYA administration methods for each MEC in hematopoietic 
stem cell transplants. 
6. Pharmacokinetic differences between morning and evening 
In studies monitoring the blood concentration of CYA and TAC for 24 h and comparing 
the pharmacokinetics of morning and evening, some studies reported that there was no 
difference in pharmacokinetics between morning and evening41,42), whereas several other 
studies reported that there was a difference43-45). In the authors’ data, the AUC0–12, AUC0–4, 
C2, and Cmax following evening administration were significant lower than those 
following morning administration both in patients treated with CYA and patients treated 
with TAC46,47) (Figure 11). As TAC shows gradual blood concentration–time curve in 
comparison with CYA, TAC is hardly affected by delayed or reduced absorption in the 
evening, so that the differences between various PK parameters between morning and 
evening were smaller in TAC (Table 4). Therefore, a drug such as TAC, which shows 
pharmacokinetics with a large AUTL/AUC% may have potential benefits because it has 
little difference in pharmacokinetics between morning and evening. However, a sustained 
release preparation of TAC administered once a day has been launched and its 
pharmacokinetics has no peak value in the evening because it is administered only in the 
morning, but its efficacy is equal to that of a drug administered twice a day. From this 
fact, it is possible that the pharmacokinetic difference between morning and evening is 
not a clinical problem. 
Optimal Pharmacokinetics of Cyclosporine and 






































CYA (N = 35)
TAC (N= 28)
Time (h)
24 hours between CYA  and TAC. p.o p.o
Morning(8:00 AM) (8:00 PM) Evening
 




AUC0-12（ng･hr/ml) 0.91±0.10 0.77±0.31 0.0073
*
AUTL/AUC(%) 1.22±0.18 1.42±0.27 0.0538
AUC0-4（ng･hr/ml) 0.74±0.14 0.56±0.19 0.0144
*
C2（ng/ml) 0.70±0.31 0.51±0.25 0.1382
Cmax（ng/ml) 0.79±0.26 0.55±0.14 0.0161*
Cmin（ng/ml) 1.17±0.21 1.28±0.30 0.3131
Cmax/Cmin 0.71±0.32 0.45±0.16 0.0343*
Tmax(ｈｒ） 2.67±1.42 1.63±0.80 0.0287*
 
Table 4. Comparison of pharmacokinetic parameter ratios of evening to morning 
administrations between TAC and CYA 
       .     p.
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
228 
may be closer than those of CYA and that pharmacokinetics showing a gentle blood 
concentration time curve (large AUTL/AUC%) may be suitable. 
 
MEC 24-hCIV 4 h×1 p.o.×2* 3 h×2 10 h×1
300 ng/mL 100% 73% 69% 69% 69%
400 ng/mL 100% 61% 54% 51% 43%








Fig. 10. T%>MEC of various CYA administration methods for each MEC in hematopoietic 
stem cell transplants. 
6. Pharmacokinetic differences between morning and evening 
In studies monitoring the blood concentration of CYA and TAC for 24 h and comparing 
the pharmacokinetics of morning and evening, some studies reported that there was no 
difference in pharmacokinetics between morning and evening41,42), whereas several other 
studies reported that there was a difference43-45). In the authors’ data, the AUC0–12, AUC0–4, 
C2, and Cmax following evening administration were significant lower than those 
following morning administration both in patients treated with CYA and patients treated 
with TAC46,47) (Figure 11). As TAC shows gradual blood concentration–time curve in 
comparison with CYA, TAC is hardly affected by delayed or reduced absorption in the 
evening, so that the differences between various PK parameters between morning and 
evening were smaller in TAC (Table 4). Therefore, a drug such as TAC, which shows 
pharmacokinetics with a large AUTL/AUC% may have potential benefits because it has 
little difference in pharmacokinetics between morning and evening. However, a sustained 
release preparation of TAC administered once a day has been launched and its 
pharmacokinetics has no peak value in the evening because it is administered only in the 
morning, but its efficacy is equal to that of a drug administered twice a day. From this 
fact, it is possible that the pharmacokinetic difference between morning and evening is 
not a clinical problem. 
Optimal Pharmacokinetics of Cyclosporine and 






































CYA (N = 35)
TAC (N= 28)
Time (h)
24 hours between CYA  and TAC. p.o p.o
Morning(8:00 AM) (8:00 PM) Evening
 




AUC0-12（ng･hr/ml) 0.91±0.10 0.77±0.31 0.0073
*
AUTL/AUC(%) 1.22±0.18 1.42±0.27 0.0538
AUC0-4（ng･hr/ml) 0.74±0.14 0.56±0.19 0.0144
*
C2（ng/ml) 0.70±0.31 0.51±0.25 0.1382
Cmax（ng/ml) 0.79±0.26 0.55±0.14 0.0161*
Cmin（ng/ml) 1.17±0.21 1.28±0.30 0.3131
Cmax/Cmin 0.71±0.32 0.45±0.16 0.0343*
Tmax(ｈｒ） 2.67±1.42 1.63±0.80 0.0287*
 
Table 4. Comparison of pharmacokinetic parameter ratios of evening to morning 
administrations between TAC and CYA 
       .     p.
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
230 
7. Calculation of optimal dose and blood trough concentration on switching 
between CYA and TAC 
The authors calculated the optimal dose and the Ct concentration on switching between 
CYA and TAC, with a comparison of the pharmacokinetics (AUC, Cp, and Ct) of CYA and 
TAC. AUC/D/BW is equal, but the Ct of TAC is relatively higher than that of CYA as a 
result of the pharmacokinetic differences; considering this, the dosage ratio is as follows: 
CYA:TAC = 25:1, and the targeted Ct ratio is as follow: CYA:TAC = 13:148,49) (Figure 12). 





Fig. 12. Conversion rate of dose and target trough level derived from pharmacodynamic and 
pharmacokinetic analyses.  
8. Conclusion 
Although both CYA and TAC belong to CNIs and the availabilities (AUC/D/BW) are the 
same, significant differences in the pharmacokinetics (blood concentration-time curve) of 
both drugs were found. Given that the AUC is the parameter that is most closely 
associated with clinical effect, it is optimal to monitor Cp and Ct for oral CYA and TAC, 
respectively.  
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However, even if both drugs show identical AUC, the clinical effects, such as effectiveness 
or side effects, may vary according to differences in the blood concentration time curve 
based on the relative correlation of Cp and Ct. From the report on inhibitory action of CN 
and blood concentration32) and the results of PK/PD analysis, It is also thought that CYA 
status is shown in Figure 13-A. On this basis, it is supposed that the clinical effect of CYA is 
slightly lower than that of TAC50-52). It is plausible that the Ct of CYA can be reduced on a 
temporary basis to avoid nephrotoxicity, as is done with AGs (Figure 13-A). Conversely, 
there is a possibility that Cp is associated with side effects as shown in Figure 13-B. CYA can 
reduce the Cp (Figure 13-D) and can also keep the AUC in the blood concentration time 
curve to elevate the Ct. In fact, CYA shows good results by continuous intravenous infusion 
for hematopoietic stem cell transplantation38). However, it has been found that there is a 
slight difference in the clinical results of the hematopoietic stem cell transplantation40) 
(Figure 14). Therefore, CYA has wide tolerance of blood concentration, even if it is 
administered at various dosages or if it has various blood concentration time curves.  
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CYA and TAC are used equally in clinical practice in terms of the existing therapeutic dose 
and the AUC, and there are no particular problems (Figure 13-C). On the other hand, it is 
thought that a gentle (with AUTL/AUC% high) blood concentration time curve is suitable 
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Fig. 14. Difference in range of effective and side effect bllod concentrations between CYA 
and TAC. 
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1. Introduction 
The market values of ornamental species are dictated by the qualities of their skin 
pigmentation, body shape, fin shape and body size (Paripatananont et al., 1999). Among 
ornamental fish, ‘fancy carp’ (Cyprinus carpio) is being popular worldwide due to the 
increasing number of hobbyists. One of the frequently found problems includes the color of 
fancy carp which often turns pale after being raised for a period of time, the fact not 
preferred by hobbyists. In order to make the fancy carp color remain constantly vivid, 
certain sort of diet, such as ‘carotenoids’ is believed to help. However, carotenoids cannot be 
synthesized by most animals, including fish, and must be obtained from dietary sources 
(Goodwin, 1984). There has been suggestion to modify alimentary carotenoids and store 
them in the integument and other tissues.  
Once digested, carotenoids are absorbed into the plasma, bound to serum lipoproteins 
(Ando et al., 1986) and subsequently transported and distributed to various tissues and 
organs. The liver is the main metabolic and excretory organ for carotenoids (Torrissen and 
Ingebrigtsen, 1992) and is considered to have the major responsibility for the metabolic of 
carotenoids. The liver is therefore either catabolizing astaxanthin to other pigments or to 
metabolites of carotenoids. The exact process of carotenoids metabolism in the liver is 
unknown. While the available evidence points to the role of the liver in carotenoid 
metabolism, no studies have attempted to elucidate its role or to quantify its potential in 
carotenoid clearance. 
Once established, pharmacokinetic studies on the given compound, i.e. the fraction of the 
feeding dose that is absorbed into the circulation, will be an important determinant of its 
efficiency and safety (Evan, 2004). In this case, this chapter deals with the quantitative 
aspects of carotenoid uptake, elimination and metabolic of carotenoid in fancy carps. 
Pharmacokinetics provides a mathematical basis to assess the time course of carotenoids 
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With this background, this chapter presents the reported evidence for the potential role of 
the liver in carotenoid utilization and investigation outcomes of the pharmacokinetics of the 
carotenoids in order to determine the absorption and disposition levels of carotenoids that 
can partially be ascribed to hepatic first-pass of fancy carps.  
2. Carotenoids 
Carotenoids can be found in plants and animals. These color-generating materials are in 
plastids that are naturally occurring in chromoplasts of plants and some other 
photosynthetic organisms like algae, some types of fungus and some bacteria. Though 
animals cannot produce carotenoids by themselves, they can keep carotenoids as 
polyunsaturated C40 hydrocarbons which consist of carbon atoms, single bonds along with 
double bonds. Carotenoids are dissolved in fat called lipophore. Carotenoids are 
tetraterpenes containing 4 connected isoprenes forming the ring structure. They come in 
yellow, orange, and red. Light absorption is at 400-600 nm. There are over 600 known 
carotenoids. 
 
Fig. 1. Chemical structure of carotenoids; A: astaxanthin and B: lutein  
Their colors, ranging from pale yellow through bright orange to deep red, is directly linked 
to their structure. Xanthophylls are often yellow, hence their class name. The double carbon-
carbon bonds interact with each other in a process called conjugation, which allows 
electrons in the molecule to move freely across these areas of the molecule. As the number of 
double bonds increases, electrons associated with conjugated systems have more room to 
move, and require less energy to change states. This causes the range of energies of light 
absorbed by the molecule to decrease. As more frequencies of light are absorbed from the 
short end of the visible spectrum, the compounds acquire an increasingly red appearance.  
3. Digestion and absorption 
Carotenoids are lipid soluble and follow the same absorptive path ways as other dietary 
lipids. This property has been used as a basis for the carotene absorption test, a screening 
test for lipid malabsorption. Although efficient digestion and absorption of dietary lipid is a 
prerequisite for optimum absorption of carotenoids, it is suggested that carotenoids are 
simply absorbed by dietary lipid. 
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Carotenoid absorption involves several steps from the breakdown of the food matrix and 
release of carotenoids into the lumen of the gastrointestinal tract through their incorporation 
into lymphatic lipoproteins. This includes mechanical and chemical disruption of the food 
matrix, dispersion in lipid emulsion particles, solubilization into mixed bile salt micelles, 
movement across the unstirred water layer adjacent to the microvilli, uptake by the 
enterocyte, and incorporation into lymphatic lipoproteins. A perturbation at any point along 
this chain of events will alter carotenoid bioavailability (Furr and Clark, 1997).  
Before absorption, carotenoids must be released from the food matrix, as they are not free in 
food but are associated with protein in a variety of plant cell structures (Erdman et al., 1993). 
Once the food is ingested, its mechanical breakdown continues as it is chewed, swallowed, 
and mixed in the stomach. Gastric hydrolysis of dietary lipids and proteins results in partial 
release of carotenoids and lipids from the food matrix. The extent of release and the 
physical-chemical state of the carotenoids in the stomach is not known. Once they are 
released, however, the lipophilic carotenoids would dissolve in an oily phase of lipid 
droplets. With mixing, the lipid droplets in the gastric contents become emulsified particles. 
Thus bile salt and fats are required upon carotenoids absorption process (Simpson and 
Chichester, 1981). 
Shearing forces from normal digestive tract motility bring about the formation of a fine lipid 
emulsion as the contents of the stomach pass into the duodenum. The emulsion has a 
triacylglycerol core surrounded by a monomolecular layer of partially digested proteins, 
polysaccharides and lipids, especially phospholipid and partially ionized fatty acids. The 
solubility and location of the polar carotenoids (xanthophylls) and the nonpolar carotenoids 
(carotenes) in emulsions differ. Carotenes are thought to incorporate almost exclusively in 
the triacylglycerol core of the emulsion, whereas the more polar xanthophylls distribute 
preferentially at the emulsion surface (Borel et al., 1996). Other lipid soluble nutrients with 
polar groups such as tocopherol and trans-retinoic acid are also thought to locate at the 
droplet surface. The significance of location in an emulsion is that the surface components 
can spontaneously transfer from lipid droplets to mixed micelles, whereas components 
associated with the emulsion core require digestion of triacylglycerol before transfer (Borel 
et al., 1996). The enzyme best suited to hydrolyze triacylglycerol in emulsions is pancreatic 
colipase-dependent lipase which is one reason why pancreatic insufficiency decreases 
plasma carotenoid concentrations (Leo et al., 1995). 
The products of lipid digestion and minor dietary lipids, including the carotenoids, transfer 
from the emulsion particle to mixed bile salt micelles. Whereas the mechanism of carotenoid 
solubilization into mixed micelles is unclear, the presence of bile salt micelles is obligatory, 
as carotenoid absorption is minimal or nonexistent when intraluminal bile salts are below 
the concentration required for aggregation into micelles (Hollander and Ruble, 1978). A 
major difference between absorption of other dietary lipid and carotenoids is that the 
carotenoids seem to have an absolute requirement for bile salt micelles, whereas fatty acids, 
the major product of lipid digestion, can be absorbed in the absence of micelles. 
The solubility of carotenoids in mixed micelles is limited and varies with intraluminal 
concentration of the carotenoid. Canfield et a1., (1990) studied the incorporation of β-
carotene into mixed micelles designed to resemble those seen in the lumen of the small 
intestine. The incorporation of β-carotene into the micelles varied from approximately 4 to 
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13% with the percent incorporated decreasing with increasing initial concentration of 
carotenoid. Whereas the solubility of carotenoids differs in emulsions, the polar and 
nonpolar carotenoids have similar solubility in bile salt micelles (Borel et al., 1996). 
Accumulating of carotenoids in fish could be affected from various factors. Apart from the 
mentioned external and internal ones; digestibility, absorption, blood flowing by lipoprotein 
and absorbing of carotenoids in muscle fiber can affect digestibility. Apparent digestibility 
coefficient (ADC) of astaxanthin in rainbow trout shows that the percentage of ADC is at 
70% which is higher than 35-70% of canthaxanthin. Differences of ADC and pigmenting 
efficiency do not depend only at the type of carotenoid, but also at the geometic isomer of 
each carotenoids themselves. 
Addition of fat in the fodder causes enhanced color change in atlantic salmon (Einen and 
Skrede, 1998). This goes along with a research study conducted by Choubert et al. (1991) 
which reports that adding more fat results in improvement of carotenoids digestion and 
retention efficiency in rainbow trout (Nickell and Bromage, 1998). It can be concluded that 
using fat affects pigmentation regimes. The area where high absorption of carotenoids is 
found lies in posterior intestine. Absorption ability depends on variation in feed intake and 
is varied upon different types of fish whose triacyglycerols are packaged in chylomicron in 
enterocytes and pumped throughout the body by metabolized-like chylomicrons. They 
associate with lipoprotein which acts as the limiting factor. Superfluous carotenoids were 
discarded without affecting accumulated ones. However, digestibility depends on types of 
carotenoids. It is found that astaxanthin is well digested in the form of esterified compared 
to free form.  
Polar carotenoids (xanthophylls) are around emulsion while non-polar carotenoids 
(carotenes) are found in emulsion. Emulsion, however, consists of triacylglucerol core where 
monomolecular layer e.g. digested protein, plysaccharides and lipids, particularly 
phospholipids are found. Specifically in ionized fatty acid, polar carotenoids, carotenoids 
absorption are highly improved compared to non-polar carotenoids. Such absorption is 
passive diffusion by concentration gradient. It is also found that adding more fat results in 
better absorption. Carotenoids found in blood circulation are delivered through lipoprotein. 
Normally, 75% of plasma carotenoids are delivered via LDL and the rest via VLDL and 
HDL. Non-polar carotnoids such as α, β-carotene, lycopene are delivered via LDL whilst 
polar carotenoids such as lutein, astaxanthin are delivered via HDL and LDL (Babin and 
Vernier, 1989). 
4. Distribution of carotenoids among plasma lipoproteins 
Carotenoid content and relation concentrations in human blood, the hydrocarbon carotenes 
(for example, α, β-carotene and lycopenes) are transported primarily on LDL plus VLDL, 
whereas the xanthohylls (lutein, zeaxanthin, β-cryptoxanthin) are distributed approximately 
equally between HDL and LDL in human serum (Johnson and Russell, 1992). Parker (1996) 
suggested that the actual content of β-carotene per unit lipid (triacylglycerol plus 
cholesterol) may be greater in HDL than in LDL. Parker also noted that although the total 
surface area of LDL is approximately twice that of HDL in human plasma, the content of 
xanthophylls (lutein plus zeaxanthin) is greater in HDL than in LDL. 
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5. Uptake and transport into blood 
Being fat-soluble, dietary astaxanthin is assumed to be in micellar form in the intestine, 
together with bile salts, fatty acids, monoglycerides and other fat-soluble vitamins. It is 
believed to passively diffuse into the intestinal lumen, together with fatty acids, and the 
uptake seems to be a slow process taking between 18 and 30 hours (Choubert et al., 1994). The 
fatty acids are converted into triacylglycerols (TAG), and the astaxanthin, like other 
xanthophylls (Zaripheh and Erdman, 2002), is incorporated together with TAGs in lipoprotein 
spheres called chylomicrons. These are then transported into the blood and due to its polarity, 
astaxanthin is assumed to be attached to the surface of the chylomicron spheres. 
In mammals, transport of chylomicrons from the intestinal lumen into the blood is carried 
out through lymphatic vessels. While being transported along the blood stream, 
chylomicrons undergo hydrolysis by lipoprotein lipase (LPL), a triacylglycerol lipase found 
on the surface of endothelial cells of the tissue capillaries, to yield free fatty acids. The fatty 
acids and monoglycerols that are derived from chylomicrons in this way are subsequently 
taken up by the tissues or serum albumin. Changes in the lipid composition of a 
chylomicron modify the affinity of the associated lipoproteins for its surface, causing the 
chylomicron to change its apolipoprotein signature. When the chylomicrons have lost about 
80% of their initial TAG content, they become small enough to pass through the 
endothelium in the liver, and in addition their apolipoprotein signature can then be 











Source: Hannah et al., (2006) 
Fig. 2. Variation in pigment level due to variation in intestinal uptake likely accounted  for 
by variation in weight to a substantial degree. 
The fate of chylomicron-associated xanthophylls is poorly understood in mammals as well as 
in fish. It is hypothesized that non-triglyceride components of the chylomicron, including 
surface molecules such as xanthophylls, may be taken up by extra-hepatic tissues or 
transferred to other blood lipoproteins. When the chylomicrons reach the liver, however, they 
still contain a considerable amount of their original carotenoid content. Since fish do not seem 
to have a lymph system similar to the mammalian one, the chylomicrons are assumed to be 
transported through the primary blood vessels in the intestine. Aside from this, there is reason 
to assume that chylomicron-based astaxanthin transport and delivery in salmon are quite 
similar to that in mammals, as discussed above. Studies in salmon have provided evidence 
that astaxanthin is strongly associated with a protein likely to be serum albumin. Albumin is 
the major transporter of free fatty acids released during lipolysis by LPL to tissues (including 
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liver and muscle). This suggests that albumin may acquire astaxanthin from chylomicrons 
during lipolysis as well as directly from chylomicrons in the bloodstream. 
6. Liver metabolism and excretion 
The liver is the main metabolic and excretory organ for Carotenoids (Torrissen and 
Ingebrigtsen, 1992) and is considered to have the major responsibility for the metabolic loss 
of astaxanthin. The liver secretes bile into the intestine to aid in lipid digestion as well as in 
the excretion of metabolic breakdown products, and radioactive labelling studies with 
canthaxanthin found bile radioactivity levels to be 8 times higher than the level in blood. 
The astaxanthin metabolites in the bile are secreted into the intestine and re-absorbed. 
Radiolabeling experiments also indicate that either astaxanthin or its metabolites are 
excreted by the kidneys of salmon and rainbow trout (Hardy et al., 1990). The liver is 
therefore either catabolizing astaxanthin to other pigments or to metabolites that no longer 
have a chromophore. The exact process of astaxanthin metabolism in the liver is unknown, 
as is the case with β-carotene metabolism.  
7. Transport and deposition in muscle 
Despite numerous studies, the mechanism by which free fatty acids enter cells remains 
poorly understood. Astaxanthin association with LDLs has been observed in salmon (Aas et 
al., 2000) and rainbow trout (Chapman et al., 1978), suggesting that astaxanthin-containing 
LDLs may contribute substantially to the LPL-mediated uptake of astaxanthin by circulating 
albumin. Astaxanthin is then assumed to be brought to the muscle by circulating albumin. 
Binding to the muscle cell wall is thought to be non-specific and saturable. After having 
entered the muscle cell, astaxanthin is deposited in the myotome and binds to actomyosin 
by weak hydrophobic bonds, forming a complex. The presence of hydroxyl and keto groups 
at the β-end of the carotenoid increases the binding strength, explaining the higher 
deposition of astaxanthin compared to other carotenoids in salmon. Metabolites of 
astaxanthin have also been found in the connective tissues between myotomes.  
During VLDL and LDL flow through the blood, some of the TAG found in these lipoproteins 
is transferred to high density lipoprotein packets (HDL) by the cholesteryl ester transfer 
protein (CETP) (Tyssandier et al., 2002). Given that astaxanthin is transported along with the 
TAGs to the HDLs, this mechanism is likely to explain the observed high levels of HDL 
associated astaxanthin in immature salmon (Aas et al., 2000), where there is no pigment 
transport out of the muscle. An interesting feature here is that unlike in mammalian systems, 
Atlantic salmon muscle has been found to express albumin. Carotenoids are highly 
accumulated around adipose tissue and liver which are considered significant organs to 
accumulate carotenoids. The level of carotenoids  in each organ directly affects the intake. 
8. Pharmacokinetics and metabolized caroteniods in liver of single dose 
administration in fancy carp (Cyprinus carpio) 
8.1 Fish and feed trial 
Mixed sexes of fancy carp with average weight of 26.93 ± 5.14 g/fish were maintained on a 
non-pigmented diet for a co-variant period of two weeks prior to feeding the experimental 
diets, tested in four replicates. Each treatment was randomly distributed to each of 20-liter 
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aquarium tanks. The diets were designed to achieve a target level of 200 µg for astaxanthin 
and lutein per fish.  
Astaxanthin was supplied at a finished product concentration of 10% astaxanthin (BASF, 
Thailand). Lutein from marigolds extract (Tagetes spp.) was supplied in a finished product 
containing 15000 ppm (Kemin Industries, Thailand). After administration of a single dose 
orally, fish were not fed further meals.  
8.2 Sampling procedure 
Fish were not fed for 3 days before receiving a single dose feeding. A control liver sample at 
0 hr, was taken to measure basal liver astaxanthin and lutein levels prior to experiment. 
Liver sampling occurred at 15, 30 min 1, 3, 6, 12, 24, 48, 72, 96 and 120 hr after single dose 
meal, three fish were sampled at each sampling time. Liver was immediately separated from 
blood and stored at -20° C until samples analysis was performed. 
8.3 Carotenoids determination 
All experimental diets were extracted with acetone, together with BHT (250 ppm) added as 
antioxidant, until samples showed no color. After that, petroleum ether was added at 5 ml. 
and mixed, and water was added in a separating funnel. Mixing was carried out with a 
careful swirling and the two phases were found separated. In this study, only the 
hyperphase of diets was collected.  
8.4 Liver distribution of carotenoids after its oral administration in fancy carp 
Approximately 1 g of each liver was quickly excised after sampling (n 3, each). Each liver 
sample was rinsed with cold 0.9% NaCl solution, blotted dry with tissue paper and 
weighed. Then each liver was homogenized with acetone, together with BHT (250 ppm) 
added as antioxidant, until samples showed no color and saponified by addition of 0.2 ml of 
60% KOH, followed by 1 hr incubation at 70°C. The saponified mixture was extracted 3 
times with petroleum (containing 250 ppm of BHT. In this study, only the hyperphase was 
collected then determined maximum absorbance wavelength range over 350-600 nm. Merely 
the maximum absorbance value ( max) was recorded and calculated total carotenoids were 
calculated based on Beer-Lambert’s Law (Britton, 1995). 
8.5 Instrumentation and chromatographic conditions 
The resulting hyperphase of experimental diets and liver from petroleum ether extraction were 
evaporated under a gentle stream of nitrogen gas. This was followed by redissolving crude 
carotenoids in petroleum ether and the solution 5 µl were spotted on pre-coated silica gel 60 
(10 x 20 cm) with 0.25 mm thickness (Merck, Germany) using a CAMAG Linomat IV 
(Switzerland) sample applicator. A constant application rate of 4 ul/s was employed and 
spaces between two spots were 14 mm. The slit dimension was kept at 5 mm x 0.45 mm and 20 
mm/s scanning speed was employed. The mobile phase consisted of petroleum ether - diethyl 
ether - acetone (75:15:10, v/v/v). Linear ascending development was carried out in a twin 
trough glass chamber saturated with mobile phase. The optimized chamber saturation time for 
the mobile phase was 30 min at room temperature (25 ± 2° C). The length of chromatogram run 
was 70 mm. Densitometric scanning was performed on CAMAG TLC scanner III in the 
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liver and muscle). This suggests that albumin may acquire astaxanthin from chylomicrons 
during lipolysis as well as directly from chylomicrons in the bloodstream. 
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by weak hydrophobic bonds, forming a complex. The presence of hydroxyl and keto groups 
at the β-end of the carotenoid increases the binding strength, explaining the higher 
deposition of astaxanthin compared to other carotenoids in salmon. Metabolites of 
astaxanthin have also been found in the connective tissues between myotomes.  
During VLDL and LDL flow through the blood, some of the TAG found in these lipoproteins 
is transferred to high density lipoprotein packets (HDL) by the cholesteryl ester transfer 
protein (CETP) (Tyssandier et al., 2002). Given that astaxanthin is transported along with the 
TAGs to the HDLs, this mechanism is likely to explain the observed high levels of HDL 
associated astaxanthin in immature salmon (Aas et al., 2000), where there is no pigment 
transport out of the muscle. An interesting feature here is that unlike in mammalian systems, 
Atlantic salmon muscle has been found to express albumin. Carotenoids are highly 
accumulated around adipose tissue and liver which are considered significant organs to 
accumulate carotenoids. The level of carotenoids  in each organ directly affects the intake. 
8. Pharmacokinetics and metabolized caroteniods in liver of single dose 
administration in fancy carp (Cyprinus carpio) 
8.1 Fish and feed trial 
Mixed sexes of fancy carp with average weight of 26.93 ± 5.14 g/fish were maintained on a 
non-pigmented diet for a co-variant period of two weeks prior to feeding the experimental 
diets, tested in four replicates. Each treatment was randomly distributed to each of 20-liter 
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aquarium tanks. The diets were designed to achieve a target level of 200 µg for astaxanthin 
and lutein per fish.  
Astaxanthin was supplied at a finished product concentration of 10% astaxanthin (BASF, 
Thailand). Lutein from marigolds extract (Tagetes spp.) was supplied in a finished product 
containing 15000 ppm (Kemin Industries, Thailand). After administration of a single dose 
orally, fish were not fed further meals.  
8.2 Sampling procedure 
Fish were not fed for 3 days before receiving a single dose feeding. A control liver sample at 
0 hr, was taken to measure basal liver astaxanthin and lutein levels prior to experiment. 
Liver sampling occurred at 15, 30 min 1, 3, 6, 12, 24, 48, 72, 96 and 120 hr after single dose 
meal, three fish were sampled at each sampling time. Liver was immediately separated from 
blood and stored at -20° C until samples analysis was performed. 
8.3 Carotenoids determination 
All experimental diets were extracted with acetone, together with BHT (250 ppm) added as 
antioxidant, until samples showed no color. After that, petroleum ether was added at 5 ml. 
and mixed, and water was added in a separating funnel. Mixing was carried out with a 
careful swirling and the two phases were found separated. In this study, only the 
hyperphase of diets was collected.  
8.4 Liver distribution of carotenoids after its oral administration in fancy carp 
Approximately 1 g of each liver was quickly excised after sampling (n 3, each). Each liver 
sample was rinsed with cold 0.9% NaCl solution, blotted dry with tissue paper and 
weighed. Then each liver was homogenized with acetone, together with BHT (250 ppm) 
added as antioxidant, until samples showed no color and saponified by addition of 0.2 ml of 
60% KOH, followed by 1 hr incubation at 70°C. The saponified mixture was extracted 3 
times with petroleum (containing 250 ppm of BHT. In this study, only the hyperphase was 
collected then determined maximum absorbance wavelength range over 350-600 nm. Merely 
the maximum absorbance value ( max) was recorded and calculated total carotenoids were 
calculated based on Beer-Lambert’s Law (Britton, 1995). 
8.5 Instrumentation and chromatographic conditions 
The resulting hyperphase of experimental diets and liver from petroleum ether extraction were 
evaporated under a gentle stream of nitrogen gas. This was followed by redissolving crude 
carotenoids in petroleum ether and the solution 5 µl were spotted on pre-coated silica gel 60 
(10 x 20 cm) with 0.25 mm thickness (Merck, Germany) using a CAMAG Linomat IV 
(Switzerland) sample applicator. A constant application rate of 4 ul/s was employed and 
spaces between two spots were 14 mm. The slit dimension was kept at 5 mm x 0.45 mm and 20 
mm/s scanning speed was employed. The mobile phase consisted of petroleum ether - diethyl 
ether - acetone (75:15:10, v/v/v). Linear ascending development was carried out in a twin 
trough glass chamber saturated with mobile phase. The optimized chamber saturation time for 
the mobile phase was 30 min at room temperature (25 ± 2° C). The length of chromatogram run 
was 70 mm. Densitometric scanning was performed on CAMAG TLC scanner III in the 
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absorbance mode at 450 nm. The source of radiation utilized was a tungsten lamp (compiled 
from Mantiri et al., 1996 and Sherma and Bernard, 2003). In order to identify the correct value 
of astaxanthin, lutein and β-carotene, TLC runs were always conducted including authentic 
standards for astaxanthin and β-carotene (Sigma); lutein (Chromadex, Canada).  
8.6 Pharmacokinetic parameter analysis 
The astaxanthin and lutein concentration-time curves from liver best fitted one-
compartment pharmacokinetic model. The mean hepatic astaxanthin and lutein  
concentration-time curves data points of three from each time were then analyzed using 
pharmacokinetic equation (Evans, 2004).  
 
Fig. 3. One-compartment model Ka = absorption rate constant (h-1), k = elimination rate 
constant (h-1) 
9. Results 
9.1 Pharmacokinetic parameters of fancy carp fed with deprived diets  
The astaxanthin and lutein concentration in fancy carp were best described by one 
compartment model with first order absorption, pharmacokinetic parameters displayed in 
Table 1. The results showed that hepatic astaxanthin and lutein observed concentration time 
curve showed a steady rise after post-dosing, a slow increase to the maximum peak at 6 and 
24 hr for astaxanthin and lutein, respectively. Astaxanthin and lutein were on a gradual 
decline after post-dosing.  
 
Parameter Unit Parent diets 
Astaxanthin Lutein  
Vd (area)/kg ml/kg 1958.80 237.20
CL (area)/kg ml/hr/kg 8.92 3.50
AUC (area) µg-hr/ml 5300.00 2082.90 
C max  (obs) µg/g 54.20 78.40
T max (obs) hr 6.0 24.0
Vd (area)/kg: volume of distribution calculations 
CL (area)/kg: clearance calculations 
AUC (area): area under the serum concentration time curve 
C max (obs): maximum observed serum concentrations 
T max: observed time at which C max was achieved 
Table 1. Pharmacokinetic parameters for astaxanthin and lutein derived from hepatic 
concentration – time of fancy carp. 
Fancy carp fed with an astaxanthin diet developed a maximum concentration of astaxanthin 
(C max) of 54.20 µg/g occurred at 6 hr (T max) while fancy carp fed with a lutein diet 
contained lutein hepatic level (C max) of 78.40 µg/g within 24 hr. The volume of distribution 
(Vd) was 1958.80 and 237.20 ml/kg, respectively. The data illustrated that free astaxanthin was 
    Single component
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distributed in the liver better than lutein because the high amount of Vd demonstrates the fact 
that it can disseminate well in liver. However, the area under the curve (AUC) was 5300.00 
and 2082.90 µg-hr/ml. AUC, indicating the relationship between hepatic carotenoid 
concentration and time. It is close to the amount of carotenoids being absorbed in the liver. If 
the area under the curve (AUC) is elevated, it means that carotenoids can be highly absorbed. 
Total body clearance (CL) was 8.92 and 3.50 ml/hr/kg, indicating that the clearance of 
astaxanthin was greater than lutein. This clearance was mainly to eradicate carotenoids. 
Overall, after fancy carp were fed an astaxanthin diet, they showed better astaxanthin 
absorption than lutein. When considered together with pharmacokinetic parameter which was 
Vd and AUC, well dispersion of astaxanthin in liver has been proved. 
The results of the present study indicated that hepatic metabolism of astaxanthin and lutein 
in fancy carp following oral administration single dose feeding shows the faster rate of 
astaxanthin absorption for the fish fed with an astaxanthin diet compared to lutein diet 
which was similar to the report of Olsen and Bakker (2006). The absorption of carotenoids 
depends on disruption of food matrix. These solubility and location of the polar carotenoids 
(xanthophylls; astaxanthin and lutein) and the non polar carotenoids (carotene) in emulsions 
are different. Carotenes are thought to incorporate almost exclusively in the triacylglycerol 
core of the emulsion, whereas the more polar xanthophylls distribute preferentially at the 
emulsion surface (Furr and Clark, 1997). It has been shown by several authors, including 
Yonekura and Nagao (2007) that polar carotenoids (xanthophylls) have higher 
bioavailability characteristics leading to more transfer across the intestine compared to 
carotenes. This is related to the polar –OH side chains they possess which are absent in 
carotenes, showing the absorption of -carotene appeared to be very low compared to 
astaxanthin and lutein. In this respect, the transfer rate of astaxanthin would be expected to 
be slightly higher than that of lutein. They also showed an apparent lack of interaction 
between astaxanthin and lutein on transfer between emulsions and micelles. 
9.2 Metabolized serum carotenoids after administration of single dose of carotenoids 
diets 
Analysis of carotenoids distributed to and metabolized in liver and carotenoids derivatives 
are shown in Table 2.  
 
Parameters Unit Lutein  metabolitedfrom Astaxanthin diet 
Astaxanthin metabolited  
from Lutein diet  
Vd (area)/kg ml/kg 4349.40 810.40 
CL (area)/kg ml/hr/kg 35.94 1.27
AUC (area) µg-hr/ml 516.8 14631.10
C max  (obs) µg/g 65.00 40.9
T max (obs) hr 12.00 24.00
Vd (area)/kg: volume of distribution calculations 
L (area)/kg: clearance calculations 
AUC (area): area under the serum concentration time curve 
C max (obs): maximum observed serum concentrations 
T max: observed time at which C max was achieved 
Table 2. Pharmacokinetic parameters of metabolized of hepatic astaxanthin and lutein 
parent diets derived from concentration – time data of fancy carp 
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absorbance mode at 450 nm. The source of radiation utilized was a tungsten lamp (compiled 
from Mantiri et al., 1996 and Sherma and Bernard, 2003). In order to identify the correct value 
of astaxanthin, lutein and β-carotene, TLC runs were always conducted including authentic 
standards for astaxanthin and β-carotene (Sigma); lutein (Chromadex, Canada).  
8.6 Pharmacokinetic parameter analysis 
The astaxanthin and lutein concentration-time curves from liver best fitted one-
compartment pharmacokinetic model. The mean hepatic astaxanthin and lutein  
concentration-time curves data points of three from each time were then analyzed using 
pharmacokinetic equation (Evans, 2004).  
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constant (h-1) 
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The astaxanthin and lutein concentration in fancy carp were best described by one 
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Table 1. The results showed that hepatic astaxanthin and lutein observed concentration time 
curve showed a steady rise after post-dosing, a slow increase to the maximum peak at 6 and 
24 hr for astaxanthin and lutein, respectively. Astaxanthin and lutein were on a gradual 
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Vd (area)/kg: volume of distribution calculations 
CL (area)/kg: clearance calculations 
AUC (area): area under the serum concentration time curve 
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Table 1. Pharmacokinetic parameters for astaxanthin and lutein derived from hepatic 
concentration – time of fancy carp. 
Fancy carp fed with an astaxanthin diet developed a maximum concentration of astaxanthin 
(C max) of 54.20 µg/g occurred at 6 hr (T max) while fancy carp fed with a lutein diet 
contained lutein hepatic level (C max) of 78.40 µg/g within 24 hr. The volume of distribution 
(Vd) was 1958.80 and 237.20 ml/kg, respectively. The data illustrated that free astaxanthin was 
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distributed in the liver better than lutein because the high amount of Vd demonstrates the fact 
that it can disseminate well in liver. However, the area under the curve (AUC) was 5300.00 
and 2082.90 µg-hr/ml. AUC, indicating the relationship between hepatic carotenoid 
concentration and time. It is close to the amount of carotenoids being absorbed in the liver. If 
the area under the curve (AUC) is elevated, it means that carotenoids can be highly absorbed. 
Total body clearance (CL) was 8.92 and 3.50 ml/hr/kg, indicating that the clearance of 
astaxanthin was greater than lutein. This clearance was mainly to eradicate carotenoids. 
Overall, after fancy carp were fed an astaxanthin diet, they showed better astaxanthin 
absorption than lutein. When considered together with pharmacokinetic parameter which was 
Vd and AUC, well dispersion of astaxanthin in liver has been proved. 
The results of the present study indicated that hepatic metabolism of astaxanthin and lutein 
in fancy carp following oral administration single dose feeding shows the faster rate of 
astaxanthin absorption for the fish fed with an astaxanthin diet compared to lutein diet 
which was similar to the report of Olsen and Bakker (2006). The absorption of carotenoids 
depends on disruption of food matrix. These solubility and location of the polar carotenoids 
(xanthophylls; astaxanthin and lutein) and the non polar carotenoids (carotene) in emulsions 
are different. Carotenes are thought to incorporate almost exclusively in the triacylglycerol 
core of the emulsion, whereas the more polar xanthophylls distribute preferentially at the 
emulsion surface (Furr and Clark, 1997). It has been shown by several authors, including 
Yonekura and Nagao (2007) that polar carotenoids (xanthophylls) have higher 
bioavailability characteristics leading to more transfer across the intestine compared to 
carotenes. This is related to the polar –OH side chains they possess which are absent in 
carotenes, showing the absorption of -carotene appeared to be very low compared to 
astaxanthin and lutein. In this respect, the transfer rate of astaxanthin would be expected to 
be slightly higher than that of lutein. They also showed an apparent lack of interaction 
between astaxanthin and lutein on transfer between emulsions and micelles. 
9.2 Metabolized serum carotenoids after administration of single dose of carotenoids 
diets 
Analysis of carotenoids distributed to and metabolized in liver and carotenoids derivatives 
are shown in Table 2.  
 
Parameters Unit Lutein  metabolitedfrom Astaxanthin diet 
Astaxanthin metabolited  
from Lutein diet  
Vd (area)/kg ml/kg 4349.40 810.40 
CL (area)/kg ml/hr/kg 35.94 1.27
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Fig. 4. Hepatic astaxanthin and lutein concentration – time curve for fancy carp 
administration with a single dose of astaxanthin 200 µg 
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In this present study, the data showed that the hepatic carotenoids of fancy carp after 
feeding with an astaxanthin diet were composed of astaxanthin and lutein. Astaxanthin 
concentration decreased while the time passed, while lutein concentration was increased in 
liver. In the fancy carp fed with lutein diets, hepatic astaxanthin was found within 24 hr 
after oral administration feeding. Hepatic astaxanthin concentrations were 40.90 ± 0.03 
µg/g. The hepatic astaxanthin concentration continued to increase the serum astaxanthin 
concentration. It could possibly be assumed that lutein was precursor and converted to 
astaxanthin, making the level of hepatic astaxanthin concentration higher in liver. 
Aquatic animal carotenoids have been reviewed by Goodwin (1984) and Matsuno (2001). 
Commonly, carotenoids composition in many fishes are β-carotene, β-cryptoxanthin, 
tunaxanthins, luteins, zeaxanthins, diatoxanthin, alloxanthin, β-echinenone, canthaxanthin, 
α-doradexanthin, β-doradexanthin and astaxanthins. Carotenoid metabolism in animals 
takes place as a result of enzymes which catalyse three main types of reaction. These main 
reaction types are (i) the substitution of carotenoid end groups (often β-end groups) by 
oxygen functions (-OH and -C=O), (ii) the alteration of end groups, e.g. of β to α and (iii) 
cleavage of the polyene chain to yield apocarotenoids and even the vitamins A (Davies, 
1985). 
In this study, after fish were fed with astaxanthin diet, hepatic astaxanthin level was 
decreased because of metabolic conversions whereas the time hepatic lutein concentration 
was increased. The results indicated that lutein was carotenoids derived from reductive 
metabolite of astaxanthin. Based on a minute recovery of radioactivity in lutein after feeding 
of labeled (3S, 3’S)-astaxanthin, an analogous reductive pathway might also be occurring 
with gilthead seabeam (Gomes et al., 2002). Lutein and zeaxanthin are metabolized prior to 
-carotene, suggesting the precedence of xanthophylls biochemical conversions (Berticat et 
al., 2000). 
By contrast, after fancy carp were fed with lutein diets, hepatic astaxanthin was found 
within 24 hr after oral administration. This result suggested that lutein was oxidized to 
astaxanthin. The data shows that carotenoids were derived in liver after being fed with 
lutein; and that fancy carp can convert lutein to astaxanthin. The results of this present 
study were similar to other research studies: gold fish fed with lutein and zeaxanthin diets 
proposed the possible metabolic pathways from lutein and zeaxanthin to astaxanthin 
(Ohkubo et al., 1999). This indicates that lutein is converted into β-doradexanthin, leading to 
the formation of astaxanthin by oxidative pathway (Tanaka et al., 1976).  
The chapter suggesting that absorbed carotenoids in the liver are rapidly metabolized. 
Torrissen and Ingebrigsten (1992) recovered a high level of radioactivity in the bile of 
salmon fed 14C astaxanthin, suggesting a role of the liver in pigment metabolism. This is 
consistent with earlier findings obtained by Schiedt et al. (1988) who reported that 
astaxanthin represented only 27% of the total carotenoids recovered. Together, the findings 
suggest that trout may have an efficient hepatic metabolic capacity for the conversion of 
these carotenoids. Conversely, it appears that salmon are comparatively slower at metabolic 
conversion of absorbed carotenoids by the liver as evidenced by the fact that the relative 
hepatic carotenoid level associated with diet was two-fold higher than in trout. Salmon have 
either a slower hepatic metabolism, a fundamental shift in the tissue responsible for 
carotenoid catabolism (e.g. kidney or hind gut), or white muscle pigment uptake potential is 
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In this present study, the data showed that the hepatic carotenoids of fancy carp after 
feeding with an astaxanthin diet were composed of astaxanthin and lutein. Astaxanthin 
concentration decreased while the time passed, while lutein concentration was increased in 
liver. In the fancy carp fed with lutein diets, hepatic astaxanthin was found within 24 hr 
after oral administration feeding. Hepatic astaxanthin concentrations were 40.90 ± 0.03 
µg/g. The hepatic astaxanthin concentration continued to increase the serum astaxanthin 
concentration. It could possibly be assumed that lutein was precursor and converted to 
astaxanthin, making the level of hepatic astaxanthin concentration higher in liver. 
Aquatic animal carotenoids have been reviewed by Goodwin (1984) and Matsuno (2001). 
Commonly, carotenoids composition in many fishes are β-carotene, β-cryptoxanthin, 
tunaxanthins, luteins, zeaxanthins, diatoxanthin, alloxanthin, β-echinenone, canthaxanthin, 
α-doradexanthin, β-doradexanthin and astaxanthins. Carotenoid metabolism in animals 
takes place as a result of enzymes which catalyse three main types of reaction. These main 
reaction types are (i) the substitution of carotenoid end groups (often β-end groups) by 
oxygen functions (-OH and -C=O), (ii) the alteration of end groups, e.g. of β to α and (iii) 
cleavage of the polyene chain to yield apocarotenoids and even the vitamins A (Davies, 
1985). 
In this study, after fish were fed with astaxanthin diet, hepatic astaxanthin level was 
decreased because of metabolic conversions whereas the time hepatic lutein concentration 
was increased. The results indicated that lutein was carotenoids derived from reductive 
metabolite of astaxanthin. Based on a minute recovery of radioactivity in lutein after feeding 
of labeled (3S, 3’S)-astaxanthin, an analogous reductive pathway might also be occurring 
with gilthead seabeam (Gomes et al., 2002). Lutein and zeaxanthin are metabolized prior to 
-carotene, suggesting the precedence of xanthophylls biochemical conversions (Berticat et 
al., 2000). 
By contrast, after fancy carp were fed with lutein diets, hepatic astaxanthin was found 
within 24 hr after oral administration. This result suggested that lutein was oxidized to 
astaxanthin. The data shows that carotenoids were derived in liver after being fed with 
lutein; and that fancy carp can convert lutein to astaxanthin. The results of this present 
study were similar to other research studies: gold fish fed with lutein and zeaxanthin diets 
proposed the possible metabolic pathways from lutein and zeaxanthin to astaxanthin 
(Ohkubo et al., 1999). This indicates that lutein is converted into β-doradexanthin, leading to 
the formation of astaxanthin by oxidative pathway (Tanaka et al., 1976).  
The chapter suggesting that absorbed carotenoids in the liver are rapidly metabolized. 
Torrissen and Ingebrigsten (1992) recovered a high level of radioactivity in the bile of 
salmon fed 14C astaxanthin, suggesting a role of the liver in pigment metabolism. This is 
consistent with earlier findings obtained by Schiedt et al. (1988) who reported that 
astaxanthin represented only 27% of the total carotenoids recovered. Together, the findings 
suggest that trout may have an efficient hepatic metabolic capacity for the conversion of 
these carotenoids. Conversely, it appears that salmon are comparatively slower at metabolic 
conversion of absorbed carotenoids by the liver as evidenced by the fact that the relative 
hepatic carotenoid level associated with diet was two-fold higher than in trout. Salmon have 
either a slower hepatic metabolism, a fundamental shift in the tissue responsible for 
carotenoid catabolism (e.g. kidney or hind gut), or white muscle pigment uptake potential is 
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lower than in rainbow trout. The liver and kidney appeared to be important sites of 
carotenoid catabolism based on the relative proportion of the peak chromatogram of the fed 
carotenoid in rainbow trout and Atlantic salmon. Liver catabolism is suspected to be a 
critical determinant in carotenoid clearance, with higher catabolism expected in Atlantic 
salmon than in rainbow trout (Page and Davies, 2006). 
In conclusion, this chapter presents the evidence for the potential role of the liver in 
carotenoid utilization and confirms that the liver plays a significant role in carotenoid 
metabolism. In addition, the liver appears to be an important organ for the metabolic 
transformation of carotenoids. Hepatic carotenoids ascribed to first-pass metabolism by 
pharmacokinetic were designed to investigate dose - response effects on uptake parameters 
for both astaxanthin and lutein derived from commercial beadlet sources for fancy carp. The 
first reported evidence for the potential role of the liver in carotenoid utilization showed 
that liver plays a direct relationship to its potential in metabolism. In addition, the results 
suggest that the observed discrepancy between absorbed and retained levels of carotenoids 
can partially be ascribed to first-pass metabolism by the liver, which can be applied in other 
species research. 
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pharmacokinetic were designed to investigate dose - response effects on uptake parameters 
for both astaxanthin and lutein derived from commercial beadlet sources for fancy carp. The 
first reported evidence for the potential role of the liver in carotenoid utilization showed 
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can partially be ascribed to first-pass metabolism by the liver, which can be applied in other 
species research. 
10. References 
Aas, G.B., B. Bjerkeng, T. Storebakken and B. Ruyter. 2000. Blood appearance, metabolic 
transformation and plasma transport proteins of (C 14) - astaxanthin  in  Atlantic  
salmon (Salmo salar L.) Fish Physiol. Biochem. 21: 325-334. 
Ando, S., T. Takeyamaand M. Hatano. 1986. Isolation and characterization of a carotenoid 
carrying lipoprotein in the serum of Chum salmon (Oncorhynchus keta) during 
spawning migration. Agric. Biol. Chem. 50: 907-914. 
Babin, J.N. and G.P. Vernier. 1989. Plasma lipoprotein in fish. J. lipid Res. 30: 467-489. 
Berticat, O., G. Negre-Sadargues and R. Castillo. 2000. The metabolism of astaxanthin 
during the embryonic development of the crayfish Astacus leptodactylus, 
Eschscholtz. Comp. Biochem. Physiol. 127B: 309-318. 
Borel, P., P. Grolier, M. Armand, A. Partier, H. Lafont, D. Lairon and V. Azais-Braesco. 1996. 
Carotenoids in biological emulsions: solubility, surface-to-core distribution  and 
release from lipid droplets. J. Lipid Res.37: 250-261 
Britton, G. 1995. UV/Visible Spectroscopy, pp 13-63. In G. Britton, S. Liaaen-Jensen and H. 
Pfander.eds. Carotenoids: Spectroscopy,vol 1B. Birkhäuser Verlag. Basel. 
Canfield, L.M., T.A. Fritz and T.E. Tarara. 1990. Incorporation of beta-carotene into mixed 
micelles. Enzymol Methods. 189: 418-422. 
Chapman, M.J., S. Goldstein, G.L. Mills and C. Leger. 1978. Distribution and 
characterization of serum lipoproteins and their apoproteins in rainbow trout 
(Salmo gairdneri). Biochemistry (N. Y.). 17: 4455-4464. 
Choubert G., D.L. Noue and J.M. Blanc. 1991. Apparent digestibility of canthaxanthin in  
rainbow trout, effect of dietary fat level, antibiotics and number of pyloric caeca. 
Aquaculture 99: 323-329. 
Choubert, G., J.C.G. Milicua and R. Gomez. 1994. The transport of astaxanthin in immature 
rainbow trout Oncorhynchus mykiss serum. Comp. Biochem. Physiol. Physiol. 108A: 
245-248. 
Pharmacokinetics and Metabolized  
Caroteniods in Liver of Single Dose Administration in Fancy Carp (Cyprinus carpio) 
 
249 
Davies, B.H. 1985. Carotenoid metabolism in animals: a biochemist’s view. Pure Appl. 
Chem. 57: 679-684. 
Einen O. and G. Skrede. 1998. Quality characteristics in raw and smoked fillets of Atlantic 
salmon, Salmo salar, fed high-energy diets. Aquac. Nutr. 4: 99-108. 
Erdman, J.W., T.L. Bierer and E.T. Gugger. 1993. Absorption and transport of carotenoids. 
Ann. NY Acad. Sci. 691: 76-85. 
Evans, G. 2004. A Handbook of Bioanalysis and Drug Metabolism. CRC Press. Boca Raton, 
Fla. 
Furr, H.C. and R.M. Clark. 1997. Intestinal absorption and tissue distribution of carotenoids. 
Nutr. Biochem. 8: 364-377. 
Gomes, E., J. Dias, P. Silva, L. Valente, J. Empis, L. Gouveia, J. Bowen and A. Young. 2002. 
Utilization of natural and synthetic source of carotenoids in the skin pigmentation 
of gilthead seabeam (Sparus aurata). Eur. Food Res. Technol. 214: 287-293. 
Goodwin, T.W. 1984. The Biochemistry of the Carotenoids. Volume II Animals. Chapman 
and Hall. New York. 
Hannah, R., L. Oyehaug, D.I. Vage and S.W. Omholt. 2006. Carotenoid dynamics in Atlantic 
salmon. BMC Biology. 4: 1-15. 
Hardy, R.W.,O.J. Torrisse and T.M. Scott. 1990. Absorption and distribution of 14C- labeled 
canthaxanthin in rainbow trout (Oncorhynchus mykiss). Aquaculture 87: 331-340. 
Hollander, D. and P.E. Ruble. 1978. Beta-Carotene intestinal absorption: bile, fatty acid, pH, 
and flow rate effects on transport. Am. J. Physiol. 235: 686-691. 
Leo, M.A., S. Ahmed, S.I Aleynik, J.H. Siegel, F. Kasmin and C.S. Lieber. 1995. Carotenoids 
and tocopherols in various hepatobiliary conditions. J. Hepatol. 23: 550-556. 
Mantiri, D.M.H., G. Negre-Sadargues, G. Charmantier, J.P. Trilles, J.C.G. Milicua and R. 
Castillo. 1996. Nature and metabolism of carotenoid pigments during the 
embryogenesis of the European lobster Homarus gammarus. Comp. Biochem. 
Physiol. 115A: 237-241. 
Matsuno, T. 2001. Aquatic animal carotenoids. Fish. Sci. 67: 771-783. 
Nickell, D.C. and N.R. Bromage. 1998. The effect of dietary lipid level on variation of flesh 
pigmentation in rainbow trout (Oncorhynchus mykiss). Aquaculture 161: 237-251. 
Ohkubo, M., M. Tsushima, T. Maoka and T. Matsuno. 1999. Carotenoids and their 
metabolism in goldfish (Carassius auratus, Hibuna). Comp. Biochem. Physiol. 
124B: 333-340. 
Olsen, R.E. and R.T.M Baker. 2006. Lutein does not influence flesh astaxanthin pigmentation 
in the Atlantic salmon (Salmo salar L.). Aquaculture 258: 558-564. 
Page, G.I. and S.J. Davies. 2006. Tissue astaxanthin and canthaxanthin distribution in 
rainbow trout (Oncorhynchus mykiss) and Atlantic salmon (Salmo salar). 
Comparative Biochemistry and Physiology, Part A. 143:  125–132. 
Paripatananont, T., J. Tangtrongpairoj, A. Sailasuta and N. Chansue. 1999. Effect of 
astaxanthin on pigmentation of goldfish (Carassius auratus). J. World  Aquac. Soc. 
30: 454-460. 
Schiedt, K., M., Vecchi, E., Glinz and T., Storebakken. 1988. Metabolism of carotenoids in 
salmonids. III. Metabolites of astaxanthin and canthaxanthin in the skin of Atlantic 
salmon (Salmo salar, L.). Helv. Chim. Acta. 71: 887–896. 
Sherma, J. and F. Bernard. 2003.  Handbook of Thin Layer Chromatography. Marcel Dekker 
Inc. New York. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
250 
Simpson, K.L., C.O. Chichester. 1981. Metabolism and nutrition significance of carotenoids. 
Ann. Rev. Nutr. 1: 351-374. 
Tanaka, Y., T. Katayama, K.L. Simpson and C.O. Chichester. 1976. Biosynthesis of 
astaxanthin. XIX. Distribution of α-doradexanthin and metabolism of carotenoids 
in goldfish. Bull. Jap. Soc. Fish. 42: 885-892. 
Torrissen, O.J. and K., Ingebrigsten. 1992. Tissue distribution of 14C-astaxanthin in the 
Atlantic salmon (Salmo salar). Aquaculture 108: 381–386. 
Tyssandier, V., G. Choubert, P. Grolier and P. Borel. 2002. Carotenoids, mostly the 
xanthophylls, exchange between plasma lipoproteins. Int. J. Vitam. Nutr. Res. 72: 
300-308. 
Yonekura, L. and A. Nakao. 2007. Intestinal absorption of dietary carotenoids. Mol. Nutr. 
Food Res. 51: 107-11. 
Zaripheh, S. and J.W. Erdman. 2002.  Factors that influence the bioavailability of 
xanthophylls. J. Nutr. 132: 531-534. 
13 
Correlation of in vitro Dissolution  
Profiles with in vivo Pharmacokinetic  
Parameters of Some Commercial Brands  
of Aspirin Tablets Marketed in Nigeria 
Emmanuel Adelaja Bamigbola  
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy,  
Niger Delta University, Wilberforce Island, Amassoma, Bayelsa State,  
Nigeria 
1. Introduction 
From biopharmaceutical point of view, in vitro-in vivo correlation (IV-IVC) is a predictive 
mathematical treatment describing the relationship between an in vitro property of a dosage 
form (usually the rate or extent of drug release) and a relevant in vivo response (e.g. plasma 
or urine drug concentrations or amount of drug absorbed). IV-IVC is recommended by 
various regulatory bodies and mostly applicable to drug dosage forms for oral routes and 
sustained release products. It is a useful tool for drug dosage form development, because a 
successful correlation can assist in the selection of drug formulation with appropriate and 
acceptable dissolution criteria, and depending on its predictiveness, it can be used as a 
forecast or surrogate for further bioequivalence studies. There are different categories of IV-
IVC; A, B, C and D. 
In biopharmaceutics classification system (BCS), aspirin belong to class 2, and because of its 
poor water solubility, the dissolution rate is the rate limiting step, which controls the 
absorption and bioavailability parameters of oral aspirin drug products. This criterion 
makes aspirin a good candidate for IV-IVC evaluation. In vitro–in vivo correlation of four 
commercial brands of aspirin tablets (one soluble brand and three regular brands) marketed 
in Nigeria are presented. USPXXI rotating basket apparatus and urinary excretion profiles 
from eight human volunteers were employed for in vitro and in vivo assessments 
respectively. Various dissolution parameters such as percent dissolved in 30 min, 
dissolution rate constants (k) and time for 50 % dissolution (DT50%) and pharmacokinetic 
parameters such as cumulative amount excreted up to 8 h (E8), maximum excretion rate 
(dE/dt)max and time for maximum excretion rate (Tmax) were obtained for all the brands.  
The soluble aspirin had the highest percent dissolved in 30 minutes and highest dissolution 
rate constant with shortest time for 50% dissolution compared with other regular aspirin 
brands. Comparatively, the soluble aspirin had the highest E8 and highest (dE/dt)max with 
the shortest Tmax. Significant rank order correlations were observed between all the in vitro 
dissolution parameters such as percent dissolved at 30 min, dissolution rate constants (k) 
and time for 50 % dissolution (DT50%) and all the in vivo bioavailability parameters such as 
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cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and time for 
maximum excretion rate (Tmax). However, no correlation could be established between the 
cumulative amount excreted up to 24 h (E24) and any of the in vitro dissolution parameters. 
Moreover statistical analysis showed no significant inter-subject variation among the human 
subjects that participated in the experiments.  
Soluble aspirin tablet exhibited a higher in vitro dissolution and in vivo bioavailability 
profiles than regular aspirin tablets. The three regular aspirin brands were not bioequivalent 
to the soluble brands of aspirin. Good IV-IVC was established for the four brands of aspirin 
tablets. Therefore, with proper standardization of methods of assessment, in vitro 
dissolution parameters can be used to predict in vivo bioavailability of these aspirin tablets 
marketed in Nigeria. 
1.1 Quality assessment of drug products  
1.1.1 In vitro quality assessment of drug products 
The quality of drug product especially oral solid dosage forms such as tablets and capsules 
are often assessed by carrying out certain in vitro tests as contained in the monographs of 
various pharmacopoeias. Such test include: assay of active ingredients; weight uniformity; 
content uniformity; hardness; friability; disintegration and dissolution tests. These are to 
ensure batch to batch uniformity of quality during manufacturing processes. 
The general assumption was that if the physical and chemical integrity of a drug product 
were assured, satisfactory pharmacologic or therapeutic performance would be obtained 1, 2 
1.1.2 In vivo quality assessment of drug products   
In addition to the vitro quality assessment of drug products as prescribed in various 
pharmacopeias, in vivo bioavailability requirement is now an essential parameter in quality 
control of a number of medicinal products, particularly, those which have low or high 
therapeutic index or those which are poorly water soluble.  This became necessary in view of 
apparent inadequacy of the in vitro pharmacopoeia tests which did not take into consideration 
whether or not the active ingredient would be released from the dosage form, nor at what rate 
it gets into the biologic system.3 Many formulations were produced and marketed that 
satisfied all the required legal standards but which were not therapeutically active.4  
Events and certain realizations have revealed that percentage chemical strength was not the 
sole criterion for clinical effectiveness. It became obvious that a dosage form must not only 
contain the correct amount of labeled drugs, but must also release the drugs on 
administration for absorption in the patient. So apart from chemical purity and percentage 
strength, bioavailability, clinical efficacy and safety became additional criteria for effective 
product development.5 It is now recognized that various physicochemical properties and 
formulation factors can influence the biologic availability of medicaments from dosage from 
in the body system.1     
1.2 Rate limiting step in drug bioavailability  
Systemic absorption of most drug products consists of a succession of rate processes. These 
processes include: (i) disintegration of the drug product and subsequent release of the drug; 
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(ii) dissolution of the drug in an aqueous environment: and (iii) absorption across cell 
membrane into the systemic circulation. In the process of drug disintegration, dissolution 
and absorption, the rate at which drug reaches the circulatory system is determined by the 
slowest step in the sequence. 
The slowest step in a series of kinetic process is called the rate-limiting step, except for 
sustained release or prolonged-action products; disintegration of a solid drug product is 
usually more rapid than dissolution and drug absorption. For drugs that have very poor 
aqueous solubility for example aspirin, the rate at which the drug dissolves (dissolution) is 
often the slowest step, and therefore, exerts a rate-limiting effect on drug bioavailability. In 
contrast, for a drug that has a high aqueous solubility, the dissolution rate is rapid and the 
rate at which the drug crosses or permeates cell membranes (absorption) is the slowest or 
rate limiting step 3, 5 
1.3 In vivo dissolution and drug bioavailability  
In biologic systems, drug dissolution in an aqueous medium is an important condition for 
systemic absorption and subsequent bioavailability. The rate at which drug with poor 
aqueous solubility dissolve from an intact or disintegrated solid dosage form in the gastro 
intestinal tract often controls the rate of systemic absorption of the drug. 
Dissolution is the process by which a drug substance is released from the dosage from into a 
dissolution medium. A drug administered in a tablet or capsule form must be released, 
dissolved and reach its site of action before it can exert a pharmacological response. 
Dissolution of drug in the body represents the end of the release process and precedes the 
absorption of drugs from solid dosage forms. Various theories of tablet dissolution that have 
been proffered include: (i) the diffusion layer model, (ii) the Noyes-Whitney theory, (iii) the 
Wagner’s, (iv) the Kitazawa, (v) the El-Yazigi, (vi) the Carstensen’s theories, (vii) the 
Danckwert’s model 5  
Dissolution kinetics of a drug product can be influenced by various factors such as (i) the 
physicochemical characteristics of the drug substance e.g. particle size, particle shape, 
polymorphism, crystal form, salt ester formation; (ii) formulation factors such as the nature 
and amount of excipients e.g. diluents, disintegrants, binders, lubricants, etc. (iii) 
manufacturing procedures such as the method of granulation, the size and density of the 
granules, moisture content, age of the granules, compressional force used in tabletting 
process, the quality of the personnel, the sophistication of the equipment and level of in-
process quality control 4, 5 
Drug in the body particularly, in the gastrointestinal tract, is considered to be dissolving in 
an aqueous environment. Therefore, temperature of the medium and the agitation rate also 
affect the rate drug dissolution. The in vivo temperature is maintained at a constant 
temperature of 37oc, and the agitation (primarily peristaltic movement in the gastro- 
intestinal tract) is reasonably constant 2, 3, 5  
1.4 In vitro dissolution tests  
Dissolution test is an in vitro physicochemical testing of solid oral dosage form. It 
determines the amount of active ingredient(s) released from a solid oral dosage from, 
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cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and time for 
maximum excretion rate (Tmax). However, no correlation could be established between the 
cumulative amount excreted up to 24 h (E24) and any of the in vitro dissolution parameters. 
Moreover statistical analysis showed no significant inter-subject variation among the human 
subjects that participated in the experiments.  
Soluble aspirin tablet exhibited a higher in vitro dissolution and in vivo bioavailability 
profiles than regular aspirin tablets. The three regular aspirin brands were not bioequivalent 
to the soluble brands of aspirin. Good IV-IVC was established for the four brands of aspirin 
tablets. Therefore, with proper standardization of methods of assessment, in vitro 
dissolution parameters can be used to predict in vivo bioavailability of these aspirin tablets 
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(ii) dissolution of the drug in an aqueous environment: and (iii) absorption across cell 
membrane into the systemic circulation. In the process of drug disintegration, dissolution 
and absorption, the rate at which drug reaches the circulatory system is determined by the 
slowest step in the sequence. 
The slowest step in a series of kinetic process is called the rate-limiting step, except for 
sustained release or prolonged-action products; disintegration of a solid drug product is 
usually more rapid than dissolution and drug absorption. For drugs that have very poor 
aqueous solubility for example aspirin, the rate at which the drug dissolves (dissolution) is 
often the slowest step, and therefore, exerts a rate-limiting effect on drug bioavailability. In 
contrast, for a drug that has a high aqueous solubility, the dissolution rate is rapid and the 
rate at which the drug crosses or permeates cell membranes (absorption) is the slowest or 
rate limiting step 3, 5 
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systemic absorption and subsequent bioavailability. The rate at which drug with poor 
aqueous solubility dissolve from an intact or disintegrated solid dosage form in the gastro 
intestinal tract often controls the rate of systemic absorption of the drug. 
Dissolution is the process by which a drug substance is released from the dosage from into a 
dissolution medium. A drug administered in a tablet or capsule form must be released, 
dissolved and reach its site of action before it can exert a pharmacological response. 
Dissolution of drug in the body represents the end of the release process and precedes the 
absorption of drugs from solid dosage forms. Various theories of tablet dissolution that have 
been proffered include: (i) the diffusion layer model, (ii) the Noyes-Whitney theory, (iii) the 
Wagner’s, (iv) the Kitazawa, (v) the El-Yazigi, (vi) the Carstensen’s theories, (vii) the 
Danckwert’s model 5  
Dissolution kinetics of a drug product can be influenced by various factors such as (i) the 
physicochemical characteristics of the drug substance e.g. particle size, particle shape, 
polymorphism, crystal form, salt ester formation; (ii) formulation factors such as the nature 
and amount of excipients e.g. diluents, disintegrants, binders, lubricants, etc. (iii) 
manufacturing procedures such as the method of granulation, the size and density of the 
granules, moisture content, age of the granules, compressional force used in tabletting 
process, the quality of the personnel, the sophistication of the equipment and level of in-
process quality control 4, 5 
Drug in the body particularly, in the gastrointestinal tract, is considered to be dissolving in 
an aqueous environment. Therefore, temperature of the medium and the agitation rate also 
affect the rate drug dissolution. The in vivo temperature is maintained at a constant 
temperature of 37oc, and the agitation (primarily peristaltic movement in the gastro- 
intestinal tract) is reasonably constant 2, 3, 5  
1.4 In vitro dissolution tests  
Dissolution test is an in vitro physicochemical testing of solid oral dosage form. It 
determines the amount of active ingredient(s) released from a solid oral dosage from, 
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such as from tablets or capsules, using a know volume of dissolution medium, with a 
predetermined length of time. The general principle of dissolution test is that the solid 
dosage form is tested under uniform agitation in an attempt to achieve dissolution. 
Agitation is accomplished by either using stirrer inside the apparatus or rotating the 
container holding the dosage form. In vitro dissolution test can be used to guide 
formulation development, identify critical manufacturing variables, monitor formulation 
quality from batch to batch, predict in vitro performance, monitor manufacturing process, 
assure batch to batch product performance and serve as a surrogate for bioavailability and 
bioequivalence.  
The choice of dissolution apparatus varies from one drug to another, depending on the 
nature of the drug. Conditions employed for the in vitro dissolution test are made in such a 
way to give the best and reproducible results for the particular drug under test. Such 
conditions include the size and shape of the dissolution vessel, the agitation rate, 
temperature of the dissolution medium which for most dissolution test is temperature of 
37oc which is similar to the in vivo temperature. The nature and volume of the dissolution 
media is also important e.g. simulated gastric fluid, simulated intestinal fluid, water, 0.1N 
Hcl, phosphate and acetate buffer depending on the nature of the drug and the location in 
the gastro-intestinal tract where the drug is expected to dissolve. The volume of the 
dissolution medium ranges from 500ml to 1000ml. 6, 7, 5  
There are several official methods of carrying out dissolution test of tablets and capsules e.g. 
rotating basket method (Apparatus 1); paddle method (Apparatus 2); transdermal product 
testing (Apparatus 3) transdermal product testing (Apparatus 4); transdermal product 
testing (Apparatus 5).2 Other unofficial methods are rotating bottle method; flow-through 
dissolution method; intrinsic dissolution method, and peristalsis method.8 
1.5 Bioavailability assessment 
Bioavailability of a drug refers to the measurement of the rate and extent of active drug that 
reaches the systemic circulation. The in vivo behaviours of a dosage form can be explained 
more precisely by its bioavailability. Bioavailability studies are carried out for both 
approved drugs and those not yet approved for marketing by drug regulatory agencies. 
This is to ensure that such drugs are safe and effective for their labeled indications for use 
and that they meet all applicable standards of identity, strength, quality and purity. In vivo 
bioavailability assessments are also performed for new formulations of active drug 
ingredients or therapeutic moieties that have full new drug application approvals. Various 
factors affecting the dissolution of a drug will invariable affect its bioavailability e.g. the 
physicochemical properties of the drug, formulation factors and manufacturing processes.9, 5  
1.6 Methods of assessing bioavailability 
There are several direct and indirect methods of assessing bioavailability in humans. The 
selection of a method depends on the purpose of the study, analytical method of drug 
measurement, and nature of the drug product. The methods are namely: 
i. Pharmacokinetic method: this is the measurement of the active drug substance or its 
metabolite(s) in biological fluids such as blood, plasma, urine, saliva, bile, sweat, milk, 
breath, feaces and other tissues. 
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ii. Acute pharmacologic effect. An acute pharmacologic effect such as effect on pupil 
diameter, heart rate or blood pressure can be useful as an index of drug bioavailability. 
This may require demonstration of dose related responses.    
iii. Clinical observation: such as lack of response (therapeutic failure) good response or 
toxicity in patience receiving similar drug products may be used to determine drug 
bioavailability. 
iv. iv. In-vitro dissolution test: this is done in selected case where in vitro / in vivo 
correction has been established for such drug product. 
Because the free or therapeutically active drug can be accurately quantified in biological 
fluids, pharmacokinetic method is often preferred. Among all the body fluids, plasma and 
urine data gives the most objective information on bioavailability while the rest are less 
reliable. 
The urine method of assessment has some advantages over the blood: 
i. Samples are more easily obtained than blood, 
ii. Urine collection is more pleasant to the subjects and more convenient, 
iii. The concentration of the drugs in the urine is often higher than in the blood, so, simple 
analytical method (e.g. U.V. spectrophotometer) can be used,  
iv. Lack of protein in the urine of a healthy individual obviates the need for denaturation 
step. 
However, the following conditions are necessary for obtaining valid urinary excretion data.  
i. Frequent sampling is necessary for a good curve description. 
ii. Urine sample should be collected periodically until almost the entire drug has been 
excreted (a period of approximately seven elimination half lives) 
iii. Urinary pH must be kept constant to avoid significant variation in urinary excretion 
rate. 
iv. Subject participating in the study should submit a complete urine specimen i.e. 
completely emptying the bladder.10, 1, 11, 2, 5  
1.7 Pharmacokinetic parameters for bioavailability assessment  
There are various pharmacokinetic parameters usually employed in evaluating 
bioavailability when drugs are assessed in biological fluids. 
Plasma:  
i. AUC- area under the plasma level-time curve and it reflects the total amount of active 
drug reaching the systemic circulation. 
ii.  Cmax - is the maximum plasma drug concentration obtained after administration of 
drug. 
iii. Tmax – time of maximum plasma concentration, it corresponds to the time required to 
reach maximum drug concentration. At Tmax, rate of absorption equals rate of 
elimination. Absorption continues after Tmax but at a slower rate.  
Urine: 
i. [E]∞ - Cumulative amount of drug excreted in the urine over a sufficient period of time 
(usually above 7 half-lives). It is directly related to the total amount of drug absorbed  
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excreted (a period of approximately seven elimination half lives) 
iii. Urinary pH must be kept constant to avoid significant variation in urinary excretion 
rate. 
iv. Subject participating in the study should submit a complete urine specimen i.e. 
completely emptying the bladder.10, 1, 11, 2, 5  
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There are various pharmacokinetic parameters usually employed in evaluating 
bioavailability when drugs are assessed in biological fluids. 
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i. AUC- area under the plasma level-time curve and it reflects the total amount of active 
drug reaching the systemic circulation. 
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drug. 
iii. Tmax – time of maximum plasma concentration, it corresponds to the time required to 
reach maximum drug concentration. At Tmax, rate of absorption equals rate of 
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ii. [dE/dt]max –Maximum rate of drug excretion, is the maximum rate at which drug is 
excreted in the urine after the administration of the drug.  
iii. Tmax - Time of maximum urinary excretion rate, it is the time required to reach 
maximum rate of drug excretion after drug administration. 
The AUC and [E]∞   are similar in the sense that they both measure the extend of drug 
absorption (bioavailability) while Tmax  indicate the rate of drug absorption. Cmax and 
[dE/dt]max are analogous in the sense that they reflect both the rate and extent of absorption. 
If the rate of drug excretion in urine is proportional to the concentration in blood, the curve 
obtained by plotting [dE/dt] against time will be the same as the plasma concentration-time 
curve, and Tmax will be the same. 12, 4, 2, 13, 3, 5 
1.8 In vitro – in vivo correlation of aspirin tablets 
The formulation and implementation of regulations concerning bioavailability of drugs 
made considerable attention to be given to correlation of in vitro dissolution rate with in 
vivo bioavailability14. It has been observed that with proper attention to the operating 
conditions, dissolution test can become a valuable indicator for potential in-vivo 
performance. In vitro-in vivo correlation (IV-IVC) is a predictive mathematical treatment 
describing the relationship between an in vitro property of a dosage form (usually the rate 
or extent of drug release) and a relevant in vivo response (e.g. plasma drug concentrations 
or amount of drug absorbed). Establishing an IV-IVC needs an extensive study of drug 
release from an oral drug delivery system. The study of drug in vitro availability and 
bioavailability are important part of the IV-IVC procedure for suitable drugs.15 In order to 
develop safe and effective drugs and validate their formulation, it is important to identify 
the exact drug pharmacokinetic parameters and biopharmaceutical properties of the 
dosage forms.  
The main objective of establishing IV-IVC is to use dissolution test as a surrogate for in vivo 
bioavailability studies and reduce the need for expensive human studies.16, 17 When in vitro-
in vivo correlations are established on a formulation, dissolution specifications can be used 
as a means of controlling drug bioavailability and hence a substitute for human 
bioequivalence studies.5 There are different categories of IV-IVC; A, B, C and D. Level A 
correlation represents a point-to-point relationship between in vitro dissolution rate and in 
vivo input rate of drug from the dosage form. 
Level B correlation utilizes the principle of statistical moment analysis, where the mean in 
vitro dissolution time (MDTvitro) of the product is compared to either mean in vivo resident 
time (MRT) or the mean in vivo dissolution time (MDTvivo). Level C correlation, compares 
one or several dissolution time points (t50%, t90%, etc.) to  one or several mean 
pharmacokinetic parameter such as AUC, tmax, or Cmax, 
Level D correlation is a rank order and qualitative analysis and is not considered useful for 
regulatory purposes. It is not a formal correlation but serves as an aid in the development of 
a formulation or processing procedure.14 
In the last few years aspirin has become a life saver against cardiovascular complications in 
addition to its age long usefulness as an analgesic, antipyretic and anti-inflammatory agent. 
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Aspirin is rapidly absorbed by first order kinetics, following oral administration but is 
subjected to extensive metabolism to form salicylates which is rapidly and extensively 
distributed throughout body fluids. The salicylate level in the urine rapidly increases and 
can be easily detected and analyzed through colorimetric method.18,19,20,11 In 
biopharmaceutics classification system (BCS), aspirin belong to class 2 (drug with low 
solubility but high permeability). Therefore, because, of its poor water solubility, the 
dissolution rate is the rate limiting step, which controls the absorption and bioavailability 
parameters of oral aspirin drug products. This criterion makes aspirin a good candidate for 
IV-IVC study, because any physico-chemical and formulation factors influencing its in vitro 
dissolution profile is expected to affect its in vivo bioavailability. In vitro–in vivo correlation 
of four commercial brands of aspirin tablets (one soluble brand and three regular brands) 
marketed in Nigeria are presented21, 22. Good correlations between various dissolution and 
bioavailability parameters of some drugs have been documented12, 23, 24, 25, 26, 27. However, in 
some cases, no good correlation could be obtained as reported by some investigators28, 29, 30. 
The following investigations were conducted:   
a. In vitro dissolution profiles  
In vitro dissolution profiles of the four brands of aspirin were evaluated, using USPXXI 
rotating basket apparatus. The dissolution profiles expressed as percents aspirin dissolved 
as a function of time for all the brands are shown in Figure 1. Various dissolution 
parameters such as percent dissolved in 30 min, dissolution rate constants (k) and time for 
50% dissolution (DT50%) were obtained for all the brands using standard methods 2. These 
are presented in Table 1.  
 
 




Time for 50% 
dissolution,  
dt50% (min) 
A1 75.71 0.059 11.79 
A2 65.75 0.040 17.41 
A3 63.47 0.037 18.53 
A4 68.90 0.043 16.23 
Table 1. Dissolution parameters obtained from the dissolution tests of the various brands of 
aspirin tablets 
Figure 1 shows that A1 exhibited the highest dissolution rate while the other three brands 
(A2 - A4) has similar dissolution rates (p <0.05). Table 1 shows that overall relative ranking 
of all the brands in terms of  the percent dissolved in 30 min and dissolution rate constant 
(k) followed the order of A1>A4>A2>A3 while the ranking of time for 50% dissolution 
(DT50%)  follows the reverse order (i.e. A1<A4<A2<A3). A1 is a soluble brand of aspirin 
containing calcium carbonate which can provide a reactive medium by changing the pH of 
the environment adjacent to the drug to alkaline, thus making the acidic drug like aspirin 
form a water soluble salt, thereby enhancing its rapid dissolution. This possibly accounted 
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as a means of controlling drug bioavailability and hence a substitute for human 
bioequivalence studies.5 There are different categories of IV-IVC; A, B, C and D. Level A 
correlation represents a point-to-point relationship between in vitro dissolution rate and in 
vivo input rate of drug from the dosage form. 
Level B correlation utilizes the principle of statistical moment analysis, where the mean in 
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for its highest solubility rate and shortest time for dissolution compared with the other plain 
brands31. Brands A2, A3 and A4 are all plain aspirin tablets; various factors such as particle 
size and shape of the aspirin content, type and/or amount of excipients, method of 
formulation and compression force employed may influence their dissolution rates 32, 5 The 
analysis of variance (ANOVA) performed on the percent dissolved in 30 min shows no 
significant difference (P>0.05) among all the brands, they all indicated similar statistical 
behaviors in their in vitro dissolution profiles.  
 
Fig. 1. Percent of actual amount of aspirin dissolved as a function of time for the four 
different brands. 
b. In vivo bioavailability 
In vivo bioavailability of the same set of aspirin tablets were assessed in eight human 
volunteers using urinary excretion profiles and various in vivo pharmacokinetic parameters 
such as cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and 
time for maximum excretion rate (Tmax) were calculated using standard methods30 and are 
presented in Table 2. The cumulative salicylate excreted and excretion rate profiles of the 
soluble aspirin and the three plain aspirin tablets are presented in figure 2 and 3 
respectively. Pharmacokinetic parameters determined were cumulative amount excreted up 
to 8h (E8) and 24h (E24), maximum excretion rate (dE/dt)max  and time for maximum 
excretion rate (Tmax) 
Correlation of in vitro Dissolution Profiles with in vivo Pharmacokinetic  






up to 8h (E8) 
Cumulative amount 





Time for maximum 
excretion rate 
(Tmax) 
A1 173.49 290.59 32.76 2.50 
A2 165.15 275.68 29.93 3.38 
A3 164.36 247.63 29.64 3.50 
A4 169.79 281.10 31.36 3.13 
Table 2. Pharmacokinetic parameters obtained from urinary excretion analysis of various 
brands of aspirin.  
 
Fig. 2. Cumulative amount of salicylate excreted up to 24 h for the different brands of Aspirin. 
The analysis of variance (ANOVA) performed on the pharmacokinetic parameters shows 
that all the four brands are bioequivalent in terms of (E8), (E24) and (dE/dt)max, but the Tmax 
of the three plain brands are inequivalent to the soluble brand A1 which has the fastest time 
for maximum excretion rate. Figure 3 shows that graphs for A2, A3 and A4 were almost 
super imposable attesting further to their equivalence. The formulation factors that 
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Fig. 1. Percent of actual amount of aspirin dissolved as a function of time for the four 
different brands. 
b. In vivo bioavailability 
In vivo bioavailability of the same set of aspirin tablets were assessed in eight human 
volunteers using urinary excretion profiles and various in vivo pharmacokinetic parameters 
such as cumulative amount excreted up to 8 h (E8), maximum excretion rate (dE/dt)max and 
time for maximum excretion rate (Tmax) were calculated using standard methods30 and are 
presented in Table 2. The cumulative salicylate excreted and excretion rate profiles of the 
soluble aspirin and the three plain aspirin tablets are presented in figure 2 and 3 
respectively. Pharmacokinetic parameters determined were cumulative amount excreted up 
to 8h (E8) and 24h (E24), maximum excretion rate (dE/dt)max  and time for maximum 
excretion rate (Tmax) 
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A1 173.49 290.59 32.76 2.50 
A2 165.15 275.68 29.93 3.38 
A3 164.36 247.63 29.64 3.50 
A4 169.79 281.10 31.36 3.13 
Table 2. Pharmacokinetic parameters obtained from urinary excretion analysis of various 
brands of aspirin.  
 
Fig. 2. Cumulative amount of salicylate excreted up to 24 h for the different brands of Aspirin. 
The analysis of variance (ANOVA) performed on the pharmacokinetic parameters shows 
that all the four brands are bioequivalent in terms of (E8), (E24) and (dE/dt)max, but the Tmax 
of the three plain brands are inequivalent to the soluble brand A1 which has the fastest time 
for maximum excretion rate. Figure 3 shows that graphs for A2, A3 and A4 were almost 
super imposable attesting further to their equivalence. The formulation factors that 
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enhanced the in vitro dissolution of the soluble aspirin are possibly responsible for increase 
in its in vivo bioavailability, compared to other plain brands, since its dissolution process is 
the rate limiting step 14, 29. 
 
 
Fig. 3. Excretion rate profiles of the four different brands of Aspirin. 
c. In vitro-in vivo correlation (IV- IVC)  
To establish the relevance of the in vitro dissolution performances to the in vivo 
pharmacokinetic parameters of the four aspirin brands, level C IV-IVC was employed. 
When various dissolution parameters were correlated with various bioavailability 
parameters, no significant IV-IVC could be established using E24 value. However, significant 
IV-IVC was observed when cumulative amount excreted up to 8 hours (E8)  
was employed (Figure 4) with correlation coefficients r2 > 0.8. As shown in Figure 4, good 
quantitative correlation coefficients were observed between percent dissolved in 30 min 
and: (a) cumulative amount excreted up to 8 hours (E8) (r2 = 0.9532, p < 0.05),  
(b) Maximum excretion rate (dE/dt)max, r2 = 0.9697, p < 0.05) and (c) Time for maximum 
excretion rate (Tmax) (r2 = 0.9932, p < 0.05), thus the in vitro parameter correlated well  
with the in vivo parameters. Similarly, from Figure 5, good quantitative correlation 
coefficients were also observed between dissolution rate constant (k) and Tmax (r2 = 0.9813,  
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p < 0.05). With regards to E8 and (dE/dt)max, the correlation was not as perfect as that of 
Tmax, with correlation coefficients just above 0.8, with exact values of 0.8564 and 0.8879 
respectively.  
 
y = 0.7822x + 114.65
R2 = 0.9532
y = 0.267x + 12.649
R2 = 0.9697
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Fig. 4. Correlation of in vitro dissolution parameter (percent dissolved in 30 min) with 
various in vivo bioavailability parameters. 
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y = 408.41x + 149.95
R2 = 0.8564
y = 140.71x + 24.638
R2 = 0.8879
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Fig. 5. Correlation of in vitro dissolution rate constant with various in vivo bioavailability 
parameters. 
Finally, Figure 6 equally shows that good quantitative correlations were established 
between time for 50% dissolution (DT50%) and (a) E8 (r2 = 0.9041, p < 0.05), (b) (dE/dt) max  
(r2 = 0.9297, p < 0.05) and (c) Tmax (r2 = 0.9954, p < 0.05) 
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y = -1.373x + 190.15
R2 = 0.9041
y = -0.4711x + 38.457
R2 = 0.9297
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Fig. 6. Correlation of time for 50 % in vitro dissolution with various in vivo bioavailability 
parameters. 
In all the IV-IVC performed, best correlation was obtained between the in vivo parameter 
Tmax, and all the in vitro parameters used for the correlation. The correlation coefficient 
recorded in each case was higher than others. The significant IV-IVC observed were in 
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agreement with the observations of some workers 12, 25 who carried out their own studies on 
aspirin in centers outside Nigeria. 
2. Summary  
Using USPXXI rotating basket dissolution apparatus, soluble brand of aspirin tablet A1 
exhibited the highest dissolution profile, when compared to other plain brands of aspirin 
ANOVA of pharmacokinetic data obtained from colorimetric assay of urinary salicylate 
excretion of the four brands of aspirin showed that all the four brands are bioequivalent in 
terms of (E8), (E24) and (dE/dt)max , but  the Tmax of the three plain brands are not equivalent 
to the soluble brand A1 which has the fastest time for maximum excretion rate. 
Good in vitro-in vivo correlations were established between various dissolution and 
bioavailability parameters of four commercial brands of aspirin tablets using Level C in 
vitro-in vivo correlation approach. Therefore, with proper standardization of methods of 
assessment, in vitro dissolution parameters can be used to predict in vivo bioavailability of 
these aspirin tablets marketed in Nigeria. 
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Bioavailability of Citrus  
Polymethoxylated Flavones and Their Biological 
Role in Metabolic Syndrome and Hyperlipidemia 
Malkanthi Evans, Prachi Sharma and Najla Guthrie 
KGK Synergize Inc. 
Canada 
1. Introduction 
Flavonoids are a group of polyphenolic compounds ubiquitous in many plants including 
fruits, vegetables, nuts, seeds, grains, tea and wine (Hollman & Katan, 1999). Flavonoids 
belong to two classes i) Flavanones and ii) Flavones. The most common flavanones are 
hesperetin from oranges and naringenin from grapefruit. The most common flavones, also 
known as polymethoxylated flavones, are tangeretin and nobiletin, present in orange and 
tangerine peel (Kurowska & Manthey, 2004).  
Recently, there has been an increasing interest in the health promoting properties of PMFs, 
which are known to play an important role in a number of biological functions as well as 
having anti-cancer (Silalahi, 2002), anti-inflammatory (Lin et al., 2003), and neuroprotective 
properties (Datla et al., 2001). Previously our team had performed pilot studies to 
investigate the biological properties of both nobiletin and tangeretin in small-animal and 
human clinical trials. Results of these studies have shown significant decreases in serum 
triglycerides, total cholesterol, and low density lipoprotein cholesterol and very low density 
lipoprotein cholesterol levels (Kurowska & Manthey, 2004; Roza et al., 2007) and increases in 
glucose tolerance (Li et al., 2006).  
Metabolic syndrome is a constellation of medical disorders that substantially increases the 
risk of individuals developing cardiovascular disease and diabetes. Metabolic syndrome has 
become increasingly common in Western society with a prevalence of 20-25% in the adult 
US population (Li et al., 2006). Early identification, prevention and treatment of metabolic 
syndrome portray a major challenge for the healthcare industry. During recent years, 
dietary supplements have been reported to be promising in reducing hyperglycemia and 
lipid disorders in individuals with type II diabetes or with predisposition to type II diabetes 
or hyperlipidemia. To date, little research has been conducted in investigating dietary 
supplements for their efficacy as hypolipidemic and antidiabetic therapeutic agents.  
Sufficient absorption of a drug or nutrient is important to obtain a successful therapeutic 
response. Bioavailability of a nutrient is simply the quantity or fraction of the ingested dose 
that is absorbed. Since oral bioavailability appears to be a limiting factor in the metabolism 
of citrus flavonoids and polyphenols, future studies are recommended to further investigate 
the biochemical factors influencing the bioavailibility of polymethoxylated flavones. This 
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of citrus flavonoids and polyphenols, future studies are recommended to further investigate 
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chapter focuses on bioavailability of polymethoxylated flavones and presents results from in 
vitro, in vivo and human studies.  
2. Polymethoxylated flavones (PMFs)  
PMFs are a group of methoxylated phenolic compounds found exclusively in tissues and 
peels of Citrus reticulata (tangerine), Citrus paradisi (grapefruit), Citrus sinensis (sweet 
orange), and Citrus aurantium L. (sour orange) (Horowitz & Gentili, 1977; Dugo & McHale, 
2002). These various citrus species show very high variability in their content of PMFs. 
The main reason for the low oral bioavailability of the dietary flavonoids is the extensive 
conjugation of the free hydroxyl groups (Walle, et al., 2004; Manach & Donovan, 2004; 
Walle, et al., 2005). PMFs have a benzo-gamma-pyrone skeleton with a carbonyl group at 
the C-3 position and methoxy groups in different positions on the benzo-gamma-pyrone 
skeleton (Fig.1). The exclusive feature in the chemical structure of PMFs is the 
polymethylation of polyhydroxylated flavonoids, one of the major naturally occurring 
polyphenolic compounds. This results in increased metabolic stability and membrane 
transport in the intestine and liver, improving oral bioavailability (Walle, 2007).  
 
Fig. 1. Chemical structures of nobiletin and tangeretin (Ishii et al., 2010) 
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The two most common PMFs are nobiletin and tangeretin. They exhibit distinctive chemical 
and physical properties in comparison to other plant flavonoids which influence the 
metabolism and pharmacokinetics of these compounds in animals. Nobiletin (5,6,7,8,3′,4′-
hexamethoxyflavone) has a molecular formula of C21H22O8. Tangeretin (5,6,7,8,4′-
pentamethoxyflavone) has a molecular formula of C20H20O7. The bioavailability of PMFs is 
considered to be high in comparison to other citrus flavonoids because of the lipophilic 
nature of the multiple methoxy groups on the PMF structure. The smaller methoxyflavones, 
sinensetin, eupatorin and rutin, with one to three methoxy groups and without any 
hydroxyl groups, have been much less studied.  
3. Biological role of PMFs 
3.1 Metabolic syndrome 
Metabolic syndrome refers to a group of risk factors that increase the risk for heart disease 
and diabetes. The main risk factors of metabolic syndrome include central obesity, insulin 
resistance, hypertension and cholesterol abnormalities. Obesity contributes to insulin 
resistance, which has been proposed as the major underlying cause of type II diabetes, 
dyslipidemia, hypertension, and atherosclerosis (Kopelman, 2000). 
Results from previous experimental and clinical studies have suggested that citrus PMFs 
may improve glycemic control and reduce insulin resistance (Kurowska & Manthey, 2004., 
Miyata et al., 2011; Li et al., 2006; Judy et al., 2010). 
It is known that an increase in the number and size of adipocytes in adipose tissues leads to 
obesity-related insulin resistance. In a recent study, both nobiletin and tangeretin were 
found to increase the secretion of adiponectin (insulin-sensitizing factor) and decrease the 
secretion of MCP-1 (insulin-resistance factor) in 3T3-L1 adipocytes demonstrated by lower 
intracellular triglyceride levels as compared to vehicle-treated adipocytes. Further, nobiletin 
also decreased the secretion of resistin, which serves as an insulin-resistance factor (Miyata 
et al., 2011).  
Mulvihill & Huff, 2011, reported on the ability of nobiletin to improve whole-body insulin 
sensitivity and decrease hepatic gluconeogenesis induced in Ldlr-/- mice when fed a high-fat 
Western type diet. This effect of nobiletin was achieved by both an increase in peripheral 
glucose disposal and enhanced suppression of hepatic glucose production by insulin 
(Mulvihill & Huff, 2011). Prevention of insulin resistance, glucose intolerance and adiposity 
required 0.3% nobiletin suggesting that prevention of obesity and improved glucose 
tolerance by nobiletin are linked (Mulvihill & Huff, 2011).  
Furthermore, in Ldlr-/- mice, nobiletin supplementation reduced bodyweight, very low 
density lipoprotein cholesterol–triglyceride secretion and improved dyslipidemia. A 
study by Lee et al., 2010 suggested that nobiletin improved hyperglycemia and insulin 
resistance in obese diabetic ob/ob mice by regulating expression of glucose transporter 
(Glut) 4 levels in the whole plasma membrane, white adipose tissue (WAT) and muscle, 
and by regulating expression of adipokines in WAT. In addition, a mixture of nobiletin 
and tangeretin were found to regulate glucose metabolism in hamsters with fructose-
induced insulin resistance by modulating adipokines (Li et al., 2006). In this study PMF 
supplementation also reduced triglyceride content in both the liver and heart and was 
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able to significantly suppress serum tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), 
interleukin-1β (IL-1β) and interleukin-6 (IL-6) expression and increased serum 
adiponectin protein in insulin resistant hamsters. Additionally, in a study in hamsters 
with insulin resistance induced by feeding 60% fructose, the addition of 1% PMFs 
improved glucose tolerance, as demonstrated by the reduced area under the curve (AUC) 
measured after the intra-peritoneal injection of glucose (3g/kg body weight)(Kurowska & 
Manthey, 2004).  
In a recent study, the anti-diabetic potential of Diabetinol®, a dietary supplement 
consisting of >62% PMF extract from dried fruit and orange peel, composed mainly of 
nobiletin and tangeretin in a 4:1 ratio, was tested in fructose induced insulin resistant 
male Syrian golden hamsters. The Diabetinol® treatment group and positive control group 
were fed a fructose-enriched diet for three weeks to induce hypertriglyceridemia and 
insulin resistance (Taghibiglou et al., 2000). Hamsters (n=18) were fed regular chow, 60% 
fructose or a 60% fructose diet + 1% Diabetinol®. At the end of the study (Day 49), 
hamsters fed 60% fructose + 1% Diabetinol® demonstrated lower blood glucose, total 
cholesterol and triacylglycerol levels as compared to the fructose-fed animals (Judy et al., 
2010).  
3.2 Effect of Diabetinol® on symptoms of metabolic syndrome – A human pilot study 
3.2.1 Subjects and study design 
The objective of the study was to investigate the efficacy of Diabetinol® (2 × 525 mg/day) vs. 
Placebo (Cellulose, 2 × 525mg/day) in glycemic control and management of risk factors of 
metabolic syndrome when supplemented for 12 weeks. Nineteen subjects with impaired 
fasting glucose (IFG) on stable oral medications were presented with a standard oral glucose 
challenge for the study.  
The study was a randomized, double-blind, placebo-controlled study. Subjects included 
were between ages of 18-75 years and had a body mass index (BMI) 25.0 to 39.9kg/m2, were 
weight stable (for 3 months prior to study), had a fasting glucose level between 6.1 and 
9.0mmol/L (109.8–162.0mg/dL), and a HbA1c level<7%. Subjects were excluded from 
participating if they were diabetic and required insulin therapy (Judy et al., 2010).  
The study included 5 clinic visits, which occurred at screening, baseline (Day 0), day 28, 56 
and 84.  
At baseline (randomization visit) and at all other visits anthropometric measurements were 
recorded, and BMI and waist/hip ratio were calculated. Fasting blood was collected for the 
determination of glucose, insulin and HbA1c. An oral glucose tolerance test (OGTT), where 
subjects consumed 100g of a glucose beverage over a 10min period was conducted and 
blood samples collected at 30, 60, 120, 180 and 240min post glucose consumption for 
analysis of glucose and insulin. On day 84, prior to the OGTT an additional 10mL of blood 
was collected for serum chemistry, hematology and for the determination of the lipid 
profile.  
Fasting glucose, insulin, HbA1c and AUC glucose and insulin were compared within group 
and HbA1c levels between the two groups by Student’s t-test. Statistical significance was 
established at p<0.05. 
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3.2.2 Results  
Analysis of subject demographics demonstrated that baseline fasting glucose was not different 
between groups (Diabetinol® 130.33 ± 3.64 mg/dL and placebo 129.80 ± 8.52mg/dL) but was 
above acceptable levels (<100mg/dL) and indicated that subjects in both groups had mild 
hyperglycemia (100–150mg/dL). Baseline HbA1c levels were not significantly different 
between subjects on placebo and Diabetinol® (6.53 ± 0.22% and 6.39 ± 0.22%, respectively).  
At baseline, 28, 56 and 84 days the peak in the plasma glucose curve following the glucose 
challenge, occurred between 60 and 120min in subjects on Diabetinol® or placebo (Fig. 2 a 
and 2 b). After supplementation for 56 and 84 days the glucose response curve of subjects on 
the Diabetinol® group was blunted as compared to the levels in the baseline OGTT curve.  
(a)  
(b)  
Fig. 2. Plasma glucose response curves to a standard glucose tolerance test before and after 
28, 56 and 84 days of (a) Diabetinol® and (b) placebo supplementation. The plasma response 
curve at 84 days was significantly different (p<0.01) from baseline at 30, 60 and 120min for 
Diabetinol® by Student’s t-test. Each data point is represented as mean ± SEM. 
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Further, after 84 days of supplementation subjects on Diabetinol® demonstrated a significant 
reduction in plasma glucose at 30, 60 and 120min after the glucose challenge when 
compared to baseline (Day 0) plasma glucose levels after the OGTT (p<0.01). The plasma 
glucose response curves after a glucose challenge at 28, 56 and 84 days for subjects on the 
placebo were not significantly different from that of their baseline values (Fig. 2b). 
There was no significant difference in mean fasting glucose values at baseline or day 84 
between, Diabetinol® (from 130.33 ± 3.64mg/dL at baseline to 123.33 ± 6.70mg/dL) or 
placebo (129.80 ± 8.52 to 123.90 ± 5.04mg/dL) (Fig. 2a and b). 
There was an increase of 9.0mg/dL in mean plasma glucose on day 28 and a reduction of 
9.0mg/dL on Day 56, and a significant reduction of 56.0mg/dL (p<0.01) on day 84 from 
baseline in subjects on Diabetinol® compared to those on placebo (data not shown). A mean 
reduction in AUC of 127mg/dL/h from baseline to day 84 was demonstrated in the 
Diabetinol® group while there was a 10mg/dL/h increase in subjects in the placebo group. 
There was no difference in plasma HbA1c levels between placebo and Diabetinol® groups 
at baseline, day 28, 56 or 84 (Fig. 3). HbA1c levels are not expected to change for 3-4 
months after an intervention. However, in this study after 84days of supplementation 
decreasing trends in the HbA1c were observed in subjects supplemented with Diabetinol® 
compared to subjects on placebo. Fasting plasma insulin levels were not significantly 
different between subjects on placebo and Diabetinol® at baseline, day 28, 56 or 84 and did 
not change significantly from baseline to day 28, 56 or 84 in the Diabetinol® or placebo 
groups.  
 
Fig. 3. Plasma HbAlc levels for placebo and Diabetinol® after 28, 56 and 84 days of 
supplementation. Statistical analysis was determined using Student’s t-test. Each data point 
is represented as mean ± SEM. 
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There were no statistically significant differences between subjects on placebo and 
Diabetinol® at baseline for total plasma cholesterol, triacylglycerols, low density lipoprotein 
cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) levels (Fig. 4). This 
cohort of subjects had lipid levels which were higher than the clinically acceptable range for 
these parameters. Subjects in the Diabetinol®group demonstrated a 13.29% reduction in total 
cholesterol (p<0.01) and a 22.79% reduction in LDL-C (p<0.01) from baseline to 84 days (Fig. 
5a). There were no significant changes in the lipid profiles from baseline to day 84 in 





Fig. 4. Baseline (Day 0) plasma lipids for placebo and Diabetinol®. Statistical analysis of 
plasma lipids were determined using Student’s t-test. Data points are represented as mean ± 
SEM. 
3.3 Hyperlipidemia 
Elevated blood total cholesterol, higher LDL-C and reduced HDL-C are established risk 
factors of cardiovascular disease. Interest in PMFs has increased in recent years because of 
strong evidence showing that PMFs might lower total cholesterol, triglycerides, LDL-C and 
increase HDL-C in a number of in-vivo (Kurowska & Manthey, 2004; Li et al., 2006), in-vitro 
(Kurowska & Manthey, 2002; Kurowska et al., 2004) and human studies (Kurowska et al., 
2000; Roza et al., 2007). 
Previous studies demonstrated that PMFs from citrus, especially tangeretin and nobiletin, 
produce hypolipidemic responses in cells (Kurowska & Manthey, 2002; Kurowska et al., 
2004) and animals (Kurowska & Manthey., 2004), and that they also normalize some 
metabolic defects associated with experimentally induced insulin resistance (Kurowska & 
Manthey, 2004). 
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Fig. 5. (a) ∗ Diabetinol® group plasma lipids levels after 84 days of supplementation 
compared to the baseline (Day 0) levels (b) placebo control group plasma lipids levels after 
84 days of supplementation compared to the baseline (Day 0) levels. ∗p<0.01, day 84 values 
are significantly different from baseline values by Student t-test. Each data point is 
represented as mean ± SEM. 
Cell culture studies, demonstrated that several natural and synthetic PMFs have the ability 
to inhibit the net secretion of apolipoprotein B (Apo-B) in human liver cell line HepG2 
(Kurowska & Manthey, 2002). In HepG2, tangeretin substantially reduced the secretion of 
Apo-B and the synthesis of triacylglycerols which was associated with the activation of 
peroxisome proliferator-activated receptor (PPAR). PPAR is the nuclear transcription factor 
which is known to possess positive regulatory impact on sugar, fatty acids and lipoprotein 
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metabolism (Kurowska et al., 2004). Nobiletin has been reported to inhibit macrophage 
acetylated LDL metabolism, resulting in the blockage of formation of macrophage foam-
cells, which are essential to atherosclerotic plaque formation (Whitman et al., 2005).  
Results from animal studies demonstrated that dietary supplementation with 1% tangeretin 
or 1% PMFs (largely tangeretin and nobiletin) significantly reduced serum total cholesterol, 
very low density lipoprotein cholesterol and LDL-C (by 19−27 and 32−40%, respectively) 
and also decreased serum and liver triglycerides in hamsters with diet-induced 
hypercholesterolemia (Kurowska & Manthey, 2004). Positive effects of PMFs were also 
reported with respect to adipocytokine production and PPAR in insulin resistant hamsters. 
The PMF supplementation showed a reversal in metabolic defects including a reduction in 
insulin level and an improvement in glucose tolerance, thus confirming their 
antiinflammatory and antidiabetic effects (Li et al., 2006). This action is speculated to occur 
via the inhibition of the synthesis of core protein Apo-B required for LDL synthesis in the 
liver (Borradaile et al., 1999). 
In human studies, the responses to dietary supplements containing citrus PMFs in subjects 
with moderate hypercholesterolemia and baseline characteristics consistent with metabolic 
syndrome, demonstrated that a four week period improved blood lipid profiles without 
causing any adverse effects (Kurowska et al., 2001). Previously lipid lowering effects were 
also seen in hypercholesterolemic subjects taking orange juice for four weeks (Kurowska et 
al., 2000). Consistently, in moderately hypercholesterolemic men, mixtures of nobiletin and 
tangeretin at a dose of 270 mg/day, in combination with tocotrienols (30 mg/day), reduced 
plasma LDL-C, Apo-B and triglycerides (Roza et al., 2007). This suggests that PMFs have 
substantial cholesterol and triacylglycerol lowering potential.  
4. The importance of pharmacokinetics studies of PMFs  
Pharmacokinetics is the study of the mechanisms of absorption, metabolism and routes of 
excretion of the metabolites of an administered drug or nutrient. Bioavailability of a 
nutrient is simply the quantity or fraction of the ingested dose that is absorbed. 
Pharmacokinetic studies on PMFs are important in identifying the composition of 
metabolites of administered supplements. They may also help in differentiating different 
supplements on the market which have different levels and ratios of PMFs (i.e. nobiletin, 
tangeretin). Additionally, these studies may further provide information regarding 
absorption and metabolism of different formulations (i.e. soft gel capsule, hard shell 
capsule etc).  
There are multiple challenges in the development of PMFs which must be overcome to 
increase their bioavailability. For example, PMFs exist as aglycones. The solubility of 
aglycone forms is low, which may lead to slower dissolution rates in addition to the fact that 
absorbed aglycones are rapidly conjugated to glucuronides and sulfates in the intestine and 
liver (Li et al., 2007). Therefore, it is important to perform systematic studies to demonstrate 
how changes in PMF structures affect solubility and dissolution rates. 
Previous studies in hamsters showed, that when they were fed a tangeretin-enriched diet for 
35 days, the main PMF metabolites identified in serum, urine and in liver tissue included 
dihydroxytrimethoxyflavone and monohydroxytetramethoxyflavone glucuronides and 
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compared to the baseline (Day 0) levels (b) placebo control group plasma lipids levels after 
84 days of supplementation compared to the baseline (Day 0) levels. ∗p<0.01, day 84 values 
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represented as mean ± SEM. 
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metabolism (Kurowska et al., 2004). Nobiletin has been reported to inhibit macrophage 
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aglycones (Kurowska & Manthey, 2004). This demonstrated considerable intestinal 
absorption of tangeretin based on urinary excretion of several metabolites. However, no 
unchanged (parental) tangeretin was detected in the circulating plasma (Kurowska & 
Manthey, 2004). 
In a recent study by Manthey et al., 2011, nobiletin and tangeretin were administered to rats 
by gavage and intraperitoneal (ip) injection. By using high-performance liquid 
chromatography−electrospray ionization−mass spectrometry (HPLC-ESI-MS), blood serum 
concentrations of metabolites were monitored. Over 24 hours, two metabolites of tangeretin 
and eight metabolites of nobiletin were detected with the administered compounds. Results 
from this study demonstrated that with identical oral doses nearly 10-fold higher absorption 
of nobiletin occurred in comparison to tangeretin. Further, in the blood serum, maximum 
levels of glucuronidated metabolites occurred later than nobiletin and tangeretin and 
occurred at higher concentrations than aglycone metabolites (Manthey et al., 2011). It is also 
confirmed in previous trials that overall expression of biological actions of nobiletin and 
tangeretin in animals is due to the biological actions of aglycone metabolites (Eguchi et al., 
2007; Li et al., 2007; Lai et al., 2008; Xiao et al., 2009). 
Wan & Walle, 2006, demonstrated that the flavonoid chrysin (5,7-dihydroxyflavone) has 
poor bioavailability, but when two hydroxyl groups in chrysin were methylated, as in 5,7-
dimethoxyflavone (5,7-DMF), using cofactors for glucuronidation, sulfation and oxidation,  
chrysin was rapidly metabolized within 20 minutes of incubation showing no parent 
compound at the end. In contrast, over the whole 60-min time-course studied, 5,7-DMF was 
found to be metabolically stable (Wen & Walle, 2006). Further, there is evidence of the role 
of different cytochrome P450 isozymes, in oxidative demethylation in PMFs metabolism 
(Koga et al., 2007; Breinholt et al., 2003). 
Results from these studies on oral bioavailability thus indicated that the methoxylated 
flavones have a great advantage over the nonmethylated flavones. Future studies are 
needed to investigate the biochemical factors influencing the pharmacokinetics of PMFs.  
5. Pharmacokinetics of PMFs in Sytrinol® 
5.1 Sytrinol®: A proprietary supplement consisting of PMFs and Tocotrienols  
Sytrinol® is a proprietary supplement developed by KGK Synergize Inc and consists of PMFs, 
mainly tangeretin and nobiletin (1:1 v/v) and palm oil tocotrienols. Tocotrienols are a group of 
dietary constituents, which are analogues of tocopherol (vitamin E), found mainly in palm oil 
and cereal grains. Tocotrienol-rich fractions from palm oil usually contain tocotrienols α, λ and 
∆, as well as 15-40% α-tocopherol (Guthrie & Carroll, 1998). The cholesterol-lowering potential 
of PMFs and tocotrienols has been investigated in preclinical studies and in clinical trials 
(Kurowska et al., 2004; Kurowska & Manthey, 2004; Roza et al., 2007).  
5.2 Human bioavailability study of three Sytrinol® formulations in healthy subjects 
5.2.1 Subjects & study design 
The objective of this study was to determine whether PMFs may be detected and quantified 
in serum obtained from healthy adults after a single dose administration of Sytrinol® 
capsules (containing 1053 mg of total PMFs). The study compared oral bioavailability of 
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three Sytrinol® formulations in healthy subjects. The endpoints were the determination of 
various pharmacokinetic parameters, specifically area under the concentration-time curve 
(AUC0-48h), time at maximum concentration (Tmax) and maximum serum concentration 
(Cmax) for each of tangeretin and nobiletin.  
The study was conducted as a randomized crossover trial. Ten healthy subjects, five  
men and five women, age 23  3 years, were recruited for the study. Prior to the start of 
the study, subjects had blood drawn for routine tests to confirm eligibility. All subjects 
were asked to avoid caffeine-containing products 12 h prior to the study and during the 
study.  
Subjects were administered a single dose of the first Sytrinol® product (either Sytrinol® soft 
gel capsules (Product A), Sytrinol®  powder hard shell capsules (Product B) or Sytrinol® 
hard shell capsules with added lecithin (Product C), containing 1053 mg of PMFs, largely 
tangeretin and nobiletin (1:1 v/v) and tocotrienols. Standard citrus-free meals (breakfast, 
lunch and dinner) were provided on each of the days of the multiple blood sampling. 
Participants took the second PMF product 14 days later and the third product after another 
14 day washout period.  
Peripheral blood was taken by venipuncture at time 0 (baseline), 0.25, 0.5, 1, 2, 4, 6, 8, 24 
and 48 hours after ingestion of Sytrinol® capsules. Quantitation of tangeretin and 
nobiletin in serum was done by Liquid chromatography/Mass spectrometry (Varian 1200 
L LC/MS/MS system equipped with ESI and APCI sources). The identities of these PMFs 
were verified by comparing fragment ion mass spectra of authentic tangeretin and 
nobiletin standards. 
5.2.2 Results 
The serum samples obtained from healthy subjects following oral administration of three 
different Sytrinol® formulations demonstrated detectable amounts of parental tangeretin 
and nobiletin. Tangeretin and nobiletin peaks were identified and quantitated in all serum 
samples collected after administration of Sytrinol® formulations A, B or C.  
Results demonstrated that for both tangeretin and nobiletin, the AUC0-48h and Cmax values 
were significantly higher (P<0.001) after administration of formulation A than after 
treatment with products B or C, suggesting greater bioavailability of formulation A vs. B or 
C (Tables 1 & 2). For all three formulations, the AUC0-48h values were higher for nobiletin 
than for tangeretin indicating that nobiletin might be more bioavailable than tangeretin. The 
time-concentration curves and pharmacokinetic results demonstrated that for both 
tangeretin and nobiletin, significantly higher AUC0-48h and Cmax values were obtained 
following the administration of formulation A than following the administration of either B 
or C (Figure 6 & 7). The effects of the Sytrinol® formulations A, B and C on AUC0-48h and 
Cmax of tangeretin and nobiletin derivatives are depicted in Figures 8 & 9. For nobiletin, the 
AUC0-48h values were 2.7-3.0 times higher for supplement A than for B or C whereas for 
tangeretin, the AUC0-48h values were 1.7-2.3 times higher for A than for B or C. Changes in 
mean serum concentrations of tangeretin and nobiletin products after a single-dose 
administration of Sytrinol® A, B or C formulations are shown in Figures 6 and 7. The Tmax 
values were not affected by the type of treatment and also were similar for tangeretin and 
nobiletin peaks (1.3-1.4 h).  
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Cmax (µg /L) 1006.4 ± 555.3 51.8 ± 18.8*** 63.7 ± 33.2*** <0.0001 
Tmax (h) 1.4 ± 0.5 1.48 ± 0.8 1.4 ± 0.6  
***A vs. B, C are significantly different (p<0.001) by ANOVA followed by Tukey’s test. 
Table 1. Pharmacokinetics of serum nobiletin (means ± SD). 
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Fig. 6. Changes in serum concentrations of nobiletin after a single dose administration of 
Sytrinol® formulations A, B and C (1053 mg PMFs per product) (means ± SEM).  
Capsules contained both PMFs in equal amounts, however, more nobiletin than tangeretin 
was generally found in the blood. The differences were particularly striking in blood 
samples collected after administration of supplements A and B (with the AUC0-48h ratios of 
nobiletin to tangeretin 1.85 and 1.42, respectively) but also tended to occur after the 
administration of C (with the nobiletin to tangeretin ratio 1.14). The results suggest that in 
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healthy human subjects, nobiletin might be more bioavailable than tangeretin. The 
pharmacokinetic results showed that in healthy human subjects, Sytrinol®  product A (Soft 
Gel) was significantly more bioavailable than the remaining two products, B (hard shell) 
and C (hard shell + lecithin). Formulation A differed from B and C in respect to AUC0-48h 
and Cmax but not in respect to Tmax, which was not affected by treatments. Our data also 
suggest that nobiletin present in Sytrinol® formulations is more bioavailable than tangeretin.  
 
 A B C P value 
Initial conc. (µg /L) 31.4 ± 5.7 37.2 ± 25.6 29.9 ± 21.6  
AUC0-48h (µg x min/L) 2509.6 ± 1092.8 1085.8 ± 198.8** 1499.3 ± 864.0* 0.0041 
Cmax (µg /L) 532.3 ± 335.7 76.4 ± 49.9*** 48.0 ± 30.1*** <0.0001 
Tmax (h) 1.3 ± 0.5 1.3 ± 0.8 1.2 ± 0.6  
*A vs. C is p<0.05, **A vs. B is p<0.01,  
***A vs. B, C are p<0.001 by ANOVA followed by Tukey’s test. 
Table 2. Pharmacokinetics of serum tangeretin (means ± SD) 
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Fig. 7. Changes in serum concentrations of tangeretin after a single-dose administration of 
Sytrinol® formulations A, B and C (1053 mg PMFs per each dose (means ± SEM). 
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Fig. 7. Changes in serum concentrations of tangeretin after a single-dose administration of 
Sytrinol® formulations A, B and C (1053 mg PMFs per each dose (means ± SEM). 
 




























*     - p < 0.05
**    - p < 0.01
***  - p < 0.001
 
Fig. 8. Effects of Sytrinol® formulations A, B and C on AUC0-48h of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  
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Fig. 9. Effects of Sytrinol® formulations A, B and C on Cmax of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  
***A vs. B, C are significantly different (p<0.001). 
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Bioavailability of a drug or nutrient supplement is largely determined by the properties of 
the dosage form. Yet, further characterizations of the metabolism and the biochemical 
factors influencing these compounds’ pharmacokinetics are essential, especially as oral 
bioavailability appears to be a significant limiting factor to the efficacy of these and other 
citrus PMFs.  
Both nobiletin and tangeretin have demonstrated efficacy in metabolic syndrome and 
hyperlipidemia, but vary in their pharmacokinetic properties. Research has demonstrated 
that nobiletin has greater bioavailability and efficacy as compared to tangeretin.  
Diabetinol® was developed with this concept in mind in order to address metabolic 
syndrome and hyperlipidemia.  
The pharmacokinetic profiles of nobiletin and tangeretin were previously based on the 
detection and quantification of their metabolites. In this chapter we have presented data on 
the detection of the parental compound nobiletin and tangeretin and suggest that in future 
research it is important to determine these compounds in human pharmacokinetic studies. 
Differences in bioavailability among formulations of a given supplement may have clinical 
significance; thus, knowing whether nutrient or drug formulations are equivalent is 
essential in making reasonable conclusions.  
7 Acknowledgements 
We would like to thank the volunteers of the Sytrinol® and Diabetinol® studies for their 
willingness and diligence in complying with the protocol. These studies were conducted at 
KGK Synergize, Inc London, ON, Canada and SIBR Research, Inc., West Bradenton, FL, 
USA respectively. The results of the Diabetinol® study are published in Judy et al., 2010. The 
authors would like to thank J. Baisley for his technical expertise. 
8. References 
Borradaile, N.M., Carroll,  K.K., & Kurowska, E.M. (1999) Regulation of HepG2 cell 
apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. 
Lipids, Vol.34, No.6, pp.(591-598), ISSN 0024-4201 
Breinholt, V. M., Rasmussen, S. E., Brosen, K., & Friedberg, T. H. (2003) In vitro metabolism 
of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol. 
Toxicol., Vol. 93, pp.(14– 22), ISSN 0742-8413 
Datla, K. P., Christidou, M., Widmer, W. W., Rooprai, H. K., & Dexter, D. T. (2001) Tissue 
distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat 
model of Parkinson's disease. NeuroReport, Vol.12, No.17, pp. (3871–3875), ISSN 
0959-4965 
Dugo, P., & McHale, D. (2002). The oxygen heterocyclic compounds of citrus essential oils. 
Citrus. The Genus Citrus, pp. (355− 390), CRC Press, ISBN 04152-84910 
Eguchi, A., Murakami, A., Li, S., Ho, C. T., & Ohigashi, H. (2007) Suppressive effects of 
demethylated metabolites of nobiletin on phorbol ester-induced expression of 
scavenger receptor genes in THP-1 human monocytic cells. Biofactors, Vol. 31, pp. 
(107– 116), ISSN 0951-6433 
 




























*     - p < 0.05
**    - p < 0.01
***  - p < 0.001
 
Fig. 8. Effects of Sytrinol® formulations A, B and C on AUC0-48h of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  














1200 Tangeretin  
Nobiletin 
A         B         C                     A          B         C
*** ***
*** - p < 0.001
*** ***
 
Fig. 9. Effects of Sytrinol® formulations A, B and C on Cmax of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  
***A vs. B, C are significantly different (p<0.001). 
Bioavailability of Citrus  




Bioavailability of a drug or nutrient supplement is largely determined by the properties of 
the dosage form. Yet, further characterizations of the metabolism and the biochemical 
factors influencing these compounds’ pharmacokinetics are essential, especially as oral 
bioavailability appears to be a significant limiting factor to the efficacy of these and other 
citrus PMFs.  
Both nobiletin and tangeretin have demonstrated efficacy in metabolic syndrome and 
hyperlipidemia, but vary in their pharmacokinetic properties. Research has demonstrated 
that nobiletin has greater bioavailability and efficacy as compared to tangeretin.  
Diabetinol® was developed with this concept in mind in order to address metabolic 
syndrome and hyperlipidemia.  
The pharmacokinetic profiles of nobiletin and tangeretin were previously based on the 
detection and quantification of their metabolites. In this chapter we have presented data on 
the detection of the parental compound nobiletin and tangeretin and suggest that in future 
research it is important to determine these compounds in human pharmacokinetic studies. 
Differences in bioavailability among formulations of a given supplement may have clinical 
significance; thus, knowing whether nutrient or drug formulations are equivalent is 
essential in making reasonable conclusions.  
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1. Introduction 
Purines are natural compounds that are found in all of the body's cells. They are the most 
widely distributed kind of N-heterocyclic substances in nature. Purines provide part of 
the chemical structure of some important co-enzymes and the genes of plants and 
animals. These compounds also participate in membrane signal transduction, translation 
and protein synthesis and in the form of purine nucleosides act as neurotransmitters in a 
variety of tissues. Purine base is also present in the structure of some important drugs 
such as 6-mercaptopurine (6-MP) and azathioprine (AZT). In addition, it can be found as a 
nucleobase in some synthetic nucleoside analogues with various pharmacological effects 
including antiviral and antitumor properties and numerous nucleoside analogues and 
their prodrugs were developed for cancer chemotherapy, treatment of patients with 
infections of human immunodeficiency virus (HIV) and infections caused by herpes and 
hepatitis viruses. 
Different enzymes can participate in the metabolism of a drug and alter its function. 
Aldehyde oxidase (EC 1.2.3.1: aldehyde: oxygen oxidoreductase, AO), and xanthine 
oxidase (EC 1.17.3.2: xanthine: oxygen oxidoreductase, XO) which are collectively referred 
as “molybdenum hydroxylases”, are two important cytosolic enzymes that are widely 
distributed throughout the animal kingdom. They are involved in the metabolism of an 
extensive range of exogenous and endogenous compounds with physiological, 
pharmacological and toxicological relevance (Beedham, 2010; Rashidi & Nazemiyeh, 
2010). The reactions catalyzed by AO and XO usually involve a nucleophilic attack at an 
electron-deficient carbon atom adjacent to a ring nitrogen atom in N-heterocyclic 
compounds or found within an aldehyde group. Therefore, purines as N-heterocyclic 
compounds can act as a substrate for both AO and XO (Hall & Krenitsky, 1986; Krenitsky 
et al, 1972, 1986; Rashidi et al., 1997, 2007). In spite of having many physicochemical 
properties in common, AO and XO have different substrate specificities and product 
regiospecificities. In addition, pronounced species variation is present in the levels of 
molybdenum hydroxylases activity, in particular in that of AO (Alfaro et al., 2009; Jones et 
al., 1987; Krenitsky et al., 1984; Rashidi et al., 1997). Therefore, a metabolic pathway 
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properties in common, AO and XO have different substrate specificities and product 
regiospecificities. In addition, pronounced species variation is present in the levels of 
molybdenum hydroxylases activity, in particular in that of AO (Alfaro et al., 2009; Jones et 
al., 1987; Krenitsky et al., 1984; Rashidi et al., 1997). Therefore, a metabolic pathway 
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mediated by AO or XO could be completely different. This will be more pronounced for 
those compounds that have several sites for oxidation by these two oxidative enzymes. 
Purine nucleus has three sites that could be oxidized by molybdenum hydroxylases. It 
would be difficult, thus, to predict which metabolite will be produced from a purine-
based drug by AO or XO, and the recognition of AO and XO contribution in the 
metabolism of this group of drugs will be a subject for scientific studies. This review 
highlights the involvement of AO and XO in the metabolism of important purine related 
drugs focusing on recent studies. 
1.1 Biological and pharmacological importance of purines  
Purines are an important group of nitrogen-containing compounds that are present in all 
forms of plant and animal life and play a vital role in biological processes. They serve as the 
source of cellular energy in ATP and together with pyrimidine, are the building blocks of 
DNA and RNA. Purines also participate in the structure of the co-enzymes (e.g. NAD+, 
NADP+ and FAD) and they are involved in membrane signal transduction, translation and 
protein synthesis (GTP, cAMP, cGMP, RNA). Over the last decades, a great deal of attention 
has been focused on the extracellular functions of purine nucleosides as neurotransmitters 
in a variety of tissues and different types of specific membrane purinergic receptors have 
been recognized (Di Iorio et al., 1998; Ralevic, 2009). 
Purine nucleus is also present in the structure of some important drugs such as 6-
thioguanine (6-TG), 6-MP and AZT. In addition, it can be found as a nucleobase in some 
synthetic nucleoside analogues which are structurally similar to natural nucleosides. Many 
nucleoside analogues have antiviral and antitumor properties. During the last decades, 
numerous nucleoside analogues and their prodrugs were developed for cancer 
chemotherapy, treatment of patients with infections of human immunodeficiency virus 
(HIV) and infections caused by herpes and hepatitis viruses (Li et al., 2008). In spite of 
having excellent pharmacological activity, they often suffer from a poor oral bioavailability 
due to low intestinal absorption. Therefore, intense research efforts have been focused on 
developing nucleoside analogues prodrugs, mainly in the acyclic form, to improve oral 
absorption (Li et al., 2008).  
1.2 Chemistry of purine 
In 1776, uric acid was isolated in a pure form from urinary calculi (stones), although the 
identification of its structure was not made until about 100 years later. It was this event that 
later was commemorated in the generic name, “purine” (from purum uricum) for the 
heterocyclic system (Hitchings, 1978). Xanthine and hypoxanthine were recognized as other 
members of the system in 1838 and 1850 respectively (Hitchings, 1978). In 1889, the term 
“nucleic acid” was introduced by Altmann and general methods for isolation of nucleic 
acids from various sources were developed by this investigator (Hurst, 1980). Then, purines 
and pyrimidines were discovered in nucleic acids and isolated from calf thymus nucleic acid 
in 1894 (Hurst, 1980). 
The purine nucleus consists of fused pyrimidine and imidazole rings having the 
numbering system shown in Fig. 1 it is an aromatic compound with -deficient ring 
 
Role of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of Purine-Related Drugs 
 
287 
system; therefore, all its carbon atoms are susceptible towards nucleophilic attack and are 
deactivated towards electrophilic attack. Because of the electron-attracting character  
of the  C=N   moiety, the 2-, 6- and 8-sites favor nucleophilic attack, although the 8-
position would be expected to be less  electron deficient than the two other sites due to 
the electron-releasing character of the -NH- moiety present in imidazole ring.  
The calculated electron densities of the various sites in purine are given in Figure 1. 
Purine is a weak base with an overall pKa = 2.3 (Joule, 1995). According to 13C NMR 
studies all three protonated forms are present in solution but it is suggested that the 
predominant cation is formed by N1 protonation (Joule, 1995). Purine is also a weak acid 




































Fig. 1. The numbering system and electron densities of purine. Upper and lower numbers in 
(b) are - and -charges respectively (Shaw, 1984) 
1.3 Purines as substrates for aldehyde oxidase and xanthine oxidase 
Different enzymes can participate in the metabolism of a drug either through conversion of 
a prodrug to an active form or elimination of a drug via its metabolic pathway. AO and XO 
as two drug metabolizing enzymes can utilize purines as their substrates (Hall & Krenitsky, 
1986; Krenitsky et al, 1972, 1986; Rashidi et al., 1997, 2007). They have many properties in 
common; both enzymes are large homodimeric proteins with a molecular mass of ~ 300,000 
Da, composed of two identical subunits. Each subunit contains one atom of molybdenum, 
one molecule of enzyme-bound flavin adenine dinucleotide (FAD) and two iron–sulfur 
(2Fe–2S) centers. In spite of these similarities and the existence of an overlap in substrate 
utilization between AO and XO, they have different substrate specificities and product 
regiospecificities. As it was mentioned before, molybdenum hydroxylases can catalyze the 
oxidation of a wide range of aldehydes and N-heterocyclic compounds (Beedham, 2010; 
Rashidi & Nazemiyeh, 2010). Purines are among those N-heterocyclic compounds that may 
be oxidized by AO and XO either as a prodrug converted to its active form (Krenitsky et al., 
1984; Rashidi et al., 1997) or during their catabolic pathways (Rashidi et al., 2007). However, 
the manner of oxidation by these two enzymes could be different from one compound to 
another. 
1.4 Metabolism of endogenous purines 
Purine metabolism in man may be divided into four interfacing compartments which are 
illustrated in Fig. 2 (Palella & Fox, 1991). 
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mediated by AO or XO could be completely different. This will be more pronounced for 
those compounds that have several sites for oxidation by these two oxidative enzymes. 
Purine nucleus has three sites that could be oxidized by molybdenum hydroxylases. It 
would be difficult, thus, to predict which metabolite will be produced from a purine-
based drug by AO or XO, and the recognition of AO and XO contribution in the 
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and pyrimidines were discovered in nucleic acids and isolated from calf thymus nucleic acid 
in 1894 (Hurst, 1980). 
The purine nucleus consists of fused pyrimidine and imidazole rings having the 
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Fig. 2. Overview of purine metabolism in man (Palella & Fox, 1991) 
a. De novo purine synthesis: The biosynthetic pathway through which non-purine 
precursors are combined to form the purine ring is referred to as de novo purine 
synthesis. These non-purine precursors are provided through dietary intake of amino 
acids (1). The first reaction in this synthetic process is the formation of 5phosphoribosyl-
-1-pyrophosphate which is finally converted to inosine-5’-monophosphate (IMP) in a 
ten step pathway (2).  
b. Nucleotide interconversion: Once IMP is formed it may be metabolized to other purine 
ribonucleotides such as AMP and GMP by interconversion pathways (3).  
c. Salvage of performed purine bases: These ribonucleotides may be converted to 
diphosphate and triphosphate forms which serve as essential substrates for variety of 
pathways (4), or to be broken down to purine bases or nucleosides (5). 
d. Degradation: As a final step in human purine metabolism, nucleosides and purine bases 
are metabolised to uric acid (6) which is excreted primarily in urine with small amounts 
excreted into intestine thereby bacterial uricolysis occurs (7). The conversion of 
hypoxanthine to xanthine and xanthine to uric acid is catalyzed by XO. 
2. Purine-related drugs and their metabolism by molybdenum hydroxylases 
2.1 Thiopurines: 6-mercaptopurine, azathioprine and 6-thioguanine  
Thipurines, 6-MP, AZT and 6-TG, are the analogues of purine nucleosides that serve as the 
backbone of current childhood acute leukemia treatment. They have also been effective 
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immunosuppressive agents for the past half a century and remain the immunosuppressive 
of choice for Crohn’s disease (Ansari et al., 2008; Fotoohi et al., 2010). In the early 1940s, the 
first studies on purine analogues as antimetabolites were begun by Hitchings and his group 
in which 8-azaguanine and 2,6-diaminopurine were found to possess marked anticancer 
activity in experimental tumors (Elion et al., 1951). Subsequently, 6-MP was synthesized by 
Elion and Hutchins in 1951 and found to have a high order of activity against human 
leukemia (Elion et al., 1952); it was successfully employed in the treatment of leukemia in 
man in 1953. This discovery was an important point in the development of antineoplastic 
and immunosuppressive agents. In 1958, the immunosuppressive activity of 6-MP in rabbits 
was demonstrated by Schwartz et al. (1958). Shortly, 6- (1-methyl-4-nitro-5-imidazolyl) 
thiopurine, AZT, was synthesized by the Hitchings–Elion laboratory and shown that this 
analogue of 6-MP acts as a pro-drug and is reduced non-enzymatically in body to 6-MP 
which is converted by sensitive neoplasms to the active form 6-thioinosinate by 
hypoxanthine-guanine phosphoribosyl-transferase (Van Scoik et al., 1985). AZT has a higher 
therapeutic index than 6-MP (Van Scoik et al., 1985). AZT has more potent 
immunosuppressive effect than 6-MP and is preferred drug to prevent or delay graft 
rejection and treat rheumatoid arthritis (Chabner et al., 2001). 6-MP together with 
methotrexate are the drugs of choice in the treatment of childhood acute lymphocytic 
leukemia, especially in those cases where prolonged duration of remission is required 
(Knoester et al., 1993; Van Scoik et al., 1985); however, this thiopurine is not effective for the 
treatment of chronic lymphocytic leukemia, Hodgkings disease or other 
lymphomas/carcinomas (Rider, 2008). 
Although thiopurines have been used for over 50 years, many aspects of their complex 
pharmacology and metabolism remain unclear. However, it has been suggested that (Zimm 
et al., 1984; Chabner et al., 2001) in the cell, 6-MP is converted first to thioinosinic acid, by 
hypoxanthine-guanine phosphoribosyl-transferase which is then metabolized to 
thioguanine ribonucleotide and deoxyribonucleotide; incorporation of these compounds 
into RNA and DNA results in the antitumour effect of the drug. In addition, thioinosinic 
acid can be methylated to 6-methylthioinosinate which like thioinosinic acid is able to 
inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme 
unique to the de novo pathway for purine ribonucleotide synthesis. 
The oral bioavailibility of 6-MP in man is low and highly variable (Knoester et al., 1993; 
Meerten et al., 1995), however, this is the usual rout of administration. The mechanism for 
this variability is not fully known but it may be due to a combination of differences in the 
rate of absorption, distribution, elimination and first-pass metabolism of drug (Knoester et 
al., 1993). After intravenous injection, 6-MP undergoes rapid cellular uptake, hepatic 
metabolism, and renal excretion. Approximately 50% of an administered dose of the drug is 
excreted in the urine within 24 hours, with 22% eliminated as unchanged drug (Rider, 2008).  
6-MP, after administration, may enter into either anabolic or catabolic metabolic pathways 
(Lennard et al., 1991; Van Scoik et al., 1985). The anabolic pathway is responsible for 
conversion of 6-MP to its active form, whereas the drug is degraded to inactive forms in the 
catabolic pathway via two major inactivation routes (Fig. 3). One is thiol methylation, which 
is catalyzed by the enzyme thiopurine S-methyltransferase, to form the inactive metabolite 
methyl-6-mercaptopurine. The second route is thought to involve the initial oxidation of 6-
MP to 8-oxo-6-MP followed by conversion to 6-thiouric acid (Elion, 1967; Van Scoik et al., 
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catabolic pathway via two major inactivation routes (Fig. 3). One is thiol methylation, which 
is catalyzed by the enzyme thiopurine S-methyltransferase, to form the inactive metabolite 
methyl-6-mercaptopurine. The second route is thought to involve the initial oxidation of 6-
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1985). However, Zimm et al., (1984) have identified 6-thioxanthine in the urine samples of 
some patients who received 6-MP by intravenous infusion which may indicate that 6-MP is 
converted to 6-thiouric acid via 6-thioxanthine. The oxidative inactivation of 6-MP has been 
attributed to XO activity in intestinal mucosa and liver. The Km value for the oxidation of 6-
MP by calf liver and bovine milk xanthine oxidase (BMXO) is 20-30 µM (Chalmers et al., 
1969; Krenitsky et al., 1972). 6-MP is also a substrate for rabbit liver AO with a reported Km 
of 1.6 mM (Hall & Krenitsky, 1986). The second catabolic pathway for 6-MP is methylation 
of the sulphur atom catalyzed by thiopurine methyltransferase. 6-Methylmercaptopurine 
then undergoes oxidation at position 8 catalyzed by XO and/or AO (Van Scoik et al., 1985); 
the difference in metabolite profile between oral and intravenous administration may be 
indicative of the significant role of AO in 8-hydroxylation (Beedham, 2002). These metabolic 



























































Fig. 3. Proposed metabolic pathways for 6-mercaptopurine (6-MP) (Van Scoik et al., 1985; 
Zimm et al., 1984). AO: aldehyde oxidase, XO: xanthine oxidase 
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Although 6-thiouric acid has been detected as the major metabolite of 6-MP after oral 
administration of drug (Elion, 1967; Van Scoik et al., 1985; Zimm et al., 1984), there is no 
direct evidence in the involvement of molybdenum hydroxylases in these oxidative 
reactions and the results obtained from in vitro studies are controversial. 8-Oxo-6-MP (Elion, 
1967; VanScoik et al., 1985), 6-methylmercapto-8-hydoxypurine (Keuzenkamp-Jansen et al., 
1996)  and 6-thioxanthine (Zimm et al., 1984), all have been suggested to be the intermediate 
in the conversion of 6-MP to 6-thiouric acid. Recently, Rashidi et al. (2007) have 
demonstrated that 6- MP is more likely oxidized to 6-thiouric acid via 6-thioxanthine rather 
than 8-oxo-6-MP. The first step which is the rate limiting step is catalyzed solely by XO, 
whereas both XO and AO are involved in the oxidation of 6-thiouric acid to 6-thiouric acid 









Fig. 4. Proposed metabolic pathway for the oxidation of 6-mercaptopurine by partially 
purified guinea pig liver fractions (Rashidi et al., 2007). AO: aldehyde oxidase,  
XO: xanthine oxidase 
The metabolism of 6-TG is very similar to that of 6-MP, however, there is a clinically 
important difference between catabolic pathway of these two thiopurines (Fig. 5). Unlike 6-
MP which is first metabolized to 6-thioxanthine by XO and then 6-thiouric acid by both XO 
and AO (Rashidi et al., 2007), 6-TG must first be metabolized by guanine deaminase 
(guanase) to 6-thioxanthine, which is then metabolized to 6- thiouric acid (Evans & Relling, 
1994; Hogarth et al., 2008). As guanase is not as abundant as XO, more of 6-TG is directly 
activated to thioguanine nucleotides without oxidation to the inactive metabolite, 6-thiouric 
acid (Hogarth et al., 2008). This could be a reason for some clinical findings (Lennard et al., 
1993) indicating that in children with acute lymphoblastic leukemia, significantly higher 
concentrations of thioguanine nucleotides are achieved with oral 6-TG therapy compared 
with oral 6-MP therapy (Evans & Relling, 1994). 
In addition, taking into account the important role of XO in the catabolic pathway of 6-MP, 
co-administration of 6-MP and XO inhibitors such as allopurinol can lead to severe forms of 
mercaptopurine toxicity and dosage modification of the drug is necessary, whereas in the 
case of 6-TG dosage modification is not warranted, because the first step of drug 
inactivation is not catalyzed by XO (Hande & Garrow, 1996). 
AO is also involved in the metabolism of 6-TG (Fig. 5). According to Kitchen et al. (1999), 6-
TG can be oxidized to 8-hydroxythioguanine by AO. 8-Hydroxythioguanine has been found 
to be the predominant circulating metabolite in patients receiving continuous i.v. infusion of 
thioguanine and is likely generated by the action of AO (Kitchen et al., 1999).  
AZT can also undergo two different metabolic routes. In the first route, AZT is extensively 
converted to 6-MP which is then metabolized as in Fig. 6. In the second route, AZT may be 
directly oxidized to 8-oxo-azathioprine, catalyzed by AO. Cleavage of 8-oxo-azathioprine by 
glutathione or other nucleophilic compounds gives 8-oxo-6-mercaptopurine which may 
then be oxidized to 6-thiouric acid by XO (Fig. 6). 
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Fig. 5. Metabolic pathways of 6-TG. PRPP: phosphoribosyl pyrophosphate, HPGT: 
hypoxanthine-guanine phosphoribosyl transferase, TPMT: thioguanosine monophosphate, 
AO: aldehyde oxidase, XO: xanthine oxidase (from: Kitchen et al., 1999) 
The Km value for the oxidation of azathioprine by rabbit liver AO is 80 µM (Chalmers et al., 
1969), whereas azathioprine is very poor substrate for XO such that kinetic constants have 
been measured competitively against the oxidation of 6-methylaminopurine catalyzed by 
human liver XO (Ki = 340 µM) (Krenitsky et al., 1986). Therefore, it is likely that AZT is 
oxidized by AO in vivo if the drug comes in contact with the enzyme (Chalmers et al., 1969). 
It is estimated that the effects of XO and AO activity leaves only about 16% of the total dose 
of 6-MP available for systemic distribution (Fotoohi et al., 2010). 
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Fig. 5. Metabolic pathways of 6-TG. PRPP: phosphoribosyl pyrophosphate, HPGT: 
hypoxanthine-guanine phosphoribosyl transferase, TPMT: thioguanosine monophosphate, 
AO: aldehyde oxidase, XO: xanthine oxidase (from: Kitchen et al., 1999) 
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Fig. 6. The metabolic pathways for azathioprine (Van Scoik et al., 1985). AO: aldehyde 
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Famciclovir 2-[2-(2-Amino-9H-purin-9-yl) ethyl]-1,3-propanediol diacetate (ester) is a 
synthetic guanine derivative which is metabolized to the potent antiviral compound 
penciclovir. Penciclovir is active against herpes simplex virus (HSV) types 1 and 2, varicella 
zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis B (Perry & Wagstaff, 1995).  
The mechanism of action of penciclovir is similar to that of aciclovir. Both drugs are 
selectively phosphorylated in virus-infected cells to a monophosphate ester by thymidine 
kinase, followed by further phosphorylation to a triphosphate ester which inhibits virus 
DNA polymerases (Vere Hodge & Cheng, 1993). However, the concentration of 
triphosphate ester of penciclovir within infected cells is higher than that of aciclovir and it 
has a more prolonged intracellular half-life in cells infected with HSV (10-20 hours) and 
VZV (7-14 hours) compared to aciclovir triphosphate (1 hour) (Perry & Wagstaff, 1995; Vere 
Hodge & Cheng, 1993). Like aciclovir, penciclovir has very low oral bioavailibility, but its 
prodrug, famciclovir, is absorbed rapidly and extensively after oral administration, and little 
or no parent compound can be detected in plasma or urine (Mondal, 2008). The absolute 
bioavailability of penciclovir is about 77% (Pue & Benet, 1993), which is about four times 






































Fig. 7. The major metabolic pathway of famciclovir in man (Vere Hodge et al., 1989) 
Metabolism of famciclovir involves sequential hydrolysis of both acetyl groups to give 6-
deoxypenciclovir which can be oxidized to penciclovir (Fig. 7); however, both in vivo and in 
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vitro studies have also shown that penciclovir is the major metabolite of famciclovir 
metabolism (Pue & Benet, 1993; Pue et al., 1994; Rashidi et al., 1997). Although the oxidative 
step was initially attributed to XO, on the basis of studies performed with 6-deoxyaciclovir and 
a structural similarity between 6-deoxypenciclovir and guanine which is a substrate of XO 
(Harrell et al., 1993; Krenitsky et al., 1984; Vere Hodge et al., 1989), later studies demonstrated 
that AO is the major enzyme in oxidative conversion of famciclovir to penciclovir (Clarke et 
al., 1995; Rashidi et al., 1997).  
According to Rashidi et al. (1997), both famciclovir and 6-deoxypenciclovir are 
predominantly oxidized at carbon 6 by human, guinea pig and rat hepatic AO, whereas 
the major metabolites with rabbit enzyme are 8-oxo- and 6-oxo-derivatives with the 
former metabolite having higher contribution. 6-Deoxypenciclovir is oxidized only at the 
6-position by rat liver and BMXO. Famciclovir is a better substrate than 6-
deoxypenciclovir for hepatic AO from all species tested (Table 1). The oxidation rate of 
both compounds is comparable with probe substrates of AO such as phenanthridine and 


















Human Liver AO  
(N = 1-2) 0.42 16 0.038 0.15 61 0.407 
Guinea pig liver 
AO  (N = 3-5) 
0.41± 
0.01a 209±38 0.510 0.17±0.01 439±48 2.582 
Rabbit liver AO  
(N = 2) 0.44 114 0.259  ND
b  
AO-Active rat 
enzyme (N = 3)a 0.37±0.05 26±6 0.070 0.08±0.02 41±10
 0.506 
AO-Deficient rat 
enzyme (N = 3)a 0.26±0.01 4±2 0.015  NR
c  
BMXO (N = 2) 0.90 155 0.172  NR  
a Mean±SD 
b ND: Not determined  
c NR: No reaction 
Table 1. Kinetic parameters for 6-oxo-metabolite formation by partially purified guinea pig, 
human, rabbit, rat liver aldehyde oxidase (AO) and bovine milk xanthine oxidase (BMXO) 
determined by HPLC (Rashidi et al 1997) 
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Although 6-deoxypenciclovir is oxidized very slowly by rat liver XO and BMXO, 
famciclovir did not serve as a substrate for either enzyme. In Figures 8-10, the metabolic 












































Fig. 8. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified guinea pig, aldehyde oxidase-active rat and human liver fractions (Rashidi, 1996; 
Rashidi et al., 1997). AO: aldehyde oxidase, XO: xanthine oxidase 
 
















































Fig. 9. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified rabbit liver fractions (Rashidi, 1996; Rashidi et al., 1997). AO: aldehyde oxidase, XO: 
xanthine oxidase 
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Fig. 9. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
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Fig. 10. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified aldehyde oxidase-deficient rat liver fractions (Rashidi, 1996). XO: xanthine oxidase 
2.3 Ganciclovir 
Ganciclovir is an acyclic nucleoside analog of 2’-deoxyguanosine from which the 2’ carbon 
has been deleted. It is used for the treatment of cytomegalovirus (CMV) infections, most 
commonly retinitis, colitis, and esophagitis, in immunocompromised patients and is 
administered to transplant patients at risk for CMV retinitis (Mondal, 2008; Physician’s Desk 
Reference, 2000).  
Ganciclovir is much more effective than aciclovir against CMV and HSV (De Clercq & Field, 
2006; Noble & Faulds, 1998), although it has greater potential toxicity (Crumpacker, 1996). It 
is more easily phosphorylated in CMV infected cells than aciclovir and its triphosphate has 
a 5-fold higher affinity for CMV DNA polymerase than aciclovir triphosphate (Krogsgaard-
Larsen, 1992). Ganciclovir is also active against VZV and EBV; however, it causes 
neutropenia and its clinical use is restricted to the treatment of CMV infections in 
immunocompromised patients (Krogsgaard-Larsen, 1992). 
Like aciclovir, the absorption of ganciclovir following oral administration is low. Its absolute 
bioavailability after oral administration of 1000 mg of ganciclovir capsules three times a day 
was approximately 8.5% (Anderson et al., 1995). To overcome this problem, in accordance 
with the prodrug approaches, various analogues of ganciclovir were synthesized. One of the 
strategies used was the synthesis of C-6 deoxy 2-aminopurine prodrugs of ganciclovir. 
Significant success with this strategy had been achieved previously by aciclovir. The 
dipivalate ester of 6-deoxyganciclovir was one of the prodrugs of ganciclovir that was 
produced using this strategy (Krasny et al., 1995). The dipivalate ester was introduced to 
increase lipophilicity of the molecule. Because of chemical similarity of aciclovir and 
ganciclovir, it was also expected that the 6-deoxy prodrug would be converted to 
gannciclovir. According to preclinical studies in rats, a 7-fold enhancement in oral 
bioavailability of the compound was observed and the prodrug was rapidly converted to 
ganciclovir and 6-deoxy ganciclovir in vivo; however, the 6-deoxy ganciclovir was not 
oxidized to ganciclovir by XO. Rat liver sometimes has insufficient XO activity and the 
results obtained from this animal model cannot be extrapolated to human, in particular with 
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nucleobase antiviral agents (Rashidi et al., 1997). Therefore, the involvement of AO or XO in 
conversion of 6-deoxyganciclovir produced from its dipivalate ester analogue to ganciclovir 
cannot be ruled out and further studies may be required. 
The other example of the use of prodrug approach to increase the oral bioavailability of 
ganciclovir is HOE 602, the bis-isopropyl ether of 6-deoxy ganciclovir. HOE 602 is a 
nucleobase analog of ganciclovir with high therapeutic efficacy against HSV and MCMV 
infections in mice (Winkler et al., 1990). Pharmacokinetic studies in mice and rhesus 
monkeys indicated that this prodrug is converted to ganciclovir via a three-step pathway 
(Fig. 11) and yields a 4 to 21-fold increase in exposure after oral administration in monkeys 
compared to an equivalent oral dose of ganciclovir (Winkler et al., 1990). The first step, 
oxidation of the 6-aminopurine moiety to guanine, is mediated by XO (Winkler et al., 1990). 




























Fig. 11. Conversion of HOE 602 prodrug to ganciclovir (Winkler et al., 1990). XO: xanthine 
oxidase 
Valganciclovir, a valine ester of ganciclovir, is another example of prodrug approach to 
overcome the poor oral absorption of ganciclovir (Maag, 2002). Following oral 
administration of valganciclovir in human, the absolute bioavailability of ganciclovir could 
be 10-fold higher than that from oral ganciclovir (Jung & Dorr, 1999; Pescovitz et al., 2000). 
According to these studies, no significant amount of the prodrug was detected in plasma 
which may be indicative of rapid and complete hydrolysis of valganciclovir to ganciclovir in 
vivo (Li et al., 2008).  
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Conversion of valganciclovir to ganciclovir is a hydrolytic reaction and therefore is not 
dependent to molybdenum hydroxylases. However, C-8 carbon in both valganciclovir and 
ganciclovir, like other purine-based antiviral agents such as 6-deoxypenciclovir and 
aciclovir, is susceptible for oxidation by these oxidative enzymes which is subject for further 
studies. Interestingly, according to Krasny et al. (1995), after oral administration of 
dipivalate ester of 6-deoxyganciclovir to cynomolgus monkey, but not rat, the 8-hydroxy 
analogs of ganciclovir and 6-doxyganciclovir are also detected alongside of other 
metabolites. 
2.4 Aciclovir and valaciclovir 
Acyclovir, 9-[(2-hydroxy ethoxy) methyl] guanine is a guanosine analogue antiviral agent 
that has a high therapeutic index. It was the first specific antiviral drug described in the 
early 1980s (Dollery, 1999) and then the spectrum compound of the first aciclovir were 
boarded to vital therapies for DNA virus and retrovirus infections (Field & De Clercq 2004; 
De Clercq & Holy, 2005). Aciclovir is initially phosphorylated to a monophosphate 
derivative by a virus-specific thymidine kinase, and not by the thymidine kinase of 
uninfected cells (Rajalakshmi et al., 2010) and then to a triphosphate which inhibits 
competitively DNA synthesis in the infected cells. Phosphorylation does not occur in 
healthy cells which accounts for its strong selectivity of action (Clercq & Holy, 2005). 
Consequently, the amount of aciclovir triphosphate formed in the virally infected cells is 40-
100 times greater than that in normal uninfected cells (Rajalakshmi et al., 2010). Aciclovir is a 
potent and selective inhibitor of herpes virus DNA replication. It acts as a substrate for the 
enzyme viral DNA polymerase in competition with normal deoxy adenosine triphosphate 
and results in complete and irreversible inhibition of herpes virus DNA polymerase and 
viral DNA chain termination (Rajalakshmi et al., 2010). 
Clinically, aciclovir has been found effective against all types of HSV and VZV but not 
against other species of viruses (Hirsch & Schooley, 1983). In spite of its effective antiviral 
activity, aciclovir has some important limitations. Firstly, it is significantly less effective 
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against VZV than against HSV (Safrin & Phan, 1993) (Easterbrook & Wood, 1994). 
Furthermore, some cases of HSV and VZV isolates resistant to aciclovir have been 
reported(Safrin & Phan, 1993) (Easterbrook & Wood, 1994).  In addition, aciclovir has 
relatively low (15-20%) and unpredictable oral bioavilability (Easterbrook & Wood, 1994) 
(de Miranda & Blum, 1983) resulting in the need for frequent high doses or intravenous 
therapy in conditions where high plasma aciclovir levels are necessary to inhibit less 
sensitive viruses as in like VZV (de Miranda & Burnette, 1994; Safrin & Phan, 1993). 
Consequently, many attempts have been made to improve aciclovir efficiency when given 
orally in humans or to find new successors to aciclovir. Development of a prodrug of 
aciclovir with a better absorption from the gastrointestinal tract and then conversion in vivo 
to aciclovir has been one of the most common strategies used to achieve this goal (Burnette, 
T.C. & de Miranda 1994; Hay CM, Reichman 2008; Krenitsky et al., 1984).   
One such prodrug is 6-deoxyaciclovir or desciclovir, 2-amino-9-[2-hydroxyethoxy) methyl]-
9H-purine. 6-Deoxyciclovir is an analog of aciclovir which is 18 times more water soluble 
than aciclovir (Krenitsky et al., 1984). The prodrug is extensively absorbed following oral 
administration to healthy volunteers and converted to aciclovir in vivo by the XO; however, 
XO cannot further oxidize aciclovir (Fig. 12) (Krenitsky et al., 1984). On the other hand, 
aciclovir is hydroxylated at C-8 by AO, but this enzymatic reaction is a minor metabolic 
pathway in patients (Beedham, 1997). 
Although 6-deoxyaciclovir has been reported as XO-activated prodrugs (Krenitsky et al., 
1984; Jones et al., 1987), the compound is a better substrate for AO than XO (Table 2). Like 6-
deoxypenciclovir, 6-deoxyaciclovir is oxidized to 8-oxo-metabolite as the major metabolite 
by rabbit liver AO (Fig. 13) and its Vmax/Km value is 57-fold higher than that of BMXO 
(Krenitsky et al., 1984). It has been reported that allopurinol was less effective in inhibition 
of 6-deoxyaciclovir oxidation to aciclovir in isolated perfused Sprague-Dawley rat livers 
(Jones et al., 1987) whose liver AO is very variable. The ratio of 8-oxo-metabolite to 6-oxo-
metabolite (aciclovir) from the oxidation of 6-deoxyaciclovir by rabbit liver AO is 95 to 5 
(Krenitsky et al., 1984). Although the bioavailability of 6-deoxyaciclovir was improved, 
further development of the prodrug was terminated due to the chronic toxicity problems 


















Fig. 12. 6-Deoxyaciclovir as a prodrug of aciclovir is activated by xanthine oxidase (XO) 
(Krenitsky et al., 1984) 
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Fig. 12. 6-Deoxyaciclovir as a prodrug of aciclovir is activated by xanthine oxidase (XO) 
(Krenitsky et al., 1984) 
 






































Fig. 13. Metabolism and inactivation of 6-deoxyaciclovir by rabbit liver aldehyde oxidase 
(Krenitsky et al., 1984) 
AO converts 6- Deoxyaciclovir to 8-hydroxy-6-deoxyaciclovir and aciclovir with the ratio of 
95 to 5 respectively, and both of them are turned more oxidase to 8-hydroxyaiclovir 
(Krenitsky et al., 1984).  
Valaciclovir, 2-[2-amino-1, 6-dihydro-6-oxo-9H-purin-9-yl-methoxy] ethyl valinate 
hydrochloride, is another oral prodrug of aciclovir with an oral bioavailibility of higher than 
that of acyclovir (Burnette, T.C. & de Miranda 1994; Hay CM & Reichman, 2008). 
Valaciclovir is well absorbed following oral administration and is rapidly converted to 
aciclovir by hydrolysis of the valyl ester during first pass intestinal and/or hepatic 
metabolism (Burnette, T.C. & de Miranda, 1994; de Miranda, P. & Burnette, 1994). Therefore, 
the mechanism of action and spectrum of activity of valaciclovir are the same as that of 
acyclovir (Rajalakshmi et al., 2010). 
2.5 Carbovir 
Carbovir is a carbocyclic guanosine derivative with a potent and selective inhibitory effect 
on HIV-1 replication (Vince et al., 1988). As its oral bioavailability is low (Huang et al., 1991), 
its prodrug, 6-deoxycarbovir was synthesized in attempt to increase its oral absorption. The 
chemical structure of 6-deoxycarbovir is very similar to that of 6-deoxypenciclovir and 6-
deoxyaciclovir. Like 6-deoxyaciclovir, 6-deoxycarbovir has been reported as XO-activated 
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prodrug (Vince et al., 1995), but it is also a better substrate for AO than XO (Table 2). 6-
Deoxycarbovir is oxidized at C-8 position and 8-hydroxy-6-deoxycarbovir is the main 
metabolite produced from incubation of 6-deoxycarbovir with rabbit liver AO, but with 
guinea pig liver AO, 6-hydroxylation is the major metabolic pathway and carbovir is 
produced as almost the only oxidative metabolite.  
8-Hydroxy-6-deoxyaciclovir lacks appreciable activity against herpes simplex type I in vitro 
(Krenitsky et al., 1984). As substitution at carbon 8 generally results in loss of antiviral 
activity (Beedham, 1997), 8-hydrox-6-deoxycarbovir is expected to be dvoid of antiviral 
activity. It is likely that AO from other sources like guinea pig liver, which is a better animal 
model for human liver AO (Rashidi, 1996), acts as the main enzyme in oxidative conversion 
of 6-deoxyaciclovir to aciclovir as it is the case with 6-deoxypenciclovir and 6-
deoxycarbovir. The assay of 6-deoxyaciclovir oxidation by hepatic AO from species such as 
guinea pig and human and pharmacokinetics of 6-deoxyaciclovir following administration 

























Guinea pig 0.41 27  0.40 100  ND ND 
Rabbit 0.44 0.9  0.11 0.3  0.06 0.05 
Rat liver XO 0.26 a  0.22 a  ND ND 
BMXO 0.90 a  ND ND  0.9 a 
a: 6-Oxo-metabolite was the only metabolite produced. 
ND: Not determined 
Table 2. The Km value for the formation of 6-oxo-metabolite and the ratio of 6-oxo- to 8-oxo-
metabolite for the oxidation of 6-deoxypenciclovir, 6-deoxycarbovir and 6-deoxyaciclovir 
catalyzed by guinea pig, rabbit, rat liver xanthine oxidase (XO) and bovine milk xanthine 
oxidase (BMXO) (Krenitsky et al., 1984; Rashidi 1996; Rashidi et al., 1997). 
2.6 Vidarabine  
Vidarabine (9-β-D-Arabinosyladenine, adenine arabinoside, Ara-A, Vira-A), a marine-
derived drug has been shown to have antitumor activity. However, it has become more 
notable for its antiviral activity with a high therapeutic index (Hansel et al., 2004; Hirsch & 
Schooley, 1983). In the 1964, the first study on the antiviral activity of vidarabine was 
explained by Private de Grilhe and De Rudder (Private de Grilhe & De Rudder, 1964). 
Following, Whiley described vidarabine activity in the treatment of herpes encephalitis and 
the other herpes infection in newborns (Field & De Clerq, 2004). Vidarabine possess 
significant activity against infections caused by herpes viruses, pox viruses, rhabdoviruses, 
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hepadnaviruses, the vaccinia virus, VZV, and some RNA tumor viruses. Although 
vidarabine is supplanted by acyclovir and other analogs for most applications, it is still used 
as an alternative therapy for acyclovir-resistant HSV and VZV infections (Gentry et al., 
2008). 
However, vidarabine is extensively deaminated in the body by adenosine deaminase (ADA) 
to 9-β-D-arabinofuranosylhypoxanthine (hypoxanthine arabinoside) that has less antiviral 
activity than vidarabine, which is a major limitation in its clinical use (Shen et al., 2009; 
Shope et al., 1983; Sloan et al., 1977). Inhibition of ADA by co-administration of modified 
purine analogues with vidarabine, such as deoxycoformacine, can improve the therapeutic 
effect of vidarabine (Bryson et al., 1974, 1976).  In addition, vidarabine has limited lipid 
solubility which the low delivery from cell membrane and very low solubility in water 
(about 0.47 mg/ml), therefore, the large fluid volumes is needed for intravenous 
administration (Baker et al., 1978; Hirsch & Schooley, 1983; Whitley et al., 1980). 
Vidarabine is a nucleoside analog; therefore, it has to be phosphorylated and to be active. It 
is phosphorylated to its monophosphate, di- and triphosphate nucleotides which during the 
synthetic (S) phase inhibit DNA polymerase and strongly in the virus such as herpes, 
vaccinia and varicella zoster viruses than in the host cells (Dicioccio & Srivastava, 1977; 
Doering et al., 1966; Rose & Jacob, 1978; Shipman et al., 1976). As well, vidarabine is 
integrated into RNA in virus and inhibit RNA polyadenylation reaction (Rose & Jacob, 
1978).  
In mammalian cell, vidarabine is rapidly converted by ADA to hypoxanthine arabinoside 
which has less antiviral activity than vidarabine. Hypoxanthine arabinoside is the major 
metabolite of vidarabine is excreted renally and biotransformed by XO to xanthine 
arabinoside (Fig. 14) (Connor et al., 1975; Friedman & Grasela, 1981; Hirsch & Schooley, 
1983; Shen et al., 2009). Allopurinol as an inhibitor of XO can interfere with the metabolism 
of vidarabine and, therefore, co-administration of allopurinol with vidarabine should be 
avoided or used with caution (Woster, 2007). The role of AO in this metabolic pathway, in 
particular oxidation of xanthine arabinoside at C-8, has not been investigated and could be a 
subject for future studies.  
Deamination
Vidarabine Hypoxanthine arabinose Xanthine arabinoside
Oxidation

































Fig. 14. The biotransformation of vidarabine in mammalian cells. Vidarabine is converted to 
hypoxanthine arabinoside through deamination by adenosine deaminase (ADA), followed 
by oxidation to xanthine arabinoside by xanthine oxidase (XO) (Connor et al., 1975; 
Friedman & Grasela, 1981; Gannon et al., 1984; Shen et al., 2009). 
 




Theophylline (1,3-dimethylxanthine) is a methylxanthine which is widely distributed in 
nature. It is widely used as a bronchodilator agent for the treatment of various asthmatic 
and pulmonary conditions under a variety of brand names and is one of the most widely 
prescribed drugs for the treatment of airway diseases worldwide (Barnes, 2003). 
Theophylline acts as an effective drug in clinical trials against air way narrowing and 
prevents wheezing, cough, shortness of breath and difficulty breathing which is caused by 
asthma and different lung disease. It is also helpful in patient with chronic obstructive 
pulmonary disease (COPD) including chronic bronchitis and emphysema which opens air 
way lung to make breach easer (Aronson et al., 1992; Pauwel, 1987; Vielhaber & Kavuru, 
2001).  
Theophylline is metabolized in the human liver through N-1 or N-3 demethylation followed 
by hydroxylation at C-8 producing three main products including 3-methylxanthine (3MX), 
1-methyluric acid (1MU) and 1,3-dimethyluric acid (1,3DMU) (Fig. 15) (Brikett et al., 1983; 
Lu et al., 2003; Yao et al., 2001). It is thought that cytochrome P450 1A2 (CYP1A2) is the most 
important enzyme involved in the catalysis of these reactions (HR et al., 1995; Tjia et al., 
1996). Cytochrome P450 2E1 (CYP2E1) can also mediate C-8 hydroxylation but its 





















































Fig. 15. The biotransformation of theophylline through CYP450 family and xanthine oxidase  
(Brikett et al., 1983;  HR et al 1995; Lu et al., 2003; Tjia, et al 1996; Yao et al., 2001). CYP1A2: 
Cytochrome P450 1A2, CYP2E1: Cytochrome P450 2E1, XO: Xanthine Oxidase 
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1-Methyluric acid is the secondary metabolic pathway of theophylline. It is produced 
following a rapid oxidation from 1-methylxanthin by XO (Fig. 15) (Brikett et al., 1983). In 
contrast to the other methylxanthines, 1-methylxanthin is a good substrate for XO 
(Bergmann & Dikstein, 1956; Krenitsky et al., 1972; Lohmann & Miech, 1976) and used as a 
XO activity index for plasma concentration of oxypurinal in man (Graham et al., 1996). The 
involvement of XO in the metabolism of theophylline has also been used for the 
construction of amperometric enzyme electrodes to quantitative measurement of 
theophylline (Stredansky et al., 2000). Allopurinal as a potent inhibitor of XO activity 
decreases the formation of 1-methyleuric acid from the 1-methylxanthine in theophylline 
oxidation (Brikett et al., 1983; German DC, 1986). 
3. Conclusion 
Drug metabolism is one of the important factors that may play a major role in drug 
development and toxicity. AO and XO are two molybdenum-containing enzymes that are 
involved in the metabolism of an extensive range of aldehydes and N-heterocyclic 
aromatic compounds (Beedham, 1997; Rashidi & Nazemiyeh, 2010). Although the 
importance of molybdenum hydroxylases in drug metabolism has usually been 
overshadowed by that of CYP450 as the most important drug metabolizing enzyme 
system, we will witness a significant increase in the importance of XO and AO in drug 
metabolism over the next decade (Alfaro et al 2009; Obach et al., 2004). Purines as  
N-heterocyclic compounds, thus, can serve as substrate for AO and XO and the 
importance of molybdenum hydroxylases in the metabolism of purines and also the 
development of purine related prodrugs has been demonstrated by several authors 
(Clarke et al., 1995; Kitchen et al., 1999; Krenitsky et al., 1984; Rashidi et al., 1997, 2007; 
Van Scoik et al., 1985). 
The reaction catalyzed by AO and XO involves a nucleophilic attack on an electron-deficient 
sp2-hybridized carbon atom adjacent to a ring nitrogen atom in N-heterocyclic compounds. 
Therefore, nitrogen-containing aromatic compounds including purines can act as 
appropriate substrates for XO and AO. Purine nucleus contains several nitrogen atoms and 
is sequentially oxidized at three different positions; in a substituted purine analogue, any of 
these sites could be attacked by AO and XO with varying affinities and/or rates (Beedham, 
2010).  
On the other hand, significant interspecies variations exist in both the number and activity 
of both AO and XO, in particular the former enzyme (Alfaro et al., 2009; Jones et al., 1987; 
Krenitsky et al., 1984; Rashidi et al., 1997). Therefore, not only it is difficult to predict which 
metabolite will be produced from a purine-based drug by AO or XO, but also it would be a 
hard task to recognize which of these two enzymes has a dominant contribution in the 
metabolic pathway. In addition, it would be difficult to find a suitable animal model and 
extrapolate the results obtained from the animal studies to man. 
As it was shown in the previous sections, there are several purine related drugs or 
prodrugs that are metabolized by AO and/or XO; however, the manner of the oxidation 
sites could be completely different for these two enzymes. For example, famciclovir and 6-
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deoxycarbovir are converted to their corresponding active agent by AO with purine 
oxidation occurs at carbon 6. But, rabbit liver enzyme acts differently and attacks mainly 
at carbon 8 of the purine nucleus. In contrast to AO, XO has a little contribution to the 
activation of these purine analogues. Not surprisingly, Krenitsky et al. (Krenitsky et al., 
1972,1984) has shown that the oxidation occurs at carbons 6 and 8 with XO and rabbit 
liver AO, respectively. 6-Deoxyaciclovir which is also a purine-based prodrug is oxidized 
at the 6-position by XO, whereas rabbit enzyme oxidizes 6-deoxyaciclovir to 8-oxo-6-
deoxyaciclovir (Krenitsky et al., 1984). However, it has been found that (Iyer, 1992; 
Rashidi et al., 1997) rabbit liver AO differs to the enzyme from other species in oxidizing 
carbon 8 of 2-NH2-9-substituted purines instead of the 6-position. Therefore, it is more 
likely that 6-deoxyaciclovir is predominantly oxidized to aciclovir by AO from human, 
guinea pig or rat livers which are subject for further studies. This could be case for other 
purine related drugs that their metabolism has been attributed to XO. Conducting 
comparative studies, the like of which has been carried out with famciclovir (Rashidi et 
al., 1997), would be of great value in elucidating the contribution of AO and XO in the 
metabolism of these purine-based agents. In these studies, the selection of an appropriate 
animal model for human AO would be a problem because of the different substrate 
specificity of enzyme from each species.  
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As it was shown in the previous sections, there are several purine related drugs or 
prodrugs that are metabolized by AO and/or XO; however, the manner of the oxidation 
sites could be completely different for these two enzymes. For example, famciclovir and 6-
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deoxycarbovir are converted to their corresponding active agent by AO with purine 
oxidation occurs at carbon 6. But, rabbit liver enzyme acts differently and attacks mainly 
at carbon 8 of the purine nucleus. In contrast to AO, XO has a little contribution to the 
activation of these purine analogues. Not surprisingly, Krenitsky et al. (Krenitsky et al., 
1972,1984) has shown that the oxidation occurs at carbons 6 and 8 with XO and rabbit 
liver AO, respectively. 6-Deoxyaciclovir which is also a purine-based prodrug is oxidized 
at the 6-position by XO, whereas rabbit enzyme oxidizes 6-deoxyaciclovir to 8-oxo-6-
deoxyaciclovir (Krenitsky et al., 1984). However, it has been found that (Iyer, 1992; 
Rashidi et al., 1997) rabbit liver AO differs to the enzyme from other species in oxidizing 
carbon 8 of 2-NH2-9-substituted purines instead of the 6-position. Therefore, it is more 
likely that 6-deoxyaciclovir is predominantly oxidized to aciclovir by AO from human, 
guinea pig or rat livers which are subject for further studies. This could be case for other 
purine related drugs that their metabolism has been attributed to XO. Conducting 
comparative studies, the like of which has been carried out with famciclovir (Rashidi et 
al., 1997), would be of great value in elucidating the contribution of AO and XO in the 
metabolism of these purine-based agents. In these studies, the selection of an appropriate 
animal model for human AO would be a problem because of the different substrate 
specificity of enzyme from each species.  
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Development of tumor resistance to chemotherapeutics is related to inherent tumor 
variations regarding sensitivity to chemotherapeutics and to sub-optimal dosing regimens, 
including variation in patient pharmacokinetics that result in suboptimal exposure of tumor 
cells to anti-neoplastic drugs [1, 2]. The rate and extent of drug efficacy depends on the 
extent of drug exposure at the tumor site and the time above the effective concentration [3]. 
In vitro models that incorporate these pharmacokinetic and pharmacodynamic (PK/PD) 
principles to optimize therapeutic response may be considered the method of choice for 
optimizing dosing schedules before translating data from static assays to animals and 
clinical trials [4, 5]. The hollow fiber bioreactor was recently used to evaluate 
pharmacokinetic/pharmacodynamic (PK/PD) effects of gemcitibine in lung and breast 
cancers and to model HIV treatments [4-6].  
2. Hollow fiber bioreactor model 
The hollow fiber bioreactor model (Figure 1) is a dynamic system that provides a cell culture 
with constant flow of fresh medium through a 3D polysulfone cartridge (support for cell 
growth) with capillary sized passages (cells grow in the extracapillary space), at 
physiologically relevant flow rates. Automatic programmable pumps accurately regulate 
dosing of chemotherapeutics into the system.  
The hollow fiber cartridge consists of two compartments, the porous capillaries through 
which medium flows and the extra-capillary space (ECS) that separates the cell culture from 
the flowing medium. Medium is constantly perfused through the fibers into the ECS, 
carrying nutrients and infused drugs to the cell culture. Due to the dynamic nature of the  
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Fig. 1. Schematic of the bioreactor setup 
model, cells can be exposed to carefully chosen drug concentrations that simulate patient 
pharmacokinetics from published clinical data, simulating drug half-life and renal clearance 
[6]. This change in concentration over time cannot be achieved in static assays. To monitor 
cell growth and viable counts in undisturbed hollow fiber cultures, we used an assay based 
on measurement of fluorescence resulting from the reduction of non-fluorescent resazurin to 
its red fluorescent form (resorufin) by metabolically active cells [7]. The intensity of the 
fluorescence is proportional to the viable cell count [8]. Achievement of cell cycle arrest, as a 
surrogate marker of the therapeutic outcome, was measured by flow cytometry. We 
hypothesized that we could use the proposed dynamic model to accurately simulate (R)-
roscovitine (ROSC) pharmacodynamics, incorporating pharmacokinetic data. To achieve 
this, we used the MCF-7 human breast cancer cell line and compared the peak values from 
two proposed dosing regimens of ROSC to untreated controls.  
MCF-7 cells are derived from the pleural effusion of an estrogen receptor positive, human 
breast adenocarcinoma [9, 10]. Cells were cultured in EMEM, 2mM L-glutamine, 0.1mM 
non-essential amino acids, 1mM sodium pyruvate, 0.01mg/mL bovine insulin and 10% fetal 
bovine serum; grown in 5% CO2 at 37o C and dispersed when confluent with of 0.25% 
trypsin/0.5mM EDTA. Hollow fiber cartridges were prepared according to manufacturers 
instructions. To prepare hollow fiber cultures, briefly, trypsinized cells were diluted to 1.67 
x 106/mL; 3mL were seeded into the ECS of each cartridge. Two cartridges were seeded for 
each experiment; one for drug treatment and one control. Cartridges were placed on a dual 
recirculating pump in the incubator at 37°C with 5% CO2 to circulate fresh sterile medium to 
each cartridge simultaneously while establishing the cultures.  
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2.1 Pharmacokinetic simulation for (R)-roscovitine 
After 24 hours, cartridges were removed from the recirculating pump, connected to a linear 
pump system (Masterflex) and a digital syringe pump was used to control the rate of drug 
infusion (Figure 1). Mathematical pharmacokinetic drug profiles were simulated by 
adjusting the input of ROSC and medium in the system. Infusion of the drug at peak 
concentration was followed by simulation of its clearance rate over a 6 hour period. Controls 
were perfused with drug free medium under the same conditions. Each dosing schedule 
was performed at least in duplicate.  
2.2 PK/PD simulation for the bioreactor 
A one compartment model, oral absorption and first order elimination was constructed 
using STELLA software (isee systems inc., Lebanon, NH). This model simulated 
pharmacokinetic profiles of peak and trough plasma levels after 800 mg twice daily (BID) 
and three times daily (TID) dosage regimens using pharmacokinetic parameters from a 
previously published clinical trial [11]. STELLA simulation provided a profile range of 
several Cmax from which to mimic the Css (steady state concentration) in the bioreactor. To 
accomplish this infusion, peak and trough concentrations of the Css range were used to 
determine the final dose, which represented the population pharmacokinetics and was 
infused to the central reservoir. Simulated BID peak and trough concentrations were 3167 
ng/mL and 808 ng/mL, respectively. Simulated TID peak and trough concentrations were 
3893 ng/mL and 1923 ng/mL, respectively. Flow rates for the pumps were determined 
using the following equation for oral administration: 
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where Cl is clearance of drug and is equal to the rate set on the Masterflex pumps, ke is the 
elimination rate constant for ROSC, Vd is central reservoir volume, C1 is Cmax from the 
simulation during the steady state, C2 is Cmin from the simulation during the steady state, 
and t (time) is the experiment duration. The rate of the digital pumps simulated the patient 
drug clearance.  
2.3 LC/MS 
To confirm the achievement of peak drug concentrations, samples were collected from the 
ECS of the hollow fiber cartridge and analyzed by LC/MS. The system included two 
Shimadzu LC- 20AD pumps, SIL-20AC autosampler, 2010 EV mass spectrometer with 
cosense module. A BDS Hypersil C18 (30mm x 2.1mm x 3µm) analytical column was used in 
conjunction with the co-sense system fitted with a Shimadzu MAYI-ODS 10L x 4.6 column. 
Mobile phase; A ( 10% ACN/ 90%, 0.1% Formic Acid) v/v and B (80% ACN and 20%, 0.1% 
Formic Acid) v/v; gradient at 50 % B increasing to 100% B over 1 min and remained 
isocratic at 100% B for 6 minutes until returning to 50% B. Flow rate was 0.150 ml/min with 
detection wavelength of 292 nm with an injection volume of 10μL. Mass spectrometry peaks 
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were analyzed using Shimadzu’s data analysis program. Peak integrations were compared 
to a standard curve to obtain the concentrations of ROSC. 
2.4 Resazurin assay 
Fluorescent conversion of resazurin is directly related to the number of metabolically active 
cells in culture and serves as a surrogate probe for viable cell count. Medium containing 5% 
v/v resazurin was added to the hollow fiber system and circulated for 30 minutes for 
homogenous distribution of resazurin containing medium. System valves were closed and 
the cartridge incubated 2 hours; 200 µl samples were drawn from medium in the ECS. 
Fluorescence was measured on a microplate reader (Biotek, Winooski, VT). Resazurin was 
removed by pumping fresh medium through the system with linear pumps, collecting the 
resazurin medium as waste. Assays were performed before and after treatment for assessing 
baseline fluorescence and the effect of drug on cell proliferation. Resazurin has been 
reported to be cytotoxic at high concentrations and exposure beyond 24 hours [12]. Since cell 
lines respond differently to resazurin, [13], we conducted a static assay to establish that 5% 
(v/v) resazurin could be used over at least a 24 hour period without toxicity to the MCF-7 
cell line. Cells incubated with resazurin, and untreated controls, were harvested, stained 
with trypan blue and counted at the conclusion of the experiment. This confirmed that 
growth and viability were unaffected by resazurin at 5% v/v (unpublished data).  
2.5 Flow cytometry 
MCF-7 cells were harvested from the hollow fiber cartridge by trypsinization and 
centrifuged at 300x g for 5 minutes. Supernatant was removed and the pellet resuspended in 
0.5ml of PBS-T with 20 µg/mL of RNAse and incubated at 37°C for 30 min. 10μg/ml 
propidium iodide was added to the cell suspension and incubated at 37°C for 30 min. The 
stained nuclei (200,000 per sample) were analyzed with a Becton Dickinson FACSCalibur 
(San Jose, California) flow cytometer using medium flow mode. Cell cycle distribution was 
analyzed with Modfit LT program (Verity, Maine). 
3. Results 
Pharmacokinetic simulation of ROSC was used to predict the Cmax of BID and TID dosing 
regimens. The predicted bolus dose values for the BID and TID were 3167ng/mL (8.9µM) 
and 3893ng/mL (10.9µM), respectively. From this data, we modeled a one dose peak profile 
that we could assess in the in vitro hollow fiber model. Actual concentrations of ROSC 
achieved in the model reached a Cmax of 2953 ng/mL (8.3µM) for the BID schedule, an 
accuracy of 93.2% compared to the predicted value. Actual concentration for the TID 
schedule was 3307ng/mL (9.3µM) as compared to the mathematical profile Cmax of 
3893ng/mL, an accuracy of 85.0%. This level of accuracy for infused drug is consistent with 
the reports of Kirstein, et al. in their PK/PD studies in the hollow fiber model [5, 6]. To 
monitor cell proliferation and viability before treatment, without disturbing established 
cultures, we used the resazurin assay on all cartridges. There was no significant difference in 
cell proliferation between cartridges before treatment (p=0.86), indicating consistency in 
seeding the hollow-fiber cartridges. In post-treatment resazurin assays, ROSC treated 
cartridges had decreased cell proliferation compared to control cartridges. The TID (9.3µM) 
simulated dose had a 15-20% decrease in growth that was not evident with the BID (8.3 µM) 
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simulated dose (Figure 2). To determine the effect of ROSC on cell cycle, cells were collected 
by trypsinization from the hollow-fiber cartridge at 24 hours post-treatment and analyzed 
by flow cytometry. An increase was seen in the proportion of cells in the G1 phase in both 
the BID and TID treatments compared to the control. Correspondingly, there was a 
statistically significant decrease of the proportion of S phase cells in both the TID (p=0.004) 
and BID (p=0.003) doses compared to the control and a statistically significant increase in G2 
for BID simulation (Table 1).  
 













































Fig. 2. Evaluation of cell proliferation in undisturbed cultures in the hollow fiber cartridge. 
Samples were taken for each set of cartridges for each experiment (n=2). A sample was 
taken from each cartridge before treatment (n=6). ROSC was infused at steady state value 
and clearance rate was simulated over 6 hours. Sample was taken at 24 hours (18 hours after 
infusion). Fluorescence was quantified as RFU and all values were normalized to the 
untreated control (final average value as 100%).  
 
  G1 (%) S (%) G2 (%) 
Control (n=5) 48.75 ± 3.71 33.93 ± 6.36 17.23 ± 2.68 
BID (n=6) 54.51 ± 3.69 23.15 ± 1.89 22.34 ± 1.86 
TID (n=5) 59.77 ± 3.86 22.49 ± 1.86 17.72 ± 5.55 
n= number of experimental repetitions; BID 800mg twice daily; TID 800mg three times daily. 
Table 1. Effect of ROSC dose increase on cell cycle distribution.  
MCF-7 cells in each measured phase of growth cycle (G1, S or G2) are expressed as a 
percentage (+ Standard Deviation) of the total number of cells.  
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simulated dose (Figure 2). To determine the effect of ROSC on cell cycle, cells were collected 
by trypsinization from the hollow-fiber cartridge at 24 hours post-treatment and analyzed 
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Uncontrolled proliferation is a defining characteristic of tumor cells. This is known to occur 
through mutation in genes that produce regulatory proteins which modulate cell cycle, such 
as the Cyclin Dependent Kinases (Cdks) [14-16]. Cdks are highly conserved 
serine/threonine kinases whose activation depends on formation of a heterodimeric 
complex with cyclins [17-19]. Thus, Cdks are a promising therapeutic target for cancer 
treatment [20]. ROSC is a novel Cdk inhibitor that induces cell cycle arrest and apoptosis 
through multiple intracellular targets in a variety of tumor cell lines. When tested in static in 
vitro assays, IC50 values of about 14µM are reported with 24 hours of drug exposure [21-24]. 
However, dosing schedules of 2500 mg/day over 5 days in 3 week cycles or the reduced 
dose of 1600mg/day BID for 10 days were recommended based on early human trials [25] 
and a concomitant Phase one trial that indicated a dose limiting toxicity of 800 mg BID for 7 
days. With this dosing schedule, peak plasma levels were achieved in 1-4 hours with 
elimination by 2-5 hours. The highest plasma concentration achieved clinically was 10µM 
within a treatment period. There was no tumor response to this dose, although the disease 
was stabilized over several courses of treatment [11]. To investigate the effect of 
administration of ROSC as a monotherapy by altering the dosing schedule, we employed a 
dynamic hollow fiber model in this study. We established our model using STELLA to 
simulate pharmacokinetic profiles of ROSC derived from clinical data. These profiles were 
simulated in the in vitro hollow fiber model for assessing the effectiveness of two dosing 
regimens against MCF-7 cells by using flow cytometry to measure cell cycle distribution 
under each condition. The results revealed increasing numbers of MCF-7 cells accumulating 
in G1 phase after simulating the BID and TID dosing peaks with ROSC, and indicating a 
significant difference between TID and the control. Also, BID dosing simulation had a 
significant increase in G2 arrest (p<0.05). This data is consistent with previous studies which 
indicated arrest of MCF-7 cell proliferation at the G1/S transition and G2/M transition with 
accumulation in G2. However, Wesierska-Gadek, et al. revealed ROSC activity only at the 
G2/M transition and accumulation of arrested MCF-7 cells only in the G2 phase. The 
differences may be attributed to differences in their experimental design, as they exposed 
MCF-7 cells in a static system to 10µM ROSC for 24 hours [26]. In this study, we tested 
concentrations of ROSC based on human clinical trial values of a maximum value of 10µM 
over 1-4 hours, with ROSC clearance within 5 hours, which were below the levels tested in 
static systems [11]. In this case, dose limiting toxicity of the drug precludes achievement of 
effective plasma concentrations in humans, which is consistent with the clinical trials. 
Consequently, ROSC is now being tested in combination therapies [27]. In conclusion, this 
study demonstrated the application of the dynamic hollow fiber model with controlled 
pharmacokinetic profiles to simulate clinically relevant dosing schedules of ROSC for 
treatment of breast tumor cells and the use of a resazurin assay for monitoring cell viability 
of hollow fiber cell cultures. With this methodology, cells can be recovered for further 
analysis. The applied hollow fiber model in this study can be used for PK/PD assessment of 
different anti-neoplastic drugs (single and in combination), with different exposure times 
against many tumor cell lines.  
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1. Introduction 
In the past decade, there have been major advances in our knowledge of severe CNS 
neurotoxicity in mice, rats, dogs, and rhesus monkeys repeatedly administered the oil-soluble 
artemisinins (ARTs) of arteether (AE) or artemether (AM), and water-soluble artelinic acid 
(AL). Studies have shown that those drugs are toxic to the central nervous system and induce 
neuropathologic changes in these animals (Li & Hickman, 2011). Pharmocokinetic and 
toxicokinetic studies of model animals administered various artemesinin derivitives through 
different routes have yielded important information that is relevant and useful in predicting 
possible neurotoxicity in man, particularly as artemesinin drugs are used more widely for 
other indications beyond malaria treatment such as cancer therapy. 
The fat soluble artemesinin derivitives AE and AM are particularly prone to induce 
neuropathological damage at low doses. For example, in rats, CNS damage was induced by 
dosing with AE intramuscularly at a daily dose of  12.5 mg/kg  for 7 days , while a daily 
dose of 6 mg/kg  for 28 days was required to induce neuropathological changes in dogs, 
and dosing of 8 mg/kg daily for 14 days was required to induce similar damage in rhesus 
monkeys (Brewer et al., 1994a; Classen et al., 1999; Genovese et al., 1995, 1998; 
Kamchonwongpaisan et al., 1997; Li et al., 2007a; Petras et al., 1997). A similar finding was 
observed for rats treated with oral AL, which was reported to have similar pathological 
neurotoxicity following an oral dose at 160 mg/kg daily for 9 days (Si et al., 2007).  
Despite extensive studies of AE, AM, and AL neurotoxicity, there is no evidence of  
neurotoxicity in animals related to another water soluble ART derivative, artesunate (AS), the 
most widely used ART in humans (Li & Weina, 2010). AS was designed for intravenous 
injection and, up to now, no neurotoxicity (pathologic or behavioural) has been observed in 
animals following intravenous administration at any repeated doses up to its maximum 
tolerated doses (MTD). The MTD of AS has been shown to be 240 mg/kg following 
intravenous injection daily in rats for 3 days, but no neurotoxicity was detected in these 
animals (Xie et al., 2005). In another study, intravenous AS in sodium bicarbonate dosed daily 
for 7 days at 120 mg/kg  had no effect on neurotoxicity scores (our unpublished data). A third 
study of AS treatment in rats administered one intramuscular injection of AS at a high dose of 
420 mg/kg did not induce any neuronal necrosis. In addition, dosing of up to 200 mg/kg of 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications  
 
322 
[20] Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Clinical anticancer 
drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005;92:7-
12.  
[21] McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the 
cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 
2002;102:463-8.  
[22] Węsierska-Gądek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H. Pleiotropic effects 
of selective CDK inhibitors on human normal and cancer cells. Biochemical 
Pharmacology 2008;76:1503-14.  
[23] Węsierska-Gądek J, Kramer MP, Maurer M. Resveratrol modulates roscovitine-
mediated cell cycle arrest of human MCF-7 breast cancer cells. Food and Chemical 
Toxicology, 2008;46:1327-33.  
[24] Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. Rapid onset of 
nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis 
of human MCF-7 breast cancer cells. Int J Cancer 2003;106:486-95.  
[25] Pierga JY, Fiavre S, Vera K, Laurence V, Delbaldo C, Bekradda M, Armand JP, Gianella-
Borradori A, Dieras V, Raymond E: A phase 1 and pharmacokinetic (PK) trial of 
CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) 
with advanced solid tumors. Proc am soc clin oncol 2003;22:abstr 840.  
[26] Węsierska-Gądek J, Maurer M, Schmid G. Inhibition of farnesyl protein transferase 
sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle 
arrest. J Cell Biochem 2007;102:736-47.  
[27] Appleyard MV, O'Neill MA, Murray KE, et al. Seliciclib (CYC202, R-roscovitine) 
enhances the anti-tumor effect of doxorubicin in vivo in a breast cancer xenograft 
model. Int J Cancer 2008;124:465-72.  
17 
Pharmacokinetic (PK) and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence  
Drug Neurotoxicity in Animals 
Qigui Li and Mark Hickman 
Division of Experimental Therapeutics  
Walter Reed Army Institute of Research,  
Silver Spring, MD,  
USA  
1. Introduction 
In the past decade, there have been major advances in our knowledge of severe CNS 
neurotoxicity in mice, rats, dogs, and rhesus monkeys repeatedly administered the oil-soluble 
artemisinins (ARTs) of arteether (AE) or artemether (AM), and water-soluble artelinic acid 
(AL). Studies have shown that those drugs are toxic to the central nervous system and induce 
neuropathologic changes in these animals (Li & Hickman, 2011). Pharmocokinetic and 
toxicokinetic studies of model animals administered various artemesinin derivitives through 
different routes have yielded important information that is relevant and useful in predicting 
possible neurotoxicity in man, particularly as artemesinin drugs are used more widely for 
other indications beyond malaria treatment such as cancer therapy. 
The fat soluble artemesinin derivitives AE and AM are particularly prone to induce 
neuropathological damage at low doses. For example, in rats, CNS damage was induced by 
dosing with AE intramuscularly at a daily dose of  12.5 mg/kg  for 7 days , while a daily 
dose of 6 mg/kg  for 28 days was required to induce neuropathological changes in dogs, 
and dosing of 8 mg/kg daily for 14 days was required to induce similar damage in rhesus 
monkeys (Brewer et al., 1994a; Classen et al., 1999; Genovese et al., 1995, 1998; 
Kamchonwongpaisan et al., 1997; Li et al., 2007a; Petras et al., 1997). A similar finding was 
observed for rats treated with oral AL, which was reported to have similar pathological 
neurotoxicity following an oral dose at 160 mg/kg daily for 9 days (Si et al., 2007).  
Despite extensive studies of AE, AM, and AL neurotoxicity, there is no evidence of  
neurotoxicity in animals related to another water soluble ART derivative, artesunate (AS), the 
most widely used ART in humans (Li & Weina, 2010). AS was designed for intravenous 
injection and, up to now, no neurotoxicity (pathologic or behavioural) has been observed in 
animals following intravenous administration at any repeated doses up to its maximum 
tolerated doses (MTD). The MTD of AS has been shown to be 240 mg/kg following 
intravenous injection daily in rats for 3 days, but no neurotoxicity was detected in these 
animals (Xie et al., 2005). In another study, intravenous AS in sodium bicarbonate dosed daily 
for 7 days at 120 mg/kg  had no effect on neurotoxicity scores (our unpublished data). A third 
study of AS treatment in rats administered one intramuscular injection of AS at a high dose of 
420 mg/kg did not induce any neuronal necrosis. In addition, dosing of up to 200 mg/kg of 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 324 
AS orally daily for 5-7 days did not result in neuronal changes or any specific clinical signs 
(Dayan, 1998), and there was little clinical or neuropathological evidence of neurotoxicity 
found at high dose levels of over 200 mg/kg/day for 28 days in mice treated with oral AS and 
dihydroartemisinin (DHA), as well as oral AM (Nontprasert et al., 1998, 2000, 2002). 
To date, no systematic toxicity has been reported in humans, despite the use of ART and its 
derivatives in clinical trials designed with special emphasis to detect changes in neurological 
indicators such as movement, hearing, vestibular, or cerebral abnormalities (Efferth & Kaina 
2010). Although ART agents, mainly the oil-soluble derivatives, have been shown to induce 
fatal neurotoxicity in animal models, a striking fact in treating patients with the ARTs is the 
lack of any serious adverse events, despite careful monitoring in several clinical studies. Severe 
malarial infection, particularly cerebral malaria in multi-drug resistant strains in the 
developing world, often leaves patients with decreases in neural function. This development 
has made characterization of potential neurotoxic effects of the ART derivatives very difficult 
to ascertain, even though these drugs are clinically utilized in ever growing numbers 
(Karbwang et al., 1994; Van Vugt et al., 2000; Angus et al., 2002). In a study of 3500 patients in 
Thailand, evidence of serious toxicity was not noticed (Price et al., 1999). From other reports, 
rare neurologic side effects have been noted in humans receiving ART drugs, however, these 
findings were difficult to dissect from the effects of malaria infection (Li & Hickman 2011).  
Five cases have been reported that suggest episodes of neurotoxicity due to multiple courses 
of ARTs therapy (Elias et al., 1999; Franco-Paredes et al., 2005; Haq et al., 2009; Miller & 
Panosian 1997; Panossian et al., 2005). These reports may constitute evidence of a causal 
association that merits further investigation. The possibility exists that repeated and longer 
duration administration of ART compounds in malaria endemic areas could result in 
cumulative neuronal damage, especially since these drugs are often freely available for use 
in tropical countries. Although the authors reported that the toxicity observed in these five 
cases is drug related, there is considerable disagreement regarding these putative episodes 
of neurotoxicity, and the evidence of such a causal association may or may not be only 
related to ART administration (Gachot et al., 1997; Newton et al., 2005; White et al., 2006).  
Several perplexities still continue to vex us with the ARTs. Why is neurotoxicity so easily 
observed in animal models but not seen in humans getting equal or even higher doses of the 
drug? Why does this neurotoxicity mostly occur in animals treated with intramuscular AE, 
AM, and oral AL, but not with AS? Why does neurotoxicity mostly take place with the 
intramuscular and oral dosing routes, but not in intravenous injections? In this chapter, 
pharmacokinetic characteristics will be evaluated and discussed that may shed light on 
some of these questions.  Principally, we will discuss:  
i. the role of DHA in neurotoxicity and the conversion rates of AM, AE, AL, and AS to DHA;  
ii. the role of drug tissue distribution levels in cerebrospinal fluid (CSF) and brain tissue at 
the onset of neurotoxicity;  
iii. the role of drug total exposure levels (AUC and Cmax) in plasma  in neurotoxicity; and  
iv. the role of drug half-life in neurotoxicity.  
In addition, the drug PK parameters required to induce neurotoxicity in animals after 
administration of ARTs will be discussed in depth from the available pharmacological 
literature. We will outline the data that supports the hypothesis that drug accumulation 
with prolonged exposure time (half-life) demonstrated by PK profiling accompanies the 
neurological effects shown by Pharmacodynamic (PD) profiling. As will be shown, there is 
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considerable data to support the view that the drug exposure time is a more important 
marker to determine and predict ART-driven neurotoxicity than other factors.  
2. Key PK parameters associated with artemisinin induced neurotoxicity in 
animals 
2.1 The role of DHA in artemisinin-induced neurotoxicity 
DHA is obtained by sodium borohydride reduction of ART, an endoperoxide containing 
sesquiterpene lactone. Through in vitro bioassays, DHA has been shown to have similar 
antimalarial activity to AS and it is 1.4-5.2 fold more active than other ARTs (Li et al., 2007b). AS 
has also been shown to be 2-4 fold more toxic than other ARTs in vitro and in vivo (Li et al., 
1998a; 2002; Fishwick et al., 1995; McLean & Ward, 1998; Wesche et al., 1994). Due to its poor 
solubility in water or oils, DHA has only been formulated as an oral preparation and has been 
used primarily as a semisynthetic compound for derivatization to other oil soluble and water-
soluble ARTs. The effectiveness of AS has been attributed to its rapid and extensive hydrolysis 
to DHA (Li & Weina 2010). The efficacy of AM and AE has also been credited to their conversion 
to DHA, but their rates of conversion were significantly lower and less complete than in AS (Li et 
al., 1998b; Navaratnam et al., 2000). AL is a very stable ART agent in vitro and in vivo, and AL has 
almost no biotransformation to DHA in animals (Li et al., 1998c; Lin et al., 1987).  
Accordingly, evaluating the conversion rates of various ART drugs is very important for 
assessing the risk of neurotoxicity for the four compounds that are the focus of this chapter. 
Conversion evaluations of AM, AE, AS, or AL to DHA in laboratory animals are 
summarized in Table 1. This summary also illustrates the conversion of ART drugs to DHA 
in humans, which seems to be much more efficient than in animals. When comparing the 
data from animals and humans treated with AM or AS in various regimens, one difference 
that is immediately apparent is that the ratios of AUCDHA to AUCAM or AUCAS are 
significantly higher in humans (0.41-9.71) than in animals (0.04-2.96), suggesting that the 
human hydrolysis system is more active and complete (Li et al., 2007a).  
The conversion rates of the four ART agents to DHA are different in various animal species. 
The most extensive hydrolysis of AS to DHA has been shown to be in rats and dogs with a 
DHA/AS ratio in the range of 0.31-2.74, while the ratio of AM or AE conversion to DHA is 
less than 0.23.  In addition, the calculated ratio of AL conversion to DHA in rats and dogs 
lies in the range of 0.001-0.03, so it appears that DHA is not contributing as much to the 
effects of neurotoxicity associated with dosing these three drugs (AM, AE, and AL) while it 
appears to be a much larger contributor to DHA after AS dosing (Table 1).  Data derived 
from pharmacokinetic studies has demonstrated that the AUC of DHA hydrolyzed from AS 
is in the range of 236–596 ng·h/ml compared to the AUC of DHA hydrolyzed from AM and 
AE which lies in the range of 29-71 ng·h/ml at the same dose level in rats (Li et al., 1998b). 
AM and AE treatment has been shown to induce severe neurotoxicity in animals, AS 
treatment has not been shown to do so (Genovese et al., 2000). Similar results have been 
observed in dogs, where the AUC of DHA produced from AS was shown to be 1,109 
ngh/ml at a dose of 10 mg/kg with no neurotoxicity symptoms observed (Li et al., 1999a). 
In comparison,  the AUC of DHA derived from AM and AE dosing in dogs is 312 and 181 
ngh/ml, respectively, at a dose of 20 (AM) and 15 (AE) mg/kg, and those treatments have 
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been shown to result in fatal neurotoxicity following intramuscular injection (Classen et al., 
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Table 1. Mean ratios of AUCDHA (an active metabolite) /AUCAM, AE, AS, and AL, and the 
concentration values (ng·h/ml) of AUCDHA/AUCAM, AE, AS, and AL as the conversion 
evaluation of artemisinin derivatives (AM, AE, AS, and AL) to DHA in animals and humans 
(Li et al., 2007a) 
The maximum tolerated dose (MTD) of intravenous AS has been shown to be 240 mg/kg 
dosed daily for 3 days (Xie et al., 2005). In this study, animals were sacrificed at 24 hrs (day 
1) and 192 hrs (day 8) after the last dose. Histopathological evaluation demonstrated mild 
renal tubular necrosis in uninfected rats treated with AS at 240 mg/kg, however, fewer 
pathological lesions (minimal tubular necrosis) were observed in malaria infected rats. The 
renal injury was reversible in all cases by day 8 after cessation of dosing, and also no 
neurotoxicity was found after any of the intravenous AS dosing regimens (Li et al., 2007c). 
The AUC of DHA derived from a dose of AS of 240 mg/kg ranged from 6,984– 
15,768 ng·h/ml. This AUC can be simulated daily in rats using this regimen according to our 
previous published study (Li et al., 1998c). Although DHA is 2-4 fold more active and more 
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toxic than other ART derivatives (Fishwick et al., 1995; Li et al., 1998a, 2002; McLean & Ward 
1998; Wesche et al., 1994), the high level of DHA generated from AS did not seem to have a 
key role in the induction of neurotoxicity in these animal studies. 
In another comparative PK study of DHA hydrolysis, AL and AS were administered to 
malaria-infected rats using 3 daily equimolar doses (96 µmoles/kg, which equals 36.7 mg/kg 
for AS and 40.6 mg/kg for AL) via intravenous administration. The plasma concentration of 
AS observed was one-third less on day 3 than on day 1, similar to the plasma concentrations of 
its active metabolite, DHA (Li et al., 2005a). The results were similar for other ART drugs with 
an auto-induction  metabolic profile (van Agtmael et al., 1999; Ashton et al., 1996, 1998; Khanh 
et al., 1999), but not for AL. The PK parameters of AL were very comparable from day 1 to day 
3 at the same molecular doses of AS (40.6 mg/kg daily). AS seems to be the pro-drug of DHA 
with a DHA/AS ratio of 5.26 (AUCDHA of 13,051 ng·h/ml) compared to the ratio of 0.01 
(AUCDHA of 524 ng·h/ml) for DHA/AL. In this study, dosing with the two drugs did not 
induce any CNS toxicity (Li et al., 2005a), but the general toxicity of AL was 3-fold greater than 
that of AS in malaria-infected rats (Xie et al., 2005). In conclusion, we believe the conclusions 
drawn from our data and from other published work support the hypothesis that DHA is not 
an important factor in induction of neurotoxicity in animals.  
2.2 The impact of ARTs distributed in the CNS on neurotoxicity 
There are only a few studies of tissue distribution of ART derivatives in the animal brain, 
and these published studies used a variety of methods that differ significantly. Therefore, 
there are no comparative published results for quantitative evaluation of the ART drugs 
distributed in the central nervous system (CNS).  
The first quantitative determination study of ARTs in the CNS using the thin-layer 
chromatography densitometry method found that ART, AM, and AS can cross the blood-
brain barrier (BBB) and the blood-placenta barrier in rats (China Cooperative Research 
Group, 1982). ART has been noted to be more readily detected in the brain after oral 
administration than after intravenous injection (Niu et al., 1985). By radioimmunoassay, the 
highest level of AS was found in the rat intestine 10 minutes after intravenous 
administration, followed by the brain, liver, kidney, and other organs, in decreasing order. 
After one hour, the AS drug levels dropped significantly but not uniformly in all tissues, 
with high levels still remaining in the brain, fat, intestine and serum. The highest levels were 
found in rat brains 5 minutes after intravenous injection (Zhao & Song, 1989). Moderate 
levels of AM were also found in the heart, lung and skeletal muscles, while AM levels in 
liver and kidney were low (Jiang et al., 1989).  
Using the tissue homogenate method, intramuscular injection of 14C-arteether resulted in 
higher levels of radioactivity detected 24h after dosing in the intestinal tract, liver, kidneys, 
and spleen, while lower amounts of drug were found in the brown fat and in the brain  . 
High-performance liquid chromatographic data from this work indicated that three 
metabolites of arteether, but not arteether itself, could cross the BBB. The calculated 
apparent concentration in the whole brain was 0.89% of the total radioactivity after 
intramuscular injection of 25 mg/kg AE (Li et al., 2007a).   
Using the whole body autoradiograph method, administration of 14C-AL showed 
widespread distribution of the radiolabeled drug in rats one hour following dosing. The 
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been shown to result in fatal neurotoxicity following intramuscular injection (Classen et al., 
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dosed daily for 3 days (Xie et al., 2005). In this study, animals were sacrificed at 24 hrs (day 
1) and 192 hrs (day 8) after the last dose. Histopathological evaluation demonstrated mild 
renal tubular necrosis in uninfected rats treated with AS at 240 mg/kg, however, fewer 
pathological lesions (minimal tubular necrosis) were observed in malaria infected rats. The 
renal injury was reversible in all cases by day 8 after cessation of dosing, and also no 
neurotoxicity was found after any of the intravenous AS dosing regimens (Li et al., 2007c). 
The AUC of DHA derived from a dose of AS of 240 mg/kg ranged from 6,984– 
15,768 ng·h/ml. This AUC can be simulated daily in rats using this regimen according to our 
previous published study (Li et al., 1998c). Although DHA is 2-4 fold more active and more 
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toxic than other ART derivatives (Fishwick et al., 1995; Li et al., 1998a, 2002; McLean & Ward 
1998; Wesche et al., 1994), the high level of DHA generated from AS did not seem to have a 
key role in the induction of neurotoxicity in these animal studies. 
In another comparative PK study of DHA hydrolysis, AL and AS were administered to 
malaria-infected rats using 3 daily equimolar doses (96 µmoles/kg, which equals 36.7 mg/kg 
for AS and 40.6 mg/kg for AL) via intravenous administration. The plasma concentration of 
AS observed was one-third less on day 3 than on day 1, similar to the plasma concentrations of 
its active metabolite, DHA (Li et al., 2005a). The results were similar for other ART drugs with 
an auto-induction  metabolic profile (van Agtmael et al., 1999; Ashton et al., 1996, 1998; Khanh 
et al., 1999), but not for AL. The PK parameters of AL were very comparable from day 1 to day 
3 at the same molecular doses of AS (40.6 mg/kg daily). AS seems to be the pro-drug of DHA 
with a DHA/AS ratio of 5.26 (AUCDHA of 13,051 ng·h/ml) compared to the ratio of 0.01 
(AUCDHA of 524 ng·h/ml) for DHA/AL. In this study, dosing with the two drugs did not 
induce any CNS toxicity (Li et al., 2005a), but the general toxicity of AL was 3-fold greater than 
that of AS in malaria-infected rats (Xie et al., 2005). In conclusion, we believe the conclusions 
drawn from our data and from other published work support the hypothesis that DHA is not 
an important factor in induction of neurotoxicity in animals.  
2.2 The impact of ARTs distributed in the CNS on neurotoxicity 
There are only a few studies of tissue distribution of ART derivatives in the animal brain, 
and these published studies used a variety of methods that differ significantly. Therefore, 
there are no comparative published results for quantitative evaluation of the ART drugs 
distributed in the central nervous system (CNS).  
The first quantitative determination study of ARTs in the CNS using the thin-layer 
chromatography densitometry method found that ART, AM, and AS can cross the blood-
brain barrier (BBB) and the blood-placenta barrier in rats (China Cooperative Research 
Group, 1982). ART has been noted to be more readily detected in the brain after oral 
administration than after intravenous injection (Niu et al., 1985). By radioimmunoassay, the 
highest level of AS was found in the rat intestine 10 minutes after intravenous 
administration, followed by the brain, liver, kidney, and other organs, in decreasing order. 
After one hour, the AS drug levels dropped significantly but not uniformly in all tissues, 
with high levels still remaining in the brain, fat, intestine and serum. The highest levels were 
found in rat brains 5 minutes after intravenous injection (Zhao & Song, 1989). Moderate 
levels of AM were also found in the heart, lung and skeletal muscles, while AM levels in 
liver and kidney were low (Jiang et al., 1989).  
Using the tissue homogenate method, intramuscular injection of 14C-arteether resulted in 
higher levels of radioactivity detected 24h after dosing in the intestinal tract, liver, kidneys, 
and spleen, while lower amounts of drug were found in the brown fat and in the brain  . 
High-performance liquid chromatographic data from this work indicated that three 
metabolites of arteether, but not arteether itself, could cross the BBB. The calculated 
apparent concentration in the whole brain was 0.89% of the total radioactivity after 
intramuscular injection of 25 mg/kg AE (Li et al., 2007a).   
Using the whole body autoradiograph method, administration of 14C-AL showed 
widespread distribution of the radiolabeled drug in rats one hour following dosing. The 
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relative activity of 14C-AL found in various body tissues (as density per unit area) was, from 
highest to lowest, in the intestinal tract followed by the liver, kidney, bone marrow, spleen, 
brown fat and salivary glands, heart & testes, and lastly by the brain. At 48 h, the relative 
activity of 14C-AL found in various body tissues (as density per unit area) was, from highest 
to lowest, in the intestinal tract, followed by the spleen,  kidney,  liver,  salivary glands,  
brown fat and bone marrow,  testes, and lastly by the brain. The low residual activity found 
in the brain appeared to be uniformly distributed. Autoradiographic evidence confirmed the 
presence of 14C-AL in the brain from 1 to 192h. However, the presence of 14C-AL in the brain 
was at a lower level than the presence of 14C-AL in most other tissues. There was no 
evidence of a label concentration in any area of the brain that was visible in the whole body 
sections. Penetration of the BBB by 14C-labelled AL was shown to be very poor. An apparent 
concentration of 0.1% of total radioactivity/brain was calculated from an intravenous and 
oral administration of 10 mg/kg AL (Li et al., 2005a). 
Another neurotoxic dose range study showed that neuronal damage occurred in all beagle 
dogs dosed with multiple daily intramuscular treatments of AM at 40 and 80 mg/kg. After 
dosing with AM at 20 mg/kg administered through multiple daily treatments, minimal 
neuronal effects were observed in 5 out of 8 dogs. Two hours after the eighth administration 
(on day 8), only low levels of AM (25, 60, and 71 ng/ml)were found in the cerebrospinal 
fluid (CSF)  after dosing with 20, 40, and 80 mg/kg respectively. AM levels in the CSF were 
< 10% of the AM observed in the plasma concentration (Classen et al., 1999).  
These limited and incomparable data indicates that the oil-soluble derivatives, AE (0.89% of 
total dose in brain) and AM (10% of plasma level in CSF) appear to possess the ability to cross 
the BBB more readily than water-soluble ART compounds, like AL (0.1% of total dose in 
brain). If this is true, then the higher degree of neurotoxicity of AE and AM compared to the 
neurotoxicity observed after treatment with water soluble forms of artemisinin is easily 
understood. However, this deduction is not supported by the observation that AS has the 
ability to easily cross the BBB. The largest fraction of AS has been found in rat brains after 
intravenous administration by radioimmunoassay (Zhao & Song, 1989). Recent studies found 
that the levels of 14C-AS in rat brains were more than 2 fold higher in the brain than in plasma, 
and the AUCs of radioactivity observed in the brain and in plasma were 70.7 µg·h/g and 29.4 
µg·h/ml, respectively, by both of quantitative whole-body autoradiography (QWBA) and 
tissue dissection techniques (LSC) methods (Li et al., 2008). During a 192 hour period, 1.27% of 
the total radioactivity dose was detected in the rat brain. The half-life of 14C-AS in the brain 
tissue was 94.2 hours, which is significantly longer than the 63.7 hour half-life observed in the 
plasma  (Li et al., 2006a; Li et al., 2008). These results showed that the resident time of 14C-AS 
was longer in the brain than in plasma. This may reflect a “sink effect” of DHA uptake transfer 
by the lipid-rich structures of the brain (Kearney & Aweeka, 1999). 
After intravenous AS injection, samples were found in CSF that contained no parent drug 
which is consistent with the low lipid solubility of the metabolites of AS (Davis et al., 2001). 
The types of AS metabolites present in the CNS are completely unknown (Li et al., 2005a), 
and whether these metabolites in the brain are associated with neurotoxicity is also 
unknown. AS is converted stoichiometrically to DHA and the DHA concentrations observed 
peak at 5-10 min after dosing in plasma (Batty et al., 1998; Davis et al., 2001). DHA is highly 
lipid soluble and has a low molecular mass (284 Da), and both of these factors favor 
penetration of DHA into the CSF (Kearney & Aweeka, 1999). Since DHA is poorly soluble in 
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water, it should be able to cross cell membranes and the BBB. After treatment with AS in 
patients, however, the parent drug (AS) cannot be detected in the CSF.  DHA levels in the 
CSF after AS treatment increase with time while DHA levels in plasma decrease. These 
finding suggest a continuing influx but a slower efflux of DHA in which DHA might 
accumulate in the CSF during frequent AS dosing (Davis et al., 2003; Kearney & Aweeka, 
1999). 
AS and/or its metabolites have been shown to easily cross the BBB and have higher  
accumulation in brain tissues when compared to the other ARTs, as described above 
(Kearney & Aweeka, 1999; Jiang et al., 1989; Li et al., 2005a; Zhao & Song, 1989). After 
intravenous injection of 120 mg AS in malaria patients, DHA levels in the CSF were shown 
to increase ranging from 1,100-1,450 ng/ml, which is much higher than the DHA levels 
observed in plasma which ranged from 104-120 ng/ml (Davis et al., 2003). No neurotoxicity, 
however, was observed in these studies. Therefore, while the ART agents distribute in brain 
tissue and CSF, they do not appear to be an important factor in induction of neurotoxicity.   
2.3 The role played by the drug exposure level of artemisinins in neurotoxicity 
Recognizing the fact that if there is no drug exposure, there is no toxicity leads us to the 
conclusion that if there is exposure, toxicity can ensue when exposure exceeds a certain level 
and/or time and that will be dependent on pharmacokinetics and pharmacodynamics.  
2.3.1 PK profiles of ARTs in rats 
After daily intramuscular injections of AE at a dose of 25 mg/kg for 7 days, accumulation 
and prolonged exposure of AE in plasma was noted in rats with severe neurotoxicity. This 
accumulation was shown to be due to slow and prolonged absorption of AE in the muscle 
injection site (Li et al., 1999b). The absorption of AE from muscle at the injection site was 
incomplete in the first 48 hours after a single injection. At 24 and 48 hours after dosing, 38% 
and 22% of the total dose of AE still remained in the injection site, respectively. The amount 
of AE in muscle rapidly decreased for 1-2 hours and then exhibited a much slower rate of 
decrease. Half-lives for the fast and slow absorption phases in the muscle were 1.0 hour and 
26.3 hours, respectively. It was expected that the remaining dose amount would be absorbed 
later because an intramuscular total dose of AE with sesame oil should be 100% absorbed in 
the absence of decomposition or metabolism at the injection site.  
The analysis of toxicokinetic (TK) parameters on day 1 of this study was similar to that of 
the single intramuscular dose. After day 1, however, the kinetic data estimates from days 2-7 
showed a notable change in the TK parameter estimated for day 1 (Figure 1, top). The Cmax 
of AE (410 ng/ml) on day 7 was found to be three times higher than on day 1 (130 ng/ml). 
The AUC of AE observed after the intramuscular dose was found to be 4.5-fold higher on 
day 7 at steady state (4367 ng·h/ml) than on day 1 (905 ng·h/ml) (Table 2). This indicates 
that the exposure concentration of AE was significantly increased, and the system of 
excretion and biotransformation in the rats in this study may not have been normal 
(Rowland & Tozer, 1995). Only a pathophysiological factor could change the slopes of 
distribution and elimination associated with biotransformation, excretion, and protein or 
tissue binding (Mayer, 1995; Shargel & Yu, 1993).  
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relative activity of 14C-AL found in various body tissues (as density per unit area) was, from 
highest to lowest, in the intestinal tract followed by the liver, kidney, bone marrow, spleen, 
brown fat and salivary glands, heart & testes, and lastly by the brain. At 48 h, the relative 
activity of 14C-AL found in various body tissues (as density per unit area) was, from highest 
to lowest, in the intestinal tract, followed by the spleen,  kidney,  liver,  salivary glands,  
brown fat and bone marrow,  testes, and lastly by the brain. The low residual activity found 
in the brain appeared to be uniformly distributed. Autoradiographic evidence confirmed the 
presence of 14C-AL in the brain from 1 to 192h. However, the presence of 14C-AL in the brain 
was at a lower level than the presence of 14C-AL in most other tissues. There was no 
evidence of a label concentration in any area of the brain that was visible in the whole body 
sections. Penetration of the BBB by 14C-labelled AL was shown to be very poor. An apparent 
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oral administration of 10 mg/kg AL (Li et al., 2005a). 
Another neurotoxic dose range study showed that neuronal damage occurred in all beagle 
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dosing with AM at 20 mg/kg administered through multiple daily treatments, minimal 
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(on day 8), only low levels of AM (25, 60, and 71 ng/ml)were found in the cerebrospinal 
fluid (CSF)  after dosing with 20, 40, and 80 mg/kg respectively. AM levels in the CSF were 
< 10% of the AM observed in the plasma concentration (Classen et al., 1999).  
These limited and incomparable data indicates that the oil-soluble derivatives, AE (0.89% of 
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neurotoxicity observed after treatment with water soluble forms of artemisinin is easily 
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the total radioactivity dose was detected in the rat brain. The half-life of 14C-AS in the brain 
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plasma  (Li et al., 2006a; Li et al., 2008). These results showed that the resident time of 14C-AS 
was longer in the brain than in plasma. This may reflect a “sink effect” of DHA uptake transfer 
by the lipid-rich structures of the brain (Kearney & Aweeka, 1999). 
After intravenous AS injection, samples were found in CSF that contained no parent drug 
which is consistent with the low lipid solubility of the metabolites of AS (Davis et al., 2001). 
The types of AS metabolites present in the CNS are completely unknown (Li et al., 2005a), 
and whether these metabolites in the brain are associated with neurotoxicity is also 
unknown. AS is converted stoichiometrically to DHA and the DHA concentrations observed 
peak at 5-10 min after dosing in plasma (Batty et al., 1998; Davis et al., 2001). DHA is highly 
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water, it should be able to cross cell membranes and the BBB. After treatment with AS in 
patients, however, the parent drug (AS) cannot be detected in the CSF.  DHA levels in the 
CSF after AS treatment increase with time while DHA levels in plasma decrease. These 
finding suggest a continuing influx but a slower efflux of DHA in which DHA might 
accumulate in the CSF during frequent AS dosing (Davis et al., 2003; Kearney & Aweeka, 
1999). 
AS and/or its metabolites have been shown to easily cross the BBB and have higher  
accumulation in brain tissues when compared to the other ARTs, as described above 
(Kearney & Aweeka, 1999; Jiang et al., 1989; Li et al., 2005a; Zhao & Song, 1989). After 
intravenous injection of 120 mg AS in malaria patients, DHA levels in the CSF were shown 
to increase ranging from 1,100-1,450 ng/ml, which is much higher than the DHA levels 
observed in plasma which ranged from 104-120 ng/ml (Davis et al., 2003). No neurotoxicity, 
however, was observed in these studies. Therefore, while the ART agents distribute in brain 
tissue and CSF, they do not appear to be an important factor in induction of neurotoxicity.   
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Recognizing the fact that if there is no drug exposure, there is no toxicity leads us to the 
conclusion that if there is exposure, toxicity can ensue when exposure exceeds a certain level 
and/or time and that will be dependent on pharmacokinetics and pharmacodynamics.  
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After daily intramuscular injections of AE at a dose of 25 mg/kg for 7 days, accumulation 
and prolonged exposure of AE in plasma was noted in rats with severe neurotoxicity. This 
accumulation was shown to be due to slow and prolonged absorption of AE in the muscle 
injection site (Li et al., 1999b). The absorption of AE from muscle at the injection site was 
incomplete in the first 48 hours after a single injection. At 24 and 48 hours after dosing, 38% 
and 22% of the total dose of AE still remained in the injection site, respectively. The amount 
of AE in muscle rapidly decreased for 1-2 hours and then exhibited a much slower rate of 
decrease. Half-lives for the fast and slow absorption phases in the muscle were 1.0 hour and 
26.3 hours, respectively. It was expected that the remaining dose amount would be absorbed 
later because an intramuscular total dose of AE with sesame oil should be 100% absorbed in 
the absence of decomposition or metabolism at the injection site.  
The analysis of toxicokinetic (TK) parameters on day 1 of this study was similar to that of 
the single intramuscular dose. After day 1, however, the kinetic data estimates from days 2-7 
showed a notable change in the TK parameter estimated for day 1 (Figure 1, top). The Cmax 
of AE (410 ng/ml) on day 7 was found to be three times higher than on day 1 (130 ng/ml). 
The AUC of AE observed after the intramuscular dose was found to be 4.5-fold higher on 
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excretion and biotransformation in the rats in this study may not have been normal 
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Neurotoxic Severity 




25 mg/kg x 7 
Arteether, IM 
(1:2 CRM/ saline) 
25 mg/kg x 7 
Arteether, IM** 
(Sesame oil) 
12.5 mg/kg x 7 
Artesunate, IM 
(5% NaHCO3) 
25 mg/kg x 7 
AUC1-7D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
16.92 ± 4.04 
130 ± 39 
410 ± 91 
13.74 ± 1.71 
31.24 ± 4.31 
41.32 
164.3 ± 7.9 
46.29 ± 2.06 
1227 ± 171 
1826 ± 118 
6.96 ± 0.93 
9.06 ± 1.69 
41.32 
103.0 ± 5.3 
12.31 ± 1.57 
65 ± 19 
205 ± 45 
13.23 ± 1.32 
22.03 ± 4.83 
41.32 
67.1 ± 5.6 
8.57 ± 3.34 
3981 ± 992 
2078 ± 416 
0.43 ± 0.05 
0.39 ± 0.04 
NA 
NA 
Sprague-Dawley Rats  
Artelinic acid 
Oral (Suspension) 
160 mg/kg x 9 
Artelinic acid 
Oral (Suspension) 
288 mg/kg x 5 
Artelinate 
IM (5% NaHCO3) 
25 mg/kg x 7 
AUC1-7 or 9D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7 or 9 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7 or 9 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
 
1420 ± 454 
11293 ± 8291 
12230 ± 7139 
2.84 ± 0.52 
10.68 ± 1.84 
346.26 
186.0 ± 28.0 
1302 ± 905 
14069 ± 10905 
14341 ± 9339 
3.33 ± 0.25 
3.60 ± 0.25 
346.26 
75.0 ± 12.0 
86.84 ± 5.59 
20044 ± 3459 
15585 ± 1476 
1.89 ± 0.22 






15 mg/kg x 14 
Artemether, IM 
(Peanut oil) 
40 mg/kg x 7 
Artemether, IM 
(Peanut oil) 
20 mg/kg x 7 
Artelinic acid 
Oral (Capsules) 
25 mg/kg x 14 
AUC1-7, 14, or 28D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7, 14,or 28 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7, 14,or 28 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
24.39 ± 18.04 
90 ± 15 
352 ± 203 
9.23 ± 1.32 
21.53 ± 2.08 
40.92 















191.14 ± 90.80 
6279 ± 2995 
7177 ± 6248 
1.51 ± 0.16 
1.94 ± 0.56 
346.26  
14.6 ± 1.8 
Rhesus monkeys***  
Arteether, IM 
(Sesame oil) 
16 mg/kg x 14 
Arteether IM** 
(Sesame oil) 
8 mg/kg x 14 
 
AUC1-14D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 14 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 14 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr)* 
 
70.96  ± 4.59 
63 ± 9 
1038 ± 622 
22.59 ± 1.55 
82.09 ± 41.98 
193.80 
307.4 
31.25 ± 2.61 
38 ± 5 
527 ± 306 
16.56 ± 1.20 




*The neuro-exposure times above LONEL concentration were calculated with neurotoxic outcome.  
** PK data were simulated from our previous studies.  
***The monkey results are from our unpublished data. Neurotoxic severity were graded as minimal = 1-5 
neurons affected, moderate = 10-30 neurons affected, and severe = >40 neurons affected. 
DHA = Dihydroartemisinin; CRM = cremophore; AUC = area under the curve; IM = intramuscular 
Table 2. Drug accumulation, exposure level  and neurotoxic exposure time of arteether  
(AE), Artemether (AM), artesunate (AS) and artelinic acid (AL) at above the lowest  
observed neurotoxic effect level (LONEL) in rats, dogs, and monkeys concerning  
with histopathological neurotoxicity after various dose regimens (Li et al., 2007a;  
Si et al., 2007).  
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Fig. 1. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted 
curves (solid line) of 25 mg/kg of arteether with sesame oil (top, n = 4, Li et al., 2007a). 
Artelinate (middle) and artesunate (bottom) with 5% NaHCO3/0.9% saline following daily 
intramuscular injection 25 mg/kg daily for 7 days in male rats. (n = 3, Li et al., 2005b). The 
lowest observed neurotoxic effect level (LONEL) from AE measurement was estimated at 
41.32 ng/ml (dashed line) in male rats. 
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Neurotoxic Severity 




25 mg/kg x 7 
Arteether, IM 
(1:2 CRM/ saline) 
25 mg/kg x 7 
Arteether, IM** 
(Sesame oil) 
12.5 mg/kg x 7 
Artesunate, IM 
(5% NaHCO3) 
25 mg/kg x 7 
AUC1-7D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
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130 ± 39 
410 ± 91 
13.74 ± 1.71 
31.24 ± 4.31 
41.32 
164.3 ± 7.9 
46.29 ± 2.06 
1227 ± 171 
1826 ± 118 
6.96 ± 0.93 
9.06 ± 1.69 
41.32 
103.0 ± 5.3 
12.31 ± 1.57 
65 ± 19 
205 ± 45 
13.23 ± 1.32 
22.03 ± 4.83 
41.32 
67.1 ± 5.6 
8.57 ± 3.34 
3981 ± 992 
2078 ± 416 
0.43 ± 0.05 
0.39 ± 0.04 
NA 
NA 
Sprague-Dawley Rats  
Artelinic acid 
Oral (Suspension) 
160 mg/kg x 9 
Artelinic acid 
Oral (Suspension) 
288 mg/kg x 5 
Artelinate 
IM (5% NaHCO3) 
25 mg/kg x 7 
AUC1-7 or 9D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7 or 9 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7 or 9 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
 
1420 ± 454 
11293 ± 8291 
12230 ± 7139 
2.84 ± 0.52 
10.68 ± 1.84 
346.26 
186.0 ± 28.0 
1302 ± 905 
14069 ± 10905 
14341 ± 9339 
3.33 ± 0.25 
3.60 ± 0.25 
346.26 
75.0 ± 12.0 
86.84 ± 5.59 
20044 ± 3459 
15585 ± 1476 
1.89 ± 0.22 






15 mg/kg x 14 
Artemether, IM 
(Peanut oil) 
40 mg/kg x 7 
Artemether, IM 
(Peanut oil) 
20 mg/kg x 7 
Artelinic acid 
Oral (Capsules) 
25 mg/kg x 14 
AUC1-7, 14, or 28D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 7, 14,or 28 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 7, 14,or 28 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr) * 
24.39 ± 18.04 
90 ± 15 
352 ± 203 
9.23 ± 1.32 
21.53 ± 2.08 
40.92 















191.14 ± 90.80 
6279 ± 2995 
7177 ± 6248 
1.51 ± 0.16 
1.94 ± 0.56 
346.26  
14.6 ± 1.8 
Rhesus monkeys***  
Arteether, IM 
(Sesame oil) 
16 mg/kg x 14 
Arteether IM** 
(Sesame oil) 
8 mg/kg x 14 
 
AUC1-14D (µgh/ml) 
Cmax Day 1 (ng/ml) 
Cmax Day 14 (ng/ml) 
t1/2 Day 1 (hr) 
t1/2 Day 14 (hr) 
LONEL (ng/ml) 
Neuro-exposure time (hr)* 
 
70.96  ± 4.59 
63 ± 9 
1038 ± 622 
22.59 ± 1.55 
82.09 ± 41.98 
193.80 
307.4 
31.25 ± 2.61 
38 ± 5 
527 ± 306 
16.56 ± 1.20 




*The neuro-exposure times above LONEL concentration were calculated with neurotoxic outcome.  
** PK data were simulated from our previous studies.  
***The monkey results are from our unpublished data. Neurotoxic severity were graded as minimal = 1-5 
neurons affected, moderate = 10-30 neurons affected, and severe = >40 neurons affected. 
DHA = Dihydroartemisinin; CRM = cremophore; AUC = area under the curve; IM = intramuscular 
Table 2. Drug accumulation, exposure level  and neurotoxic exposure time of arteether  
(AE), Artemether (AM), artesunate (AS) and artelinic acid (AL) at above the lowest  
observed neurotoxic effect level (LONEL) in rats, dogs, and monkeys concerning  
with histopathological neurotoxicity after various dose regimens (Li et al., 2007a;  
Si et al., 2007).  
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Fig. 1. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted 
curves (solid line) of 25 mg/kg of arteether with sesame oil (top, n = 4, Li et al., 2007a). 
Artelinate (middle) and artesunate (bottom) with 5% NaHCO3/0.9% saline following daily 
intramuscular injection 25 mg/kg daily for 7 days in male rats. (n = 3, Li et al., 2005b). The 
lowest observed neurotoxic effect level (LONEL) from AE measurement was estimated at 
41.32 ng/ml (dashed line) in male rats. 
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The drug exposure level shown by the total AUC data observed after a 7 day intramuscular 
treatment dosing of 25 mg/kg AE was 16.92 µg·h/ml, and this dosing regimen induced 
severe neurotoxicity and animal death (Li et al., 1999b). Following intramuscular injection, 
the exposure concentration level of AE in this study was just one-fifth of the total AUC of 
AL (86.84 µg·h/ml) with the same dosing regimen (Table 2) (Li et al., 2005b). Clinical 
observation of rats in this experiment treated with AL did not show any indications of 
neurotoxicity (Figure 1, middle), even after multiple intramuscular injections of high AL 
doses of 100 mg/kg (our unpublished data). Computer simulation indicated that the total 
AUC after 7 day treatment with 100 mg/kg AL was 341.88 µg·h/ml, 21 times higher than 
that of AE treated rats. This result suggests that the 5-21 fold higher exposure concentrations 
of AL did not seem to be a principal independent factor in causing neurotoxicity (Table 2).  
In order to demonstrate that the neurotoxicity of AE is related to drug accumulation in 
blood as a consequence of slow and prolonged absorption from the intramuscular injection 
sites, a study was conducted designed to decrease the accumulation and toxicity of AE 
through the replacement of traditional sesame oil with a cremophore vehicle (Li et al., 2002). 
When administered at a daily dose of 25 mg/kg for 7 days, the AUC of AE formulated in 
sesame oil (AESO) was 7.5-fold higher on day 7 (last day of dosing) than on day 1 (first day 
of dosing), while treatment with AE formulated with cremophore (AECM) resulted in only a 
1.8-fold higher AUC. The Cmax of AECM (1826 ng/ml) on day 7 was found to be only 
slightly higher than on day 1 (1227 ng/ml).  
Although the accumulation of AECM was greatly reduced, its total exposure level (total 
AUC1-7D of 46.29 µg·h/ml) was still 2.7-fold higher than AESO (total AUC1-7D of 16.92 
µg·h/ml) due to the higher bioavailability of AECM (74.5%) compared with AESO (20.3%), 
and the data for this study are shown in Table 2. While the histopathological examinations 
of the brain demonstrated neurotoxic changes in both groups, the animals in the AESO 
group showed significantly more severe neurotoxicity than in the AECM group. Brain 
injury scores in animals treated with AECM were mild to moderate (severity index 2.3 to 
3.0), but in animals treated with AESO they were moderate to severe (3.0 to 4.7) on day 7 
and day 10, respectively. This study further demonstrates that the toxicity of AE is not 
dependent on its exposure level in animals. 
2.3.2 PK profiles of ARTs in dogs 
Daily intramuscular administration of 15 mg/kg AE for 14 days resulted in drug accumulation 
in the plasma of beagle dogs who also presented clinically with severe neurotoxicity and death 
(Li et al., 2000). The peak concentration (Cmax) of AE (352 ng/ml) was found to be four times 
higher on the last dosing day (day 14) compared to the Cmax observed on the first dosing day 
(90 ng/ml). The AUC (7.09 µg·h/ml) of AE observed on the last dosing day was 8.7-fold 
higher than on the first dosing day (0.81 µg·h/ml), indicating that the exposure concentration 
of AE had been greatly increased (Figure 2, middle). The total AUC observed during the 14 
days of daily intramuscular AE dosing at 15 mg/kg was 24.39 µg·h/ml (Table 2). 
Similar accumulation results for AM were reported in dog plasma after daily intramuscular 
administration of 20, 40, and 80 mg/kg for 7 days (Classen et al., 1999). The PK profiles of 
AM dosed IM at 20 and 40 mg/kg in beagles is shown in Table 2. The analysis of the 
toxicokinetic parameters on day 2-7 was changed, with the parameter estimated on day 1. In 
the dogs treated with 20 mg/kg dosed IM minimal neurotoxicity was observed, and the 
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Cmax of AM (346 ng/ml) doubled on day 7 from the Cmax observed on day 1 (190 ng/ml). The 
AUC (6.16 µg·h/ml) of AM observed on day 7 was 2.7-fold higher than the AUC of AM 
observed on day 1 (2.25 µg·h/ml) after IM dosing. Similar results were found in animals 
treated IM with AM at 40 mg/kg daily for 7 days. The Cmax of AM (720 ng/ml) on day 7 was 
much higher than on day 1 (580 ng/ml), and the AUC (12.52 µg·h/ml) doubled on day 7 
from the AUC observed on day 1 (6.70 µg·h/ml), indicating that the exposure concentration 
of AM had been increased (Classen et al., 1999). 
In comparison to the dogs treated with intramuscular AE, the total AUCs observed in 
animals treated with AM dosed IM at 20 mg/kg (32.13 µg·h/ml) and 40 mg/kg (86.27 
µg·h/ml) were significantly higher than the AUC observed after dosing with AE at 15 
mg/kg  (24.39 µg·h/ml) (Classen et al., 1999; Li et al., 1999a). The severity of neurotoxicity 
observed after dosing with intramuscular AM in dogs, however, was minimal in the 20 
mg/kg group and moderate in the 40 mg/kg group.  The observed neurotoxicity was much 
less in AM treated animals than in AE treated dogs who presented with severe neurotoxicity 
and death. These comparison studies demonstrate that the neurotoxicity of AE and AM is 
not dependent on plasma concentrations in dogs.      
In another comparison study, dogs treated with oral AL showed much higher plasma 
concentrations. The AUC observed after daily oral dosing with AL for 14 days at 20 mg/kg 
in a suspension formulation was 231.6 µg·h/ml. The AUC value dropped to 191.1 µg·h/ml 
in animals dosed with oral AL in a 25 mg/kg capsule formulation given daily for 14 days 
(Table 2). The dogs in both groups did not show any clinical toxicity (Li et al., 1994). In dogs 
treated with AL at two different dose regimens the exposure concentrations were 2-9 times 
higher than in dogs treated with AE and AM. No neurotoxicity was detected in those 
animals, however, dosed with 20 or 25 mg/kg oral AL daily for 14 days (Noker & Lin, 2000).  
The drug exposure levels of these treatments suggest that a much higher total exposure 
concentration of AL in dogs (AUC1-14D = 191.14 µg·h/ml) does not correlate with clinical 
observations of neurotoxicity while the drug exposure levels of AE (AUC1-14D = 24.39 
µg·h/ml) and AM (AUC1-7D = 32.13 µgh/ml), correlated well with neurotoxicity at much 
lower exposure concentrations in dogs (Li et al., 2007a). These results also showed the 
exposure level of AM at daily dose of 20 and 40 mg/kg (AUC1-7D = 32.13 and 86.27 µg·h/ml) 
is higher than the exposure level of AE in dogs (AUC1-14D = 24.39 µg·h/ml), but the clinical 
observations of neurotoxicity were less severe in dogs treated with AM than with AE (Table 
2). These studies further demonstrate that the toxicity of AE, AM or AL is not dependent on 
exposure levels in dogs. 
2.3.3 PK studies in monkeys 
Significant accumulations of AE were shown in the plasma of rhesus monkeys after daily 
intramuscular administration of AE at 16 mg/kg for 14 days (Figure 2, bottom). The 
concentration-time profile of AE dosed at 16 mg/kg in monkeys showed that the Cmax of AE 
(1038 ng/ml) on day 14 was 19-fold higher than the Cmax of AE observed on day 1 (63 ± 9 
ng/ml). The AUC (53.10 µg·h/ml) of AE observed on the last dosing day was shown to be 
60-fold higher than the AUC of AE observed after intramuscular dosing on the first day 
(0.88 µg·h/ml), indicating that the exposure concentration of AE was greatly increased. The 
total AUC of AE observed during the entire 14 days of treatment was 70.96 µg·h/ml (Li & 
Hickman, 2011).  
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Daily intramuscular administration of 15 mg/kg AE for 14 days resulted in drug accumulation 
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(Li et al., 2000). The peak concentration (Cmax) of AE (352 ng/ml) was found to be four times 
higher on the last dosing day (day 14) compared to the Cmax observed on the first dosing day 
(90 ng/ml). The AUC (7.09 µg·h/ml) of AE observed on the last dosing day was 8.7-fold 
higher than on the first dosing day (0.81 µg·h/ml), indicating that the exposure concentration 
of AE had been greatly increased (Figure 2, middle). The total AUC observed during the 14 
days of daily intramuscular AE dosing at 15 mg/kg was 24.39 µg·h/ml (Table 2). 
Similar accumulation results for AM were reported in dog plasma after daily intramuscular 
administration of 20, 40, and 80 mg/kg for 7 days (Classen et al., 1999). The PK profiles of 
AM dosed IM at 20 and 40 mg/kg in beagles is shown in Table 2. The analysis of the 
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Cmax of AM (346 ng/ml) doubled on day 7 from the Cmax observed on day 1 (190 ng/ml). The 
AUC (6.16 µg·h/ml) of AM observed on day 7 was 2.7-fold higher than the AUC of AM 
observed on day 1 (2.25 µg·h/ml) after IM dosing. Similar results were found in animals 
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less in AM treated animals than in AE treated dogs who presented with severe neurotoxicity 
and death. These comparison studies demonstrate that the neurotoxicity of AE and AM is 
not dependent on plasma concentrations in dogs.      
In another comparison study, dogs treated with oral AL showed much higher plasma 
concentrations. The AUC observed after daily oral dosing with AL for 14 days at 20 mg/kg 
in a suspension formulation was 231.6 µg·h/ml. The AUC value dropped to 191.1 µg·h/ml 
in animals dosed with oral AL in a 25 mg/kg capsule formulation given daily for 14 days 
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treated with AL at two different dose regimens the exposure concentrations were 2-9 times 
higher than in dogs treated with AE and AM. No neurotoxicity was detected in those 
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is higher than the exposure level of AE in dogs (AUC1-14D = 24.39 µg·h/ml), but the clinical 
observations of neurotoxicity were less severe in dogs treated with AM than with AE (Table 
2). These studies further demonstrate that the toxicity of AE, AM or AL is not dependent on 
exposure levels in dogs. 
2.3.3 PK studies in monkeys 
Significant accumulations of AE were shown in the plasma of rhesus monkeys after daily 
intramuscular administration of AE at 16 mg/kg for 14 days (Figure 2, bottom). The 
concentration-time profile of AE dosed at 16 mg/kg in monkeys showed that the Cmax of AE 
(1038 ng/ml) on day 14 was 19-fold higher than the Cmax of AE observed on day 1 (63 ± 9 
ng/ml). The AUC (53.10 µg·h/ml) of AE observed on the last dosing day was shown to be 
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(0.88 µg·h/ml), indicating that the exposure concentration of AE was greatly increased. The 
total AUC of AE observed during the entire 14 days of treatment was 70.96 µg·h/ml (Li & 
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Fig. 2. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted 
curves (solid line) of arteether (AE) in sesame oil in rats at daily dose of 12.5 mg/kg for 7 
days (top, Li et al., 1999b), in beagle dogs at daily dose of 15 mg/kg for 14 days (middle, Li 
et al., 2000), and in rhesus monkeys at daily dose of 16 mg/kg for 14 days (bottom, Li & 
Hickman, 2011). The lowest observed neurotoxic effect level (LONEL, dashed line) from AE 
measurement was estimated 41.32 ng/ml in rats, 40.92 ng/ml in dogs, and 193.8 ng/ml in 
rhesus monkeys, respectively. 
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2.4 The importance of artemisinin drug half-life in neurotoxicity 
While the exposure level of ARTs has not been shown to be a major factor involved in the 
induction of neurotoxicity, the exposure time may play a role in causing neurotoxicity. 
There are a number of similar reports of exposure investigations in the literature that have 
obtained the same observations that continued exposure of artemisinins over time (drug 
exposure time) rather than a high concentration (drug exposure level) over a short time 
(interval time)  substantially contribute to neurotoxicity (Jorgensen, 1980; Rangan et al., 
1997; Rozman & Doull 2000). 
2.4.1 Half lives of ARTs in rats 
The biological half-life of test drugs in blood controls the time exposure of drugs in animals 
and humans. The biological half-life is the amount of time it takes the body to eliminate one 
half of the drug initially present. In the animal PK studies with ARTs, the half lives of drugs 
administered were noted. Rats treated with daily intramuscular injections of AE at 25 
mg/kg for 7 days presented with clinical observations of severe neurotoxicity (Li et al., 
1999b). The absorption of AE from the muscle at the injection site was incomplete in the first 
48 hours after a single injection. The elimination half life of AE in plasma after 7 daily doses 
was prolonged from 13.74 hours on day 1 to 31.24 hours on day 7, suggesting that the 
elimination half life of AE had been greatly extended.  
To examine the question of whether AE accumulation in blood is due to the slow and 
prolonged absorption of drug from the intramuscular injection sites, a comparison study 
was conducted designed to decrease the accumulation of AE through the replacement of the 
sesame oil formulation with a cremophore vehicle (Li et al., 2002). When administered at a 
daily dose of AE at 25 mg/kg for 7 days, the half life (13.74 hr) of AE with sesame oil 
(AESO) on the first dosing day (day 1) showed a 2.5-fold higher half life than AE formulated 
with cremophore (AECM, 6.96 hr). Similar results were observed on the last dosing day (day 
7), and the half life of AE in animals treated with AESO was 31.24 hr, which was 3.3-fold 
higher than AECM treated rats (9.06 hr) on the same day. Although the new formulation of 
AE with cremophore greatly increased the absorption rate from the muscles of rats, the half 
life observed in AECM treated animals was  slightly lengthened from 6.96 hr on day 1 to 
9.06 hr on day 7, suggesting that the exposure time of AECM was greatly reduced compared 
to animals treated with AESO. In this comparison, the neurotoxic severity observed was also 
significantly reduced from severe with death in animals treated with AESO to moderate in 
animals treated with AECM, and the drug half-lives appear to strongly correlate to clinical 
observations of neurotoxicity observed in these animals (Li et al., 2002). 
No prolonged half lives and neurotoxicity were found in animals treated with intramuscular 
AL and AS at a dose of 25 mg/kg per day for 7 days, which closely follows the conditions of 
the experiments conducted in the previously mentioned AE study (Li et al., 1999b; Li et al., 
2005b). The half-lives of AL and AS, both of which are water soluble, were very short 
ranging from 0.39 to 1.89 hr (Table 2), which is significantly shorter than the half life 
observed after dosing with AE intramuscularly. In addition, the half lives of AL and AS 
were not prolonged when comparing the half life observed on day 7 to the half life observed 
on day 1 post-injection (Figure 1, middle & bottom), suggesting that  drug accumulation was 
not observed in those animals treated with repeated intramuscular doses of AL and AS. This 
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Fig. 2. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted 
curves (solid line) of arteether (AE) in sesame oil in rats at daily dose of 12.5 mg/kg for 7 
days (top, Li et al., 1999b), in beagle dogs at daily dose of 15 mg/kg for 14 days (middle, Li 
et al., 2000), and in rhesus monkeys at daily dose of 16 mg/kg for 14 days (bottom, Li & 
Hickman, 2011). The lowest observed neurotoxic effect level (LONEL, dashed line) from AE 
measurement was estimated 41.32 ng/ml in rats, 40.92 ng/ml in dogs, and 193.8 ng/ml in 
rhesus monkeys, respectively. 
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not observed in those animals treated with repeated intramuscular doses of AL and AS. This 
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result suggests that the significantly shorter half-lives of AL and AS compared to the half-
life of AE seem to be an important element in avoiding clinical neurotoxicity. In other 
words, treatment of animals with intramuscular AL and AS is one means by which these 
animals avoided neurotoxic risk.  
After changing the administration route from intravenous and intramuscular to intragastric, 
AL showed moderate neurotoxicity in rats treated with 160 mg/kg daily in 9 multiple doses 
for 9 days but not in animals dosed with 288 mg/kg every other day in 5 multiple doses for 
9 days (Si et al., 2007). The elimination t½ of  AL in plasma after oral dosing at 160 mg/kg 
daily for 9 days doses was prolonged from 2.84 hrs on day 1 to 10.68 hrs on day 9, 
suggesting that the elimination half life of AL had been greatly extended (Figure 4, middle). 
A slight increase of the half life, however, from 3.33 hrs on day 1 to 3.60 hrs on day 9 was 
noted in the rats treated with 288 mg/kg every other day in 5 multiple doses for 9 days 
(Figure 4, bottom). The neurotoxic severity of  AL changed from moderate in the group 
treated with an oral daily dose of 160 mg/kg for 9 days to minimal in the group treated 
orally with AL every other day at a dose of 288 mg/kg for 9 days. These results indicate a 
correlation between observed clinical symptoms of neuropathology in rats and prolonged 
AL half lives in the animals dosed daily. The data further suggest that if the drug half life 
were shortened it might be possible to reduce the neurotoxic risk in animals treated with 
ARTs (Li et al., 2006b).   
2.4.2 Half lives of ARTs in dogs 
Beagle dogs treated with multiple daily intramuscular doses of AE at 15 mg/kg for 14 days 
developed severe neurotoxicity with death (Li et al., 2000). Similar to what was observed in 
the rat AE PK studies; the dogs demonstrated prolonged AE half-lives and drug 
accumulation. (Figure 2, middle).  In this study, the most striking data observed was the 
elimination t½ of AE during the two weeks of daily dosing. The half life was prolonged 
from 9.23 hrs on the first dosing day (day 1) to 21.53 hrs on the last dosing day (day 14), 
suggesting that the exposure time of AE had been extended by two-fold (Table 2).  In 
addition, half life extensions s were also reported in dog plasma after daily AM 
intramuscular administration of 20, 40, and 80 mg/kg dissolved in peanut oil for 7 days 
(Classen et al., 1999). The concentration-time profile of AM dosed at 20 and 40 mg/kg in 
beagles is shown in Table 2 and Figure 4. The elimination t½ of AM dosed at 20 mg/kg after 
7 days daily dosing was prolonged from 10.93 hours on day 1 to 20.75 hours on day 7, 
suggesting that the exposure time of AM had been significantly increased. Similar results 
were found in animals treated with AM dosed intramuscularly at 40 mg/kg. Daily AM 
dosing for 7 days did not result in severe neurotoxicity, unlike the 14 day treatment with AE 
where severe neurotoxicity and death were noted. The difference in dosing time from 7 days 
to 14 days is the most likely factor related to this difference in clinical outcomes (Classen et 
al., 1999). 
The minimal AE dose of multiple intramuscular injections which induced neuropathological 
findings was 6 mg/kg for 28 days in dogs (Brewer et al., 1994b;  Davidson, 1994; Dayan, 
1998). Through PK simulation of data from our dogs treated with intramuscular AE, the 
elimination half-lives of AE were found to be slightly prolonged from 8.22 hrs on day 1 to 
10.45 hrs on day 28 with no significant difference. The neurotoxicity findings were also 
significantly reduced when comparing different compound dosing groups and treatment 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 337 
durations.  Severe neurotoxicity was observed in dogs treated with AE at 15 mg/kg daily 
for 14 days, and minimal toxicity in animals treated with AE at 6 mg/kg daily dose for 28 
days (Table 2). When compared to the drug half-lives of AE and AM, much shorter half lives 
were found in dogs treated with AL orally at 25 mg/kg daily for 14 days. The half lives of 
AL in dogs were 1.51 hrs on day 1 and 1.94 hrs on day 14 after oral capsule administration. 
The half life of AL observed was much shorter and no prolonged elimination half lives were 
found after oral daily dosing for 14 days. No neurotoxicity was observed in any of the AL 
treated animals (Noker & Lin, 2000). These studies further demonstrate that the 
neurotoxicity in beagles following AE, AM or AL administration is likely dependent on the 
half life of drug.  
These studies strongly support the findings that neurotoxicity is half life (exposure time) 
dependent in the animals regardless of drug formulations and administration routes. As a 
result, the half lives of ARTs in animals are critical elements in the induction of 
neurotoxicity (Li et al., 2006b). Other pharmacokinetic parameters, such as drug distribution 
in the brain, toxicity of DHA, the active metabolite of ARTs or drug exposure level, tend to 
be of minor importance. 
2.4.3 Half lives of ARTs in monkeys 
AE dissolved in sesame oil formulation showed high plasma concentrations in rhesus 
monkeys after daily intramuscular administrations of AE at 16 mg/kg for 14 days (Li & 
Hickman, 2011). The concentration-time profile of monkeys dosed with AE at 16 mg/kg 
showed the Cmax of AE (1038 ng/ml) on day 14 was 19 fold higher than on day 1 (63 ng/ml). 
The half lives of intramuscular AE were 22.59 hrs on day 1 and 82.09 hrs on day 14 after 
daily multiple dose regimens. Accordingly, the half life of AE was significantly prolonged 
from the first dosing day to the last dosing day after intramuscular AE administrations. The 
monkey showed moderate neurotoxicity after this intramuscular AE dosing regimen (Petras 
et al., 1997, 2000).  
Since AE-induced brainstem neuropathology in monkeys has been shown to occur at a 
minimal dose of 8 mg/kg dosed daily for 14 days, we chose to simulate the main AE PK 
parameters on day1 and day 14 from our own rhesus PK data (Table 2).  We noted a drug 
half life of 50.28 hrs on day 14 which was extended from 16.56 hrs on day 1 in monkeys 
treated with multiple doses of 8 mg/kg. This half life value is still shorter than the 82.09 hrs 
half life observed in animals treated with multiple intramuscular doses of AE at 16 mg/kg. 
The former dose induced minimal neurotoxicity, and the latter doses produced moderate 
toxicity in monkeys. Therefore, the AE half lives in monkeys appear to also have an 
important impact on the induction of neurotoxicity. 
In conclusion, the data on ART half lives in animals supports the hypothesis that induction 
of neurotoxicity is much more dependent on the exposure time than other PK parameters. 
The summary data illustrates that the water-soluble ARTs, AL and AS, have very short half 
lives of 0.39-1.94 hrs in  animals without any neurotoxic observations with the exception of 
oral AL dosed in rats at a very high dose of 160 mg/kg daily for 9 days. High dose AL 
treatment resulted in a significantly prolonged drug half life on day 9, the animals showed 
moderate neurotoxicity, and this treatment was also associated with GI toxicity. In rats or 
dogs treated with the oil-soluble ARTs, AE and AM, the drug half-lives were significantly 
extended due to slow absorption from the site of the intramuscular injection. Those animals 
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result suggests that the significantly shorter half-lives of AL and AS compared to the half-
life of AE seem to be an important element in avoiding clinical neurotoxicity. In other 
words, treatment of animals with intramuscular AL and AS is one means by which these 
animals avoided neurotoxic risk.  
After changing the administration route from intravenous and intramuscular to intragastric, 
AL showed moderate neurotoxicity in rats treated with 160 mg/kg daily in 9 multiple doses 
for 9 days but not in animals dosed with 288 mg/kg every other day in 5 multiple doses for 
9 days (Si et al., 2007). The elimination t½ of  AL in plasma after oral dosing at 160 mg/kg 
daily for 9 days doses was prolonged from 2.84 hrs on day 1 to 10.68 hrs on day 9, 
suggesting that the elimination half life of AL had been greatly extended (Figure 4, middle). 
A slight increase of the half life, however, from 3.33 hrs on day 1 to 3.60 hrs on day 9 was 
noted in the rats treated with 288 mg/kg every other day in 5 multiple doses for 9 days 
(Figure 4, bottom). The neurotoxic severity of  AL changed from moderate in the group 
treated with an oral daily dose of 160 mg/kg for 9 days to minimal in the group treated 
orally with AL every other day at a dose of 288 mg/kg for 9 days. These results indicate a 
correlation between observed clinical symptoms of neuropathology in rats and prolonged 
AL half lives in the animals dosed daily. The data further suggest that if the drug half life 
were shortened it might be possible to reduce the neurotoxic risk in animals treated with 
ARTs (Li et al., 2006b).   
2.4.2 Half lives of ARTs in dogs 
Beagle dogs treated with multiple daily intramuscular doses of AE at 15 mg/kg for 14 days 
developed severe neurotoxicity with death (Li et al., 2000). Similar to what was observed in 
the rat AE PK studies; the dogs demonstrated prolonged AE half-lives and drug 
accumulation. (Figure 2, middle).  In this study, the most striking data observed was the 
elimination t½ of AE during the two weeks of daily dosing. The half life was prolonged 
from 9.23 hrs on the first dosing day (day 1) to 21.53 hrs on the last dosing day (day 14), 
suggesting that the exposure time of AE had been extended by two-fold (Table 2).  In 
addition, half life extensions s were also reported in dog plasma after daily AM 
intramuscular administration of 20, 40, and 80 mg/kg dissolved in peanut oil for 7 days 
(Classen et al., 1999). The concentration-time profile of AM dosed at 20 and 40 mg/kg in 
beagles is shown in Table 2 and Figure 4. The elimination t½ of AM dosed at 20 mg/kg after 
7 days daily dosing was prolonged from 10.93 hours on day 1 to 20.75 hours on day 7, 
suggesting that the exposure time of AM had been significantly increased. Similar results 
were found in animals treated with AM dosed intramuscularly at 40 mg/kg. Daily AM 
dosing for 7 days did not result in severe neurotoxicity, unlike the 14 day treatment with AE 
where severe neurotoxicity and death were noted. The difference in dosing time from 7 days 
to 14 days is the most likely factor related to this difference in clinical outcomes (Classen et 
al., 1999). 
The minimal AE dose of multiple intramuscular injections which induced neuropathological 
findings was 6 mg/kg for 28 days in dogs (Brewer et al., 1994b;  Davidson, 1994; Dayan, 
1998). Through PK simulation of data from our dogs treated with intramuscular AE, the 
elimination half-lives of AE were found to be slightly prolonged from 8.22 hrs on day 1 to 
10.45 hrs on day 28 with no significant difference. The neurotoxicity findings were also 
significantly reduced when comparing different compound dosing groups and treatment 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 337 
durations.  Severe neurotoxicity was observed in dogs treated with AE at 15 mg/kg daily 
for 14 days, and minimal toxicity in animals treated with AE at 6 mg/kg daily dose for 28 
days (Table 2). When compared to the drug half-lives of AE and AM, much shorter half lives 
were found in dogs treated with AL orally at 25 mg/kg daily for 14 days. The half lives of 
AL in dogs were 1.51 hrs on day 1 and 1.94 hrs on day 14 after oral capsule administration. 
The half life of AL observed was much shorter and no prolonged elimination half lives were 
found after oral daily dosing for 14 days. No neurotoxicity was observed in any of the AL 
treated animals (Noker & Lin, 2000). These studies further demonstrate that the 
neurotoxicity in beagles following AE, AM or AL administration is likely dependent on the 
half life of drug.  
These studies strongly support the findings that neurotoxicity is half life (exposure time) 
dependent in the animals regardless of drug formulations and administration routes. As a 
result, the half lives of ARTs in animals are critical elements in the induction of 
neurotoxicity (Li et al., 2006b). Other pharmacokinetic parameters, such as drug distribution 
in the brain, toxicity of DHA, the active metabolite of ARTs or drug exposure level, tend to 
be of minor importance. 
2.4.3 Half lives of ARTs in monkeys 
AE dissolved in sesame oil formulation showed high plasma concentrations in rhesus 
monkeys after daily intramuscular administrations of AE at 16 mg/kg for 14 days (Li & 
Hickman, 2011). The concentration-time profile of monkeys dosed with AE at 16 mg/kg 
showed the Cmax of AE (1038 ng/ml) on day 14 was 19 fold higher than on day 1 (63 ng/ml). 
The half lives of intramuscular AE were 22.59 hrs on day 1 and 82.09 hrs on day 14 after 
daily multiple dose regimens. Accordingly, the half life of AE was significantly prolonged 
from the first dosing day to the last dosing day after intramuscular AE administrations. The 
monkey showed moderate neurotoxicity after this intramuscular AE dosing regimen (Petras 
et al., 1997, 2000).  
Since AE-induced brainstem neuropathology in monkeys has been shown to occur at a 
minimal dose of 8 mg/kg dosed daily for 14 days, we chose to simulate the main AE PK 
parameters on day1 and day 14 from our own rhesus PK data (Table 2).  We noted a drug 
half life of 50.28 hrs on day 14 which was extended from 16.56 hrs on day 1 in monkeys 
treated with multiple doses of 8 mg/kg. This half life value is still shorter than the 82.09 hrs 
half life observed in animals treated with multiple intramuscular doses of AE at 16 mg/kg. 
The former dose induced minimal neurotoxicity, and the latter doses produced moderate 
toxicity in monkeys. Therefore, the AE half lives in monkeys appear to also have an 
important impact on the induction of neurotoxicity. 
In conclusion, the data on ART half lives in animals supports the hypothesis that induction 
of neurotoxicity is much more dependent on the exposure time than other PK parameters. 
The summary data illustrates that the water-soluble ARTs, AL and AS, have very short half 
lives of 0.39-1.94 hrs in  animals without any neurotoxic observations with the exception of 
oral AL dosed in rats at a very high dose of 160 mg/kg daily for 9 days. High dose AL 
treatment resulted in a significantly prolonged drug half life on day 9, the animals showed 
moderate neurotoxicity, and this treatment was also associated with GI toxicity. In rats or 
dogs treated with the oil-soluble ARTs, AE and AM, the drug half-lives were significantly 
extended due to slow absorption from the site of the intramuscular injection. Those animals 
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presented with a moderate to severe neurotoxicity and some died. It is notable that the drug 
half-lives (9.23 – 82.09 hrs) in animals treated with AE and AM were extremely extended 
compared to the half lives observed after AL and AS treatment. Although we lacked a full 
set of PK data after  AE dosing  in monkeys, we noted  several PK results in different 
animals that showed the half lives on day 14 after intramuscular AE was dosed at 16 mg/kg 
daily were much longer than those observed in rats and dogs.  
In addition, the monkeys dosed with AE for 14 days showed moderate neurotoxicity, 
suggesting that monkeys appear less sensitive to AE-induced neurotoxicity than rats and dogs 
which showed severe neurotoxicity and death when dosed with AE for 14 days. We conclude, 
from the dose amounts of ARTs used in various experiments to induce  neurotoxicity, that the 
rank order of ARTs in terms of toxic potency is AE first followed by AM, AL, and lastly by AS. 
There is a strong correlation between the drug half-lives and the severity of neurotoxicity 
observed after treatment which supports the hypothesis that the drug exposure time during 
treatment plays a very important role in the induction of neurotoxicity. 
3. Blood accumulation of ARTs leads to prolonged half-lives 
The studies described thus far support the hypothesis that neurotoxicity induced by ARTs is 
highly dependent on the half-lives of these drugs. These studies also show that the ART 
drug half-life is due to the accumulation of ART drugs in the plasma following multiple 
doses of AE and AM administered intramuscularly and AL administered orally. In 
accordance with the published literatures and our research experience, ARTs (QHS, AS, 
AM, and DHA) elicit auto-induction of a drug metabolism pathway during multiple oral 
treatments in malaria patients and healthy subjects (van Agtmael et al., 1999; Ashton et al., 
1996 and 1998; Khanh et al., 1999: Li et al., 2004; Park et al., 1998). The Cmax and AUC values 
of these patients were markedly reduced from one-third to one-seventh on the last dose day 
compared with the first dosing day. The decrease in drug exposure levels during treatment 
is not disease-related, since the PK parameters of ART drugs in treated patients is similar to 
that reported in healthy subjects. Similar time-dependent declines were also found in 
animals treated with intravenous AS (Figure 3, top, Li et al., 2005a), intramuscular AS 
(Figure 3, middle, Li et al., 2007a), and oral AM (Figure 3, bottom, Classen et al., 1999).  This 
data leads to pertinent questions: if all ART drugs have a pathway of metabolism auto-
induction, why do drugs accumulate in animals treated with AE and AM after multiple 
intramuscular doses and with AL after repeated oral dosing?  
3.1 Cause of AM and AE accumulation after intramuscular injection 
PK data from various animal studies have shown that AE and AM will accumulate in the 
plasma of rats (Li et al., 1999b), beagle dogs (Classen et al., 1999), rhesus monkeys (Li et al., 
2007a), and humans (Kager et al., 1994) following multiple intramuscular injections. Data 
collected from rat studies showed that the accumulation of AE in the plasma is due to a slow 
and prolonged absorption from the injection sites. The elimination t½ of AE after 7 daily 
doses at 25 mg/kg was prolonged from 13.7 hr on the first dosing day to 31.2 hr on the last 
dosing day (Li et al., 1999b) (Fig. 1, top). AE accumulation was also observed in beagle dogs 
with severe neurotoxicity and death after daily intramuscular administration of AE at  
15 mg/kg for 14 days (Li et al., 2006b). The elimination t½ of AE after dosing the dogs for  
14 days was prolonged from 9.23 hr on day 1 to 21.53 hr on day 14 (Fig. 2, middle).  
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Fig. 3. Auto-induction metabolic profiles measured by HPLC-ECD (markers) and computer 
fitted curves of 36.7 mg/kg of intravenous artesunate (AS, top, dashed line), and its active 
metabolite DHA (top, solid line) once daily for 3 days (Li et al., 2005a). Study of 25 mg/kg of 
intramuscular AS (middle) was dosed daily for 7 days in rats (Li et al., 2007a). Another PK 
profiles after oral dose at 600 mg/kg of AM (bottom) daily for 7 days in beagle dogs 
(Classen et al., 1999).  
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presented with a moderate to severe neurotoxicity and some died. It is notable that the drug 
half-lives (9.23 – 82.09 hrs) in animals treated with AE and AM were extremely extended 
compared to the half lives observed after AL and AS treatment. Although we lacked a full 
set of PK data after  AE dosing  in monkeys, we noted  several PK results in different 
animals that showed the half lives on day 14 after intramuscular AE was dosed at 16 mg/kg 
daily were much longer than those observed in rats and dogs.  
In addition, the monkeys dosed with AE for 14 days showed moderate neurotoxicity, 
suggesting that monkeys appear less sensitive to AE-induced neurotoxicity than rats and dogs 
which showed severe neurotoxicity and death when dosed with AE for 14 days. We conclude, 
from the dose amounts of ARTs used in various experiments to induce  neurotoxicity, that the 
rank order of ARTs in terms of toxic potency is AE first followed by AM, AL, and lastly by AS. 
There is a strong correlation between the drug half-lives and the severity of neurotoxicity 
observed after treatment which supports the hypothesis that the drug exposure time during 
treatment plays a very important role in the induction of neurotoxicity. 
3. Blood accumulation of ARTs leads to prolonged half-lives 
The studies described thus far support the hypothesis that neurotoxicity induced by ARTs is 
highly dependent on the half-lives of these drugs. These studies also show that the ART 
drug half-life is due to the accumulation of ART drugs in the plasma following multiple 
doses of AE and AM administered intramuscularly and AL administered orally. In 
accordance with the published literatures and our research experience, ARTs (QHS, AS, 
AM, and DHA) elicit auto-induction of a drug metabolism pathway during multiple oral 
treatments in malaria patients and healthy subjects (van Agtmael et al., 1999; Ashton et al., 
1996 and 1998; Khanh et al., 1999: Li et al., 2004; Park et al., 1998). The Cmax and AUC values 
of these patients were markedly reduced from one-third to one-seventh on the last dose day 
compared with the first dosing day. The decrease in drug exposure levels during treatment 
is not disease-related, since the PK parameters of ART drugs in treated patients is similar to 
that reported in healthy subjects. Similar time-dependent declines were also found in 
animals treated with intravenous AS (Figure 3, top, Li et al., 2005a), intramuscular AS 
(Figure 3, middle, Li et al., 2007a), and oral AM (Figure 3, bottom, Classen et al., 1999).  This 
data leads to pertinent questions: if all ART drugs have a pathway of metabolism auto-
induction, why do drugs accumulate in animals treated with AE and AM after multiple 
intramuscular doses and with AL after repeated oral dosing?  
3.1 Cause of AM and AE accumulation after intramuscular injection 
PK data from various animal studies have shown that AE and AM will accumulate in the 
plasma of rats (Li et al., 1999b), beagle dogs (Classen et al., 1999), rhesus monkeys (Li et al., 
2007a), and humans (Kager et al., 1994) following multiple intramuscular injections. Data 
collected from rat studies showed that the accumulation of AE in the plasma is due to a slow 
and prolonged absorption from the injection sites. The elimination t½ of AE after 7 daily 
doses at 25 mg/kg was prolonged from 13.7 hr on the first dosing day to 31.2 hr on the last 
dosing day (Li et al., 1999b) (Fig. 1, top). AE accumulation was also observed in beagle dogs 
with severe neurotoxicity and death after daily intramuscular administration of AE at  
15 mg/kg for 14 days (Li et al., 2006b). The elimination t½ of AE after dosing the dogs for  
14 days was prolonged from 9.23 hr on day 1 to 21.53 hr on day 14 (Fig. 2, middle).  
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Fig. 4. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted curves 
(solid line) of intramuscular artemether (AM) in peanut oil at 20 mg/kg daily for 7 days in 
beagle dogs (top, Classen et al., 1999). Oral artelinic acid (AL) in suspension at 160 mg/kg daily 
for 9 dosages (middle, n = 5) and oral AL at 288 mg/kg every other daily for 5 dosages in rats 
(bottom, n = 4, Si et al., 2007). The two regimens of AL have the same total dose with 1440 
mg/kg and same treatment period for 9 days. The lowest observed neurotoxic effect level 
(LONEL) was defined as the plasma level of 75.69 ng/ml of AM in dogs and 346.26 ng/ml of 
AL in rats, at which anorectic and neuropathological toxicities were noted in daily dosing 
cohort. 
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Similar accumulation results for AM were reported in dog plasma after daily 
intramuscular administration of AM at 20, 40, and 80 mg/kg for 7 days (Classen et al., 
1999). The analysis of TK parameters on day 2-7 was significantly different when 
compared to the parameters estimated on day 1. The elimination t½ of AM at 20 mg/kg 
after 7 daily doses increased from 10.93 hr on the first day of dosing day to 20.75 hr on the 
last day of dosing (Table 2; Figure 4, top), suggesting that the exposure time of AM had 
greatly increased. In addition, accumulation of AE was shown in the plasma of rhesus 
monkeys after daily intramuscular administration of AE at 16 mg/kg for 14 doses (Fig. 2, 
bottom). The elimination t½ of AE after 14 daily doses increased from 22.59 hr on day 1 to 
82.09 hr on day 14 (Li et al., 2006b).  
The intramuscular administration of AM and AE was associated with slow absorption 
because the drugs were dissolved in sesame oil or peanut oil that, when injected, formed a 
depot from which the drug was slowly released (Kager et al., 1994: Li et al., 2004). The slow 
elimination of AE was recently demonstrated in a rat study, which also found significant 
accumulation of AE in the plasma from injection sites (Li et al., 1999b). The results of a rat 
study conducted by  daily intramuscular injections of AE at 25 mg/kg  in sesame oil  for 7 
days confirmed and extended the results of earlier studies (Li et al., 1998b) by 
demonstrating that the absorption of AE from the injection site of the muscle was 
incomplete. This study also indicated that up to 38% of the total single dose of AE remained 
in the injection site for 24 hr after dosing, and 22% of the total single dose still remained in 
the muscle 48 hr after dosing. Following 7 days of daily intramuscular injections of AE (25 
mg/kg), 91.4% of a single dose (25 mg/kg/day) was still left in the muscles from the 
injection sites 24 hr after the last dose (Li et al., 1999b). 
 













1.50 ± 0.50 3.00 ± 0.58 2.00 ± 0.0 P = 0.0045 
      
Finding severity were grading as 0 = no significant lesions, 1 = minimal, 2 = mild, 3 = moderate,  
4 = marked, and 5 = severe. *Day 7 and 10 are one day after last treatment of daily dose for 7 and  
10 days. The date is given the dosing day as day 0. **The t-test was conducted between animals  
treated both with AE and AM in sesame oil.    
Table 3. Muscle injury severity in the injection site areas following repeated arteether (AE) 
and artemether (AM) injection with vehicle sesame oil by multiple daily intramuscular 
dosing at 25 mg/kg for 7 days (n = 3) in rats (Li & Hickman, 2011). 
Our histopathological data demonstrated that the cytotoxicity induced by AE in muscle cells 
occurred at the injection site. The severity of the damage  observed after dosing was graded 
where  no significant lesion detected was scored as 0; subacute to minimal damage and mild 
inflammation was scored as 1-2; damage along the connective tissue and between major 
skeletal muscle bundles showing subacute to chronic inflammation was scored as 2-3;  
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Fig. 4. Pharmacokinetic profiles measured by HPLC-ECD (markers) and computer fitted curves 
(solid line) of intramuscular artemether (AM) in peanut oil at 20 mg/kg daily for 7 days in 
beagle dogs (top, Classen et al., 1999). Oral artelinic acid (AL) in suspension at 160 mg/kg daily 
for 9 dosages (middle, n = 5) and oral AL at 288 mg/kg every other daily for 5 dosages in rats 
(bottom, n = 4, Si et al., 2007). The two regimens of AL have the same total dose with 1440 
mg/kg and same treatment period for 9 days. The lowest observed neurotoxic effect level 
(LONEL) was defined as the plasma level of 75.69 ng/ml of AM in dogs and 346.26 ng/ml of 
AL in rats, at which anorectic and neuropathological toxicities were noted in daily dosing 
cohort. 
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Similar accumulation results for AM were reported in dog plasma after daily 
intramuscular administration of AM at 20, 40, and 80 mg/kg for 7 days (Classen et al., 
1999). The analysis of TK parameters on day 2-7 was significantly different when 
compared to the parameters estimated on day 1. The elimination t½ of AM at 20 mg/kg 
after 7 daily doses increased from 10.93 hr on the first day of dosing day to 20.75 hr on the 
last day of dosing (Table 2; Figure 4, top), suggesting that the exposure time of AM had 
greatly increased. In addition, accumulation of AE was shown in the plasma of rhesus 
monkeys after daily intramuscular administration of AE at 16 mg/kg for 14 doses (Fig. 2, 
bottom). The elimination t½ of AE after 14 daily doses increased from 22.59 hr on day 1 to 
82.09 hr on day 14 (Li et al., 2006b).  
The intramuscular administration of AM and AE was associated with slow absorption 
because the drugs were dissolved in sesame oil or peanut oil that, when injected, formed a 
depot from which the drug was slowly released (Kager et al., 1994: Li et al., 2004). The slow 
elimination of AE was recently demonstrated in a rat study, which also found significant 
accumulation of AE in the plasma from injection sites (Li et al., 1999b). The results of a rat 
study conducted by  daily intramuscular injections of AE at 25 mg/kg  in sesame oil  for 7 
days confirmed and extended the results of earlier studies (Li et al., 1998b) by 
demonstrating that the absorption of AE from the injection site of the muscle was 
incomplete. This study also indicated that up to 38% of the total single dose of AE remained 
in the injection site for 24 hr after dosing, and 22% of the total single dose still remained in 
the muscle 48 hr after dosing. Following 7 days of daily intramuscular injections of AE (25 
mg/kg), 91.4% of a single dose (25 mg/kg/day) was still left in the muscles from the 
injection sites 24 hr after the last dose (Li et al., 1999b). 
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and artemether (AM) injection with vehicle sesame oil by multiple daily intramuscular 
dosing at 25 mg/kg for 7 days (n = 3) in rats (Li & Hickman, 2011). 
Our histopathological data demonstrated that the cytotoxicity induced by AE in muscle cells 
occurred at the injection site. The severity of the damage  observed after dosing was graded 
where  no significant lesion detected was scored as 0; subacute to minimal damage and mild 
inflammation was scored as 1-2; damage along the connective tissue and between major 
skeletal muscle bundles showing subacute to chronic inflammation was scored as 2-3;  
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inflammation observed rarely extending into or between muscle fibers was scored as  3-4; 
prominent muscle damage with coagulative necrosis surrounded by a reparative response 
of fibroplasia, fibrosis, skeletal muscle regeneration, and muscle atrophy was scored as 4-5.  
The distribution of damage observed involves major muscle bundles and occurred in linear 
tracts, suggesting the damage may have been the result of a direct effect of the injected drug 
and/or vehicle on the muscle. Overall, the rats in the 7-day group (24 hr after last treatment) 
had more severe lesions than those in the 10-day group (96 hr after last dosing), and animals 
treated with AE had significantly more severe lesions than those treated with AM. The 
results showed that the chronic inflammation of the muscle located at the site of AE injection 
is more severe (moderate severity 3.00-3.17) than the inflammation noted at the AM 
injection site (mild severity 2.00-2.50)(Table 3). The inflammation of muscles induced by AE 
and AM injection may, therefore, be a factor prolonging the absorption of drugs from the 
muscles (Li & Hickman, 2011).  
3.2 Cause of AL accumulation after intragastric administration 
Oral administration of AL has also been shown to result in gastrointestinal toxicity that is 
associated with delayed gastric emptying. Similar findings of gastrointestinal toxicity were 
observed in rats treated intramuscularly with other ARTs (Li et al., 1998a). Rats treated with 
AL at a daily oral dose of 160 mg/kg for 9 days showed moderate neurotoxicity during 
treatment which was associated with prolonged absorption of AL in the stomach. 
Comparison of the day 1 and day 9 results revealed that the PK parameters were very 
different. A significantly longer (3.82-fold) elimination half-life was noted on day 9 (10.68 hr) 
in comparison to that observed on day 1 (2.84 hr), and this prolonged elimination results in 
drug accumulation (Figure 4, middle). The mean AUC of AL was higher on day 9, the last 
dosing day, (168.01 µg·h/ml) than the AUC observed on day 1, the first dosing day (128.38 
µg·h/ml). Furthermore, progressive delays in gastric emptying and drug accretion were 
only found in rats treated with oral AL at 160 mg/kg. These results imply that the 
observations of delayed gastric emptying in turn results in AL accumulation, and the mean 
half-life of AL was correspondingly extended on the last dosing day compared to day 1 (Si 
et al., 2007). 
This report of drug accumulation is illustrated in rats dosed daily with 160 mg/kg of AL 
orally for 9 days. These rats showed moderate neurotoxicity due to prolonged oral 
absorption in the stomach. This reservoir is similar to the depot effect seen with the oil-
soluble ARTs (AM and AE) at intramuscular injection sites. The stomach contents of rats 
dosed orally with AL at 160 mg/kg daily for 9 days were examined at 8 and 24 hr after 
dosing at different time points during the study. On days 3, 5, 7, and 9, we detected 0, 46.52, 
178.59, and 486.21 µg of AL/g in the stomach contents at 8 hr after the last dose. The 
increasing amount of AL observed remaining in the stomach over the course of dosing 
showed that gastric emptying was inhibited. The inhibition of gastric emptying progressed 
from mild inhibition seen on day 5 to severe inhibition observed on day 9.  The inhibition of 
gastric emptying persisted even at 24 hr post dosing.  At twenty-four hr post dosing on days 
5, 7, and 9, we observed 5.74, 25.50, and 29.11 µg of AL/g, respectively, in the stomach 
contents. Similar anorectic toxicity was also reported in animals treated with AM, AE and 
DHA (Li et al., 1998a). It is postulated that this decrease in GI motility could result from a 
decrease in vagal tone as a consequence of a decline in sympathetic outflow (Hull & Maher 
1990; Si et al., 2007). 
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4. Lowest observed neurotoxic effect level (LONEL) as a neurotoxic indicator 
The body of literature cited supports the hypothesis that drug accumulation extends the 
drug exposure time, which we believe is a major causative factor in ART-induced 
neurotoxicity (Li et al., 2006b). The current methodology for assessing the no observed 
adverse effect level (NOAEL) involves identifying the highest concentration or dose 
administered that does not cause a statistically significant or biologically significant 
response to treatment in comparison to the control group. The lowest observed neurotoxic 
effect level (LONEL) represents the minimal plasma concentration associate with the lowest 
dose that is found to cause a neurologically and/or statistically significant response to 
treatment in comparison to the control group. Therefore, determining the neurotoxic 
exposure time (drug exposure time spent above the LONEL) is critical, and the LONEL 
should also be determined before evaluating the drug neurotoxic exposure time for each 
drug in various animals.  
4.1 Neurotoxicity induced by intramuscular AE and oral AL in rats 
A minimal daily dose of AE at 6.25 mg/kg for 7 days was estimated as a no observed 
neurotoxic effect dose (NONED), which was defined by AE dosing that did not result in 
histopathological findings in rats (Genovese et al., 1998). Significant changes of 
neuropathology in brain stem nuclei, however, were observed in a group of rats treated 
with AE at 12.5 mg/kg for 7 days.  These results demonstrate that AE-induced brainstem 
neuropathology in rats can occur at the relatively high dose of 12.5 mg/kg for 7 days. The 
lowest plasma concentration of AE in rats was shown to be 41.32 ng/ml following 
intramuscular dosing of AE at 12.5 mg/kg in previous studies (Li et al., 1999b and 2002). 
Based on the NONED value of 6.25 mg/kg obtained in previous studies, it was possible to 
correctly identify the minimal neurotoxic effect level at 41.32 ng per ml, which has thus been 
defined as a LONEL in rat plasma (Figure 2, top). Administration above this concentration 
with a certain exposure time should result in neuropathological effects (Dayan 1998; van 
Agtmael et al., 1999; Brewer et al., 1994b).  
In a PK simulation, 7 multiple AE treatments at a dose of 12.5 mg/kg were administered 
intramuscularly in rats (Li et al., 2002). The exposure time of 67.1 hr in plasma was 
estimated as the minimum time spent above the LONEL concentration of 41.32 ng/ml that 
was sufficient to induce positive neurotoxicity (Figure 2, top). After histological examination 
this estimate of 67.1 hours of AE dosing above LONEL to induce brainstem injury was 
confirmed by histopathological examination (Genovese et al., 1998) (Table 2). This finding 
confirmed the estimated LONEL (41.32 ng/ml) for AE in rats after dosing at 12.5 mg/kg for 
7 days to induce neurotoxicity based on 100% positive findings of  neuropathology (Fig. 2, 
top) (Li et al., 1999b & 2002). 
Recently, AL was shown to induce moderate neurotoxicity after treatment with 160 mg/kg 
daily for 9 days confirmed by histopathology, and a minimal neuronal degeneration was 
observed following 5 doses of AL at 288 mg/kg every other day in rats. Although the total 
dose (1440 mg/kg) and duration (9 days) were identical (Si et al., 2007), different neurotoxic 
results were observed. This observation could be due to a prolonged exposure time in the 
160 mg/kg group in comparison to the shorter time spent above the LONEL in the 
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treated with AE had significantly more severe lesions than those treated with AM. The 
results showed that the chronic inflammation of the muscle located at the site of AE injection 
is more severe (moderate severity 3.00-3.17) than the inflammation noted at the AM 
injection site (mild severity 2.00-2.50)(Table 3). The inflammation of muscles induced by AE 
and AM injection may, therefore, be a factor prolonging the absorption of drugs from the 
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Oral administration of AL has also been shown to result in gastrointestinal toxicity that is 
associated with delayed gastric emptying. Similar findings of gastrointestinal toxicity were 
observed in rats treated intramuscularly with other ARTs (Li et al., 1998a). Rats treated with 
AL at a daily oral dose of 160 mg/kg for 9 days showed moderate neurotoxicity during 
treatment which was associated with prolonged absorption of AL in the stomach. 
Comparison of the day 1 and day 9 results revealed that the PK parameters were very 
different. A significantly longer (3.82-fold) elimination half-life was noted on day 9 (10.68 hr) 
in comparison to that observed on day 1 (2.84 hr), and this prolonged elimination results in 
drug accumulation (Figure 4, middle). The mean AUC of AL was higher on day 9, the last 
dosing day, (168.01 µg·h/ml) than the AUC observed on day 1, the first dosing day (128.38 
µg·h/ml). Furthermore, progressive delays in gastric emptying and drug accretion were 
only found in rats treated with oral AL at 160 mg/kg. These results imply that the 
observations of delayed gastric emptying in turn results in AL accumulation, and the mean 
half-life of AL was correspondingly extended on the last dosing day compared to day 1 (Si 
et al., 2007). 
This report of drug accumulation is illustrated in rats dosed daily with 160 mg/kg of AL 
orally for 9 days. These rats showed moderate neurotoxicity due to prolonged oral 
absorption in the stomach. This reservoir is similar to the depot effect seen with the oil-
soluble ARTs (AM and AE) at intramuscular injection sites. The stomach contents of rats 
dosed orally with AL at 160 mg/kg daily for 9 days were examined at 8 and 24 hr after 
dosing at different time points during the study. On days 3, 5, 7, and 9, we detected 0, 46.52, 
178.59, and 486.21 µg of AL/g in the stomach contents at 8 hr after the last dose. The 
increasing amount of AL observed remaining in the stomach over the course of dosing 
showed that gastric emptying was inhibited. The inhibition of gastric emptying progressed 
from mild inhibition seen on day 5 to severe inhibition observed on day 9.  The inhibition of 
gastric emptying persisted even at 24 hr post dosing.  At twenty-four hr post dosing on days 
5, 7, and 9, we observed 5.74, 25.50, and 29.11 µg of AL/g, respectively, in the stomach 
contents. Similar anorectic toxicity was also reported in animals treated with AM, AE and 
DHA (Li et al., 1998a). It is postulated that this decrease in GI motility could result from a 
decrease in vagal tone as a consequence of a decline in sympathetic outflow (Hull & Maher 
1990; Si et al., 2007). 
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4. Lowest observed neurotoxic effect level (LONEL) as a neurotoxic indicator 
The body of literature cited supports the hypothesis that drug accumulation extends the 
drug exposure time, which we believe is a major causative factor in ART-induced 
neurotoxicity (Li et al., 2006b). The current methodology for assessing the no observed 
adverse effect level (NOAEL) involves identifying the highest concentration or dose 
administered that does not cause a statistically significant or biologically significant 
response to treatment in comparison to the control group. The lowest observed neurotoxic 
effect level (LONEL) represents the minimal plasma concentration associate with the lowest 
dose that is found to cause a neurologically and/or statistically significant response to 
treatment in comparison to the control group. Therefore, determining the neurotoxic 
exposure time (drug exposure time spent above the LONEL) is critical, and the LONEL 
should also be determined before evaluating the drug neurotoxic exposure time for each 
drug in various animals.  
4.1 Neurotoxicity induced by intramuscular AE and oral AL in rats 
A minimal daily dose of AE at 6.25 mg/kg for 7 days was estimated as a no observed 
neurotoxic effect dose (NONED), which was defined by AE dosing that did not result in 
histopathological findings in rats (Genovese et al., 1998). Significant changes of 
neuropathology in brain stem nuclei, however, were observed in a group of rats treated 
with AE at 12.5 mg/kg for 7 days.  These results demonstrate that AE-induced brainstem 
neuropathology in rats can occur at the relatively high dose of 12.5 mg/kg for 7 days. The 
lowest plasma concentration of AE in rats was shown to be 41.32 ng/ml following 
intramuscular dosing of AE at 12.5 mg/kg in previous studies (Li et al., 1999b and 2002). 
Based on the NONED value of 6.25 mg/kg obtained in previous studies, it was possible to 
correctly identify the minimal neurotoxic effect level at 41.32 ng per ml, which has thus been 
defined as a LONEL in rat plasma (Figure 2, top). Administration above this concentration 
with a certain exposure time should result in neuropathological effects (Dayan 1998; van 
Agtmael et al., 1999; Brewer et al., 1994b).  
In a PK simulation, 7 multiple AE treatments at a dose of 12.5 mg/kg were administered 
intramuscularly in rats (Li et al., 2002). The exposure time of 67.1 hr in plasma was 
estimated as the minimum time spent above the LONEL concentration of 41.32 ng/ml that 
was sufficient to induce positive neurotoxicity (Figure 2, top). After histological examination 
this estimate of 67.1 hours of AE dosing above LONEL to induce brainstem injury was 
confirmed by histopathological examination (Genovese et al., 1998) (Table 2). This finding 
confirmed the estimated LONEL (41.32 ng/ml) for AE in rats after dosing at 12.5 mg/kg for 
7 days to induce neurotoxicity based on 100% positive findings of  neuropathology (Fig. 2, 
top) (Li et al., 1999b & 2002). 
Recently, AL was shown to induce moderate neurotoxicity after treatment with 160 mg/kg 
daily for 9 days confirmed by histopathology, and a minimal neuronal degeneration was 
observed following 5 doses of AL at 288 mg/kg every other day in rats. Although the total 
dose (1440 mg/kg) and duration (9 days) were identical (Si et al., 2007), different neurotoxic 
results were observed. This observation could be due to a prolonged exposure time in the 
160 mg/kg group in comparison to the shorter time spent above the LONEL in the 
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288 mg/kg group (Table 2). Based on the minimal inhibition of gastric emptying on day 5 
and histopathological data obtained from animals treated with oral AL daily for 9 days, the 
LONEL was calculated as 346.26 ng/ml in this study (Figure 4, middle). This data 
demonstrates that AL induced moderate brainstem injury in rats at a severity of 3.25 during 
a neurotoxic exposure time of 186.0 hr at daily doses of 160 mg/kg, and AL induced 
minimal brainstem injury in rats at a severity of 1.17 during a neurotoxic exposure time of 
75.0 hr at a daily dose of 288 mg/kg dosed every other day. The reduction of the neurotoxic 
exposure time from 186.0 hrs to 75.0 hrs correlates well with the reduction of neurotoxicity 
observed between the two doses regimens.  
This study also showed that the LONEL value (346.26 ng/ml) following oral AL 
administration in rats is approximately 8-fold higher than the LONEL observed after dosing 
with intramuscular AE (41.32 ng/ml). A tissue distribution study was also conducted 
comparing the intramuscular injection of 14C-AE to intravenous administration of 14C-AL in 
rats.  The results of this study showed 0.89% total radioactivity in the brain after 14C-AE 
administration while the administration of 14C-AL in rats showed 0.1% of total radioactivity 
in the brain (Li et al., 2005a). This result suggests that 14C-labelled AL seems to be less 
capable of penetrating through the blood-brain barrier than 14C-AE. 
4.2 Neurotoxicity induced by intramuscular AE and AM in dogs 
Davidson (1994) showed that a daily dose of AE at 3 mg/kg for 28 days is a NONED that 
does not cause clinical neurotoxicity or pathology in beagles. AE-induced brainstem 
neuropathology in dogs has been detected after administration of a dose as low as 5 
mg/kg/day as shown by Brewer (1994a, 1994b, 1998), 6.25 mg/kg observed by Dayan 
(1998), and 6.75 mg/kg dosed daily for 28 days observed by Davidson (1994). Based on 
these three findings, the calculated average of the minimal dose necessary to produce 
neurotoxicity by histopathology in dogs is 6 mg/kg daily for 28 days. The minimal plasma 
concentration of AE with a dose of 6.0 mg/kg daily for 28 days has been estimated at 40.92 
ng/ml, and this value could, therefore, be defined as a LONEL in plasma. The LONEL of 
40.92 ng/ml should be the first “at risk” level for causing neurotoxicity in dogs at a daily 
dose of 6 mg/kg for 28 days (Li et al., 2006b). As a result, the LONEL for toxicity of AE in 
dogs was estimated based on all positive findings of neuropathology in these animal 
studies. 
A TK simulation of 28 repeated AE treatments at 6 mg/kg dosed intramuscularly in beagles 
was conducted, and an exposure time of 103.7 hr in plasma was estimated as a minimum 
time above the LONEL (40.92 ng/ml) to induce positive neurotoxicity, which was confirmed 
by histopathological examination (Brewer et al., 1994b; Davidson 1994; Dayan 1998) (Table 
2). The result demonstrated that AE-induced brainstem injury in dogs occurred during a 
minimal period of 103.7 hr with plasma exposure of AE above this LONEL. Therefore, the 
LONEL for neurotoxicity of AE was simulated based on 100% positive findings of 
neuropathology at a daily dose of 6 mg/kg for 28 days in beagles (Li et al., 2006b and 
2007a). 
Classen (1999) showed that a minimal daily dose of AM at 20 mg/kg given for 7 days 
caused a minimal clinical neurotoxicity or pathology in beagles. The minimal plasma 
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concentration of AM achieved after a dose of 20 mg/kg given daily for 7 days has been 
estimated at 75.69 ng/ml, and this value could, therefore, be defined as a LONEL in dog 
plasma. The LONEL of 75.69 ng/ml should be the first “at risk” level for causing 
neurotoxicity in dogs at a daily dose of 20 mg/kg for 7 days (Figure 4, top).  As a result, the 
LONEL for toxicity of AM in dogs was estimated based on all positive findings of 
neuropathology in these animals (5 out of 8 dogs). PK analyses of 7 repeated AM treatments 
of beagles at 20 and 40 mg/kg dosed intramuscularly were conducted, and  exposure times 
of 153 and 188 hrs, respectively, were estimated as a minimum time above the LONEL (75.69 
ng/ml) to induce  neurotoxicity, which was confirmed by histopathological examination 
(Table 2). The results of this study showed that AM-induced brainstem injury occurred 
during a minimal period over 153 hrs at drug plasma level above this LONEL. It is to be 
noted that the LONEL of AM (75.69 ng/ml) has been shown to be much higher than that of 
AE in beagles (40.92 ng/ml), suggesting that AE may have a higher potential for 
neurotoxicity than AM.  
4.3 Neurotoxicity induced by intramuscular AE in monkeys 
Since AE-induced brainstem neuropathology in rhesus monkeys occurred at a minimal dose 
of 8 mg/kg dosed daily for 14 days (Petras et al., 1997, 2000), the LONEL of AE was 
estimated to be 193.8 ng/ml. This estimate is based on our TK analysis conducted by dosing 
monkeys with AE at 16 mg/kg dosed daily for 14 days which should, based on a number of 
repeat dosing studies, result in evidence of AE-induced neurotoxicity (Petras et al., 1997; Li 
et al., 2006b, 2007a). By conducting TK simulations of 14 repeated AE treatments of monkeys 
dosed intramuscularly at 8 mg/kg, a neurotoxic exposure time of 179.5 hr in plasma was  
calculated as the minimum time spent above the LONEL (193.8 ng/ml) required to  induce 
pathological neurotoxicity (Figure 2, bottom). The results of this study showed that AE-
induced brainstem injury occurred during a minimal duration of 179.5 hr spent above the 
LONEL of AE (Li et al., 2006b, 2007a). The data also showed that the LONEL value of 193.8 
ng/ml in rhesus monkeys is 4-fold higher than that of rats (41.32 ng/ml) and dogs (40.92 
ng/ml), indicating that rats and dogs appear to be more vulnerable than rhesus monkeys to 
neurotoxic ART-induced toxicity.  
5. TK/TD analysis of artemisinin-induced neurotoxicity 
To determine the relationship between drug exposure time (toxicokinetics, TK) and 
neurotoxic effects (toxicodynamics, TD) after administration of ARTs in varying dose and 
time regimens, we calculated the time required for the drug plasma concentration to reach a 
neurotoxic level above the LONEL. Although the LONEL is a minimum observed 
neurotoxic effect level, a certain exposure time was required to be necessary to determine 
the neurotoxic effects in our previous studies where ARTs were shown to produce 
neurotoxicity. This process gave us an initial estimate of drug LONEL and exposure times 
and allowed us to correlate these data with observed histopathology or neurotoxic effects 
from ARTs tested in various regimens in different animal species. For the evaluation of 
toxicity, if the recovery (consisting of adaptation, repair and reversibility) half-life of an 
organism is longer than the half-life of the causative agent in the organism, then TD would 
become the rate-determining or rate-limiting step, and the organism would survive.  If the 
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288 mg/kg group (Table 2). Based on the minimal inhibition of gastric emptying on day 5 
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exposure time from 186.0 hrs to 75.0 hrs correlates well with the reduction of neurotoxicity 
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rats.  The results of this study showed 0.89% total radioactivity in the brain after 14C-AE 
administration while the administration of 14C-AL in rats showed 0.1% of total radioactivity 
in the brain (Li et al., 2005a). This result suggests that 14C-labelled AL seems to be less 
capable of penetrating through the blood-brain barrier than 14C-AE. 
4.2 Neurotoxicity induced by intramuscular AE and AM in dogs 
Davidson (1994) showed that a daily dose of AE at 3 mg/kg for 28 days is a NONED that 
does not cause clinical neurotoxicity or pathology in beagles. AE-induced brainstem 
neuropathology in dogs has been detected after administration of a dose as low as 5 
mg/kg/day as shown by Brewer (1994a, 1994b, 1998), 6.25 mg/kg observed by Dayan 
(1998), and 6.75 mg/kg dosed daily for 28 days observed by Davidson (1994). Based on 
these three findings, the calculated average of the minimal dose necessary to produce 
neurotoxicity by histopathology in dogs is 6 mg/kg daily for 28 days. The minimal plasma 
concentration of AE with a dose of 6.0 mg/kg daily for 28 days has been estimated at 40.92 
ng/ml, and this value could, therefore, be defined as a LONEL in plasma. The LONEL of 
40.92 ng/ml should be the first “at risk” level for causing neurotoxicity in dogs at a daily 
dose of 6 mg/kg for 28 days (Li et al., 2006b). As a result, the LONEL for toxicity of AE in 
dogs was estimated based on all positive findings of neuropathology in these animal 
studies. 
A TK simulation of 28 repeated AE treatments at 6 mg/kg dosed intramuscularly in beagles 
was conducted, and an exposure time of 103.7 hr in plasma was estimated as a minimum 
time above the LONEL (40.92 ng/ml) to induce positive neurotoxicity, which was confirmed 
by histopathological examination (Brewer et al., 1994b; Davidson 1994; Dayan 1998) (Table 
2). The result demonstrated that AE-induced brainstem injury in dogs occurred during a 
minimal period of 103.7 hr with plasma exposure of AE above this LONEL. Therefore, the 
LONEL for neurotoxicity of AE was simulated based on 100% positive findings of 
neuropathology at a daily dose of 6 mg/kg for 28 days in beagles (Li et al., 2006b and 
2007a). 
Classen (1999) showed that a minimal daily dose of AM at 20 mg/kg given for 7 days 
caused a minimal clinical neurotoxicity or pathology in beagles. The minimal plasma 
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concentration of AM achieved after a dose of 20 mg/kg given daily for 7 days has been 
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neurotoxicity in dogs at a daily dose of 20 mg/kg for 7 days (Figure 4, top).  As a result, the 
LONEL for toxicity of AM in dogs was estimated based on all positive findings of 
neuropathology in these animals (5 out of 8 dogs). PK analyses of 7 repeated AM treatments 
of beagles at 20 and 40 mg/kg dosed intramuscularly were conducted, and  exposure times 
of 153 and 188 hrs, respectively, were estimated as a minimum time above the LONEL (75.69 
ng/ml) to induce  neurotoxicity, which was confirmed by histopathological examination 
(Table 2). The results of this study showed that AM-induced brainstem injury occurred 
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noted that the LONEL of AM (75.69 ng/ml) has been shown to be much higher than that of 
AE in beagles (40.92 ng/ml), suggesting that AE may have a higher potential for 
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estimated to be 193.8 ng/ml. This estimate is based on our TK analysis conducted by dosing 
monkeys with AE at 16 mg/kg dosed daily for 14 days which should, based on a number of 
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calculated as the minimum time spent above the LONEL (193.8 ng/ml) required to  induce 
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ng/ml), indicating that rats and dogs appear to be more vulnerable than rhesus monkeys to 
neurotoxic ART-induced toxicity.  
5. TK/TD analysis of artemisinin-induced neurotoxicity 
To determine the relationship between drug exposure time (toxicokinetics, TK) and 
neurotoxic effects (toxicodynamics, TD) after administration of ARTs in varying dose and 
time regimens, we calculated the time required for the drug plasma concentration to reach a 
neurotoxic level above the LONEL. Although the LONEL is a minimum observed 
neurotoxic effect level, a certain exposure time was required to be necessary to determine 
the neurotoxic effects in our previous studies where ARTs were shown to produce 
neurotoxicity. This process gave us an initial estimate of drug LONEL and exposure times 
and allowed us to correlate these data with observed histopathology or neurotoxic effects 
from ARTs tested in various regimens in different animal species. For the evaluation of 
toxicity, if the recovery (consisting of adaptation, repair and reversibility) half-life of an 
organism is longer than the half-life of the causative agent in the organism, then TD would 
become the rate-determining or rate-limiting step, and the organism would survive.  If the 
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TK half-life of the compound is longer than the recovery half-life, then TK will be a rate-
determining or rate limiting step. In this scenario, the TK exposure time would be identical 
to a TD exposure time, and the organism might die. Therefore, neurotoxicity induced by 
ARTs in animals may be determined through either TD or TK/TD processes. 
5.1 Exposure time with neurotoxic effects of AE and AL in SD rats 
A neurotoxicity study was conducted to compare AE in two vehicles, sesame oil and 
cremophore (Li et al., 2002). The authors calculated the neurotoxic exposure time in rats of 
AE in sesame oil to be 164.3 hrs after dosing over the LONEL (41.32 ng/ml) during 
treatment with 25 mg/kg AE dosed intramuscularly daily for 7 days (Figure 1, top). The 
total neurotoxic exposure time of AE in a formulation of 1:2 cremophore/saline at the 
same dose regimen was 103.0 hrs. The exposure time for AE in a cremophore formulation 
was over one-third less than the exposure time observed with AE in sesame oil. 
Neurotoxicity outcomes in these rats were reduced from severe to moderate. After 
simulating the TK data on daily dosing at 12.5 mg/kg for 7 days (Li et al., 2007a), the drug 
exposure time spent over the LONEL was only 67.1 h, and the severity of 
neuropathological toxicity was further reduced to a minimum (Genovese et al., 1998), 
demonstrating that drug exposure time plays a key role that correlates with the 
development of neurotoxicity (Figure 2, top).  
In a further study, the neurotoxic exposure time (drug exposure time spent over the LONEL 
at 346.26 ng/ml) for oral AL was shown to be 186 hr which defines the exposure period 
threshold to achieve neurotoxicity (Fig. 4, middle). These results indicated a correlation 
between the neuropathology observed in rats and a prolonged AL exposure time. In this 
study, the AL exposure time was related to an accumulation of drug in plasma likely 
resulting from delayed gastric emptying, which, in turn, was hypothesized to induce 
prolonged absorption of the drug from the stomach (Si et al., 2007). When rats were treated 
intermittently with 5 doses of AL at 288 mg/kg every other day for 9 days, neuronal 
degeneration was minimal until day 7 after the last treatment (Table 2). The minimal 
exposure time required to induce neurotoxicity in these animals was calculated to be 75 hr 
(Fig. 4, bottom). The data, therefore, supports the hypothesis that shortening the drug 
exposure time above LONEL level may reduce the risk of neurotoxicity.  
The LONEL cannot be estimated for intramuscular AL and AS dosed in rats daily at 25 
mg/kg for 7 days because no neurotoxicity (pathological or/and behavioral neurotoxicity) 
was detected in those animals. PK data showed that drug accumulation in the plasma was 
not observed in these animals. The lack of AL and AS drug accumulation is likely due to 
their rapid elimination and short half-lives with clear and long time intermissions between 
each dosing without drug exposure (Figure 1, middle and bottom). Confirmation of the 
hypothesis that the short drug exposure times of AL and AS after intramuscular injection do 
not induce neurotoxicity (Table 2) is a very relevant finding as animals treated with AL and 
AS intramuscularly would likely avoid the risk of neurotoxic outcome due to a reduction of 
drug exposure times. This result suggests that the shorter exposure times of AL and AS 
without drug exposure at LONEL appears to be a major contributing factor for avoiding 
clinical neurotoxicity.  
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5.2 Exposure time with neurotoxic effects of AE, AM and AL in dogs  
Drug accumulation was also observed in the plasma of beagles after daily intramuscular 
administration of AE at 15 mg/kg for 14 days (Li et al., 2006). The mean concentration-time 
profile of AE in beagles obtained from this experiment is shown in Fig. 2 (middle). The most 
significant data observed were found to involve different parameters of the AUC and the drug 
half-lives. The elimination t½ of AE was prolonged from 9.23 hr on the first dosing day to 
21.53 hr on the last dosing day, suggesting that the exposure time of AE had nearly doubled. 
Also, the LONEL of AE (40.92 ng/ml) in beagles was first reached in that study on day 6-7 (Li 
et al., 2006b). At this time, the food intake of these animals decreased by 70%, and the QT 
interval also increased by more than 25%. We believe, based on the TK data analysis, that day 
6-7 is the earliest time possible to induce minimal neurotoxicity in beagles, which also showed 
GI toxicity, following high level AE dosing. The exposure time of AE in this 14 day study 
which induced severe neurotoxicity and death involved daily intramuscular injections of 15 
mg/kg AE in dogs was estimated to be at concentrations above the LONEL (40.92 ng/ml), and 
the exposure period was calculated to be 277.6 (Table 2).  
Although AM and AE are both oil-soluble ARTs, there are differences in the TK and TD 
profiles of these two drugs: 1) AM injection has been shown to result in  less local 
inflammatory toxicity at the muscle injection site than AE  formulated with the same 
sesame oil vehicle; 2) AM has been shown to have a significantly higher  absorption rate 
(Cmax) from intramuscular injection sites than AE; 3) AM has been shown to have  much 
higher drug exposure levels (total AUC) than AE which likely results in much less drug 
accumulation; and 4) AM has been shown to have a LONEL that is almost two fold higher 
(75.69 ng/ml) than AE (41.32 ng/ml) in beagles. Although the multiple dose levels of AM 
employed in this study were higher than those used for AE (Table 2), the AM dosing 
period of 7 days was half that of the 14 day AE dosing period. Therefore, the LONEL data 
for AM and AE would suggest that the predicted neurotoxic exposure time for AM (113.2 
– 147.8 hrs) required to induce neurotoxicity should be significantly shorter than the 
neurotoxic exposure time for AE (277.6 hrs) required to induce neurotoxicity. 
Correspondingly, the clinical observations of animals dosed with AM   showed a lower 
degree of neurotoxicity than dogs treated with AE intramuscularly (Table 2). This finding 
supports the hypothesis that intramuscular AM treatment is less prone to induce 
neurotoxicity in animals than intramuscular AE.             
The neurotoxic exposure time spent above the LONEL after oral AL dosing (346.26 ng/ml) 
in dogs was calculated to be 17.9 hr for a suspension formulation of AL (Li et al., 2005b) and 
14.6 hr for a capsule formulation of AL both dosed at 25 mg/kg daily for 14 days (Table 2). 
Similar to intramuscular administration, animals treated with oral AL did not show any 
evidence of induction of neurotoxicity due to the shorter drug exposure times above the 
LONEL. The drug exposure times observed for AL were much shorter than the neurotoxic 
exposure time above the LONEL of 75.0 h, which is required to induce a minimal 
pathological neurotoxicity in rats (Table 2).  
5.3 Exposure time with neurotoxic effects of AE in rhesus monkeys 
Substantial plasma accumulation of AE was shown in the plasma of rhesus monkeys after 
daily intramuscular administration of AE at 16 mg/kg for 14 days (Fig. 2, bottom). Based on 
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was over one-third less than the exposure time observed with AE in sesame oil. 
Neurotoxicity outcomes in these rats were reduced from severe to moderate. After 
simulating the TK data on daily dosing at 12.5 mg/kg for 7 days (Li et al., 2007a), the drug 
exposure time spent over the LONEL was only 67.1 h, and the severity of 
neuropathological toxicity was further reduced to a minimum (Genovese et al., 1998), 
demonstrating that drug exposure time plays a key role that correlates with the 
development of neurotoxicity (Figure 2, top).  
In a further study, the neurotoxic exposure time (drug exposure time spent over the LONEL 
at 346.26 ng/ml) for oral AL was shown to be 186 hr which defines the exposure period 
threshold to achieve neurotoxicity (Fig. 4, middle). These results indicated a correlation 
between the neuropathology observed in rats and a prolonged AL exposure time. In this 
study, the AL exposure time was related to an accumulation of drug in plasma likely 
resulting from delayed gastric emptying, which, in turn, was hypothesized to induce 
prolonged absorption of the drug from the stomach (Si et al., 2007). When rats were treated 
intermittently with 5 doses of AL at 288 mg/kg every other day for 9 days, neuronal 
degeneration was minimal until day 7 after the last treatment (Table 2). The minimal 
exposure time required to induce neurotoxicity in these animals was calculated to be 75 hr 
(Fig. 4, bottom). The data, therefore, supports the hypothesis that shortening the drug 
exposure time above LONEL level may reduce the risk of neurotoxicity.  
The LONEL cannot be estimated for intramuscular AL and AS dosed in rats daily at 25 
mg/kg for 7 days because no neurotoxicity (pathological or/and behavioral neurotoxicity) 
was detected in those animals. PK data showed that drug accumulation in the plasma was 
not observed in these animals. The lack of AL and AS drug accumulation is likely due to 
their rapid elimination and short half-lives with clear and long time intermissions between 
each dosing without drug exposure (Figure 1, middle and bottom). Confirmation of the 
hypothesis that the short drug exposure times of AL and AS after intramuscular injection do 
not induce neurotoxicity (Table 2) is a very relevant finding as animals treated with AL and 
AS intramuscularly would likely avoid the risk of neurotoxic outcome due to a reduction of 
drug exposure times. This result suggests that the shorter exposure times of AL and AS 
without drug exposure at LONEL appears to be a major contributing factor for avoiding 
clinical neurotoxicity.  
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period of 7 days was half that of the 14 day AE dosing period. Therefore, the LONEL data 
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– 147.8 hrs) required to induce neurotoxicity should be significantly shorter than the 
neurotoxic exposure time for AE (277.6 hrs) required to induce neurotoxicity. 
Correspondingly, the clinical observations of animals dosed with AM   showed a lower 
degree of neurotoxicity than dogs treated with AE intramuscularly (Table 2). This finding 
supports the hypothesis that intramuscular AM treatment is less prone to induce 
neurotoxicity in animals than intramuscular AE.             
The neurotoxic exposure time spent above the LONEL after oral AL dosing (346.26 ng/ml) 
in dogs was calculated to be 17.9 hr for a suspension formulation of AL (Li et al., 2005b) and 
14.6 hr for a capsule formulation of AL both dosed at 25 mg/kg daily for 14 days (Table 2). 
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evidence of induction of neurotoxicity due to the shorter drug exposure times above the 
LONEL. The drug exposure times observed for AL were much shorter than the neurotoxic 
exposure time above the LONEL of 75.0 h, which is required to induce a minimal 
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Substantial plasma accumulation of AE was shown in the plasma of rhesus monkeys after 
daily intramuscular administration of AE at 16 mg/kg for 14 days (Fig. 2, bottom). Based on 
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the minimal injury observed to the neuronal tissues in the monkeys treated with 8 mg/kg 
daily for 14 days, it was possible to correctly identify 193.8 ng/ml as the LONEL (Li & 
Hickman, 2011). The neurotoxic exposure period of AE was calculated as 307.4 hr in this 
study following daily intramuscular injection of 16 mg/kg for 14 days in monkeys with 
moderate neurotoxicity (Petras et al., 1997 and 2000) (Table 2). This calculation was based on 
the estimated exposure time of AE above the LONEL concentration (193.8 ng/ml). The 
rhesus monkeys treated with intramuscular AE at 8 mg/kg daily for 14 days showed that 
the drug exposure time spent above LONEL with minimal pathological toxicity was 
estimated at 179.5 hr, which was shorter than the exposure time (307.4 hr) from a previous 
study following daily intramuscular administration of AE at 16 mg/kg for 14 days (Li et al., 
2006b). The longer neurotoxic exposure time is likely the key factor involved in the 
induction of neurotoxicity in rhesus monkeys (Li et al., 2007a).       
6. Neurotoxic consideration of ARTs in antimalarial and anticancer 
treatments 
Though no animal model exists capable of completely mimicking ARTs-induced 
neurotoxicity, the comparison of monkeys to humans is the closest that can be achieved. 
With animal experiments, only certain aspects of the whole complex TK/TD environment 
can be analyzed. In order to achieve the best prediction of neurotoxicity based on TK/TD 
parameters, the choice of animals and experimental design requires careful consideration to 
represent the conditions existing in humans in as suitable a model as possible. The more the 
model deviates from human TK/TD conditions, the less likely the prediction will be 
relevant. Today more information is available on the TK/TD properties of ARTs in animals. 
This body of literature will provide data on the neurotoxic doses of ARTs and on their non–
neurotoxic doses relevant to man.  
Studies with laboratory animals have demonstrated fatal neurotoxicity associated with 
intramuscular administration of AM and AE or oral administration of AL. These effects 
suggest that the exposure time of ARTs was extended in these studies due to the 
accumulation of drug in the bloodstream, and this accumulation, in turn, resulted in 
neurotoxicity. In our previous studies, the drug exposure time with a neurotoxic outcome 
(neurotoxic exposure time) was evaluated as a predictor of neurotoxicity in vivo (Li & 
Hickman, 2011). The neurotoxic exposure time represents a total time spent above the 
lowest observed neurotoxic effect levels (LONEL) in plasma. The effects of ARTs do vary in 
different animal species. For example, the dose of AE required to induce minimal 
neurotoxicity requires a 2-3 fold longer exposure time in rhesus monkeys (179.5 hr) than in 
rats (67.1 hr) and dogs (103.7 hr) when using a daily dose of 6-12.5 mg/kg for 7-28 days. 
This finding suggests that the safe drug dosing of LONEL duration in monkeys should be 
longer than 7.0 days (> 168 hrs) under this exposure.  
In addition, the effects of ARTs vary from compound to compound. For example the 
LONEL for intramuscular AM required to induce neurotoxicity (75.69 ng/ml)  is twice as 
high as the LONEL for intramuscular AE required to induce neurotoxicity (40.92 ng/ml). 
Oral AL treatment required a LONEL to induce neurotoxicity (346.26 ng/ml) that is 4-fold 
higher than the LONEL of AM required to induce neurotoxicity (75.69 ng/ml) and 8-fold 
higher than the LONEL of AE (40.92 ng/ml), required to induce neurotoxicity. A 
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determination of LONEL for oral and injectable AS was not possible because no 
neurotoxicity was observed in  animals treated with various AS dose regimens, 
suggesting that water-soluble ARTs (AS and AL) appear to be much safer than oil-soluble 
ARTs.  
The various animal species treated with different ARTs clearly show the different 
neurotoxic effects associated with corresponding exposure times.  The current marketed 
drugs for ART therapy are based on oral administration of drug and combination 
therapies to malaria patients. Oral administration results in lower peak concentrations 
and shorter exposure times which is less likely to induce neurotoxicity than intramuscular 
ARTs. Since more than 99% of malaria patients have been treated with oral ARTs or 
intravenous AS, this may be the reason for the lack of neurotoxicity observed in malaria 
patients. When relating the animal and human neurotoxicity of ARTs, the different 
neurotoxic exposure times may possibly provide a greater margin of safety in humans. 
The current clinical dose regimens of three-day ART combined therapies (ACTs) for 
uncomplicated cases of malaria, and the dose regimens recommended for intravenous AS 
treatments for severe malaria, which include a few days of a loading dose, may be too 
short of a drug exposure time to induce neurotoxicity in humans. Also, with regard to 
acute toxicity, humans appear to be less sensitive than animals (Geyer et al., 1990; 
Kimbrough 1990), and humans have much better repair capabilities than animals to 
respond to such toxicity (Culotta & Koshland 1994).  
Although the water-soluble ARTs, like AS, appear to be much safer, further study is 
needed when employing ARTs as anticancer agents (Li & Hickman, 2011). At high 
concentrations, ARTs appear to be active against cancer in vivo. The use of ARTs at high 
concentrations or for long drug exposure times, however, has substantial risk of inducing 
severe toxicities, such as the neurotoxic effects we have described here. Animal studies 
have shown that high concentrations of AS and DHA can induce embryotoxicity, and 
longer exposure times have been shown to be associated with fatal neurotoxicity (Li et al., 
2007a). To provide maximum benefit and minimal risk of toxicity, ARTs should be 
combined with other anticancer agents to increase the efficacy of cancer drugs, enhance 
the survival rate of patients with cancer, and prolong the time to progression (Zhang et 
al., 2008). The diversity in targets of ARTs supports the possibility that these compounds 
could be used in combination with other agents, which mimics the current strategy 
promoted by the WHO as policy recommendations on the use of ARTs for malaria 
therapy (WHO 2006).  
7. Conclusion 
Studies with laboratory animals have demonstrated neurotoxicity following administration 
of some intramuscular doses of oil-soluble AM and AE, or intragastric treatment of water-
soluble AL. The various PK studies of ARTs conducted using numerous animal models 
show that the drug exposure time appears to be a more important factor than other PK 
parameters measured for inducing neurotoxicity. There are significant differences in 
neurotoxicity observed when comparing the effects of ARTs on rats, dogs and monkeys 
suggesting that the exposure time required inducing neurotoxicity after dosing with ARTs is 
likely to be longer in humans. Extensive TK/TD analyses of neurotoxicity after ART 
treatment of rats, dogs, and monkeys have provided a wealth of data which can be used to 
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estimated at 179.5 hr, which was shorter than the exposure time (307.4 hr) from a previous 
study following daily intramuscular administration of AE at 16 mg/kg for 14 days (Li et al., 
2006b). The longer neurotoxic exposure time is likely the key factor involved in the 
induction of neurotoxicity in rhesus monkeys (Li et al., 2007a).       
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can be analyzed. In order to achieve the best prediction of neurotoxicity based on TK/TD 
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represent the conditions existing in humans in as suitable a model as possible. The more the 
model deviates from human TK/TD conditions, the less likely the prediction will be 
relevant. Today more information is available on the TK/TD properties of ARTs in animals. 
This body of literature will provide data on the neurotoxic doses of ARTs and on their non–
neurotoxic doses relevant to man.  
Studies with laboratory animals have demonstrated fatal neurotoxicity associated with 
intramuscular administration of AM and AE or oral administration of AL. These effects 
suggest that the exposure time of ARTs was extended in these studies due to the 
accumulation of drug in the bloodstream, and this accumulation, in turn, resulted in 
neurotoxicity. In our previous studies, the drug exposure time with a neurotoxic outcome 
(neurotoxic exposure time) was evaluated as a predictor of neurotoxicity in vivo (Li & 
Hickman, 2011). The neurotoxic exposure time represents a total time spent above the 
lowest observed neurotoxic effect levels (LONEL) in plasma. The effects of ARTs do vary in 
different animal species. For example, the dose of AE required to induce minimal 
neurotoxicity requires a 2-3 fold longer exposure time in rhesus monkeys (179.5 hr) than in 
rats (67.1 hr) and dogs (103.7 hr) when using a daily dose of 6-12.5 mg/kg for 7-28 days. 
This finding suggests that the safe drug dosing of LONEL duration in monkeys should be 
longer than 7.0 days (> 168 hrs) under this exposure.  
In addition, the effects of ARTs vary from compound to compound. For example the 
LONEL for intramuscular AM required to induce neurotoxicity (75.69 ng/ml)  is twice as 
high as the LONEL for intramuscular AE required to induce neurotoxicity (40.92 ng/ml). 
Oral AL treatment required a LONEL to induce neurotoxicity (346.26 ng/ml) that is 4-fold 
higher than the LONEL of AM required to induce neurotoxicity (75.69 ng/ml) and 8-fold 
higher than the LONEL of AE (40.92 ng/ml), required to induce neurotoxicity. A 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 349 
determination of LONEL for oral and injectable AS was not possible because no 
neurotoxicity was observed in  animals treated with various AS dose regimens, 
suggesting that water-soluble ARTs (AS and AL) appear to be much safer than oil-soluble 
ARTs.  
The various animal species treated with different ARTs clearly show the different 
neurotoxic effects associated with corresponding exposure times.  The current marketed 
drugs for ART therapy are based on oral administration of drug and combination 
therapies to malaria patients. Oral administration results in lower peak concentrations 
and shorter exposure times which is less likely to induce neurotoxicity than intramuscular 
ARTs. Since more than 99% of malaria patients have been treated with oral ARTs or 
intravenous AS, this may be the reason for the lack of neurotoxicity observed in malaria 
patients. When relating the animal and human neurotoxicity of ARTs, the different 
neurotoxic exposure times may possibly provide a greater margin of safety in humans. 
The current clinical dose regimens of three-day ART combined therapies (ACTs) for 
uncomplicated cases of malaria, and the dose regimens recommended for intravenous AS 
treatments for severe malaria, which include a few days of a loading dose, may be too 
short of a drug exposure time to induce neurotoxicity in humans. Also, with regard to 
acute toxicity, humans appear to be less sensitive than animals (Geyer et al., 1990; 
Kimbrough 1990), and humans have much better repair capabilities than animals to 
respond to such toxicity (Culotta & Koshland 1994).  
Although the water-soluble ARTs, like AS, appear to be much safer, further study is 
needed when employing ARTs as anticancer agents (Li & Hickman, 2011). At high 
concentrations, ARTs appear to be active against cancer in vivo. The use of ARTs at high 
concentrations or for long drug exposure times, however, has substantial risk of inducing 
severe toxicities, such as the neurotoxic effects we have described here. Animal studies 
have shown that high concentrations of AS and DHA can induce embryotoxicity, and 
longer exposure times have been shown to be associated with fatal neurotoxicity (Li et al., 
2007a). To provide maximum benefit and minimal risk of toxicity, ARTs should be 
combined with other anticancer agents to increase the efficacy of cancer drugs, enhance 
the survival rate of patients with cancer, and prolong the time to progression (Zhang et 
al., 2008). The diversity in targets of ARTs supports the possibility that these compounds 
could be used in combination with other agents, which mimics the current strategy 
promoted by the WHO as policy recommendations on the use of ARTs for malaria 
therapy (WHO 2006).  
7. Conclusion 
Studies with laboratory animals have demonstrated neurotoxicity following administration 
of some intramuscular doses of oil-soluble AM and AE, or intragastric treatment of water-
soluble AL. The various PK studies of ARTs conducted using numerous animal models 
show that the drug exposure time appears to be a more important factor than other PK 
parameters measured for inducing neurotoxicity. There are significant differences in 
neurotoxicity observed when comparing the effects of ARTs on rats, dogs and monkeys 
suggesting that the exposure time required inducing neurotoxicity after dosing with ARTs is 
likely to be longer in humans. Extensive TK/TD analyses of neurotoxicity after ART 
treatment of rats, dogs, and monkeys have provided a wealth of data which can be used to 
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predict the neurotoxic exposure time of ARTs in humans. Based on the dose amounts of 
ARTs used in various experiments to induce neurotoxicity we would rank the ARTs in 
terms of toxic potential with AE being the most toxic followed in order by AM, AL, and 
lastly by AS. There is a strong correlation between the drug half-lives of ARTs and the 
severity of neurotoxicity observed after treatment which supports the hypothesis that the 
drug exposure time during treatment plays a very important role in the induction of 
neurotoxicity. 
In the this chapter, the lowest observed neurotoxic effect level (LONEL) represents the 
minimal plasma concentration associated with the lowest dose that is found to cause a 
neurologically and/or statistically significant response to treatment in comparison to the 
control group. Based on the determination of the LONEL in various animal species for 
ARTs, the neurotoxic exposure time (drug exposure time spent above the LONEL) was 
evaluated. Our analysis of this data leads us to the prediction that the safe dosing duration 
of AE or AM in humans should be longer than 7 days (> 168 hr), and the safe dosing 
duration of AS therapy is likely much longer than that. Accordingly, the 3-5 days dosing 
duration currently used in antimalarial therapy of ARTs should be quite safe. Neurotoxicity 
may be caused in humans, however, treated with inappropriate dose regimens, and 
therefore, evaluation of the sustained drug exposure times appears to be the critical factor to 
assess and prevent neurotoxicity. Advances in our knowledge of ART-induced 
neurotoxicity can help refine the treatment regimens used as therapies for malaria and 
cancer with ART-based combination therapy and injectable AS products to avoid drug 
accumulation and reduce the risk of toxicity.  
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predict the neurotoxic exposure time of ARTs in humans. Based on the dose amounts of 
ARTs used in various experiments to induce neurotoxicity we would rank the ARTs in 
terms of toxic potential with AE being the most toxic followed in order by AM, AL, and 
lastly by AS. There is a strong correlation between the drug half-lives of ARTs and the 
severity of neurotoxicity observed after treatment which supports the hypothesis that the 
drug exposure time during treatment plays a very important role in the induction of 
neurotoxicity. 
In the this chapter, the lowest observed neurotoxic effect level (LONEL) represents the 
minimal plasma concentration associated with the lowest dose that is found to cause a 
neurologically and/or statistically significant response to treatment in comparison to the 
control group. Based on the determination of the LONEL in various animal species for 
ARTs, the neurotoxic exposure time (drug exposure time spent above the LONEL) was 
evaluated. Our analysis of this data leads us to the prediction that the safe dosing duration 
of AE or AM in humans should be longer than 7 days (> 168 hr), and the safe dosing 
duration of AS therapy is likely much longer than that. Accordingly, the 3-5 days dosing 
duration currently used in antimalarial therapy of ARTs should be quite safe. Neurotoxicity 
may be caused in humans, however, treated with inappropriate dose regimens, and 
therefore, evaluation of the sustained drug exposure times appears to be the critical factor to 
assess and prevent neurotoxicity. Advances in our knowledge of ART-induced 
neurotoxicity can help refine the treatment regimens used as therapies for malaria and 
cancer with ART-based combination therapy and injectable AS products to avoid drug 
accumulation and reduce the risk of toxicity.  
8. Acknowledgments 
This report was supported by the United States Army Research and Materiel Command. 
The opinions or assertions contained herein are the private views of the author and are not 
to be construed as official, or as reflecting true views of the Department of the Army or the 
Department of Defense.  
9. References 
van Agtmael, M.A., Cheng-Qi, S., Qing, J.X., Mull, R., van Boxtel, C.J. (1999) Multiple dose 
pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum 
malaria. Int. J. Antimicrob Agents. 12, 151-158. 
Angus, B.J., Thaiaporn, I., Chanthapadith, K., Suputtamongkol, Y., White, N.J. (2002) Oral 
artesunate dose-response relationship in acute falciparum malaria. Antimicrob 
Agents Chemother. 46, 778-782. 
Ashton, M., Sy, N.D., Gordi, T., Hai, T.N., Thach, D.C., Huong, N.V., Johansson, M., Coeng, 
L.D. (1996) Evidence for time-dependence artemisinin kinetics in adults with 
uncomplicated malaria. Pharm Pharmacol Lett. 6, 127-130. 
Ashton, M., Hai, T.N., Sy, N.D., Huong, D.X., Van Huong, N., Nieu, N.T., Cong, L.D. (1998) 
Artemisinin pharmacokinetics is time-dependent during repeated oral 
administration in healthy male adults. Drug Metab Dispos. 26, 25-27.  
Batty, K.T., Thu, L.T., Davis, T.M., Ilett, K.F., Mai, T.X., Hung, N.C., Tien, N.P., Powell, S.M., 
Thien, H.V., Binh, T.Q., Kim, N.V. (1998) A pharmacokinetic and 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 351 
pharmacodynamic study of intravenous vs oral artesunate in uncomplicated 
falciparum malaria. Br. J. Clin. Pharmacol. 45, 123-129. 
Brewer, T.G., Grate, S.J., Peggins, J.O., Weina, P.J., Petras, J.M., Levine, B.S., Heiffer, M.H., 
Schuster, B.G. (1994a) Fatal neurotoxicity of arteether and artemether. Am. J. Trop. 
Med. Hyg. 51, 251-259. 
Brewer, T.G., Peggins, J.O., Grate, S.J., Petras, J.M., Levine, B.S., Weina, P.J., Swearengen, J., 
Heiffer, M.H., Schuster, B.G. (1994b) Neurotoxicity in animals due to arteether and 
artemether. Trans. R Soc. Trop. Med. Hyg. 88 (Suppl, 1), S33-36. 
Brewer, T.G., Genovese, R.F., Newman, D.B., Li, Q.G., 1998. Factors relating to neurotoxicity 
of artemisinin antimalarial drugs "listening to arteether". Med. Trop. (Mars). 58(3 
Suppl), 22-27. 
China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials. 
(1982) Metabolism and pharmacokinetics of qinghaosu and its derivatives.  J. Trad. 
Chin. Med, 2, 25-30. 
Classen, W., Altmann, B., Gretener, P., Souppart, C., Skelton-Stroud, P., Krinke, G. (1999) 
Differential effects of orally versus parenterally administered qinghaosu 
derivatives artemether in dogs. Exp. Toxicol. Pathol. 51, 507-516. 
Culotta, E., Koshland, D.E Jr. (1994) DNA repair works it works its way to the top. Science. 
266(5193), 1926-1929. 
Davis, T.M., Phuong, H.L., Ilett, K.F., Hung, N.C., Batty, K.T., Phuong, V.D., Powell, S.M., 
Thien, H.V., Binh, T.Q. (2001) Pharmacokinetics and pharmacodynamics of 
intravenous artesunate in severe falciparum malaria. Antimicrob Agents 
Chemother. 45, 181-186. 
Davis, T.M., Binh, T.Q., Ilett, K.F., Batty, K.T., Phuong, H.L., Chiswell, G.M., Phuong, V.D., 
Agus, C. (2003)  Penetration of dihydroartemisinin into cerebrospinal fluid after 
administration of intravenous artesunate in severe falciparum malaria. Antimicrob 
Agents Chemother. 47, 368-370.   
Davidson, D.E. (1994) Role of arteether in the treatment of malaria and plans for further 
development. Trans. R Soc. Trop. Med. Hyg. 88 Suppl, 1, S51-52. 
Dayan, A.D. (1998) Neurotoxicity and artemisinin compounds do the observations in 
animals justify limitation of clinical use? Med Trop (Mars). 58(3 Suppl), 32-37. 
Efferth, T., Kaina, B. (2010) Toxicity of the antimalarial artemisinin and its derivatives. Crit. 
Rev. Toxicol. 16, 1-17. 
Elias, Z., Bonnet, E., Marchou, B., Massip, P. (1999) Neurotoxicity of artemisinin: possible 
counseling and treatment of side effects. Clin. Infect. Dis. 28, 1330-1331. 
Fishwick , J., McLean, W.G., Edwards, G., Ward, S.A. (1995) The toxicity of artemisinin and 
related compounds on neuronal and glial cells in culture. Chem. Biol. Interact. 96, 
263-271. 
Franco-Paredes, C., Dismukes, R., Nicolls, D., Kozarsky, P.E. (2005) Neurotoxicity due to 
antimalarial therapy associated with misdiagnosis of malaria. Clin. Infect. Dis. 40, 
1710-1711. 
Gachot, B., Eliaszewicz, M., Dupont, B. (1997) Artesunate and cerebellar dysfunction in 
falciparum malaria. N. Engl. J. Med. 337, 792-793. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 352 
Genovese, R.F., Petras, J.M., Brewer, T.G. (1995) Arteether neurotoxicity in the absence of 
deficits in behavioural performance in rats. Ann. Trop. Med. Parasitol. 89, 447-449. 
Genovese, R.F., Newman, D.B., Li, Q.G., Peggins, J.O., Brewer, T.G. (1998) Dose-dependent 
brainstem neuropathology following repeated arteether administration in rats. 
Brain Res. Bull. 45, 199-202. 
Genovese, R.F., Newman, D.B., Brewer, T.G. (2000) Behavioral and neural toxicity of the 
artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. 
Pharmacol. Biochem. Behav. 67, 37-44. 
Geyer, H.J., Scheuntert, I., Rapp, K., Kettrup, A., Korte, F., Greim, H., Rozman, K. (1990) 
Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
and total body fat content in mammals. Toxicology 65, 97-107. 
Haq, M.Z., Mishra, B.R., Goyal, N., Sinha, V.K. (2009)  alpha/beta-Arteether-induced mania 
in a predisposed adolescent. Gen. Hosp. Psychiatry. 31, 391-393. 
Hull, K.M., Maher, T.J. (1990) L-Tyrosine potentiates the anorexia induced by mixed- 
acting sympathomimetic drugs in hyperphagic rats. J. Pharmacol. Exp. Ther. 255, 
403-409. 
Jiang, J.R., Zou, C.D. Shu, H.L., Zeng, Y.L. (1989) Assessment of absorption and distribution 
of artemether in rats using a thin layer chromatography scanning technique. 
Zhongguo Yao Li Xue Bao. 10, 431-434. 
Jorgensen, R.J. (1980) Dictyocaulus viviparous: Migration in agar of larvae subjected to a 
variety of physicochemical exposure. Exp Parasit. 49, 106-115. 
Kager, P.A., Schultz, M.J., .Zijlstra, E.E., van Berg, B., van Boxtel, Ch.J. (1994) Arteether 
administration in humans: preliminary studies of pharmacokinetics, safety and 
tolerance. Trans. R. Soc. Trop. Med. Hyg. 88 (Suppl 1), S53-54. 
Kamchonwongpaisan, S., McKeever, P., Hossler, P., Ziffer, H., Meshnick, S.R. (1997) 
Artemisinin neurotoxicity: Neuropathology in rats and mechanistic studies in vitro. 
Am. J. Trop. Med. Hyg. 56, 7-12. 
Karbwang, J., Na-Bangchang, K., Wattanakoon, Y., Thanavibul, A., Harinasuta, T. (1994) 
Artemether 5 versus 7 day regimen for severe falciparum malaria. Southeast Asian 
J Trop. Med. Public Health. 25, 702-706. 
Kearney, B.P., Aweeka, F.T. (1999) The penetration of anti-infectives into the central nervous 
system. Neurol Clin. 17, 883-900.   
Khanh, N.X., de Vries, P.J., Ha, L.D., van Boxtel, C.J., Koopmans, R., Kager, P.A. (1999) 
Declining concentrations of dihydroartemisinin in plasma during 5-day oral 
treatment with artesunate for falciparum malaria. Antimicrob Agents Chemother. 
43, 690-692. 
Kimbrough, R.D. (1990) How toxic is 2,3,7,8-tetrachlorodibenzodioxin to humans? J. Toxicol. 
Environ. Health. 30, 261-271. 
Li, Q., Peggens, J.O., Brown, L.D., Brewer, T.G. (1994) Pharmacokinetics and hydrolysis of 
sodium artelinate in dogs. AM. J. Trop. Med. Hyg. 51, 260. 
Li, Q., Peggins, J.O. (1998a) Anorectic toxicity of dihydroartemisinin, arteether and 
artemether in rats following multiple intramuscular doses. Int. J. Toxicol. 17, 663-
676. 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 353 
Li, Q., Peggins, J.O., Fleckenstein, L.L., Masonic, K., Heiffer, M.H., Brewer, T.G. (1998b) The 
pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, 
artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50, 173-182. 
Li, Q., Peggins, J.O., Lin, A.J., Masonic, K., Trotman, K.M., Brewer, T.G. (1998c) 
Pharmacology and toxicology of artelinic acid: Preclinical investigation on 
pharmacokinetics, metabolism, protein and RBC binding, acute and anorectic 
toxicities. Trans. R. Soc. Trop. Med. Hyg. 92, 332-340. 
Li, Q. Carpenter, C., Trotman, C., Kathcart, A.K., Donahue, R., Milhous, W.K. (1999a) 
Pharmacokinetic comparison of artesunate and dihydroartemisinin in beagle dogs. 
Am. J. Trol. Med. Hyg. 61, 274. 
Li, Q., Brueckner, R.P., Peggins, J.O., Trotman, K.M., Brewer, T.G. (1999b) Arteether 
toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and 
multiple doses. Eur. J. Drug Metab. Pharmacokinet. 24, 213-223. 
Li, Q., Bossone, C.A., Ohrt, C., Chung, H., Harris, D., Harre, J., Lee, P., Kathcart, A.K., 
Brueckner, R.P. (2000) Early signs and biomarkers of neurotoxicity: toxicokinetic 
and toxicodynamic evaluation following 15-mg/kg arteether daily intramuscular 
injections for two weeks in beagle dogs. Am. J. Trol. Med. Hyg. 62, 142. 
Li, Q., Mog, S.R., Si, Y.Z., Kyle, D.E., Gettayacamin, M., Milhous, W.K. (2002) Neurotoxicity 
and efficacy of arteether related to its exposure times and exposure levels in 
rodents. Am. J. Trop. Med. Hyg. 66, 516-525.  
Li, Q., Lugt, C.B., Looareesuwan, S., Krudsood, S., Wilairatana, P., Vannaphan, S., 
Chalearmrult, K., Milhous, W.K. (2004) Pharmacokinetic investigation on the 
therapeutic potential of artemotil (beta-arteether) in Thai patients with severe 
Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 71, 723-731. 
Li, Q., Xie, L.H., Si, Y., Wong, E., Upadhyay, R., Yanez, D., Weina, P.J. (2005a) Toxicokinetics 
and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 
24, 241-250. 
Li, Q., Milhous, W.K., Weina, P.J. (2005b) Regimen strategy to decrease artemisinin  
agents related failure and recrudescence in severe and complicated malaria 
treatment. Medicine and Health in the Tropics (Marseille-France) Abstract Book 
2005, 131. 
Li, Q., Xie, L.H., Haeberle, A., Zhang, J., Weina, P. (2006a) The evaluation of radiolabeled 
artesunate on tissue distribution in rats and protein binding in humans. Am. J. 
Trop. Med. Hyg. 75, 817-826. 
Li, Q., Milhous, W.K., Weina, P.J. (2006b) Fatal neurotoxicity of the artemisinin derivatives  
is related to drug pharmacokinetic profiles in animals. Curr. Topics Toxicol, 3,  
1-16. 
Li, Q., Milhous, W.K., Weina, P.J. (2007a) Antimalarial in Malaria Therapy. 1st edition. Nova 
Science Publishers Inc, New York, pp. 1-133. 
Li, Q., Gerena, L., Xie, L.H., Zhang, J., Kyle, D.E., Milhous, W.K. (2007b) Development and 
validation of flow cytometric measurement for parasitemia in cultures of P. 
falciparum vitally stained with YOYO-1. Cytometry Part A. 71A, 297-307. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 352 
Genovese, R.F., Petras, J.M., Brewer, T.G. (1995) Arteether neurotoxicity in the absence of 
deficits in behavioural performance in rats. Ann. Trop. Med. Parasitol. 89, 447-449. 
Genovese, R.F., Newman, D.B., Li, Q.G., Peggins, J.O., Brewer, T.G. (1998) Dose-dependent 
brainstem neuropathology following repeated arteether administration in rats. 
Brain Res. Bull. 45, 199-202. 
Genovese, R.F., Newman, D.B., Brewer, T.G. (2000) Behavioral and neural toxicity of the 
artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. 
Pharmacol. Biochem. Behav. 67, 37-44. 
Geyer, H.J., Scheuntert, I., Rapp, K., Kettrup, A., Korte, F., Greim, H., Rozman, K. (1990) 
Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
and total body fat content in mammals. Toxicology 65, 97-107. 
Haq, M.Z., Mishra, B.R., Goyal, N., Sinha, V.K. (2009)  alpha/beta-Arteether-induced mania 
in a predisposed adolescent. Gen. Hosp. Psychiatry. 31, 391-393. 
Hull, K.M., Maher, T.J. (1990) L-Tyrosine potentiates the anorexia induced by mixed- 
acting sympathomimetic drugs in hyperphagic rats. J. Pharmacol. Exp. Ther. 255, 
403-409. 
Jiang, J.R., Zou, C.D. Shu, H.L., Zeng, Y.L. (1989) Assessment of absorption and distribution 
of artemether in rats using a thin layer chromatography scanning technique. 
Zhongguo Yao Li Xue Bao. 10, 431-434. 
Jorgensen, R.J. (1980) Dictyocaulus viviparous: Migration in agar of larvae subjected to a 
variety of physicochemical exposure. Exp Parasit. 49, 106-115. 
Kager, P.A., Schultz, M.J., .Zijlstra, E.E., van Berg, B., van Boxtel, Ch.J. (1994) Arteether 
administration in humans: preliminary studies of pharmacokinetics, safety and 
tolerance. Trans. R. Soc. Trop. Med. Hyg. 88 (Suppl 1), S53-54. 
Kamchonwongpaisan, S., McKeever, P., Hossler, P., Ziffer, H., Meshnick, S.R. (1997) 
Artemisinin neurotoxicity: Neuropathology in rats and mechanistic studies in vitro. 
Am. J. Trop. Med. Hyg. 56, 7-12. 
Karbwang, J., Na-Bangchang, K., Wattanakoon, Y., Thanavibul, A., Harinasuta, T. (1994) 
Artemether 5 versus 7 day regimen for severe falciparum malaria. Southeast Asian 
J Trop. Med. Public Health. 25, 702-706. 
Kearney, B.P., Aweeka, F.T. (1999) The penetration of anti-infectives into the central nervous 
system. Neurol Clin. 17, 883-900.   
Khanh, N.X., de Vries, P.J., Ha, L.D., van Boxtel, C.J., Koopmans, R., Kager, P.A. (1999) 
Declining concentrations of dihydroartemisinin in plasma during 5-day oral 
treatment with artesunate for falciparum malaria. Antimicrob Agents Chemother. 
43, 690-692. 
Kimbrough, R.D. (1990) How toxic is 2,3,7,8-tetrachlorodibenzodioxin to humans? J. Toxicol. 
Environ. Health. 30, 261-271. 
Li, Q., Peggens, J.O., Brown, L.D., Brewer, T.G. (1994) Pharmacokinetics and hydrolysis of 
sodium artelinate in dogs. AM. J. Trop. Med. Hyg. 51, 260. 
Li, Q., Peggins, J.O. (1998a) Anorectic toxicity of dihydroartemisinin, arteether and 
artemether in rats following multiple intramuscular doses. Int. J. Toxicol. 17, 663-
676. 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 353 
Li, Q., Peggins, J.O., Fleckenstein, L.L., Masonic, K., Heiffer, M.H., Brewer, T.G. (1998b) The 
pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, 
artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50, 173-182. 
Li, Q., Peggins, J.O., Lin, A.J., Masonic, K., Trotman, K.M., Brewer, T.G. (1998c) 
Pharmacology and toxicology of artelinic acid: Preclinical investigation on 
pharmacokinetics, metabolism, protein and RBC binding, acute and anorectic 
toxicities. Trans. R. Soc. Trop. Med. Hyg. 92, 332-340. 
Li, Q. Carpenter, C., Trotman, C., Kathcart, A.K., Donahue, R., Milhous, W.K. (1999a) 
Pharmacokinetic comparison of artesunate and dihydroartemisinin in beagle dogs. 
Am. J. Trol. Med. Hyg. 61, 274. 
Li, Q., Brueckner, R.P., Peggins, J.O., Trotman, K.M., Brewer, T.G. (1999b) Arteether 
toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and 
multiple doses. Eur. J. Drug Metab. Pharmacokinet. 24, 213-223. 
Li, Q., Bossone, C.A., Ohrt, C., Chung, H., Harris, D., Harre, J., Lee, P., Kathcart, A.K., 
Brueckner, R.P. (2000) Early signs and biomarkers of neurotoxicity: toxicokinetic 
and toxicodynamic evaluation following 15-mg/kg arteether daily intramuscular 
injections for two weeks in beagle dogs. Am. J. Trol. Med. Hyg. 62, 142. 
Li, Q., Mog, S.R., Si, Y.Z., Kyle, D.E., Gettayacamin, M., Milhous, W.K. (2002) Neurotoxicity 
and efficacy of arteether related to its exposure times and exposure levels in 
rodents. Am. J. Trop. Med. Hyg. 66, 516-525.  
Li, Q., Lugt, C.B., Looareesuwan, S., Krudsood, S., Wilairatana, P., Vannaphan, S., 
Chalearmrult, K., Milhous, W.K. (2004) Pharmacokinetic investigation on the 
therapeutic potential of artemotil (beta-arteether) in Thai patients with severe 
Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 71, 723-731. 
Li, Q., Xie, L.H., Si, Y., Wong, E., Upadhyay, R., Yanez, D., Weina, P.J. (2005a) Toxicokinetics 
and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 
24, 241-250. 
Li, Q., Milhous, W.K., Weina, P.J. (2005b) Regimen strategy to decrease artemisinin  
agents related failure and recrudescence in severe and complicated malaria 
treatment. Medicine and Health in the Tropics (Marseille-France) Abstract Book 
2005, 131. 
Li, Q., Xie, L.H., Haeberle, A., Zhang, J., Weina, P. (2006a) The evaluation of radiolabeled 
artesunate on tissue distribution in rats and protein binding in humans. Am. J. 
Trop. Med. Hyg. 75, 817-826. 
Li, Q., Milhous, W.K., Weina, P.J. (2006b) Fatal neurotoxicity of the artemisinin derivatives  
is related to drug pharmacokinetic profiles in animals. Curr. Topics Toxicol, 3,  
1-16. 
Li, Q., Milhous, W.K., Weina, P.J. (2007a) Antimalarial in Malaria Therapy. 1st edition. Nova 
Science Publishers Inc, New York, pp. 1-133. 
Li, Q., Gerena, L., Xie, L.H., Zhang, J., Kyle, D.E., Milhous, W.K. (2007b) Development and 
validation of flow cytometric measurement for parasitemia in cultures of P. 
falciparum vitally stained with YOYO-1. Cytometry Part A. 71A, 297-307. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 354 
Li, Q., Xie, L.H., Johnson, T.O., Si, Y.Z., Haeberle, A.S., Weina, P.J. (2007c) Toxicity 
evaluation of artesunate and artelinate in Plasmodium berghei-infected and 
uninfected rats. Trans. R. Soc. Trop. Med. Hyg. 101, 104-112. 
Li, Q., Xie, L., Zhang, J., Weina, P.J. (2008) The distribution pattern of intravenous [14C] 
artesunate in rat tissues by quantitative whole-body autoradiography and tissue 
dissection techniques. J Pharm Biomed Anal. 48, 876-884. 
Li, Q., Weina, P., (2010) Artesunate: the best drug in the treatments of severe and 
complicated malaria. Pharmaceuticals. 3, 2322-2332. 
Li, Q., Hickman, M. (2011) Toxicokinetic and toxicodynamic (TK/TD) evaluation to 
determine and predict neurotoxicity of artemisinins. Toxicology. 279, 1-9. 
Lin, A.J., Klayman, D.L., Milhous, W.K. (1987) Antimalarial activity of new water-soluble 
dihydroartemisinin derivatives. J. Med. Chem. 30, 2147-2150. 
Mayer, P.R. (1995) Absorption, metabolism, and other factors that influence drug exposure 
in toxicology studies. Toxicol. Pathol. 23, 165-169.  
McLean, W.G., Ward, S.A. (1998) In vitro neurotoxicity of artemisinin derivatives. Med. 
Trop. (Mars). 58(3 Suppl), 28-31. 
Miller, L.G., Panosian, C.B. (1997) Ataxia and slurred speech after artesunate treatment for 
falciparum malaria. N. Engl. J. Med. 336, 1328. 
Navaratnam, V., Mansor, S.M., Sit, N.W., Grace, J., Li, Q., Olliaro, P. (2000) 
Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39, 255-
270. 
Newton, P.N., Day, N.P., White, N.J. (2005) Misattribution of central nervous system 
dysfunction to artesunate. Clin. Infect. Dis. 41, 1687-1688. 
Niu, X.Y., Ho, L.Y., Ren, Z.H., Song, Z.Y. (1985) Metabolic fate of Qinghaosu in rats; a new 
TLC densitometric method for its determination in biological material. Eur. J. Drug 
Metab. Pharmacokinet. 1985, 10, 55-59. 
Noker, P., Lin, T.T. (2000) Toxicity dose range study of 14 days oral administration of 
artelinic acid in dogs. Contract Research Reports, Southern Research Institute, 
Birmingham, USA (Contract Report, our unpublished data) 
Nontprasert, A., Nosten-Bertrand, M., Pukrittayakamee, S., Vanijanonta, S., Angus, B.J., 
White, N.J. (1998) Assessment of neurotoxicity of parenteral artemisinin derivatives 
in mice. Am. J. Trop. Med. Hyg. 59, 519-522. 
Nontprasert, A., Pukrittayakamee, S., Nosten-Bertrand, M., Vanijanonta, S., White, N.J. 
(2000) Studies of neurotoxicity of oral artemisinin derivatives in mice. Am. J. Trop. 
Med. Hyg. 62, 409-412.  
Nontprasert, A., Pukrittayakamee, S., Prakongpan, S., Supanaranond, W., Looareesuwan, S., 
White, N. (2002) Assessment of neurotoxicity of oral dihydroartemisinin in mice. 
Trans. R. Soc. Trop. Med. Hyg. 96, 99-101. 
Panossian, L.A., Garga, N.I., Pelletierm D. (2005) Toxic brainstem encephalopathy after 
artemisinin treatment for breast cancer. Ann. Neurol. 58, 812-813. 
Park, B.K., O’Neill, P.N., Maggs, J.L., Pirmohamed, M. (1998) Safety assessment of  
peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol. 
46, 521-529. 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 355 
Petras, J.M., Kyle, D.E., Ngampochjana, M., Young, G.D., Bauman, R.A., Webster, H.K., 
Corcoran, J.D., Peggins, J.O., Vane, M.A., Brewer, T.G. (1997) Arteether: Risks of 
two-week administration in macaca mulatta. Am. J. Trop. Med. Hyg. 57, 390-396. 
Petras, J.M., Young, G.D., Bauman, R.A., Kyle, D.E., Gettayacamin, M., Webster, H.K., 
Corcoran, K.D., Peggins, J.O., Vane, M.A., Brewer, T.G. (2000) Arteether-induced 
brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular 
nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat. Embryol. 
(Berl). 201, 383-397. 
Price, R., van Vugt., M., Phaipun, L., Luxemburger, C., Simpson, J., McGready, R., ter Kuile, 
F., Kham, A., Chongsuphajaisiddhi, T., White, N.J., Nosten, F. (1999) Adverse 
effects in patients with acute falciparum malaria treated with artemisinin 
derivatives. Am. J. Trop. Med. Hyg. 60, 547-555. 
Rangan, U., Hedli, C., Gallo, M., Lioy, P., Snyder, R. (1997) Exposure and risk assessment 
with respect to contaminated soil: Significance of biomarkers and bioavailability. 
Int. J. Toxicol. 16, 419-432. 
Rowland, M., Tozer, T.N. (1995) Clinical Pharmacokinetics: Concepts and applications, 
Malcolm Rowland and Thomas N. Tozer (Ed.), Willianms & Wilkins, Baltimore, 
USA, pp. 83. 
Rozman, K.K., Doull, J. (2000) Dose and time as variable of toxicity. Toxicology 144, 169- 
178. 
Shargel, L., Yu, A.B.C. (1993) Applied Biopharmaceutics and Pharmacokinetics, Leon 
Shargel and Andrew B.C (Ed.), YU. Appleton & Lange, Norwalk, CN, pp. 353. 
Si, Y., Li, Q., Xie, L., Bennett, K., Weina, P.J., Mog, S., Johnson, T.O. (2007) Neurotoxicity and 
toxicokinetics of artelinic acid following repeated oral administration in rats. Int. J. 
Toxicol. 26, 401-410. 
Van Vugt, M., Angus, B.J., Price, R.N., Mann, C., Simpson, J.A., Poletto, C., Htoo, S.E., 
Looareesuwan, S., White, N.J., Nosten, F. (2000) A case-control auditory evaluation 
of patients treated with artemisinin derivatives for multidrug-resistant 
Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 62, 65-69. 
Wesche, D.L., DeCoster, M.A., Tortella, F.C., Brewer, T.G. (1994) Neurotoxicity of 
artemisinin analogs in vitro. Antimicrob Agents Chemother. 38, 1813-1819. 
White, N.J., Ashley, E.A., Nosten, F. (2006) Toxic brainstem encephalopathy after 
artemisinin treatment for breast cancer. Ann. Neurol. 59, 725-726. 
WHO. (2006) Assessment of the safety of artemisinin compounds in pregnancy. In The 
Special Pro–gramme for Research and Training Diseases (TDR) and The Global 
Malaria Programme of the World Health Organization; World Health 
Organization: Geneva, Switzerland. 
Xie, L. H., Johnson, T. O., Weina, P. J., Si, Y. Z., Haeberte, A., Upadhyay, R., Wong, E., Li 
Q.G. (2005) Risk Assessment and Therapeutic Indices of Artesunate and Artelinate 
in Plasmodium berghei-infected Rats. Int. J. Toxicol. 24, 251-264. 
Zhang, Z.Y., Yu, S.Q., Miao, L.Y., Huang, X.Y., Zhang, X.P., Zhu, Y.P., Xia, X.H., Li, D.Q. 
(2008)Artesunate combined with vinorelbine plus cisplatin in treatment of 
advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie 
He Xue Bao. 6, 134-138. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 354 
Li, Q., Xie, L.H., Johnson, T.O., Si, Y.Z., Haeberle, A.S., Weina, P.J. (2007c) Toxicity 
evaluation of artesunate and artelinate in Plasmodium berghei-infected and 
uninfected rats. Trans. R. Soc. Trop. Med. Hyg. 101, 104-112. 
Li, Q., Xie, L., Zhang, J., Weina, P.J. (2008) The distribution pattern of intravenous [14C] 
artesunate in rat tissues by quantitative whole-body autoradiography and tissue 
dissection techniques. J Pharm Biomed Anal. 48, 876-884. 
Li, Q., Weina, P., (2010) Artesunate: the best drug in the treatments of severe and 
complicated malaria. Pharmaceuticals. 3, 2322-2332. 
Li, Q., Hickman, M. (2011) Toxicokinetic and toxicodynamic (TK/TD) evaluation to 
determine and predict neurotoxicity of artemisinins. Toxicology. 279, 1-9. 
Lin, A.J., Klayman, D.L., Milhous, W.K. (1987) Antimalarial activity of new water-soluble 
dihydroartemisinin derivatives. J. Med. Chem. 30, 2147-2150. 
Mayer, P.R. (1995) Absorption, metabolism, and other factors that influence drug exposure 
in toxicology studies. Toxicol. Pathol. 23, 165-169.  
McLean, W.G., Ward, S.A. (1998) In vitro neurotoxicity of artemisinin derivatives. Med. 
Trop. (Mars). 58(3 Suppl), 28-31. 
Miller, L.G., Panosian, C.B. (1997) Ataxia and slurred speech after artesunate treatment for 
falciparum malaria. N. Engl. J. Med. 336, 1328. 
Navaratnam, V., Mansor, S.M., Sit, N.W., Grace, J., Li, Q., Olliaro, P. (2000) 
Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39, 255-
270. 
Newton, P.N., Day, N.P., White, N.J. (2005) Misattribution of central nervous system 
dysfunction to artesunate. Clin. Infect. Dis. 41, 1687-1688. 
Niu, X.Y., Ho, L.Y., Ren, Z.H., Song, Z.Y. (1985) Metabolic fate of Qinghaosu in rats; a new 
TLC densitometric method for its determination in biological material. Eur. J. Drug 
Metab. Pharmacokinet. 1985, 10, 55-59. 
Noker, P., Lin, T.T. (2000) Toxicity dose range study of 14 days oral administration of 
artelinic acid in dogs. Contract Research Reports, Southern Research Institute, 
Birmingham, USA (Contract Report, our unpublished data) 
Nontprasert, A., Nosten-Bertrand, M., Pukrittayakamee, S., Vanijanonta, S., Angus, B.J., 
White, N.J. (1998) Assessment of neurotoxicity of parenteral artemisinin derivatives 
in mice. Am. J. Trop. Med. Hyg. 59, 519-522. 
Nontprasert, A., Pukrittayakamee, S., Nosten-Bertrand, M., Vanijanonta, S., White, N.J. 
(2000) Studies of neurotoxicity of oral artemisinin derivatives in mice. Am. J. Trop. 
Med. Hyg. 62, 409-412.  
Nontprasert, A., Pukrittayakamee, S., Prakongpan, S., Supanaranond, W., Looareesuwan, S., 
White, N. (2002) Assessment of neurotoxicity of oral dihydroartemisinin in mice. 
Trans. R. Soc. Trop. Med. Hyg. 96, 99-101. 
Panossian, L.A., Garga, N.I., Pelletierm D. (2005) Toxic brainstem encephalopathy after 
artemisinin treatment for breast cancer. Ann. Neurol. 58, 812-813. 
Park, B.K., O’Neill, P.N., Maggs, J.L., Pirmohamed, M. (1998) Safety assessment of  
peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol. 
46, 521-529. 
Pharmacokinetic and Pharmacodynamic  
Profiles of Artemisinin Derivatives Influence Drug Neurotoxicity in Animals 355 
Petras, J.M., Kyle, D.E., Ngampochjana, M., Young, G.D., Bauman, R.A., Webster, H.K., 
Corcoran, J.D., Peggins, J.O., Vane, M.A., Brewer, T.G. (1997) Arteether: Risks of 
two-week administration in macaca mulatta. Am. J. Trop. Med. Hyg. 57, 390-396. 
Petras, J.M., Young, G.D., Bauman, R.A., Kyle, D.E., Gettayacamin, M., Webster, H.K., 
Corcoran, K.D., Peggins, J.O., Vane, M.A., Brewer, T.G. (2000) Arteether-induced 
brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular 
nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat. Embryol. 
(Berl). 201, 383-397. 
Price, R., van Vugt., M., Phaipun, L., Luxemburger, C., Simpson, J., McGready, R., ter Kuile, 
F., Kham, A., Chongsuphajaisiddhi, T., White, N.J., Nosten, F. (1999) Adverse 
effects in patients with acute falciparum malaria treated with artemisinin 
derivatives. Am. J. Trop. Med. Hyg. 60, 547-555. 
Rangan, U., Hedli, C., Gallo, M., Lioy, P., Snyder, R. (1997) Exposure and risk assessment 
with respect to contaminated soil: Significance of biomarkers and bioavailability. 
Int. J. Toxicol. 16, 419-432. 
Rowland, M., Tozer, T.N. (1995) Clinical Pharmacokinetics: Concepts and applications, 
Malcolm Rowland and Thomas N. Tozer (Ed.), Willianms & Wilkins, Baltimore, 
USA, pp. 83. 
Rozman, K.K., Doull, J. (2000) Dose and time as variable of toxicity. Toxicology 144, 169- 
178. 
Shargel, L., Yu, A.B.C. (1993) Applied Biopharmaceutics and Pharmacokinetics, Leon 
Shargel and Andrew B.C (Ed.), YU. Appleton & Lange, Norwalk, CN, pp. 353. 
Si, Y., Li, Q., Xie, L., Bennett, K., Weina, P.J., Mog, S., Johnson, T.O. (2007) Neurotoxicity and 
toxicokinetics of artelinic acid following repeated oral administration in rats. Int. J. 
Toxicol. 26, 401-410. 
Van Vugt, M., Angus, B.J., Price, R.N., Mann, C., Simpson, J.A., Poletto, C., Htoo, S.E., 
Looareesuwan, S., White, N.J., Nosten, F. (2000) A case-control auditory evaluation 
of patients treated with artemisinin derivatives for multidrug-resistant 
Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 62, 65-69. 
Wesche, D.L., DeCoster, M.A., Tortella, F.C., Brewer, T.G. (1994) Neurotoxicity of 
artemisinin analogs in vitro. Antimicrob Agents Chemother. 38, 1813-1819. 
White, N.J., Ashley, E.A., Nosten, F. (2006) Toxic brainstem encephalopathy after 
artemisinin treatment for breast cancer. Ann. Neurol. 59, 725-726. 
WHO. (2006) Assessment of the safety of artemisinin compounds in pregnancy. In The 
Special Pro–gramme for Research and Training Diseases (TDR) and The Global 
Malaria Programme of the World Health Organization; World Health 
Organization: Geneva, Switzerland. 
Xie, L. H., Johnson, T. O., Weina, P. J., Si, Y. Z., Haeberte, A., Upadhyay, R., Wong, E., Li 
Q.G. (2005) Risk Assessment and Therapeutic Indices of Artesunate and Artelinate 
in Plasmodium berghei-infected Rats. Int. J. Toxicol. 24, 251-264. 
Zhang, Z.Y., Yu, S.Q., Miao, L.Y., Huang, X.Y., Zhang, X.P., Zhu, Y.P., Xia, X.H., Li, D.Q. 
(2008)Artesunate combined with vinorelbine plus cisplatin in treatment of 
advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie 
He Xue Bao. 6, 134-138. 
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 356 
Zhao, K.C., Song, Z.Y. (1989) Distribution and excretion of artesunate in rats. Proc. Chin. 
Acad. Med. Sci. Peking Union Med. Coll. 4, 186-188. 18 
One Step Closer to the Target:  
Intracellular Pharmacokinetics of Gemcitabine 
Matthew Links and Peter Galettis 
St. George Cancer Pharmacology and Therapeutic Group, University of New South Wales 
St. George Clinical School, South Eastern Illawarrawa Area Health Service 
Australia 
1. Introduction 
Drug dosing is based on the premise that the amount of drug given influences the toxicity 
and response. The premise of pharmacokinetics is that it is not the amount of drug given, 
but the amount the patient is exposed to, that determines drug effect. Measurements of drug 
exposure are usually performed by determining the concentration in serum or plasma. This 
accounts for variability in drug clearance in determining the patient’s exposure. This has 
resulted in such dosing strategies as carboplatin dosing based on creatinine clearance, 
therapeutic dose monitoring of methotrexate and pharmacogenetically modified dosing for 
irinotecan. 
However it is well recognised that the plasma is not the compartment that is most relevant 
in determining tissue effects. For example for the antibiotic azithromycin the organ 
concentrations in the site of infection, such as lung are the critical feature in determining 
drug effect for pneumonia (Olsen et al., 1996; Schentag & Ballow, 1991). This argument has 
been extended to cancer anti-metabolites (Shewach & Lawrence, 2003). 
The situation in the treatment of a patient with cancer is even more complex. Tumours occur 
in an organ of interest such as the lung, or brain and liver. Regional concentrations in these 
organs are important variables (Reid, et al 1990; Breedveld et al., 2005). However tumours 
also create their own microenvironment with alterations in blood supply, interstitial 
pressure and local secretion of growth factors and cytokines (Liotta & Kohn, 2001; Wiig, et 
al, 2010). The drug concentration of interest is the concentration at the tumour site. 
Differences in tissue PK (C. Presant et al., 1990) and inter-tumoural and intra-tumoural PK 
are additional considerations (Zamboni et al., 2002). Therefore variation in the 
pharmacokinetics of plasma is only one source of variation between patients. 
The reason why plasma is sampled is, of course because it is easily accessible. There are 
limited possibilities for repeated tumour biopsies, although this has been done (Eisbruch et 
al., 2001) and although there are some techniques for sampling closer to the tumour such as 
microdialysis (Jain, 1987), nuclear magnetic resonance spectroscopy (Müller et al., 1997) and 
positron emission tomography (Gupta et al 2002) these have had limited application. 
Nevertheless it is important to recognise the limitations of plasma and aim for sampling 
closer to the target where possible. 
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A special case is that of intra-cellularly activated drugs. The most important class of these 
drugs in oncology are the nucleoside analogues such as ara-C, fludarabine and gemcitabine. 
In this situation the drug administered is a pro-drug, which is activated intracellularly. 
Because the enzymatic pathways required for drug activation are well characterised there is 
therefore an excellent opportunity to move the consideration of drug pharmacokinetics one 
step closer to the target, by considering intra-cellular pharmacokinetics. 
The pharmacogenetics of gemcitabine are summarized with a curated bibliography at 
PharmGKB. The reader is also referred to previous reviews for more detailed reports 
(Danesi et al., 2009; Galmirini et al., 2001; Nakano et al., 2007; Veltkamp et al., 2008). The 
purpose of this chapter is to bring together the data on pharmacokinetics, pharmacogentics, 
pharmacodynamics and associated models to provide a worked example of the potential for 
integrating this information and the utility and limitation of moving one step closer to the 
target. 
2. Gemcitabine background 
Gemcitabine (GEM) is a deoxcytidine analogue (2′,2′-Difluorodeoxycytidine) which mimics 
the normal actions of the pyrimidine nucleoside deoxycytidine in its transport, 
phosphorylation to the tri-phosphate and then incorporation into DNA. Its structure is 
shown in Figure 1. However during DNA synthesis only one further base can be added then 
the DNA polymerase is unable to pass the altered base and DNA chain termination results. 
This causes an S-phase specific cell cycle arrest and programmed cell death (P. Huang, et al, 
1991).  
 
Fig. 1. Chemical structure of Gemcitabine (Creative commons license Wikimedia commons)  
The enzymes responsible for each step of these processes are well characterised and 
variation in their activity are potential causes of variation in the response to GEM. Details on 
each gene of interest are provided on the entrez-gene link provided. Understanding which 
steps are causes of variation in toxicity and response and how to model the effects of 
multiple variables are key issues in understanding this variation. This requires 
understanding the relationship between the pharmacokinetics of GEM in the plasma and the 
intracellular activity of gemcitabine triphosphate (GEM-TP). The pathway of GEM 
activation and inactivation is illustrated in Figure 2. 
The importance of understanding this is underlined by the fact that GEM is a commonly 
used drug in a wide range of important cancer types including non-small cell lung, breast, 
pancreatico-biliary and bladder. 
 




Fig. 2. Gemcitabine pathway (copyright PharmGKB, permission has been given by 
PharmGKB and Stanford University) 
2.1 Uptake 
The first step in activation is an active process of transport into the cell. The main 
mechanism of uptake is via hENT1 (SLC289A1) (Mackey et al., 1998) although a smaller 
portion is carried via other transporters SLC28A1 and SLC28A3 (Graham et al., 2000).  
2.2 Phosphorlyation 
Intracellular retention requires phsophorylation via the kinases, deoxyctidine kinase (DCK) 
and CMPK1. The rate- limiting step in this process is DCK. Phosphorlyation promotes 
intracellular retention and allows incorporation of GEM-TP into DNA. 
2.3 Inactivation 
The major route of inactivation is via deamination via Cytidine deaminase(CDA). CDA is 
ubiquitously expressed and converts GEM to difluorodeoxyuridine (dFdU). dFdU has low 
level activity and is water soluble and excreted almost entirely by renal excretion. A minor 
route of deactivation is through dephosphorylation of GEM-TP via 5’Nucleotidase 
(Dumontet et al., 1999). 
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2.4 Self- potentiation 
One of the remarkable aspects of GEM pharmacology is that it has multiple mechanisms of 
self-potentiation (W Plunkett et al, 1996). The most important mechanism is that GEM-TP 
and GEM-DP block the salvage pathway of nucleotide synthesis through inhibition of 
Ribonucleotide reductase. This has the effect of reducing the pool of nucleotides that are 
competing with GEM-TP for incorporation and thereby increasing GEM-TP incorporation 
into DNA. Ribonucelotide reductase is composed of 2 subunits RRM1 and RRM2. The 
importance of this pathway is underlined by the data that variation in RRM1 is a critical 
determinant of GEM response (see later). 
A second mechanism of self-potentiation occurs via inhibition by GEM of dCMP deaminase, 
which results in a reduced catabolism for GEM-TP (Heinemann et al., 1992) and a third 
mechanism of self-potentiation is that the main metabolite of GEM, dFdU (Hodge, et al,, 
2011) increases GEM-TP accumulation in a time dependent manner. 
3. Pharmacogenetics of GEM 
There is considerable inter-patient variability in gemcitabine accumulation and there are 
polymorphisms described in many of the genes involved in transport, activation and 
inactivation. Data on pharmacogenetics for key drugs is agregated on the PharmGKB wesite 
(http://www.pharmgkb.org) and gemcitabine is included in this collection. An excellent 
review has been published by Wong et al (2009). 
3.1 Understanding the significance of polymorphisms 
Understanding the significance of a polymorphism will depend upon its changes in 
structure, functional significance and the frequency of variation. Non coding SNP’s can be 
associated by chance, by linkage disequilibrium or potentially through influences on , 
alternate splicing, microRNA binding or DNA morphology. Changes in the promoter region 
can lead to variation in expression. The significance depends more fundamentally on the 
impact that the coded protein has on function. There are two issues here –how much does 
each gene product impact on function and how much of human variation is accountable by 
variation in this gene. 
For example there are 23 snp's in the gene SLC28A3 in the dbnsnp database 
http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=64078 . Of these most are very 
infrequent with the heterozygozity rate of 15 loci are > 1% and only 6 are > 5%. Of the six 
most frequent SNP’s, 3 are synonymous. These considerations are complicated by the issue 
that infrequent polymorphisms with major effects on function can have severe 
consequences. 
Understanding the functional importance of a hapoltype or SNP ultimately requires 
demonstration of an effect on toxicity or efficacy. Pharmacokinetics however plays a crucial 
intermediate role in mediating pre-target variation. An association between a genetic 
variation and pharmacokinetics of the drug greatly increases the pre-test probability that 
functional differences will be found that are not related to chance. 
3.2 CDA 
A summary of SNP’s in CDA is found in the geneview of the dbDNP database. 
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In European populations CDA:79A>C ( K27Q)  where the C allele is seen with a frequency 
of 0.36. Patients with a copy of the variant  allele have reduced clearance and increased 
haematological toxicity. In Japanese patients this SNP is uncommon but a less common 
variant G208A has been associated with markedly reduced clearance and increased toxicity. 
The comparison between the two SNP’s shows the importance of both common variations 
(in contribution to interpatient variability) and uncommon but functionally very important 
variants in contributing to toxicity “outliers”. 
3.3 RRM1 
A summary of SNP’s in RRM1 is found in the gene view of the dbSNP database. RRM1 is of 
particular interest because there is strong data to support the influence of mRNA protein 
expression on survival in patients with NSCLC treated with gemcitabine (Ceppi et al., 
2006)(Rosell et al., 2004). The data supporting a relationship between RRM1 polymorphisms 
is not as strong. There are two relatively common polymorphism in the European 
population c.2223A>G and 2464G>A with minor allele frequencies of 0.5 and 0.16 
respectively. The 2464G>A has been shown to be associated with GEM sensitivity in vitro 
(Kwon et al., 2006)and haplotype is associated with response (but not survival) in patients 
with NSCLC treated with GEM (Kim et al., 2008). A small study suggested a relationship 
between -37C>A and progression free survival (PFS) (S. Dong et al., 2010).  
3.4 hENT1 
In patients with pancreatic cancer treated with gemcitabine hENT1 transcript levels were 
associated with survival (Giovannetti et al., 2006). However identified polymorphisms are 
infrequent (SNP:Geneview) and 201A>G has been identified with increased neutropenia 
(Tanaka et al., 2010). Sugiyama found no relationship with gemcitabine pharmacokinetics 
(Sugiyama et al., 2001) 
Polymorphisms of other potentially important genes such as other transporters and DCK 
have not yet been shown to have clinical importance.  
3.5 Haplotypes 
There is a growing view that polymorphism in single genes are unlikely to be informative 
and that more relevant information is likely to come from sets of informative genes 
(haplotypes)(Kalow, 2006) or more complex genetic variations (Lee & Morton, 2008). 
Because of linkage disequilibrium, some combinations will occur more frequently than 
others and it is therefore possible to map the most common gene combinations and test their 
significance.  
This approach has been taken with CDA in the Japanese population where one haplotype 
(of various CDA SNP’s) termed *3 was associated with reduced clearance of gemcitabine 
and increased toxicity (Sugiyama et al., January 2010).  
Tanaka et al have taken a comprehensive approach (Tanaka et al., 2010; Okazaki et al, 2010). 
They first screened 17 polymorphisms in relevant (CDA, dCK, RRM1, hCNT2, hCNT3, and 
hENT1) genes in a sample of 149 patients with pancreatic cancer receiving chemo-radiation 
and identified polymorphisms with significant associations for toxicity or trends for effects 
on survival. None of the SNP’s singly was associated significantly with survival. 
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2.4 Self- potentiation 
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polymorphisms described in many of the genes involved in transport, activation and 
inactivation. Data on pharmacogenetics for key drugs is agregated on the PharmGKB wesite 
(http://www.pharmgkb.org) and gemcitabine is included in this collection. An excellent 
review has been published by Wong et al (2009). 
3.1 Understanding the significance of polymorphisms 
Understanding the significance of a polymorphism will depend upon its changes in 
structure, functional significance and the frequency of variation. Non coding SNP’s can be 
associated by chance, by linkage disequilibrium or potentially through influences on , 
alternate splicing, microRNA binding or DNA morphology. Changes in the promoter region 
can lead to variation in expression. The significance depends more fundamentally on the 
impact that the coded protein has on function. There are two issues here –how much does 
each gene product impact on function and how much of human variation is accountable by 
variation in this gene. 
For example there are 23 snp's in the gene SLC28A3 in the dbnsnp database 
http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=64078 . Of these most are very 
infrequent with the heterozygozity rate of 15 loci are > 1% and only 6 are > 5%. Of the six 
most frequent SNP’s, 3 are synonymous. These considerations are complicated by the issue 
that infrequent polymorphisms with major effects on function can have severe 
consequences. 
Understanding the functional importance of a hapoltype or SNP ultimately requires 
demonstration of an effect on toxicity or efficacy. Pharmacokinetics however plays a crucial 
intermediate role in mediating pre-target variation. An association between a genetic 
variation and pharmacokinetics of the drug greatly increases the pre-test probability that 
functional differences will be found that are not related to chance. 
3.2 CDA 
A summary of SNP’s in CDA is found in the geneview of the dbDNP database. 
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In European populations CDA:79A>C ( K27Q)  where the C allele is seen with a frequency 
of 0.36. Patients with a copy of the variant  allele have reduced clearance and increased 
haematological toxicity. In Japanese patients this SNP is uncommon but a less common 
variant G208A has been associated with markedly reduced clearance and increased toxicity. 
The comparison between the two SNP’s shows the importance of both common variations 
(in contribution to interpatient variability) and uncommon but functionally very important 
variants in contributing to toxicity “outliers”. 
3.3 RRM1 
A summary of SNP’s in RRM1 is found in the gene view of the dbSNP database. RRM1 is of 
particular interest because there is strong data to support the influence of mRNA protein 
expression on survival in patients with NSCLC treated with gemcitabine (Ceppi et al., 
2006)(Rosell et al., 2004). The data supporting a relationship between RRM1 polymorphisms 
is not as strong. There are two relatively common polymorphism in the European 
population c.2223A>G and 2464G>A with minor allele frequencies of 0.5 and 0.16 
respectively. The 2464G>A has been shown to be associated with GEM sensitivity in vitro 
(Kwon et al., 2006)and haplotype is associated with response (but not survival) in patients 
with NSCLC treated with GEM (Kim et al., 2008). A small study suggested a relationship 
between -37C>A and progression free survival (PFS) (S. Dong et al., 2010).  
3.4 hENT1 
In patients with pancreatic cancer treated with gemcitabine hENT1 transcript levels were 
associated with survival (Giovannetti et al., 2006). However identified polymorphisms are 
infrequent (SNP:Geneview) and 201A>G has been identified with increased neutropenia 
(Tanaka et al., 2010). Sugiyama found no relationship with gemcitabine pharmacokinetics 
(Sugiyama et al., 2001) 
Polymorphisms of other potentially important genes such as other transporters and DCK 
have not yet been shown to have clinical importance.  
3.5 Haplotypes 
There is a growing view that polymorphism in single genes are unlikely to be informative 
and that more relevant information is likely to come from sets of informative genes 
(haplotypes)(Kalow, 2006) or more complex genetic variations (Lee & Morton, 2008). 
Because of linkage disequilibrium, some combinations will occur more frequently than 
others and it is therefore possible to map the most common gene combinations and test their 
significance.  
This approach has been taken with CDA in the Japanese population where one haplotype 
(of various CDA SNP’s) termed *3 was associated with reduced clearance of gemcitabine 
and increased toxicity (Sugiyama et al., January 2010).  
Tanaka et al have taken a comprehensive approach (Tanaka et al., 2010; Okazaki et al, 2010). 
They first screened 17 polymorphisms in relevant (CDA, dCK, RRM1, hCNT2, hCNT3, and 
hENT1) genes in a sample of 149 patients with pancreatic cancer receiving chemo-radiation 
and identified polymorphisms with significant associations for toxicity or trends for effects 
on survival. None of the SNP’s singly was associated significantly with survival. 
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They then went on to examine the relationship between SNP's and identified that two or 
three SNPs each of the dCK, RRM1, hCNT2, hCNT3, and hENT1 (IVS12-201A>G and IVS2-
549T>C) genes were in linkage disequilibrium (|D'|>0.5, P < 0.01). This enabled 
identification of relevant haplotypes. 
They next examined relationships between haplotypes and overall survival (OS). The CDA 
C111T and A-79C TA haplotype was significantly associated with increased risk and the 
hENT1 A-201G, T-549C, and C913T ACT haplotype was significantly associated with 
reduced risk of death compared with the most common haplotype of each gene respectively 
(P < 0.05). 
They were also able to examine the effects of gene dose by comparing outcomes according 
to the number of poor risk genotypes. Patients carrying 0 to 1 (n = 43), 2 to 3 (n = 77) or 4 to 6 
(n = 30) variant alleles had a Median Survival time T of 31.5, 21.4, and 17.5 mo, respectively. 
This work shows the need to consider multiple significant genes in determining significance 
and the added power this analysis brings. However as discussed below there are 
fundamental limitations to the SNP approach, that relate to the relationship between 
genotype and phenotype. 
3.6 Considering the influence of transcription and translation 
One of the limitations of focusing on genetic polymorphisms as causes of functional 
variation is the potential influence of gene silencing (Meister & Tuschl, 2004) transcriptional 
(Goth-Goldstein et al, 2000) and post transcriptional regulation on protein expression (Cress 
& Seto, 2000). DNA sequence is only one determinant of ultimate function. Genes can be 
silenced by methylation or acetylation, alternate splicing of gene transcripts can lead to 
differences in function and allelic imbalance can lead to increased expression. 
Environmental influences on transcription such as inhibition or induction by drugs or 
endogenous messages are critical. One way of accounting for these variations is to 
concentrate on measurement of phenotype rather than genotype (Mahgoub et al, 1977).  
With CDA phenotype has been assessed ex vivo by incubation of mononuclear cells, plasma 
or red cell extracts with pyrimidine analogues and measurement of deamination.  
Similarly a furthers study found phenotype as assessed by in vitro deamination correlated 
with toxicity whereas specific polymorphisms did not (Ciccolini et al., 2010; Mercier et al, 
2007) 
4. Challenges in measurement of intracellular PK 
There are a number of challenges in the measurement of both GEM and the intracellular 
metabolite GEM-TP. The first of these is related to the fact that CDA is present in plasma, 
therefore every blood collection tubes requires the presence of tetrahydrouridine (THU) to 
inhibit CDA. If THU is not included all of the GEM will be converted to dFdU its inactive 
metabolite in plasma before it can even enter the cell to be converted to the active metabolite 
GEM-TP. The next challenge is the fact that white cells cannot be stored frozen without the 
loss of triphosphates, therefore the triphosphates need to be extracted from leucocytes 
before any of the sample is frozen. This is not a complex processes but does require time and 
some experience is necessary thus can not easily be performed by a nurse that generally 
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collects the blood samples and adds to the complexity of the studies and probably the main 
reason why more intracellular measurements are not routinely conducted. The amount of 
leucocytes present in an individual blood sample is highly variable and can be effected 
markedly when patients are on chemotherapy. While the analysis of GEM and dFdU in 
plasma are relatively straight forward and can be quality controlled and give reliable 
results, the same cannot be said about the assay used to measure GEM-TP. This involves the 
use of an ion exchange column and high concentrations of salt to remove the triphosphate 
from the column. This makes the assay difficult to convert to more sensitive LCMS assays. It 
is not easy to quality control this assay which could lead to varying data being reported by 
different laboratoties. 
5. Pharmacokinetics and dose optimisation 
The pharmacokinetics of plasma Gemcitabine and its main metabolite have been described 
in multiple studies. The findings of the original phase 1 remain typical (JL Abbruzzese, et 
al., 1991). 77% of Gemcitabine was metabolised to dFdU and excreted in the urine in the first 
24hrs dFdU clearance was proportional to creatinine clearance. The clearance of 
Gemcitabine in the plasma was rapid with a T1/2 of 8 mins. The clearance of GEM was 
independent of dose. The pharmacokinetics of GEM in some representative studies are 
shown in Table 1. 
 
 Clearance (L/h/m2) T1/2 min AUC(μM*min) Vss (L) CMax(μM) 
 Soo et al., 2006      
Arm A (n29) 
FDR 164.0±64.0 18.2±4.2 1,346 ±1113 65 ± 37 21 ± 17 
Arm B (n=29)  
30 min 181.6±74.5 17.1±3.1 1,432 ±529 75 ±41 41 ± 14 
Tempero,   
et al., 2003      
FDR     26  ± 6 
Standard  
(higher dose)     100 ± 19 
Grimison,  
et al 2007      
FDR n=31   1279±629  19± 6 
Standard n=30   1642 ± 796  50± 18 
Table 1. Representative Plasma Pharmacokinetic Data 
The major clinical determinants of clearance are size and gender. The influence of size has 
been demonstrated through a correlation with BSA, which justifies the use of BSA to adjust 
dose. The influence of gender has been more variable although some studies show reduced 
clearance in women.  
There is much less data on the pharmacokinetics of GEM-TP. Data from some representative 
studies are shown in Table 2. In the early development of Gemcitabine it was identified that 
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They then went on to examine the relationship between SNP's and identified that two or 
three SNPs each of the dCK, RRM1, hCNT2, hCNT3, and hENT1 (IVS12-201A>G and IVS2-
549T>C) genes were in linkage disequilibrium (|D'|>0.5, P < 0.01). This enabled 
identification of relevant haplotypes. 
They next examined relationships between haplotypes and overall survival (OS). The CDA 
C111T and A-79C TA haplotype was significantly associated with increased risk and the 
hENT1 A-201G, T-549C, and C913T ACT haplotype was significantly associated with 
reduced risk of death compared with the most common haplotype of each gene respectively 
(P < 0.05). 
They were also able to examine the effects of gene dose by comparing outcomes according 
to the number of poor risk genotypes. Patients carrying 0 to 1 (n = 43), 2 to 3 (n = 77) or 4 to 6 
(n = 30) variant alleles had a Median Survival time T of 31.5, 21.4, and 17.5 mo, respectively. 
This work shows the need to consider multiple significant genes in determining significance 
and the added power this analysis brings. However as discussed below there are 
fundamental limitations to the SNP approach, that relate to the relationship between 
genotype and phenotype. 
3.6 Considering the influence of transcription and translation 
One of the limitations of focusing on genetic polymorphisms as causes of functional 
variation is the potential influence of gene silencing (Meister & Tuschl, 2004) transcriptional 
(Goth-Goldstein et al, 2000) and post transcriptional regulation on protein expression (Cress 
& Seto, 2000). DNA sequence is only one determinant of ultimate function. Genes can be 
silenced by methylation or acetylation, alternate splicing of gene transcripts can lead to 
differences in function and allelic imbalance can lead to increased expression. 
Environmental influences on transcription such as inhibition or induction by drugs or 
endogenous messages are critical. One way of accounting for these variations is to 
concentrate on measurement of phenotype rather than genotype (Mahgoub et al, 1977).  
With CDA phenotype has been assessed ex vivo by incubation of mononuclear cells, plasma 
or red cell extracts with pyrimidine analogues and measurement of deamination.  
Similarly a furthers study found phenotype as assessed by in vitro deamination correlated 
with toxicity whereas specific polymorphisms did not (Ciccolini et al., 2010; Mercier et al, 
2007) 
4. Challenges in measurement of intracellular PK 
There are a number of challenges in the measurement of both GEM and the intracellular 
metabolite GEM-TP. The first of these is related to the fact that CDA is present in plasma, 
therefore every blood collection tubes requires the presence of tetrahydrouridine (THU) to 
inhibit CDA. If THU is not included all of the GEM will be converted to dFdU its inactive 
metabolite in plasma before it can even enter the cell to be converted to the active metabolite 
GEM-TP. The next challenge is the fact that white cells cannot be stored frozen without the 
loss of triphosphates, therefore the triphosphates need to be extracted from leucocytes 
before any of the sample is frozen. This is not a complex processes but does require time and 
some experience is necessary thus can not easily be performed by a nurse that generally 
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collects the blood samples and adds to the complexity of the studies and probably the main 
reason why more intracellular measurements are not routinely conducted. The amount of 
leucocytes present in an individual blood sample is highly variable and can be effected 
markedly when patients are on chemotherapy. While the analysis of GEM and dFdU in 
plasma are relatively straight forward and can be quality controlled and give reliable 
results, the same cannot be said about the assay used to measure GEM-TP. This involves the 
use of an ion exchange column and high concentrations of salt to remove the triphosphate 
from the column. This makes the assay difficult to convert to more sensitive LCMS assays. It 
is not easy to quality control this assay which could lead to varying data being reported by 
different laboratoties. 
5. Pharmacokinetics and dose optimisation 
The pharmacokinetics of plasma Gemcitabine and its main metabolite have been described 
in multiple studies. The findings of the original phase 1 remain typical (JL Abbruzzese, et 
al., 1991). 77% of Gemcitabine was metabolised to dFdU and excreted in the urine in the first 
24hrs dFdU clearance was proportional to creatinine clearance. The clearance of 
Gemcitabine in the plasma was rapid with a T1/2 of 8 mins. The clearance of GEM was 
independent of dose. The pharmacokinetics of GEM in some representative studies are 
shown in Table 1. 
 
 Clearance (L/h/m2) T1/2 min AUC(μM*min) Vss (L) CMax(μM) 
 Soo et al., 2006      
Arm A (n29) 
FDR 164.0±64.0 18.2±4.2 1,346 ±1113 65 ± 37 21 ± 17 
Arm B (n=29)  
30 min 181.6±74.5 17.1±3.1 1,432 ±529 75 ±41 41 ± 14 
Tempero,   
et al., 2003      
FDR     26  ± 6 
Standard  
(higher dose)     100 ± 19 
Grimison,  
et al 2007      
FDR n=31   1279±629  19± 6 
Standard n=30   1642 ± 796  50± 18 
Table 1. Representative Plasma Pharmacokinetic Data 
The major clinical determinants of clearance are size and gender. The influence of size has 
been demonstrated through a correlation with BSA, which justifies the use of BSA to adjust 
dose. The influence of gender has been more variable although some studies show reduced 
clearance in women.  
There is much less data on the pharmacokinetics of GEM-TP. Data from some representative 
studies are shown in Table 2. In the early development of Gemcitabine it was identified that 
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exposed cells demonstrate saturable accumulation of the Triphosphate. This correlates with 
the biochemistry of accumulation and retention being limited by intracellular conversion to 
the Triphosphate by DCK.  In phase 1 studies this translated to a saturation of Gemcitabine 
accumulation in mononuclear cells with increasing dose. This is accompanied by a change in 
the pattern of elimination with monophasic elimination at low concentrations and biphasic 
elimination described after the threshold has been reached. 
 
 Clearance (L/h/m2) AUC(μM*min) CMax(μM) 
Soo et al., 2006    
Arm A (n29) FDR 5.2±2.0 35 079±18 216 174 ± 77 
Arm B (n=29) 30 min 7.0±2.61 32 249±11 267 225 ± 74 
(Tempero,  et al., 2003)    
FDR   398 
Standard (higher dose)   188 
 (Grimison, et al 2007)    
FDR n=31  2600 ± 2483   
Standard n=30  1833± 1833  
Table 2. Representative Intracellular Pharmacokinetic Data 
The clinical correlate of this finding is that accumulation can be maximised by prolonging 
infusion time and indeed this is the case. Based on accumulation in leukemic blasts a target 
concentration and rate of administration was determined to maximise accumulation. There 
are several problems with this process. The target concentration and optimal rate of infusion 
has not been determined in solid tumours, where the kinetics are known to be different. 
Secondly the “optimum” rate of administration does not take into account inter-individual 
variation. Differential expression of DCK between tumours and normal tissue and between 
individuals would be expected to determine different optimum rates of administration. 
The rationale for prolonged dosing received a major boost when a randomised phase 2 
study demonstrated proof of principle that in a clinically relevant scenario (pancreatic 
cancer) prolonged infusion at a rate of 10 mg/m2/min (compared to a standard 30 min 
infusion) was associated with not only increased accumulation of GEM-TP, but with a trend 
for increased survival. This lead to a proliferation of similar studies in other tumour types 
confirming the pharmacokinetic finding but underpowered to demonstrate survival 
differences. Unfortunately a large phase 3 study, in pancreatic cancer, demonstrated that the 
pharmacological advantage obtained failed to translate into a significant survival advantage.  
The challenges in optimising accumulation of Gemcitabine have been highlighted by data 
from our group showing an increase in Gemcitabine accumulation between week 1 and 2 
with weekly administration (Grimison, et al., 2007). This suggests auto induction of 
Gemcitabine accumulation. In vivo modelling suggests this is a generic response to DNA 
damaging agents (Metharom, et al, 2010). The significance of this increase is not certain, 
with one study showing a non significant increase (de Lange et al., 2005), but it potentially 
complicates strategies to achieve a target intracellular concentration if the target changes 
over time.  
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We have furthered examined potential explanations for the discordance between the 
pharmacological advantage seen previously and the negative phase 3 study. Analysis of 
SNP’s from our study has suggested that the pharmacological advantage of prolonged dose 
rate Gemcitabine is restricted to patients with the variant allele of c.CDA79A>C (Metharom 
et al., 2011). If this finding is confirmed, then the phase 3 study would have been 
underpowered to detect a survival difference in this population and consideration of the 
optimum dosing schedule may require individualisation according to genotype. 
5.1 Pharmacokinetic/Pharmacodynamic relationships 
The availability of pharmacokinetic data for both the prodrug and the active intracellular 
metabolite leads to the possibility of exploring differences in the ability of these parameters 
to predict drug effects of toxicity and efficacy. 
There is data that demonstrates correlations between the concentration of Gemcitabine at 
the end of the infusion and haematological toxicity, however the relationship is weak. There 
is very limited data exploring the relationship between the pharmacokinetics of intracellular 
GEM-TP and toxicity. No relationship was seen in combination with Carboplatin ( Soo et al., 
2006) In our data GEM-TP cMax correlate with AUC and was used for pharmacodynamic 
correlations. Modelling GEM-TP concentrations to % reduction in white cells improved the 
fit of the model although the relationship remained modest (r2 = 0.3739) (Grimison et al., 
2007). This provides proof of concept that moving from the plasma to intracellular 
compartment did improve predictive ability, but that the proportion of variance related to 
pharmacodynamic variability and the relationship of the sampled compartment to the 
compartment of interest will determine the utility of this approach. 
The relationship of pharmacokinetics to tumour response is much more difficult to assess as 
tumour Reponses are heterogeneous and seen in a minority of patients treated with 
Gemcitabine. This then requires PK sampling in large populations of patients, which is 
unattractive to designers of clinical trials and enrolled patients. As a result there are no large- 
scale studies correlating clinical benefit, response or survival endpoints with PK parameters. 
Reported pharmacokinetic/pharmacodynamic relationships are summarised in Table 3. 
 
Treatment Tumour n variable Finding 
Carboplatin and FDR  
GEM 
(Wang et al., 2007)
NSCLC 21  % reduction WBC and GEM-CMax R2= 0.4575 
   % reduction plat  and GEM CMax R2= 0.5671 
Paclitaxel GEM 
(Fogli et al., 2001)   
% reduction plat and 
GEM CMax  
High dose GEM and 
autologous stem cells  








Gemcitabine and RT   
(Eisbruch et al., 2001) 
Head and 
neck 29  
Poor correlation 
between dose and 
tumour concentration   
Table 3. Pharmacokinetic/Pharmacodynamic relationships 
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exposed cells demonstrate saturable accumulation of the Triphosphate. This correlates with 
the biochemistry of accumulation and retention being limited by intracellular conversion to 
the Triphosphate by DCK.  In phase 1 studies this translated to a saturation of Gemcitabine 
accumulation in mononuclear cells with increasing dose. This is accompanied by a change in 
the pattern of elimination with monophasic elimination at low concentrations and biphasic 
elimination described after the threshold has been reached. 
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Arm A (n29) FDR 5.2±2.0 35 079±18 216 174 ± 77 
Arm B (n=29) 30 min 7.0±2.61 32 249±11 267 225 ± 74 
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FDR   398 
Standard (higher dose)   188 
 (Grimison, et al 2007)    
FDR n=31  2600 ± 2483   
Standard n=30  1833± 1833  
Table 2. Representative Intracellular Pharmacokinetic Data 
The clinical correlate of this finding is that accumulation can be maximised by prolonging 
infusion time and indeed this is the case. Based on accumulation in leukemic blasts a target 
concentration and rate of administration was determined to maximise accumulation. There 
are several problems with this process. The target concentration and optimal rate of infusion 
has not been determined in solid tumours, where the kinetics are known to be different. 
Secondly the “optimum” rate of administration does not take into account inter-individual 
variation. Differential expression of DCK between tumours and normal tissue and between 
individuals would be expected to determine different optimum rates of administration. 
The rationale for prolonged dosing received a major boost when a randomised phase 2 
study demonstrated proof of principle that in a clinically relevant scenario (pancreatic 
cancer) prolonged infusion at a rate of 10 mg/m2/min (compared to a standard 30 min 
infusion) was associated with not only increased accumulation of GEM-TP, but with a trend 
for increased survival. This lead to a proliferation of similar studies in other tumour types 
confirming the pharmacokinetic finding but underpowered to demonstrate survival 
differences. Unfortunately a large phase 3 study, in pancreatic cancer, demonstrated that the 
pharmacological advantage obtained failed to translate into a significant survival advantage.  
The challenges in optimising accumulation of Gemcitabine have been highlighted by data 
from our group showing an increase in Gemcitabine accumulation between week 1 and 2 
with weekly administration (Grimison, et al., 2007). This suggests auto induction of 
Gemcitabine accumulation. In vivo modelling suggests this is a generic response to DNA 
damaging agents (Metharom, et al, 2010). The significance of this increase is not certain, 
with one study showing a non significant increase (de Lange et al., 2005), but it potentially 
complicates strategies to achieve a target intracellular concentration if the target changes 
over time.  
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We have furthered examined potential explanations for the discordance between the 
pharmacological advantage seen previously and the negative phase 3 study. Analysis of 
SNP’s from our study has suggested that the pharmacological advantage of prolonged dose 
rate Gemcitabine is restricted to patients with the variant allele of c.CDA79A>C (Metharom 
et al., 2011). If this finding is confirmed, then the phase 3 study would have been 
underpowered to detect a survival difference in this population and consideration of the 
optimum dosing schedule may require individualisation according to genotype. 
5.1 Pharmacokinetic/Pharmacodynamic relationships 
The availability of pharmacokinetic data for both the prodrug and the active intracellular 
metabolite leads to the possibility of exploring differences in the ability of these parameters 
to predict drug effects of toxicity and efficacy. 
There is data that demonstrates correlations between the concentration of Gemcitabine at 
the end of the infusion and haematological toxicity, however the relationship is weak. There 
is very limited data exploring the relationship between the pharmacokinetics of intracellular 
GEM-TP and toxicity. No relationship was seen in combination with Carboplatin ( Soo et al., 
2006) In our data GEM-TP cMax correlate with AUC and was used for pharmacodynamic 
correlations. Modelling GEM-TP concentrations to % reduction in white cells improved the 
fit of the model although the relationship remained modest (r2 = 0.3739) (Grimison et al., 
2007). This provides proof of concept that moving from the plasma to intracellular 
compartment did improve predictive ability, but that the proportion of variance related to 
pharmacodynamic variability and the relationship of the sampled compartment to the 
compartment of interest will determine the utility of this approach. 
The relationship of pharmacokinetics to tumour response is much more difficult to assess as 
tumour Reponses are heterogeneous and seen in a minority of patients treated with 
Gemcitabine. This then requires PK sampling in large populations of patients, which is 
unattractive to designers of clinical trials and enrolled patients. As a result there are no large- 
scale studies correlating clinical benefit, response or survival endpoints with PK parameters. 
Reported pharmacokinetic/pharmacodynamic relationships are summarised in Table 3. 
 
Treatment Tumour n variable Finding 
Carboplatin and FDR  
GEM 
(Wang et al., 2007)
NSCLC 21  % reduction WBC and GEM-CMax R2= 0.4575 
   % reduction plat  and GEM CMax R2= 0.5671 
Paclitaxel GEM 
(Fogli et al., 2001)   
% reduction plat and 
GEM CMax  
High dose GEM and 
autologous stem cells  








Gemcitabine and RT   
(Eisbruch et al., 2001) 
Head and 
neck 29  
Poor correlation 
between dose and 
tumour concentration   
Table 3. Pharmacokinetic/Pharmacodynamic relationships 
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6. Population models of Gemcitabine PK 
6.1 Population PK models 
Pharmacokinetic models are a mathematical shorthand way of describing PK data. In the 
most common approach to estimation of pharmacokinetic parameters, data from an 
individual is used to fit to a model and calculate variables such as clearance. Individual 
estimates of clearance then describe the population. In the population pharmacokinetic 
approach the data from the whole population is used to develop the model parameters and 
calculate variables, like clearance. The population approach is more complicated and 
requires more computing and human resources but has several advantages including the 
handling of sparse data. It is well positioned to include other co-variates in the model 
development such as clinical parameters (age, BSA, measure of renal or hepatic function) as 
well as novel laboratory measures. In both cases the model “compartments” are 
mathematical constructs rather than physiological compartments. Population PK modelling 
does lend itself to conforming the model to physiological compartments, which may also be 
sampled, such as plasma or an intracellular compartment. For a review of population PK 
modelling of anticancer agents the readers is referred to the review by Zandvliet et al.  
(2008). 
6.2 Population PK models for Gemcitabine  
There are 3 reported population pharmacokinetic models for plasma Gemcitabine and dFdU 
and one model that includes GEM-TP. Each GEM model fits for a 2 compartment model 
with a presumed peripheral and central compartment. Jiang et al derived our model from 94 
patients with various malignancy treated on PK studies. Sugiyama et al derived a model 
from a population of 250 Japanese patients included in previous PK studies. Zhang et al 
derived their model from the data from original phase 1 studies. The model parameters for 
all three models are summarised in Table 4.  
 
Study Compartments CL L/min VC (l) VP RV 
STG 2 2.7 (31%) 15 (39%)  40 
Sugiyama *  1.24  12.6 9.54  
Zhang  2 NR NR NR  
Pham 2 5.1 2.96 47.6 35 
CL=clearance; VC= volume central compartment VP = volume peripheral compartment and  
RV = residual variation 
*calculated assuming a BSA of 1.78, Cr=100mg/dL age 62.67 and median values for male and female 
Table 4. Parameters from Gemcitabine Population Pk Models.  
The models allow some significant observations. Significant covariates included in the final 
version of all models include BSA, age and sex. This confirms univariate observations from 
individual PK data. The inclusion of BSA is an important observation given the debate over 
whether clinical doses should be adjusted for BSA for anticancer drugs. 
The models also allow evaluation of potential drug interactions with co-administered drugs. 
The Jiang model compared the impact of co-administered of oxaliplatin with a 35-45% 
decrease in the Vc for dFdU. 
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The patients in the Sugiyama paper were administered a variety of partner drugs and this 
allowed evaluation of potential interactions. They were able to demonstrate a 20% increase 
in the clearance of GEM following S1, a potentially clinically relevant observation. The 
speculative mechanism is an increase in hENT1 expression. This demonstrates the relevance 
of considering intracellular pharmacokinetics because an increase in clearance into the 
intracellular compartment (which is greater in tumours) has a different implication to an 
increase in clearance due to increased excretion. A summary of findings of each model for 
significant covariates is given in Table 5. 
 
Author n Examined  Significant Comments 
Sugiyama  248 
(BSA), weight, age








of clearance  
 
 S-1 significantly 
increased CL  
Age and sex did not 
significantly affect the 
CL and V1 of 
Gemcitabine. 
Zhang  353 
age, sex,(BSA), 






BSA on Clpc, 
Vpc,and Vpp,gen- 
der on Clpc and 
Vpc,ageon Clpc, and 
duration of infusion 
on Vpp. 
Note plasma CDA 
not significant 
Tham 56 






Weight and height 
No improvement 
with allometric 
scaling; fat content 
can be ignored when 
using size variable. 




Table 5. Co-variates examined versus included in GEM models 
6.3 GEM Pop PK including pharmacogenetic variables 
The Sugiyama model also investigated the influence of several pharmacogenetic variants in 
the Japanese population. They had previously reported a variant CDA 208G>A (associated 
with the*3 haplotype) with a minor allele frequency of 0.022 in the Japanese population as 
associated with increased toxicity in homozygous patients (Sugiyama, et al., 2009). 
They investigated the role of this other polymorphisms in CDA, DCK and hent1 (SLC29A1) 
and evaluated included the following found common polymorphism in the base model 
CDA A79>C variant (allele frequency 0.208); –31delC (0.44); 2 polymorphisms in the hENT 1 
gene–3797A>G (0.398) and –3268_–3249del AGGCTCGCGAGCGGAGGTGC (0.398). The 
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significance of the final model was driven by CDA*3 , although -31delc and CDA A79>C 
also contributed. The significance of the *2 haplotype in the absence of *3 (as is seen in 
Caucasians) is not clear from their model. 
One interesting piece of data relating pharmacogenetic and PK comes from a very simple 
study where the deamination rate of red cell extracts was measured and correlated with 
genotype (Giovannetti et al., June xx 2008). Mean enzymatic activity was significantly lower 
in patients carrying the CDA Lys27Lys than in patients with the Lys27Gln or Gln27Gln 
protein. This highlights the potential of measuring activity in accessible targets (such as ex-
vivo plasma) to model phenotype, and explores phenotype-genotype correlations. 
6.4 Population PK including intracellular GEM-TP 
Zhang et al were able to extend the population model to include estimation of GEM-TP. 
They used the existing plasma GEM model and added an extra compartment (the 
intracellular compartment). GEM-TP concentrations were explained by a simple Michaelis- 
Menten formula. No additional parameters were investigated and the Km was fixed at the 
median value and the infusion rate was fixed at 10mg/m2/min. 
(Tham et al., 2008) also derived a population PK model with intracellular compartment by 
adding an extra compartment to the Gemcitabine plasma 2 compartment model. They 
concluded, in comparison, that the GEM-TP was equally as well explained by a linear 
model, and therefore saturable metabolism did not occur. Interpretation of their data is 
complicated because it appears that fixed dose rate and standard dose rate Gemcitabine data 
has been lumped together despite previous data that saturation only occurs with the 
standard dose rate regimen. 
The disparity in interpretations also highlights the assumptions brought to bear in selecting 
pharmacokinetic models. Tham et al have selected the most parsimonious model and 
concluded that there was no evidence to support a saturable model; Zhang et al have fitted a 
Michaelis-Menten model based on previous data and found that it describes their data 
adequately. This reflects a basic debate about whether science is assumption free. Karl 
Popper has eloquently argued that all science is based on assumptions. Rejecting the 
saturable PK model on the basis of lack of improvement in the objective variable should not 
be taken to mean that saturable metabolism does not occur, just that in this data set the 
model did not improve performance.  
6.5 Physiological modelling 
A very sophisticated approach has been taken by (Battaglia & Parker, 2011) they have 
constructed an intracellular accumulation model based on existing plasma PK models. They 
have created a physiological based model of Gemcitabine intracellular accumulation with 
initial estimates based on cell line measurements. They have modelled each of the 
parameters as first order but the overall model produces saturable metabolism due to the 
interactions built in. The model includes a variable for the dose rate and includes such 
physiologic processes as self- potentiation and cell cycle specificity, and diffusion through 
the interstitial space into solid tumours. 
This work demonstrates the potential of combining measurement of clinically relevant 
compartments with an understanding of the biology involved. One application of such 
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models is that it can be used to drive clinical trial design to determine the optimum 
conditions for maximising tumour exposure under a variety of circumstances. This can 
potentially lead to more efficient clinical trial design. 
6.6 Modelling of response 
The relationship of pharmacokinetics to response is much more difficult to assess as tumour 
reponses are heterogeneous and seen in a minority of patients treated with Gemcitabine. 
This then requires PK sampling in large populations’ of patients, which is unattractive to 
designers of clinical trials and to enrolled patients. There is however one very interesting 
attempt to do this in the literature. Data from a randomised phase 2 study of fixed dose 
versus standard dose rate administration of Gemcitabine was used to provide PK data and 
measurements of individual tumours. The pharmacokinetic parameters were estimated 
from the previously derived 4 compartment population model. The tumour effect 
compartment was then modelled according to a delayed exposure to estimate tumour 
exposure. The inhibitory effect of drug exposure on tumour growth was then modelled 
(from the change in size of the tumour) by a Gompterzian tumour growth model. The 
impact of drug exposure on tumour inhibition was then tested by Emax, or sigmoid Emax, 
models with exposure estimated by either dose or estimated AUC. In the final model using 
Intra-cellular GEM-TP AUC did not improve the fit over using Gemcitabine dose. 
Interestingly the dose response variability of 146% was much greater than the interpatient 
variability in Gemcitabine clearance, suggesting that a target concentration approach would 
not be helpful in dose individualisation. 
This work represents a “heroic” attempt to take the PK/PD modelling to its logical extreme, 
however the interpretation of the observation that intra-cellular GEM-TP did not improve 
the –prediction of response should be coloured by a realisation of the limitation of the 
model. Firstly the PK model, the tumour growth model and the final PK/PD model are all 
based on data from a relatively small number of patients. Secondly the measurements that 
they are based upon e.g. GEM-TP and tumour size –have relatively large errors. Thirdly the 
three inter-related models are all based on the assumptions outlined in the paper. Many of 
these are unlikely to be true, such as the independence of Gemcitabine and Carboplatin. 
Finally the significance of the observation that a particular co-variate does not improve the 
fit of the model does depend on the overall fit of the model. Obviously a very poor model 
will not be sensitive to variations in the inputs chosen; it will perform equally well – or 
equally poorly. In this regard the overall model has very wide confidence interval the 
median tumour size at 12 weeks is approximately 4cm with a 95% confidence interval of 2.5-
12cm, clinically very significant differences. The relevance of the Gomptzerian model is also 
in question as it is now very clear that a major part of the benefit of cytotoxic therapy relates 
to the achievement of prolonged stable disease and tumour dormancy rather than tumour 
response. Nevertheless this work is a very exciting demonstration of the possibilities of 
incorporating tumour response into well understood pharmacokinetic models.  
6.7 Discussion 
These data demonstrate some of the possible applications of a population PK approach. The 
limitations of each model also demonstrate the potential of using models, which are one step 
closer to the source. 
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The Sugiyama model is a very exciting step towards the incorporation of pharmacogenetic 
data to inform model development. Any pharmacogenetic model will be constrained by the 
population it is developed in hence the dominant effect of the *3 mutation, which is 
extremely infrequent in the Caucasian population, may obscure the effects of other 
polymorphisms in other populations. 
The major step towards developing a physiologically based model would be to apply the 
polymorphisms to the model in a physiologically informed way. CDA is going to be the 
main determinant of plasma clearance, so its incorporation into the elimination from the 
central or peripheral compartment is most relevant. However DCK and hENT1 are 
determinants of uptake into the intracellular compartment. The greatest potential then 
would be to model them as variants of the transfer into the intracellular compartment. 
A further step towards more informative models would be to use preclinical data to inform 
initial model parameters for variables such as the relationship between GEM-TP 
accumulation and drug concentration.  
7. Discussion and future directions 
Gemcitabine provides a model for the study of intracellular pharmacokinetics as a way of 
moving one step closer to the target. The improved correlation of GEM-TP 
pharmacokinetics with pharmacodynamic endpoints such as dose reduction or leukocyte 
nadir is proof of principle that this provides important additional information. Given the 
accessible nature of this compartment it is difficult to see why correlative studies should 
continue to pursue plasma pharmacokinetics as an endpoint. 
However the data presented also demonstrates the limitations of intracellular-
pharmacokinetics. The tissue sampled in this literature is leucocytes, which are presumed to 
be a surrogate marker of normal tissue and or tumour uptake. The correlation with other 
normal tissues is the less problematical assumption, as the genotype is the same. It is worth 
considering in what ways leucocytes are different from other target tissues such as bone 
marrow progenitor cells.  
Firstly the regulation and expression of genes is tissue specific with upregulation of DCK 
and CDA in tumour tissue (Spasokoukotskaja et al., 1995; van der Wilt et al., 2003). Lack of 
correlation between genotype and phenotype is an issue with highly regulated genes such 
as CYP450, which are induced and inhibited by drugs and environmental exposures (Shiran 
et al., 2003). Secondly issues around tissue penetration into compartments such as the CSF, 
brain, etc are highly relevant for tumour metastases. Finally the tumour microenvironment 
is one that provides multiple barriers to drug access such as tumour hypoperfusion, 
increased interstitial pressure (Willett et al., 2004) and stromal reactions around 
tumours(Minchinton & Tannock, 2006). There is some evidence that these factors are critical 
in determining intratumoral and intertumoural heterogeneity in drug exposure (Zamboni et 
al., 2002; C. A. Presant et al., 1994).  
Even given these limitations there are still a number of significant opportunities 
associated with the ability to measure pharmacokinetics in the intracellular compartment. 
The first is the ability to assess the clinical significance of availability in genes of known 
importance. As summarised above there are a great number of potential sources of 
 
One Step Closer to the Target: Intracellular Pharmacokinetics of Gemcitabine 
 
371 
variability in intracellular Gemcitabine uptake. However the source of human variability 
in uptake is an empirical question. Early pharmacogenetic evidence already suggests that 
this may be population specific (Fukunaga et al., 2004). Measurement of intracellular 
pharmacokinetics allows questions to be asked regarding correlation between variation in 
genes such as CDA and intracellular uptake. The time taken to perform studies with 
surrogate makers such as intracellular uptake is much shorter than those requiring clinical 
endpoints such as survival. This allows prioritisation of potential markers for prospective 
validation. 
A second possibility for the utility of intracellular pharmacokinetics is in the development of 
strategies for therapeutic dose monitoring. Moving closer to the target increases the 
possibility of developing an effective TDM strategy. However data from pharmacodynamic 
modelling suggest the greater part of interpatient variability comes from pharmacodynamic 
variables suggesting limited value from pharmacokinetic monitoring (Tham et al., 2008). 
Related to this is a third possibility of pharmacogenetically derived dosing where known 
polymorphisms in genes of interest affects the dose or scheduling of the drug administered 
(Ciccolini et al, 2011). 
A significant challenge relates to application of pharmacogenetic strategies where drugs are 
given in combinations. This requires a clear understanding of the effects of the drugs on 
each other, for example the effect of DNA damaging agents on Gemcitabine accumulation 
(Metharom et al, 2010) and the conditions under which drugs act synergistically (Luk et al, 
2011).  
Optimising the dosing of Gemcitabine according to a rational understanding of an 
individual patients threshold for saturation of GEM-TP is a rational strategy for reducing 
toxicity and improving efficacy. 
A conventional strategy for optimising dose is to build upon a population pharmacokinetic 
model where clinical or laboratory variables of interest are correlated with clinical outcomes. 
The next step with such a model would be to incorporate pharmacogenetic variables of 
interest such as measurement of CDA genotype of phenotype. Determining the coefficients 
by which the impact of such variables can be adjusted will require very large clinical 
studies. Intracellular PK measurements offer the possibility of providing initial estimates of 
such variables from smaller correlative studies both in vivo and in-vitro. The advantage 
over other scenarios such as liver oxidation or glucuronidation is that the genes are 
measurable and the pharmacokinetic intermediate is assessable. This is an important area of 
inquiry to lead us to a goal of a pharmacogenetically guided individualised dosing strategy. 
These strategies are of course complimentary to those aimed at measuring drug distribution 
directly in tissues of interest by the use of tracer radio-pharmaceuticals, microdialysis, NMR 
or PET. The common theme is that facilitating the contribution of pharmacokinetics to 
optimising drug administration in oncology requires us to move closer and closer to the 
target of interest. A variety of techniques to measure intracellular uptake as well as tissue 
penetration and access to the tumour microenvironment are likely to be required to 
minimise the effect of drug variability on the response to anticancer treatments. Combining 
mesurement of more relevant compartments with physiologic modelling and incorporation 
of pharmacogenetic variation, raises a real possibility of predicting drug response in a way 
that realises the hopes of individualised medicine. 
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moving one step closer to the target. The improved correlation of GEM-TP 
pharmacokinetics with pharmacodynamic endpoints such as dose reduction or leukocyte 
nadir is proof of principle that this provides important additional information. Given the 
accessible nature of this compartment it is difficult to see why correlative studies should 
continue to pursue plasma pharmacokinetics as an endpoint. 
However the data presented also demonstrates the limitations of intracellular-
pharmacokinetics. The tissue sampled in this literature is leucocytes, which are presumed to 
be a surrogate marker of normal tissue and or tumour uptake. The correlation with other 
normal tissues is the less problematical assumption, as the genotype is the same. It is worth 
considering in what ways leucocytes are different from other target tissues such as bone 
marrow progenitor cells.  
Firstly the regulation and expression of genes is tissue specific with upregulation of DCK 
and CDA in tumour tissue (Spasokoukotskaja et al., 1995; van der Wilt et al., 2003). Lack of 
correlation between genotype and phenotype is an issue with highly regulated genes such 
as CYP450, which are induced and inhibited by drugs and environmental exposures (Shiran 
et al., 2003). Secondly issues around tissue penetration into compartments such as the CSF, 
brain, etc are highly relevant for tumour metastases. Finally the tumour microenvironment 
is one that provides multiple barriers to drug access such as tumour hypoperfusion, 
increased interstitial pressure (Willett et al., 2004) and stromal reactions around 
tumours(Minchinton & Tannock, 2006). There is some evidence that these factors are critical 
in determining intratumoral and intertumoural heterogeneity in drug exposure (Zamboni et 
al., 2002; C. A. Presant et al., 1994).  
Even given these limitations there are still a number of significant opportunities 
associated with the ability to measure pharmacokinetics in the intracellular compartment. 
The first is the ability to assess the clinical significance of availability in genes of known 
importance. As summarised above there are a great number of potential sources of 
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variability in intracellular Gemcitabine uptake. However the source of human variability 
in uptake is an empirical question. Early pharmacogenetic evidence already suggests that 
this may be population specific (Fukunaga et al., 2004). Measurement of intracellular 
pharmacokinetics allows questions to be asked regarding correlation between variation in 
genes such as CDA and intracellular uptake. The time taken to perform studies with 
surrogate makers such as intracellular uptake is much shorter than those requiring clinical 
endpoints such as survival. This allows prioritisation of potential markers for prospective 
validation. 
A second possibility for the utility of intracellular pharmacokinetics is in the development of 
strategies for therapeutic dose monitoring. Moving closer to the target increases the 
possibility of developing an effective TDM strategy. However data from pharmacodynamic 
modelling suggest the greater part of interpatient variability comes from pharmacodynamic 
variables suggesting limited value from pharmacokinetic monitoring (Tham et al., 2008). 
Related to this is a third possibility of pharmacogenetically derived dosing where known 
polymorphisms in genes of interest affects the dose or scheduling of the drug administered 
(Ciccolini et al, 2011). 
A significant challenge relates to application of pharmacogenetic strategies where drugs are 
given in combinations. This requires a clear understanding of the effects of the drugs on 
each other, for example the effect of DNA damaging agents on Gemcitabine accumulation 
(Metharom et al, 2010) and the conditions under which drugs act synergistically (Luk et al, 
2011).  
Optimising the dosing of Gemcitabine according to a rational understanding of an 
individual patients threshold for saturation of GEM-TP is a rational strategy for reducing 
toxicity and improving efficacy. 
A conventional strategy for optimising dose is to build upon a population pharmacokinetic 
model where clinical or laboratory variables of interest are correlated with clinical outcomes. 
The next step with such a model would be to incorporate pharmacogenetic variables of 
interest such as measurement of CDA genotype of phenotype. Determining the coefficients 
by which the impact of such variables can be adjusted will require very large clinical 
studies. Intracellular PK measurements offer the possibility of providing initial estimates of 
such variables from smaller correlative studies both in vivo and in-vitro. The advantage 
over other scenarios such as liver oxidation or glucuronidation is that the genes are 
measurable and the pharmacokinetic intermediate is assessable. This is an important area of 
inquiry to lead us to a goal of a pharmacogenetically guided individualised dosing strategy. 
These strategies are of course complimentary to those aimed at measuring drug distribution 
directly in tissues of interest by the use of tracer radio-pharmaceuticals, microdialysis, NMR 
or PET. The common theme is that facilitating the contribution of pharmacokinetics to 
optimising drug administration in oncology requires us to move closer and closer to the 
target of interest. A variety of techniques to measure intracellular uptake as well as tissue 
penetration and access to the tumour microenvironment are likely to be required to 
minimise the effect of drug variability on the response to anticancer treatments. Combining 
mesurement of more relevant compartments with physiologic modelling and incorporation 
of pharmacogenetic variation, raises a real possibility of predicting drug response in a way 
that realises the hopes of individualised medicine. 
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